<SEC-DOCUMENT>0001493152-22-013539.txt : 20220516
<SEC-HEADER>0001493152-22-013539.hdr.sgml : 20220516
<ACCEPTANCE-DATETIME>20220516090049
ACCESSION NUMBER:		0001493152-22-013539
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		60
CONFORMED PERIOD OF REPORT:	20220331
FILED AS OF DATE:		20220516
DATE AS OF CHANGE:		20220516

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			GT Biopharma, Inc.
		CENTRAL INDEX KEY:			0000109657
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				941620407
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40023
		FILM NUMBER:		22925843

	BUSINESS ADDRESS:	
		STREET 1:		8000 MARINA BLVD
		STREET 2:		SUITE 100
		CITY:			BRISBANE
		STATE:			CA
		ZIP:			94005
		BUSINESS PHONE:		(800) 304-9888

	MAIL ADDRESS:	
		STREET 1:		8000 MARINA BLVD
		STREET 2:		SUITE 100
		CITY:			BRISBANE
		STATE:			CA
		ZIP:			94005

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	OXIS INTERNATIONAL INC
		DATE OF NAME CHANGE:	19940916

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	DDI PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19920703

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	DIAGNOSTIC DATA INC /DE/
		DATE OF NAME CHANGE:	19850312
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>form10-q.htm
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:us-roles="http://fasb.org/us-roles/2022" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:srt="http://fasb.org/srt/2022" xmlns:GTBP="http://gtbiopharma.com/20220331">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02B_US%2DGAAP%2D2022 -->
<!-- Field: Set; Name: xdx; ID: xdx_03C_GTBP_gtbiopharma.com_20220331 -->
<!-- Field: Set; Name: xdx; ID: xdx_048_20220101_20220331 -->
<!-- Field: Set; Name: xdx; ID: xdx_05D_edei%2D%2DEntityCentralIndexKey_0000109657 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_050_edei%2D%2DDocumentFiscalYearFocus_2022 -->
<!-- Field: Set; Name: xdx; ID: xdx_051_edei%2D%2DCurrentFiscalYearEndDate_%2D%2DLS0xMi0zMQ== -->
<!-- Field: Set; Name: xdx; ID: xdx_05F_edei%2D%2DDocumentFiscalPeriodFocus_Q1 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_069_Pure_4_xbrli%2D%2Dpure -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Sqft_0_utr%2D%2Dsqft -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2022-01-01to2022-03-31" name="dei:EntityCentralIndexKey">0000109657</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-01-01to2022-03-31" format="ixt:booleanfalse" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-01-01to2022-03-31" name="dei:DocumentFiscalYearFocus">2022</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-01-01to2022-03-31" name="dei:CurrentFiscalYearEndDate">--12-31</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-01-01to2022-03-31" name="dei:DocumentFiscalPeriodFocus">Q1</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2021-12-31" id="xdx2ixbrl0060" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DepositsAssetsNoncurrent" contextRef="AsOf2021-12-31" id="xdx2ixbrl0063" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2021-12-31" id="xdx2ixbrl0081" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2021-12-31" id="xdx2ixbrl0090" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2022-03-31" id="xdx2ixbrl0113" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2021-12-31" id="xdx2ixbrl0114" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GTBP:CommonStockIssuable" contextRef="AsOf2022-03-31" id="xdx2ixbrl0133" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:Revenues" contextRef="From2022-01-01to2022-03-31" id="xdx2ixbrl0152" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:Revenues" contextRef="From2021-01-012021-03-31" id="xdx2ixbrl0153" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2021-01-012021-03-31" id="xdx2ixbrl0173" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:InterestExpenseDebtExcludingAmortization" contextRef="From2022-01-01to2022-03-31" id="xdx2ixbrl0175" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" contextRef="From2021-01-012021-03-31" id="xdx2ixbrl0182" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueCancellation" contextRef="From2022-01-012022-03-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0209" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueCancellation" contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0210" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueCancellation" contextRef="From2022-01-012022-03-31_custom_CommonSharesIssuableMember" id="xdx2ixbrl0211" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueCancellation" contextRef="From2022-01-012022-03-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0212" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueCancellation" contextRef="From2022-01-012022-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0213" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueCancellation" contextRef="From2022-01-01to2022-03-31" id="xdx2ixbrl0214" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2022-01-012022-03-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0218" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0219" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2022-01-012022-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0222" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2022-01-01to2022-03-31" id="xdx2ixbrl0223" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueEquityCompensationToOfficersAndBoardOfDirectors" contextRef="From2022-01-012022-03-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0228" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueEquityCompensationToOfficersAndBoardOfDirectors" contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0229" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueEquityCompensationToOfficersAndBoardOfDirectors" contextRef="From2022-01-012022-03-31_custom_CommonSharesIssuableMember" id="xdx2ixbrl0230" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueEquityCompensationToOfficersAndBoardOfDirectors" contextRef="From2022-01-012022-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0232" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2022-01-012022-03-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0237" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0238" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2022-01-012022-03-31_custom_CommonSharesIssuableMember" id="xdx2ixbrl0239" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2022-01-012022-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0241" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2022-01-012022-03-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0323" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0324" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2022-01-012022-03-31_custom_CommonSharesIssuableMember" id="xdx2ixbrl0325" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-03-31_custom_CommonSharesIssuableMember" id="xdx2ixbrl0332" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-03-31_custom_CommonSharesIssuableMember" id="xdx2ixbrl0341" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_custom_CommonSharesIssuableMember" id="xdx2ixbrl0345" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2020-12-31_custom_CommonSharesIssuableMember" id="xdx2ixbrl0352" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GTBP:ExtinguishmentOfDebtDiscountUponAdoptionOfAsu202006" contextRef="From2021-01-012021-03-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0354" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GTBP:ExtinguishmentOfDebtDiscountUponAdoptionOfAsu202006" contextRef="From2021-01-012021-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0355" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GTBP:ExtinguishmentOfDebtDiscountUponAdoptionOfAsu202006" contextRef="From2021-01-012021-03-31_custom_CommonSharesIssuableMember" id="xdx2ixbrl0356" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2021-01-012021-03-31_custom_CommonSharesIssuableMember" id="xdx2ixbrl0363" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2021-01-012021-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0365" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2021-01-012021-03-31" id="xdx2ixbrl0366" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueCommonSharesIssuedUponMandatoryConversionOfNotesPayableAndAccruedInterest" contextRef="From2021-01-012021-03-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0372" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueCommonSharesIssuedUponMandatoryConversionOfNotesPayableAndAccruedInterest" contextRef="From2021-01-012021-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0376" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueCommonSharesIssuedUponExerciseOfWarrants" contextRef="From2021-01-012021-03-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0382" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueCommonSharesIssuedUponExerciseOfWarrants" contextRef="From2021-01-012021-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0383" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueCommonSharesIssuedUponExerciseOfWarrants" contextRef="From2021-01-012021-03-31_custom_CommonSharesIssuableMember" id="xdx2ixbrl0384" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueCommonSharesIssuedUponExerciseOfWarrants" contextRef="From2021-01-012021-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0386" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueIssuanceOfCommonStockInPublicOfferingNetOfCost" contextRef="From2021-01-012021-03-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0391" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueIssuanceOfCommonStockInPublicOfferingNetOfCost" contextRef="From2021-01-012021-03-31_custom_CommonSharesIssuableMember" id="xdx2ixbrl0393" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueIssuanceOfCommonStockInPublicOfferingNetOfCost" contextRef="From2021-01-012021-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0395" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueIssuanceOfCommonStockForResearchAndDevelopmentAgreement" contextRef="From2021-01-012021-03-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0400" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueIssuanceOfCommonStockForResearchAndDevelopmentAgreement" contextRef="From2021-01-012021-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0401" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueIssuanceOfCommonStockForResearchAndDevelopmentAgreement" contextRef="From2021-01-012021-03-31_custom_CommonSharesIssuableMember" id="xdx2ixbrl0402" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueIssuanceOfCommonStockForResearchAndDevelopmentAgreement" contextRef="From2021-01-012021-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0404" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2021-01-012021-03-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0409" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2021-01-012021-03-31_custom_CommonSharesIssuableMember" id="xdx2ixbrl0411" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2021-01-012021-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0413" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueEquityCompensationToOfficersAndBoardOfDirectors" contextRef="From2021-01-012021-03-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0418" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueEquityCompensationToOfficersAndBoardOfDirectors" contextRef="From2021-01-012021-03-31_custom_CommonSharesIssuableMember" id="xdx2ixbrl0420" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueEquityCompensationToOfficersAndBoardOfDirectors" contextRef="From2021-01-012021-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0422" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2021-01-012021-03-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0427" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2021-01-012021-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0428" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2021-01-012021-03-31_custom_CommonSharesIssuableMember" id="xdx2ixbrl0429" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2021-01-012021-03-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0430" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GTBP:ConvertibleNotesPayableIssuedForConsultingServices" contextRef="From2022-01-01to2022-03-31" id="xdx2ixbrl0462" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" contextRef="From2021-01-012021-03-31" id="xdx2ixbrl0469" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" contextRef="From2021-01-012021-03-31" id="xdx2ixbrl0472" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GTBP:IncreaseDecreaseInDeposit" contextRef="From2021-01-012021-03-31" id="xdx2ixbrl0481" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="From2021-01-012021-03-31" id="xdx2ixbrl0487" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncreaseDecreaseInInterestPayableNet" contextRef="From2022-01-01to2022-03-31" id="xdx2ixbrl0489" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromSalesOfAssetsInvestingActivities" contextRef="From2021-01-012021-03-31" id="xdx2ixbrl0499" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2021-01-012021-03-31" id="xdx2ixbrl0502" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2022-01-01to2022-03-31" id="xdx2ixbrl0507" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromWarrantExercises" contextRef="From2022-01-01to2022-03-31" id="xdx2ixbrl0510" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfMediumTermNotes" contextRef="From2022-01-01to2022-03-31" id="xdx2ixbrl0513" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2022-01-01to2022-03-31" id="xdx2ixbrl0516" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:InterestPaid" contextRef="From2022-01-01to2022-03-31" id="xdx2ixbrl0534" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:InterestPaid" contextRef="From2021-01-012021-03-31" id="xdx2ixbrl0535" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="From2022-01-01to2022-03-31" id="xdx2ixbrl0537" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="From2021-01-012021-03-31" id="xdx2ixbrl0538" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GTBP:RightofuseAssetsAndLeaseLiabilitiesRecognizedPursuantToLeaseAgreement" contextRef="From2021-01-012021-03-31" id="xdx2ixbrl0544" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GTBP:ExtinguishmentOfUnamortizedDebtDiscountAndAdjustmentToAccumulatedDeficitUponAdoption" contextRef="From2022-01-01to2022-03-31" id="xdx2ixbrl0546" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssued1" contextRef="From2022-01-01to2022-03-31" id="xdx2ixbrl0549" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NotesIssued1" contextRef="From2022-01-01to2022-03-31" id="xdx2ixbrl0552" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2021-01-012021-03-31_custom_OptionsToPurchaseCommonStockMember" id="xdx2ixbrl0602" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGain" contextRef="From2022-01-012022-03-31_us-gaap_CashAndCashEquivalentsMember" id="xdx2ixbrl0627" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss" contextRef="From2022-01-012022-03-31_us-gaap_CashAndCashEquivalentsMember" id="xdx2ixbrl0629" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGain" contextRef="From2022-01-012022-03-31_custom_ShortTermInvestmentMember" id="xdx2ixbrl0635" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGain" contextRef="From2022-01-01to2022-03-31" id="xdx2ixbrl0643" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGain" contextRef="From2021-01-012021-12-31_us-gaap_CashAndCashEquivalentsMember" id="xdx2ixbrl0651" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss" contextRef="From2021-01-012021-12-31_us-gaap_CashAndCashEquivalentsMember" id="xdx2ixbrl0653" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGain" contextRef="From2021-01-012021-12-31_custom_ShortTermInvestmentMember" id="xdx2ixbrl0659" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGain" contextRef="From2021-01-012021-12-31" id="xdx2ixbrl0667" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FairValueNetAssetLiability" contextRef="AsOf2022-03-31_us-gaap_FairValueInputsLevel2Member_us-gaap_MoneyMarketFundsMember" id="xdx2ixbrl0677" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FairValueNetAssetLiability" contextRef="AsOf2022-03-31_us-gaap_FairValueInputsLevel3Member_us-gaap_MoneyMarketFundsMember" id="xdx2ixbrl0678" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FairValueNetAssetLiability" contextRef="AsOf2022-03-31_us-gaap_FairValueInputsLevel1Member_custom_CorporateNotesAndCommercialPaperMember" id="xdx2ixbrl0681" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FairValueNetAssetLiability" contextRef="AsOf2022-03-31_us-gaap_FairValueInputsLevel3Member_custom_CorporateNotesAndCommercialPaperMember" id="xdx2ixbrl0683" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FairValueNetAssetLiability" contextRef="AsOf2022-03-31_us-gaap_FairValueInputsLevel3Member" id="xdx2ixbrl0688" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FairValueNetAssetLiability" contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_MoneyMarketFundsMember" id="xdx2ixbrl0692" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FairValueNetAssetLiability" contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_MoneyMarketFundsMember" id="xdx2ixbrl0693" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FairValueNetAssetLiability" contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel1Member_custom_CorporateNotesAndCommercialPaperMember" id="xdx2ixbrl0696" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FairValueNetAssetLiability" contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_custom_CorporateNotesAndCommercialPaperMember" id="xdx2ixbrl0698" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FairValueNetAssetLiability" contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member" id="xdx2ixbrl0703" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" contextRef="From2022-01-01to2022-03-31" id="xdx2ixbrl0710" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" contextRef="From2021-01-012021-03-31" id="xdx2ixbrl0711" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GTBP:ExtinguishmentOfWarrants" contextRef="From2022-01-01to2022-03-31" id="xdx2ixbrl0716" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GTBP:ExtinguishmentOfWarrants" contextRef="From2021-01-012021-03-31" id="xdx2ixbrl0717" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DerivativeLiabilityMeasurementInput" contextRef="AsOf2022-03-31_us-gaap_MeasurementInputExpectedDividendRateMember" id="xdx2ixbrl0800" unitRef="Pure" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DerivativeLiabilityMeasurementInput" contextRef="AsOf2021-12-31_us-gaap_MeasurementInputExpectedDividendRateMember" id="xdx2ixbrl0802" unitRef="Pure" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" contextRef="From2022-01-01to2022-03-31" id="xdx2ixbrl0899" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue" contextRef="From2022-01-01to2022-03-31" id="xdx2ixbrl0901" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeited" contextRef="From2022-01-01to2022-03-31" id="xdx2ixbrl0903" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue" contextRef="From2022-01-01to2022-03-31" id="xdx2ixbrl0905" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" contextRef="From2022-01-01to2022-03-31" id="xdx2ixbrl0907" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GTBP:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2022-01-01to2022-03-31" id="xdx2ixbrl0909" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" contextRef="From2022-01-01to2022-03-31" id="xdx2ixbrl0925" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2022-01-01to2022-03-31" id="xdx2ixbrl0927" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" contextRef="From2022-01-01to2022-03-31" id="xdx2ixbrl0929" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="From2022-01-01to2022-03-31" id="xdx2ixbrl0931" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionEquityInstrumentsExercised" contextRef="From2022-01-01to2022-03-31" id="xdx2ixbrl0933" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2022-01-01to2022-03-31" id="xdx2ixbrl0935" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" contextRef="AsOf2022-03-31" id="xdx2ixbrl1023" unitRef="USD" xs:nil="true"></ix:nonFraction>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="gtbp-20220331.xsd" xlink:type="simple" />
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2022-01-01to2022-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-05-16">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-05-16</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_us-gaap_SeriesCPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_SeriesCPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_custom_OfficersAndDirectorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">GTBP:OfficersAndDirectorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-03-31_custom_OfficersAndDirectorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">GTBP:OfficersAndDirectorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_CommonSharesIssuableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GTBP:CommonSharesIssuableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_CommonSharesIssuableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GTBP:CommonSharesIssuableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_custom_CommonSharesIssuableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GTBP:CommonSharesIssuableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-03-31_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-03-31_custom_CommonSharesIssuableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GTBP:CommonSharesIssuableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_custom_CommonSharesIssuableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GTBP:CommonSharesIssuableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_custom_CommonSharesIssuableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GTBP:CommonSharesIssuableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_custom_OfficeSpaceAndEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">GTBP:OfficeSpaceAndEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_custom_OptionsToPurchaseCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">GTBP:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-03-31_custom_OptionsToPurchaseCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">GTBP:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_custom_WarrantsToPurchaseCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">GTBP:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-03-31_custom_WarrantsToPurchaseCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">GTBP:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_custom_UnvestedRestrictedCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">GTBP:UnvestedRestrictedCommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-03-31_custom_UnvestedRestrictedCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">GTBP:UnvestedRestrictedCommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_us-gaap_CashAndCashEquivalentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_us-gaap_CashAndCashEquivalentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_custom_ShortTermInvestmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">GTBP:ShortTermInvestmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_custom_ShortTermInvestmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">GTBP:ShortTermInvestmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_CashAndCashEquivalentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_CashAndCashEquivalentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_ShortTermInvestmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">GTBP:ShortTermInvestmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_ShortTermInvestmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">GTBP:ShortTermInvestmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_us-gaap_MoneyMarketFundsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_us-gaap_FairValueInputsLevel1Member_us-gaap_MoneyMarketFundsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_us-gaap_FairValueInputsLevel2Member_us-gaap_MoneyMarketFundsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_us-gaap_FairValueInputsLevel3Member_us-gaap_MoneyMarketFundsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_custom_CorporateNotesAndCommercialPaperMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">GTBP:CorporateNotesAndCommercialPaperMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_us-gaap_FairValueInputsLevel1Member_custom_CorporateNotesAndCommercialPaperMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">GTBP:CorporateNotesAndCommercialPaperMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_us-gaap_FairValueInputsLevel2Member_custom_CorporateNotesAndCommercialPaperMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">GTBP:CorporateNotesAndCommercialPaperMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_us-gaap_FairValueInputsLevel3Member_custom_CorporateNotesAndCommercialPaperMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">GTBP:CorporateNotesAndCommercialPaperMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_us-gaap_FairValueInputsLevel1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_us-gaap_FairValueInputsLevel2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_MoneyMarketFundsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_MoneyMarketFundsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_MoneyMarketFundsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_MoneyMarketFundsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_CorporateNotesAndCommercialPaperMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">GTBP:CorporateNotesAndCommercialPaperMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel1Member_custom_CorporateNotesAndCommercialPaperMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">GTBP:CorporateNotesAndCommercialPaperMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel2Member_custom_CorporateNotesAndCommercialPaperMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">GTBP:CorporateNotesAndCommercialPaperMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_custom_CorporateNotesAndCommercialPaperMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">GTBP:CorporateNotesAndCommercialPaperMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_custom_VendorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">GTBP:VendorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_custom_AuguestOneTwentyEighteenAndJanuaryTwentySixTwentyTwentyOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">GTBP:AuguestOneTwentyEighteenAndJanuaryTwentySixTwentyTwentyOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-02-16_custom_AuguestOneTwentyEighteenAndJanuaryTwentySixTwentyTwentyOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">GTBP:AuguestOneTwentyEighteenAndJanuaryTwentySixTwentyTwentyOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-02-16</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-02-152021-02-16_custom_AuguestOneTwentyEighteenAndJanuaryTwentySixTwentyTwentyOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">GTBP:AuguestOneTwentyEighteenAndJanuaryTwentySixTwentyTwentyOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-02-15</xbrli:startDate>
        <xbrli:endDate>2021-02-16</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-02-16_custom_NotesPayableIssuedForSettlementAgreementsMember_custom_FiscalTwentyNinteenandTwentyTwentyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:NotesPayableIssuedForSettlementAgreementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">GTBP:FiscalTwentyNinteenandTwentyTwentyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-02-16</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-02-152021-02-16_custom_NotesPayableIssuedForSettlementAgreementsMember_custom_FiscalTwentyNinteenandTwentyTwentyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:NotesPayableIssuedForSettlementAgreementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">GTBP:FiscalTwentyNinteenandTwentyTwentyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-02-15</xbrli:startDate>
        <xbrli:endDate>2021-02-16</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-23_custom_ForbearanceAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:ForbearanceAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-23</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-02-152021-02-16_custom_NotesPayableIssuedForForbearanceAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:NotesPayableIssuedForForbearanceAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-02-15</xbrli:startDate>
        <xbrli:endDate>2021-02-16</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-02-16_custom_ForbearanceAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:ForbearanceAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-02-16</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-02-152021-02-16_custom_ForbearanceAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:ForbearanceAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-02-15</xbrli:startDate>
        <xbrli:endDate>2021-02-16</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-02-152021-02-16_custom_ConsultingAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:ConsultingAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-02-15</xbrli:startDate>
        <xbrli:endDate>2021-02-16</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-02-16_custom_ConsultingAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:ConsultingAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-02-16</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-02-152021-02-16">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-02-15</xbrli:startDate>
        <xbrli:endDate>2021-02-16</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_AdoptionofAsuTwentyTwentyZeroSixMember_custom_DuringTwentyTwentyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:AdoptionofAsuTwentyTwentyZeroSixMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">GTBP:DuringTwentyTwentyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_custom_AdoptionofAsuTwentyTwentyZeroSixMember_custom_JanuaryOneTwentyTwentyOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:AdoptionofAsuTwentyTwentyZeroSixMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">GTBP:JanuaryOneTwentyTwentyOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_custom_AdoptionofAsuTwentyTwentyZeroSixMember_custom_DuringTwentyTwentyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:AdoptionofAsuTwentyTwentyZeroSixMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">GTBP:DuringTwentyTwentyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_custom_AdoptionofAsuTwentyTwentyZeroSixMember_custom_JanuaryOneTwentyTwentyOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:AdoptionofAsuTwentyTwentyZeroSixMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">GTBP:JanuaryOneTwentyTwentyOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_us-gaap_MeasurementInputRiskFreeInterestRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_us-gaap_MeasurementInputPriceVolatilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_MeasurementInputPriceVolatilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_us-gaap_MeasurementInputExpectedTermMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_MeasurementInputExpectedTermMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_us-gaap_MeasurementInputExpectedDividendRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_MeasurementInputExpectedDividendRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_CommonStockIssuableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GTBP:CommonStockIssuableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_custom_CommonStockIssuableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GTBP:CommonStockIssuableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_srt_ChiefExecutiveOfficerMember_custom_EmploymentAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:EmploymentAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_srt_ChiefFinancialOfficerMember_custom_EmploymentAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:EmploymentAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_srt_DirectorMember_custom_EmploymentAgreementsMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:EmploymentAgreementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_srt_DirectorMember_custom_EmploymentAgreementsMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:EmploymentAgreementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_custom_EmploymentAgreementsMember_srt_DirectorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:EmploymentAgreementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-03-31_custom_EmployeesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">GTBP:EmployeesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_custom_EmployeesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">GTBP:EmployeesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_custom_OfficersEmployeesAndBoardOfDirectorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">GTBP:OfficersEmployeesAndBoardOfDirectorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-02-152021-02-15_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-02-15</xbrli:startDate>
        <xbrli:endDate>2021-02-15</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-02-152021-02-15_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-02-15</xbrli:startDate>
        <xbrli:endDate>2021-02-15</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-02-16">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-02-16</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_custom_ConsultingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">GTBP:ConsultingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_custom_ConsultingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">GTBP:ConsultingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_custom_SeriesCPreferredStocksMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">GTBP:SeriesCPreferredStocksMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_custom_SeriesCPreferredStocksMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">GTBP:SeriesCPreferredStocksMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-02-152021-02-16_custom_SeriesKPreferredStocksMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">GTBP:SeriesKPreferredStocksMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-02-15</xbrli:startDate>
        <xbrli:endDate>2021-02-16</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-02-16_custom_SeriesKPreferredStocksMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">GTBP:SeriesKPreferredStocksMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-02-16</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_custom_SeriesKPreferredStocksMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">GTBP:SeriesKPreferredStocksMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_SeriesKPreferredStocksMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">GTBP:SeriesKPreferredStocksMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-02-062022-02-07">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-02-06</xbrli:startDate>
        <xbrli:endDate>2022-02-07</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-012020-10-05">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2020-10-05</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_custom_MasterServicesAgreementMember_custom_CytovanceBiologicsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:MasterServicesAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">GTBP:CytovanceBiologicsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_custom_TwoThousandSixteenPatentLicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandSixteenPatentLicenseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_custom_TwoThousandSixteenPatentLicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandSixteenPatentLicenseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_srt_MinimumMember_custom_TwoThousandSixteenPatentLicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandSixteenPatentLicenseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_srt_MaximumMember_custom_TwoThousandSixteenPatentLicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandSixteenPatentLicenseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-03-252021-03-26_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandAndTwentyOnePatentLicenseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-03-25</xbrli:startDate>
        <xbrli:endDate>2021-03-26</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandAndTwentyOnePatentLicenseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_srt_MinimumMember_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandAndTwentyOnePatentLicenseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_srt_MaximumMember_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandAndTwentyOnePatentLicenseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandAndTwentyOnePatentLicenseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-11-19_custom_AimmuneTherapeuticsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">GTBP:AimmuneTherapeuticsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-11-19</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-11-182021-11-19_custom_AimmuneTherapeuticsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">GTBP:AimmuneTherapeuticsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-11-18</xbrli:startDate>
        <xbrli:endDate>2021-11-19</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-282022-04-29_us-gaap_SubsequentEventMember_srt_ChiefExecutiveOfficerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-28</xbrli:startDate>
        <xbrli:endDate>2022-04-29</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Sqft">
      <xbrli:measure>utr:sqft</xbrli:measure>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 4pt solid; font-size: 1pt; border-bottom: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt">UNITED
STATES</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt">Washington,
D.C. 20549</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt">FORM
<span id="xdx_906_edei--DocumentType_c20220101__20220331_zhBTkfjKJBci"><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" name="dei:DocumentType">10-Q</ix:nonNumeric></span></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" border="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
  <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_edei--DocumentQuarterlyReport_c20220101__20220331_zvdT9ABiOhA2"><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" format="ixt:booleantrue" name="dei:DocumentQuarterlyReport">&#9746;</ix:nonNumeric></span></span></td>
  <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Quarterly report pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934</b></span></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
the quarterly period ended <span id="xdx_90F_edei--DocumentPeriodEndDate_c20220101__20220331_z9DK6vkS9pF5"><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">March 31, 2022</ix:nonNumeric></span>.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" border="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
  <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_edei--DocumentTransitionReport_c20220101__20220331_zHt5JDAAq2W4"><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" format="ixt:booleanfalse" name="dei:DocumentTransitionReport">&#9744;</ix:nonNumeric></span></span></td>
  <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Transition report pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934</b></span></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
the transition period from  __________ to ____________.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Commission
File Number <span id="xdx_902_edei--EntityFileNumber_c20220101__20220331_z1Z5Dr9Ud7m5"><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" name="dei:EntityFileNumber">001-40023</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><span style="text-decoration: underline"><span id="xdx_900_edei--EntityRegistrantName_c20220101__20220331_zt8Rf7EQZ0p5"><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" name="dei:EntityRegistrantName">GT
BIOPHARMA, INC.</ix:nonNumeric></span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Exact
name of registrant as specified in its charter)<br />
<br />
</b></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_900_edei--EntityIncorporationStateCountryCode_c20220101__20220331_zmvBkBWKcsf8"><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></span></td>
    <td style="text-align: center; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_901_edei--EntityTaxIdentificationNumber_c20220101__20220331_ztQV26yzeJmc"><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" name="dei:EntityTaxIdentificationNumber">94-1620407</ix:nonNumeric></span></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(State
    or other jurisdiction of </b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>incorporation
    or organization)</b></span></p></td>
    <td style="text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(I.R.S.
    Employer </b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Identification
    Number)</b></span></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 2.9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 2.9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_904_edei--EntityAddressAddressLine1_c20220101__20220331_zARTBS2tAKCe"><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" name="dei:EntityAddressAddressLine1">8000
Marina Blvd</ix:nonNumeric></span>, <span id="xdx_908_edei--EntityAddressAddressLine2_c20220101__20220331_zDrcOqKaO7E9"><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" name="dei:EntityAddressAddressLine2">Suite 100</ix:nonNumeric></span><br />
<span id="xdx_909_edei--EntityAddressCityOrTown_c20220101__20220331_zgkJH4w2qEw1"><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" name="dei:EntityAddressCityOrTown">Brisbane</ix:nonNumeric></span>, <span id="xdx_90F_edei--EntityAddressStateOrProvince_c20220101__20220331_zQGIv9KgN7ud"><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" name="dei:EntityAddressStateOrProvince">CA</ix:nonNumeric></span> <span id="xdx_901_edei--EntityAddressPostalZipCode_c20220101__20220331_zH08xDzpm37c"><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" name="dei:EntityAddressPostalZipCode">94005</ix:nonNumeric></span><br />
(Address of principal executive offices and zip code)<br />
<br />
</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_908_edei--CityAreaCode_c20220101__20220331_zJZXXSP9jPk3"><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" name="dei:CityAreaCode">415</ix:nonNumeric></span>-<span id="xdx_908_edei--LocalPhoneNumber_c20220101__20220331_zBEUEg8UoQoj"><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" name="dei:LocalPhoneNumber">919-4040</ix:nonNumeric></span><br />
(Registrant&#8217;s telephone number, including area code)<br />
<br />
</b></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
registered pursuant to Section 12(b) of the Act:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 38%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title
    of Each Class</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Trading
    Symbol</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 40%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name
    of exchange on which registered</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_edei--Security12bTitle_c20220101__20220331_zigXGk7rCf9i"><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" name="dei:Security12bTitle">Common
    Stock, $0.001 par value per share</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_edei--TradingSymbol_c20220101__20220331_zEFbb0v9iaE5"><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" name="dei:TradingSymbol">GTBP</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_edei--SecurityExchangeName_c20220101__20220331_zo0DZRtr2tFe"><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities
Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such
reports), and (2) has been subject to such filing requirements for the past 90 days. <span id="xdx_90F_edei--EntityCurrentReportingStatus_c20220101__20220331_zhcN7bllXE5"><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" name="dei:EntityCurrentReportingStatus">Yes</ix:nonNumeric></span>
&#9746; No &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 1.05pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule
405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
<span id="xdx_90D_edei--EntityInteractiveDataCurrent_c20220101__20220331_zzChKwLvukgf"><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" name="dei:EntityInteractiveDataCurrent">Yes</ix:nonNumeric></span> &#9746; No &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
company or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221;
&#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large
    accelerated filer &#9744;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated
    filer &#9744;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_edei--EntityFilerCategory_c20220101__20220331_zmd4gfbBn2ij"><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory">Non-accelerated
    filer</ix:nonNumeric></span> &#9746;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller
    reporting company <span id="xdx_902_edei--EntitySmallBusiness_c20220101__20220331_zM94FXbWVwh"><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" format="ixt:booleantrue" name="dei:EntitySmallBusiness">&#9746;</ix:nonNumeric></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging
    growth company <span id="xdx_904_edei--EntityEmergingGrowthCompany_c20220101__20220331_zAnxyZ9SytRa"><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes &#9744; <span id="xdx_90E_edei--EntityShellCompany_c20220101__20220331_zJbO6BGFKmdh"><span id="xdx_902_edei--EntityShellCompany_c20220101__20220331_zIsrK4A5lTVc"><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" format="ixt:booleanfalse" name="dei:EntityShellCompany"><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" format="ixt:booleanfalse" name="dei:EntityShellCompany">No</ix:nonNumeric></ix:nonNumeric></span></span> &#9746;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of May 16, 2022, the issuer had <span id="xdx_909_edei--EntityCommonStockSharesOutstanding_iI_pid_c20220516_ziHF9AHsjdO"><ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="AsOf2022-05-16" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">30,500,717</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt; border-bottom: Black 4pt solid">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin: 0"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: right">&#160;</td></tr></table></div>
    <div style="margin: 0; break-before: page"><p style="margin: 0">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">GT
Biopharma, Inc. and Subsidiaries</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Table of Contents</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PART
    I &#8211; FINANCIAL INFORMATION</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    1.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
    Statements</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#sur_001">Condensed Consolidated Balance Sheets as of March 31, 2022 (Unaudited) and December 31, 2021</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">3</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#sur_002">Condensed Consolidated Statements of Operations for the three months ended March 31, 2022 and 2021 (Unaudited)</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">4</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#sur_003">Condensed Consolidated Statements of Stockholders&#8217; Equity (Deficit) (Unaudited)</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">5</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#sur_004">Condensed
    Consolidated Statements of Cash Flows for the three months ended March 31, 2022 and 2021 (Unaudited)</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">7</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#sur_005">Condensed
    Notes to Consolidated Financial Statements (Unaudited)</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">8</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    2.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#sur_006">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">17</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    3.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#sur_007">Quantitative
    and Qualitative Disclosures About Market Risks</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">19</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    4.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#sur_008">Controls and Procedures</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">19</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td colspan="3" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#sur_009">PART
    II &#8211; OTHER INFORMATION</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    1.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#sur_010">Legal Proceedings</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">20</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    6.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#sur_016">Exhibits</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">20</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#sur_017">SIGNATURES</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">21</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GT
BIOPHARMA, INC AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="sur_001"></span>CONDENSED
CONSOLIDATED BALANCE SHEETS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(in
thousands, except shares and par value)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_308_111_pn3n3_z2owz9VjxRk4" summary="xdx: Statement - Condensed Consolidated Balance Sheets" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49E_20220331_zffwgkZLUb5f" style="font-weight: bold; text-align: center">March 31,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_497_20211231_zuRul3Ou02Rj" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">(Unaudited)</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center"></td><td>&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AssetsAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: center">ASSETS</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--AssetsCurrentAbstract_i01B" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--CashEquivalentsAtCarryingValue_i02I_pn3n3_maACzTIz_zSzI2r9jHJO2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; width: 64%; text-align: left">Cash and cash equivalents</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,286</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8,968</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--ShortTermInvestments_i02I_pn3n3_maACzTIz_zSohNjjov9P1" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Short-term investments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShortTermInvestments" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">19,454</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShortTermInvestments" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">23,011</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--PrepaidExpenseCurrent_i02I_pn3n3_maACzTIz_zRr3RSjZiIB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Prepaid expenses and other current assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseCurrent" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">453</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">190</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AssetsCurrent_i02TI_pn3n3_mtACzTIz_maAzxs7_zRft22UqUdLf" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Total current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">27,193</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">32,169</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--OperatingLeaseRightOfUseAsset_i02I_pn3n3_maAzxs7_z2WD13voQA6f" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Operating lease right-of-use asset</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">237</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0060">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--DepositsAssetsNoncurrent_i02I_pn3n3_maAzxs7_zySWgRHUtDh7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; padding-bottom: 1.5pt">Deposits</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:DepositsAssetsNoncurrent" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0063">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--Assets_i02TI_pn3n3_mtAzxs7_zPt7ixJGuoHi" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 30pt; text-align: left; padding-bottom: 2.5pt">TOTAL ASSETS</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">27,439</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">32,169</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: center">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--LiabilitiesCurrentAbstract_i01B" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Current liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--AccountsPayableCurrent_i02I_pn3n3_maLCz4kA_zj4u36KCvP7" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8,113</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8,220</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--AccruedLiabilitiesCurrent_i02I_pn3n3_maLCz4kA_zNNWWR8joCeh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,170</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,901</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--OperatingLeaseLiabilityCurrent_i02I_pn3n3_maLCz4kA_zTcGkkSu7Yu4" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Current operating lease liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">100</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0081">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DerivativeLiabilitiesCurrent_i02I_pn3n3_maLCz4kA_zvGq0Pm8THo3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Derivative liability</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">120</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">138</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--LiabilitiesCurrent_i02TI_pn3n3_mtLCz4kA_maLz16Q_ztUepP20bgk5" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt"><span style="font-family: Times New Roman, Times, Serif">Total current liabilities</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9,503</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">10,259</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--OperatingLeaseLiabilityNoncurrent_i02I_pn3n3_maLz16Q_zQVkBq1dCov9" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Non-current operating lease liability</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">147</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0090">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--Liabilities_i02TI_pn3n3_mtLz16Q_maLASEzONQ_maLASEzKab_zNp7T3AY1ed9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt">Total liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9,650</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">10,259</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--StockholdersEquityAbstract_i01B" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Stockholders&#8217; equity </td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Convertible Preferred stock, par value $<span id="xdx_903_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20220331_zwl11ecBpWuf" title="Preferred stock, par value"><span id="xdx_90D_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20211231_zCUEy8BaCl1k" title="Preferred stock, par value"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.01</ix:nonFraction></ix:nonFraction></span></span>, <span id="xdx_902_eus-gaap--PreferredStockSharesAuthorized_iI_pp0p0_c20220331_zDDSozak5er3" title="Preferred stock, shares authorized"><span id="xdx_902_eus-gaap--PreferredStockSharesAuthorized_iI_pp0p0_c20211231_zA1IKU0L2fsg" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="Shares">15,000,000</ix:nonFraction></ix:nonFraction></span></span> shares authorized</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--PreferredStockValue_i02I_pn3n3_hus-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_z3rUB6cKId16" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Series C &#8211; <span id="xdx_906_eus-gaap--PreferredStockSharesIssued_iI_pp0p0_c20220331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zlhIZJVyQ2dh"><span id="xdx_90C_eus-gaap--PreferredStockSharesOutstanding_iI_pp0p0_c20220331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zevglGWqyuec"><span id="xdx_908_eus-gaap--PreferredStockSharesIssued_iI_pp0p0_c20211231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zjL7s9cFauH2"><span id="xdx_907_eus-gaap--PreferredStockSharesOutstanding_iI_pp0p0_c20211231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zUKzJo9lr5cf"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2022-03-31_us-gaap_SeriesCPreferredStockMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2022-03-31_us-gaap_SeriesCPreferredStockMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2021-12-31_us-gaap_SeriesCPreferredStockMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2021-12-31_us-gaap_SeriesCPreferredStockMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="Shares">96,230</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span>
    </span>shares issued and outstanding at March 31, 2022 and December 31, 2021, respectively</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2022-03-31_us-gaap_SeriesCPreferredStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2021-12-31_us-gaap_SeriesCPreferredStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--PreferredStockValue_i02I_pn3n3_maSEzhl5_zF7GcI3Wo5F7" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Convertible Preferred stock</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0113">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0114">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_400_eus-gaap--CommonStockValue_i02I_pn3n3_maSEzhl5_zQXz899mhHf9" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Common stock, par value $<span id="xdx_90C_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20220331_z14J3Wx5hxxd" title="Common stock, par value"><span id="xdx_90D_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20211231_z0LCqOvcBwIl"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></ix:nonFraction></span></span>,
    <span id="xdx_905_eus-gaap--CommonStockSharesAuthorized_iI_pp0p0_c20220331_zedYXcPgbMgj" title="Common stock, shares authorized"><span id="xdx_904_eus-gaap--CommonStockSharesAuthorized_iI_pp0p0_c20211231_zOavN9fkQTHa"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="Shares">750,000,000</ix:nonFraction></ix:nonFraction></span></span> shares authorized, <span id="xdx_905_eus-gaap--CommonStockSharesIssued_iI_pp0p0_c20220331_zinwS99IRg35" title="Common stock, shares issued"><span id="xdx_901_eus-gaap--CommonStockSharesOutstanding_iI_pp0p0_c20220331_zylvHgCFbqTc" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="Shares">32,345,717</ix:nonFraction></ix:nonFraction></span>
    </span>shares and <span id="xdx_90D_eus-gaap--CommonStockSharesIssued_iI_pp0p0_c20211231_zcfob1ipTFq" title="Common stock, shares issued"><span id="xdx_903_eus-gaap--CommonStockSharesOutstanding_iI_pp0p0_c20211231_zYSPoRPQ3JK9" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="Shares">32,061,989</ix:nonFraction></ix:nonFraction></span></span>
    shares issued and outstanding as of March 31, 2022 and December 31, 2021, respectively</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">32</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">32</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--CommonStockIssuable_i02I_pn3n3_maSEzhl5_ztmWGwv79fs2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Common stock issuable <span id="xdx_906_ecustom--CommonStockIssuableShares_pp0p0_c20220101__20220331_zEncicTudCH1" title="Common stock issuable, shares"><ix:nonFraction name="GTBP:CommonStockIssuableShares" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="Shares">0</ix:nonFraction></span> shares and <span id="xdx_90B_ecustom--CommonStockIssuableShares_pp0p0_c20210101__20211231_zM2DaTfRdROh" title="Common stock issuable, shares"><ix:nonFraction name="GTBP:CommonStockIssuableShares" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="Shares">327,298</ix:nonFraction></span> shares at March 31, 2022 and December 31, 2021, respectively</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0133">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GTBP:CommonStockIssuable" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,113</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--AdditionalPaidInCapital_i02I_pn3n3_maSEzhl5_zMOrMew83st5" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Additional paid in capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">676,780</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">674,348</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--RetainedEarningsAccumulatedDeficit_i02I_pn3n3_maSEzhl5_zXv0QN8jRoMc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Accumulated deficit</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">659,024</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">653,584</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_409_eus-gaap--StockholdersEquity_i02TI_pn3n3_maLASEzKab_mtSEzhl5_zDyTroSU4UJc" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt">Total stockholders&#8217; equity</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">17,789</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">21,910</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--LiabilitiesAndStockholdersEquity_i01TI_pn3n3_mtLASEzKab_zLbVzBIO66Q3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 30pt; text-align: left; padding-bottom: 2.5pt">TOTAL LIABILITIES AND STOCKHOLDERS&#8217; EQUITY </td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">27,439</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">32,169</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>The
accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GT
BIOPHARMA, INC AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="sur_002"></span>CONDENSED
CONSOLIDATED STATEMENTS OF OPERATIONS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(in
thousands, except per share data)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" id="xdx_301_113_pn3n3_zLMIMBpStbC8" summary="xdx: Statement - Condensed Consolidated Statements of Operations (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_492_20220101__20220331_z0TqZMiXHTf2" style="font-weight: bold; text-align: center">2022</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_496_20210101__20210331_zFdiTTwNfi5i" style="font-weight: bold; text-align: center">2021</td><td style="font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">For the three months ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">(unaudited)</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">(unaudited)</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--Revenues_maOILzLix_zdz7Zf38MxB6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-style: normal; font-weight: normal; padding-bottom: 1.5pt">Revenues</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0152">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0153">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--OperatingExpensesAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-style: normal; font-weight: normal; text-align: left">Operating Expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--ResearchAndDevelopmentExpense_i01_pn3n3_msOILzLix_zJR3GzLqclFg" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 64%; text-align: left">Research and development</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,087</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2021-01-012021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,640</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--SellingGeneralAndAdministrativeExpense_i01_pn3n3_msOILzLix_zMVSRKJikDrj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Selling, general and administrative (including $<span id="xdx_902_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20220101__20220331__srt--TitleOfIndividualAxis__custom--OfficersAndDirectorsMember_zrIQskjB4ZI5"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2022-01-012022-03-31_custom_OfficersAndDirectorsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">447</ix:nonFraction>
    </span>and $<span id="xdx_90D_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20210101__20210331__srt--TitleOfIndividualAxis__custom--OfficersAndDirectorsMember_zLXHKbrfxR3f"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2021-01-012021-03-31_custom_OfficersAndDirectorsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">14,296</ix:nonFraction>
    </span>expense from stock compensation granted to officers, employees and directors during the three months ended March 31,
    2022 and 2021, respectively)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,355</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="From2021-01-012021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">27,362</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--OperatingIncomeLoss_i01NT_pn3n3_di_mtOILzLix_maNILzkhy_zdAiwwTsWuL8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Loss from Operations</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">5,442</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2021-01-012021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">29,002</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--NonoperatingIncomeExpenseAbstract_i01B" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-style: normal; font-weight: normal; text-align: left">Other (Income) Expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--OtherNonoperatingIncomeExpense_i01N_pn3n3_di_maNIEzyVv_zmqezwdimosh" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Interest income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0173">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--InterestExpenseDebtExcludingAmortization_i01_pn3n3_msNIEzyVv_zY5xC6FKmfn5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Interest expense</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0175">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InterestExpenseDebtExcludingAmortization" contextRef="From2021-01-012021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">696</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--DerivativeGainLossOnDerivativeNet_i01N_pn3n3_di_maNIEzyVv_zNduaurBefU7" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Change in fair value of derivative liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">18</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="From2021-01-012021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">21</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--MarketableSecuritiesUnrealizedGainLoss_i01N_pn3n3_di_maNIEzyVv_zHK72sBehX8f" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Unrealized loss on marketable securities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">24</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0182">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--NonoperatingIncomeExpense_i01NT_pn3n3_di_mtNIEzyVv_maNILzkhy_z5cYoKlwaZm5" style="vertical-align: bottom; background-color: White">
    <td style="font-style: normal; font-weight: normal; text-align: left; padding-bottom: 1.5pt">Total Other (Income) Expense</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2021-01-012021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">675</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--NetIncomeLoss_iT_pn3n3_mtNILzkhy_zKQhjPaTcZ2h" style="vertical-align: bottom; background-color: White">
    <td style="font-style: normal; font-weight: normal; text-align: left; padding-bottom: 2.5pt">Net Loss</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">5,440</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">29,677</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--EarningsPerShareBasic_pid_z6CvuOdhyD0k" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Net loss per share - basic and diluted</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.17</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2021-01-012021-03-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">1.83</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_zfmWYeF6vRMg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Weighted average common shares outstanding - basic and diluted</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">32,486,116</ix:nonFraction></p></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2021-01-012021-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">16,239,938</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>The
accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GT
BIOPHARMA, INC AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="sur_003"></span>CONDENSED
CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY (DEFICIT)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(in
thousands)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<table cellpadding="0" cellspacing="0" id="xdx_305_124_pn3n3_z4eHlMyzZGF6" summary="xdx: Statement - Condensed Consolidated Statements of Stockholders&apos; Equity (Deficit) (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold">Shares</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_4BE_us-gaap--StatementEquityComponentsAxis_us-gaap--PreferredStockMember_zCeOqTorphj1" style="text-align: center; font-weight: bold">Amount</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold">Shares</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_4BF_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_z6ZVpf03PoAb" style="text-align: center; font-weight: bold">Amount</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold">Shares</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_4B4_us-gaap--StatementEquityComponentsAxis_custom--CommonSharesIssuableMember_z9pcZPxBZbId" style="text-align: center; font-weight: bold">Amount</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_4B9_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_zYw9DwXPmq9b" style="text-align: center; font-weight: bold"> Capital</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_4BA_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_zFpYQVl3FG6k" style="text-align: center; font-weight: bold">Deficit</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_4BA_zm9eDRXqrZIl" style="text-align: center; font-weight: bold">Total</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="16" style="border-bottom: Black 1.5pt solid; font-weight: bold">For The Three Months Ended March 31, 2022 (Unaudited)</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Preferred Shares</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Common Shares</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Common Shares Issuable</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold">Additional Paid in</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold">Accumulated</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Shares</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Amount</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Shares</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Amount</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Shares</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Amount</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"> Capital</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Deficit</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Total</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_431_c20220101__20220331_eus-gaap--StockholdersEquity_iS_zo1k3c0YEe07" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%">Balance, December 31, 2021</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--SharesOutstanding_iS_pn3n3_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zSxVlR2kPp43" title="Beginning balance, shares" style="width: 4%; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">96</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 4%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--SharesOutstanding_iS_pid_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zwjk3hvjm8ba" title="Beginning  balance, shares" style="width: 4%; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">32,062</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 4%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">32</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--SharesOutstanding_iS_pn3n3_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__custom--CommonSharesIssuableMember_zsFA1W5RT7oe" title="Beginning  balance, shares" style="width: 4%; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-12-31_custom_CommonSharesIssuableMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">327</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 4%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_custom_CommonSharesIssuableMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,113</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 4%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">674,348</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 4%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">653,584</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 4%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">21,910</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--StockIssuedDuringPeriodValueCancellation_zKzAf3RVpBO9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Cancellation of common stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0209">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_ecustom--StockIssuedDuringPeriodSharesCancellation_pid_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zJwCS2NCaLAh" title="Cancellation of common stock, shares" style="text-align: right">(<ix:nonFraction name="GTBP:StockIssuedDuringPeriodSharesCancellation" contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">291</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0210">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0211">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0212">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0213">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0214">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--StockIssuedDuringPeriodValueOther_zEeK7kiaqXqg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Issuance of common shares for common shares issuable</p></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0218">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--StockIssuedDuringPeriodSharesOther_pid_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zDMaPTdsQJv1" title="Issuance of common shares as equity, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesOther" contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">327</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0219">&#160;</span></td><td style="text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">-</p></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_pn3n3_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__custom--CommonSharesIssuableMember_zMYNDvquU9Sa" style="text-align: right">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="From2022-01-012022-03-31_custom_CommonSharesIssuableMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="Shares">327</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2022-01-012022-03-31_custom_CommonSharesIssuableMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,113</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2022-01-012022-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,113</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0222">&#160;</span></td><td style="text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">-</p></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0223">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--StockIssuedDuringPeriodValueEquityCompensationToOfficersAndBoardOfDirectors_i_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Issuance of common shares as equity compensation to officers, employees, and board of directors</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0228">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_ecustom--StockIssuedDuringPeriodSharesEquityCompensationToOfficersAndBoardOfDirectors_pn3n3_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z9I0D9SmYND9" title="Equity compensation to officers and board of directors, shares" style="text-align: right"><ix:nonFraction name="GTBP:StockIssuedDuringPeriodSharesEquityCompensationToOfficersAndBoardOfDirectors" contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">85</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0229">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0230">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueEquityCompensationToOfficersAndBoardOfDirectors" contextRef="From2022-01-012022-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">447</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0232">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueEquityCompensationToOfficersAndBoardOfDirectors" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">447</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_i_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Issuance of common shares for services</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0237">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_pn3n3_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zHkjVmJj9sS9" title="Issuance of common stock for services, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">163</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0238">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">-</p></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0239">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2022-01-012022-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">872</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0241">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">872</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40D_ecustom--ExtinguishmentOfDebtDiscountUponAdoptionOfAsu202006_i_pp0p0" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Extinguishment of debt discount upon adoption of ASU 2020-06</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_402_eus-gaap--StockIssuedDuringPeriodValueNewIssues_i_pn3n3" style="display: none; vertical-align: bottom; background-color: White">
    <td>Conversion of Preferred Series J-1 to common stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_z34RaxFJN12" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Conversion of Preferred Series J-1 to common stock, Shares</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_400_ecustom--StockIssuedDuringPeriodValueCommonSharesIssuedUponMandatoryConversionOfNotesPayableAndAccruedInterest_i_pn3n3" style="display: none; vertical-align: bottom; background-color: White">
    <td>Common shares issued upon mandatory conversion of notes payable and accrued interest</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40C_ecustom--StockIssuedDuringPeriodSharesCommonSharesIssuedUponMandatoryConversionOfNotesPayableAndAccruedInterest_i_pdd" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Common shares issued upon mandatory conversion of notes payable and accrued interest, Shares</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40F_ecustom--StockIssuedDuringPeriodValueCommonSharesIssuedUponExerciseOfWarrants_i_pn3n3" style="display: none; vertical-align: bottom; background-color: White">
    <td>Common shares issued upon exercise of warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40D_ecustom--StockIssuedDuringPeriodSharesCommonSharesIssuedUponExerciseOfWarrants_i_pdd" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Common shares issued upon exercise of warrants, Shares</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40A_ecustom--StockIssuedDuringPeriodValueIssuanceOfCommonStockInPublicOfferingNetOfCost_i_pn3n3" style="display: none; vertical-align: bottom; background-color: White">
    <td>Issuance of common stock in public offering, net of cost</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40A_ecustom--StockIssuedDuringPeriodSharesIssuanceOfCommonStockInPublicOfferingNetOfCost_i_pdd" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Issuance of common stock in public offering, net of cost, Shares</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40C_ecustom--StockIssuedDuringPeriodValueIssuanceOfCommonStockForResearchAndDevelopmentAgreement_i_pn3n3" style="display: none; vertical-align: bottom; background-color: White">
    <td>Issuance of common stock for research and development agreement</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40C_ecustom--StockIssuedDuringPeriodShareIssuanceOfCommonStockForResearchAndDevelopmentAgreement_i_pdd" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Issuance of common stock for research and development agreement, Shares</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_406_eus-gaap--ProfitLoss_i_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left">Net loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0323">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0324">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0325">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2022-01-012022-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">5,440</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">5,440</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_43F_c20220101__20220331_eus-gaap--StockholdersEquity_iE_zr17ZJeksip5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Balance, March 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--SharesOutstanding_iE_pn3n3_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zmG3ech3bcx1" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-03-31_us-gaap_PreferredStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">96</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-03-31_us-gaap_PreferredStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--SharesOutstanding_iE_pn3n3_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zZDQ3PVzAAD2" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">32,346</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">32</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--SharesOutstanding_iE_pn3n3_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__custom--CommonSharesIssuableMember_zFysuWdCEq25" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0341">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0332">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">676,780</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">659,024</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">17,789</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td colspan="16" style="border-bottom: Black 1.5pt solid; font-weight: bold">For The Three Months Ended March 31, 2021 (Unaudited)</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Preferred Shares</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Common Shares</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Common Shares Issuable</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Additional </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Paid in</b></span></p></td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold">Accumulated</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Shares</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Amount</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Shares</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Amount</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Shares</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Amount</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Capital</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Deficit</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Total</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_43A_c20210101__20210331_eus-gaap--StockholdersEquity_iS_z4sGG4KIgWoh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%">Balance, December 31, 2020</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--SharesOutstanding_iS_pn3n3_c20210101__20210331__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_z5RFh60llp8a" title="Beginning balance, shares" style="width: 4%; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2020-12-31_us-gaap_PreferredStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">2,450</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 4%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_us-gaap_PreferredStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--SharesOutstanding_iS_pn3n3_c20210101__20210331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zpmHwDIOrUN2" style="width: 4%; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">5,218</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 4%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--SharesOutstanding_iS_pn3n3_c20210101__20210331__us-gaap--StatementEquityComponentsAxis__custom--CommonSharesIssuableMember_zso5T55P0aXd" style="width: 4%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0352">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0345">&#160;</span></td><td style="width: 4%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 4%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">566,356</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 4%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">595,797</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 4%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">29,433</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--ExtinguishmentOfDebtDiscountUponAdoptionOfAsu202006_zvCdwnG35tRf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Extinguishment of debt discount upon adoption of ASU 2020-06</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0354">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0355">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0356">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="GTBP:ExtinguishmentOfDebtDiscountUponAdoptionOfAsu202006" contextRef="From2021-01-012021-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">4,745</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GTBP:ExtinguishmentOfDebtDiscountUponAdoptionOfAsu202006" contextRef="From2021-01-012021-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">226</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="GTBP:ExtinguishmentOfDebtDiscountUponAdoptionOfAsu202006" contextRef="From2021-01-012021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">4,519</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--StockIssuedDuringPeriodValueNewIssues_zHcpXxTNh6yh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Conversion of Preferred Series J-1 to common stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pn3n3_c20210101__20210331__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_z9eEbUMEc0Za" title="Conversion of Preferred Series J-1 to common stock, Shares" style="text-align: right">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2021-01-012021-03-31_us-gaap_PreferredStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="Shares">2,354</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2021-01-012021-03-31_us-gaap_PreferredStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pn3n3_c20210101__20210331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zXrKyYCfNaTb" title="Conversion of Preferred Series J-1 to common stock, Shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2021-01-012021-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">692</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2021-01-012021-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0363">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2021-01-012021-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0365">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0366">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--StockIssuedDuringPeriodValueCommonSharesIssuedUponMandatoryConversionOfNotesPayableAndAccruedInterest_zDKcV8Z4T1w7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Common shares issued upon mandatory conversion of notes payable and accrued interest</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0372">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_ecustom--StockIssuedDuringPeriodSharesCommonSharesIssuedUponMandatoryConversionOfNotesPayableAndAccruedInterest_pn3n3_c20210101__20210331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zgup1ePXS7U" title="Common shares issued upon mandatory conversion of notes payable and accrued interest, Shares" style="text-align: right"><ix:nonFraction name="GTBP:StockIssuedDuringPeriodSharesCommonSharesIssuedUponMandatoryConversionOfNotesPayableAndAccruedInterest" contextRef="From2021-01-012021-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">3,779</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueCommonSharesIssuedUponMandatoryConversionOfNotesPayableAndAccruedInterest" contextRef="From2021-01-012021-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_ecustom--StockIssuedDuringPeriodSharesCommonSharesIssuedUponMandatoryConversionOfNotesPayableAndAccruedInterest_pn3n3_c20210101__20210331__us-gaap--StatementEquityComponentsAxis__custom--CommonSharesIssuableMember_zxnhSvZMNVTc" style="text-align: right"><ix:nonFraction name="GTBP:StockIssuedDuringPeriodSharesCommonSharesIssuedUponMandatoryConversionOfNotesPayableAndAccruedInterest" contextRef="From2021-01-012021-03-31_custom_CommonSharesIssuableMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">7,634</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueCommonSharesIssuedUponMandatoryConversionOfNotesPayableAndAccruedInterest" contextRef="From2021-01-012021-03-31_custom_CommonSharesIssuableMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">25,956</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueCommonSharesIssuedUponMandatoryConversionOfNotesPayableAndAccruedInterest" contextRef="From2021-01-012021-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">12,846</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0376">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueCommonSharesIssuedUponMandatoryConversionOfNotesPayableAndAccruedInterest" contextRef="From2021-01-012021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">38,806</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--StockIssuedDuringPeriodValueCommonSharesIssuedUponExerciseOfWarrants_z6sR6N2FQe4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Common shares issued upon exercise of warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0382">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_ecustom--StockIssuedDuringPeriodSharesCommonSharesIssuedUponExerciseOfWarrants_pn3n3_c20210101__20210331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z9iwilqCVzTd" title="Common shares issued upon exercise of warrants, Shares" style="text-align: right"><ix:nonFraction name="GTBP:StockIssuedDuringPeriodSharesCommonSharesIssuedUponExerciseOfWarrants" contextRef="From2021-01-012021-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">95</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0383">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0384">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueCommonSharesIssuedUponExerciseOfWarrants" contextRef="From2021-01-012021-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">58</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0386">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueCommonSharesIssuedUponExerciseOfWarrants" contextRef="From2021-01-012021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">58</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--StockIssuedDuringPeriodValueIssuanceOfCommonStockInPublicOfferingNetOfCost_z4xhaQmBncKf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Issuance of common stock in public offering, net of cost</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0391">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_ecustom--StockIssuedDuringPeriodSharesIssuanceOfCommonStockInPublicOfferingNetOfCost_pn3n3_c20210101__20210331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zdBQ8hhMbtXl" title="Issuance of common stock in public offering, net of cost, Shares" style="text-align: right"><ix:nonFraction name="GTBP:StockIssuedDuringPeriodSharesIssuanceOfCommonStockInPublicOfferingNetOfCost" contextRef="From2021-01-012021-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">4,945</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueIssuanceOfCommonStockInPublicOfferingNetOfCost" contextRef="From2021-01-012021-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0393">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueIssuanceOfCommonStockInPublicOfferingNetOfCost" contextRef="From2021-01-012021-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">24,674</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0395">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueIssuanceOfCommonStockInPublicOfferingNetOfCost" contextRef="From2021-01-012021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">24,679</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--StockIssuedDuringPeriodValueIssuanceOfCommonStockForResearchAndDevelopmentAgreement_zjnCbJqVbq93" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Issuance of common stock for research and development agreement</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0400">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_ecustom--StockIssuedDuringPeriodShareIssuanceOfCommonStockForResearchAndDevelopmentAgreement_pn3n3_c20210101__20210331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zV4O67iMf0w8" title="Issuance of common stock for research and development agreement, Shares" style="text-align: right"><ix:nonFraction name="GTBP:StockIssuedDuringPeriodShareIssuanceOfCommonStockForResearchAndDevelopmentAgreement" contextRef="From2021-01-012021-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">190</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0401">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0402">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueIssuanceOfCommonStockForResearchAndDevelopmentAgreement" contextRef="From2021-01-012021-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,355</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0404">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueIssuanceOfCommonStockForResearchAndDevelopmentAgreement" contextRef="From2021-01-012021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,355</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_zyAjfRRGSqn2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Issuance of common stock for services</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0409">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_pn3n3_c20210101__20210331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zCA0ycy2DA0h" title="Issuance of common stock for services, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2021-01-012021-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">1,957</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2021-01-012021-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0411">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2021-01-012021-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8,450</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0413">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2021-01-012021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8,452</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--StockIssuedDuringPeriodValueEquityCompensationToOfficersAndBoardOfDirectors_zyWWaoQmSZgk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Equity compensation to officers and board of directors</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0418">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_ecustom--StockIssuedDuringPeriodSharesEquityCompensationToOfficersAndBoardOfDirectors_pn3n3_c20210101__20210331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zbyx6tMLZbtf" title="Equity compensation to officers and board of directors, shares" style="text-align: right"><ix:nonFraction name="GTBP:StockIssuedDuringPeriodSharesEquityCompensationToOfficersAndBoardOfDirectors" contextRef="From2021-01-012021-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">3,641</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueEquityCompensationToOfficersAndBoardOfDirectors" contextRef="From2021-01-012021-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0420">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueEquityCompensationToOfficersAndBoardOfDirectors" contextRef="From2021-01-012021-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">14,292</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0422">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueEquityCompensationToOfficersAndBoardOfDirectors" contextRef="From2021-01-012021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">14,296</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--ProfitLoss_z02qD4qBpzp3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left">Net loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0427">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0428">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0429">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0430">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2021-01-012021-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">29,677</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2021-01-012021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">29,677</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_43D_c20210101__20210331_eus-gaap--StockholdersEquity_iE_zvsnawWH7fr2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; font-weight: bold">Balance, March 31, 2021</td><td style="padding-bottom: 2.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--SharesOutstanding_iE_pn3n3_c20210101__20210331__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zLNeAMQpWhU4" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-03-31_us-gaap_PreferredStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">96</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-03-31_us-gaap_PreferredStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--SharesOutstanding_iE_pn3n3_c20210101__20210331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zdikqcZQ1udh" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">20,517</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">21</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--SharesOutstanding_iE_pn3n3_c20210101__20210331__us-gaap--StatementEquityComponentsAxis__custom--CommonSharesIssuableMember_zpWWm07jbU4a" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-03-31_custom_CommonSharesIssuableMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">7,634</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-03-31_custom_CommonSharesIssuableMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">25,956</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">623,287</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">625,248</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="padding-bottom: 2.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">24,017</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>The
accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GT
BIOPHARMA, INC AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="sur_004"></span>CONDENSED
CONSOLIDATED STATEMENTS OF CASH FLOWS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(in
thousands)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" id="xdx_304_112_pn3n3_zguxaapUbEdk" summary="xdx: Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_493_20220101__20220331_zP6gTtSV2jyc" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_493_20210101__20210331_zmM0tWI5dome" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">For the three months ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">(unaudited)</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">(unaudited)</td><td style="font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">CASH FLOWS FROM OPERATING ACTIVITIES</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--ProfitLoss_i01_pn3n3_maNCPBUzvRU_z1u7XtJZkhS2" style="vertical-align: bottom; background-color: White">
    <td style="width: 64%; text-align: left">Net loss</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">5,440</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2021-01-012021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">29,677</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_i01B" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Adjustments to reconcile net loss to net cash (used in) operating activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--StockBasedCompensationForServices_i02_pn3n3_maNCPBUzvRU_z5wLmqc7BZ09" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Stock based compensation for services</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GTBP:StockBasedCompensationForServices" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">872</ix:nonFraction></td><td style="text-align: left"></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GTBP:StockBasedCompensationForServices" contextRef="From2021-01-012021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9,807</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--StockBasedCompensationToOfficersAndBoardOfDirectors_i02_pn3n3_maNCPBUzvRU_z03P4i8sKei1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Stock based compensation to officers, employees and board of directors</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GTBP:StockBasedCompensationToOfficersAndBoardOfDirectors" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">447</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GTBP:StockBasedCompensationToOfficersAndBoardOfDirectors" contextRef="From2021-01-012021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">14,296</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--ConvertibleNotesPayableIssuedForConsultingServices_i02_pn3n3_maNCPBUzvRU_zKtXC6fYxPOa" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Convertible notes payable issued for consulting services</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0462">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GTBP:ConvertibleNotesPayableIssuedForConsultingServices" contextRef="From2021-01-012021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">720</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--DerivativeGainLossOnDerivativeNet_i02N_pn3n3_di_msNCPBUzvRU_zlvlQuVw0Vtf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Change in fair value of derivative liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">18</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="From2021-01-012021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">21</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--OperatingLeaseRightOfUseAssetAmortizationExpense_i02_pn3n3_maNCPBUzvRU_zq3fi0B85rnl" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Change in operating lease right-of-use assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">23</ix:nonFraction></p></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0469">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--MarketableSecuritiesUnrealizedGainLoss_i02N_pn3n3_di_msNCPBUzvRU_zmkFYJ1h3Yyl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Unrealized loss on marketable securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">24</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0472">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--IncreaseDecreaseInOperatingCapitalAbstract_i02B" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Changes in operating assets and liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--IncreaseDecreaseInPrepaidExpense_i03N_pn3n3_di_msNCPBUzvRU_zXQCKqjW2dH2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">(Increase) decrease in prepaid expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidExpense" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">263</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidExpense" contextRef="From2021-01-012021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">276</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--IncreaseDecreaseInDeposit_i03_pn3n3_maNCPBUzvRU_zelwuLdl22V3" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Increase in deposits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">(<ix:nonFraction name="GTBP:IncreaseDecreaseInDeposit" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">9</ix:nonFraction></p></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0481">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_i03_pn3n3_maNCPBUzvRU_zZCbMn6KSGqg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Increase (decrease) in accounts payable and accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">838</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" contextRef="From2021-01-012021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">219</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--IncreaseDecreaseInOperatingLeaseLiability_i03_pn3n3_maNCPBUzvRU_z02VWfEKgqY1" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">(Decrease) in operating lease liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">13</ix:nonFraction></p></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0487">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--IncreaseDecreaseInInterestPayableNet_i03_pn3n3_maNCPBUzvRU_zy0NVzn9MrL6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt">Increase in accrued interest</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0489">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInInterestPayableNet" contextRef="From2021-01-012021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">696</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--NetCashProvidedByUsedInOperatingActivities_i01T_pn3n3_mtNCPBUzvRU_maCCERCzZDe_zNN3Kin7x8db" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Net Cash (Used in) Operating Activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">5,215</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2021-01-012021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">3,684</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--NetCashProvidedByUsedInInvestingActivitiesAbstract_iB" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">CASH FLOWS FROM INVESTING ACTIVITIES</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--ProceedsFromSalesOfAssetsInvestingActivities_i01_pn3n3_maNCPBUzVCM_zfIP5E4P48u6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; padding-bottom: 1.5pt">Sale of investments</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromSalesOfAssetsInvestingActivities" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,533</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0499">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--NetCashProvidedByUsedInInvestingActivities_i01T_pn3n3_mtNCPBUzVCM_maCCERCzZDe_zAS39ARUqque" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Net Cash Provided by Investing Activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,533</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0502">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesAbstract_iB" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">CASH FLOWS FROM FINANCING ACTIVITIES</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--ProceedsFromIssuanceOfCommonStock_i01_pn3n3_maNCPBUz8lM_zKwCDXO8t8kb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Proceeds from issuance of common stock</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0507">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2021-01-012021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">24,679</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--ProceedsFromWarrantExercises_i01_pn3n3_maNCPBUz8lM_z7Vhyiwog0f" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Proceeds from exercise of warrants</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0510">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromWarrantExercises" contextRef="From2021-01-012021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">58</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--ProceedsFromIssuanceOfMediumTermNotes_i01_pn3n3_maNCPBUz8lM_zTDM4JXZjNN8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Proceeds from issuance of notes payable</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0513">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfMediumTermNotes" contextRef="From2021-01-012021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,205</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--NetCashProvidedByUsedInFinancingActivities_i01T_pn3n3_mtNCPBUz8lM_maCCERCzZDe_zodHcSuQmK14" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Net Cash Provided by Financing Activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0516">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2021-01-012021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">25,942</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_iT_pn3n3_mtCCERCzZDe_zn7JcAfotVDb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net Increase (Decrease) in Cash</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,682</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2021-01-012021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">22,258</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iS_pn3n3_zwMzcvoYSTR3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Cash at Beginning of Period</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8,968</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,297</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iE_pn3n3_z46jtUEn9Nbi" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Cash at End of Period</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,286</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">27,555</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--SupplementalCashFlowInformationAbstract_iB" style="vertical-align: bottom; background-color: White">
    <td style="text-decoration: underline; text-align: left">SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--CashPaidDuringYearFor_i01B" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Cash paid during the year for:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--InterestPaid_i02_pn3n3" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; padding-bottom: 2.5pt">Interest</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0534">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0535">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--IncomeTaxesPaidNet_i02_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Income taxes </td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0537">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0538">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--NoncashInvestingAndFinancingItemsAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline; text-align: left">SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING ACTIVITIES</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--RightofuseAssetsAndLeaseLiabilitiesRecognizedPursuantToLeaseAgreement_i01_pn3n3_zT8V6eEOBCff" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Right-of-use assets and lease liabilities recognized
    pursuant to lease agreement</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="GTBP:RightofuseAssetsAndLeaseLiabilitiesRecognizedPursuantToLeaseAgreement" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">260</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0544">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--ExtinguishmentOfUnamortizedDebtDiscountAndAdjustmentToAccumulatedDeficitUponAdoption_i01_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Extinguishment of unamortized debt discount and adjustment
    to accumulated deficit upon adoption of ASU 2020-06</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0546">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="GTBP:ExtinguishmentOfUnamortizedDebtDiscountAndAdjustmentToAccumulatedDeficitUponAdoption" contextRef="From2021-01-012021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,519</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--StockIssued1_i01_pn3n3" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Common stock issued upon conversion of notes payable and accrued interest</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0549">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockIssued1" contextRef="From2021-01-012021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">38,806</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--NotesIssued1_i01_pn3n3_zF4lzoFz6Si5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Convertible notes payable issued for accrued expenses</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0552">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:NotesIssued1" contextRef="From2021-01-012021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,525</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>The
accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">GT
BIOPHARMA, INC. AND SUBSIDIARIES</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="sur_005"></span>NOTES
TO  CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
31, 2022 and 2021</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Unaudited)</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 157.1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-03-31" escape="true" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"><p id="xdx_80C_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_zTytNuG4E3N5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
1 &#8211; <span id="xdx_828_z33dYldWWUKi">Organization and Operations</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
1965, the corporate predecessor of GT Biopharma Inc. (Company), Diagnostic Data, Inc. was incorporated in the State of California. Diagnostic
Data changed its incorporation to the State of Delaware in 1972 and changed its name to DDI Pharmaceuticals, Inc. in 1985. In 1994, DDI
Pharmaceuticals merged with International BioClinical, Inc. and Bioxytech S.A. and changed its name to OXIS International, Inc. In July
2017, the Company changed its name to GT Biopharma, Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">The
Company is a clinical stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products
based on our proprietary Tri-specific Killer Engager (TriKE<sup>&#174;</sup>) fusion protein immune cell engager technology platform.
The Company&#8217;s TriKE<sup>&#174;</sup> platform generates proprietary therapeutics designed to harness and enhance the cancer killing
abilities of a patient&#8217;s own natural killer cells, or NK cells. Once bound to an NK cell, our moieties are designed to enhance
the NK cell, and precisely direct it to one or more specifically targeted proteins expressed on a specific type of cancer cell or virus
infected cell, resulting in the targeted cell&#8217;s death. TriKE<sup>&#174;</sup>s can be designed to target any number of tumor antigens
on hematologic malignancies or solid tumors and do not require patient-specific customization.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" escape="true" name="us-gaap:SignificantAccountingPoliciesTextBlock"><p id="xdx_800_eus-gaap--SignificantAccountingPoliciesTextBlock_zd3oRPjYPGv1" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Note
2 &#8211; <span><span id="xdx_827_z9CGeKu4Kdkg">Summary of Significant Accounting Policies</span></span></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-03-31" escape="true" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"><p id="xdx_84C_eus-gaap--BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_ziwXdnXm6Eo" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86C_zZA5OqiTgsti">Basis
of Presentation and Principles of Consolidation</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Oxis Biotech, Inc. and
Georgetown Translational Pharmaceuticals, Inc. All intercompany transactions and balances have been eliminated in consolidation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying condensed consolidated financial statements are unaudited. These unaudited interim condensed consolidated financial statements
have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) and
applicable rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;) regarding interim financial reporting.
Certain information and note disclosures normally included in the financial statements prepared in accordance with GAAP have been condensed
or omitted pursuant to such rules and regulations. Accordingly, these interim condensed consolidated financial statements should be read
in conjunction with the consolidated financial statements and notes thereto contained in the Company&#8217;s Annual Report on Form 10-K
for the fiscal year ended December 31, 2021 filed with the SEC on March 28, 2022 (the &#8220;2021 Annual Report&#8221;). The consolidated
balance sheet as of December 31, 2021 included herein was derived from the audited consolidated financial statements as of that date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the opinion of management, the accompanying unaudited condensed consolidated financial statements contain all adjustments necessary to
fairly present the Company&#8217;s financial position and results of operations for the interim periods reflected. Except as noted, all
adjustments contained herein are of a normal recurring nature. Results of operations for the fiscal periods presented herein are not
necessarily indicative of fiscal year-end results.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" escape="true" name="GTBP:LiquidityPolicyTextBlock"><p id="xdx_844_ecustom--LiquidityPolicyTextBlock_zp3rOnYqS4E4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span style="text-decoration: underline">Liquidity</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The accompanying consolidated financial statements
have been prepared under the assumption that the Company will continue as a going concern. Such assumption contemplates the realization
of assets and satisfaction of liabilities in the normal course of business. For the quarter ended March 31, 2022, the Company recorded
a net loss of $<span id="xdx_90D_eus-gaap--NetIncomeLoss_iN_pn5n6_di_c20220101__20220331_zvWfIejSWSJ3"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="-5" scale="6" sign="-" unitRef="USD">5.4</ix:nonFraction></span> million  and
used cash in operations of $<span id="xdx_902_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pn5n6_di_c20220101__20220331_zCZSXuW8NNIa"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="-5" scale="6" sign="-" unitRef="USD">5.2</ix:nonFraction>
</span>million. As of March 31, 2022, the Company had a cash and short-term investments balance of $<span id="xdx_904_ecustom--CashOnHandAndShortTermInvestment_c20220331_pn5n6"><ix:nonFraction name="GTBP:CashOnHandAndShortTermInvestment" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">26.7</ix:nonFraction>
</span>million, working capital of $<span id="xdx_904_ecustom--WorkingCapital_iI_pn5n6_c20220331_zg4BIqqFLElb"><ix:nonFraction name="GTBP:WorkingCapital" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">17.7</ix:nonFraction></span> million and
stockholders&#8217; equity of $<span id="xdx_90E_eus-gaap--StockholdersEquity_iI_pn5n6_c20220331_zDxGAycIXqF2"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">17.8</ix:nonFraction></span> million.
Management anticipates that the $<span id="xdx_902_eus-gaap--InvestmentsAndCash_c20220331_pn5n6"><ix:nonFraction name="us-gaap:InvestmentsAndCash" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">26.7</ix:nonFraction></span> million of cash and
cash equivalents, and short-term investments are adequate to satisfy the liquidity needs of the Company for at least one year from the
date the Company&#8217;s condensed consolidated financial statements for the quarter ended March 31, 2022 were issued.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Historically, the Company has financed its operations
through public and private sales of common stock, issuance of preferred and common stock, issuance of convertible debt instruments, and
strategic collaborations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 8; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" escape="true" name="us-gaap:UnusualRisksAndUncertaintiesTextBlock"><p id="xdx_842_eus-gaap--UnusualRisksAndUncertaintiesTextBlock_z1InoGYI4SHf" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_860_zdJ9LQtHssS4">COVID-19</span></span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2020, the World Health Organization declared coronavirus COVID-19 a global pandemic. This contagious disease outbreak, which has
continued to spread, has adversely affected workforces, customers, economies, and financial markets globally. It has also disrupted the
normal operations of many businesses. This outbreak could adversely affect the Company&#8217;s operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
the pandemic has impacted the Company&#8217;s operations, during the three months ended March 31, 2022, the Company believes the COVID-19
pandemic had limited impact on its operating results. The Company has not observed any impairments of its assets or a significant change
in the fair value of its assets due to the COVID-19 pandemic. At this time, it is not possible for the Company to predict the duration
or magnitude of the adverse results of the outbreak and its effects on the Company&#8217;s business or results of operations, financial
condition, or liquidity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has been following the recommendations of health authorities to minimize exposure risk for its team members, including having team members work remotely. Most vendors have transitioned to electronic submission of invoices
and payments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" escape="true" name="us-gaap:UseOfEstimates"><p id="xdx_845_eus-gaap--UseOfEstimates_zaQpHjiWj2Ug" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_86F_z6Y0sUxBSbdi">Accounting
Estimates</span></span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of financial statements in conformity with GAAP requires management
to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and
liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual
results could differ from those estimates. Significant estimates include accruals for potential liabilities, assumptions used in deriving
the fair value of derivative liabilities, valuation of equity instruments issued for services and realization of deferred tax assets.
Actual results could differ from those estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" escape="true" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock"><p id="xdx_846_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zvf7AVWQ7JVl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_868_zNZM9POImGMb">Cash
Equivalents and Short-Term Investments</span></span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company considers highly liquid investments with maturities of three months or less at the date of acquisition as cash equivalents in
the accompanying condensed consolidated financial statements. As of March 31, 2022 total cash and cash equivalents, which consist
of cash and money market funds, amounted to approximately $<span id="xdx_90D_eus-gaap--CashCashEquivalentsAndShortTermInvestments_iI_pn5n6_c20220331_zHe7zv78whkk" title="Total cash equivalents"><ix:nonFraction name="us-gaap:CashCashEquivalentsAndShortTermInvestments" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">7.3</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company also invested its excess cash in commercial paper and corporate notes and bonds. Management generally determines the appropriate
classification of its investments at the time of purchase. We classify these investments as short-term investments, as part of current
assets, based upon our ability and intent to use any and all of these investments as necessary to satisfy liquidity requirements that
may arise from our businesses. Investments are carried at fair value with the unrealized holding gains and losses reported in the accompanying
condensed consolidated statements of operations. As of March 31, 2022 total short-term investments amounted to approximately $<span id="xdx_90D_eus-gaap--ShortTermInvestments_iI_pn5n6_c20220331_zbFVx4slt7Dd" title="Short term investment"><ix:nonFraction name="us-gaap:ShortTermInvestments" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">19.5</ix:nonFraction></span> million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" escape="true" name="us-gaap:FairValueOfFinancialInstrumentsPolicy"><p id="xdx_84C_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zGMqlOyhVRBe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_86E_zeQcKVhcvrEf">Fair
Value of Financial Instruments</span></span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
Accounting Standards Board (&#8220;FASB&#8221;)</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
Accounting Standards Codification (&#8220;ASC&#8221;) 820-10 requires entities to disclose the fair value of financial instruments, both
assets and liabilities recognized and not recognized on the balance sheet for which it is practicable to estimate fair value. ASC 820-10
defines the fair value of a financial instrument as the amount at which the instrument could be exchanged in a current transaction between
willing parties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
three levels of the fair value hierarchy are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Valuations
    based on unadjusted quoted prices in active markets for identical assets or liabilities that the entity has the ability to access.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Valuations
    based on quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are
    observable or can be corroborated by observable data for substantially the full term of the assets or liabilities.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Valuations
    based on inputs that are unobservable, supported by little or no market activity and that are significant to the fair value of the
    assets or liabilities.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.05pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
carrying amount of the Company&#8217;s derivative liability of $<span id="xdx_907_eus-gaap--DerivativeLiabilitiesCurrent_iI_pn3d_c20220331_zARRNOM8kcxd" title="Derivative liability"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" unitRef="USD">120,000</ix:nonFraction></span> at March 31, 2022 and $<span id="xdx_90A_eus-gaap--DerivativeLiabilitiesCurrent_iI_pn3d_c20211231_ztYMVWP5ezf5" title="Derivative liability"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" unitRef="USD">138,000</ix:nonFraction></span> at December 31, 2021 was based
on Level 2 measurements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
carrying amounts of the Company&#8217;s other financial assets and liabilities, such as cash, prepaid expense, accounts payable and accrued
expenses approximate their fair values because of the short maturity of these instruments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" escape="true" name="us-gaap:DerivativesPolicyTextBlock"><p id="xdx_84F_eus-gaap--DerivativesPolicyTextBlock_zDqDJqg4m6qg" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_86B_z4YndwtpjxUh">Derivative
Financial Instruments</span></span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded
derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded
at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the consolidated statements
of operations. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or
as equity, is evaluated at the end of each reporting period. Derivative instrument liabilities are classified in the balance sheet as
current or non-current based on whether or not net-cash settlement of the derivative instrument could be required within 12 months of
the balance sheet date. The fair value of the embedded derivatives is determined using a Binomial valuation method at inception
and on subsequent valuation dates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>


<ix:exclude><!-- Field: Page; Sequence: 9; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" escape="true" name="us-gaap:CompensationRelatedCostsPolicyTextBlock"><p id="xdx_845_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zT4axtXtmrMa" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_86D_zqacO57IIn6l">Stock-Based
Compensation</span></span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for share-based awards to employees, nonemployees and consultants in accordance with the provisions of ASC 718, <i>Compensation-Stock
Compensation</i>. Stock-based compensation cost is measured at fair value on the grant date and that fair value is recognized as expense
over the requisite service, or vesting period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company values its equity awards using the Black-Scholes option pricing model, and accounts for forfeitures when they occur. Use of the
Black-Scholes option pricing model requires the input of subjective assumptions including expected volatility, expected term, and a risk-free
interest rate. The Company estimates volatility using a its own historical stock price volatility. The expected term of the instrument
is estimated by using the simplified method to estimate expected term. The risk-free interest rate is estimated using comparable published
federal funds rates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" escape="true" name="us-gaap:ResearchAndDevelopmentExpensePolicy"><p id="xdx_84C_eus-gaap--ResearchAndDevelopmentExpensePolicy_zNdiKDWMACGc" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_86A_z0CP2o2xfAB7">Research
and Development Costs</span></span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Costs
incurred for research and development are expensed as incurred. The salaries, benefits, and overhead costs of personnel conducting research
and development of the Company&#8217;s products are included in research and development expenses. Purchased materials that do not have
an alternative future use are also expensed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" escape="true" name="us-gaap:LesseeLeasesPolicyTextBlock"><p id="xdx_84B_eus-gaap--LesseeLeasesPolicyTextBlock_zIyeYy38CWhl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_86A_zNrwgdvKJgdf">Leases</span></span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for its leases in accordance with Accounting Standards Update (&#8220;ASU&#8221;) No. 2016-02, <i>Leases</i> (Topic
842) (&#8220;ASC 842&#8221;). ASC 842 requires lessees to (i) recognize a right of use asset (&#8220;ROU asset&#8221;) and a lease liability
that is measured at the present value of the remaining lease payments, on the consolidated balance sheets, (ii) recognize a single lease
cost, calculated over the lease term on a straight-line basis and (iii) classify lease related cash payments within operating and financing
activities. The Company has made an accounting policy election to not recognize short-term leases on the consolidated balance sheets
and all non-lease components, such as common area maintenance, were excluded. At any given time during the lease term, the lease liability
represents the present value of the remaining lease payments, and the ROU asset is measured as the amount of the lease liability, adjusted
for pre-paid rent, unamortized initial direct costs, and the remaining balance of lease incentives received. Both the lease ROU asset
and liability are reduced to zero at the end of the lease term.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 16.95pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company leases office space and equipment. At the lease inception date, the Company determines if an arrangement is, or contains a lease.
Some of the Company&#8217;s leases include options to renew at similar terms. The Company assesses these options to determine if the
Company is reasonably certain of exercising these options based on relevant economic and financial factors. Options that meet these criteria
are included in the lease term at the lease commencement date</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">During the period ended March 31, 2022, the Company
executed lease agreements for its office space and equipment and as a result, recorded operating lease right-of-use assets and the related
lease liabilities of $<span id="xdx_902_eus-gaap--OperatingLeaseRightOfUseAsset_iI_c20220331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeSpaceAndEquipmentMember_zGG1pfSFWhBk" title="Operating lease, right-of-use asset"><span id="xdx_903_eus-gaap--OperatingLeaseLiability_iI_c20220331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeSpaceAndEquipmentMember_z2hZmOW2i1ih" title="Operating lease,liability"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2022-03-31_custom_OfficeSpaceAndEquipmentMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2022-03-31_custom_OfficeSpaceAndEquipmentMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">260,000</ix:nonFraction></ix:nonFraction></span></span> pursuant to ASC 842,&#160;<i>Leases</i> (see Note 8).</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" escape="true" name="us-gaap:EarningsPerSharePolicyTextBlock"><p id="xdx_840_eus-gaap--EarningsPerSharePolicyTextBlock_zk2Uix3Jq2id" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_863_zAq2AuhKN4Yd" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Net
Earnings (Loss) Per Share</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
earnings (loss) per share is computed using the weighted-average number of common shares outstanding during the period. Common stock
issuable is included in our calculation as of the date of the underlying agreement. Diluted earnings (loss) per share is computed using
the weighted-average number of common shares and the dilutive effect of contingent shares outstanding during the period. Potentially
dilutive contingent shares, which primarily consist of convertible notes, stock issuable for the exercise of stock options and warrants
have been excluded from the diluted loss per share calculation because their effect is anti-dilutive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-03-31" escape="true" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"><p id="xdx_89C_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_z08jlg8yBhpd" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
following common stock equivalents were excluded in the computation of the net loss per share because their effect is anti-dilutive:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BC_z2TePbqZshn8" style="display: none">Schedule of Anti-dilutive Securities</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20220101__20220331_zmOg4YGJwO1a" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>March 31</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Unaudited)</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_494_20210101__20210331_zL4A4uv6tP1l" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>March 31</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2021<br /> (Unaudited)</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--OptionsToPurchaseCommonStockMember_z4SQlSsT7MUl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Options to purchase common stock</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-01-012022-03-31_custom_OptionsToPurchaseCommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">302,500</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0602">&#160;</span></td><td style="width: 14%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsToPurchaseCommonStockMember_znsSoEx839G3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Warrants to purchase common stock</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-01-012022-03-31_custom_WarrantsToPurchaseCommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,337,274</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2021-01-012021-03-31_custom_WarrantsToPurchaseCommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,319</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--UnvestedRestrictedCommonStockMember_zpEB40CpS4Wi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Unvested restricted common stock</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-01-012022-03-31_custom_UnvestedRestrictedCommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">681,270</ix:nonFraction></p></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2021-01-012021-03-31_custom_UnvestedRestrictedCommonStockMember" format="ixt:numcommadecimal" decimals="INF" unitRef="Shares">1.596,659</ix:nonFraction></p></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_zMyj6yomOmDf" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total anti-dilutive
securities</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,321,044</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2021-01-012021-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,601,978</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A3_zPgPEvpU3XJ6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i></i></span><i>&#160;</i></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" escape="true" name="us-gaap:ConcentrationRiskCreditRisk"><p id="xdx_845_eus-gaap--ConcentrationRiskCreditRisk_zRl8PF0gepF4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_86E_zmpEwVyRDgAc">Concentration</span></span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
is deposited in one financial institution. The balances held at this financial institution at times may be in excess of Federal Deposit
Insurance Corporation (&#8220;FDIC&#8221;) insurance limits of up to $<span id="xdx_904_eus-gaap--CashFDICInsuredAmount_iI_c20220331_zOTm1zFRT8fi" title="FDIC amount"><ix:nonFraction name="us-gaap:CashFDICInsuredAmount" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">250,000</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has a significant concentration of expenses incurred and accounts payable from a single vendor. Please see Note 4 for further
information.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" escape="true" name="us-gaap:SegmentReportingPolicyPolicyTextBlock"><p id="xdx_848_eus-gaap--SegmentReportingPolicyPolicyTextBlock_z5E8YT2mMjc1" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_860_zfA0RxfMt3ze">Segments</span></span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company determined its reporting units in accordance with ASC 280, &#8220;Segment Reporting&#8221; (&#8220;ASC 280&#8221;). Management
evaluates a reporting unit by first identifying its&#8217; operating segments under ASC 280. The Company then evaluates each operating
segment to determine if it includes one or more components that constitute a business. If there are components within an operating segment
that meet the definition of a business, the Company evaluates those components to determine if they must be aggregated into one or more
reporting units. If applicable, when determining if it is appropriate to aggregate different operating segments, the Company determines
if the segments are economically similar and, if so, the operating segments are aggregated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 10; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
has determined that the Company has one  operating segment. The Company&#8217;s reporting segment reflects the manner in
which its chief operating decision maker reviews results and allocates resources. The Company&#8217;s reporting segment meets the definition
of an operating segment and does not include the aggregation of multiple operating segments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" escape="true" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock"><p id="xdx_84B_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zDJDSg8lipo4" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_86D_z8QXODnl6JKc" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Recent
Accounting Pronouncements</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2021, the FASB issued ASU 2021-04, <i>Earnings Per Share (Topic 260), Debt-Modifications and Extinguishments (Subtopic 470-50), Compensation-Stock
Compensation (Topic 718), and Derivatives and Hedging-Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Issuer&#8217;s Accounting
for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options</i>. ASU 2021-04 provides clarification
and reduces diversity in an issuer&#8217;s accounting for modifications or exchanges of freestanding equity-classified written call options
(such as warrants) that remain equity classified after modification or exchange. An issuer measures the effect of a modification or exchange
as the difference between the fair value of the modified or exchanged warrant and the fair value of that warrant immediately before modification
or exchange. ASU 2021-04 introduces a recognition model that comprises four categories of transactions and the corresponding accounting
treatment for each category (equity issuance, debt origination, debt modification, and modifications unrelated to equity issuance and
debt origination or modification). ASU 2021-04 is effective for all entities for fiscal years beginning after December 15, 2021, including
interim periods within those fiscal years. An entity should apply the guidance provided in ASU 2021-04 prospectively to modifications
or exchanges occurring on or after the effective date. Early adoption is permitted for all entities, including adoption in an interim
period. Effective January 1, 2022, we adopted ASU 2021-04 using a prospective approach. It did not have a material impact on the Company&#8217;s
financial statements or disclosures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public
Accountants, and the Securities and Exchange Commission (the &#8220;SEC&#8221;) did not or are not believed by management to have a material
impact on the Company&#8217;s present or future consolidated financial statements.</span></p>

</ix:nonNumeric><p id="xdx_85F_z41n7ayvdc97" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" escape="true" name="us-gaap:FairValueDisclosuresTextBlock"><p id="xdx_807_eus-gaap--FairValueDisclosuresTextBlock_zX5FPsfe1pc5" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
3 &#8211; <span id="xdx_82B_z9In1tIzB1l8">Fair Value of Financial Instruments</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-03-31" escape="true" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock"><p id="xdx_89B_eus-gaap--DebtSecuritiesAvailableForSaleTableTextBlock_zeQohQiV5KW6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
estimated fair values of financial instruments outstanding were (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B0_zINi0pXAkORk" style="display: none">Schedule of Estimated Fair Value of Financial Instrument</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31, 2022 (Unaudited)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Unrealized</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Unrealized</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Fair</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Cost</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Gains</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Losses</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%; text-align: left">Cash and cash equivalents</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pn3n3_c20220331__us-gaap--InvestmentTypeAxis__us-gaap--CashAndCashEquivalentsMember_zNHpxSJr3vjc" title="Cost" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="AsOf2022-03-31_us-gaap_CashAndCashEquivalentsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,286</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--DebtSecuritiesAvailableForSaleRealizedGain_pn3n3_c20220101__20220331__us-gaap--InvestmentTypeAxis__us-gaap--CashAndCashEquivalentsMember_zA0l0WnF7X5j" title="Unrealized gains" style="width: 12%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl0627">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--DebtSecuritiesAvailableForSaleRealizedLoss_pn3n3_c20220101__20220331__us-gaap--InvestmentTypeAxis__us-gaap--CashAndCashEquivalentsMember_zzWNzM114vD7" title="Unrealized losses" style="width: 12%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl0629">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--DebtSecuritiesAvailableForSaleRealizedGainLoss_pn3n3_c20220101__20220331__us-gaap--InvestmentTypeAxis__us-gaap--CashAndCashEquivalentsMember_zI5kxS58pm1b" title="Fair value" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss" contextRef="From2022-01-012022-03-31_us-gaap_CashAndCashEquivalentsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,286</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Short-term investments</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pn3n3_c20220331__us-gaap--InvestmentTypeAxis__custom--ShortTermInvestmentMember_zp1sJ9jJAp6c" title="Cost" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="AsOf2022-03-31_custom_ShortTermInvestmentMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">19,496</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--DebtSecuritiesAvailableForSaleRealizedGain_pn3n3_c20220101__20220331__us-gaap--InvestmentTypeAxis__custom--ShortTermInvestmentMember_z6JcJF0hjsqj" title="Unrealized gains" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0635">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--DebtSecuritiesAvailableForSaleRealizedLoss_pn3n3_c20220101__20220331__us-gaap--InvestmentTypeAxis__custom--ShortTermInvestmentMember_zc4BCyBuHV2c" title="Unrealized losses" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss" contextRef="From2022-01-012022-03-31_custom_ShortTermInvestmentMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">42</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--DebtSecuritiesAvailableForSaleRealizedGainLoss_pn3n3_c20220101__20220331__us-gaap--InvestmentTypeAxis__custom--ShortTermInvestmentMember_zObPMSK74Ywc" title="Fair value" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss" contextRef="From2022-01-012022-03-31_custom_ShortTermInvestmentMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">19,454</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pn3n3_c20220331_zpr5X2NKUd03" title="Cost" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">26,782</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--DebtSecuritiesAvailableForSaleRealizedGain_pn3n3_c20220101__20220331_zfY6KFcS6X0g" title="Unrealized gains" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0643">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--DebtSecuritiesAvailableForSaleRealizedLoss_pn3n3_c20220101__20220331_zAugk9I5CE9g" title="Unrealized losses" style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">42</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--DebtSecuritiesAvailableForSaleRealizedGainLoss_pn3n3_c20220101__20220331_zrbNMYLOql2j" title="Fair value" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">26,740</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Unrealized</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Unrealized</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Fair</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Cost</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Gains</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Losses</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%; text-align: left">Cash and cash equivalents</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pn3n3_c20211231__us-gaap--InvestmentTypeAxis__us-gaap--CashAndCashEquivalentsMember_zUlswoZLTXe5" title="Cost" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="AsOf2021-12-31_us-gaap_CashAndCashEquivalentsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8,968</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--DebtSecuritiesAvailableForSaleRealizedGain_pn3n3_c20210101__20211231__us-gaap--InvestmentTypeAxis__us-gaap--CashAndCashEquivalentsMember_zGH3sKl27OWa" title="Unrealized gains" style="width: 12%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl0651">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--DebtSecuritiesAvailableForSaleRealizedLoss_pn3n3_c20210101__20211231__us-gaap--InvestmentTypeAxis__us-gaap--CashAndCashEquivalentsMember_zdjO2Rrzkb99" title="Unrealized losses" style="width: 12%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl0653">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--DebtSecuritiesAvailableForSaleRealizedGainLoss_c20210101__20211231__us-gaap--InvestmentTypeAxis__us-gaap--CashAndCashEquivalentsMember_pn3n3" title="Fair value" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss" contextRef="From2021-01-012021-12-31_us-gaap_CashAndCashEquivalentsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8,968</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Short-term investments</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_c20211231__us-gaap--InvestmentTypeAxis__custom--ShortTermInvestmentMember_pn3n3" title="Cost" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="AsOf2021-12-31_custom_ShortTermInvestmentMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">23,040</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--DebtSecuritiesAvailableForSaleRealizedGain_pn3n3_c20210101__20211231__us-gaap--InvestmentTypeAxis__custom--ShortTermInvestmentMember_zWVQ6LMxERjj" title="Unrealized gains" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0659">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--DebtSecuritiesAvailableForSaleRealizedLoss_c20210101__20211231__us-gaap--InvestmentTypeAxis__custom--ShortTermInvestmentMember_pn3n3" title="Unrealized losses" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss" contextRef="From2021-01-012021-12-31_custom_ShortTermInvestmentMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">29</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--DebtSecuritiesAvailableForSaleRealizedGainLoss_c20210101__20211231__us-gaap--InvestmentTypeAxis__custom--ShortTermInvestmentMember_pn3n3" title="Fair value" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss" contextRef="From2021-01-012021-12-31_custom_ShortTermInvestmentMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">23,011</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_c20211231_pn3n3" title="Cost" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">32,008</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--DebtSecuritiesAvailableForSaleRealizedGain_pn3n3_c20210101__20211231_zBqd78pn4Eta" title="Unrealized gains" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0667">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--DebtSecuritiesAvailableForSaleRealizedLoss_c20210101__20211231_pn3n3" title="Unrealized losses" style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">29</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--DebtSecuritiesAvailableForSaleRealizedGainLoss_pn3n3_c20210101__20211231_zGnGlqfREVqk" title="Fair value" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">31,979</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A2_zzIrpHtCC3R8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 11; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-03-31" escape="true" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"><p id="xdx_89E_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_zI3PgrbzMN11" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table represents the Company&#8217;s fair value hierarchy for its financial assets (cash equivalents and investments) (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B5_zDbwwi6g3JC5" style="display: none">Schedule
of Fair Value Hierarchy Financial Assets</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_499_20220331_zxeNbTSQqHAb" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20220331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zEjdov4Uo7Ij" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_492_20220331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z66fYX6UdRsg" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20220331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zLGe7PBAqEml" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31, 2022 (Unaudited)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--FairValueNetAssetLiability_iI_pn3n3_hus-gaap--InvestmentTypeAxis__us-gaap--MoneyMarketFundsMember_zlEFJ7v5qpFe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%; text-align: left">Money market funds</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:FairValueNetAssetLiability" contextRef="AsOf2022-03-31_us-gaap_MoneyMarketFundsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,299</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:FairValueNetAssetLiability" contextRef="AsOf2022-03-31_us-gaap_FairValueInputsLevel1Member_us-gaap_MoneyMarketFundsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,299</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl0677">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl0678">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--FairValueNetAssetLiability_iI_pn3n3_hus-gaap--InvestmentTypeAxis__custom--CorporateNotesAndCommercialPaperMember_zJ2eGfprqtr1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Corporate notes and commercial paper</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:FairValueNetAssetLiability" contextRef="AsOf2022-03-31_custom_CorporateNotesAndCommercialPaperMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">19,454</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0681">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:FairValueNetAssetLiability" contextRef="AsOf2022-03-31_us-gaap_FairValueInputsLevel2Member_custom_CorporateNotesAndCommercialPaperMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">19,454</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0683">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--FairValueNetAssetLiability_iI_pn3n3_zbgzUE5eDvBi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt; text-align: left; padding-bottom: 2.5pt">Total financial assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:FairValueNetAssetLiability" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">25,753</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:FairValueNetAssetLiability" contextRef="AsOf2022-03-31_us-gaap_FairValueInputsLevel1Member" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,299</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:FairValueNetAssetLiability" contextRef="AsOf2022-03-31_us-gaap_FairValueInputsLevel2Member" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">19,454</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0688">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20211231_zG2l7AhYYoMd" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_493_20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z80spwcHx7p8" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_495_20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zF69jgkUQ4jg" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zqoqfxEs4uib" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--FairValueNetAssetLiability_iI_pn3n3_hus-gaap--InvestmentTypeAxis__us-gaap--MoneyMarketFundsMember_z29ohChGhUsc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%; text-align: left">Money market funds</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:FairValueNetAssetLiability" contextRef="AsOf2021-12-31_us-gaap_MoneyMarketFundsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,484</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:FairValueNetAssetLiability" contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_MoneyMarketFundsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,484</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl0692">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl0693">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--FairValueNetAssetLiability_iI_pn3n3_hus-gaap--InvestmentTypeAxis__custom--CorporateNotesAndCommercialPaperMember_ztq6kmtGIfi3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Corporate notes and commercial paper</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:FairValueNetAssetLiability" contextRef="AsOf2021-12-31_custom_CorporateNotesAndCommercialPaperMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">23,011</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0696">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:FairValueNetAssetLiability" contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel2Member_custom_CorporateNotesAndCommercialPaperMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">23,011</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0698">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--FairValueNetAssetLiability_iI_pn3n3_zC0E2xpy5qe7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt; text-align: left; padding-bottom: 2.5pt">Total financial assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:FairValueNetAssetLiability" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">28,495</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:FairValueNetAssetLiability" contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel1Member" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,484</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:FairValueNetAssetLiability" contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel2Member" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">23,011</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0703">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A0_zvfqBGDcB504" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-03-31" escape="true" name="us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock"><p id="xdx_89C_eus-gaap--ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_zmExvcUrhL6b" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of March 31, 2022, the fair value of the derivative liability amounted
to $<span id="xdx_900_eus-gaap--DerivativeLiabilitiesCurrent_iI_pn3d_c20220331_z4SbKAkbsnCc"><span id="xdx_905_eus-gaap--DerivativeLiabilitiesCurrent_iI_pn3d_c20210331_zyuayTJ2ZRJb">120,000</span></span>. The details of derivative liability transactions for the three months ended March 31, 2022 and 2021, are as follows:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;<span id="xdx_8B9_zhINUzne4oz7" style="display: none">Schedule
of Derivative Liability Transactions</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_499_20220101__20220331_zG55aeY08pz1" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_496_20210101__20210331_zeB1f8gQSmw2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Unaudited)</b></span></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Unaudited)</b></span></td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DerivativeLiabilitiesCurrent_iS_pn3d_z0EuE0GkcdC2" style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: left">Beginning balance</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" unitRef="USD">138,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" unitRef="USD">383,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--IssuanceOfStockAndWarrantsForServicesOrClaims_pn3d_zIvGR25VX2kk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Fair value upon issuance of warrants</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0710">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0711">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--IncreaseDecreaseInDerivativeLiabilities_pn3d_zuaXPbmfw0h8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Change in fair value</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInDerivativeLiabilities" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="-3" sign="-" unitRef="USD">18,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInDerivativeLiabilities" contextRef="From2021-01-012021-03-31" format="ixt:numdotdecimal" decimals="-3" sign="-" unitRef="USD">21,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_408_ecustom--ExtinguishmentOfWarrants_pn3d_z8LLtwMnJ73a" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Extinguishment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0716">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0717">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--DerivativeLiabilitiesCurrent_iE_pn3d_zW8Qm6sz2bQe" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Ending balance</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" unitRef="USD">120,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="-3" unitRef="USD">362,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A0_zIwPi0plFWu8" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" escape="true" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"><p id="xdx_801_eus-gaap--AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_zmXy4sUY5Yw7" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
4 &#8211; <span id="xdx_824_zKdifaVeu57g">Accounts Payable</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-03-31" escape="true" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"><p id="xdx_89A_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zijFJvpzXUa2" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts
payable consisted of the following (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BA_zhJHGZcTSXc8" style="display: none">Schedule of Accounts Payable</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49C_20220331_zOJxegZvtWFl" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">March 31, <br />
2022 </td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_498_20211231_zJq5UyUkUPZ1" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><p style="margin-top: 0; margin-bottom: 0">December 31, <br />
2021</p>
                                                                  <p style="margin-top: 0; margin-bottom: 0"></p></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">(Unaudited)</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AccountsPayableRelatedPartiesCurrent_iI_pn3n3_maAPCz7ta_zgaOSxvWmmzg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Accounts payable to a third-party manufacturer</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableRelatedPartiesCurrent" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,423</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableRelatedPartiesCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,335</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AccountsPayableOtherCurrent_iI_pn3n3_maAPCz7ta_zzkEUsbFKf46" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left">Other accounts payable</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableOtherCurrent" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">690</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableOtherCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,885</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--AccountsPayableCurrent_iTI_pn3n3_mtAPCz7ta_z00cLDEcrAJ3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-align: left">Total accounts payable</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8,113</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8,220</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AD_zt5bRxPkVhNc" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company relies on a third-party contract manufacturing operation to produce and/or test our compounds used in our potential product candidates.
As of March 31, 2022 the Company was indebted $<span id="xdx_908_eus-gaap--AccountsPayableCurrent_iI_pn5n6_c20220331__us-gaap--RelatedPartyTransactionAxis__custom--VendorMember_zGLvHbeTpDU7" title="Accounts payable current"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2022-03-31_custom_VendorMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">7.4</ix:nonFraction></span> million of accounts payable to this vendor.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" escape="true" name="us-gaap:DebtDisclosureTextBlock"><p id="xdx_80A_eus-gaap--DebtDisclosureTextBlock_zsWSV5fQgRmk" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
5 &#8211; <span id="xdx_826_zIhcg88MHJI4">Convertible Notes Payable</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Notes
Payable Issued for Cash</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
part of the Company&#8217;s financing activities, the Company issued convertible notes payable totaling $<span id="xdx_906_eus-gaap--ConvertibleNotesPayableCurrent_iI_pn5n6_c20220331__us-gaap--AwardDateAxis__custom--AuguestOneTwentyEighteenAndJanuaryTwentySixTwentyTwentyOneMember_zLkEk8aFX2va" title="Convertible notes payable"><ix:nonFraction name="us-gaap:ConvertibleNotesPayableCurrent" contextRef="AsOf2022-03-31_custom_AuguestOneTwentyEighteenAndJanuaryTwentySixTwentyTwentyOneMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">25.3</ix:nonFraction></span> million between August
1, 2018 and January 26, 2021. On February 16, 2021, in accordance with the terms of the note agreements upon completion of the equity
offering, these notes were mandatorily converted at a conversion rate of $<span id="xdx_907_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20210216__us-gaap--AwardDateAxis__custom--AuguestOneTwentyEighteenAndJanuaryTwentySixTwentyTwentyOneMember_zNDMRAtkkkbf" title="Conversion rate"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextRef="AsOf2021-02-16_custom_AuguestOneTwentyEighteenAndJanuaryTwentySixTwentyTwentyOneMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.40</ix:nonFraction></span> per share into <span id="xdx_90C_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_pid_c20210215__20210216__us-gaap--AwardDateAxis__custom--AuguestOneTwentyEighteenAndJanuaryTwentySixTwentyTwentyOneMember_zS3KLaRWWsZh" title="Converted conversion of common stock"><ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" contextRef="From2021-02-152021-02-16_custom_AuguestOneTwentyEighteenAndJanuaryTwentySixTwentyTwentyOneMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,438,235</ix:nonFraction></span> shares of the Company&#8217;s
common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Notes
Pa</span>y<span style="text-decoration: underline">able Issued for Settlement Agreements</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
fiscal 2019 and 2020, the Company issued its convertible notes payable in the amount of $<span id="xdx_905_eus-gaap--ConvertibleNotesPayable_iI_pn5n6_c20191231_zS5UymwT9Tv1" title="Convertible notes payable"><span id="xdx_90B_eus-gaap--ConvertibleNotesPayable_iI_pn5n6_c20201231_zhTdbi2bppr8" title="Convertible notes payable"><ix:nonFraction name="us-gaap:ConvertibleNotesPayable" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD"><ix:nonFraction name="us-gaap:ConvertibleNotesPayable" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">2.5</ix:nonFraction></ix:nonFraction></span></span> million to resolve claims and disputes
pertaining to certain debt and equity instruments issued by the Company in prior years. On February 16, 2021 in accordance with the note
agreements upon completion of the equity offering, these notes were mandatorily converted at a conversion rate of $<span id="xdx_906_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20210216__us-gaap--DebtInstrumentAxis__custom--NotesPayableIssuedForSettlementAgreementsMember__us-gaap--AwardDateAxis__custom--FiscalTwentyNinteenandTwentyTwentyMember_zja1C7zWAJt3"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextRef="AsOf2021-02-16_custom_NotesPayableIssuedForSettlementAgreementsMember_custom_FiscalTwentyNinteenandTwentyTwentyMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.40</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share into <span id="xdx_909_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_pid_c20210215__20210216__us-gaap--DebtInstrumentAxis__custom--NotesPayableIssuedForSettlementAgreementsMember__us-gaap--AwardDateAxis__custom--FiscalTwentyNinteenandTwentyTwentyMember_zFWn4AyITj38"><ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" contextRef="From2021-02-152021-02-16_custom_NotesPayableIssuedForSettlementAgreementsMember_custom_FiscalTwentyNinteenandTwentyTwentyMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">743,529</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of the Company&#8217;s common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Notes
Pa</span>y<span style="text-decoration: underline">able Issued for Forbearance Agreements</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 23, 2020, the Company entered into Standstill and Forbearance Agreements (collectively, the &#8220;Forbearance Agreements&#8221;)
with the holders of $<span id="xdx_907_eus-gaap--DebtInstrumentFaceAmount_iI_pn5n6_c20200623__us-gaap--TypeOfArrangementAxis__custom--ForbearanceAgreementsMember_zRYIyVEPQps8" title="Debt instrument, face amount"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2020-06-23_custom_ForbearanceAgreementsMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">13.2</ix:nonFraction></span> million aggregate principal amount of the Convertible Notes (the &#8220;Default Notes&#8221;), which were in
default. Pursuant to the Forbearance Agreements, the holders of the Default Notes agreed to forbear from exercising their rights and
remedies under the Default Notes (including declaring such Default Notes (together with any default amounts and accrued and unpaid interest)
immediately due and payable) until the earlier of (i) the date that the Company completes a future financing in the amount of $<span id="xdx_905_eus-gaap--NotesPayable_iI_pn6n6_c20200623__us-gaap--TypeOfArrangementAxis__custom--ForbearanceAgreementsMember_zsZ8XwSJoOr2" title="Notes payable"><ix:nonFraction name="us-gaap:NotesPayable" contextRef="AsOf2020-06-23_custom_ForbearanceAgreementsMember" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">15</ix:nonFraction></span> million
and, in connection therewith, commences listing on NASDAQ (collectively, the &#8220;New Financing&#8221;) or (ii) January 31, 2021 (the
&#8220;Termination Date&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 16, 2021 in accordance with the note agreements upon completion of the equity offering, these notes, in the amount of $<span id="xdx_902_eus-gaap--DebtConversionConvertedInstrumentAmount1_pn5n6_c20210215__20210216__us-gaap--DebtInstrumentAxis__custom--NotesPayableIssuedForForbearanceAgreementMember_zKh7JHSyEsV8" title="Debt Conversion, Converted Instrument, Amount"><ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentAmount1" contextRef="From2021-02-152021-02-16_custom_NotesPayableIssuedForForbearanceAgreementMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">3.8</ix:nonFraction></span>
million, were mandatorily converted at a conversion rate of $<span id="xdx_90F_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20210216__us-gaap--TypeOfArrangementAxis__custom--ForbearanceAgreementsMember_zZDKE7U4rnx5"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextRef="AsOf2021-02-16_custom_ForbearanceAgreementsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.40</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share into <span id="xdx_902_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_pid_c20210215__20210216__us-gaap--TypeOfArrangementAxis__custom--ForbearanceAgreementsMember_zChZkLtWCY41"><ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" contextRef="From2021-02-152021-02-16_custom_ForbearanceAgreementsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,132,059</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of the Company&#8217;s common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>


<ix:exclude><!-- Field: Page; Sequence: 12; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Notes
Pa</span>y<span style="text-decoration: underline">able issued for Consulting Agreements</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
prior years, the Company issued its convertible notes payable in exchange for consulting services in the amount of $<span id="xdx_903_ecustom--ConvertibleNotesPayableIssuedInExchangeForConsultingServices_pn5n6_c20220101__20220331_ze3buae1LZsc" title="Notes payable in exchange of consulting services"><ix:nonFraction name="GTBP:ConvertibleNotesPayableIssuedInExchangeForConsultingServices" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.6</ix:nonFraction></span> million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 16, 2021 in accordance with the note agreements upon completion of the equity offering, these notes in the aggregate amount
of $<span id="xdx_906_eus-gaap--DebtConversionConvertedInstrumentAmount1_pn5n6_c20210215__20210216__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementsMember_zUIqzoh61lzd" title="Debt converted amount"><ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentAmount1" contextRef="From2021-02-152021-02-16_custom_ConsultingAgreementsMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.6</ix:nonFraction></span> million were mandatorily converted at a conversion rate of $<span id="xdx_900_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20210216__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementsMember_zT9AIRK5PY54" title="Conversion price per share"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextRef="AsOf2021-02-16_custom_ConsultingAgreementsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.40</ix:nonFraction></span> per share into <span id="xdx_90A_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_pid_c20210215__20210216__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementsMember_zgvys8tqU6ph" title="Converted conversion of common stock"><ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" contextRef="From2021-02-152021-02-16_custom_ConsultingAgreementsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">472,059</ix:nonFraction></span> shares of the Company&#8217;s common
stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline">Notes Payable issued for Accrued
Interest</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In prior years, the Company recorded accrued interest
of $<span id="xdx_90F_ecustom--AccruedInterestAmount_pn5n6_c20220101__20220331_zRHUntFo7Z5h" title="Accrued interest amount"><ix:nonFraction name="GTBP:AccruedInterestAmount" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">5.6</ix:nonFraction></span> million related to all notes payable. On February 16, 2021, in accordance with the note agreements upon completion of the equity
offering, the accrued interest was mandatorily converted at a conversion rate of $<span id="xdx_907_eus-gaap--DebtConversionConvertedInstrumentRate_pid_dp_uPure_c20210215__20210216_zZ6BZf04p37c" title="Debt conversion rate"><ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentRate" contextRef="From2021-02-152021-02-16" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3.40</ix:nonFraction></span> per share into <span id="xdx_904_eus-gaap--ConversionOfStockSharesConverted1_pid_c20210215__20210216_ze6kBBBndOO9" title="Conversion of common stock"><ix:nonFraction name="us-gaap:ConversionOfStockSharesConverted1" contextRef="From2021-02-152021-02-16" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,627,440</ix:nonFraction></span> shares of the Company&#8217;s
common stock.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 9.5pt 0pt 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Adoption
of ASU 2020-<span style="letter-spacing: -0.25pt">06</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 9.5pt 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 9.5pt 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
fiscal 2020, the Company recorded a note/debt discount of $<span id="xdx_907_eus-gaap--DebtInstrumentConvertibleBeneficialConversionFeature_pn5n6_c20200101__20201231__us-gaap--DebtInstrumentAxis__custom--AdoptionofAsuTwentyTwentyZeroSixMember__us-gaap--AwardDateAxis__custom--DuringTwentyTwentyMember_zdu21bJnGmzf" title="Beneficial conversion feature"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature" contextRef="From2020-01-012020-12-31_custom_AdoptionofAsuTwentyTwentyZeroSixMember_custom_DuringTwentyTwentyMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">4.7</ix:nonFraction></span> million&#160;to account for the beneficial conversion feature that existed
on the date of issuance for the above convertible notes payable. The debt discount was being amortized to interest expense over the term
of the corresponding convertible notes payable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 9.5pt 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 9.5pt 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 1, 2021 the Company chose to adopt ASU 2020-06, Debt-Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives
and Hedging-Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#8217;s
Own Equity. As a result of the adoption of ASU 2020-06, the Company extinguished the previously recorded debt discount of $<span id="xdx_900_eus-gaap--DebtInstrumentConvertibleBeneficialConversionFeature_pn5n6_c20220101__20220331__us-gaap--DebtInstrumentAxis__custom--AdoptionofAsuTwentyTwentyZeroSixMember__us-gaap--AwardDateAxis__custom--JanuaryOneTwentyTwentyOneMember_z4OGDfn5vSqh"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature" contextRef="From2022-01-012022-03-31_custom_AdoptionofAsuTwentyTwentyZeroSixMember_custom_JanuaryOneTwentyTwentyOneMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">4.7</ix:nonFraction></span> million&#160;by
charging the opening additional paid in capital at January 1, 2021. In addition, the Company also adjusted accumulated deficit to account
for the derecognition of the $<span id="xdx_90A_ecustom--InterestExpenseDueAmortizationOfDebtDiscount_iI_pn5n6_c20220331__us-gaap--DebtInstrumentAxis__custom--AdoptionofAsuTwentyTwentyZeroSixMember__us-gaap--AwardDateAxis__custom--DuringTwentyTwentyMember_zleabVONGvu4" title="Interest expense due amortization of debt discount"><ix:nonFraction name="GTBP:InterestExpenseDueAmortizationOfDebtDiscount" contextRef="AsOf2022-03-31_custom_AdoptionofAsuTwentyTwentyZeroSixMember_custom_DuringTwentyTwentyMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.2</ix:nonFraction></span> million&#160;interest expense due</span> to the amortization of the debt discount that was recorded
in fiscal 2020.<b>&#160;</b>As a result of these adjustments, the unamortized debt discount of $<span id="xdx_902_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_pn5n6_c20220331__us-gaap--DebtInstrumentAxis__custom--AdoptionofAsuTwentyTwentyZeroSixMember__us-gaap--AwardDateAxis__custom--JanuaryOneTwentyTwentyOneMember_zByyCyiGm7Ne" title="Unamortized debt discount"><ix:nonFraction name="us-gaap:DebtInstrumentUnamortizedDiscount" contextRef="AsOf2022-03-31_custom_AdoptionofAsuTwentyTwentyZeroSixMember_custom_JanuaryOneTwentyTwentyOneMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">4.5</ix:nonFraction></span> million&#160;was extinguished.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" escape="true" name="us-gaap:DerivativesAndFairValueTextBlock"><p id="xdx_80D_eus-gaap--DerivativesAndFairValueTextBlock_zuWnNIcIGt1" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Note
6 &#8211; <span id="xdx_82C_zV8MNW9ikHj1">Derivative Liability</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2020, the Company issued certain warrants that contained a fundamental transaction provision that could give
rise to an obligation to pay cash to the warrant holder upon occurrence of certain change in control type events. In accordance with
ASC 480, the fair value of these warrants is classified as a liability in the Condensed Consolidated Balance Sheet and will be
re- measured at the end of every reporting period with the change in value reported in the statement of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-03-31" escape="true" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"><p id="xdx_89F_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_zYcz0vlKIxW" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
derivative liabilities were valued using a Binomial pricing model with the following average assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B2_zdAyouL0Qnn4" style="display: none">Schedule
of Derivative Liabilities Assumptions</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">March 31</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December 31</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">2021</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0"></p></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; text-align: center"><b>(Unaudited)</b></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%">Stock Price</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><span id="xdx_904_eus-gaap--SharePrice_iI_pid_c20220331_zTYm3dbo2xX6" title="Stock Price"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.88</ix:nonFraction></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><span id="xdx_90B_eus-gaap--SharePrice_iI_pid_c20211231_z4R4jSPSkTu5" title="Stock Price"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.05</ix:nonFraction></span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Risk-free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_909_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20220331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zlyRpeVCVeh1" title="Risk-free interest rate"><ix:nonFraction name="us-gaap:DerivativeLiabilityMeasurementInput" contextRef="AsOf2022-03-31_us-gaap_MeasurementInputRiskFreeInterestRateMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">2.42</ix:nonFraction></span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90C_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zVp6pQCz6Owc" title="Risk-free interest rate"><ix:nonFraction name="us-gaap:DerivativeLiabilityMeasurementInput" contextRef="AsOf2021-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">1.26</ix:nonFraction></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90A_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20220331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zJ73JYTImDci" title="Expected volatility"><ix:nonFraction name="us-gaap:DerivativeLiabilityMeasurementInput" contextRef="AsOf2022-03-31_us-gaap_MeasurementInputPriceVolatilityMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">127</ix:nonFraction></span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90D_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zL20lNqzqNd1" title="Expected volatility"><ix:nonFraction name="us-gaap:DerivativeLiabilityMeasurementInput" contextRef="AsOf2021-12-31_us-gaap_MeasurementInputPriceVolatilityMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">129</ix:nonFraction></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected life (in years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90B_ecustom--DerivativeLiabilityFairValueAssumptionsExpectedTerm1_dtY_c20220101__20220331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zGvKIoyzrawk" title="Expected life (in years)"><ix:nonNumeric contextRef="From2022-01-012022-03-31_us-gaap_MeasurementInputExpectedTermMember" format="ixt-sec:duryear" name="GTBP:DerivativeLiabilityFairValueAssumptionsExpectedTerm1">3.3</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90E_ecustom--DerivativeLiabilityFairValueAssumptionsExpectedTerm1_dtY_c20210101__20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zE2HmJRBFaC1" title="Expected life (in years)"><ix:nonNumeric contextRef="From2021-01-012021-12-31_us-gaap_MeasurementInputExpectedTermMember" format="ixt-sec:duryear" name="GTBP:DerivativeLiabilityFairValueAssumptionsExpectedTerm1">3.6</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Expected dividend yield</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_dp_uPure_c20220331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zfp6Vho0rCQ3" title="Expected dividend yield" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0800">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_dp_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_z4ounqs98iX1" title="Expected dividend yield" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0802">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Fair Value of Warrants</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--FairValueAdjustmentOfWarrants_c20220101__20220331_zVo4G5kPuZi3" title="Fair value of warrants" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">120,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--FairValueAdjustmentOfWarrants_c20210101__20211231_zUYPRxq3FoNh" title="Fair value of warrants" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">138,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A9_z9WGbVISiQU3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
risk-free interest rate was based on rates established by the Federal Reserve Bank. The Company uses the historical volatility of its
common stock to estimate the future volatility for its common stock. The expected life of the derivative securities was determined by
the remaining contractual life of the derivative instrument. The expected dividend yield was based on the fact that the Company has not paid dividends to its common stockholders in the past
and does not expect to pay dividends to its common stockholders in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the three months ended March 31, 2022, the Company recognized a gain of $<span id="xdx_900_eus-gaap--DerivativeGainOnDerivative_c20220101__20220331_zXEqobUxBWpd"><ix:nonFraction name="us-gaap:DerivativeGainOnDerivative" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,000</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">to account for the change in fair value of the
derivative liability between the reporting periods in accordance with ASC 842.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" escape="true" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock"><p id="xdx_808_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zWMlWuj3AF94" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Note
7 &#8211; <span id="xdx_82F_zZ5QpLyKnDk9">Stockholders&#8217; Equity</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: normal 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-style: normal; font-weight: normal">The
Company&#8217;s authorized capital as of March 31, 2022 was <span id="xdx_904_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20220331_zCSijIPSZLW5" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">750,000,000</ix:nonFraction></span> shares of common stock, par value $<span id="xdx_909_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20220331_zvptnkaRREgg" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></span> per share, and <span id="xdx_908_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20220331_z1Npg8AXpNuj" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">15,000,000</ix:nonFraction></span>
shares of preferred stock, par value $<span id="xdx_90F_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20220331_zQqazY9UOWD1" title="Preferred stock, par value"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.01</ix:nonFraction></span> per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Common
Stock</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Common
Stock Issuable</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 16, 2021, as a result of the mandatory conversion of the notes payable and accrued interest in the aggregate amount of $<span id="xdx_909_eus-gaap--DebtConversionConvertedInstrumentAmount1_pn5n6_c20210215__20210216_zb8R93AKulg4"><ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentAmount1" contextRef="From2021-02-152021-02-16" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">38.8</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million, the Company issued a total of <span id="xdx_904_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_pid_c20210215__20210216_zI09xAIu2Jp9"><ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" contextRef="From2021-02-152021-02-16" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">11,413,322</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock to the respective noteholders,
of which <span id="xdx_907_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_pid_c20210101__20211231_zib2HLgLrT1j"><ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">11,086,024</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">were already issued as of December 31,
2021.</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> The remaining <span id="xdx_90B_eus-gaap--SharesIssued_iI_pid_c20211231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockIssuableMember_z6EOaou8B1L8"><ix:nonFraction name="us-gaap:SharesIssued" contextRef="AsOf2021-12-31_custom_CommonStockIssuableMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">327,298</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">common </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares
issuable at December 31, 2021 valued at $<span id="xdx_900_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn5n6_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__custom--CommonStockIssuableMember_z5aJXUB7Wzx5"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2022-01-012022-03-31_custom_CommonStockIssuableMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.1</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million,</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
were issued during the three months period ended March 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i><span style="text-decoration: underline">Cancellation of common stock</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the period ended March 31, 2022, the Company
cancelled and returned to authorized capital <span id="xdx_90D_eus-gaap--StockRepurchasedAndRetiredDuringPeriodShares_pid_c20220101__20220331_zh28nJx1ouJ5" title="Common shares cancelled and returned"><ix:nonFraction name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">290,999</ix:nonFraction></span> previously issued shares of common stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Equity
compensation to officers, employees, and board of directors</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As part of employment agreements with its former
CEO and its former CFO (&#8220;Officers&#8221;), the Officers received a fully vested stock grant equal to an aggregate of&#160;<span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_pid_dp_uPure_c20220101__20220331__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementsMember_zVMp8m7L5jf1" title="Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" contextRef="From2022-01-012022-03-31_srt_ChiefExecutiveOfficerMember_custom_EmploymentAgreementsMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">10</ix:nonFraction></span>% and&#160;<span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_pid_dp_uPure_c20220101__20220331__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementsMember_zmRVBIY3Qjf9" title="Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" contextRef="From2022-01-012022-03-31_srt_ChiefFinancialOfficerMember_custom_EmploymentAgreementsMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1.5</ix:nonFraction></span>%
of the fully diluted shares of common stock of the Company (calculated with the inclusion of the current stock holdings of the CEO) upon
conversion of options, warrants and Convertible Notes in association with a national markets qualified financing as consideration for
entering into the Agreement (with such stock to vest and be delivered within 30 days after the national markets qualified financing).
In addition, the Company also granted similar equity compensation to members of the Company&#8217;s board of directors wherein these
directors received stock grants equal to&#160;<span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_pid_dp_uPure_c20220101__20220331__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementsMember__srt--RangeAxis__srt--MinimumMember_zewLcFpVZw1g" title="Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" contextRef="From2022-01-012022-03-31_srt_DirectorMember_custom_EmploymentAgreementsMember_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1</ix:nonFraction></span>% and&#160;<span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_pid_dp_uPure_c20220101__20220331__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementsMember__srt--RangeAxis__srt--MaximumMember_z3xzAnQe2pcb" title="Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" contextRef="From2022-01-012022-03-31_srt_DirectorMember_custom_EmploymentAgreementsMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1.25</ix:nonFraction></span>% of the fully diluted shares of common stock of the Company.&#160;<span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_c20220101__20220331__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementsMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zXGci5T8VxFi" title="Share-based Compensation Arrangement by Share-based Payment Award, Description"><ix:nonNumeric contextRef="From2022-01-012022-03-31_custom_EmploymentAgreementsMember_srt_DirectorMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription">Pursuant
to the agreement, approximately 33% of the common stock to be issued vested immediately while the remaining</ix:nonNumeric></span>&#160;67% will vest over a
period of <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dc_c20220101__20220331_z3JB7VLGxlPf" title="Vesting period"><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">two years</ix:nonNumeric></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On February 16, 2021, the Company completed its
equity offering and listed its shares of common stock on the Nasdaq Capital Market. As such,&#160;<span id="xdx_900_ecustom--CommonStockSharesGrantedForConsultants_pid_c20210215__20210216_zpRJqgSrMxR9" title="Common stock shares granted for consultants"><ix:nonFraction name="GTBP:CommonStockSharesGrantedForConsultants" contextRef="From2021-02-152021-02-16" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,379,407</ix:nonFraction></span>&#160;shares of its common
stock were granted to these Officers, employees and board of directors, which had a fair value of $<span id="xdx_90E_ecustom--FairValueOfStockOptionsGrantedForConsultants_pn5n6_c20210215__20210216_zoQX27lrTJqa" title="Fair value of stock options granted f0r consultants"><ix:nonFraction name="GTBP:FairValueOfStockOptionsGrantedForConsultants" contextRef="From2021-02-152021-02-16" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">18.6</ix:nonFraction></span>&#160;million. Since the grant
of the common stock is subject to milestone or performance conditions, the Company measured the fair value of the common stock on the
respective date of the agreement, and such awards were recorded as compensation expense as the milestone or performance condition is
met and in accordance with its vesting terms.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the period ended March 31, 2021, the Company
recognized $<span id="xdx_906_eus-gaap--ShareBasedCompensation_pn5n6_c20210101__20210331__srt--TitleOfIndividualAxis__custom--EmployeesMember_z5IwEMH2Ti0f"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2021-01-012021-03-31_custom_EmployeesMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">14.3</ix:nonFraction></span> million of stock compensation expense related to vesting of shares to officers, employees and board of directors.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the period ended March 31, 2022, the Company
recognized $<span id="xdx_90B_eus-gaap--ShareBasedCompensation_c20220101__20220331__srt--TitleOfIndividualAxis__custom--EmployeesMember_zU9rwNamXxH5"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-01-012022-03-31_custom_EmployeesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">447,000</ix:nonFraction></span> of stock compensation expense related to vesting of shares to officers, employees and board of directors. <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of the remaining <span id="xdx_901_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedTounVestOutstandingNumber_iI_pid_c20220331__srt--TitleOfIndividualAxis__custom--OfficersEmployeesAndBoardOfDirectorsMember_z6bAYGFzRKnk"><ix:nonFraction name="GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedTounVestOutstandingNumber" contextRef="AsOf2022-03-31_custom_OfficersEmployeesAndBoardOfDirectorsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">291,700</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">unvested shares of common stock to officers,
employees and board of directors at March 31, 2022 was $<span id="xdx_90A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToUnVestOutstandingAggregateIntrinsicValue_iI_pn5n6_c20220331__srt--TitleOfIndividualAxis__custom--OfficersEmployeesAndBoardOfDirectorsMember_zk4fysE53Xuj"><ix:nonFraction name="GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToUnVestOutstandingAggregateIntrinsicValue" contextRef="AsOf2022-03-31_custom_OfficersEmployeesAndBoardOfDirectorsMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.4</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million and will be recognized as stock compensation
expense in future periods. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>


<ix:exclude><!-- Field: Page; Sequence: 13; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Issuance
of common shares for services</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As part of consulting agreements with certain
consultants, the Company agreed to grant these consultants common stock equal to&#160;<span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_pid_dp_uPure_c20210215__20210215__srt--RangeAxis__srt--MinimumMember_zE2MJgbn1Si8" title="Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" contextRef="From2021-02-152021-02-15_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1</ix:nonFraction></span>% and&#160;<span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_pid_dp_uPure_c20210215__20210215__srt--RangeAxis__srt--MaximumMember_z9q3JquBztld" title="Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" contextRef="From2021-02-152021-02-15_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3</ix:nonFraction></span>% of the fully diluted shares of common
stock of the Company upon conversion of options, warrants and Convertible Notes in association with a national markets qualified financing
as consideration for entering into the Agreement (with such stock to vest and be delivered within 30 days after the national markets
qualified financing).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On February 16, 2021, the Company completed its
equity offering and listed its shares of common stock on the Nasdaq Capital Market. As a result of this offering, the Company agreed
to issue to these consultants&#160;<span id="xdx_90C_eus-gaap--SharesIssued_iI_pid_c20210216_zIN88rZ4JMJe" title="Shares issued"><ix:nonFraction name="us-gaap:SharesIssued" contextRef="AsOf2021-02-16" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,850,090</ix:nonFraction></span>&#160;shares of common stock with a grant date fair value of $<span id="xdx_905_ecustom--CommonStockConsultantToFairValue_pn5n6_c20210215__20210216_zp3b2HWXjAlc" title="Common stock consultant to fair value"><ix:nonFraction name="GTBP:CommonStockConsultantToFairValue" contextRef="From2021-02-152021-02-16" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">10.7</ix:nonFraction></span>&#160;million,&#160;of
which&#160;<span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_pid_c20210216_zWAkJfHVFz21" title="Vested shares"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" contextRef="AsOf2021-02-16" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,934,817</ix:nonFraction></span>&#160;shares of common stock vested immediately while the remaining&#160;<span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pid_c20210215__20210216_zFJQBqsHU237" title="Remaining vested shares"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" contextRef="From2021-02-152021-02-16" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">915,273</ix:nonFraction></span>,&#160;shares of&#160;common stock
vests over <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dc_c20210215__20210216_z96yp33tIXV8" title="Vested period"><ix:nonNumeric contextRef="From2021-02-152021-02-16" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">two years</ix:nonNumeric></span>. Pursuant to current accounting guidelines, as the grant of the common stock is subject to milestone or performance
conditions, the Company measured the fair value of the common stock on the respective date of the agreement, and then such award is being
recorded as compensation expense based upon the vesting term of the grant.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the period ended March 31, 2021, the Company
recognized $<span id="xdx_90E_eus-gaap--ShareBasedCompensation_pn5n6_c20210101__20210331_zYxaVnBQydD9" title="Share based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2021-01-012021-03-31" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">8.5</ix:nonFraction></span> million of stock compensation expense related to the issuance of <span id="xdx_90C_eus-gaap--SharesIssued_iI_pid_c20210331_zOGACsz92y6b" title="Shares issued"><ix:nonFraction name="us-gaap:SharesIssued" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,957,374</ix:nonFraction></span> shares of common stock and the vesting of
shares to these consultants.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the period ended March 31, 2022, the</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> Company recognized
$<span id="xdx_906_eus-gaap--ShareBasedCompensation_c20220101__20220331__srt--TitleOfIndividualAxis__custom--ConsultingMember_zirSHx53TV9e"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-01-012022-03-31_custom_ConsultingMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">872,000</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of stock compensation expense related to the
issuance of <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensation_pid_c20220101__20220331__srt--TitleOfIndividualAxis__custom--ConsultingMember_zoOlMvkfQDji"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextRef="From2022-01-012022-03-31_custom_ConsultingMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">46,500</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock and the vesting of <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_pid_c20220101__20220331__srt--TitleOfIndividualAxis__custom--ConsultingMember_znxlirzZpaAb"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" contextRef="From2022-01-012022-03-31_custom_ConsultingMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">116,247</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock issued to consultants
for services in fiscal 2022. The fair value of the <span id="xdx_902_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedTounVestOutstandingNumber_iI_pid_c20220331__srt--TitleOfIndividualAxis__custom--ConsultingMember_zT64upi4Mp95"><ix:nonFraction name="GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedTounVestOutstandingNumber" contextRef="AsOf2022-03-31_custom_ConsultingMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">389,570</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">unvested shares of common stock to consultants
at March 31, 2022 was $<span id="xdx_90D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToUnVestOutstandingAggregateIntrinsicValue_iI_pn5n6_c20220331__srt--TitleOfIndividualAxis__custom--ConsultingMember_zO40t43rDWsj"><ix:nonFraction name="GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToUnVestOutstandingAggregateIntrinsicValue" contextRef="AsOf2022-03-31_custom_ConsultingMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.3</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million and will be recognized as stock compensation
expense in future periods. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Preferred
Stock</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Series
C Preferred Stock</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
March 31, 2022 and March 31, 2021, there were <span id="xdx_906_eus-gaap--PreferredStockSharesIssued_iI_c20220331__us-gaap--StatementClassOfStockAxis__custom--SeriesCPreferredStocksMember_zciSKlx8pGyb"><span id="xdx_90F_eus-gaap--PreferredStockSharesOutstanding_iI_c20220331__us-gaap--StatementClassOfStockAxis__custom--SeriesCPreferredStocksMember_zOzrPHLcdFi1"><span id="xdx_904_eus-gaap--PreferredStockSharesIssued_iI_c20210331__us-gaap--StatementClassOfStockAxis__custom--SeriesCPreferredStocksMember_zLQ9x9K2aSa2" title="Preferred stock, shares issued"><span id="xdx_908_eus-gaap--PreferredStockSharesOutstanding_iI_c20210331__us-gaap--StatementClassOfStockAxis__custom--SeriesCPreferredStocksMember_z5HX6ZLlhZb9" title="Preferred stock, shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2022-03-31_custom_SeriesCPreferredStocksMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2022-03-31_custom_SeriesCPreferredStocksMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2021-03-31_custom_SeriesCPreferredStocksMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2021-03-31_custom_SeriesCPreferredStocksMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">96,230</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of series C preferred stock, par value
$<span id="xdx_90F_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20220331__us-gaap--StatementClassOfStockAxis__custom--SeriesCPreferredStocksMember_zsYsghFFToT6"><span id="xdx_90B_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20210331__us-gaap--StatementClassOfStockAxis__custom--SeriesCPreferredStocksMember_zex8msIzdNQ6" title="Preferred stock, par value"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2022-03-31_custom_SeriesCPreferredStocksMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2021-03-31_custom_SeriesCPreferredStocksMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.01</ix:nonFraction></ix:nonFraction></span>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share (the &#8220;Series C Preferred Stock&#8221;)
issued and outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of reverse stock splits in previous years and the agreement terms for adjusting the rights of the related shares, the <span id="xdx_90D_eus-gaap--PreferredStockSharesIssued_iI_c20220331__us-gaap--StatementClassOfStockAxis__custom--SeriesCPreferredStocksMember_zuzkAd5Hlyvk"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2022-03-31_custom_SeriesCPreferredStocksMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">96,230</ix:nonFraction></span>
shares of Series C Preferred Stock are not currently convertible, have no voting rights, and in the event of liquidation, the holders
of the Series C Preferred Stock would not participate in any distribution of the assets or surplus funds of the Company. The holders
of Series C Preferred Stock also are not currently entitled to any dividends if and when declared by the Company&#8217;s board of directors
(the &#8220;Board&#8221;). No dividends to holders of the Series C Preferred Stock were issued or unpaid through March 31, 2022 and 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Series
K Preferred Stock</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 16, 2021, the Board designated <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20210215__20210216__us-gaap--StatementClassOfStockAxis__custom--SeriesKPreferredStocksMember_zFZKJ6mz6gJh" title="Preferred stock shares designated"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2021-02-152021-02-16_custom_SeriesKPreferredStocksMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">115,000</ix:nonFraction></span> shares of Series K preferred stock, par value $<span id="xdx_904_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20210216__us-gaap--StatementClassOfStockAxis__custom--SeriesKPreferredStocksMember_zsR1NQ5Ho7ak" title="Preferred stock, par value"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2021-02-16_custom_SeriesKPreferredStocksMember" decimals="INF" unitRef="USDPShares">.01</ix:nonFraction></span>. (the &#8220;Series K Preferred Stock&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
of the Series K Preferred Stock are convertible at any time, at the option of the holders, into shares of the Company&#8217;s common
stock at an effective conversion rate of <span id="xdx_90C_eus-gaap--PreferredStockConvertibleSharesIssuable_iI_c20210216__us-gaap--StatementClassOfStockAxis__custom--SeriesKPreferredStocksMember_zLXCxZzoLJz2" title="Convertible shares issuable"><ix:nonFraction name="us-gaap:PreferredStockConvertibleSharesIssuable" contextRef="AsOf2021-02-16_custom_SeriesKPreferredStocksMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">100</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock for each share of Series
K Preferred. Shares of the Series K Preferred Stock have the same voting rights as the shares of the Company&#8217;s common stock,
with the holders of the Series K Preferred Stock entitled to vote on an as-converted-to-common stock basis, subject to the beneficial
ownership limitation, together with the holders of the Company&#8217;s common stock on all matters presented to the Company&#8217;s stockholders.
The Series K Preferred Stock are not entitled to any dividends (unless specifically declared by the Board) but will participate on an
as-converted-to-common-stock basis in any dividends to the holders of the Company&#8217;s common stock. In the event of the Company&#8217;s
dissolution, liquidation or winding up, the holders of the Series K Preferred Stock will be on parity with the holders of the Company&#8217;s
common stock and will participate, on a on an as-converted-to-common stock basis, in any distribution to holders of the Company&#8217;s
common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 31, 2022 and December 31, 2021, there were <span id="xdx_90C_eus-gaap--PreferredStockSharesOutstanding_iI_pid_do_c20220331__us-gaap--StatementClassOfStockAxis__custom--SeriesKPreferredStocksMember_zT5m1bkb3zR6" title="Preferred stock, shares outstanding"><span id="xdx_905_eus-gaap--PreferredStockSharesIssued_iI_pid_do_c20220331__us-gaap--StatementClassOfStockAxis__custom--SeriesKPreferredStocksMember_zSAFXILRmPX5" title="Preferred stock, shares issued"><span id="xdx_902_eus-gaap--PreferredStockSharesOutstanding_iI_pid_do_c20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesKPreferredStocksMember_zDbF8m0J4eDc" title="Preferred stock, shares outstanding"><span id="xdx_90B_eus-gaap--PreferredStockSharesIssued_iI_pid_do_c20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesKPreferredStocksMember_zhOunByS1yXf" title="Preferred stock, shares issued"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2022-03-31_custom_SeriesKPreferredStocksMember" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2022-03-31_custom_SeriesKPreferredStocksMember" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2021-12-31_custom_SeriesKPreferredStocksMember" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2021-12-31_custom_SeriesKPreferredStocksMember" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span></span> shares of Series K Preferred stock issued and outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Warrants
and Options</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Common
Stock Warrants</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-03-31" escape="true" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"><p id="xdx_894_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_z1QoQDPZe3W6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock
warrant transactions for the three months ended March 31, 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BF_zL76BPA8JD5d" style="display: none">Schedule
of  Warrant Activity</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Weighted Average</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Warrants
</b></span></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Exercise Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%">Outstanding at December 31, 2021:</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20220101__20220331_zmsj6DS0orD9" title="Warrants Outstanding,Beginning Balance" style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,337,274</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20220101__20220331_z4mRwCIdZ5oh" title="Weighted Average Exercise Price, Beginning Balance" style="width: 16%; text-align: right"><ix:nonFraction name="GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.30</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20220101__20220331_zbM6PbxiHEng" title="Number of Warrants, Granted" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0899">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue_pid_c20220101__20220331_zWMlhOOt7pG9" title="Weighted Average Exercise Price, Granted" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0901">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Forfeited/canceled</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeited_iN_pid_di_c20220101__20220331_zJcvJ1Sr3zF5" title="Number of Warrants, Forfeited" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0903">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue_pid_c20220101__20220331_zHF7dlCWyH6b" title="Weighted Average Exercise Price, Forfeited" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0905">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Exercised</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20220101__20220331_zEoGKelxWMke" title="Number of Warrants, Exercised" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0907">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20220101__20220331_zJhvs1KP25ji" title="Weighted Average Exercise Price, Exercised" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0909">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Warrants outstanding at March 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20220101__20220331_zNxAOaFzLKi4" title="Warrants Outstanding, Ending Balance" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,337,274</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20220101__20220331_zOiOMdTfCkzf" title="Weighted Average Exercise Price, Ending Balance" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.30</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Warrants exercisable at March 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable_iI_pid_c20220331_zZkuBvyoStr2" title="Warrants Exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,337,274</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20220331_zXXcxag5t8Eb" title="Exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.30</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AE_zgZCApjehyrk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 31, 2022, all issued and outstanding warrants are fully vested, and have no intrinsic value as the exercise price of
these warrants was greater than the market price.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Common
Stock Options</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-03-31" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"><p id="xdx_89C_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zoV3yKJSBuWf" style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock option transactions for the three
months ended March 31, 2022:</span></p>



<p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B9_zbXKwz9p29kb" style="display: none">Schedule
of Options Activity</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Weighted Average</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Exercise Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%">Options outstanding at December 31, 2021:</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20220101__20220331_zgPtBAAs4vk7" title="Options outstanding, beginning" style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">302,500</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20220101__20220331_zE8is2UMksP7" title="Exercise Price of Warrants or Rights" style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.05</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20220101__20220331_zWfdsNbefRzg" title="Number of Options, Granted" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0925">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20220101__20220331_zCzO2SX6nm6f" title="Weighted Average Exercise Price, Granted" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0927">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Forfeited/canceled</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_pid_c20220101__20220331_zSaLArFlb7P8" title="Number of Options, Forfeited" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0929">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20220101__20220331_zqEnKSqrIMnh" title="Weighted Average Exercise Price, Forfeited" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0931">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Exercised</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionEquityInstrumentsExercised_pid_c20220101__20220331_zwky8LS3Vypk" title="Number of Options, Exercised" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0933">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20220101__20220331_zqYEMfzBiDXc" title="Weighted Average Exercise Price, Exercised" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0935">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Options outstanding at March 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20220101__20220331_zhwZPBmMv7s9" title="Options outstanding, Ending" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">302,500</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20220101__20220331_zBa7eB8VWFWa" title="Exercise Price of Warrants or Rights" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.05</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Options exercisable at March 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20220331_zkSnJVkHaEY5" title="Options exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">111,215</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20220331_zHow2t57AW68" title="Options Exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.05</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A8_zMLgyvdFhbj7" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 14; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
March 31, 2022, there were <span id="xdx_90B_ecustom--NumberofsharesUnvestedOptions_c20220101__20220331_zmrp065Zosng" title="Number of shares unvested"><ix:nonFraction name="GTBP:NumberofsharesUnvestedOptions" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">191,285</ix:nonFraction></span> unvested options with a grant date fair value of $<span id="xdx_90D_ecustom--NumberofValueUnvestedOptions_c20220101__20220331_zNXH7h0vhBKl" title="Number of shares unvested, value"><ix:nonFraction name="GTBP:NumberofValueUnvestedOptions" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">511,115</ix:nonFraction></span> which will be recognized as stock compensation
in future periods based upon the remaining vesting term of the applicable grants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
was <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_do_c20220331_zwK3tFSJaAE6" title="Options outstanding intrinsic value"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2022-03-31" format="ixt-sec:numwordsen" decimals="0" unitRef="USD">no
</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">intrinsic value of the outstanding options as
of March 31, 2022 as the exercise price of these options was greater than the market price.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" escape="true" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock"><p id="xdx_800_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zkNEWs4XXv5" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Note
8 &#8211; <span id="xdx_829_z5ILQcczdnc9">Commitments and Contingencies</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.7pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Litigation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> involved in certain legal proceedings
that arise from time to time in the ordinary course of our business. Except for income tax contingencies, we record accruals for contingencies
to the extent that our management concludes that the occurrence is probable and that the related amounts of loss can be reasonably estimated.
Legal expenses associated with the contingency are expensed as incurred. There is no current or pending litigation of any significance
with the exception of the matters that have arisen under, and are being handled in, the normal course of business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On
August 28, 2019, a complaint was filed in the Superior Court of California, County of Los Angeles, West Judicial District, Santa Monica
Courthouse, Unlimited Civil Division by Jeffrey Lion, an individual (&#8220;Lion&#8221;), and by Daniel Vallera, an individual (&#8220;Vallera&#8221;).
Lion and Vallera are referred to jointly as the &#8220;Plaintiffs.&#8221; The complaint was filed against GT Biopharma, Inc. and its
subsidiary Oxis Biotech, Inc. (either of them or jointly, the &#8220;Company&#8221;). The Plaintiffs alleged breach of a license agreement
between the Plaintiffs and the Company entered into on or about September 3, 2015. A settlement of the case was reached on February 7,
2022 in the amount of $<span id="xdx_90B_eus-gaap--LitigationSettlementExpense_c20220206__20220207_zNoVfISTexhd" title="Litigation settlement expense"><ix:nonFraction name="us-gaap:LitigationSettlementExpense" contextRef="From2022-02-062022-02-07" format="ixt:numdotdecimal" decimals="0" unitRef="USD">425,000</ix:nonFraction></span>. This amount was fully accrued at December 31, 2021. The settlement amount was subsequently paid on March
4, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Significant Agreements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and Development Agreements</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is a party to a scientific research agreement with the Regents of the University of Minnesota, effective June 16, 2021. This
scientific research agreement aims to work with the Company with three major goals in mind: (1) support the Company&#8217;s TriKE<sup>&#174;
</sup>product development and GMP manufacturing efforts; (2) TriKE<sup>&#174;</sup> pharmacokinetics optimization in humans; and (3) investigation
of the patient&#8217;s native NK cell population based on insights obtained from the analysis of the human data generated during our
GTB-3550 clinical trial. The major deliverables proposed here are: (1) creation of IND enabling data for TriKE<sup>&#174;</sup> constructs
in support of our product development and GMP manufacturing efforts; (2) TriKE<sup>&#174;</sup> platform drug delivery changes to allow
transition to alternative drug delivery means and extended PK in humans; and (3) gain an increased understanding of changes in the patient&#8217;s
native NK cell population as a result of TriKE<sup>&#174; </sup>therapy. Most studies will use TriKE<sup>&#174;</sup> DNA/amino acid sequences
created by us under current UMN/GTB licensing terms. The term of this agreement shall expire on June 30, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
University of Minnesota shall use reasonable efforts to complete the project for a fixed sum of $<span id="xdx_903_ecustom--ProjectFee_pn5n6_c20220101__20220331_zdoinf8BizIf" title="Project fees"><ix:nonFraction name="GTBP:ProjectFee" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">2.1</ix:nonFraction></span> million. The Company recorded expense
of $<span id="xdx_90B_ecustom--RecordedExpenses_pn5n6_c20220101__20220331_zqI1cqtO9sb9" title="Recorded expenses"><ix:nonFraction name="GTBP:RecordedExpenses" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.1</ix:nonFraction></span> million through March 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--OtherCommitmentsDescription_c20201001__20201005_z25qPgmWY3Lg" title="Other commitments, description"><ix:nonNumeric contextRef="From2020-10-012020-10-05" name="us-gaap:OtherCommitmentsDescription">On
October 5, 2020, GT Biopharma entered into a Master Services Agreement with a third-party product manufacturer to perform biologic development
and manufacturing services on behalf of the Company. Associated with this, the Company has subsequently signed five Statements of Work
for the research and development of products for use in clinical trials. At March 31 2022, the Company&#8217;s commitments in relation
to these Statements of Work and any related Change Orders totaled approximately $<span id="xdx_905_ecustom--ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurred_pn5n6_c20220101__20220331__us-gaap--TypeOfArrangementAxis__custom--MasterServicesAgreementMember__dei--LegalEntityAxis__custom--CytovanceBiologicsIncMember_z4IqnhIZpFF4" title="Commitment amount for services, total"><ix:nonFraction name="GTBP:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurred" contextRef="From2022-01-012022-03-31_custom_MasterServicesAgreementMember_custom_CytovanceBiologicsIncMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">13.0</ix:nonFraction></span> million, of which $<span id="xdx_908_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross_pn5n6_c20220101__20220331__us-gaap--TypeOfArrangementAxis__custom--MasterServicesAgreementMember__dei--LegalEntityAxis__custom--CytovanceBiologicsIncMember_z2invhO1hb5" title="Commitment cost incurred"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" contextRef="From2022-01-012022-03-31_custom_MasterServicesAgreementMember_custom_CytovanceBiologicsIncMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">8.4</ix:nonFraction></span> million was incurred at
that date and an additional $<span id="xdx_90D_ecustom--ResearchAndDevelopmentArrangementContractToPerformExpectedCostsIncurred_pn5n6_c20220101__20220331__us-gaap--TypeOfArrangementAxis__custom--MasterServicesAgreementMember__dei--LegalEntityAxis__custom--CytovanceBiologicsIncMember_z8h1UDfF6TIg" title="Compensation cost expected to be incurred in future"><ix:nonFraction name="GTBP:ResearchAndDevelopmentArrangementContractToPerformExpectedCostsIncurred" contextRef="From2022-01-012022-03-31_custom_MasterServicesAgreementMember_custom_CytovanceBiologicsIncMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">4.6</ix:nonFraction></span> million is in process during fiscal year 2022</ix:nonNumeric></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patent
and License Agreements</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>2016
Exclusive Patent License Agreement</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is party to an exclusive worldwide license agreement with the Regents of the University of Minnesota, (&#8220;UofMN&#8221;),
to further develop and commercialize cancer therapies using TriKE<sup>&#174;</sup> technology developed by researchers at the UofMN to
target NK cells to cancer. Under the terms of the 2016 agreement, the Company receives exclusive rights to conduct research and to develop,
make, use, sell, and import TriKE<sup>&#174;</sup> technology worldwide for the treatment of any disease, state, or condition in humans.
The Company is responsible for obtaining all permits, licenses, authorizations, registrations, and regulatory approvals required or granted
by any governmental authority anywhere in the world that is responsible for the regulation of products such as the TriKE<sup>&#174;</sup>
technology, including without limitation the FDA and the European Agency for the Evaluation of Medicinal Products in the European Union.
Under the agreement, the UofMN received an upfront payment of $<span id="xdx_903_ecustom--ProceedsFromUpfrontAmount_iI_pn5n6_c20220331__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_z9K1qR4xc8R4"><ix:nonFraction name="GTBP:ProceedsFromUpfrontAmount" contextRef="AsOf2022-03-31_custom_TwoThousandSixteenPatentLicenseAgreementMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.2</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million, and an annual License Maintenance fee
of $<span id="xdx_90C_ecustom--AnnualMaintananceFee_pn5n6_c20220101__20220331__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zGmFyuGQglu6"><ix:nonFraction name="GTBP:AnnualMaintananceFee" contextRef="From2022-01-012022-03-31_custom_TwoThousandSixteenPatentLicenseAgreementMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.1</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million beginning in 2021. The agreement also
includes <span id="xdx_903_ecustom--RoyaltyFeePercentage_pid_dp_uPure_c20220101__20220331__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zKl4mAtYvDkf"><ix:nonFraction name="GTBP:RoyaltyFeePercentage" contextRef="From2022-01-012022-03-31_custom_TwoThousandSixteenPatentLicenseAgreementMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4</ix:nonFraction>%
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">royalty fees, (not to exceed 6%) under
subsequent license agreements or amendments to this agreement or minimum annual royalty payments ranging from $<span id="xdx_90E_ecustom--AnnualRoyaltyPayments_pn4n6_c20220101__20220331__srt--RangeAxis__srt--MinimumMember__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_ztyoCtKLY0Ll"><ix:nonFraction name="GTBP:AnnualRoyaltyPayments" contextRef="From2022-01-012022-03-31_srt_MinimumMember_custom_TwoThousandSixteenPatentLicenseAgreementMember" format="ixt:numdotdecimal" decimals="-4" scale="6" unitRef="USD">0.25</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million to $<span id="xdx_905_ecustom--AnnualRoyaltyPayments_pn5n6_c20220101__20220331__srt--RangeAxis__srt--MaximumMember__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zgaQhcCqFhM8"><ix:nonFraction name="GTBP:AnnualRoyaltyPayments" contextRef="From2022-01-012022-03-31_srt_MaximumMember_custom_TwoThousandSixteenPatentLicenseAgreementMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">5.0</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million. The agreement also includes certain
performance milestone payments totaling $<span id="xdx_907_ecustom--PerformanceMilestonePayments_pn5n6_c20220101__20220331__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zrwhEO0YkQh9"><ix:nonFraction name="GTBP:PerformanceMilestonePayments" contextRef="From2022-01-012022-03-31_custom_TwoThousandSixteenPatentLicenseAgreementMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">3.1</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million, and one-time sales milestone payments
of $<span id="xdx_907_ecustom--SalesMilestonePayments_pn5n6_c20220101__20220331__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zPuMtqyAwnWl"><ix:nonFraction name="GTBP:SalesMilestonePayments" contextRef="From2022-01-012022-03-31_custom_TwoThousandSixteenPatentLicenseAgreementMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.0</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million upon reaching $<span id="xdx_901_ecustom--GrossSales_pn6n6_c20220101__20220331__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_z6mqku6t5Pif"><ix:nonFraction name="GTBP:GrossSales" contextRef="From2022-01-012022-03-31_custom_TwoThousandSixteenPatentLicenseAgreementMember" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">250</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million in gross sales, and $<span id="xdx_905_ecustom--SalesRevenue_pn5n6_c20220101__20220331__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zMy56DuChP9"><ix:nonFraction name="GTBP:SalesRevenue" contextRef="From2022-01-012022-03-31_custom_TwoThousandSixteenPatentLicenseAgreementMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">5.0</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million upon reaching $<span id="xdx_900_ecustom--CummulativeGrossSales_pn6n6_c20220101__20220331__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zOhmnnYP5Qt1"><ix:nonFraction name="GTBP:CummulativeGrossSales" contextRef="From2022-01-012022-03-31_custom_TwoThousandSixteenPatentLicenseAgreementMember" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">500</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million dollars in cumulative gross sales of
Licensed Products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 15; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>2021
Patent License Agreement</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 26, 2021, the Company signed an agreement specific to the B7H3 targeted TriKE<sup>&#174;</sup>. Under the agreement, the UofMN received
an upfront license fee of $<span id="xdx_90A_ecustom--UpfrontLicenseFee_c20210325__20210326__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_zgyPliO9g329" title="Upfront license fee"><ix:nonFraction name="GTBP:UpfrontLicenseFee" contextRef="From2021-03-252021-03-26_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,000</ix:nonFraction></span> and will receive an annual License Maintenance fee of $<span id="xdx_902_ecustom--LicenseMaintenanceFeeReceivable_iI_c20220331__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_z4DarsZtep43" title="License maintenance fee, receivable"><ix:nonFraction name="GTBP:LicenseMaintenanceFeeReceivable" contextRef="AsOf2022-03-31_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,000</ix:nonFraction></span> beginning in 2022, <span id="xdx_906_ecustom--NetSalesPercentage_pid_dp_uPure_c20220101__20220331__srt--RangeAxis__srt--MinimumMember__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_zycDcOcLhsG3" title="Net sales percentage"><ix:nonFraction name="GTBP:NetSalesPercentage" contextRef="From2022-01-012022-03-31_srt_MinimumMember_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">2.5</ix:nonFraction>%</span> to <span id="xdx_904_ecustom--NetSalesPercentage_pid_dp_uPure_c20220101__20220331__srt--RangeAxis__srt--MaximumMember__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_zncDE4bb855f" title="Net sales percentage"><ix:nonFraction name="GTBP:NetSalesPercentage" contextRef="From2022-01-012022-03-31_srt_MaximumMember_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5</ix:nonFraction>%</span> royalty
fees, or minimum annual royalty payments of $<span id="xdx_900_ecustom--AnnualRoyaltyPayments_pn4n6_c20220101__20220331__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_zhR2MH5smYl" title="Annual royalty payments"><ix:nonFraction name="GTBP:AnnualRoyaltyPayments" contextRef="From2022-01-012022-03-31_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember" format="ixt:numdotdecimal" decimals="-4" scale="6" unitRef="USD">0.25</ix:nonFraction></span> million beginning in the year after the first commercial sales of Licensed Product,
and $<span id="xdx_906_ecustom--MaintananceFee_pn5n6_c20220101__20220331__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_zNZRerpobAgl" title="Maintanance fee"><ix:nonFraction name="GTBP:MaintananceFee" contextRef="From2022-01-012022-03-31_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">2.0</ix:nonFraction></span> million beginning in the fifth year after the first commercial sale of such Licensed Product. The agreement also includes certain
performance milestone payments totaling $<span id="xdx_909_ecustom--PerformanceMilestonePayments_pn5n6_c20220101__20220331__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_zfkyZl5G4bl8" title="Performance milestone payments"><ix:nonFraction name="GTBP:PerformanceMilestonePayments" contextRef="From2022-01-012022-03-31_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">3.1</ix:nonFraction></span> million-, and one-time sales milestone payments of $<span id="xdx_904_ecustom--SalesMilestonePayments_pn5n6_c20220101__20220331__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_zXmlmRHF5E69" title="Sales milestone payments"><ix:nonFraction name="GTBP:SalesMilestonePayments" contextRef="From2022-01-012022-03-31_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.0</ix:nonFraction></span> million upon reaching $<span id="xdx_901_ecustom--GrossSales_pn6n6_c20220101__20220331__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_zx4cZYsF6EF1" title="Gross sales"><ix:nonFraction name="GTBP:GrossSales" contextRef="From2022-01-012022-03-31_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">250</ix:nonFraction></span> million
in gross sales, and $<span id="xdx_90C_ecustom--SalesRevenue_pn5n6_c20220101__20220331__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_zOOXqVYoN219" title="Sales revenue"><ix:nonFraction name="GTBP:SalesRevenue" contextRef="From2022-01-012022-03-31_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">5.0</ix:nonFraction></span> million upon reaching $<span id="xdx_907_ecustom--CummulativeGrossSales_pn6n6_c20220101__20220331__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_zs18T8hPDJtd" title="Cummulative gross sales"><ix:nonFraction name="GTBP:CummulativeGrossSales" contextRef="From2022-01-012022-03-31_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">500</ix:nonFraction></span> million dollars in cumulative gross sales of Licensed Products. There is no double
payment intended; if one of the milestone payments has been paid under the 2016 agreement no further payment is due for the corresponding
milestone above.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lease
Agreements</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 16.95pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 19, 2021 the Company entered into a sublease with Aimmune Therapeutics, Inc. for <span id="xdx_900_eus-gaap--AreaOfLand_iI_uSqft_c20211119__srt--CounterpartyNameAxis__custom--AimmuneTherapeuticsIncMember_zjcfzQNqhB9d" title="Area of land"><ix:nonFraction name="us-gaap:AreaOfLand" contextRef="AsOf2021-11-19_custom_AimmuneTherapeuticsIncMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Sqft">4,500</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">square feet of office space located in Brisbane,
California having a <span id="xdx_90E_eus-gaap--LesseeOperatingSubleaseOptionToExtend_c20211118__20211119__srt--CounterpartyNameAxis__custom--AimmuneTherapeuticsIncMember_zIoZsJGUss27" title="Commencement date"><ix:nonNumeric contextRef="From2021-11-182021-11-19_custom_AimmuneTherapeuticsIncMember" name="us-gaap:LesseeOperatingSubleaseOptionToExtend">commencement
date of January 1, 2022 and maturing on June 30, 2024</ix:nonNumeric></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
Additionally, on February 8, 2022, the Company entered into a lease of a photocopier, which matures on February 7, 2025. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Rent expense related to these leases reflected
on the Company&#8217;s Condensed Consolidated Statements of Operations totaled $<span id="xdx_90A_eus-gaap--PaymentsForRent_c20220101__20220331_zBCFA3X6efk7" title="Rent expense"><ix:nonFraction name="us-gaap:PaymentsForRent" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">29,000</ix:nonFraction></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-03-31" escape="true" name="GTBP:ScheduleOfOtherInformationRelatedLeasesUnderNOnCancellableTableTextBlock"><p id="xdx_891_ecustom--ScheduleOfOtherInformationRelatedLeasesUnderNOnCancellableTableTextBlock_zLGVnlqeHhB2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
information related to leases and future minimum lease payments under non-cancellable operating leases were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span><span><span id="xdx_8B1_zfme6KpWNgD8" style="display: none">Schedule of Other Information Related Leases Under Non-Cancellable</span></span>&#160;</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>March 31, 2022</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Unaudited)</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-style: normal; font-weight: normal; text-align: left">Cash paid for amounts included in the measurement of lease liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 82%; text-align: left">Operating cash flows from operating leases</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--OperatingLeasePayments_c20220101__20220331_zOvD28bx9yKi" title="Operating cash flows from operating leases" style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeasePayments" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">20,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-style: normal; font-weight: normal; text-align: left">Right-of-use assets obtained in exchange for lease liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Operating leases</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_c20220101__20220331_zrJwZZ6jXZO1" title="Right of use assets operating leases" style="text-align: right"><ix:nonFraction name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">260,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-style: normal; font-weight: normal; text-align: left">Weighted-average remaining lease term (in years):</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Operating leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90E_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20220331_ziwy9rtDmqjj" title="Weighted average remaining lease term operating leases"><ix:nonNumeric contextRef="AsOf2022-03-31" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1">2.5</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-style: normal; font-weight: normal; text-align: left">Weighted-average discount rate:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Operating leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_900_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20220331_zDW9dVBUYrN2" title="Weighted average discount rate operating leases"><ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">10</ix:nonFraction></span></td><td style="text-align: left">%</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AF_zec0kjqf9Sa8" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-03-31" escape="true" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock"><p id="xdx_897_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zgOezNxtO318" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future
minimum lease payments under non-cancellable operating leases were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B0_zJPDTRAHFnQc" style="display: none">Schedule
of Future Minimum Lease Payments</span>&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_491_20220331_z6qXdtgac6aa" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>March 31, 2022</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Unaudited)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_maOLLzd8y_zLQ1XYQeq8Nc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 82%; text-align: left">Within one year</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">90,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maOLLzd8y_zPfQgTZaLSF7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">After one year and within two years</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">122,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maOLLzd8y_zwEDGHHMoiG5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">After two years and within three years</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">65,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_iI_maOLLzd8y_zW30AWZmxwJ3" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Thereafter</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl1023">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--OperatingLeaseLiability_iTI_mtOLLzd8y_zHteqIgSavc2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total future minimum lease payments</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">277,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_zPnXSc3irq71" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Less &#8211; discount</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">30,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_zRs1RhF2rN3i" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Lease liability</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">247,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

</ix:nonNumeric></ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" escape="true" name="us-gaap:SubsequentEventsTextBlock"><p id="xdx_809_eus-gaap--SubsequentEventsTextBlock_z3ofp2iCfzj7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note
9 - <span id="xdx_824_zyRotnA9YbJ8">Subsequent Events</span></b></p>

<p style="font: normal 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-style: normal; font-weight: normal">&#160;</span></p>

<p style="font: normal 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-style: normal; font-weight: normal">On
April 29, 2022, the Company entered into a settlement agreement with its former Chief Executive Officer (&#8220;Officer&#8221;) and received
<span id="xdx_902_eus-gaap--StockRepurchasedDuringPeriodShares_pid_c20220428__20220429__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_ztJetsFNl71d" title="Number of shares received"><ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodShares" contextRef="From2022-04-282022-04-29_us-gaap_SubsequentEventMember_srt_ChiefExecutiveOfficerMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,845,000</ix:nonFraction></span> shares of its common stock in full and final settlement of all its claims against the Officer. The common stock certificates
were received by the Company on May 2, 2022 and the common shares were subsequently cancelled.</span></p>

</ix:nonNumeric><p id="xdx_81F_zaQoaGCB3zYc" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 16; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="sur_006"></span>Item
2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations. CAUTIONARY NOTICE REGARDING FORWARD-LOOKING
STATEMENTS</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Some
of the statements in this Quarterly Report on Form 10-Q are &#8220;forward-looking statements&#8221; within the meaning of the safe harbor
from liability established by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding
our current beliefs, goals and expectations about matters such as our expected financial position and operating results, our business
strategy and our financing plans. The forward-looking statements in this report are not based on historical facts, but rather reflect
the current expectations of our management concerning future results and events. The forward-looking statements generally can be identified
by the use of terms such as &#8220;believe,&#8221; &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221;
&#8220;foresee,&#8221; &#8220;may,&#8221; &#8220;guidance,&#8221; &#8220;estimate,&#8221; &#8220;potential,&#8221; &#8220;outlook,&#8221;
&#8220;target,&#8221; &#8220;forecast,&#8221; &#8220;likely&#8221; or other similar words or phrases. Similarly, statements that describe
our objectives, plans or goals are, or may be, forward-looking statements. Forward-looking statements involve known and unknown risks,
uncertainties and other factors that may cause our actual results, performance or achievements to be different from any future results,
performance and achievements expressed or implied by these statements. We cannot guarantee that our forward-looking statements will turn
out to be correct or that our beliefs and goals will not change. Our actual results could be very different from and worse than our expectations
for various reasons. You should review carefully all information, including the discussion of risk factors under &#8220;Part I. Item
1A: Risk Factors&#8221; and &#8220;Part II. Item 7: Management&#8217;s Discussion and Analysis of Financial Condition and Results of
Operations&#8221; of the Form 10-K for the year ended December 31, 2021. Any forward-looking statements in the Form 10-Q are made only
as of the date hereof and, except as may be required by law, we do not have any obligation to publicly update any forward-looking statements
contained in this Form 10-Q to reflect subsequent events or circumstances.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Throughout
this Quarterly Report on Form 10-Q, the terms &#8220;GTBP,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; &#8220;the company&#8221;
and &#8220;our company&#8221; refer to GT Biopharma, Inc., a Delaware corporation formerly known as Oxis International, Inc., DDI Pharmaceuticals,
Inc. and Diagnostic Data, Inc, together with our subsidiaries.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Overview</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a clinical stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products based
off our proprietary Tri-specific Killer Engager (TriKE<sup>&#174;</sup>) fusion protein immune cell engager technology platform. Our TriKE<sup>&#174;
</sup>platform generates proprietary therapeutics designed to harness and enhance the cancer killing abilities of a patient&#8217;s
own natural killer cells, or NK cells. Once bound to an NK cell, our moieties are designed to enhance the NK cell, and precisely direct
it to one or more specifically targeted proteins expressed on a specific type of cancer cell or virus infected cell, ultimately resulting
in the targeted cell&#8217;s death. TriKE<sup>&#174;</sup> can be designed to target any number of tumor antigens on hematologic malignancies,
sarcomas or solid tumors and do not require patient-specific customization.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are using our TriKE<sup>&#174;</sup> platform with the intent to bring to market immuno-oncology products that can treat a range of hematologic
malignancies, sarcoma and solid tumors. The platform is scalable, and we are putting processes in place to be able to produce IND-ready
moieties in a timely manner after a specific TriKE<sup>&#174;</sup> conceptual design. After conducting market and competitive research,
specific moieties can then be advanced into the clinic on our own or through potential collaborations with larger companies. We are also
evaluating, in conjunction with our Scientific Advisory Board, additional moieties designed to target different tumor antigens. We believe
our TriKE<sup>&#174;</sup> may have the ability, if approved for marketing, to be used as a monotherapy, augment the current monoclonal
antibody therapeutics, be used in conjunction with more traditional cancer therapy and potentially overcome certain limitations of current
chimeric antigen receptor, or CAR-T, therapy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are also using our TriKE<sup>&#174;</sup> platform to develop therapeutics useful for the treatment of infectious disease such as for
the treatment of patients infected by the human immunodeficiency virus (HIV). While the use of anti-retroviral drugs has substantially
improved the health and increased the longevity of individuals infected with HIV, these drugs are designed to suppress virus replication
to help modulate progression to AIDS and to limit further transmission of the virus. Despite the use of anti-retroviral drugs, infected
individuals retain reservoirs of latent HIV-infected cells that, upon cessation of anti-retroviral drug therapy, can reactivate and re-establish
an active HIV infection. For a curative therapy, destruction of these latent HIV infected cells must take place. The HIV- TriKE<sup>&#174;
</sup>contains the antigen binding fragment (Fab) from a broadly neutralizing antibody targeting the HIV-Env protein. The HIV- TriKE<sup>&#174;
</sup>is designed to target HIV while redirecting NK cell killing specifically to actively replicating HIV infected cells. The HIV- TriKE<sup>&#174;
</sup>induced NK cell proliferation, and demonstrated the ability in vitro to reactivate and kill HIV-infected T-cells. These findings
indicate a potential role for the HIV- TriKE<sup>&#174;</sup> in the reactivation and elimination of the latently infected HIV reservoir
cells by harnessing the NK cell&#8217;s ability to mediate the antibody-directed cellular cytotoxicity (ADCC).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
initial work has been conducted in collaboration with the Masonic Cancer Center at the University of Minnesota under a program led by
Dr. Jeffrey Miller, the Deputy Director. Dr. Miller is a recognized leader in the field of NK cell and IL-15 biology and their therapeutic
potential. We have exclusive rights to the TriKE<sup>&#174;</sup> platform and are generating additional intellectual property.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 17; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Results
of Operations</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Comparison
of the Three Months Ended March 31, 2022 and 2021</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Research
and Development Expenses</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the three months ended March 31, 2022 and 2021, we incurred $2.1 million and $1.6 million of research and development expenses, an increase
of $500,000. Research and development costs increased primarily due to the addition of employees.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Selling,
general and administrative expenses</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the three months ended March 31, 2022 and 2021, we incurred $3.4 million and $27.4 million of selling, general and administrative
expenses. The decrease in selling, general and administrative expenses is primarily attributable to a decrease in stock-based compensation
to consultants,  officers and directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Interest
Income</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest
income was $8,000 and $0 for the three months ended March 31, 2022 and 2021 respectively. The increase in interest income is due
to the interest earned in the three months ended March 31, 2022 as compared to the same comparable period in 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Interest
Expense</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest
expense was $0 and $696,000 for the three months ended March 31, 2022 and 2021 respectively. The decrease in interest expense is due
to the conversion of notes payable to common shares during 2021. The Company did not have any outstanding notes payable
as of and during the period ended March 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Change
in fair value of derivative liability</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
change in fair value of derivative liability due to remeasurement was a gain of $18,000 for the three months ended March 31, 2022
as compared to a $21,000 gain for the three months ending March 31, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Unrealized
loss on marketable securities</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
unrealized loss on marketable securities was $24,000 and $0 for the three months ended March 31, 2022 and 2021 respectively.<br />
<br /></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Liquidity
and Capital Resources</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s current operations have focused on business planning, raising capital, establishing an intellectual property portfolio,
hiring, and conducting preclinical studies. The Company does not have any product candidates approved for sale and has not generated
any revenue from product sales. <span style="background-color: white">The Company has sustained operating losses since inception and
expects such losses to continue over the foreseeable future. </span>We anticipate that cash utilized in the twelve months following
this filing date for selling, general and administrative expenses will range between $5 and $6 million and research
and development expenses <span style="background-color: white">will range between $14 and $16 million.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company reported cash and cash equivalents of $7.3 million, and short-term investments of $19.5 million as of March 31, 2022. Management
believes that the Company has sufficient cash and cash equivalents, and short-term investments to funds its operations for more than
twelve months from the date of this filing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
is currently evaluating different strategies to obtain the required funding for future operations. These strategies may include but are
not limited to: public offerings of equity and/or debt securities, payments from potential strategic research and development, licensing
and/or marketing arrangements with pharmaceutical companies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Critical
Accounting Policies</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
consider the following accounting policies to be critical given they involve estimates and judgments made by management and are important
for our investors&#8217; understanding of our operating results and financial condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 18; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Basis
of Presentation and Principles of Consolidation</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally
accepted in the United States of America. These condensed consolidated financial statements include the accounts of the Company
and its wholly owned subsidiaries, Oxis Biotech, Inc. and Georgetown Translational Pharmaceuticals, Inc. Intercompany transactions and
balances have been eliminated in consolidation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Accountin</span>g
<span style="text-decoration: underline">Estimates</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of financial statements in conformity with Generally Accepted Accounting Principles (&#8220;GAAP&#8221;) requires management
to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and
liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual
results could differ from those estimates. Significant estimates include accruals for potential liabilities, assumptions used in deriving
the fair value of derivative liabilities, valuation of equity instruments issued for services, and valuation of deferred tax assets. Actual results could differ from those estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Stock-Based
Compensation</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for share-based awards to employees, nonemployees and consultants in accordance with the provisions of ASC 718, Compensation-Stock
Compensation. Stock-based compensation cost is measured at fair value on the grant date and that fair value is recognized as expense
over the requisite service, or vesting, period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inflation</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that inflation has not had a material adverse impact on our business or operating results during the periods presented.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Off-balance
Sheet Arrangements</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have no off-balance sheet arrangements as of March 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="sur_007"></span>Item
3. Quantitative and Qualitative Disclosures About Market Risk</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
company qualifies as a smaller reporting company, as defined in 17 C.F.R. &#167;229.10(f)(1) and is not required to provide information
for this Item</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="sur_008"></span>Item
4. Controls and Procedures</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Evaluation
of Disclosure Controls and Procedures</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Our
Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer evaluated the effectiveness of our &#8220;disclosure
controls and procedures&#8221; (as such term is defined in Rules 13a-15(e) and 15d-15(e) of the United States Securities Exchange Act
of 1934, as amended), as of March 31, 2022. Based on that evaluation, we have concluded that our disclosure controls and procedures were
not effective as of March 31, 2022 as a result of material weaknesses in internal control over financial reporting </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">due
to (i) inadequate segregation of duties, (ii) risks of executive override and (iii) insufficient written policies and procedures for
accounting and financial reporting with respect to the requirements and application of both U.S. GAAP and SEC regulation, in each case,
as described in &#8220;Item 9A. Controls and Procedures&#8221; in the Company&#8217;s Form 10-K for the year ended December 31, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has begun to take measures to mitigate the issues identified and implement a functional system of internal controls over financial
reporting. Specifically, the Company has hired an experienced Chief Financial Officer, and engaged a forensic accountant to review the
Company&#8217;s bank records, transactions with affiliates and/or related parties, expense reimbursement practices and vendor payment
practices. The forensic accountant&#8217;s review is currently ongoing. In addition, the Company&#8217;s board of directors
previously designated a Special Committee in August 2021 charged with, among other duties, evaluating the current compliance, compensation,
operations and personnel of the Company, and determining actions appropriate to address any deficiencies or inefficiencies identified
through such evaluation. Such measures have included and/or will include, but not be limited to, hiring of additional employees in the
Company&#8217;s finance and accounting department; preparation of risk-control matrices to identify key risks and develop and document
policies to mitigate those risks; and identification and documentation of standard operating procedures for key financial activities,
with additional oversight by the Company&#8217;s board of directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes
in Internal Control over Financial Reporting</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
for the ongoing remediation of the material weaknesses in internal controls over financial reporting noted above, no changes in our internal
control over financial reporting were made during our most recent fiscal quarter that has materially affected, or is reasonably likely
to materially affect, our internal control over financial reporting.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 19; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="sur_009"></span>PART
II. OTHER INFORMATION</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="sur_010"></span>Item
1. Legal Proceedings</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On
August 28, 2019, a complaint was filed in the Superior Court of California, County of Los Angeles, West Judicial District, Santa Monica
Courthouse, Unlimited Civil Division by Jeffrey Lion, an individual (&#8220;Lion&#8221;), and by Daniel Vallera, an individual (&#8220;Vallera&#8221;).
Lion and Vallera are referred to jointly as the &#8220;Plaintiffs.&#8221; The complaint was filed against GT Biopharma, Inc. and its
subsidiary Oxis Biotech, Inc. (either of them or jointly, the &#8220;Company&#8221;). The Plaintiffs alleged breach of a license agreement
between the Plaintiffs and the Company entered into on or about September 3, 2015. A settlement of the case was reached on February 7,
2022 in the amount of $425,000. This amount was fully accrued at December 31, 2021. The settlement amount was subsequently paid on March
4, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="sur_016"></span>Item
6. Exhibits</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; width: 12%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center; vertical-align: bottom; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; width: 41%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center; vertical-align: bottom; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom; width: 7%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Filed
    Herewith</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center; vertical-align: bottom; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom; width: 7%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Form</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center; vertical-align: bottom; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom; width: 7%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center; vertical-align: bottom; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom; width: 7%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SEC
    File No.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center; vertical-align: bottom; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom; width: 7%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Filing
    Date</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/109657/000103221002000530/dex3a.txt" style="-sec-extract: exhibit">Restated Certificate of Incorporation as filed in Delaware September 10, 1996 and as thereafter amended through March 1, 2002</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-KSB</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.A</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">000-08092</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4/1/2002</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/109657/000151316011000020/ex32.htm" style="-sec-extract: exhibit">Certificate of Amendment to the Restated Certificate of Incorporation of GT Biopharma, Inc., dated February 9, 2011</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">000-08092</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3/31/2011</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/109657/000165495418002596/gtbp_ex31.htm" style="-sec-extract: exhibit">Certificate of Amendment to the Restated Certificate of Incorporation of GT Biopharma, Inc., effective as of July 19, 2017</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K/A</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">000-08092</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3/15/2018</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.4</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/109657/000165495421001479/gtbp_ex31.htm" style="-sec-extract: exhibit">Certificate of Amendment to the Restated Certificate of Incorporation of GT Biopharma, Inc., effective as of February 10, 2021</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-40023</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2/11/2021</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.5</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/109657/000119312503036323/dex3.htm" style="-sec-extract: exhibit">Bylaws, as restated effective September 7, 1994 and as amended through April 29, 2003</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-QSB</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">000-08092</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8/14/2003</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/109657/000165495421004295/gtbp_ex42.htm" style="-sec-extract: exhibit">Certificate of Designation of Preferences, Rights and Limitations of Series K Preferred Stock of GT Biopharma, Inc., dated April 3, 2019</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-40023</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4/16/2021</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex10-1.htm">Board Service Agreement with Michael Breen dated November 11, 2020</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex10-2.htm">Employment Agreement with Manu Ohri dated May 15, 2022</a></span></p>
</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex31-1.htm">Certification of Principal Executive Officer pursuant to Rule 13a-14 and Rule 15d-14(a), promulgated under the Securities and Exchange Act of 1934, as amended.</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex31-2.htm">Certification
    of Principal Financial Officer and Chief Financial Officer pursuant to Rule 13a-14 and Rule 15d-14(a), promulgated
    under the Securities and Exchange Act of 1934, as amended.</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex32-1.htm">Certification
    of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to section 906 of the Sarbanes-Oxley Act of
    2002</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex32-2.htm">Certification
    of Principal Financial Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to section
    906 of the Sarbanes-Oxley Act of 2002</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.INS</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Instance Document.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.SCH</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Schema Document.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.CAL</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Calculation Linkbase </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.DEF
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Definition Linkbase</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.LAB
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Label Linkbase Document.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.PRE
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Presentation Linkbase</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">104</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">Cover Page Interactive Data File (embedded within the Inline XBRL document)</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">X</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
    certification shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Exchange Act, or otherwise subject to the
    liability of that Section, nor shall it be deemed to be incorporated by reference into any filing under the Securities Act or the
    Exchange Act.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 20; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="sur_017"></span>SIGNATURES</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 1.1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned thereunto duly authorized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">GT
    Biopharma, Inc.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 47%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated:
    May 16, 2022</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Manu Ohri</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Manu Ohri</p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Chief Financial
                                            Officer</p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 21; Options: Last -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</body>
</html>
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!--  
       -->
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>ex10-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0"><B>Exhibit 10.1</B></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><IMG SRC="ex10-1_001.jpg" ALT="" STYLE="height: 869px; width: 670px">&nbsp;</P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>ex10-2.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
10.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EMPLOYMENT
AGREEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Employment Agreement (the &ldquo;Agreement&rdquo;) is made and entered into by and among GT Biopharma, Inc. (&ldquo;Parent&rdquo;) and
each of its subsidiaries (together with Parent, the &ldquo;Company&rdquo;) and Manu Ohri (&ldquo;Executive&rdquo;) as of May 15, 2022
and is effective as of February 14, 2022 (the &ldquo;Effective Date&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WHEREAS</B>,
the Company is desirous of employing Executive, and Executive wishes to be employed by the Company in accordance with the terms and conditions
set forth in this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOW,
THEREFORE, IN CONSIDERATION OF THE MUTUAL COVENANTS AND PROMISES AND OTHER GOOD AND VALUABLE CONSIDERATION, THE RECEIPT OF WHICH IS HEREBY
ACKNOWLEDGED, IT IS MUTUALLY AGREED AS FOLLOWS:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
<B>Position and Duties</B>: Executive shall be employed by Parent and each of its subsidiaries as its Chief Financial Officer reporting
to Parent&rsquo;s Chief Executive Officer. Executive agrees to devote the necessary business time, energy and skill to his duties at
the Company. These duties of Executive under this Agreement shall include all those duties customarily performed by a company&rsquo;s
Chief Financial Officer as well as providing advice and consultation on general corporate matters and other projects as may be assigned
by Parent&rsquo;s Chief Executive Officer and/or Board of Directors on an as needed basis. Executive shall perform his duties remotely
from his residence in Anaheim Hills, California or at the Company&rsquo;s executive offices, currently located in Brisbane, California,
unless mutually agreed by Executive and Parent. During the term of Executive&rsquo;s employment, Executive shall be permitted to serve
on boards of directors of not-for-profit entities, provided such service does not adversely affect the performance of Executive&rsquo;s
duties to the Company under this Agreement, and are not in conflict with the interests of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
<B>Term of Employment:</B> This Agreement shall remain in effect for a period of two years from the Effective Date and thereafter will
automatically renew for successive one year periods unless either party provides ninety days&rsquo; prior written notice of termination.
Upon the termination of Executive&rsquo;s employment prior to the expiration of the term of this Agreement, Executive shall receive the
applicable benefits set forth in this Agreement. Upon the termination of Executive&rsquo;s employment for any reason, neither Executive
nor the Company shall have any further obligation or liability under this Agreement to the other, except as set forth below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.
<B>Compensation</B>: Executive shall be compensated by the Parent for his services to the Company as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
<B>Base Salary</B>: Executive shall be paid a base salary of $400,000 per year (the &ldquo;Base Salary&rdquo;), effective May 15, 2022,
payable by Parent monthly in cash in accordance with Parent&rsquo;s normal payroll procedures. Executive&rsquo;s Base Salary shall be
reviewed on at least an annual basis and may be adjusted as appropriate, but in no event shall it be reduced to an amount below Executive&rsquo;s
Base Salary than in effect. In the event of such an adjustment, that amount shall become Executive&rsquo;s Base Salary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
<B>Benefits</B>: Executive shall have the right, on the same basis as other senior executives of the Company, to participate in and to
receive benefits under any of the Company&rsquo;s employee benefit plans, medical insurance (which extends to Executive&rsquo;s immediate
family), as such plans may be modified from time to time, and provided that in no event shall Executive receive less than (4) four weeks
paid vacation per annum, (6) six paid sick days per annum, and (5) five paid personal days per annum.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
<B>Performance Bonus</B>: Executive shall have the opportunity to earn a performance bonus of up to forty percent (40%) of the Base Salary
in accordance with the Parent&rsquo;s Performance Bonus Plan if in effect (&ldquo;Target Bonus&rdquo;); if the Parent does not have a
Performance Bonus Plan in effect at any given time during the term of this Agreement, then Parent&rsquo;s Compensation Committee or Board
of Directors shall have discretion as to determining bonus compensation for Executive.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
<B>General Grant</B>: At such time as the Parent may issue compensatory shares in accordance with the rules of the Nasdaq Stock Market,
LLC and subject to approval by the Compensation Committee of Parent&rsquo;s Board of Directors, the Parent shall (1) issue to Executive,
pursuant to a stock award agreement (which, among other provisions, shall prohibit Executive from transferring such shares for a period
of 6 months following issuance), 100,000 shares of common stock of the Parent, which shares shall be deemed to be fully vested on the
Effective Date; and (2) issue to Executive options to purchase 200,000 shares of common stock of the Company, with 66,667 shares vesting
on the Effective Date of the Agreement, 66,667 shares vesting on the first annual anniversary of the Effective Date, and the remaining
66,666 shares vesting on the second annual anniversary of the Effective Date, subject to Executive&rsquo;s continued service on each
such vesting dates, provided, that in the event of a Change in Control, such shares shall accelerate and vest immediately prior to the
consummation thereof. In the event the Executive shall &nbsp;leave the employment of the Company for any reason prior to the first
anniversary of the Effective Date, the Executive shall return to the Parent 50,000 shares of common stock of the Parent. In the event
the Executive shall leave the employment of the Company for any reason between the first anniversary and second anniversary of the Effective
date, the Executive shall return to the Parent 25,000 shares of common stock of the Parent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
<B>Expenses</B>: Parent shall reimburse Executive for reasonable travel, lodging, entertainment and meal expenses incurred in connection
with the performance of services within this Agreement. Executive shall be entitled to fly Business Class on any flight longer than four
(4) hours and receive full reimbursement for such flight from Parent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
<B>Travel</B>: Executive shall travel as necessary from time to time to satisfy his performance and responsibilities under this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.
<B>Effect of Termination of Employment</B>:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
<B>Voluntary Termination</B>: In the event of Executive&rsquo;s voluntary termination from employment with the Company, other than for
Change in Control Period Good Reason or for Non Change in Control Good Reason, Executive shall be entitled to no compensation or benefits
from the Company other than those earned under Section 3 through the date of his termination and in the case of each stock option, restricted
stock award or other Company stock-based award granted to Executive, the extent to which such awards are vested through the date of his
termination. In the event that Executive&rsquo;s employment terminates as a result of his death or disability, Executive shall be entitled
to a pro rata share of the performance-based bonus, if any, for which Executive is then-eligible pursuant to Section 3(c) (presuming
performance meeting, but not exceeding, target performance goals) in addition to all compensation and benefits earned under Section 3
through the date of termination.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
<B>Termination for Cause</B>: If Executive&rsquo;s employment is terminated by the Company for Cause, Executive shall be entitled to
no compensation or benefits from the Company other than those earned under Section 3 through the date of termination and, in the case
of each stock option, restricted stock award or other Company stock-based award granted to Executive, the extent to which such awards
are vested through the date of his termination. In the event that the Company terminates Executive&rsquo;s employment for Cause, the
Company shall provide written notice to Executive of that fact prior to, or concurrently with, the termination of employment. Failure
to provide written notice that the Company is terminating Executive&rsquo;s employment for Cause shall constitute an irrevocable waiver
of any contention that the termination was for Cause.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
<B>Involuntary Termination During Change in Control Period</B>: If Executive&rsquo;s employment with the Company terminates as a result
of a Change in Control Period Involuntary Termination, then, in addition to any other benefits described in this Agreement and subject
to Executive&rsquo;s execution of a general release of claims against the Company, Executive shall receive the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
all compensation and benefits earned under Section 3 through the date of the Company&rsquo;s termination of Executive&rsquo;s employment;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 67.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
a lump sum payment equivalent to the greater of (a) the bonus paid or payable to Executive for the year immediately prior to the year
in which the Change in Control occurred and (b) the Target Bonus under the Performance Bonus Plan, if any, in effect immediately prior
to the year in which the Change in Control occurs;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
a lump sum payment equivalent to the remaining Base Salary (as it was in effect immediately prior to the Change in Control) due Executive
from the date of Change in Control Period Involuntary Termination to the end of the term in this Agreement or one-half of Executive&rsquo;s
Base Salary then in effect, whichever is the greater; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)
reimbursement for the cost of medical, life, disability insurance coverage at a level equivalent to that provided by the Company for
a period expiring upon the earlier of: (a) one year; or (b) the time Executive begins alternative employment wherein said insurance coverage
is available and offered to Executive. It shall be the obligation of Executive to inform Parent that new employment has been obtained.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
otherwise agreed to by Executive, the amount payable to Executive under subsections (i) through (iii), above, shall be paid to Executive
in a lump sum within thirty (30) days following the Company&rsquo;s termination of Executive&rsquo;s employment. The amounts payable
under subsection (iv) shall be paid monthly during the reimbursement period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
<B>Termination Without Cause in the Absence of Change in Control</B>: In the event that Executive&rsquo;s employment terminates as a
result of a Non Change in Control Period Involuntary Termination, then, in addition to any other benefits described in this Agreement
and subject to Executive&rsquo;s execution of a general release of claims against the Company, Executive shall receive the following
benefits:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
all compensation and benefits earned under Section 3 through the date of the Company&rsquo;s termination of Executive&rsquo;s employment;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
a lump sum payment equivalent to the greater of (a) the bonus paid or payable to Executive for the year immediately prior to the year
in which the Non Change in Control Period Involuntary Termination occurred and (b) the Target Bonus under the Performance Bonus Plan,
if any, in effect immediately prior to the year in which the Non Change in Control Period Involuntary Termination occurs;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
a lump sum payment equivalent to the remaining Base Salary (as it was in effect immediately prior to the Non Change in Control Period
Involuntary Termination) due Executive from the date of the Non Change in Control Period Involuntary Termination to the end of the term
of this Agreement or one-half of Executive&rsquo;s Base Salary then in effect, whichever is the greater; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)
reimbursement for the cost of medical, life and disability insurance coverage at a level equivalent to that provided by the Company for
a period of the earlier of: (a) one year; or (b) the time Executive begins alternative employment wherein said insurance coverage is
available and offered to Executive. It shall be the obligation of Executive to inform Parent that new employment has been obtained.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
otherwise agreed to by Executive, the amount payable to the Executive under subsections (i) through (iii) above shall be paid to Executive
in a lump sum within thirty (30) days following the Company&rsquo;s termination of Executive&rsquo;s employment. The amounts payable
under subsection (iv) shall be paid monthly during the reimbursement period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
<B>Resignation with Good Reason During Change in Control Period</B>: If Executive resigns his employment with the Company as a result
of a Change in Control Period Good Reason, then, in addition to any other benefits described in this Agreement and subject to Executive&rsquo;s
execution of a general release of claims against the Company, Executive shall receive the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
all compensation and benefits earned under Section 3 through the date of Executive&rsquo;s termination of employment;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
a lump sum payment equivalent to the greater of (a) the bonus paid or payable to Executive for the year immediately prior to the year
in which the Change in Control occurred and (b) the Target Bonus under the Performance Bonus Plan, if any, in effect immediately prior
to the year in which the Change in Control occurs;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
a lump sum payment equivalent to the remaining Base Salary (as it was in effect immediately prior to the Change in Control) due Executive
from the date of Executive&rsquo;s Change in Control Period Good Reason termination to the end of the term of this Agreement or one-half
of Executive&rsquo;s Base Salary then in effect, whichever is the greater; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)
reimbursement for the cost of medical, life and disability insurance coverage at a level equivalent to that provided by the Company for
a period of the earlier of: (a) one year; or (b) the time Executive begins alternative employment wherein said insurance coverage is
available and offered to Executive. It shall be the obligation of Executive to inform the Parent that new employment has been obtained.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
otherwise agreed to by Executive, the amount payable to the Executive under subsections (i) through (iii) above shall be paid to Executive
in a lump sum within thirty (30) days following Executive&rsquo;s termination of employment. The amounts payable under subsection (iv)
shall be paid monthly during the reimbursement period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
<B>Resignation with Good Reason in the Absence of Change in Control: </B>If Executive resigns his employment with the Company as a result
of a Non Change in Control Period Good Reason, then, in addition to any other benefits described in this Agreement and subject to Executive&rsquo;s
execution of a general release of claims against the Company, Executive shall receive the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
all compensation and benefits earned under Section 3 through the date of Executive&rsquo;s termination of employment;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
a lump sum payment equivalent to a greater of (a) the bonus paid or payable to Executive for the year immediately prior to the year in
which Executive resigns and (b) the Target Bonus under the Performance Bonus Plan, if any, in effect immediately prior to the year in
which Executive resigns;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
a lump sum payment equivalent to the remaining Base Salary (as it was in effect immediately prior to Executive&rsquo;s resignation) due
Executive from the date of Executive&rsquo;s resignation to the end of the term of this Agreement or one-half of Executive&rsquo;s Base
Salary then in effect, whichever is the greater; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)
reimbursement for the cost of medical, life and disability insurance coverage at a level equivalent to that provided by the Companies
for a period of the earlier of: (a) one year or (b) the time Executive begins alternative employment wherein said insurance coverage
is available and offered to Executive. It shall be the obligation of Executive to inform Parent that new employment has been obtained.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
otherwise agreed to by Executive, the amount payable to the Executive under subsections (i) through (iii) above shall be paid to Executive
in a lump sum within thirty (30) days following Executive&rsquo;s termination of employment. The amounts payable under subsection (iv)
shall be paid monthly during the reimbursement period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)
<B>Resignation from Positions</B>: In the event that Executive&rsquo;s employment with the Company is terminated for any reason, on the
effective date of the termination Executive shall simultaneously resign from each position he holds as an officer and, if applicable,
on the Board of Directors of each of Parent, its subsidiaries and any of their affiliated entities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.
<B>Certain Definitions: </B>For the purpose of this Agreement, the following capitalized terms shall have the meanings set forth below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
&ldquo;Cause&rdquo; shall mean any of the following occurring on or after the date of this Agreement:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
Executive&rsquo;s theft, dishonesty, breach of fiduciary duty for personal profit, or falsification of any employment or Company record;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
Executive&rsquo;s willful violation of any law, rule, or regulation (other than traffic violations, misdemeanors or similar offenses)
or final cease-and-desist over, in each case that involves moral turpitude;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
any material breach by Executive of the Company&rsquo;s Code of Professional Conduct, which breach shall be deemed &ldquo;material&rdquo;
if it results from an intentional act by Executive and has a material detrimental effect on the Company&rsquo;s reputation or business;
or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)
any material breach by Executive of this Agreement, which breach, if curable, is not cured within thirty (30) days following written
notice of such breach from the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
&ldquo;Change in Control&rdquo; shall mean the occurrence of any of the following events:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
Parent is party to a merger or consolidation which results in the holders of the voting securities of Parent outstanding immediately
prior thereto failing to retain immediately after such merger or consolidation direct or indirect beneficial ownership of more than fifty
percent (50%) of the total combined voting power of the securities entitled to vote generally in the election of directors of Parent
or the surviving entity outstanding immediately after such merger of consolidation;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
a change in the composition of the Board of Directors of the Parent occurring within a period of twenty-four (24) consecutive months,
as a result of which fewer than a majority of the directors are Incumbent Directors;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
effectiveness of an agreement for the sale, lease or disposition by Parent of all or substantially all of Parent&rsquo;s assets; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)
a liquidation or dissolution of Parent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
&ldquo;Change in Control Period&rdquo; shall mean the period commencing on the date sixty (60) days prior to the date of consummation
of the Change in Control and ending one hundred eighty (180) days following consummation of the Change in Control.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
&ldquo;Change in Control Period Good Reason&rdquo; shall mean Executive&rsquo;s resignation for any of the following conditions, first
occurring during a Change in Control Period and occurring without Executive&rsquo;s written consent:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
a decrease in Executive&rsquo;s Base Salary, a decrease in Executive&rsquo;s Target Bonus (as a multiple of Executive&rsquo;s Base Salary)
under the Performance Bonus Plan, or a decrease in employee benefits, in each case other than as a part of any across-the-board reduction
applying to all senior executives of either Company which does not disproportionately impact Executive when compared to similarly situated
executives;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
a material, adverse change in Executive&rsquo;s title, authority and responsibilities, as measured against Executive&rsquo;s title, authority
and responsibilities immediately prior to such change;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
a requirement that Executive relocate his principal workplace from Anaheim Hills, California;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)
any material breach by the Company of any provision of this Agreement, which breach is not cured within thirty (30) days following written
notice of such breach from Executive;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)
any failure of Parent to obtain the assumption of this Agreement by any of Parent&rsquo;s successors or assigns by purchase, merger,
consolidation, sale of assets or otherwise; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vi)
any purported termination of Executive&rsquo;s employment for &ldquo;material breach of contract&rdquo; which is purportedly effected
without providing the &ldquo;cure&rdquo; period, if applicable, described in Section 5(d)(iv), above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
effective date of any resignation from employment by Executive for Change in Control Period Good reason shall be the date of notification
to Parent of such resignation from employment by Executive.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
&ldquo;Non Change in Control Period Good Reason&rdquo; shall mean Executive&rsquo;s resignation within six months of any of the following
conditions first occurring outside of a Change in Control Period and occurring without Executive&rsquo;s written consent:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
a decrease in Executive&rsquo;s total cash compensation opportunity (adding Base Salary and Target Bonus, if any) of greater than ten
percent (10%);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
a material, adverse change in Executive&rsquo;s title, authority or responsibilities, as measured against Executive&rsquo;s title, authority
or responsibilities immediately prior to such change;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
any material breach by the Company of a provision of this Agreement, which breach is not cured within thirty (30) days following written
notice of such breach from Executive;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)
a requirement that Executive relocate his principal workplace from Anaheim Hills, California; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)
any purported termination of Executive&rsquo;s employment for &ldquo;material breach of contract&rdquo; which is purportedly effected
without providing the &ldquo;cure&rdquo; period, if applicable, described in Section 5(e)(iii), above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
effective date of any resignation from employment by Executive for Non Change in Control Period Good reason shall be the date of notification
to Parent of such resignation from employment by Executive.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
&ldquo;Incumbent Directors&rdquo; shall mean members of Parent&rsquo;s Board of Directors who either (a) are members of Parent&rsquo;s
Board of Directors as of the date hereof, or (b) are elected, or nominated for election, to Parent&rsquo;s Board of Directors with the
affirmative vote of at least a majority of the Incumbent Directors at the time of such election or nomination (but shall not include
an individual whose election or nomination is in connection with an actual or threatened proxy contest relating to the election of members
of Parent&rsquo;s Board of Directors).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)
&ldquo;Change in Control Period Involuntary Termination&rdquo; shall mean during a Change in Control Period the termination by the Company
of Executive&rsquo;s employment with the Company for any reason, including termination as a result of death or disability of Executive,
but excluding termination for Cause. The effective date of any Change in Control Period Involuntary Termination shall be the date of
notification to Executive of the termination of employment by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)
&ldquo;Non Change in Control Period Involuntary Termination&rdquo; shall mean outside a Change in Control Period the termination by the
Company of Executive&rsquo;s employment with the Company for any reason, including termination as a result of death or disability of
Executive, but excluding termination for Cause. The effective date of any Non Change in Control Period Involuntary Termination shall
be the date of notification to Executive of the termination of employment by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.
<B>Dispute Resolution</B>: In the event of any dispute or claim relating to or arising out of this Agreement (including, but not limited
to, any claims of breach of contract, wrongful termination or age, sex, race or other discrimination), Executive and the Company agree
that all such disputes shall be fully addressed and finally resolved by binding arbitration conducted by the American Arbitration Association
in the State of California in accordance with its National Employment Dispute Resolution rules. In connection with any such arbitration,
Parent shall bear all costs not otherwise borne by a plaintiff in a court proceeding. The Company agrees that any decisions of arbitrator(s)
will be binding and in any state that the Company conducts the operation of its business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.
<B>Attorneys&rsquo; Fees</B>: The prevailing party shall be entitled to recover from the losing party its attorneys&rsquo; fees and costs
incurred in any action brought to enforce any right arising out of the Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>8.
Restrictive Covenants:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
<B>Nondisclosure.</B> During the term of this Agreement and following termination of Executive&rsquo;s employment with the Company, Executive
shall not divulge, communicate, use to the detriment of the Company or for the benefit of any other person or persons, or misuse in any
way, any Confidential Information (as hereinafter defined) pertaining to the business of the Company. Any Confidential Information or
data now or hereafter acquired by Executive with respect to the business of the Company (which shall include, but not be limited to,
confidential information concerning the Company&rsquo;s financial condition, prospects, technology, customers, suppliers, methods of
doing business and promotion of the Company&rsquo;s products and services) shall be deemed a valuable, special and unique asset of the
Company that is received by Executive in confidence as a fiduciary. For purposes of this Agreement &ldquo;Confidential Information&rdquo;
means information disclosed to Executive or known by Executive as a consequence of or through his employment by the Company (including
information conceived, originated, discover or developed by Executive) prior to or after the date hereof and not generally known or in
the public domain about the Company or its business. Notwithstanding the foregoing, none of the following information shall be treated
as Confidential Information: (i) information which is known to the public at the time of disclosure to Executive; (ii) information which
becomes known to the public by publication or otherwise after disclosure to Executive through no fault of Executive; (iii) information
which was rightfully received by Executive from a third party without violating any non-disclosure obligation owed to or in favor of
the Company; or (iv) information unrelated to the Company&rsquo;s business which was developed by or on behalf of Executive independently
of any disclosure hereunder as shown by written records. Nothing herein shall be deemed to restrict Executive from disclosing Confidential
Information to the extent required by law or by any court.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
<B>Non-Competition</B>. Executive shall not, while employed by the Company, engage or participate, directly or indirectly (whether as
an officer, director, employee, partner, consultant, or otherwise), in any business that manufactures, markets or sells products that
directly compete with any product of the Company. Nothing herein shall prohibit Executive from being a passive owner of less than 5%
of the stock of any entity directly engaged in a competing business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
<B>Property Rights; Assignment of Inventions.</B> With respect to information, inventions and discoveries or any interest in any copyright
and/or other property right developed, made or conceived of by Executive, either alone or with others, during his employment by the Company
arising out of such employment and pertinent to any field of business or research in which, during such employment, the Company is engaged
or (if such is known to or ascertainable by Executive) is considering engaging, Executive hereby agrees:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
that all such information, inventions and discoveries or any interest in any copyright and/or other property right, whether or not patented
or patentable, shall be and remain the exclusive property of the Company;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
to disclose promptly to an authorized representative of Parent all such information, inventions and discoveries or any copyright and/or
other property right and all information in Executive&rsquo;s possession as to possible applications and uses thereof;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
not to file any patent application relating to any such invention or discovery except with the prior written consent of an authorized
officer of Parent (other than Executive);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)
that Executive hereby waives and releases any and all rights Executive may have in and to such information, inventions and discoveries,
and hereby assigns to the Company and/or its nominees all of Executive&rsquo;s right, title and interest in them, and all of Executive&rsquo;s
right, title and interest in any patent, patent application, copyright or other property right based thereon. Executive hereby irrevocably
designates and appoints Parent and each of its duly authorized officers and agents as his agent and attorney-in-fact to act for his and
on his behalf and in his stead to execute and file any document and to do all other lawfully permitted acts to further the prosecution,
issuance and enforcement of any such patent, patent application, copyright or other property right with the same force and effect as
if executed and delivered by Executive; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)
at the request of Parent, and without expense to Executive, to execute such documents and perform such other acts as Parent deems necessary
or appropriate, for the Company to obtain patents on such inventions in a jurisdiction or jurisdictions designated by Parent, and to
assign the Company or their respective designees such inventions and any and all patent applications and patents relating thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.
<B>General:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
<B>Successors and Assigns</B>: The provisions of this Agreement shall inure to the benefit of and be binding upon the Company, Executive
and each and all of their respective heirs, legal representatives, successors and assigns. The duties, responsibilities and obligations
of Executive under this Agreement shall be personal and not assignable or delegable by Executive in any manner whatsoever to any person,
corporation, partnership, firm, company, joint venture, or other entity. Executive may not assign, transfer, convey, mortgage, pledge
or in any other manner encumber the compensation or other benefits to be received by him or any rights which he may have pursuant to
the terms and provisions of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
<B>Amendments; Waivers</B>: No provision of this Agreement shall be modified, waived or discharged unless the modification, waiver or
discharge is agreed to in writing and signed by Executive and by an authorized officer of Parent (other than Executive). No waiver by
either party of any breach of, or of compliance with, any condition or provision of this Agreement by the other party shall be considered
a waiver of any other condition or provision or of the same condition or provision at another time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
<B>Notices</B>: Any notices to be given pursuant to this Agreement by either party may be effected by personal delivery or by overnight
delivery with receipt requested. Mailed notices shall be addressed to the parties at the addresses stated below, but each party may change
its or his/her address by written notice to the other in accordance with this subsection (c). Mailed notices to Executive shall be addressed
as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Manu
Ohri</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email:
<U>manu.ohri@gmail.com</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mailed
notices to the Company shall be addressed as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">GT
Biopharma, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8000
Marina Blvd., Suite 100</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Brisbane,
CA 94005</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
<B>Entire Agreement</B>: This Agreement constitutes the entire employment agreement among Executive and the Company regarding the terms
and conditions of his employment, with the exception of any stock option, restricted stock or other Company stock-based award agreements
among Executive and the Company to the extent not modified by this Agreement. This Agreement supersedes all prior negotiations, representations
or agreements among Executive and the Company, whether written or oral, concerning Executive&rsquo;s employment by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
<B>Withholding Taxes</B>: All payments made under this Agreement shall be subject to reduction to reflect taxes required to be withheld
by law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
<B>Counterparts</B>: This Agreement may be executed by Parent and Executive in counterparts, each of which shall be deemed an original
and which together shall constitute one instrument.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)
<B>Headings</B>: Each and all of the headings contained in this Agreement are for reference purposes only and shall not in any manner
whatsoever affect the construction or interpretation of this Agreement or be deemed a part of this Agreement for any purpose whatsoever.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)
<B>Savings Provision</B>: To the extent that any provision of this Agreement or any paragraph, term, provision, sentence, phrase, clause
or word of this Agreement shall be found to be illegal or unenforceable for any reason, such paragraph, term, provision, sentence, phrase,
clause or word shall be modified or deleted in such a manner as to make this Agreement, as so modified, legal and enforceable under applicable
laws. The remainder of this Agreement shall continue in full force and effort.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
<B>Construction</B>: The language of this Agreement and of each and every paragraph, term and provision of this Agreement shall, in all
cases, for any and all purposes, and in any and all circumstances whatsoever be construed as a whole, according to its fair meaning,
not strictly for or against Executive or the Company, and with no regard whatsoever to the identity or status of any person or persons
who drafted all or any portion of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)
<B>Further Assurances</B>: From time to time, at the Company&rsquo;s request and without further consideration, Executive shall execute
and deliver such additional documents and take all such further action as reasonably requested by the Company to be necessary or desirable
to make effective, in the most expeditious manner possible, the terms of this Agreement and to provide adequate assurance of Executive&rsquo;s
due performance hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)
<B>Governing Law</B>: Executive and the Companies agree that this Agreement shall be interpreted in accordance with and governed by the
laws of the State of California.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(l)
<B>Board Approval</B>: Parent and each of its subsidiaries warrants to Executive that the Board of Directors of Parent and each of its
subsidiaries has ratified and approved this Agreement, and that Parent will cause the appropriate disclosure filing to be made with the
Securities and Exchange Commission in a timely manner.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[Signature
Page Follows]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WHITNESS WHEREOF, the parties have executed this Agreement as of the Effective Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXECUTIVE</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Manu Ohri</I></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Manu
    Ohri</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>GT
    BIOPHAMA, INC.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Michael Breen</I></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michael
    Breen</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Executive
    Chairman of the Board and</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interim
    Chief Executive Officer</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 12; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>ex31-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
31.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION
PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I,
Michael Breen, certify that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
    have reviewed this report on Form 10-Q of GT Biopharma, Inc.;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
    on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
    to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to
    the period covered by this report;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
    on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material
    respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in
    this report;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
    am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and
    15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f) for the registrant
    and have:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
    such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
    to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others
    within those entities, particularly during the period in which this report is being prepared;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
    such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our
    supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements
    for external purposes in accordance with generally accepted accounting principles;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iii)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluated
    the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about
    the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;
    and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iv)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosed
    in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s
    most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected,
    or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
    have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors
    and the audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent functions):</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">all
    significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
    reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information;
    and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
    internal control over financial reporting.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    May 16, 2022</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Michael Breen</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michael
    Breen</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interim
    Chief Executive Officer, </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;Chairman
    and Director</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 22; Options: Last -->
    <DIV STYLE="margin: 0; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>ex31-2.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
31.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION
PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I,
Manu Ohri, certify that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
    have reviewed this report on Form 10-Q of GT Biopharma, Inc.;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
    on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
    to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to
    the period covered by this report;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
    on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material
    respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in
    this report;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
    am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and
    15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f) for the registrant
    and have:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
    such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
    to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others
    within those entities, particularly during the period in which this report is being prepared;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
    such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our
    supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements
    for external purposes in accordance with generally accepted accounting principles;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iii)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluated
    the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about
    the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;
    and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iv)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosed
    in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s
    most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected,
    or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
    have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors
    and the audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent functions):</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">all
    significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
    reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information;
    and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
    internal control over financial reporting.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    May 16, 2022</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Manu Ohri</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Manu
Ohri</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer and Principal Accounting Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 23; Options: Last -->
    <DIV STYLE="margin: 0; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>ex32-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
32.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION
TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to 18 U.S.C. &sect; 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002, I, Michael Breen, Interim Chief Executive
Officer of GT Biopharma, Inc. (the &ldquo;Company&rdquo;), hereby certify that, to the best of my knowledge:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 35.3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
the Quarterly Report on Form 10-Q of the Company for the fiscal quarter ended March 31, 2022 (the &ldquo;Report&rdquo;) fully
complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended;
and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 35.3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 35.3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
the information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of
the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 35.3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    May 16, 2022</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Michael Breen</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michael
Breen</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interim
    Chief Executive Officer, </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman
    and Director</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 24; Options: Last -->
    <DIV STYLE="margin: 0; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>7
<FILENAME>ex32-2.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
32.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION
TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to 18 U.S.C. &sect; 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002, I, Manu Ohri, Chief Financial Officer and Principal
Accounting Officer of GT Biopharma, Inc. (the &ldquo;Company&rdquo;), hereby certify that, to the best of my knowledge:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 35.3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
the Quarterly Report on Form 10-Q of the Company for the fiscal quarter ended March 31, 2022 (the &ldquo;Report&rdquo;) fully
complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended;
and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 35.3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 35.3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
the information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of
the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 35.3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    May 16, 2022</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Manu Ohri</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Manu
    Ohri</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer and Principal Accounting Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 25; Options: Last -->
    <DIV STYLE="margin: 0; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>ex10-1_001.jpg
<TEXT>
begin 644 ex10-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" DV!QH# 2(  A$! Q$!_\0
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M*%BHTT:?L\O^S_[+W&+9Y.4*%"2O5"N5K6AA\K_/^>.O>K%% !1110 4444
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M?M^Z3X'U-?$>G?#>?0;/[&?!.@:V]B]EXIUT8UW6VDD9G<X&MKEV)QX?"@@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_9%_X*V_!#X^_$[P;K6F_#\_$?2_&E[JOV+6=-U*QTK_ (D U[^W-#[^(?\
MB1G/7/H:_L__ &(_^"5WPE_8P\>:O\3-/\7ZW\1O'%W9R65EXA\1Z7H^FO8G
M6G UB0+")-VMRE2Q=G4A&160M(57ZJ_:R_8Y^$W[6_P]U'P3X]T_^SM4GL6B
M\/>/-)1?^$F\)2@J1)H;Y!R%R-N-I#;N".0#X?\ ^"GG[3GPAU[_ ()^?$B?
MP[XQ\/ZW:>.['PYHO]DVMY"?$3Z8^NH^M-_8@<S QKHCQA2@0X8GI&6_"O\
MX-MOV6K[P;\4/VEOVKO']M!IWPWT3P[I2>&O$.IW?]G:8NJ$>(#KK-HG14'A
ML');@D!0&9D5OV7T+_@A?\#UATBR\<?&_P"-GC?2-*L]*LFT87FD>'=.O?[$
MX7*QK(V"<C(!  )!(!K]0W_9?^$^F_ '6OV=?".C3^"/ &N^&]4\-E- (74+
M#^VH@LFL*[(&;6Q(0XF*[@25)V;5 !_)O^T1\"_VF?\ @JI^U1\1I? !TWQ+
MX'\ J+OPT;N[5=,T+^W-9P-&_MO7E51GPX,X4!1V4 8'XK_LX>+_ (P_\$O/
M^"I6D:1JVJZ;IUMK^K^%]$UFSM+P'2SI1UK!!!'(YP1CGIBO]"#]CC]AWX7_
M +'&A^)[#P1K>L^+=4\3ZHSWWB+Q"-,?5!8*RM'HN8T5?+7#%@3N?*X"@'=\
MD?M4_P#!$S]B[]J[XGV_Q9\5:7JOACQ?<7>K79O_  ]<JI_M766_ME]8T;!4
M:#*9$D9C%$L>!\H&8]X!^-?_  =1>/-%\5? ']D'Q'X*UK3+BQU7QIXKUJSU
M>ZO =,LU&CZ"L>D$C'S-$-9W# VME0-J@G\>KS_@F;X_\;?\$L/ _P"U?\#]
M5\;GQ!:^,!K7B32;35R/[0ZZ[_R ^_AW_B>= 21^//\ 9+\>/^",?[+_ ,<?
M@+\.?@5?:W\0=/T?X<V>G6>B:^-8_P"$BU742HQ_;&M"3RQEL%@?"K>#EY)+
MA<8^OOV;?V-O '[.7[-1_9?T+5M0UGP+/I&IZ&?M5J+!M/TW7=%.A2)I")\J
M%4"%6\QCESE0 %< _![_ (-]/VV/@O+^S/XD_9\^*EUIOPV^)WA2\U/6[W4=
M6NUTY?&'A@:5#HRL6&)!XCC,1*>%4=48^(?^*'24*JC^?[]J*;2K/_@L7I^J
MSWWV:P_MCP'_ *7D?\A3^VM _P#OYTK^NSX'?\$0/V>_@EXHN?%5CX\\7W6H
M:I:_8=6^Q6>C>'#J'_$VW9;S/^$J49;Y  3R5+%<ML[?XZ_\$6/V2OC/X^'Q
M'^SZWX+\0VECI-GHS:0PU1-%_L0979)M3Q*V>,D>+5&2-H.!0!^/7_!R)\6/
MAU\6?V5OA3^QY\#]4_X335[;Q+X7\3@:1:?VD+'2]"T8Z'X&T?\ ML=&=M>.
M[D[@%)(8D#[_ /\ @W&_9(^(?[)G[$&HZ/\ $RSM;?6_B)XZU'Q5:H"-XTEB
MWEL1U57.L.%/ 8JXYP0/J#X2?\$@OV7/AO\ &RU^-%Q=^*/&_B/3WU"ZT_2_
M$6H*VF/JK(VD2:QJJ+N:::.T5_#Z1!3OC&]=RAP/US\J'T_0_P"% 'X^?M_?
M'[]GRW^-?P:_97_:/T^T;P%\3_#.K>*-4U-V,=_8L%U_0$0NJ2&-"<!F$<A4
M%F"/PM?S\_\ !:G_ ():_!W]F_X7^#_CC^R5XPUO0]1U6\U31?[).LZ-J6FW
MX/\ 8&-:T/71P3_Q/.>3]2*_J$_:X_X)U_ O]L7Q;X'\<?$<^(K#Q?X%TK^Q
MM(U;2;L1_:])_M<:ZVC:RN#Y@:4;LLP(60X9MJAM+QY_P3_^ /Q#^'7@;X9^
M(;+4CIO@76%UM=7M"O\ PDFH:E]XOK.NJ"22" 0>" ",#E@#^6?X\_%?XM:S
M_P $([[P)\<#J>MZSX?\0_#)/ ?BP:4X4A];UQCHVO:R&$;>)%V *S([H&98
MV17\(J_B_P#P0G_9%_9:^*?P]U?QA^T1JFL:=!IE]J>LVEY;ZT?#(O=2T('.
MC@*K%_#Z^'?[;^0M&&&?WB\9_L_^-'['GP=^-?P)T?X!>(M FT[X?^'+_P -
MW_AS2["]U-1HYT+>L39\PF21(=5U>)B2 1*ARBQ%8^"_9S_X)Y_LX?L[^"=<
M\%>'_"UEXIM]=O9+N]U+Q!96[W]H&4!=+T@$F70HHSM<+;S1R,6PX(Z 'SAX
M5_;'_9JU/X%_&#X,^"-9N;FV\'>'/&_PT\,V.DC5O$OVGPUK>B:^O@G6=881
MJVA)-&61C*=T>-R<,%C_ (I_V1?V9-5_:*_;"^+/PY,&HCQ?XGUC[%9FUYTO
M3P!_8)R>/QSQCV(-?WS?!W_@GI^S;\(=;\6^(-,\)WVKZQXSU1KW4;CQ#JTC
MA+#^Q4T)='&DZ*;3PT85 <,/LH=RRL#'Y91]'X7?\$]/V5?@]\5=?^,O@3X<
MIIOC;6[NRO;:<ZKK)T_PRR9$8\/Z4)UBM_F!W^<CD@[3Y11FH _B&_9(?Q=_
MP1]_X*P3:-\6--M'L_&NK+X:2^N+0,CZ0RC0];?0&4E2K*0RLN0RX(/0U_?]
M*_@#XZ_##6;+3]>T[Q)X'\?>'-2T6\U/2RQ2^TO7M)?1)&7()#,';VRJ+@*#
MGR+]H#]AC]E3]J>ZM-0^.OP7\)_$'5M*O]*UC2]6UG^T_P"TK+4-#/\ Q)9
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M O\ X+*_&3Q%\0/BK\&OV-?"FKZHVG:QXF\+:A\1_#NE:0-376QKFK(F@KK
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M_%NMZC;>';3PIX!\/:A#"NJ>&/#T?E;=$B\9>."EMX<1Y"$8MX>$I5OD,**
MB?/MI_P1!_96\,ZS:3^"O%/Q2\'Z.UC]BU?2=*O=$)U!P"3JJZV/#A;0I  6
M 1""%)!SP>A\&_\ !&K]GGPNNI-JGC?XI>)+C4KW3KNTNKJ]T33S8%#@@;?#
MC#)Q]TD,. R@Y  /SN_9V^''A#X]?\%!_P#@J)H<&D^%-7@^)'@3XZ^#/"(N
MS%J>G:SJ@UKP_H;:N^=Z-N.M_P#"1-Y9+?.6C92 X_$S_@EW^P'\:;/]O#QQ
M\)/'^A_V);^ [S5++PW:>(2=-TRPU30O^)]KO]N?\4V/^@'S_P 4?]<XP?[
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M[\%KSPI;>#=+^/WQ0M?#MMJXOKK2=7TC1M1TTG^Q3H17;H \(=% ;.[G)!
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MU[5]*T#]G+5]5OG%OIND?!/5+^Y/<:=H_@R1I?7&$QCU+8S7^>[_ ,$=-?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M^RD_;_$*Q2"(*2.SF,D \Y8EC7Y+?\$KO^"C7C;]K.'XTZ/\98_#5OJ7PO\
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MB!XP^&LGQC\.CQ1X#\-CQ3XBCMY&OM.&F!0H_L>2-6/B(@9W+X:2ZW,.6Y.
M#[5HK\Z/&O[?GPCU+]FCXD_'7X3ZY;:[J_@S2=0>S\*:M_Q+?$MGJT>L1: K
M2:(S.Y97UA6!W'*A S/\U?%?_!.W_@K+H7[3.A^,=5^*.IZ9IN@>&+/4[NU\
M:'2$"RW^BR!IXI#H44WA=8YP2?"!C023?\(]XE!<D+@ _>NBO@H?\%&?V/Y9
M;&#3OBJNHW&I:LNBP_9_#/C)#&"8\ZD/[7\.1 1+_:L9))DW!BAWQIM;[UH
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MQKX.GUOQ'\4->;4_#7@_Q8-8QXX\)LNB871M%UH<:"1_8>M[=P)\%$*1RB$
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M;_VNM,\)VGC3[#\&_AQJRZ)X?T[P]=+J&FZFZZP%;7BB_+KQ<KG:ORKT P
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MDH)24^L?%,6DS>'==36K]=)T:XTC4%U751>#3C8Z=Y<A?4O[7'^J*1!77YB
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MA70=!_X1I? ?Q*U/65TW3;27P_HI_L>-1H$C>)M__"/J_A5PWA1MK:\WF/\
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MPN/%VA>#/BEJ]W8WFKW8U)_#^I$Z[H6BA6\0<A2VM)N (!*IGE5Q]+_L.?\
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MK/[ ,O[?WP]^&L?[,/B"R\1KXI\%:2-$N;WQ'I1TO2O">G:/K7]L+J^B:YN
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M7(/'RLN/<9Z5_+KX>_9F_P""CG_!.#QO\5_"'[)/A3Q'\2/A;X_U8^-+[7]
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M*?ADVE)I&E7.K,?^$@8:*5_L;2&1&.NQIC#RO\D0&"0< _T)Q_<7Z4 >9_\
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MK:UHVN$?\)PV"NOC_A(-=E8[B,[  0-Q'X2::/$>I?#GXD?#GQ'_ &E_8_\
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M@?\ R*?_ .KY'^!OV_3;#]N#2]<OM-MKBZT?POHMGX>M/^);]@U3/_(:_/\
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MV9?A9^SYX2M?"_@O0H#.;S^V;W7[P?VAJ=]J;8^=M:95?*[<!05R&.0V%Q^
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MCU^E 'X0?LB_$B^_:H_:?_9_\'?'?^V];^R^(_"]E>?VMK&?^)7KNM:!H/\
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M[X.O_#.L>'[^/2[[49M2_L;7=$TG6$U9C_PC@?R-<+")_![8;0?#*2;Q'+@
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ML='\.'58 VDZ'J.C,CZ)*L0T68E(2@C4;2R;RL2JKN& /PT^"GC/XL?\%+/
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MN_[<^-_BCQ)_PE%]I=MXFUCQKI5AJ?/&MZWX@RWB%A@':0JX)^?(VU\7:O\
M\$]_VROAW_P4@^(/[27P>\*:;;^'_B-\4]6\3>'=??Q$1IEAI>2I&NJ?$?\
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M^+-YJ6N2:N]]H_C'PQIXT'^W75?$!^(/AQ"/$)&W_A"T? 924D4JQ!_K&HH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MX<=^OX@USFN^(-$\+:%JOB'7=1M]-TC0-*U76M6U*[ C2RTW18WDUC4G*JQ
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M7P?X6T^VT;P[X:TC3M&T72K8 1V6F:2OEPQJ%R<*IP>[,2QP7('644 %%%%
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M_P""HO[&'P&T:ZU7Q3\6+7Q)]CT@:W_97@"RU3QGJ<NG?V9YID$L"_\ ",X
MSE7\4*78@LQ+.Y_!K_@F1\(/A++^S+^U-XV\1?"K1?%I\'?!35;VS-W9/J>I
M:?J8'B#7]#_X0@J/^$F\/'PIT\;>*/"S*.Z[F7:>A_X),:1^SU^TW\1OCO\
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M(PP?$>W&H^)]>^%G@+PQXZ\/>++3^SO[1\+?\)GKYT+.5&#_ ,(]_8@ ^88
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ML.?\%$?@Q^W)X5FU;P-8ZWX3\7:4CCQ)X*\16[C4M.)^Z#JJ*(I!URQ967
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M_$?B_P#9&_;O^!/[7?@^:YT6UU_P)IWA>]U72](&GC7_ !/H>MG.B'7"3GQ
M?#AT0!3T'_"+K@  4 ?O-\(_^"@/P7^+7[07Q;_9QL;B?1?B)\,_'&J>"+:V
MO;I9#XHU+0([G^VO+1(5.D"-]*9%BE&&5BP(D!638\>_M[_LY_#[PW\2?$>N
M:_KES8?#"ZU#3=8_LC1VOFUN_3[Z>'IHGCT'76;D@F<A6.0I);?_ !!_M=>"
M?C]^SW\5?@O^U#X5TOQ)ING_ +1FCZI\0='U;2;,ZGIE_JFN_P!@?\AS//\
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M^"TW[/OQ!^&L_C#0?"'BQO$XU4Z+9^"KZ^TBP^VRY&&&LMERI&_)_P"$8&W
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M>(5(5^1[ J" &W%OO/\ 89_X*$ZA^UQKS>"=0^#U_P##W6=*\":CXUU?5O\
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MVU_:]I>?VE]@!_XD/3ITX^M?I/\ L[>//!%W_P %,?V>/$FMZIX<U.WM;O\
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MJ^\2:+J/_"0:MX8&CVJDZCIP\4'1/^)%HV@D#*L.Q'((!XP* /W>_P"":?\
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MWMI[R](M+:U4_:9[D!0H&,G@=,D9XXR.#7\T_P 2_P#@KA^T7JWQ&^*-_P#
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MM&$6(D,<",+D[0:]K_X(KQ?!;3-9^+W_  BL]U;>+_%/AWPMK-IX>U6SU?\
MX273]+T/(\<[BQ!P?$NNZ$ %RQ8J ""174?\%6OC[/H_Q%^'_P )?%/@_4[?
MP/:DZS9^(C@Z;KVJZYHN#TX'_")D<GU)/3 'CO\ P1V^!'Q#A^._QH^/EUX;
MU+1OA?J]F-%\'ZG=K_9_]H+_ &.B,VB)SE5+*7;!50=S<8H _3#_ (*G>)=:
M\._L>^.+#2;BSMSXPO#X8O/M5KN"Z9_8WB'7">V#OT+1T)QGY6!P<J/YL/V7
M?^":VE_'?]A/QS^TO9:EH^F>+O!NK>.K(:%=[=.CU'PSX'T;0]>U[5QK:L9!
MXC0)K98NBQXT2,)([EU3^H+_ (* _L[>,OVE/@!?>"O!'B"YT;7M%OH_$UCI
MNXLOB$Z3H^MK#HL9!?.NR/*%C8,44GJ0<U_.-\&_&O[2_A3X0>)_V!_!/@#Q
M7:_$'QQ\4]6OM8TO2[,#4O"&DZ'@MHV3P/ET'_A*"?0$'N" ?-_P!_9KUS]K
MG]AKX[_$N_TK4O$GQ9^#OQ?;1;+@ZD#X#T#^WO[=!/;P_P#\230R!][P8%8@
M?*V/N'X8_MB^ /VG/V7/@M^PUH?A>ZN?&'@S1?"^B7B_\3C4M2U_5-#QH6A'
M0\@G(_MOC:?%X()W+X/(4C]HOV5?@;\'_P#@GU^S^OA/XL>./ /AGQ#\1-0U
M'7/&-_JVKQZ?I>MZK'HZL^AZ*/$,@?7SX:A)C0HI9%=G< $!OR:_X(X?L?>$
MM;_:$^*W[2-G<Z'K/A#P?XDU:S\,WEMG48]?\3ZUK.O,^M:))C8/#X0EPA8,
MR)X<9 4CD*@'M_\ P59^'GAWX)?LZ_LE?"SPNR:;I'@X^*+.T5 -0^W+N\"+
MK3D<L6;7];3Q*S$[28VVA1P/COXO^#OA]>? C]D ^/\ XIZWK>H>(-(U2S\(
M?#Z[\2#^S/"A_MG7ADZ&.I\5J N3R  /NXS]E?\ !<;X;_M _%N/X3>&_A;\
M(?%GBSPSX,@U7Q/J?BK0?#FIW^FV,FN:H6UV'5];0*-"*0^'-%? ,CA-<=BQ
M1,K^<?Q4_P"":_[:T6C?LS?$?0OA=K7C:?0MNLW7P^M"-,U+PI_8@RNB^-CX
M@XT(,.05)!(*@[@: /&O@S#\0--_;ZUCX<W\^I>&[?7_  WI>BV?AZ[_ .09
M?YUK0/\ B=#^O3TQ7N_Q)\4^,/\ @G-_P4F_MR$7.G>%_P#A4&I6=Y=D9TS^
MU=<UL$'0_P#A(>,^*V4$>A (Y&1/\&OV9?\ @H!J_P"U#\/?CYXD^ ?CW43!
MXE\!W=AX@U>TT73--\*::-8;1#K"@]3X2168@ X53X[QA21^S_\ P5I_8!\=
M_MM_#KP#:_"O5M*T'Q=X-\0"YO#=VL/]I:[X6E\QY='_ +;UL* F\&1O#KC$
MDDK$.V* /Y<O#G[:7CCX*?MI:/\ %O\ X2/4KGP?KUYJE[H__$G'_4?_ .0'
MT..OK7[B_ []GKXP_&S_ ()__M#7_A6P_P"*B^-OCK3?&6CVMG?-_9M]I6BG
M76UW^Q% QX@5O[7/SN0?&13:FXN<>^_M=?\ !'CX??%3]GOX/^$OAIX=T6U^
M+/PFT?2]%&O_ &HZ<?%F-'9==9WUTLB+)XD4^)XA)Y9+*P&6RJ^[_$?]G7]H
M'0/^"<G@CX!?!?1[BX^,NA>'? &AW=K)XNTC2E=M&UI-<U@:OX@<A)-Q!&V/
M=N:11D$88 _G.^!OC#Q5^S3\;OV7X/CA!<W.L6OQ(\"66C_:[/6?^0I_;6@#
MV_Z ?Z?2O[@=.O;#4K&"^T^[@U"PN%%S:7=K=B^2\3&=R.!A@.!A&8*<9VD&
MOY4_"O\ P3*_;E^*OQH^!_B3]J'2]-TWP=X#\2:;?"T\)^(]'U(V(&M: ==U
MO6M:\/\ B/<_B$@$KM!#CP_E<Y%?JQ\"_A1^WG\/?VF],\/:[J_A!_V,?!.C
MZAX4\-Z=97&BV&J:]I*:),V@ZR^D(#XD\/Z]'X@DTM2'D,)_L:2'#FY_X3"4
M _6NBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH *KRCS8N,_Y_P _GQ5BB@#^=+_@HS_P31_:
M"^,'[0F@?'_]EV]T0:NNL:;K/B2SU/Q'HWA_&JH&WJ%UL.<H4T7Q)M R778
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M9TJ]\-ZW=>(]8EO2GA<R!X]%Y3)E5E5CKYVRL"H9?F57_1NB@#X>_9X_8-^
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MXU>'!XA\+W16\L[BT=K#5M U/:676-$UC.(I0""X4/D#D]-GTKL'J?T_PI]
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M)- 'DOQ8^$W@SXU^#M2\!_$#1X-;\*ZI'$MW; M8S6+[6<ZII&J1KNCF3.<
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_9P\4?\ ";^'?$?B/PG\+]=TC4[VS&E7G]F_V[X8UW_A'V!] P(!&>X! '%
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M>/8UQ_\ PL?X>KK]OX3/CKP:/$USFWMM!'B;13XBD? )1=$68W0((&/W&TD
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M $ ^?ITYKS?]H3QM\?OBU\$/A??3_&CQM<ZAH.C^%]%L\>)=9TW[?I?^>,4
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MXPU+QQX\_8%\+P>./B-XD/B#2_#?_",7GB&[U@ZEJ=]UZ:X>F?KQ^&*_0?\
M86_X(]Z'\9?V#_A+\5-5^,/BVY\?^*=('B;2-*%Z/^$8T[2]#/\ 8*Z,0<9\
M1$Z'M_X2D9()4XVY90#^K;3?$>A:QI2ZWI>N:-J.DE3.=5TG6-,U'2,#C/\
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M:+K&EV369^&6CKHSZ0X'B#_B>^)/[#FE9U1Y8_%\/_"2^#9)(T;P<D7]4-%
M'\R?[&?Q/_X*X?%/6+'X*_%3X<V'AOX<V_AE+#6?&VL2R:??KI6M>9@IXS;P
M\?$6N.1(X>1$621=JR.RHBKV_P#P3/\ ^":_[57[(/[1_P 0/'WC_6/ [>#M
M6O?$UA8W>C7W]I-K_AIM8$B*FB*0?#S[")!@@JA67(7'@X?T:T4 ?R_> _\
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MXC>.]0#:/\1M<97\*MK#OH(U?157PD)FVH6*1%W4;<C#KG^L6B@#^7OXH?\
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MP^%/V:?#WAGXZWVMZE\1]!\1^*-&UJ]\07FJZEJ;JNLL5#,W\/S$J0P )))
M)S]^44 ?DA_P4T^ ?[4/QU\&16'P%\1ZA9V]IX3U)-8T#2O$O_"-_P!IN^L1
M$L3_ &_"K,^@L4&U6#M@@JS&)/D']E__ ()(_$+P;\)6U7Q5XYMM-\?^.?\
MA)CK>@:K9ZP%T[2M?TAHSE\A1XB1E;>/^$0R@4Y&>O\ 1;10!_')<_\ !*?]
MI[P9\-/BE^S8GA">[\/^)OB3J?Q,TGQ7X>_XF.G(S(NC:"CKX?PR-LT:-]K!
M6\%AT;&&!,'AS_@F?^UWJ&G:!X0U?PAXCM=-6[TRT-XVD#3%55&2VNDX  '4
MG &<U_9%10!_+K^U;_P3N_:>^*%_\)M$FT7Q%KEQH7A'3M#_ +6TC6@=,T+3
M5.A: ^AC7,_\4^5*OXG91R"I! P0*_Q__P""8G[2'@CXE_![]JGX9W-IXC^)
M'PP\.>%=%LO#VE-J^I"Q.B^-AXZ311SS_P (LYUM4\4C[S$*.HK^I*B@#^7/
MX@_\$Q_VJ_VC/VE/@=^V'K6JZ5H5]/X9^U^+O#>IW8TS4M.U+6@1M5%'11K3
M *HXVD8^7 \/_P"'77[9_AO6OC#\*M#T*'6_"OQ0\0>*-?\ ^$@\0SRZE8[=
M=7<1_:H3_A'M DP?]4/%AEW?)LW_ "U_7Y10!_'K-_P2E_;0U'X;_P#"G]+\
M(:6+32M7TM]9UB[UG1=-3;C.[0V\0'&OJ!R6)QCGT%?T4?L2?"?Q#^S!^R-\
M*?A+\1=5L5OOAQX:>PO=7U/5='_T/3O[:DU@G6M;B"Z#YD?]LG#IL4HP,3.?
MFC^XJ^*/VR_V0[+]KCX<:;X';QQK7@'4- UK_A)/#VL:2IO5_M8*,G6%?)>,
M\XP[GLA?' !^,GQ:_9,^'7[8G[=&H>)/A/XK\)P>*? /BW5-;UN\T?Q#I&=1
MTP:S\VMJB[V\0'PIXD'"+N/_ !4&!DXK^F6UM3%# +B7[3/ I7[0PPQR,'N>
MHX.:_/7]B+]@'P/^QWX:@F-_;^-/BK<6>H66L?$,V1TSS=.D(VK%HP8#@@!Q
M@[BX'R 9;]%Z /!/VA_!7B/XE?!WXC>"/!MZNG>)_$OA/5-'\.W;WGV'3SJD
MD96/3-496?:CY9#\H!1I1E C!_Y]_P#@E'^Q)^V=^SY\??$/Q-^(O@-=.\,:
MG=#PWK U_P 2?V?JH5]W]MZZ% 8^(0Q5@G!#$$#)%?U!T4 ?@7^TIXE_X+">
M$/V@/$]E\!?"UKK7PN\8>,Y&\":JMIX.\::78>&59UT<ZZ/$&W_A 0'+%BV0
M6P^"V&KU[]B;]AOXF?!;5/'/[2'Q8GTW4_VG_%_@_P 5^%],TL'1]2TSP^^N
M:TNO(HUO:0ZMXC,H,BMM3PAK+0Y,@=$_9:B@#^?G]A7XX?\ !1N+]KS_ (4E
M^T]I\-O\+T\">)]<_M?4;*4ZO_:BAAH _MK6<R.,:,X* ,I5FRIYK]%/V][;
M]K'7_P!G?Q'X6_8Z\/Z/J7Q7\7#_ (1JYU74_&.F>%;[PCI$P*ZQK&AZN6"-
MXA1,(D;!E1@6"+)MQ]T-'Y@Z0'Z GC\/K^M3IT/U_H* /XH-!_8K_P""T/P]
M\06NM:KX#L]:U+5K/4_M6O\ _"9:)XV\4-JA5]"!UO6_#_B7+976)&& <K&Y
MZ(2/T]T;_@E?X[^.7['WC'X;?'XZIX:^*.N_V5K7AJ\M?$.E:CJ-GJAT(N!J
M[E0FB$>(0S%8V9E .1P:_HEHH _EC^!/_!*']I_QUX[O_"W[1GB7_A"_A/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HIGF)_>%/H **** "BBB@ HHHH **9O'H?T_QI
M] !13-X]#^G^-/H **** "BBF;QZ']/\: 'T44SS$_O"@!]%%% !1110 445
M7\Z'_GM_X\?\* +%%,WCT/Z?XT^@ HHHH **** "BBB@ HHHH **** "BBHF
MDCC') 'M_G_/X4 2T444 %%%5_.A_P">W_CQ_P * +%%,WCT/Z?XT^@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MP#\8?#'Q@4:79&\U'7] \ 2ZMI:.TFB'2)-,*S0_:/#LPUU"WB(B-('0JID
M##Z<_9D_;-^ '[7>BW6N_!3Q1<:[!!9:1=WVEZG8+IFKV2ZTWF*'TAW:4F N
MX\3 ,%MG*J78'C0\7_LE_ WXDW?Q%N/BAX1M?B3;_$ZRTRQ\3Z3XU":EIUG9
M1:2-!D719=@\2>'ED\/I)%*5\3;OF9H_*95V_C/_ ,$C?V4M<^!G[67[34]B
M-<M_AMX7U?5=$\-V>J@:H3C6#H.A'^VC@G/AP8P,DG0<>IH _I*HHHH _.U?
M^"EW[.I_:)N/V8A_PE)^*-MXY7X?W$?V+1AI:^)CJXT(0^=_PD'F>69<-O\
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M;VY\):3\>-7\,67V:UT?1F:_U/7V.A[1KS9;;D\+G:.%4    ']67G^WZ?\
MUZ^%OVZ?VQ+;]C+X8Z/\3+KP<?&]OJ'B(Z+<:79^(_[,U/3]^B>(=:.MKH^W
MS-<T1!H,B/Y3H460$\N OXS1?MH?\% ?V1]&\0>,?VE?$-KJ?@[QYHVJWGPW
M_P"$L_L;_0-3./[#7^W!_"W]MZ%N4\-@ Y(KX'_;[\'_ +=GQ!^$'A_]H+XI
M>*M0\1_!]=6TFRVZK9C3/[.U+7=:(7^P@/NK_P )&I"X &5('(H _K=_9/\
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MR8U_=.OYC/\ @Z,O(-,_8V^$&JSFZMA:_'C2@+JUZK_Q(]=^4\=?XC[MZ<D
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M_##]GSXI_P#!3+]DWQ3_ ,%0/^%T^)?"7Q1U.ZU/Q19^$_M9'A<CP+HI'!P
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M?VA?!HT3Q1\.[X^"[3Q"6?=XM70%.BMK,:(&>7/D@-XACP)5WY!^8D ^6O\
M@LW^U]\>_P!C#]F.P^*7P#T.SN]73Q*MKXAU^\VMIFA:6671ET]PNB7".9IM
M8-Q;R,$DC&@'C?O9OK3]D#]JKPI\=OV>?@3\1O%/B[P9IWQ ^*7A#PY>WOA5
MM:T>RU5?$\P#OHRZ*TWF)K>X;/(C (=4,:(B*:^"?^#B5;6/_@F/\3U-Y)9W
MC>+O ]M9!%P=1);6VN=)SWWZ"^LEN-WW2Q).!^(OB/\ 8P\8_"7_ ()@? __
M (*$>'/B+JFHW/@+X0:7\6_&'A0W?%D-<UE23H748!<+S@E@P&0I- ']O5WJ
M5O8VLU]>SVUK8VULUY>W5U<!%M+'869V.TXX4G<6P2 -S-M%<=X3^*7PZ\;S
MW%CX/^('@GQ=>VH!O+3PIXLT?Q&UD,9PW]BN[#T82!64\<=*_C=\1?\ !;_4
MOVU?A!^SQ^SGI_AK6="'Q;.G6GQ@^(-T-%']O:9HNCGQ#)H_]A@<&1CHC2'J
MS98Y8L:]+_;#7XE_\$6_CQ^RIK_PZ\7Z?X@^'/QU^*NJ?#O2DNY-5U+Q5MT3
M0@=;EUO0]9T&3PU&L@UTF,^%3'+\I;:N U ']=/B'QCX5\,:?_:?BOQ+HOAK
M33]Z\U_6=)TBP8C_ *::U)$5Z\@ >OL-;1?$.C^(=.M=:T34]/UC2=14&RU3
M2[Q=0L+K.0-CQ$H/ND'8S>C$=*_CW_;+^+/C[XOZQXP\?>*?&X\1Z-X#T@ZW
M9^$_"0 U/^UM$);1-&.A#')8DDXR223S7*?L.?\ !4']I#Q+^RQ\=_!6AWNF
MZ'#X!^&VJ:SX/\16=HRZGH7B?#:[MT8*0'4;R0KA@K$LH##- ']B.F_$7P3K
M-S-9:7XP\*ZE<VEZ-&N[6S\2:1?D:L,_\2@A;A2=:.!_HS$D_P 0)Z>2?M6>
M,KSP-\ ?BMXBT/6K?1O%.E^ O$MYX<D>]6P=M3CT8M&='9L,[ Y*XSM<D\')
MK^4']@KX+>/OB#_P3T\;?MJ^(_&)M]2TS6/'FMGP]JMFNIG7/$_]LZ$=;UMM
M!S_PC0#>(]9<*P4C*L,BOI']B'4_C!_P4&_9J^-WQ]^-7Q&U&XN?"'@3Q596
M(O++^T=38C1?$#'1 >G_  CY UUB,[B!X:;D*V #ZR_X(3_MR?'3]JSX=>.O
M#WQZU"T\5:OX6\1>*;[2/&+7FJ:CJ-WI<6L:%HRZ5(91@+$VM%E(W!&.Y@ &
M9?Z$)IO*_P _S]NG:OY4O^#:;PSK/A'PE\1=*U\BXNUO_BBVGWQZWFG?\)AX
M$!92?XO*;1QS\H!(["OZ*?VG_C%#\!/@OXT^*?V73M0OO#M@7T?2=4N8K"/4
M=5:;*1K*R/\ ZF-)=?<*%9HM'+ K)M9 #V75O%&B:#Y']MZOIFB_:"0#K&K:
M7IV.^09)2'[\@X]ZYOQ9\0O"GACP1JWCW4]6@/A#2]&'B$:O;W6E26%[IR1;
M\Z9,9&#_ "XVLV,E@J.=^:_E)_X)\7OQV_X*5?"[]HCXU>,O'Y_X2C0?$OB=
M;/Q#=73-IO\ 9;,%T'P9_82AL >'=$US<WW54>&&8A 6'H?_  1Q_;8^*'[8
M7PV_:N^ W[0]PGB#P#\)O OB2>SDT"TT;2]3LM+T37MFL1G7 0)"9'(B#9VO
MHC,HRS;@#S3]E[XS?MH_M]:O\:=#^#OQVUO0_&WA7Q)_;6-4\1:UX;_L#2M!
M\:#@*OB/) &N<!03TQ7]-'[*WAGXT>"/@OX)\._M!>*[;QM\4=,M-0M=:\06
MKR2"^_XFS*G]KZNQ:/6-?8 [I(P@D*R!AO)DK\#O^#=/X9>'-&U3]L#QD;*X
M'B?2_'H\+VFKWEZ=1-_I>OZWKVNZX!@]2VAZ$,9 Y[YX_II\1ZO8>'-#UCQ#
MJTHMM)T"RO\ 7M6NN"4T[14DUABN2 <1JPQW^8=Q0!@?$6?5!X'\7RZ5?+HN
MKCPCXF;1M6$:WXT_4$T=V@U4  <0'&W&"<$G&X@_S6?\$6?VE_VC?C+^W)^U
MQX ^,/Q;\1?$CPOX,\"?;M(M=8U<ZH-.U4>,]!T)6$:_-H9_X1_:-BLA(R58
M, K>S_L(_M?^,O\ @HG\6?VE_A5K_BOQ#I/P_P#"]]X[OK3P]I7B'(*[M \"
M2:)K6MKX>C\3Z_X?8:XQ'A@GP>%;+,CXVG\]O^")&F^*_"O_  4,_P""E]AX
M4LUUGQ1;^'?$]CI'V7^R=.\-V7B8:SH+:*D?]N.C_P!@GQ"K>&%9=Q7:3L89
MH _HG_9F_9S_ &B?A7\8OC#XZ^+OQ_N_BSX7\9RBT\):5<R:JC6D4:EWU/5]
M"?79O#>BR^&4!\,1Q1KXK9T5F%U 0F_]#?-AAC!SQZ=R?\]*_F+_ &5/^"C_
M .UAX[OO^"@EM\7O'VC7&B_!+X%^.O$_PLN['P)H>EZCX?\ '*C^P]#!&@@G
M7T/B+6M#0+XG7<6*_=3?(OPG^R9I'[?7QG^$/B_]LB']J+6KFP\">(VUOQ)<
MGQ+K.FZF=)&BZ\-?UO\ ML]0/#C*&QP-PR1N&0#^U_[3_P!,V_/_ .M4/VSW
M_P#':_A_^$O_  6O_:]\5>//C1XC'PR_X61XHNO!^I_#+X;ZL+/1M,U.PQC'
M_(O_ /%,8'B,?\)0?4<'CBO/M-_X*??MZ? ?X.>#_"WQ&\4ZCX;N=>\7ZK>7
MAM++^S=4L.<Z\/[=Z^'P/$FN<CIGGGK0!_>/]I7_ "#_ (U\?P?MA?"J7]J2
M_P#V3V-W;^.-+T%==2\N;ZR&GW^I/'_;*:)I(69Y99%\.R-))(QCC2Y)\+M&
MD\;-7Y2> /V4_P!O+X__ +*WA#46_:*MO!&H>/?%R_%IM.\07.LM_;ND^.G&
MNKK&OGP]\X4%]%?P3X7P8XU#O(T8Y/YY_#?X?ZI\,?\ @OYX7\/:YXIM]3UC
M2_!O@/1AJN"-./\ Q)-?.N#:V"K>+>,!L%3P<8H _LG^TKY>['/^><?3G'Z8
MJ'[9[_\ CM?RN3_MY?$3Q]_P6V\'_#?PAK>HZ!\-PWA;P"OAU[I=3&N^&4UX
M:-K) VX'A[Q.XUKQ2C;2RLGA9LEQN/DW[2?[5/[2'[+G_!8;PM\+++XI:S=:
M+\7K$WE^GV/1CJ-_I>A^"R/!*-H6A(GAK_A'=W]BJZO&K9R'13E0 ?V">?[?
MI_\ 7JL+L2P^<!@#C'U].O/Z5_!!^S3\!_VH?V\/C=^T1X.\'?M-:WX)N-+\
M>^/!9V=W>9^WZ7^7XXZ?\3_M7L'@WQ+^V'^Q%\0-?\ ^/O'/BSPXNAW>IV>K
M>([/Q+D6.E'G7"#X?X((QXI&,@C!SZ@']POVGY]OE-TZ\9ZX_+V]?;FGS3>5
M_G^?MT[5^2__  2V^+_B/XU^#?B#XPUKXF^)/B/IUT? >H:1=>(/$FI^(UT5
M=<T?7GEBT7S05VRI_8WF, & WL'! S[/_P %//C]X@_9M_8Q^*_Q)\):A?:5
MXV6QBT?P;JNFV(U-['6M4F;,QC8<&/0X]7>-P/ED7<I!"&@#[NO]6TO2;3[=
MJM]:Z=;?Q7-[<BP4_4$C_'OCO7G'Q>^)>G?#?X/_ !&^*I%K?Z?X$\ ^)?&E
MMD@V-Z="T5M>T@!QQMD*1!2A!^\XVD)C^6SX-?L]?$/]K+_@G?\ $G]LCQE\
M8_%MS\0K3P#XX\:^'1=ZR/[3UO4_A;I'B'6M8_M[6\[L2.KJA /*-DC )]2_
MX)__ +1'B/X__P#!*3]JSP%\1+[4;GQ#H'PM^*(MKW5AJ^[4-'.A-H.NKN(W
M!?,V,0IR3KO/&Z@#YH^ /[.WQG_X+$>$/$_[5W_"\+7PCXO'Q'U2PNO#EGJ^
ML_V98Z4NL%M"T-54$GP[M4D*H/"\"OZW? /A2Q^#_P *_"WA;5/%!U+3_A_X
M0TO2+SQ7XB:/2FOM/T*!<:KJYYBTEPL;LY$K(FT\G8 OX,?\&SWP^MO#7[".
MO>,8KS[3<>*/BMXFT2\MS:*%5O! 9%P6.2Y;7!%A?F)T50,Y8#]^/BGI=KK_
M ,-O'^CSW>GZ=!JW@GQ/IES<ZM="QTVQ&LZ1)!YNL%6S&B^86D=A\D>\8)<%
M@#X,_9E_X**?"K]JCXE?&[X=>&7@T"#X<OJ,=CJJ:O'_ &KK::-($UW_ (D?
MR8UR$,&8+N98D)"R,N#^17_!(/\ :L\'^!OB[^TQH/Q:^+5IHOA^V\8^/!X;
M;Q%XDUC^S;T-XST%=$=-#9)%+JK:[CQ.R[6R0QP2#\L_\$%?"%C=?M _M$67
MB.WN]4UCQ1:>)M#TBZU6[R=!U1M&\>KNUP==H\.'7?##''"@G''.-_P2S_8-
M^'W[7GQ4_;0/Q'G\2Z<WAGQAJUDFNZ1>J-/M7UO5VDT*/6%<J&<KH&O,%R#A
M6)PJD@ _L?\ AU\7_AS\7M N/$?PT\8Z+XLTBUNS97ESI-_YAL-31"S:5JT8
MC>72)5.T%9%#<,5R2!)P_C']JG]GWP+?0:/XM^+/@S3[^XN19-:6FM1ZI?V3
M%<DZPNB"5M#8,,'[25'0J2,X_CB_86_:(\>_L7? ?_@I?I7@(""X\+?$CQWH
MME:>(@-2U0>*-";7M#&._P!Y=;..Q4'@@$>@?LR?\$_O'W[8O[,GBCQQI?CC
M4_#8N_#FIC6/$/B#Q'H^GF_U77C_ &[KIP ?^$>&>I( 498E0"0 ?V6?#SXC
M>#?BIX:M/&7@/6K/Q%X9U)?]"U6RYCO,#!*DA<@ C&0#CMBOF+]N+]K#P[^R
M%\"?&'Q3U"XT<:_:65_:^ M*U==8.D:CXF32Y)(5UP:)OD70T54,S,%()4QD
M. T?D'_!)[]G_P <_LZ_L>>%? /CSQQ:>/-5NM;\1>)]'O[4*VGV>BZW,LFD
M0ICY^8T<L,=&)4%LE?B'_@X)^%OQ#\??L]_#;Q5X-\.>)/$7A_X8^(O%&N>.
MT\/I]MDTW26'AYUU9X^H,4>C:PC9 (.-P!." 7O^"*.C?$WXT_"C6/VG_BS\
M8O'GB[Q%JWQ)\=Z);>';S6IM1\-WB,FBE==)UF.1XU=M8*#PXVQ(AH'AN7<S
M1")_K#XH_LK_ +0>K_MV_"[X^>'/BCJ2_##26TVX\1>&X;M] 1=+2-M&UKP6
M3%X@/]MHT(7Q4F]$!9_$<:[GDA#\5_P1/^)G@GQS^QEHVE>%-+.B3^#?$>JZ
M)K%G<V"Z?]MD+QF/7]KC:?\ A)2IDP3G(R 2 *_2[XJ?&#P%\(] O];\9^([
M71DM;+[6MJ&,FJWRI@$:1I#NSRR%L\A<*0P<D_,0#YG^/O\ P47_ &8OV</'
M,'PZ^('BG6;CQ>6TPW>D^%-&/B)M._MD@0_V\8W_ .)*AY<H[H<, PW949_@
M+_@I9^R1\0/ /Q ^).D_$"\T_0/AW<"/6K+6-+DTWQ%?;%.&T+P\7.OZYG #
MF*#<2P."H:OYQ/\ @D=XX^'GQQ_::^/U]^U+>#1CK_B?Q+>>$1XCO_[+TSQ7
MJ)\; :)I .UMQ1=<UU@GR[P" P)%>0^,--LO"O[9O[0%E\,[W3;CP!_PL?QW
M]DNP<Z98>%_[9Y . 3TZ\'O@4 ?L_P"*_P#@X5_9#T+1GETOP5\4O$GBB#4+
MR"^T*ST<:=IUEIT)UK=K']KNC>)$1EMU!*^$"P,DA4(ZAVB\0_\ !?K]FZ[^
M#5C\1_ /@;QYK?B47FFVFJ^']3TEUTW0VE9_,636 /\ A)&* 1E9?^$19G9Y
M 8XRH:7\S?\ @G-\*_@O\09?^"@WC'QO-HET/!WPXU3_ (1W5KN]QX9T :Z/
M$']A$=,G=M'/3->0?L3^#_!__"D?VL/'&JSZ)J?]@_#?_BF_]#_LW3+_ %30
MM:T _A_^K% ']*'@7_@J#\'O'O[%EQ^V%H7AOQ/K6B:5>:GX<UOPMX?M&\1Z
MEH7B?1A("FKLDBNOA]72-Y/$[+Y95E(RV=OYAZ9_P<2:?XCM5U7P/^R]XO\
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M?&O?\(NTI8-X.?=)A2V%^._&OCKXW?MP_P#!2OQC^SS;:WJ/A#3K;PBVN?\
M".V?B\#2[!M%\&Z"[MH8Z;G<EV/4LQ8\DFO9O%/['G[:WQ5_;(U'X^^(OAK/
MIWA_4M8TN];2?MXT[3-/ +J=&T4DDCG67!\5'G*,#RIQ[+^S;^P_^T[\&?\
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M9IWB"_30&76SK#:6(SX@UZ3<PVPF02LNYUC**S+]P? __@A3X;^'?PT_:/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MQ\J'T_0_X5D:IH6F:S8W.E:I8VNI:;=\7NFZI:+J-C= X/S)*I'4 Y.>G*4
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M)QD@,U3PYHGB'^SSK6FV&IG2=6L-:TE-4M8[P6&JZ1@PZKI(),B2J"HC=-K
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MR+^W'X_^"?P2G_8+@_9L\77/QX'B35/#%GXL'APZB-!U771C7=%(\0>&^?\
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M^PQ_W'.OK7L__!-_X0?$;7OVS?@_X_\ @MX ^*/@#X7Z7X\TO6O&'_"<6?\
MQ_Z7_P QW^W>P_YCG\NF*_MY\J'T_0_X4>5#Z?H?\* %F_U)^@_E7\#W[5'A
M7]J'X)_M5>,+CX_> /%NM^'_ !1XEU2R\'^-_#V/[,O^_P"?\NON?[Y)8Q*N
MT\>_\ZJR64$LUO--")FMV!M<J!]E. "R_,,DX )P2  ,&@#^1/\ X-YM"^*G
MA_\ :=_::O\ QC\-_$WA3POXQ\,G6_#ES=+_ &IIUD-<UG02576NY;^P\ 'K
MD>M?TM?M@I??\,R?&B&RT/4?$EQ/X$U4+X?TAP=4U3<B#^R]) 5<RL <<?=)
M_O8'TN(H(1G'X$YXZ>W^1[5,R!^M '\6/[$7PV_:$M-&_;GTKP/\*_$NFZA\
M8_AOXH\,^#_M=Z?#6IW_ /Q)#KO_ !) #R,:(?"^#D9PV,^+01V'[%W[.O[7
MFC_L;_MD?"N#PIXC\-ZQ<_#?Q1HP\/7?.J:]_;NB$?V+_P!C%@D9STXZ=?[&
M/LD/H?S'^%(UK!(,X]O\C'Z=.^* /XM_V*/^";G[5OQ9_8]O_@IXR\(#P!K/
M@[1O[;\-:IXLO-9TUM0\3AM=70]'"C)VJ63>P&U0PW$#FNG_ ."?7[6__!4?
M]E2]\'?L9>)?V--=\:BZ^)2>&CXMU2VUR+PUH)UI@XUK0]?C9/#7_"-DJ/$[
MKG8Z;HY!X/C9E/\ 9%]DA]#^8_PI?*A]/T/^% '\5O[4'[(/[4_AC]M73?$M
MA\'?$OBW3;;5]+\47?C;P_8ZWJ&FZZ==_P"0Z-%UI@KZ\PZ,K ,IRK $''I.
ML_"#]L+4?^"G^C_''1/@O\6-1&@^!=*N_P"U]7\(:P-2_M;1-<"+K/\ ;OB#
MPWU9]="@9R20H_XH3(K^PC[)#Z'\Q_A2^5#Z?H?\* /Y0_BC^R-^V/K_ /P7
M$^#/Q^O/ARI\)WGP?U.ZOO&UOXDUC4O"_A/5=&_MY-!C;6F^]_PBY;045<$N
MS!0"6 /,:Q^RG^WE^R=_P4$\,_&SP!\)KCXI>&->T32;2TN?#;G4=/&HZ-HK
M+K6D:V5(=0Y5Q'(N,E&V$%,C^N+[)#Z'\Q_A2^5#Z?H?\* /Y/&_X)K_ +07
M_!0;XP>(/BE^T9X7U+X%:U;7FJWMGK^J^&]9TYM!U37/[=R? ^A:_P Z^HWJ
M6<[47>NY@&%?-_[-6H?\%6_^">NN^/\ ]G7P;\'?&WQ \+W?CL?\(SK*>'3X
MC\-?VEK^MKH?]M*Z>'/%K!&PI(4@,%&<BO[4_(]_U_\ K4>1[_K_ /6H _C6
M_;D_X)V?\%"?$OCGX$?'70_!UW\1SX6N]2OO&/A/_A+F\2:CH.J,2-!PQ'_"
M2MX>XY"DE1MR!N4G^M7X,WOC"]^%O@JZ^(&FVVC^-&\.Z8?$6F6EB=)2'4?(
M@)VZ*K+_ &('P[#002(2YA!!#"O5/*A]/T/^%.AABAC$40"J,\ \\]?YT ?-
MO[7?P)M_VG/V:?C-\ I=<N/#<'Q7\!ZKX5?7[2V&H'3UF".K[#G=ED"@'!P9
M""2"K?S$?LE_LA_\%0?V4O@S^T)^QOI?PMLO%GP[O/AIIVAZ=XBOM85+$1M)
MK22:OX&UMPOAS7O$7]@F!94P,2^4C^!@Y45_8;PX[]?Q!J'RH?3]#_A0!_-7
M^R;_ ,$M/%O@?]A7XN6/BNRUKPW\??B!X1\>1Z+X6 8Z5O.B_P#$@T37M$U[
MPR?$B!_$BE0[L@,AC\:+N>5%KV+_ ((2?LE_&[]F3X#3P?%_1K?P[)KND:99
M:9I]Q>9U.^U+1=4F.LZQ-HW_ "[AW4&-\AV8*J@JS$?OEY4/I^A_PJ2.,1C
M_P ^P[XH Q-?TX:IH>K:4)O(;4-+U&T^TXYC\R-H]QZ9P');V!(! K^-WPS^
MQW_P4L^ ?[2/BCQ)X4^"%SXM\+C^T_!>L^(+35]9U'4]=TO7M$!_MG1=;(!U
M_P /8(^5@& (\#$=:_M!JOY'O^O_ -:@#^8+_@E'_P $Y_VNO@C\1O''Q&^,
M^AZ)X#\/>.O OB:RM-*N=8T74_$E]JOC;2O$"L-<T70,INC?6-%$J>*SO3_A
M'B,!BM>)? C_ ((E_M,>'['Q]\./BK%X)N?"/BSQCJOC*ZU72=8T8Z82-89M
M#T08SXG  4G)P#TZD _UT_9(?0_F/\*7R/?]?_K4 ?Q/_"O]G#_@M)^ROX\U
M&Q^#OP>_LVWU.]U2R\.:MI-Y_P ))IFGZ7_;0\!_\3TY_P"$8''_ !5'T'_"
M<U_6_P#LU>&OB=X/^#'@#PY\9?$2>*OB3I.E7%GXL\0I=?VG_:$QUN;^QV&K
MJ5\USH#:29%(+.^YSR0]?0,$,$6?)&/Q_P _Y-((A'T[_P">GOCWH _*K_@L
M?^RS\1?VQ_V'_'?P7^%ME:ZSXXN/$?AGQ/I&CW=X--_MP:#+*ITDO@#$G]LY
M(.,;<MR37P!/^R9^W5X__P""<'P1_8PN/!/AW3O#!\,KX'^*J>(?$[^'?$M_
MI<:O*!K,0)']@GQ"[,PC7S9$";@RHF/Z59H?-_S_ #]NG>CRH?3]#_A0!_(U
M^V)_P1/^)7PTTG]EGQ/^QG#;^)M1^$=V++XD:9:61TV_U%CI&BIHFJZ!H_A_
MY&T*)H)!-$"7B 7S%7<M?9/[77["/[47_!1FX_8W\5?%J'P=X L_@7J[>*+S
M1[J\4ZMJ6IZQH_AZ/Q!K>N8\-[M!7Q.^C*C>%^1'N"L1D"OZ'/(]_P!?_K4G
MV2'T/YC_  H _CV^)/\ P2@_;S\'?M%_%?5OA+#HGBSX?_$C2!8>#?[7UC1A
MIMBVA:)H&A#6=:!\2 Z Q&<* 2<9KS[X!?\ !'#_ (*+?#'P+\8/#6N>%?!1
MNO'GA#4_#%F+/QWX/8WN[.TMCQ&=HX)!; ]3@U_:3#:0PQ"$#(^O/X Y].N*
M=Y4/I^A_PH _'K]A+]@3Q1\&?^";,W[(OQ9O[.XUGQUX=\>IK+:5<FP/A)?'
M6D*NC1*RD$/X5957 8_O%&4<H5'Y=?LW_P#!,W_@I7^RGX8\<_!OX9ZKH=W\
M#_$^C^.M'_L<^.]&T[4[XZYHWB#0T8@^)#@AM9W*>H901@@5_63]DA]#^8_P
MI?(]_P!?_K4 ?A3_ ,$=OV!_V@?V+M*\3GXWGPX^I:Y>>++5+6P\1_VLUAIF
ML:WH&LZ-MP&!<'1C&5/(+,."#C]<OCO\)M(^.7PD\;?"?6)EM+'QGHCZ*+S[
M,NHG3Y'=GTS550D?ZN2($NV<$D;@%8M[&(A'T[_YZ>^/>IM@]3^G^% '\V'_
M  3!_P"">?[<W["FC_%CX5&X^&P\ >/?&/BC61=WEYH^HZ7J&F?\5 =! _L
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M-[.3[-KU]J=NP;1-2748[9M(N0$7,Q:;22 NY"NLV[%E8;4 /L6BOQ"\4?\
M!=S]CKPI\3_ WP_N(?&]KHWC*]U:R'Q!U7P[)IOAG3SHVMC0W!8L6;+EB"-F
M%(7: .?V'\#>-_#7Q&\+>'_&W@[5K;6_"WBG24UGP[JUF3]@OM,D(1) >WS'
M&<8X./NE2 =;YT/F?9^,XS[=/\C_ .M0)8)AC/XD8XZ^_P#D^]?E#_P5D_;Z
M@_X)_P#[->I_$32]'N=9\>^(-9T_0_ EJ+41:7::FS$GQ%JVLZWH,WAG9X<D
M.DS?\(])(EPS,&;<6#+Q7[ W_!3SX=_'_P#95TKXF?&_5;CX?^(_!_@#2_$W
MCOQ5XIT@^%?#?CDJ/$']MZUX%TI"\FM.CZ'')XP\.6Z++;3:RCJ2<8 /V<HK
M\6='_P""Y/[&VK_$[P3\.96^('AQO'C:5::+K_B+PU'I>E6&IZT,I%KA&ODI
M&&QR 77D@YX)^T3_ ,%P_P!D']G;XC^*/AI?W'B7QKK/@ZT_XG-SX>M=VE'5
M!]W1]#UE@8]>?&&8QJI+9&YL T ?M-17X$W7_!?K]FS1O".G^-_%?PM^+?AO
MP_JGC'_A#;.\NK/2-2^W:K_932]-#:7U"]>,?+M4(J=NG_!>#]CM/B=XB^&6
MN:)\4M#NM$LEN[.\U7P[HR-K8.B#6W\K2%\1"0-LR5;.2P&"@)H _;^BOQ+^
M /\ P6]_9W^/'QLT;X'6/@#XD^"=?UZ[TFPL]6\6VNDZ=IG]I:UG8-V[)(SD
MDD[CG=UK]L(I!*NX<>W\J )**\Y^)WQ*\+?"#P!XG^)7CC4H-,\+^$-'DUG6
M;PX 6.,8W 9YWL5"C&3DMR%Q7X=6W_!P!\ +KQIJ&CV_PF\?1?#"TU75+&P^
M+4\]O_9^KN5:/0#%HIA\LCQ-KQ6" -XI'[H'S1)O84 ?O!XD\2^'?"&E2ZWX
MJU_1O#.DV:C[5K'B#6=,TK2K$]29=5UIX8P>F-[')XP#Q7D6J_M6?LTZ0/\
M3OCW\&83]KTJT^;XF>#%&[6-9&BQ=->_Y[<$G&T . V=@_"C_@N?^WY\-]#_
M ."?VN-\,=)UWXL'Q[=Z1=?;-)MM=T[2O"JIJR:Z'UW6CH#JT@QY;>&V5965
M%1BRHC'YZ_X)4?!O]F[]MSP+!?\ Q$\ ?%C3=8N?#?A?QII%M;D?\(O=Z4=$
MT#,FNZV?#J!O$'B@D,Z^9&3&&VON 5@#^M6WNX;VVAO+>:&XMI[;[5;7,)W(
MRE0=RDE@00P[@YW*R@CB;[7#ZG\A_C7%ZW?6'@/P-J^JV^E7]WI_A#PK?WMO
MH^D@7^I7>F:%HY=-+TCDNTA6&.& 'K)L.-C83^5K]DS_ (+@_M3_ !A_;M\:
M_L^:G^SWXI\<^#SXFD\.:5I?A30-*T[Q#X2TPVK:L-98%U>&",;)_+\0S>)S
M_P (E'YWF*[S-( ?TS_#W]H[X(_%;Q?XV\ > /B#H/B7QA\.KT6'BW0+&\D;
M4=/<1D9V$,-50D;0T?F@[OG(;!;UO5=8TOP_IU]J>L:C9Z9I6F61O=3U75+V
M/3K"RT^!6WZCJ.K3;(HQMC/S-(N.=^ "Z_QE_L/_ +6V@_L]?\%+_P#@HQJE
MSX!\7>-=:TKP?XI_L3PKI 33]4O"?B8VMG1E#JZ>'R5T9U^96!&@D$8.*_H-
M_8J_;Y^%?_!1KP1\3?"M[X#G^'WB'2HM2\.>.OA1KWB&/Q#J>H>%=>TN+29]
M6_MG0HO#*OX?G?6)/#TCJB7#.!LFB;$R 'U#\$/VN_V>?VBM8U[1?@U\3=$\
M?ZEX7LQ>ZNFEV>J67E+_ &LVC$ ZW! P*7'EQX5F#IJT#AE=Y*^IJ_!O_@G=
M\0_V*-%^*?Q/TKX$^#_&WA+QAI?A#Q,I/BS5/"#?;_#.B:V-<UO1M"7PX2RJ
M'T0%B<@)H#%F0 L/+=7_ ."X_B"3QM"/"?P)AN/AM>:SI5G9W>L7NL2>*+XB
M1Y==T5&T,/X:7Q"&<B-,^7$ JPKXN Y /Z-J*Y_0-577-&TS6HHVAAU.RL+M
M;1R,VBR#>P.  <<=A]W..U>0?M$_'GP;^S=\)/$_Q9\<7 _LG0$(M;9!L:^U
M63<VCZ2I4#:TD@!)[%6()/4 ]W\V'U_4_P"-6*_FA\(?\%U+R;XX:?H_Q&\
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MFJW&@^$OB?X \1^(K0&"YT#0O%^@^(-3C&!D/HVC:W-*AQG):(.H!4[<8/\
M$;^VQ>?$;QY_P38^"XOOBIXMTVWU3QYX8\,7FDW9_M+4[#2SK6?^)'_V-F?_
M "@?\5[G->Z>-_V,K;]@+_@FQX6_;,\+^.?&?C3XQ:O<:9XLU1?$5^--\.VF
MD_%-E32&UN,D.4A,L >0 KXS:>-3@E=P!_7_ ./_ (N_#;X::5?:UXU\9:;H
M=E:JGVI3YE_J"9Y&W1]%CN-?=@ 0=ELVS[K#)&;,'Q7^'G_"%Z3\0+GQ=HNB
M^"M>M--O=)\1>(+Q/#EA.FKL3!B373;(CMD,%< *69?N@O7\07PX_P""?_\
MP46_;U^'4_Q3T3XCZ9J.@ZK>:K9"[U;Q)HQ_XF:XW-[ 94%O"G +*"<L*XC7
MM-^*GP?^)?[*'@#]I/XFZ;J/@^U_M2^T>U\)_P#$M^WZI_T&M<_X2#_N!^%_
M\D4 ?V?>*/V[/V0/!DYL-;_:-^%S70LS?-_8'B*+Q,UMI_R_O"/#?_"2IN!
MSP@.!\JX&?B7]GS_ (*P> OVA_V[?$W[)'@K0M0U'0K7P;J?B;P]XV6RW)J
MT, 2:O\ ,!E&Y494$#:Q7C!2\_X)S?\ !.R\\'_\+HO?[0;PMJFD@GQN?'+
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MVC>._$GAC1+2UN_$FM:FMAJF@G0DU_1-</B#Y?$/A\-K++X*'5> V,BO7?\
M@NA-\;O"OBW]DKXQ>&OB!-HWPXUWQI\,_"[^'M%\2:OIFIZ=XJ.M_P!OC66
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M?@O4O&7[/VCCP;:[KSP@=1O]+;6=! UE3H/R<"/<R(<C^P [*OF!GQ?VS/\
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M4[7PCXHN_$FE6?ASPE=8_P"*LTS^V<:Z.F#@ *.V!QP*_G>_9@^-7B+X.?\
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ME2'T+1-SXX"E<$.Q0 _G-L_$GVS_ ().?%"^O=5N=2N+6S_TS5KO_B9:G?\
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MLNB:+$T&DF3Q#"KR0K'AU#LBN ?II>:UHEGI;:O>:EI]OHXLS=-J5S=(-/\
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M,0#XO_X(3S:+K'[-7_!1WX?7GC&W'A[5+35+[2= &KJW]@Z3K?@SQ[H.NZN
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M)!=ZN=.73-;T4KX@U37]&UUI(E\2K+A?!;H9E\&JK^27RLBZO[*/_!-;PY\
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M=5M-+_LT.=:CT=&4Q$X&%TH;FV_,70$G8HH ]L_:-@M[O]G_ ..$%Q;_ &J
M_!_XA$VPQGGP=KH'Z8''IQ7\E?\ P0#L_!,/[-W_  4-U7Q#?Z9X;\4W?A'4
MO"]I>:O<Z/X>U+^R=<T7Q^S X9=A;Q$"JN<@,5)5L[3_ &*>+?#&F>,?#'B7
MPIKL,MWI'BC0=9\.:Q!;W/V-[S2M=TQM'U= VX!&^S2R*KG.S(V[LX?^>G0_
M^""/A;P;\1_&^I^#?CIXFT;P#XJ#'PSI.K*WB3Q%H6JAM;UP!W1?"K:[EI!R
M?%IPJ2.1L0M0!\'?\$/_  +\(?%7_!/_ /;]\0^-=)\+ZFNF>._'K6NK>(VT
M@/H/]@OXXUWP-MUK7E(T'Q ->;2"S%@%D\E<,)&9/RD^&7Q(UR']A3]K#0_^
M$CUO3/#]KXP\!_8])M+S6-2TRP_XG1U[CM_T'/\ '-?U;?LN_P#!$GX7?LS?
M!OQY\-O#'QM^+5M>?$>ZU6^\47&DZMHK^&[_ %-D$GAZ36]'UK0'\3>($\)>
M(5?Q+B/Q9X5\Z5D5&C"NQZ+]F;_@BI^SG\$_AA\7OAGX_G/Q@TWXQ1Z7-KEM
MK.D1QKX?U/0P535O!P8-)&"3HKAU4 /"5,GWHV /@/7?@I_P3Y_:1_X)P:%>
MQ>*/"%K\5;32/ .M:FUSXFT;3O'5EX[.L: 6T=]#(4+X?#ZX4'B50XVA9/-)
MD,4/]%O[+7@30OA9^SS\&/AUX;UP>)- \*_#GPM8:3XBW+NUW3ETB-H]6(R2
M/.# _0J6 + #\,?@+_P;W?#CX3?&'1?B#KOQN\2^(/"&FZMJ=_\ \(?IMFNF
M/?%M7+Z$IUH%L,H7100-W*.1D#)_HG\*>';;PEX;\/\ AJRNKZXL="T?2M(L
M[S4G\S47L=&A$<9U*=ECW,8@(]P1,9P1@DD _(?_ (+V:!I^M_\ !,S]H"6]
MTNUU)= M/#/B6)18B_\ [.U"/6PJZN!U*IG:#CG(/<5^!?B,^ ]'_P"".W[$
M7C[PA/H>F^)M>T?4M'^*.E:3J_\ :.I8_MHC0UUW1"['0?#X\.KDG9& K>%5
M^<AC7]@/[5W[-'A']K3X%^/?@/XVU35M%T3QWI)L6U;0"(M3TV_ <1ZM$ NU
MF0[%"NR+C.6!(Q^6WP-_X(7?LR_#'X&^/O@_XB\8>/?&UWX]73&O?$MW>MI_
M]AZGHI_T<PZ(J&&17\0))+,?-!\61A&=0CET /)_!GP"_P"">_[='[ W[.MQ
MX@\3^$?AE<?#G3?"UUJ/BN*\T/PQXVL?&VANI\;Z4X\1L7US0/%'B*8^)/"
M\V7S5U7PS<6\,;SBVK^:F;PA\.9OVOM/@L?LVI:/I?CS2[+[7JUY_:/V_/\
MR O[=_X2#WZXK^EOX$_\&\OP<^"WQQ\)?&%OCIXS\6:7X/<W6G>"7\'Z3I^G
M7FZ_^T1Z1-JLGB/Q)G01(0KVJ^%E/E8?[2C%D3Z?\;?\$5_V7/%WQZT/X[Z7
M)K/A)X-:L/$NM>%+43Z@MYJD><-HFMOKL3^'VZ!A*GB<,V3%\K(& /S!_P"#
MF;1O#NC>%_V$M+T2TT;P]<ZM^T/JEI>#2[/1-.6/*>'A_:^L$(FY.-P9@[%F
M;+?PKXO_ ,%[?"/PTT_XX?LG^,OA=H7AW2SXRMO ^LZSJN@:.NFF^TQ79="
M*@#04_X1P:(8V*J[1["ZA]PK^A#]NC_@FS\'_P!O*7X83?$;7O$&BWOPV\3^
M'-:ADTNTTO4FOM-T-M??^R(UFW?V%K1_MV7'B>&5VA BBBA=&S%PG[0G_!)3
MX"?M#^+_ (3>*?%?B?QY:O\ #&T\,:?>6MC=Z8=1\5V7@C1-#T30B-::*-M$
MUE1H.B$W4?\ K2KL(D 8( ?SW?\ !1KP3I7PR_:E^"]CX=OKFYU"U\'_  <\
M3_:[71]&TW5-!_YCV?\ BG_?OC\^,_VTVL\%Q;0303K<6]P ;:X@'RLA!PP(
MR.H;G!'!W 5^4?[2W_!)SX0_M(_$ZR^*EWXIUGP9JUGI7A;1;JU32CXD744\
M$P0Z/HTK^;K]LT9&B:1I,17;(["+S7V/(\,7Z?>$O"]CX1\(^%_!]A/-<6'A
M?P]I?ANSN+G_ (_9+#0]+BTB%W(7/FA(4+'Y@"YP6R"P!^ ?_!R3K?Q#TS]@
M6UM? VG:A/%J?QH\$+XCU&SUK4M.-GI$6DZV#H_]A*OF^(!XE$FL !2B(-*
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !5>:7R8P>_\O7^M6*9)]QOI0!X!XA_:4^ /ACQ9
M-X(\4_'+X<>%_%:V@O6\/Z]XS\)Z1J-F!U^36)X@23]TONQ@X&",7/ 'Q_\
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MN_L'S>%? ?[4'QHU6]OM3TRXM?A9\8[WPW]KO!_IX_X0S7M"T/1/[<T $?\
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MBK7+FYT_X<WGBC_A'-)N]'_XF=_G6M?_ .0'K@_ZF3^P_"_/_EF]@#^KH?\
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M/%972I T(\KY<Q2?V,#G)W,2SN^\C^8_X\3?V#^V1_P3_OK'PK_PC?A:ZL_
M=[>:3:7F/M^J'QIKX_XGGKXB]/\ L =L4 ?K9^WK)H7AW_@J_P#L7^(KG6?L
MVG-XO\,WNMI;V6KZ=]BU31/[ W;PNY#O\.'1"WBD$@@GP*>20."_X* ZQ8V7
M_!6?]E_2?/NC<:G\1_ 8O+4V>=-.E_V+H&#GU/7..N/:ND_X*5^*-<TO_@IQ
M^Q3?Z5J=@NI>$-0D;2;6 :H)++YO[;UI]>,7#+Y6LHL1?_BD1#KL:SXF5P,+
M_@H[+K8_X*??LC6]A/:G3;KXJ> [U+1;P!?[2_L7^P=;&MXXPJX QUQD <8
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M]]C_ (+FZ18:Q^P7XCLM5@M;C26\>>$VO!=*=N/*UH'$S #20I_Y;#.T$1D
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MPYH?[=__  4@^'Y_8]OK7XH:_H'B_P !_P#">WGA^T.G:7?#0=%)).ND#/\
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M0@H"H55)7 ![#1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M,U_6%10!_F'_  ?\!ZKXP_X1_P *S_L]?'ZVUC5/^)+X;N_L>LZ;_9_]N_\
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M_P"O_P!:K%% %?R/?]?_ *U'E0^GZ'_"K%% %;[)#Z'\Q_A3?LL7]Z7\S_\
M$U;HH K?9(?0_F/\*LT44 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%8UYJ>F6/V<7M[86_VJZ%K9?:;E4^U:@0=L2YZN-N"!N*
M\9 RN=;>/0_I_C0 ^BBB@ HJOYT/_/;_ ,>/^%2[QZ']/\: 'T444 %%%% !
M1110 444S>/0_I_C0 ^BF;QZ']/\:P-6\2>'O#]J;W6M;T;1M. .+G5]4TS3
M; \]%GGD4$]\9QZ\T =%16+I>IZ9K5A;ZGIE]8:CI]V,VMWIMXE_87:L" 5D
MB!B;&/X2<'[S<8&U0 4444 %%4(KRTEDG@AG@:XMS_I-N)P3'D?QCJ.G)V@#
MH<9%6_-B_OK^= $E%>=_$7Q]X5^&7@[6/'OC+45T[PSH+Z7_ &I>,<BQ&L:O
M!HBRN%YR)]7B7 P<*"/>_P##_P ;^'?B1X0T;QMX3OAJ7A_7K1;[2[H@'=&V
M5].S"@#M:*** "BBB@ HIF\>A_3_ !I] !1110 45C:;KFBZNLXTO5-/U+[,
M<7(L[N.]$?7AC&S?@0"#P,9(K9H **** "BBB@ HHHH **** "BBB@ HKBM5
M\:^$="UG1/#VM>+?#NC:[XAN'MO#ND:QXBTG3-7UQRORC0M'>59M9] L<#NC
M \*V >UH ***YS6/$WA_PU83ZIK>MZ/HVC6@)NM3U75-.TW3[-1V:>9XXU8Y
M.%D9><<\T ='17FTWQ/^'</AG_A-C\0/!/\ PA>S;_PF'_"7:1_PC!YZC71,
M?#_3@YG^AS6SX7\8^%O&VD6^N>#_ !'HWB31;E<KJGAW5-,U/3O0YFC9P,^F
MW=@\CI0!V%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 457E/E1<9_S_ )_/FOG7XC?M2_L^_">XUBU^(OQ=\$>$KC018"\L
M]6UOR]05M9!6$#248S:P'X*M#%*8P6R%<?. ?25%<%X$^(/@CXG^$]'\<_#_
M ,1Z9XK\+ZZAN]'UG2;HMI^H ]T?)S@\E64G< <'(S>\6^*]#\#^&]8\7>)=
M6M=&\.Z!I]]K&L:Q>$_8;/3HLL7D9<9/W"!GKNR<,* .OHKP?X9?'_X/?&.[
MU>P^&7Q"\.>+]0\-+IUSK%KI%]NU#3AK(=XS-I)'FJ&4,"Q5U#L1N+,ID]XH
M **** "BL;5-8TS1K2?4-5U"PTVRM1BYN]2O$T^QC&,DM),VP>F"<'.,L>GY
MN^*?^"M7[ _A+Q3KOA6_^/6BZAJ/A^YOK2YG\,:7J_B;P[?2 $NFD:_X?6Z\
M,ZZR9"[XIYR2&VOQO< _3NBOGWX'?M%?"7]HC1M6\0?"+Q59>+M(TJZT^SNM
M3LVW6 U'6=)36AI@=P&W)$ZF7"G:[!59@06^@J "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BJDL\,$1EFFA@M_[Q( ]N<@?@HJKIVHV
M.L6%OJFE7EMJ.GWEN+BTO+.Z6\L;J-P<,DB$JR@]-I'<'#*5 !JT5S6MZ[I&
M@:/JFNZW?6FF:1HEAJ6KZMJ5\ EE8:;HBO-J^IR8#%!#%YCMU; ) 8Y#^&_
MW]J;X(?M$:?X@U/X1^/].\6Z;X9W?VO=_8]7TM5'!.K1_P!N>4XT!UR4;YMF
MUB2ORAP#Z7HKYC\!?M9_LY_$[QQ=_#;P1\8?"?B'QQ:#4[D>%["]W:M>IH9$
M>MR:/O79X@2#<TKOX8$RQ()'8X+9^F/-B_OK^= $E%,WCT/Z?XUBZ1K^B:];
M&[T;5-.UBU@N3:M<:==I?QI>+A7C,D18!E#G)W<*<Y % &[13-X]#^G^-/H
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M+EL-D$\CC#88 'Z9T50M[NWO(8;BTGAGMKE<VUS;D.I&"<@\@CKT([Y J_0
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M -![FOU\_P""WVKZ'!^SKX+\+:KIFB_\5GX]^P#7KRT_XF6FA=%.#H>MY/\
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MJTOO MW?:OJ>F:<CLZIKN@Z'A2T#F.1?&'ALHHE76RPS@D_FK_P3GO;?P_\
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M\([32;_Q;I'B#1G&I_V9KNC_ /"1:$VD+HSW7F/XET)?.M6WJ(V8J NP._\
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MAS6_'-UXA\6>#;OQ+>VB:E>WOAE4T';HDP+CP\4W$9\E&88 ) )R ;O[&/\
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M]CZKXD^VV=IXL_XENFV'_$ZT#_B2\>)/\?\ A"STZXK[,_X*X6'@;X1?MO\
MP_U#PG=6?A71KKP[X:36=*\(6NBOI=@T>D-&P.AX7$B^'4/B:5, QRCPUXU/
M*<@'[=?M/_\ !6+]F[]G3Q._A./[?\4-7MK73[S5[?P+>Z5J5C81SHKS8?>#
MK+MHQ=QY;.BQI&%PP#1U/CE\7/A;^VY_P3T\?_%_P#=WMWX>MK3Q/K-G!:7B
M_P!HV&IZ&LNAY8@+]WP[K/\ PDI 4X,D1_B;;_/)^W5H_P #_&WQ!^+'B/\
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MM$_MS5KO2GTWQ+J-A+RK:,T6@SL#K8RO[D, HR"02IKY;E_X+*?LECPS\/\
MQE WBRX\/>,<7FJZLJ:'_9_A#2.^K:X3XC(\L87:  PY)8X%?SJ_LTZ]!9_\
M$W?^"A'PRU7Q3_:7A?\ X1O[;X;TF[&C?Z!JG]M:![Y_YCFN?KZBI_#GP"^%
M6H_\$-/&_P 6O^$B@MM8\,?VH+RUN[K1SJ=^?[$8_P!BZ)@'^WN ?^*7.U<Z
M#XF\;@EB 0#^@KQQ_P %FOV6/"=UX6N],@\0>)O!_B@?;-*^(=TB^&O"VJZ8
M_P#;SZ3)HNKZ^ %::31)&*^+&\(C+[V+%F6OT3UW]HCX3>'/AE9_%O4_%>C6
M_A'4M).J:->MJNFB]UI3&LPT?1HY+A$N_$7*H?#\):3S6,1*^7,$_C:\;? C
MPGK'_!"#]D_XEW&K7.I:SJ@)\2:M]LT;4O[!U/.OC0M&'';P[H8R!]W(SU&[
MYQ^,WC;Q5H/[)?\ P3?_ +#\1ZW<Z?=>//"][>>(;3_./^$=/]N9_3O0!_8)
M\%/^"E7P)^,OQ7\7?".<ZS\.?$6@)]KT=OB(=,\.#7=.9-KLRF?=HNN,RZOF
MW>11L0YD9M@'IGQ _;\_9K^'<GCW2I?&*^(O%/@'1AK%[X1\.J=1\1Z[&H(V
M^'XQ)MULA<#*$@8P0PP!_.K\0OV4?!WC'7O@Q\1O''QA^&]SK&IZ/X7UK[)X
M3U@:D/"6J8U__B3#7!S@=#G!)'3&,^$?L"?"71/C!_P6+_:(\ ^*O$?]N>&/
M^%/BQUC2;2\UHZF3H73_ )#X/'/)(.!KY/;- ']6W[+_ .VW\#?VL_"&K^)_
MAEKXMY_##E?&'A3Q!<Z7IOBCPG;A6QJNMZ/]J#IHK#/^EE@I*\HK%*\B^*__
M  5 _9>^&$MN;/6]1\?:=_:ZZ)K&O>"+1M3TG0-2&L#0<:WJ^1'&1)G&!(=H
M +$'"?S"^#O </P!_;U_X*#^"/"NMW6M:?H/@/Q/HUII%IHXTTZ>="T7IH>,
M@D9P<$C/?G-?:O\ P0UF_9I^,W_!/;Q/X'_:0U?X?CQS_P +A\=7FLW7B[5=
M&\/>)#I6O>#_  [_ &+_ &'KFOLCZ^_EAPC!BBEM[)(%"$ _I0TSX_?"#7OA
MYI?Q9T/XB>%]3^'NK*6L/%-GJ'VW3;IO(&KB)7BA#KKN%8KX?SYZ[MH0!0@\
M4^!_[?W[/GQR\07/@_2/%=KX:\8VVL?V/8>'?$%]I<>I:[)CKI 20+*"<$@J
MN ,'<2"/Y%?VY-'@_9O^(.G?"OX2?&*YU+X3_P#"R/[:T?Q#:?\ (,_[ O'_
M !2_B'M_V.A_"OJ'0?V/[&]^,GP'^+8^.%MXV\4?;/#%C_PCWA,?\3._\49/
M]A:+U_XJ#_/44 ?V-W>HI96QO)PHMX.;PY&;4  $G')QNP?8CH#7YL?$_P#X
M*C_LY_#_ ,3Z!H6GMKOCSPWJUUI]I>>.?!1TB_\ #N@22ZT=#_?'5)8 Y60Y
M;RW4$ A7!)D/W/\ $R]T:'X;_$*\\66XN?#MKX0\4GQ#:CJ-(70]:&NAC@9)
M\/F3VVC'>OX1/$NF^%=8_9:^)-]^SE?6VF^!_P"V#9>,+35KS_B9Z#WUW^P^
MW?W_ *T ?VR>._VO/@'\/_A?#\8+[QOINL^$;D*='?P]<?VCJ6MWTH"O!;Z2
MGEOO+ZDKR@D;?,C8@[8U'D/P'_X*'?!SXY_$31_AGI-CK/AWQ%XGTC5=<\-M
MJR(!K1T9UDET= S*ZZ\=" N)$:5VPI52=L:U_*S^S3\$_'WQW_9%M_AG\'O&
M5S<_M#W/C#2[/^R=7UC&-+&-!_Y#IX_Y%PC/./\ D:*^C_V"_&VJ_ [_ (*#
M_!#X'?M)Z5JEM\8+4>*-%\-[;0#3K_\ MW1?["QK98C!\*#6R,DCGN.H /['
M99!$NX\^W\Z^+?BA^W'\"OAOJ/BGP[9:XWCWQMX$U1=&\8>"?"CL^J>%9'T5
MM:8ZX\@70XI$A5<'S@5\S:,F)B_LWQ_U7Q7H'P5^)VN>"8?.\3Z9X%\3WFC-
MN*O:S1Z+<-_:*_(I;58%+20*".<]5WA_Y;O^""D/A7XY>*/^"@]CXX\/:=IE
MOXH.E66L6=U=_P!I_P!A#7O^$@T#71HFN>( > =$!)!4C;EB%# @'],/P2_:
M9^&/[07P_P!7\<^#KUV;PTA'B?0SM.I:%J,+,8XI/NXYTN1HRJCA&#'(&?Y>
M?V*OAOX;_P""DO[?/[8/A7]H"[GUKP;\/D\*_$"Q\->'$TC3A>W^M:T/[>&L
M:O#&[NWBB(:*?&4$: R,JQ*4!WKK?\$4-3\4^%/^"A/_  4P\ >#]=UKQ9\+
M]+O?$X\-ZMJUGC.F:'K6-!UD?\RQSZ=_[?QS77?\$*)5O/\ @HQ^WO<W,%S;
M3S>#],:SMKLGY=+_ .$RT)=#;/7A=%;I_P#J /Z&? _PR^#7[!G[.OBVP\ Z
M3J&G?#KP'9>)_'\NFWNJM>ZCOATE<Z1'JSM*RAQHFC^'(-SR;<1AW<$,/Q'^
M#_\ P4.\5_M[> _V[O"OQ%@_L3X;>#?@1JGB?2/#UK9'P6;$:%K.@G^VAKN?
M^$G4;B,$Y  V@9((_HI^-5J;OX/?%6WAA@\^Z^&WCNRM?M R-S>$=:6,$G)"
MY+ \_<W$^I_D6_X)_1>#] F_X*'P3^(M.\.#7_@1XIL;.UNMOAL+J@703_8^
MB<@D$J%^4,<D?+M!90#E_P#@D;^T)X!_9>^+'Q)O=;N-2U"P-EIECJ]KI.KY
M_L_3"-?QK>N#@'_D!Y(/7IWK^L'X0_MB?L_?&SX/7?QL\"?$3PYK7@;0M&BU
MKQ??6=\M\/"*-I']N.FL["71HH5!5@H#,R[6!#;?Y-_V!/@#\+/B;??M47U[
M-J5U]E^"GCN]_P!$.WC0_!FO#1#G!.571"0!UP!D$@C\[_ ?B3QQ\-_@9<>#
MOAQ?:EIOA_7M8/\ :]G_ ,PS7O[!_P"@X <>(.?U]: /[:?%O_!1S]EGP=;?
M\)#KGQ*L;3P#J6E:>=(\<L-66RUWQ/KVJ^1X?\%:)I6K^'()Y-?\4J%:&4RI
MX8"! ]PK*0OVYX-\=>%OB1X=M_$O@C7=.\1:#=C_ $74[-BT>1W&0.>F#A2>
M>.*_@I\$_L3S?M7?!NWOO&/QWTVYT?P;J_A>RT?P]I//]O:I_;6O_P!N]1_P
MC';0Q@__ *_Z\?\ @F9\%+SX&_LM^'O!.H:Y/KHN?$OB76;&XO;W^U-1L-/,
MJ:$FCMK.UO[=,<FA:NRRX)0,6P-JF@#\:_\ @L=^U!XJ^+'[67@?_@G/X';6
M]._XH\_$WQ?XBL[QP+] V@_VSHFAZ$[N?$3+'KF@JTI.?"!'B9\ ;57]5O '
M_!(_]D/PK\,[;P)XO\"VWC[6!<>)I;[QK>W.NZ?JTAUV"32'12OB0+&4M_+N
M5D8RK)XS#>,"D=P1L_GT_P""C%[>_L=_\%M_!W[5'Q3TO6S\)M>\'Z7_ &/X
MM_LC=IE^-=UKP_H6N:+GG_D5%P03U&@@]Z_L*\"?%_P)\1? EI\1?"?BK3-1
M\)WEC]K&KW;KIUE9!5_YC1DS_8A7(SYAP,[R3C! /S&_8M_9:M?^"9^E_'_Q
M#\2OBWIMA\'-<UK3-:MK_5KQUTE&CW(VLZV1@:#,CAD*@_\ %6R:X3)LE1$?
MWF__ ."G7[+^CZ3I/B37]4UGP[X+UZ]TK2-&\5ZO:Z-%I,LNM >6LDB^(9&5
M"54,51V51G8^-I_//_@NO\1M)^,?_!,GX@WWP'\4CQ%/H7QY\"^&M8NO#MX=
M.']K:*S.^C9.#\SOHO!X Z8S@?%_Q9OO@QX]_P""*&CZG#=^$_%OQET%/"VC
M^(Y=R_\ "2V&K_VX0T97(;7R%T,,K?,K L&VD , ?T-?'+_@H;^R3^SOX<\*
M^*OB;\7-%TO2/'6E:7K?@][$_;W\0:5K#$0ZMI 0?O8MK,Q#.O  VY9MOC'Q
M3_X+!_L'?",:!_PD?Q;75(/%/AP^)]'N])TJ1%O]+_MC^PRP7Q#_ ,(N QG]
M@!&3][;M;^-_XP>#_%7BKX5?"_0_'&E:W]FM='TO_A&_[6_XENF7_A?7=;]_
M\\=*^F/VY/A[\,]'UG_@F_X'_P"$<TVVM[J\\47OC"[M?^);C_BM/^0+KA^O
M]A=O^*+ZT ?U0>"?^"K?[$WC;Q]X!^'<'Q6MO#GBCXI.MI\-K3Q99MI9\<ZH
MHBSH>@D,?^)\S:M&6C^4'Y@6(.#Z5\<O^"A'['W[.7CBQ^%/QC^-/AWPA\2M
M6LS=Z-X*NK/7+S5=>1-(_MM&T>2+0VT"1VA^96,ZDG!D2%R57\ O^"H_AOX)
M>%OVL_\ @DU8^ _#7A#2[<>)]-"?\(-;:/X>TUDW: 5?7M=\/HA4D:'SXF&X
M)C =AS7,?M_^$/AS\6_^"R_[/T/_ !+M3!^(_P !]&U?5K6Y?4--L%/]@:%K
M897SX;#!2 X;:V[P^V54_* #]E-?_P""V7[!6A>*;GP-/X^UF[\86XTL-X>T
MRST9]3SK1_=87_A)$''WV.00PP"3\P]L_9G_ ."E7[,'[57Q.\:_![X8^(]3
M/Q'\!V2:MK/AS7;)]-U+^S7>.-1Y8#[==!8O-X<.9(D4OO*@[?Y<=-^ _P )
M/#7_  4LU#P?!I6B:EI]IXPU2RO1JW]C:EJ?]E_VU^/]>E>?> X=6^#/_!4K
M_@I!!\*]4N=,\0:7H_B?PQX#U72<:9C_ (G?_0<Z9_,<\=: /[%_&_[;/[-_
MA"Z\6Z)/\3O#VM^)?#'A'4/%%]X:TDZEJ"W.F1*<-'K:PMX<82$!6#7'RJYV
M[5#*?E?5/^"R?["NA?!2'XX3?%>VU+1;I +G1_#%AJFK7RZHWRLBZPB1>'2N
MU0>;CDD#D*17\I/[)?[*,_[3GQ@^('PY^)O[1FI?"7QAXHL_%%[K%WJVL?V8
M/%NE_P#,=SKGX8SS^5>O?M??\$\_V=?V6?@/\,?!W@CXVM\8-.USQ[XGN[O2
M7O4U/3+(:%K"Z'N77$=O^$@\.*VB:\C;MK;T8A3&8W< _H:_X?I_L/\ _",:
M5XJFU?QKIFCZKXCT_P -1ZMJWAR33]*621M#)9]7,FQE UU"HP#GS"-N_%?;
MW[2/[;_P(_9>\*^'_%/CSQ#]OF\7V:WO@_P_X?0:EX@U_2V9W.M0H)%*Z(HV
MEK@J5!8*@8ATB_F)_P""EFF_ F\_X)"? "?P=X-\)Z;\4!\7_@U97EYI.#J=
MA_Q6N@Z!KW]N=\^+/#@T(G.!R,'.ZOCW6_BGKOPM_;X^"/QH^+3:IXJ^%&F+
MIBW>@KH^KZGIVMDC0!H.CZT'5TW+D, Z.IQAE(!! /ZT+/\ X*O?L93_ !>\
M/_ ]O&VO1>.==\(KXR8-X0ULZ3HL0T$:\=&US6BC"'Q%_8(+^4OF@@+F4%L)
MT7Q7_P""E/[(/PL^#OB#XWR?%?0_%7A_0;[1-*;1?#]VG_"4:GK&MN1H^D:-
MH>M+"SRM;0:MK^0856#17^:4((Z\._:'\??L4ZQX+U_QUX1T'X:^+OC/\3/A
M#K&C^#=4MO#D2^(FTV31Y-H/E)&VB>((48I$'_XK'RS&\JR>#HS*G\FW["_[
M)GP=_:?^*?CGX6_'CXP7?AVXN;/5+[PZOBGQ=H^G^'+_ ,3D\D:T,%AXK'S%
M5!=@,*KL0I /ZHY_^"[/[#,/PF\4?%M?$GB&?1/!HL?^$CVZ?C3M.,I!_P"0
MUN,38.=Q>,[CCH"V?*3_ ,'#_P"QA%%X>GG\,_%"UT_Q19Z3>Z/JUWH@_LTK
MKG.C L3P)25Y4#;C(R<8_!K]I?\ 9C_9V^&/[!'[4_P_^''CW6?&TG_"WO Q
MTG6/LNCC3QIVA'7?[;70M9\0(59&4Z.68R*R%?$BA'#EH_N#]MWPU\$/#7_!
M,K]CK1/#GA[X7Z-XW\4^!/"VM:O<Z59:(/$MZ/[#\/@C6B%'BD@_VX6)=F()
M(! &T 'Z<?#_ /X+P?LM>//B+X'^'.I^"?BOX)N?'=Z;&SU7Q%HVFC3+"$AA
M_:^LE;C,6B$8!NE!(Y/E'C'WU^TM^W+^SK^ROI_A6?XI^-(+;4?'C^;X3T#0
M)--U/4]>T_;_ ,AM5\[CPR#U\09$(#$CE<-_*?\ MO3_  DU+X7_ +!^MZ5/
MHEOXPTOP'JEGK%Y]C_X1O4[_ /XK3_B19XS[5XO\9K.?6/BA^R__ ,+;_MO0
M_A_JGC#2_MGBRTL_[2U/_A%]!UK_ (GO_A*8X\+<]Z /Z#?!_P#P7[_8GUCQ
M-XG\-:M%\0/#UUH%WJ 9CH^C:@6*$$L=GB, ,>6(4!<\ !<UYUJ__!QS^QW;
MS7,.A?#3X[^+?[+M=5O]6_LOPGIK?V?IFB_?UD[IR&4G[J@*B?PK7P=^U#_P
M3?\ V&?@_P"(A\0/AG\6AXL\8^*++[;>^'?[(T;4]+!_L77]>.M:WKOA\#('
M;PM@'V';Q#_@F;_P@%GXC_:XUS5=#TVYU#5/@_JFB^#_ .R;/_A(_L&J=L>G
M7_D:?^9T],^$>0#].OV@O^"WO@#QK^R1XG\9?L]^'/%6F>+_ !/HFH:>+KQG
MIYC/A'3-9T64'6B?#\C!M='F?N82/W3!VWN6 3ZU_P""*G[2?B7]H7]D#1)O
M&=_-K6L^&;U+6UUZ\^]J>EZM)K;1MQ@@Q3:+K!SC!W@$XQ7\N$V@Z'K'PTUB
MQT/^P[;3_P#CRL_[)O/^)7?_ /UN#_Z@WT_HE_X(0:A\/-*_9T\3>#_#?B#3
M;KQ[I.L:0WB_0+21ETS3]-,FO+HXT1$AED:0:Z==/BV-%=?"DN8)/)+1R, ?
MI]^W8T;_ +&G[4!.H7.DR/\  SXF"VNK.]72M0-^_@_68]'TH2N,$^)-:,?A
MSR^#,-7,<8+DLOX"?\&RW@.+QO\ L<?%76_%-W<:G8>,+Q_!^JPFZCL3>:?K
M0UX:Y&FL:"Z,SS0OI2!D92J[U+#?7] 7[:?BW0O!_P"R1^T;JWB*^MK.RNO@
M]\4-&M&N%R/[2USP=KNB:*G<8D9L'C<PW'.1FOY]_P#@VS^.OP(\(?LJ>,/!
M^J_%3P7X<\1+XO:Z72/%?B/2?#U^--T?^WDW:1#KSQB5$X)#,,(&*LI^8 'Q
MS_P4S_9(_P"'5OQ<\/?M+?L]>(]:\-^'O$&L:99^&=6U.].J>)=#U DG6-(&
MNLB9\S7RCL,$(Q\,H&?;N;]J/AM_P6:^&^HZS\,/A'KG@;QKXV^)VJ?"K2O$
MWB_5?#MWHPTW^U1X-T'Q I_L7)./%)UW]VJX$>#MS\H7\UO^"TOQVT+]N+QK
MX._8\^"EJWC+_A#_ !=I&M_\)EX5M1J6EW6IZXBKKD:ZRCM"FT#!$3%"<G<V
M03^<GC;XJ>'/AO\ M&^']#\.3VVB>(-!^&^E^&+V[U6S_LWKHN@:#GU.?_F7
MH _HS\,_\%O/A#\3/@[XY\6>!OA_XMTSXD:#=ZIHMGX;N[W2-2B)_LEY="UT
M:N&\G7Y3(^YO#>SS&.-SM@8^&_\ @B%_P4(CO/AC^TKXH^-ESK/A#X<Z3XH^
MW^&7OAK&J)'JXU:3^V-),3*PT;Q'XFFUV+PZL3-$/,\.(XE5D ;\J/V5_B1X
M LO&7Q(\'7VN:;<ZA=6?BB^L[3['_:6I_P!EZ%K6-=_Y%_\ [#G&.N.W;M?V
M:O&OABS_ ."87_!07X$>'+ZXU+XJ^,?%_AG6_A9I-GI##Q1OT+6EUWQOK7'R
ME?\ A&M%D##PKT;7H_ ZC() !^TOQV_X.*?AG\+X_$[>'/V??B#XEM])Q86>
MKWFL:-IN[41K/]A'67T('8= ,AW^:/%J/C"Y^\S?M5^R1^T)HG[4?P'\ ?&G
MPY]GM;3QAHZO>Z7:;2-$U/YM\>TG/3!.0 =RX)PPK^:K]D#QA_P3$^/O["'A
M[X(?'Z]\-^'/B/H7B35+S63JUIHH^)FN:H 2#H>MX!/AP^'-<VGPL"?X2%_X
M3O)'] O[#GP_^"'PX^$FJ:/\!)I[CP8OB^^L_P#B8Z"--UC3DT?1]"31?"+A
MD0:RD'AX>=',KNY_MERH0KM8 \8_;Z_X*9:/^PUXS^&'@J\^#VJ?$B?XCZ1J
MVJB]M?%Y\,:?IZ0NT1&W_A%_%)UMF*MN5$3:3P.!GY<\!?\ !=#PAXKU+Q#I
M6N_L[^+O#>IZ8NG+I%K'X[T;4=1U[5I#G^R%CE\.>%E#+SM#;U.6#*5X'QW_
M ,%_/B!X-\/_ !S_ &?['6K&ZTSQA;V>E6?AWQ";0G33IFN:QKR DDG)_P"$
MA49.><9SGD_DC\&/B=\.8?VD?A?X<UR^TW4K>ZUC2[+6/M?_ "__ /$ZSKNM
M?]3!Z_EF@#]1] _X.1?C%XU^*?B?X.>"/V-?[4\<:!B].EG6-8R=,&M?V#N(
M "@G . H /0#BOU1_8'_ ."KOAO]L7Q-\0_AGX^^'!^!7Q)^$_AO^VO'MIK_
M (MT0V);0]6$6MM')G*Z$,:S^]E9E5?#_B?>50!D_#7_ ((HS^&_&O\ P5Q_
M;@^($,6F3^'M"\(>)KL&U(U$6!T77/#R+K0W#!;<0%7PH#N8JIZU\@?"G7?&
M7Q2_;X_X*S>*?AG9G1KKQCX:^,=YX<TO2]8T33&8ZYHFO Z.VN*%7)_Y%@A5
M49/R@#  !^X?[77_  6!\0_$'PU\9_A!^S!^S/XM^,?A?4_A5\8%U;XLV6LZ
MS'I]CX8T#P;XAT+QWK3:-'X<0Z$GA9G4'Q&WC#RRPSL)8@=;_P &U&NWVI_L
M%+!?:1<::=*\2FRR0,WAVL P[YYQV.">:^0/V#OVW_V8/A3_ ,$=O%OPD^)O
MCKPKX ^-J^!OCIX!O? ]S#-=>)]>U;6-(U^30#O@\.AI/#;'7 LGB&0-#X24
M;9?DW))]/_\ !MU\4/!'B+]B^Z^'/AOQ9H>L:MX7\8ZQXHU+2[6[TO"W^N:J
MZZ[KF@Z*@/B(:$)GB\,@3_*(1X?D4'_A*F90#];_ -NC]LSP+^Q#\%;CXM^,
M-#UGQ"UQJVG^&_#7AW3K=D.N^*+ILZ-I$FK F+12[H[K+*C'?NVIG>Q_)WX+
M?\%B/VF?BCKNHZ1KG[)6G:5I]MX=37+6[T?5M5)?4M;(_L2-_,\0R I+X@7R
MI" '$9/EO&V&'V]_P5UM/A=J7[*%O8?$+Q5X;\) ?%/PK>^$;GQ#>%=+N_%0
MCUPK&T+G=K+>6^LL(]J8!W,H)&_^;7X>_$[QQ^S'XM_X1S[=;?&RXU[1_"][
M9VGAZ\UG4O?Z=.?^ITZ9% 'GW[+'[8O[1G[+WQC^(/C[X2? FZ^+7]F6?BC[
M9X36T.H'0?[=UK/WO#N""?8C/MFOZ1/V5/\ @KY\)/C%^R;XP_:8^,]CIOPD
MO/AUXDU72-8\.B\345O')SHG]B'[[&9G/AMF;+>8KLS_ #A1^0?_  1Z\4Z5
MK_[3?QHGU6#[-<:]X$^,=]9Z3=7IU'_B: YUT'!R?$)\.  ]BN5/!(KY&_98
M^*?P>^$/[%O[8NK?$SX:0>/;BX^*WBBS\"*+Q=-U+PKJ?]L,H5MWB%O#(4%@
MX*%'\%NBY8H71P#[R@_X.%?C?IOBC6-<U7]GK3;GX/6NLZK>_P#"0W=[_P >
M'@,\Z%_R+Y_Y&+G&/?IVJ+_@M-\6?"WQW^'7[/?C[2[6*+0/&/P[;6[(R7*+
MJ:!_&>NZ&(XRD<0>)%T37%#DR-D,K^#"ZL!^%GQ:^,WP=U[]F[Q!8P>,?[$\
M8:KK&E_;/#UIHYU+[!_;N?\ B2Z%Q_S*8^A_YGGZ_?W[:/Q?^'/B_P#9'_8Q
M\$>%;[4_[8\"_!7P%HWC '22P&J?VQKJZZ%!_P"0[XASK7_"4[0-I;+>/OF9
MJ /5_P!NZSMY_P!G[_@GGJE]I<!N+3X*^)[$BULS@:9_PF.N'"_]3!C1 >.
MQ;W _K(_8O\ (_X93^ 'D0J+;_A6WAG[+]GY4*$]> %^Z3DXVELU_)C_ ,%#
M-1T,?!']@#1+^Y-O]F^"FJ68Z8O1_P )EKV@:$!ZC.MEN><L1G%?UF?L80SP
M?LK_  '@OC;"ZM?AMX:L[K[+>G4P"J <:NI4R@=2N20<D$$B@#Y/_P""A?\
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MP?[,G[17Q:_9V_:E^*'B/P1X<N/%M_=V?CVQ-G:V6L_V98_V]K6#K6NCP_\
M]"I[BOUA_9V_X);:C^T)XD\??M3?M9ZO/%XY^,K>*M9\-^';+PZ-/:Q&M:3Y
M&D>-=:5=QT'R)F3Q+X/\+'"PALR,&&T@'YQ^&_'?[=?_  40^'OQP\8P>#QJ
M&KW>MDWGQ-MFT;PWI?A+3M'D)T+P5H6B,>OA7P^^%4'ACXF\;^/!C 'R5\?O
MA7\8O ?PYU#P/XX^(_B33O$%UG_2_L>C'3/[+T+_ *#F1GQ!_P"[I[5]_77[
M"/[>G[)OQV\?^$/AE/XD\6?"?XCZOIE]I'B'PII&L'3%QU4Z(K%1XB4\-AB
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M]'UK5=)M?MVI62:1KVB>($V+G:TCRZ-'&!(1\S-SNP&^-/\ @GS_ ,$]KO\
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M=H<>H>&(=(MO FNWEB-7L+[3- +EX?&D,.@>%C)-XF4,7%LD@\)@Q_9)+H@
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MFM^+O$)^.^M:K>:SX>\279.FZ?I6N[?[:T5E7YM=D?>F/$,OESDDC9E37$_
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M[K[PUX@"-_:?A/Q+@;-;T9FZ2*,#).&'!4L 5_*+X8_\$J?VM_!>G6_AV/\
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M@YX Y_G_ -&_X-=?V7=(TZ#2_P#A?WQC%M:?VM]E%I::)IY4ZT<,#L+9(/4
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MMKL78UU=!TD>)1J0T<:,)O[85%G#G0V^S&,2A3!CI]VN_HHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?2+/Q%K7B!=2T]M(>1@VCZ^A&7>1_#K'#,5>2XVLK%B ?EW^S1XG\+?M_?\
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M^IVVB>&/#UH-0TC1=4>31H9M53^WWWR>(_$C:PC7".@B3^QK5E9Y,>7\:_\
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MV='U@K_Q/(Y A42J29#YD;;?+4M^F\,WF_Y_SQU[5_/QHG[$'_!1KX(?L?\
MPL_9U_9[^)WP<\-:AIGB+5[WQY(+WQGIVH#2=;(+'1M<4X"KSGPVR^7%DJTG
MB\R*/"/[J>!M-US1O!OAK1/%FJG7?$&F^'M)LO$/B!MJ?VYJ\>E1)J^J@\DK
M+.&</Z-@\!0 #NZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** /,/BW\+?!GQL^'/B[X3?$
M;2AK7@GQWHVH:'XETK[2UF;W2Y67?&'3D;B(\M]T?*S C%9'P-^"?@#]G;X5
M>"/@S\,K"XTWP1\.]&71/#5E=W37TECIB;F"&1B"R[BVT;5QN; P6S[-10 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MRENY[..X@^TVT9N+JSSF]0?>5C&" 1P!GGC"Y% &O16=]J'3 \_T[]/3&/\
MZ]+]L]__ !V@#0HK*L[^WO//%O-;7!MV-L?LUR&P>,@XX4],,"3E3M)J[Y_M
M^G_UZ +%%-_@_P" _P!*@\R;U@_[Z/\ \50!-O'H?T_QI]?S_>)_^"F/QO\
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M^(O WC;X.Z=KUVMEX:\6>-[W2-1T[42FD,Z[](T!F?0>H!#$]7R"&*C\:/\
M@MO\0?&/CO\ X*#>!O@?XCN/^+<>!3\,;_PYI&=6Q>ZMX@;07;6-<;757PLP
M1F*[MNYMH9V9RS';_P""ROP;T/\ 93^%'[/_ (ZTFP\-^&O$&F?#C33XZ^R6
M@.I-XF#$:WKHT12P*R>(=;'AI><A6PV&R  ?TF_M<_MT?![]CSP[X>UWQW+K
MGB35_&&+/P;X1\%6JZIXF\7:J=CZ#HVBJH*!O$[#:A!;&"0>0Q^6/V0/^"MO
M@7]J'Q_;?#KQ5\)?$/P6\1Z]=BQ\(_\ "0^)-)\0+X@U7@-HRX\.>%F0CE@"
M)"V I8??'\P7[+^O>,OVL_VZOV.-*^(GBG4;NQ^Q>&-%5=8\3'4-*T+3!HO_
M !/-$T1@K>&5\0YQE@K?\)F!D*2,5]+_ /!>OQ+X=_8Z_;E_9?U7X::%IFAG
MQYX<TSQ/J^D GP[X9_M+_A-CH*$_V JD%ET-69<85B5!<*&8 _>G]MG_ (*E
M^&_V9?%^I?"WX7?#^W^/GQ:ATEVO=)T?QC_9>G>$/$K:V-!2/QL1H4XC(18Q
M(T$B+).K^#D6-Y./5OV'_P#@HCX3_:FO-2^'WB_P[;_"SX[Z'HUCK>L?#.;7
M3K[7VFG']KZKH<D,)=(E/7P_B2YAV(Q\XEG3^>W_ (()WM]\4_\ @I+^V1XW
M^)OD^+O$[^!-4\8'5_%+#Q#JFG>*)/&G@) VAN65E \/$<QYD#%2JGFJ_P &
M_$/BKX1?\'&OQO\ #6CK;OI'BCQW':W>DLNJ-I^G^'/&S+HB2 $&$2IH.M+(
MA V+(JL,8!H _LC\5^-?#/@;PYKWBKQ3J]MHWA_PSI.I:SK>IW+!8[#3-'.9
MY7R#N"#. 02S':!\V1_,GXE_X+M?&;Q9XV^)NJ?L^_ +P5XQ^!W@"^TW1KSQ
MQ?\ _"8/J;:J^L:)X>(.N$8V_P#"0RM@+X.7"X3/E@^,C^F?_!9?XI:Y\)?V
M&O'&H>&S;"_\4>(_#/@J\NKHC;9Z8W]N:^78#J1_8)"G/ 9LYR,?E+_P1L^'
M'A'QI_P3V_;4U;Q;;:H\/BC7-1UC64U4KJ LM1\#Z1KOCC1M<.C:$I $/B!S
M/L4K)(80B9!((!^NGAK_ (*C_LS7_P"R+XY_:[\5^)M-\&^%?A/BQ^(^@7GB
M1-3U+0/$^P_V/I#YVC7=YPI\211[6?0?$T@!'A6<Q?DUX0_X++?MC>)O#Q_:
MSN?@WX*U+]A70O&/A31?&'BOP[I.NKJ7]DZUHNM_\3;0M;U[Q, NN-XCB\/^
M; O_  F$/A!=?\-++&Z.X;^57PW\9M5F_9X_; ^&5]/K>I6]U\5/%%G9ZM9_
M\3+3/^)[K7]O?J?4U_6!-H]CH/\ P:]ZQ!!/_P @O]F/Q1>V=YC&-4'Q.U_&
MLXZ^N/H?Q /Z&?V</VAOA3^U-\)?#_QG^"WBBS\7>!O%2!+74[1U2]L=4CV?
MVQH>KQL',>N^&R1%/&0VT[57>,2OT?QQ^(]C\&/@Y\5_BE?G3S;?#SX>>-_&
MY&JWB:?87[^'-"UO7DTJ9V.=KBV,1*KN;>,%224_"G_@V%U?5-7_ ."8OA9I
M]/TS3=*M?'^O65I:0F0W@U)-,T$ZYM3/E_V*=VC>257<UP-=\T[5AQ]Q_P#!
M8+X"V7Q^_8-^-&B3_P#"1WESX%L%^*-KIGA<".776\%0ZSYVAZU  &U;P\?#
M^L:S-<6Y4*TFCB7S/,#1D _';]G3_@I+_P %9/VZ? ]QXW_9KT/X76VGZ5XP
MU31/$EII7@_1M3U2PTO'_$B/]N^(2?#.?4Y))SWYK^F+]GB[^,,WP@\'S?M
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M;:6_F&P.@Z5H>@:]HNMMN?:N=".(\CR5QXT*($V* >7_  =_:F^._P#P3O\
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M@#MOVM-(\>^+O^"V'P?TO0]<TR_^)OB3]F[PQ>WN<7_A>]U+6O[ !T70\^)
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M_:# DE4!8 _.[_@O)97UW_P3I^*$VDM<F^TOQ%X6 2TU;^S=0O/[;+: <,%
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M*:Q\"/CC\0)O VI_LI?%&W1=7NE_LC4FU#P[H@US04UK1M=B5W7"JA>0J?\
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MY_%Z*.<Z=KP^#OCT*+2[6_6QU)/!>N'='K&O*D6W+@[_ !)&(B3ACNK\DO\
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M3_@I?^UG^T!X"^+GCG6?A_<:]X1\2ZQ=WG@J^VZD6D9476-<T3#?,[,JJ/\
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M?M;>$]-T;5;TWNC^'_L7C+%]_86M8T$Z[D@G=X=VHJKN?P:S#:I4,0 >T?\
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M^*__  <P1WK_  "_9RAM;BT-]_PM?5@-+NM(U74TO]-!T 2J-A)RL@T8/O\
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M ,'^-+;4+CPMK=EK5OI=^='OOLC BSU,!0=,<>6F). ",$#CYB,;0#N****
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M/^%6** *_E0^GZ'_  H\F'_GC_XZ?\:)IO*_S_/VZ=J3[7#ZG\A_C0!^(/\
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M[US_ (?\+>'_  SI-MH7AS1=(T#2+-2;/2]$T^/2].M0<%=NDP!(4Y /W,G
MX7K70?:X?4_D/\:LT 9O]G67F?:?L]O]HQC[3CYLY^O7\?QK U#PEX8U*^TC
M4]2T'1]0U'0GU)M&O[JP6_O]';6@JZN=+F=6?2#.J1K(\#C**L?R8^;L:* *
M_DP_\\?_ !T_XU8HHH *K^5#Z?H?\*L44 5_*A]/T/\ A2>3#Y>,?+USGO\
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MDMSK,SALE+=&?YT957)" ':^3#_SQ_\ '3_C2>3#Y>,?+USGO].GO_7%6:*
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M/<9'7(!]"S^?_P LL?C^'^>?>O(-!^./PM\1^%_%WC3P[X]\*ZWX8\"'5?\
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M2@#^3_\ ;N_;0_;?\$_\%(+#X5_"7XEZ;X;\#Z)=^&+32M'M_P"QM4TW.O\
M]@DKKO\ PD/AU_[ 4;B H9D\9#Y%P@45^G?_  4X^$'[8/Q'_9\^'_Q _9B\
M;#PE\;?@JQ\;:KI?AZR.H:KKV-#7^WH_!FM2L)1(&\T"/8H\7)'Y3*FP*?Q-
M_P""G<U_H_\ P4N\&:KI6N9U'_A(M*S:?;&U(G2_[8\/YT4Z$Q+YR.=_S=O
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M4*[@TB$AJ /ZA['XT_"K4_ D_P 3-,^(WA+4OA_:QFZO/&FE>)-&U+PQ9*"
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MFD>(H[0^9)I6<Q,_EJ9M,E!\S:7;=\CKM)]J_P"67^?[M?S"?\&[,4/@B_\
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MM#\$MX<U_P#9J\2:GXG\=)XBNX_$>HZTH_X0'^W50(B$+_Q(Q]\N<:_D$<T
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M_P""IGB']H/X8? +]B.V\*_'O6O%5YIUUJ/B_6?BSX?NH],?Q]XD\/:1HK>
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MM=:6Z_9\:_T;X#W-IE;/5=$UK7VDUU3_ ,)#'N#2M(1(4!E&O?\ "&9/F9H
M_HI_9N_:F^"O[6?@1OB;\$?&%KXL\/VU]_8^J_Z,UAJ>AZH #_8VM(_$;!MQ
MVH&'1LDD@?@O_P $G/$?[2&I?&?]KCX.Z;^T%IE[;>&?BIXG\8%=6\-IXUTS
M7E=AH,FLZ(791H"#Q"-#>1,DLB-A'.$/R%_P18\:^./AG^WGJ/P.N!_PCGA>
M[T?QW9:QI/VW^S=+O]4T+1>-VA J3X@_XD>A[ES_ ,4:N5((\88/U]_P1RUF
M"[_;W_;A,4%O;6MQ>>/+^VM%32K%]!4>-/ )_L76%B)D+YUP,I16;(P%)P0
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M==UK7_[=^4^)/^$HU_\ X1/Q)_Q2Y\4$\'0/^$&..WK_ /P3R^!'[1?[2G[
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M+SX?O_$W_":BZ7^RE\-H/,\X.=I*H H).#E-JJ6;!_E+_P""1W[*G@[XK_\
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M_P""W4/@CQM^VC\'[WX.ZUJ-_P#%_2KSX#7GB+Q!I%Z--TS0-)&L#7M"!UL
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MP:EXPLO#]L6\&VOB*WTG?*JZZS;COGFB^V>'Y!/+X16?PVDS>;+',OQ)I/\
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M_P %$?VL?$7QN_:H_8OMOBGX/@\%ZAX7O=6L_$OA^WM38-H6JNQ=CGQ$3XG
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M ! ^$7A71=+T?PYH^D#QF=4L/[!'AXZ'C_A(!\Q T5"RJ20-#0X&]<_T1T4
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M6MDDD0NC$2>6ZR(O]8%,V#U/Z?X4 ?@AX[_X)N?M9_$G]LO]F7]K/Q3^TO\
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M$_C_ .%6J:A?Z5I_CWPUJGAF[U/2V U&PCUA=K/#C@8W)NR?N>G#4 ?R;?\
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M\.ZKI&CK_: T0$<,OS+Z;AR#R#WK]NZ* /RO_P""A?\ P33\$?M[V'A&XO\
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MC:46!U@[9PNQXV.>%7GY2,[6R5KZ ^U6_P#SW'Y?_8U/PX[]?Q!H ^2OA?\
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M;K"G^RM4TZ56>%HY1B0.JJA4-)ND 1FZ.@"M]DA]#^8_PH^R0^A_,?X59HH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH ***@F_P!2?H/Y4 <MXT\;^%/A[X>O_%OC?7],\->&-*3?
MJVO:O>&PT^Q3.T,[MN^\V0,'/HS8./S:\%_\%:_V8O$OC/Q'X6\1VOQ&^'%O
MH7B3Q7HMCXJ\5^#=8'AKQ!'X(_Y#^J23:(MR_A^('!4>)8X , ;2#7X\?M3_
M !9^*/[<_P#P5(;]@;Q%JNG>&O@?IJ^)]'OKW36US_A)[ : O&M:)HDF?#*>
M(!XCRQ\3D#_A,_!A?P05#,Q/]-&M? GX8^)/A[:^ O$/@GPEK&F6NDBTM)]6
M\-:1J3V>I'11H)UO?)&X'B,1!F.OQI'+D$B51]X [[P7XR\+?$+0K/Q3X.UG
M3O$'AW5)=4^QZOI5VM_I]]_9&K2:/++'(I(<B737C!&,,L@&XY8]M7YB_ KP
M;HW_  3O_9Y^(/B?XR>-[5O![>+-2\;7VD^'M'E;2_":ZR^@Z"4T8@?\)#K8
M8:3H0".Q?PLAF388H68;'Q[_ ."EG[.G[._PM^%_QM\:-\1+_P"%'Q9O%LM'
M\;>$_!K:CING:@.%76'UF2W>+<OF!7^?8VB.%R@,9 /TBHK\?_B1_P %F/V.
MOAEJ?A72M8O?B1K5SXPTG2]:T8>$O"FEZGE=:&A+'HTK#Q(C3^(6770TB>&C
M(@=B-S[5D/G/Q!_X+Z_L1?#+6=&T+Q-H/[0?V[7[A1X>N;/X0M)IVO:?SOU?
M1'?Q$/-A ) +*K-R64!L  _<:BOR+^#O_!9S]CGXY?&?PC\"?!__  MO3/&'
MCO5CHOAN\\5> /\ A'O#=_J8&65=:_X2%RQ.,;0A+<  G /-_$S_ (+7_L9_
M#'XY>./V>=>LOC;J?Q!^'7C'_A&-:_X1[X;C4M,U#5<LXFT/6AXBCBUW1'E8
M>'W=80?,)7YE1" #]F*YK7]4DT'1=5UJ/2]1UPZ9IM]??V5I-M]NU74'1-RZ
M7I2*8]\DDD8780<X0X&TA?PG\,?\'"/[&VK^/_$'PQNO"WQPM_'.E:MK%I9Z
M7I/@677V.GKJ0BB37"W_  C0\/\ B%G+._AN59T18T3_ (2VX=C*GV-^RM_P
M5 _9G_:_\3^(O!OPKF^(&G^*/#&D:MK.LZ3XV\)OI[V.EZ+,"TC-H'B;Q4,A
M,,H7!\5[2EON4JE 'HW[.W[>7PK_ &G/%6L^$OAKH?C>/4M!TWQ+K5[=>)M$
M&E6+Z/HOC2+PSHDNE9G07)\1QM)<R+&$F\()$D7C&-)E02_=,,WF_P"?\\=>
MU?CMX>_X*B?LJ?$VR^..E_!+4M3T;XK^&?AU\4->\.:IJW@71].&OZMHA<:'
MJVAAP?[>B\3Z^(O$R#Q/Y0D=9'E7,K[OB3_@E-^WG\??V@/"/[2_C_XBZWK.
MHZSX6\(_%#6K/2[L'4O#6G>)_ YQHI4J5*Z ZEAO5@59O^$((;_A$"" ?TR>
M</-\G ]._3_'%6*_F<_X)'?\%"_BC\?_ (G?&:;]H?5-0VKX=U#6UN;R\U?4
MM*T%_#[Z[K^L#0]#(/\ PCOAT>'QK+)MP0X7'8'](_'/_!6;]C#P+\$+GX^2
M_$\>*O#%IXOT[X?7GA3PC!HVK_$JR\32E]R?\(6WB&.92N%=AL0#<FR1]K!0
M#]0**_+[0/\ @K'^QMXB^"8^.EOX]U;3= 2_TJSN/#^IZ,8?&ZC6]8.@Q8T%
M0Q4*H7Q"Z[\-""> QB/.:O\ \%F_V"].^,?PP^"$/Q3U#6?$?Q<T8ZSX1\1:
M/X;UB3P-M (4:WKS(IT$#@G>AYR,'DD _62BO(?B?\4=!^%GPR\9?%C64U#6
M?#W@[PSJOC.]M-!C_M._U'2]#T8ZXXT6,-&'#(O!/!4@]" ?S<UG_@M3^R'X
M;T&X\1^(M*^-FB:1:79L[N[N_ FCJ+%L#&XCQ(?E[=&(^M '[ T5^3'QK_X*
MX_LG? /X'_!K]H+QE+\5+KPG\?K6RN?AOH_AWX=S:KXEO8YM<_L9T8[QX70^
M'!)YL\?_  E>W<;9B)AXAMG?Q?0O^"Z?[+OBSXL_"#X;Z5X)^,=M:_&6\TK0
M_#>IZOHFAZ?J'_"2Z[KO]AZ*O]@OXC9O^$=DC/\ PD1\4%R@7&V-<8H _<66
M7RHNGGG\.>>_4?US7Y]> O\ @I#^S3X]_:[\7?L2>'M1\57'QG\'ZAJ]I<)=
M^&FL?#%\NAZ)_;FNG2-='E+*WAPB30;E3$#]HTF4+)(5$TFMX_\ V_?@3X'^
M,UA\ E3X@^._B?>8.K^'_AOX-_X3%_"I9 W]F:\B,K98E0T7AA?%,RLKA@OR
MBOP2^#WQ-N_B]_P<6?$;3]:M2EKX.U#QUX8\-W/AO5'L=._L[X7_  V&@NVO
MK'N8EY-'9YIFRJDR>#9GV"1Z /ZYJ*\K^+WQ+T'X-_#7QA\4/$=OJ]SX?\#Z
M++K>K6V@67]HZHVGQ!$<:5!E-[C() (^53C9A37XVV?_  <'?L0WGPFG^.,/
M@S]I_P#X5Q;:R?"[:P?A#HX8>)1K']A_V&/^+ADMX@,IV^66 $9+[R?W1 /W
MFHK\2=1_X+N?L:Z5\-K?XJ2^%/VA+CPM=W9L[:6S\!Z)J$KR9_B1?B&$((YW
M%P0> A'S5][?'']L[]G[]G;X+^'_ -H3XJ^-;70_A?XQ'AK_ (1K6$#:@VNG
MQ!HIUS1#HFDJP9GD0*Q ^92JN[;C&: /L"BORF_:#_X*]_L7?LZ^*?AQX0\1
M>.==\::S\4/"C>./#EC\/M)T7Q,MGX9 V@Z[YGB/PP?#2L!N5?$Q0@$;L'('
M@]E_P7T_8CN_&.G^!_[#^/7]LZE]A_L\CX<:1J>GWH+J=94R:)XCF_Y%=!^_
M;:?G.44\,0#]T:\D^,7Q3\(?!'X;^+?BOXZG>U\->#]+CU74Q;V@DOWB61(=
M-TZ/RR29)=4E5(23L220 @KO+_DK\/?^"\O[$OQ-BUAM#A^.-AJ>E7QL%T+5
M?AUI<&I:A?-,Q*Z1$OB69)GAA*A#E$DD,GDCQ(C#%[4_V\_V4O\ @H!^R=^U
M]IGP_O\ QUI]Y\-/#.K6?C3P7XZL_"O@_P ;V6L:!K;MH<G]B>(O$\EOJWA\
M^(M)T9,*(WEAUVWM4;_A,_$$$,8!]]?LO?MC_![]K;P[XA\5_">;73IOAK6C
MH-Y;^(M(;2-082LZQZKI*,[B;07?2-:3S<YFDT:0^4AVI)]>U_#Y_P $RO\
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MNV3$ _?JBOYEK7_@Y0^ _D^&M>\0_L^?%#PWX+\0>,=,\'W/BZ6Z_M6/3IS
M=6UV1XXO#D)D7PJC$R1EU!YV&-OF'Z<?'_\ X*2_"+X(:%\&O$.AZ/XL^+VA
M_&'5O"JQZOX+V2:7X7\,ZZ&_XG>NZNI*KK:C9M\+>8DTC%TVP*BM. ?IC5>:
M;RO\_P _;IVK\L_A7_P4Z^&/Q8_;AUC]BW2_"7B;1_%2_"?2?BQX8\5>([F+
M3M,\3Z9KFC:'X@T?2H=$2+[2TL_AC7-6\0R"6>9#%;0;$#FX/A;\IO\ @G%_
MP4H_:+_:C_X*0_&;PWX]O/$-S\(?#WA[XH/X7\*W?AK6 ?#OAG1=:;6]&E31
M/#Z/CQ.(]'TCPQ]WQCYA=D<CQS(QH _>/0_VN-%UK]J_Q!^RE_P@OBG3M?T#
MP<WBH^+KJ\TH:7?P%=";;'I22"1&/]N(6G)<-L)$2A@J?95?BM\ _P#@K7^S
M9^T%^V5KO[,VC>!?&'A_QOX5\,^/+L_$#Q=I&CZ6ECI7@4EM<DUM=;:/Q+X>
MT;>NK,)F601&)AXTCMVE=J^.X?\ @Y3^"FO>*/B?HGPZ_9Y^*'Q TGX7>(?$
M^@WWB.SU5=,.H)H/S-JW]B-X:9O+8\E2Q([$-@T ?TVT5^6_[$'_  5(_9V_
M;>^"/Q!^-WAV74?AUHOPE\2+X8^(]IX\_P! &@:IY7]KZ*J:Q@)K2M$,$1;5
M+2.2F"P?Y*^,'_!='X=>"/!=_P"/?!OPG\3>*_#.E^+AX8OM9N;L'3;)L ;O
M^)()2>GRAF;MDMUH _?VO(/BO\:OAC\#O!NJ?$/XL^,-"\ ^"=$NM.L[[Q!X
M@O%CL%U'57(BTKY9"3JTLG$2 .3YRM\R>;M^6O\ @G]^W3X<_;P^&&L?$?0O
M"NI^%/["UDZ->6EZ PO#M/S+GGK_  YXSQ@9!_G?_:.\1:#_ ,%"/^"P?@GX
M ZWJVNW/P-TJ]L-(UGPI+*[:6#X'=I=?^>5F*Z]XJ9B$0'RX8M>6.)4\<1HB
M@']2TO[3?P+M?@[I_P ?M1^(VAZ5\&M58&U\?:F^JV.C[3K#>'/G>2W231@O
MB-FT$"1!NG 4N57->D> _B9X'^)FA0>)? /B70_%V@W-VUD-8\/ZHNI:?]O7
M!:/<H7@-@]!]"037BOBO]DSX%>.?@5I_[.VK_#[2?^%.Z7816/A[P]8G"Z$=
M!#_V%K.BL49DUQ&9W5VR1\_&<A_@R2S_ &?/^",?P,^+7Q#U7Q7K_BE?B-XR
MM+GP-X OKZVTWQ/K)AD*>'O!NB())MQ\.KKVLW?BWQ0R%3;$/<B"4I!( ?M'
M17X4:1_P6W^&T&K_  7'Q+^"?Q.^%O@GXW,+O1_B%>W#:GH^@6_G#0VU;6XE
MT"/&@_VV3"DX?"N%E:)T!@;R7XQ_\'#?P8^&/QHO?A+X,^!7Q&^,=FNKRZ+X
M:\<>'-7&GZ;XY71M&;7M<U;0='E\,M(RQ*VW=\GF$;BB(1"H!_1C17\Z5G_P
M<&?#J\N3I4W[+_Q:T/Q#]MT^R7P[X@U;^S=1U#?WT=/^$<(<J>I)4-GD<YKU
M+]AO_@M9\,/VN+[XL:1XA^%?Q ^%&O>!M)U/6O#WA*_M=8\1>)_%>E:$6<Z1
M'HT<7F#Q,/W2QJ)$3Q>NL0>28Q$ X!^[=%?S,>$/^#BWP9XQ\2?';1-+_97^
M)^I77P;O-&.H:6-6_L[4K$:Q(=&0:TK^'&5,2G<#\S*O (949+FH?\'#WAG5
MO _Q \1>!OV7?'VHZQX#TC[?K.E77B07_P!B/J=GAI0W;C !X)!'- '](>K:
MI8:-IE]JE_<):V&G6C7=W<X"_9;) 69P0"< 1L1QQC/85X9^SY^T)X/_ &C_
M  =K'CKP/IFOZ;I.D^*-4\'7G_"56!TK4?[4T?2="UPOL#,?[%\K7!&LS,V]
MP^U$$C(/@K]G#_@J3\-_VC_V*?B%^UGI'A3Q"NO_  C\):OK?Q)^#=JXU74[
M/5&.NOH6A#6G0A5\6+&%.TX\'C=/*C^$5M[WQ5\?^'_^"NVH_&[]F/\ :XU?
MX&_L\>)O WC#X6_"_P 3^)],NO#JZ8^E^%DUN*701K&M@2^$?$,7B+PJ[*6E
M\,QS!D\/GQHH7P4;>>$ _HWBE!'Z\?Y_,?B*LU_)'^S]_P %6/VG-;_X)B_$
M3QUH/PO\3^,_$_A32/B@;_\ :"U35_%I71EUW^W]>_X3'Q =#B=AK_\ Q._^
M*(,?C*-L_P#",9/ %>^?\$@/^"I5[XP_8F\7_$+]KKQ!XR/B#P?XQU :7XIU
MB[U;QIXD\=Z5K&C?\) FE:$1"\CRQ'0M:$:M(B@9*LK@$@'],%%?S<>,?^#A
M'X<^"=5\$0Z[^SYXVM]!\4^/M+\'7?B'_A.M'*:"VMZV= C+(?#I+A%V^)]N
MY4+J?!@5)2K+]@_M-?\ !7O]GKX,>'0?AG?VOQK\;W 8+HME=:MX;TO3L\ Z
MRVOQHR#&05&>W/&* /V&HK\+_P!@/_@L+H'[9/QPE_9_U+X;W'@OQ-/X1\2^
M*-'U6"^:33B- D\S^R-<T=R\F@R#0"LVYRY9DP-K-O'[H4 >*_&[X\?"S]G;
MP3/\2/C!XOTOP5X.M[_3M$;5=6PJ7>KZS(\>DZ1'M5F,LC%B < C)+ [M_G'
MQQ_:[^!G[._@SP'\1_B?XJ?0OAS\0[[2M.T;QFMH^H:19KK.D'6]$U?6HT#:
M\D$T*+Y<D<+L%??)&LHVC\U_^"^O[,7QT_:;_8^TK3_@3_PDVM:U\/\ QWIO
MC/5OA]X7NEC;Q=IL2Y_M9LE7:7PJJRRH%4CR];F<$*N3\5?LV_MT_LK?M'?L
MU6W[)?[?M[I/PH\<_">_T<>']3\8R/XA4JTL*Z-(CA)BK16^MR^&HX!$J7'A
M'8CRVZN\Z@']16A:_I?B32-/U[0[VVU/1-9L=.U?2=3MK@265_I^L#?#)&P)
M!RAW*,$Y=5PKET'0R?<;Z5^;?[9G[7-Q^QG\"/!VN?#7X?7?Q@\3:_8:;HW@
M3PWI5X4\/7FFZ+HF@I_;:RHY*: BZWHZ[XGY$@97  +?(W[/_P#P5A\<_$3]
MISX;_LU_$KX7Z;X:UWXBG4;57T&QU73M2T.6+15U]6F77_$ 5A(%"2;0I1#F
MV/BR0(Z@'Z6Z+^TLVH?M :Q\ M9^''B/PO?VVE:IK7A_Q#JUPG]F>(-*T4XD
MUJ(J49-$=CA)&:0AC@HY-?5<,OG1D]_Y^G]*_%/]F7_@IW??'K]L75_V?-=^
M!3>"0M[X\T;P=XJ^W?VCXCO],T)9-;;^W@NTZ&K+HW*2%D#*CJJNNZNC\:?\
M%$_BIXC^)7Q'^'W[+'PFTWXXZ=\-KHVVM>+-+.L:^(=072#*JRZ-X=ED7/B;
M7PL?A!UF,,^QV8")@B@'T[^RE^WK\%/VO/'OQO\ AY\.S<P^(O@-XE;PUXDM
MM4GCWWH&L:UHG]J0!8\K&QMXFVL[LQUF)6+G!'V5XI\5:'X*T+6/%7B.\M],
M\/\ A_2-3UG6M3N#A++3M'4/*YP#D*&+ $_>R!RPQ_']_P &TOB/7/$O[5'_
M  4 O?%6B+X:\0'6-5^V^'FL?[/U"Q'_  F>@[@XRN4/B'^W1]X#)&?2OV;_
M ."Y_BSQ1X=_X)O?'O3_  EX0UKQ);>+=+TSPMXGU;1[S^SO^$&\-R:M'.=<
MR.,-XBTG0_#14+][Q &4A1@@#/!W_!7CP3XIU_P-8GX0^(Y/"WCSQ;I7A7P[
MXDT+7T\232?VZY.BZT^BQ>&XX3&Z@!D'B@8.6!R1M_8B&4RB;,1@QP=V,G@\
MG X_GCWZ?SC_ /!,_P"//AW]DS_@FJOQN^-NEZ5HGA^UUG^V_!&D6CZ.NK>*
M_$C:'HF@:XV@!>23*JJ-Q5=@D(;<H!\D^*'_  7Q^)?@M/@SXMT/X$^%+CX=
M?$CQ%K&G:NUV=9;Q-IFDZ,-:#ZRB:%XC:/#&!&PRLN[<>CL" ?U/45_/)^T3
M_P %K?!USX5T3PU^R-8:AXZ^,$M_IC:]I6KV?F-X=8'1=='@Y&=1_;G_  ER
M2-X57Q)&H2W#R00N?&GEQITG_!-S_@L%XN_;"^/_ ,0/V=?BS\)],^'/C'P_
MI$=_X=N_#XUQM/U#4HM%&N:[H^N?V\KR:+)''DQKM9G<*N03N !^^]4;N[2S
MM9[N;F&W7<?(^9MHP.1Z@D<#I[\5^?W[??[:D_[%O@GP?XDT_P (IXTU7QCX
MB;1[;3KK54TW3;33M&\K^V;AVQYBL@U?28UP-KAR6):)<?-'[-/[<_[4'QPT
M7X]WGCKP)\/_  GH'@/X#^)O'WAOQSX+M-7$FC^/$1VT'1-<T37O$GBL%B1K
MLC[5VD>'I 4VDX /M?\ 91_;=^"'[9-E\0=6^#5QX@N;7X=>(AH&JOXAT4Z3
M]N6:364TC6-(=IV,VB7)T'61%)L!#)@G+X?[/K^$G_@GY\1/VSO@QXZ_:=^*
M?[)OP8\%_%FW\#>"/&^L?$4>*=9?3-/LM/#CQ$BJ(CX0=O$ _L O*/">8_&<
M*R-X(S LAK]_?@1_P5$\2?%3]@76_P!J76O 6CZ;\5]&\7^)/A\?!6AVFM:M
MX4_X3I8I=8T)-1@$Z>(+31.3X7N+@>(R\GBO1Y+>*0!LVP!^W-?!7[7G[>/P
M6_8WU#X;6?Q&_M#4M6^)'BW2= M=)\/M8G5=$TC7-:317\::W"]PJP>'XKA0
M+59(WD\1F.Y\@(^@W&S^>7X@_P#!:_\ ;>^#OQ$^&_C#XC:+\*$\ ^._B-X:
M\+7/PKT8C3;!-+?07CUW6_[;\1A_$>A[?$4A\4JD_BR:(NJ^"'C9E4U]6?\
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M\4:)=ZMXJU76V\2WWBC7>26/AX84 #72-Q!\''"('<JI^I_V'/C-\;?V#?\
M@H5IW[+/Q\^*EQ8^#?&GBW5?#6JMXTO=8_LS45T1#_8.N1N&'A?YD;1 OBM6
M'#9W 'QF: /[(YKL>5D?C_GID_3@U\7? ;QU^UIXB^+'QGT/XX_"/P=X+^&V
ME:N(_A/XL\/>(4U/_A(XQJLBI$2\L?B+72V@2H5\32^#O"49&ANHC'F&:/\
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MD^XWTI]% '\>G[17P\^(G_!.#_@LEX6_;?\ %7AJ?Q9^SO\ &/6/$]EJ^O\
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MAW7?B+9FT\0>$K*UTE?#C>(79_[5UW2D>)'AE=4VR@1E!(DFP ?ND /Y6/\
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M]=OQ-^%7P_\ B]X7N/"'Q%\+:9XL\/7-RMX=)U8$QG4$W%".RD!CT)&"<JV
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M['/Q;TWPOXH^/'@[X5_$CPW^R_X\\8:IK7AO2+N\UG_0#_T&O[<_Y%CQ#_R
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MRSC<5*JJXKD3_P $3_V)9[C4;_5+3XB:UJ&J'46^U:MXFT1S9))(4CVX\/(
M?#@!$)+8WD##D$  _"W_ ()J>+_@O#X(_;'@^(NB>$=1T;7? FJMX=L]6N]&
MT[^T?$^O:QH0QGMR5\59&<[?% QSQUO_  2R^(GP_P#"/_!/S]N[P3K=QX<3
M4_$WAOQ[8Z-X+N=IU77DUY_'6AZ-JW]MLK+L\+_VPJOQN Y1T<*X_;F'_@BS
M^Q+#!=&W\.>-K>XU*S^Q7MU:>(]&THWRD9RPT+PVOHQ[#&1VS1X6_P""-W[&
MOA'5M7O--M?B'<V.JZ5JFB:QX>U;Q=I,OAN^&L:;Y5SK!A7P[&P\0J ?$(N0
MY2.=Q))"8U,;@'Y:?\$9/B;\.M&_X(R_%OP3K>M:+I^OWEG\>].;P]K^JZ(=
M4UW5?'.AMHGA_2=&T9F#Z\OBD+I$8"[BSW RH&6'P7\&?$GP[O/^")R^#_%5
MQH6F>-=*_:R\>ZS::1@EK%M>T8;2-$\/'&O+XJ\0[AC:Q8N.4V$/_11X0_X(
MB_L:>%=!M_#D,_Q1U'3[49O+2\\1Z/\ V7?$#)#Z*/#;*.P'7N 6SQ4@_P""
M&O[#\6C6^AP6/Q/_ +.M;O2K_P"Q#QAI!T_^TM$.%8I_PC089(((( !'48(
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M.KS-X;\S^QE0MO\ *'B@1B4GQ,2?%07_ (2[_2C($4H #\._V$_CE\(?!O\
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M>:IH.KMH>[1?[ 8$J?\ A-];3Y-S;F4E=@9E_KI^#/[!7[*O[/\ H'CGP_\
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M3O$^D176!J&GZMHK;XY=(D*[XR5#*P 927+X.%H _(W]F6T_X)4^,/VF=/\
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M:)MN)%(CKYN\&_\ !.K]B3X;^*$\7^"OV9_A?HFNVMPUU9W$>BM?6%H[:/\
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M &CVL_AI_P %%=%E\'ZW<:A<? GQ/\9[ZZ-F2#J/@?P;KP;1-H\/QKO\6#7
M59@^W^P"%0L<5\)_LW_M=?M"_ W]EGXT?"OX+?"O4O%O_"T+S2_^$P^R:/\
M\3/0=+_XG_\ R _Z^F?PK_0&T/P)X+\*27$_AKPCX=\/7%US=76A:+I6EEB.
M<MY,28'^SM9>Y'2ETCP3X0\-2W$_A_PMX?T6>ZM_LUT='T?2]--ZH'"-Y,:9
M4'/R2%@01O+[: /\V#]HOX\0?&;X&?"?0X-*UL>*- ^)&EWNL:5]DT;^T[#^
MPM%Q^76OV._X*P_\% /A_P#M3_"O]E'3/"OA/XC?\+)\,^)-+\3^,F&C#3/
MY_MS1= &N:+HG_%2$^(2OB+ R2?^$+_L _\ ">  XK^O7_A3WPM\WS_^%;>
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M1%*_VY^5#Z?H?\*K2Z=93&W^TVEO/]FN3<V>;9!]D?'#)CHW)RP W$C*G:,
M'\AG[='QQ_:Y_:<_9$O/B=\2OV=/'GAWPEX[T?4M6^'O@JZ\-IIK^$M-\<JK
M^'U\0ZZO.0FC*ZJV!XS20%0%8$_MA_P1HL_&.C_\$Z/V<=!\<>%==\*Z_P"&
M/#FJZ1<67B&S%@][8_\ "7Z[K*:O"KKMC20:TT6 2SRZ0W*[BQ_4O[+;_P#/
M ?G_ /94L$,$6?)&/Q_S_DT ?AU_P7(;]M*\_9H\'^'OV/? WB3XBVWBOQ^-
M%^-'ASP5X2U_QOXYO/"1(U>WCT30]&CC:'1"D6L?:=?P6BNV\.*69F#-_*'J
M_P %/VW]3^('P?N+W]@3]J'PEIVE_$G3,VMW\$_B6=2UXC1CKK#CPV?^*C'A
MW0M=!&>""#W _P!(#R899!..2./Z?Y_QI?*A]/T/^% '\@WCKX>_MM?'[_@I
MKX5_:9L_V2OC%\+_  EI?B_X7_9?[?\ #6LZ@+$^!=%\/YUP:UXA\.>$_#(0
MG0^ 6; X+$\UU'[7_P"SM^UOXF_X*U7GQS\*_"#XLVW@S2O$7P=C\!_$+P;X
M2U/QOIU@_A[1-#_LCQ>WEG_A$0T?B1) \7B;$,01T\<(D,85?ZT/LMO_ ,\!
M^?\ ]E2^5#Z?H?\ "@#S#XF:IJVG_#GQM?\ AKPW;>./$&F^!?%%YX>\*W+H
MW_"4ZJFC2G1=!8C&Y?%$B& @8(+X."K8_A>^/_[!_P"U=\6O#GG^!_V(/BC\
M-O&&O>,=4UGQY>6O@36<:\2< ?\ %/\ AO\ Y%XD@#\!CH*_OP\J'T_0_P"%
M'DP_\\?_ !T_XT ?Q5?M ?L$?MS_ +&/QR^"'[<'P#^%'B_]HOQEX?\  _@9
M-8^'.A:1JOB353XZ3P>?#WC?2=;T/PV\B^7X970TFA^;_A#Q'(J^"(XIA)"G
MW9IVL?\ !7+]L?P=XP^,7BCX)>*?V:=$L?AW_P (NW[--WXOU/PUK'Q1L3J:
M/KG]CZ)K7B%!H'B7[+JVK[3XM4,8(HO YRJH3_33Y,/_ #Q_\=/^-'E0^GZ'
M_"@#^?'_ ((!?LW?'O\ 9\^$_P >+?X^_"[5_A1K_COQ_P"&/$GAW2=5TE=/
M:^\-C2=;0+M!/*LX#@D,C%1CGCPS_@N1_P $M/CA^UK\7/A3^T#^SQI32^,/
M"WA&7P9K-IH0T?2M1_M&/79-:T+7M:9@/^$@C<:P?#P5F=D31%RVPJ:_J&\M
M/[HJ'R891\T(';)&/\YSTP: /D?]EWX/^(O@A^S%\-?AG>RV;>/_  ]X!+:S
M>WB%R/'VO*-=UEM8FR1KC)X@DD4^),9DCTCS%8 2!_P _8^_X)8?M-6'AK_@
MI9X>^.UAJ/A*/X]'4M&\$-IFKZ7J&J^.+]]8.NK)_;6O0OR/%&B1B3Q/*T"^
M,(-?\/7#R 6[*W]7'E0^GZ'_  J7RT_NB@#^.GX ^#_^"]'['5I<_LY_!WX+
M:9XE^ V@:SJEAX=\0>+#HVIZG8:9KW']L:)K@\2?\)-W^ZV?^$+SS_PF1-<-
M^T)_P2"_X*'^"KSX#_M0? #5[7XD_&G0?$FF?$+QYX'U;Q+_ ,(WXFT#Q0-9
M5M"_L37>W^L0X//@M=!!Q7]I7E0^GZ'_  IOV2WV8\D8ZX[Y_P _C[9H _GQ
M_9Q^)7_!;+XXI?Z#\<?A;X'_ &;X=*\':O?6GBU;?1AJ6O\ B=&2/1M(D4-X
MM30AXE;:KOX6#&#. 4)(/Q'\6/V0_P#@H/\ M36&A:7XV_91\)^$O&.A6VIE
M_%=H_A#3]2\5:M_:R)KFL>-=9\0^)F'COQ!L5"?$OBCQ<B>-69I2N^1W;^NS
MR8?^>/\ XZ?\:/)A_P">/_CI_P : /A[_@GS^RYJ_P"QY^R_X*^"NM^*#XLU
MS2K[Q5XCU;5I %-MJ7C+6UUZ328E)RT4,DYC9R!F3=MW*4=OQW^._P"QI_P4
M+O?^"N2?MN_"OP%X5\7> /#/AEO"_A&U\0>+?ASX;%WIJZ"FBN)]''B)?$VK
M:#M<,%G\F1B?E&X8']-RH$Z4>6G]T4 ?S%?L.?\ !/7]MKX>?\%#-?\ VJ_B
MWI?A3P%X;U5O$]Y>Q#Q9I/B35=;&OM*NMZ1I&AZ!XB\6B&&1M5E$,LI2/PDR
M%+=I'**WSWX3_P"",W[2/CC]L#Q?K_Q8T/3_  7\%M5\=^.]:N_&UIXB\'^(
MFUXXQH6L:+H+^(U\4(WBMLAED\'H8V&)-N./Z^?+3^Z*B\F'_GC_ ..G_&@#
M^+O]F+]A3_@N3^PCXM^,?AS]D[P_\/M'\ ?$'QWJ>N,OBGQA\,_%&GWFE:(G
M]B:!K137?$AD'B1T(9 %W.I'_"=@Y%?I!^V3_P $_OVG?C1^R%>^%#I'_"W_
M -J'XUVFKW_QJ\9ZIXL\&^'O#WA4G29&T3PEX?T/6)/"_ABY\.>'P\7AR".*
M,W#OHFV0-X,E,$7]$GE0^GZ'_"CRH?3]#_A0!_-#\4_^"-7QO\8_L?\ [$'P
M=\-^,/A1I_QA_96\(?$_3]9\0ZJ=8;2==U/QQK>BZ]H.D8'APC7_  YX5=6C
M?PO_ ,4<X8*/ OC;P6B[A\0_%G_@C_\ \%B_VJO$?P,?X]_&;X16UC\$](TW
MPYX(\1)J\>EMX6T]$2,L^B^ /#BCQ"ZQQQQ[I'&U412P15Q_9YY4/I^A_P *
M/*A]/T/^% '\I.I?\$3_ -N#1_B0/CA\,_CE\!]#^-]W?2W=YXN\0ZM\2M47
M3S$V@?V#K7@C9\.F;P_XAD70B\9 *^"P/+<^+KAD\7'"\2?\$</^"H?Q1_:8
MTW]I3XF?M9? W7O$]P^FS^)%M=5\8E$U;PZ770D\#Z-#\%/"MOX>\.@Q,F%E
M(CDV^,I/^$ON"(3_ %I^5#Z?H?\ "CRH?3]#_A0!_--XM_X)/_MK_%#]L+1_
MVH/'GQT^!NNL? _A_P $^(T&H?$6PU;4?^$<TSRI&&ACX>MX6\O<0<%P?%RD
M>,I4AG @'M7[/G_!)SXG?";]O,_M3ZW\5O"VI>$=+L)+/1O#OAYM5TSQ/D:1
MY<0UT#P\SZ[]HSHC^,F_X2W'C%5;S_*<;#^]_E0^GZ'_  H\F'_GC_XZ?\:
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MT0O&&BT$/O"PK*3AEW.2PV_5% '\@>L_\&T_Q9USXG?\)SXC_;2M]3)Y5/\
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M!/!0U@VND:EXYF>POQK@,NL?VNFP>;YFN_\ %3$C8%G!13*<HO[!T4 ?A%X
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M: .NHHHH **YJU\1Z5>ZI<Z'!JNFSZO:*?MNEV]VIU"R&,DNN<_+U.0N,=2
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M@,#D">34K=+N*S:> 7%Q:-<VMF2POF"C!8*68;>2I/&"&!R <@&M5;[5;_\
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MZQT@^(_#O]H:D#]BTHZSI?\ :U^2 ?ETG/F-VSL.X< \G% ':T57FF\K_/\
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M-/$/QVT>Z\3:OX;\::Q:R+#KFBJ?[<.BZWK&NNOB(>(XXV8@-&=X54)0*K(
M?NI\+/V@/@O\<%\23_![XF^"OB2G@O66\.^)SX+U_1]5_L'6"NUM(U4QN6@?
M:LAV@*'_ +*)4LRM&?=:_._]FCX4?L3_ ++?A'XO:_\ !'Q'\,;/0T\<^+?&
M/Q4\:V7BCX<ZE>^%-1DE77M=\':]K7AX(FA:%X42$%/"QR]L)'4<2,7CM/\
M@JG_ ,$_+UO)LOVF/!]U<6UV;!K:UT?QD2=0YRN/^$:Y!). 3CG.,\4 ?HI1
M7S1H?[67[/?B3X?WWQ1T/XR^!-4\#Z;IYUB[UJSU52R::H_US:(1_;ZGD;5\
MD[F/"E%=5Y_1_P!LC]F?7OAQXK^+>A_&3P3J7PZ\!L]KXA\0VNH3/]B83>9N
MET=@WB(EE$?DK]G_ .*E;>+8.BB@#ZWJM+/##][&?3KQ^/%?%OBG]OW]D'P3
M+X2@\1_'OP5:3^/=+L=;\+V:IK&IB]TIPVTRG0]!E;05SAE'B5K8C.TQHNX+
M^4U__P %AM-^(W[;?PN^"'PQ&G:+X"TKXBZ9H7B/Q%J^M'3SK.D^(2NB3KK&
MCL/-8^&Y];-Q<32L_A3PI-B2XED*1! #^C2BOD?XM?MD? /X&^+-/\#_ !$\
M<VNF>,-4%@UIX?TG1]9\1:G86+XQ)K*:(DQC7<7(_A7=]R56)JI\/_VX/V:?
MB9K'B_PSX:^+'AIM:\"VS7_B9=5OQX;&GZ5AYEU;/B!8<PC0=OB!5*_- 07
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MX@\DLIDD\-_:XT4-,[1QABOV!7\4W[#G[0GP!^#7_!0WQ#XJOOM'AOP/I?\
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M1+#6;-8[W1]0DT3S5RNDZFVBR&*.:(AAM+,%4AB45E4_EU_P7X^"O@WXH?\
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M'/Q\_P"$=_L/X5-X"U;1+"ZN[%[ Z]JNN:T!OT*.,CPVR*=%7>5*@!AEU!R
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MM^,_A7XM:GX+\-?"F\?1-7N;FT?Q)IWCSQ-K>L$Z+I T-/$?A-E\-I_PA&M
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MZI_8OF>($&ML>0ZZQH@(12P&6P I=0#]I**** "BBB@ HHHH **** "BBB@
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M_P"%DW-[X"7PAX>M/#@_X2:^8ZSKQUP:)H>3@GQ%HJGQL#@D,/'/\0H ]?\
MVS?V8/VB]8_X)Y_$_P#:T^)OQJU'QOJ/C[P?X$\9:Q\/=6*ZB- ?7/&?A_1!
MH6A@G_A&O$#E-</AH *1XS7768E1C=^VG_!'S4)]9_X)Z_L[ZA?P"UUBX\+K
M)J=Y9.7L=0*>8-)UM-6$;2:V3X8DT"W6X\0&2XD.F;&B AA+_CQK/CK]NKX^
M_P#!-;Q]^QMK_P"ROXM\6_$*V\#^&/#-Q=W]IK+>)EDT+XDZ#K9_X3,.3_;K
M>3H3Y$8'_":KYK8^>0M^U'_!++P#\3/A7^R%X,^&WQ<\)7/@?Q?X,ND\,WUE
M>V1COM2;1_"GAJ.+66N=K#7G=D>!?$ YNCHVS:0A90#Z^^/UQ);_  ,^,U[9
MZQ?>'+^S^%OCR^LO$&D:N?#VH:%J4'A#79(-:TC7WC \/SP39D@\1?\ +!@T
MBMN137\?7_!+_P""7B[P)^T9^T=^T+XF^./CBU\0_![X7^.?B5XAN;JZ=V\0
M/HK;=;T36U\.*Q\0^'!XCR\GAG&R*)7\&>!V2*)W7^S#XD>%?^$Y\ ^./!,&
MJ7&BOXT\(^)O"ZZS;6RWKZ/_ &[HUQHHU)5;AC!&[.@9L,02Q3:S#^6;X$?L
MC_\ !0WX%?&7XZ^!6^"T'B+PI\9?AQXW^&MSXLTN[EA\.W_AC7M&!13K)\1I
MX>\.NV0G@F%O%P;P=N:&1#O9" <CK?Q=_:2_X*:^(M!_:3^!^K_$#3O&'P(\
M//XJ\"?#3PK_ &QIOAK0=59F;^V?[$  _P"$A\4*1&F?%Y\:^,XT0> R=I\&
M5^AW[=>J?%OXA?\ !,/PIXR_:%\(2?#7XK6/B_PQ<>+=$M(62W&I-'XTT,:T
MC:(&.@MXG.MMB3Q"UO;,)FAEC\*7'B0O#^>OP$TK_@JW_P $R]1\7_"WX5_L
M'V/Q6\!>,(M.U?1O&]D__"1ZD-1TG:!H[V_PC^([0Z#H ?6-:\KPS+"SQD2>
M-4(CEN$E_3?XY:-^VY^V%_P3NM[K7_A%I7@+XW^*]5OY?%OP;:PG\/ZK8Z=H
M_B*4^'1H)\?>(G1RB#$WAKQ2JS>,+;6!<>%9O"D21>$?%8!\/^$/^"BTGP._
MX)X_#CX8_" WD/QCTN^\3^&=6U4MK*IX!\*KXRUS7E\8Z*FNA%G1'UI_#L1N
MA/)#-HLK>-WC5@HS?@#X6_X*.?LU_$O4/%'@?PM\3O%_@_Q1I!UOQ'XA\6:1
MJ^J>&?%IUA]>UUM;UO0N?^*CCD #>*@#XU1]? /_  F/@6OGSQG_ ,$D/VW?
M#'[,:>.M(\*P:G\?_"%YI5]=^"-*U3PCXC/BS^PP^=9T8-XB4ZWXC&QO"K+(
M%;QCX.UX1N%=@I_0?X0?M=?\%BOB/:M\)_%O_!//0_AO;7GA*_\ "UGXY-_J
M^E:;I[CP@%CU4-X]\2)X:8-*WEB-F;S&+1$,'9& /SSU#XF?M=_MW?MA6'P6
M\4_$7Q)X2T_5+S4_#%H;.\.G:;X4U0:&-<!T71- +'06VZ%H(+,68A1XX).*
M]/\ V0/V[?C]^R#\;[[_ ()W_M&>%M3UJW\3>,=3T:RU;Q7>#3=3T+2]=T77
M\#1 5_XJ$>+!_8GB?'0;B1AO%JLORQ^S+\?/B;^S[_P4TT_2+[P%JEQ]K.IV
M>KM<WNC>&=4T\C1@VN>"]<T/Q!QX?P1DAMWC+P:,JZLI*G[XLO@!^U=^T_\
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M ,(X^@:,L:D?\46?!S!!_P 5\0/!WYU?M]?"#XZ^+/\ @HW\!?&?[2'BO6O
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M_P!JKPA\"_"6K? CQ[\)_$:?'"S8-I%IX?T9M3\3>+=6UPJ#X,&MAU\2''B
MR;!*DB";_A(IBA\D*_R'^V7^RY^TG^U./$/C?P-\"(/@5\>/!MZVMZQX>^'V
MDECKVF:(VOMH?4D^'_$/BLGY?% ('C)<*H55  !_5_H27MOI6GV^L3VESJWV
M*,:I<6MN%BNM35?^)L4C4%0AD4  <GC (4*/F_\ ;!\8?M!^"O@MXAU7]F#X
M<P?$GXO7EUI^B>'-*O=6TC2TT4:Q)(DGC5D\0)Y&NCPPS^</#(99+D,6QY46
MU>J_9F;Q<_P&^$$WCXW%OXPN/AUX6O\ 7(+R\_M&_35-5TF-W#R= R\C'/S!
MU;;M?;\D?\%9/!W[1_CO]DW6?"G[+P\:7'Q,U/QAX97[)X'R-3U/PU_Q/7UW
M2=:  4>'69])\W<"Q=5()&20#^5;XL_''XT?L!?M#:=\;O&'B+Q7<_&>U\7C
MQ/XCTC50-2&O>.]<'_"!>.=$UL#CQ ,8]O&G_,A#_A/*^QOVG_VU?VP_$'[:
MG[&MWX,U6#PD/BQ\-?"RCP1H-^WA_3L:WXS&@#6]%\>.7=_#Y&M@L\C-X-8Y
M9V9B2?BCXM_LC_\ !0C]I3X2VVAQ?L^:SXT\8:$5T3Q)JQ\.:QIFIZ#JK,%U
ML#)');1548Y8LJ@$D5]<Z;^P'^W!K'Q]_8W^,4_PL\6Z;I_P:\->%]%\26>K
M6?\ Q,Q_87C3&NDCW^G_ %/..X /J.Z^,7Q9_P""<?\ P4Y^ /[.?B+QQJ'B
MWX=?M::?IUWXYUG5K'0]/\-H=$&OAM:&[_BIM _X10J-_B9CL? 5^,BO:C\2
M/CI_P4[^.?QH^#'AWQ';?#?X$_L_?$GQ-H=Y>BQUG3F\0:IX%ULZ$ =;1<G#
M.S'"A5RS$*-QKSW_ (*K_LF?M6?&;_@HO^R#\8?AO\&[KQI\(/AOX2U?1=;\
M;>%$;Q!J>A,7\0EM(UO06P2DC:XS+("5;)^8D&ODCX%?!O\ X* _\$R_VJ_V
MCOBWHOPLO/%GPW_:(^(&I:CXCN_%.NR^(-+L&UO6CKH_L81>)T\,2Z__ ,3P
MD^)) \3$#P0RED4@ ]8_X)->"O&/P-_X*6_M,_!#5"]Q;>#?'?B?PR?$*8+^
M+=*&C:]K[:R/[?#>*,'Q#PWEYD(SY9_X0;::_K4K^7G_ ()H_LT?M2^'_P!O
M'XD?M+?%OX:^*_#7@7XD>+-8U/1-2\07H,SQ:O\ #+6UE?6(B=SA/$DNKJ6"
MLJ/+$&YD4'^H:@#^8;_@N]^T-X^^%_BKX>?#S5H)T^$?C*RCU."^\)Z@T&J/
MJ40;1M9CUHNB^9K<;7.D-'L9XD\(2W 4^:9ZJ_L(?M>Z#^SM^Q[\:?B!?>/1
MXDTAM%_X23X1>%=4O3?V%_XE&B/_ &#M=,/PVC'_ (37#+M_L-F4AB0?T4_;
MNU'XLZOXLLO"E[^S7X<^(_P)MI=.O_$_C=K0ZIJS^&>/[=TAB1NT#=K_ )95
M>1"N@KXR4JL2HOX*?#W_ ()&_'77KG]K"X\#6?Q'NOA=XR\.:IK'[/9\5G_A
M'!KS_P!NZ^A3^P]?_P"9>\5^'QHGB8C_ )G-OE."#0 ?#)?VY?CSXAM_VUOA
M9J<^N>+M5\='Q+K"7G@X'POX3U'0QC!7IM(T/&,8(XQU%>;_ +:O[8G[;'QU
M\?\ A;X8>(MUM?KJZZ?9>%-+=_#^G6.IJH W:,[,[^(R!KF6=F8L2Q)\"GP<
M3]>_L:_$C_@K[^R1X F_8^B_9$T_Q#;?#J]\1FQ^(5XTFO:F6U]AKT:Z+K7_
M  DJ>&?$'_"+,RH?$CCQCYA(C=&^[4>O_L+?\%'_ (F_M#> /B1XY^%>BZ*-
M=\=F]\2^*[OQ?X.\2FPTL9UXZUKBCQ&6;H< 9R,>!ER"* .,_:P_8F_:Z_8@
M_9\^'_Q5^'OCB[\2ZN"?^%C^']+T^3Q#_86J!GUO*ET4.I*ZZRLNY7\8E9%+
M1R(S?26N?MW>-_VB/V:?V.-/\,^(?$5G\7KOQ+IMI\2;G1[L*->?16;1)'/_
M  CV 6=V+L< LQ9F)+&OW]_::^$MC\=O@-\3_A7/#;7%QXP\(:KI^D;[PV&G
MCQ, QT+?)GY2?$(1BS[N.&)9@1_/?_P13_X)D_'W]DOX^_$CQ=\??"R?\(WI
MW@UCX"N;[G[!XZUS6T#OH:CYG5?#CZT"  /!KNB%D\P-0!!^V7^T%\7_ -G/
M]MSP!X&L_B%XU\27FC7/AC[--?\ B%=3!'B+1"732$\094YW$2*<@L6!R,Y]
M'^(7[2OQ"_;J_P""@_C#_@G[I/BFV\(_!70/ GACX@V?BVS\-G3O$]]XHT;2
M-WB!R3SM+DOX,8\  L3A>.'_ ."B?[*O[4OQ&_;R_P"%B_#'X>W&O:#':> M
M6M]6TNSU;Q)8+X<&A+H3+,L854E/B'15=E557:P95"%37QW^VE^S+_P4E_8N
M_:PL?VP_V9/AQ;_$?1_$W@3POX7.K>'_ !$=,U+PEP#KNBZWHA ##G 9=RYW
M+DD$4 ?=GAWXI?M%_P#!)S4M=TSXQ^'(O'GP(N&U*6Q'AS4-)C;Q9XJVLO\
M;.CZSKS#Q-H2@.=T4H>,OAF0LBE?S$N_C7^V)XU^)<_[>GPXUS6QX_N?$G]B
M78NK+^T?#&@> M"UO^W1H@T,<>(!@8P!Q_V(0K](_&WA;_@HW_P4X^'NGGXR
M_LW^'/@Y\-[;PAJ&K>&_[,\3:1X=U._\4/+H.MPKMU_Q(?$V2^CA!)M_X0YP
M%\UW*9'@?[*_PX_X*R?LI?\ "R/@#??LO>&O&_@_5+/Q/XGM+NZ\2^#?$GV_
MPOKNBZ]H0SKG/_%18_ML_P#"+9_Y',CKX"/(!_1[^Q;\6O'GQQ^ G@;XB?$O
M0QH?BC48M4L;R>Q(33M=71M:,<>L)P!MEV%%7</WT?B#"\$UH_M=:E\8-(_9
M\\?7_P "KK3K'XC+I^G)I>K:G+*(O#NFC4\^(M9/F^:^L>7H(N(PK/$MJS'Q
M/DM"BM+^R)X%\>_#SX(^&/"_Q(2QTSQ4E[JNL7_A[21I A\+#7-6FUO^Q =%
MVV[!&F\Z1H]Q8ZOY;EO+V+@_MM^%/C%XY^ 'C#P7\!]"T'Q'XW\4S:?IEQIF
MNZQ_PCL=]IK.[3*==C&V)GG71EG\W'F>%%\1JS-*(D4 _B#_ &EOC!\:?V5Y
M;CX[ZY\1O']M\<+GXJ:7K6C^(;2\_M+3/%NJ:[HO_$]UH:YU_P"8%QU^OI^L
MG[:O_!0/XW_$KX9>!/#'C#POXX\)_!CQO\+? /BCQYK_ ((T<!/%6IZUJZ^'
MM<UE-:55'A_PZ?$:EF=]_@]B0C2'QO%#''^?7C;]D#_@IG^T?^QO\0/AC??L
MOZ;XC^('@[X\> ]:%WXBO/\ A&]3U# U_0O^)%H8X_X1['(!_P"*,('AGQT.
M <?MY\"_%/\ P40\'_";P7\*_P!J']D[P#J_[-.A_!8^"O'>D76M1_\ "3RZ
M9H*2>!O[6UP:&K$^(@/[%E(C"O\ \(7'_P )R3_PG"NK '<_\$:]*T[_ (1R
M?7_ /Q*M;OP7J>C>7JW@#5M7_M+5;[4]&9"WC/0]%R#X>B9M9C,R@[7&N+N#
M$!:_>JY^[^7\S7\WO_!.C]B_]H/]G#]M6Y\8:3HGB#1/V;_'GAWQ-J[65\P_
MLNPTMSKO]AH1GCQ*_B!M""*1SX-91C!Y_I$FA\W_ #_/VZ=Z /YOOVIOVB;O
M]N7]NR'_ ()L^&=6&A_"C3;#QS:_$J/46U72]2U_XH> ]"UW7%P=!D3Q!_PC
MZQA4/AHLF^../QN6V1QJNEXPNOVM_P#@D[\,-:\6S^./AC\4/V:M+^(NG>']
M)\/W>CZ]>>/+%-<TEU_MO;^[<@2>'W;Q?X>_X3#(!>2VD"2LS^+_ +?O["O[
M5OP _;7L?V^?V'],U#Q=>:UK.HZS\0-'N=8TG3?[-U;Q G]C:UH3Z&Z*=<T/
MQ9&4F?Q$W[V-)(_!#@+)&S^G^*?"7_!17_@IE^RK\0?!/Q$^'_PS^!>I>'O$
MNH:?X=6ZU+7;"^\<>)O#J'P_K>CZS \GB^.%,G6DD\56T2EF97\$ JIE0 YW
MQCXR_:M_:/\ A)K'_!1_X3>);0>./@.=3L?AOX3T#2 -,/@-VT#7/&_]AY(_
MX2#>V%\:CQ9][P;H( RW7YF^._\ P6<\;_&#_@GW\4(=#LM4\)?''P8WABU\
M8>(=)TK23IGBW3""N#\Q&@)_PD1_XK:/&Q6QX)"AO%@(] _90\*_\% ?V;/@
ME\4/V(?&_P 'PWC#XG:QIR?"LV7B4-I=]I@<#Q[HAU[GPQX>\/+X>C*L 1CP
M:"&&Y?E\P\>?\$8_VG]!_8?^+&D>!_#WANY^-/C'XD:IK.L_#+5=9_M+3!X9
M 5O[8T/7/#W_ "'SM8./"A^8J<C_ (KO)H \W^,OQL_;F^#_ .SK_P $^OVH
M?"GQ+M]:UG5/".IC2;4KMTS1&_X3'7"-'!\08WC_ (1K753_ (1CQ8?^**\%
MJ? G\-?8GC?]L7]I7]EC]J3]B+QOX[^(7_"Q;?\ :[^%_ASQ+\;?#NE:#I.C
M^&;'3FTGS-(9=Z)_88\,2DNTJ;D\(.?%#!V/BXFN)^,_[-'[2'Q+_8:_8Q^!
M?PS\'>(5\<_ #X<:CH?CW0+7PAK&H::WBG^VPD>KG7CX;.?^$M;1?^$G11_$
M^/'@RQ+9/Q@_9(_;)^-K_P#!.GQIX4^%HM[+X,Z*G@Z^U3[;K/\ :H31=<<(
MVNCQ!D^'@QUAQX'_ .$L[HWH: /I7_@IC^TY^V9X)_;V_9=_9M^%>M:EX/\
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M;C4OA5<>,/%/B?X;7>JD_P!IC2VT3_A/&UC("EESCPP5(P2J/@,JD<G^T/\
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MY8Z?8:2IUYM<&QMK(Y*Z$!N4,"I& PX\!_;S_P""?_B33?B>/VROV;AKEO\
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M1DZ?$Q4X*GP_#X8UPLI^8!IY%)P"K#((!^B/[,7CRV^)?P"^$_C&WGFNVO\
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MHH C\J+^XOY5)110 S8/4_I_A1L'J?T_PI]% $?E1?W%_*I*** &;!ZG]/\
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M8%?[?\(^)=(\1Z0W&X*FK:)))$#@$\#H">@R0#OZ*** "BBB@ HHHH ****
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M_AG1_"7B*]\':;XF\6ZGD?V'XT^5?"GB@GQ8NAD^-@%/@SQJV/''_(^$^#
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M_8B^ /Q"_P""./Q>_:#\5>'-1UKQQX$\.:7>^$-6M=8.F9_L)="T+71K>AZ
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M(Z"GB-]$_L;0E::/7'T*71_$ 0HQ6/60\:QJR ]C\!_VP/V;_P!J"X\3:?\
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M?%?B'^VU)!PQ!("@X !_6A:_\%2?V$KSPIIWC2#]H'1G\*ZM=-8:1K5YX/\
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M'B/Q?9^'/$]G(6U9WU3RM;UO0="T4(FN_,\GA0 HF#\I8,%D_P"$K\J3X"^
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M_A_X<TSPIH-SJVIZVVF:2H\MM2UJ5#-JG+,5\X*5P2P '))2@##^+WQ@\%_
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M$\)ZUX:U>Z6^\)W>KZ:WA'1]&*%_&&A.5+!'\/1Q>&652H=]:C+9"@5]9?\
M!+?X=_!C]H/_ ((S?&WXH^,H]$\2?%7P?IOQFO5^*?B#3])U/QUH.K^!?AIG
M0Y"X\0N'15&N*Q#Q+XM9E$HF;PW;^4 ?T2?'G]OK]GG]F_X<_#'XH^/_ !1J
M%_X/^,5YI-C\-W\.627NI>(/[8,7EZO#'KLGADI;NNMZ1N$CK)&) %C8LQ7Y
MOU#_ (+6_L3:/XQ'@#5]9^(VE^*A:_;A9ZIX$^P+_9W;7LMXA4G0!W8C/3))
MZ?R.:;\5/C%J7[ 'P'\#^/\ 5;;4O!_@WXUB]T>[U;^QM2\3?VIKNM'&B_\
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MXT?MS^*O&]OX3US4K?QYIEY8W?B'1M(T[2]!TT+H6A@Z+H>O _\ ".J=N#G
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M]:\*[]6\3MY2JT<PA\</YJ3'ROQ/TC]G#]H3X[_L 3^/OAE\.O%EQXI^#OA
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M^%686UR6CN'# ']/E?Q1_P#!6^\GF_X*6ZY97UOIUQ<:7'X O;,&W,I&E_\
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M0?@G/^RS\%O@?HG@#0!X;_L7_A+-);QIJ7B:PU,:R==\<ZT0" 1XLW$\@_\
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MA^%.D^'/#[Z-HQT1_%03P[XGBTA;LHQ$GA+Q5F6TCN254_TDT4 ?SG?M2_\
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M=(M=TG[1H?AGQ/%NCC<3^#/$>?.VK*OC5+AD D_I!HH _![PI_P2G\<^'O\
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MQ^,?PG\4_&C2+GQO\0_&.G^)K75=)T[7?^$<OS%K9##6X]GF:#G!:(>$%/\
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M+W4=9\&Z5K'AWQ?INEZ)JK#C8/#WB8OX?.?E(\*JI)!VAE^:OM"W^)W[/_\
MP3D^"]S^P/\ MZ?M2Z=^T3??$/2#H'@/X:/X.&FZQX:\!ZSI3J1KVM D+;A<
MR6[ES(YT7<%\6^./%C+<_P!(4V[ROW/KVQZ^_P#GIFOD[X[?L4_LO_M-ZCHV
MN?'3X,>"?B/K?AJRU2RT75M;LY+#4['3M9&)575]%>*4C:IVX8 <R$8SO /S
MC_X(G_L>6/[.GPW^*/Q3MFTRXT#X[^)-)UOX<_9+T:F=/\":(=?\L?VU_$)&
MUOR]N59O[!PI#<C]T]@]3^G^%<EX0\&^'/ 'AS1O!W@_0]/\.^%M!LUTK1=
MTJVV:=8:>I&V-4P"%X.0Q/WCNW9)'84 ?C)_P4+_ ."5VE_MB?%#X<_'7X9^
M/;KX%?';P%=-9ZM\0=+M]9\[7_#8TR2/1% T9P?[>\,/M^R.6\ME.TF-1&'R
MO"/_  2Y\1>)/VC_ (4?'W]J#XIZ=\<+_P"#WA+2=.T:'5K34M0U+6_%6CY
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MM;>"/#'@J[\/Z/(7:_AT,81WUG^WD*L=!(A$:>8 I$IF;)4=9\%/^"8WP_\
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M (^O[8TOPQH]CJH?N6U6&!'.><@2* /FX&#7H7DPRCYH0.V2,?YSGI@U9HH
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MA]VN)NW <Z(BJS-N"_MK10!_-+\&?^";?Q,^+=]XA\*_%OPL/@[H^@7AL?\
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M+XO\1_\ "'Z:3+NU[6M>\.^&AX:70&&DR*3NZ,V,,\A< _J%HK^?#PK_ ,'
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M8_:,\1_!;6_$GP'^*&C^%]%L[OP]>:S_ &9H.J:[]/\ F8O^$C_XJC_BD_\
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MP_6@#^/W_@DI_P %5/@5^S]^S2OP<\1?"?Q_I?CRU\=O>2:-9Z,VEZKJ09=
MT %)->='UME.AY#KG@D !MKI\X?\%-OB]9?'?]JGP!\:/#WP[UOP[X7U32?#
M-G=VOB#PSK*ZGKJ^!M<)35_[;&1H'B)4*IN!'_"&[=WCT#.!_3QXL_X)J_LU
M>,/VBH_VD=0\,&'Q3_:6FZCJ^AV@9O"^HZO&VS^VY='6%(Q(V"KX1(4NR?%N
MX3;4;U_XW_L??!?X]_"31_A/XN\,10Z)X:?3;WP9>V]G!_:?A/5-'EVP:O$=
M:!$B2 K_ ,)>I_>>,XLM=.7(P ?QI_M[?M":'XV_:O\ V1_^$ T/1/L_@WX#
MZ79>)+O2='QJ=C_Q.2-"_P"$XY[_ /,D5VW[+7C9KS_@H#\ K?Q/IX;2O^$N
M\,V.K#5V*:46UW6=!VZ&SJK'703_ ,5.?#"JQ\9?>"MTK^I3P3_P3+_9T\)J
M=^F7^LL4TRS1GM-$L1J&E:(,1:5KB1^'P7B8C@;XRV" R]:]"\"?L%_L[?#[
MQ=<>,-(\(7MQJY=TT=KN[V?\(^HU?^W0VBZWI"P^*L-*P1#XD\57@;"_+B0[
M0#^=C_@N!8Z?=?\ !6C_ ()L7^N?#FV\7>&-#\.Z:WB:\U>RU?4=-L=,_P"%
MG:^!HC% H/\ PE*A8U)!;:@W,2":SO\ @X\^%7C.;QK^RO\ &+P_X5U&Y^$'
M@/P?JNC!?"5H[#3C_;/]O.NAZ-H>&T,#P_\ V-L;;&"A4!%QS_4SXR_9V^#W
MQ!\?^%OBCXO^'^F^(_'?@:Q:T\-:OJ9U1A8:<^9'TM=':;_A&W5F<CF!LN0Y
M(3.>W\2?#'P-XP\$7'P[\4>%M%\1>$+O2?[&;2-6LEU'39--V;0CAP2. N-I
M4G:N&*Y! /Y&OV9-7_X)1_$/0?@_/-\+/B/_ ,+ _P")39:OXA\/W?\ PCGV
M#5/[<SH@_L/Q P!_X11>%Z>-%/S'>/EKR7_@F)JWA;X6_P#!4W]HG6O%.F?V
M7\/V\7^*-$LSXLL=8T[4]/&A>-!_8>M:YH3 J3X4\1?V)XG&X%?!1.2& _X3
M,_T7_ [_ ()._LB_ CQ;/XQT+PSJ^MZ@^JM?MI/B./2-0\-N5UZ?6-!581X:
M>[;_ (1>2%A"R^)V2Z4JWC%K@,*^I=2_8M_9HUWQKXA^(NN_";1=2\<>)[L7
M?B+Q+=WFL>9J3?VQ_;FYU&O%%/F?,2B;1@$J$RI /XO?%VHW$'[>?_!7Z]@8
MO!\3_'7CH:/>VVCC^SM1\+CP5X?UW76; 4:_X?/AS).U5&?$'_"<@ <#]4_^
M#<SQ1!K?ACXL>&[[59+K6-+M!>WEG-))$UB&&@QMG18W7PT %?13_P )4"S^
M,2%DB7SH_%Y'[A:_^P=^S-K&M'Q4/A-INFZW]M9?^)%J&IZ8/[+WC&BH5(_L
M+P\5;=;Q^%Q W@\*%\%/;.=U<]\ /^"??P!_9@^+/Q!^,/PE\.ZGX>U7XAVY
MM[O2+6XN3IUC'J<D>_2<+!NU[1$F!DM(_%*S'PLL2/ Q20R0@'Q-_P %MOV<
M_P!IGXQ?!70/$W[..M:SJ*^ ;/QV/%_PST6S U#Q9IFNZ(0VK* Q;7_#D17'
MC7PIA4\8QF-$/RL%_/W_ ((_?\%5OAI\*/V:/"G[.WQ9\,^)-*^)_A;Q'J6B
M6WANU#-J4BHXT,*/W@6-&&B2?\(;L7?,RP>!I&;QM"89?ZV/^67^?[M?F_=_
M\$P?V3=2_:DOOVJ+KP!ITOB[5-'TFQO/"MG9:38>!1XHT/53*OC;^Q45]WB%
M@$&X\?\ $D')8A' /YC?B)^U9;?#/_@I*?VUOB!X-UK1/AKXS\7:9K'ARS\0
M^(]7(L%\# Z!C74/AHKH'B'&B<A@5\%_V_XG!!7Q<16S_P %9O[*_;>_;:^&
MWC']FWQAH?C[PQX-^&WA:^\?#P[:'3]2T_3-"UG^WC_;>O$*6YUS0_F*C_A#
M/O$ U_5A^T]^Q7\%?VK/ EK\/OB-X?@TW^R]276_#7BC0='T<:OH>J+G=*JR
M>'FT+/5764.2RKAMV]I/._V1_P#@FU^SW^QU8^+H/!EEK7C>_P#&.;/6=?\
MB8-'\2ZK)IB_,NA(_P#PCZ*OA\D<A\@C(8*N30!_+7_P3_\ %-_X/_X*6?'#
M^U(+G3#JG[,GQB\%F[N[0#^WO'>A,/[$_L/7/#X8?\([MR,8'C4_V#_PG 9/
M GS+[!_P3A_:#T7PWKO[7'@[Q#I=I/!X\^$'Q.\,Z064^)A?ZEKC:]O &ONO
M]O\ A]DT-@K$D>,6*N5< HW]+FF_L$?LUZ'?:GJ&E?#JTL[_ %_Q%IOBAC:W
M$F=#W:S_ &WJVCZ-J[*LL?AYG;6BUL1'('U]U^T 0^#E\*/T'_@G]^R_H.MZ
MKKT/PX\XZI9:M:M8R:OJTFG6":QK(UV5=&DCE77H95=@"QF=2%; )SL /Y3_
M /@D+XCTJS_8;_:_^"_C&'Q+<W_C'QWJWB:SLM6NQJ8U$G1DT('7-$\0#_A&
M=?/BH*1@$ C0B6!VKM^HO^"+/[:/[-?PR_X)U_'3PK\2=;'@OQ)_PLGXQM;^
M'?$?AY$U'7=,UK2%T#0=$"Z!;R^'&9ET=_#JE7C EU6%-R++*Q_97]J+]FGX
M$_!CX._%'XC_  Y^$\$/C#5-(?1[72M,M%U+3[S5O$&O:(W]IG0==UZ$*($T
M-$1?#"I=B,)_PAJ)<;V?^>?_ ((@_P#!/OX??M,?"?\ :!C^,G@[X@>"1=?&
M%?$O@[Q!HZ'PZUAJNB:WKRZY_887PUPHS_PC#.V$C0-+*R>.$9U /PZF_8)_
M:;\-_LY_$#]HS5?@MX_N?@_KWQXU2]O/$/\ 8_\ PC?V#PO_ &U_8.A:T=#\
M0'GC_BE_^I+]L&OZ%/V<9?\ @DQ>?LI>%K^7]GS4/C%\=M!\!ZCHOB75M NM
M:;4] U1=)!<*H\2K_8!\,1G15#MX2 B94;RY064_UR6'PX\%:/X&L?AK8>&-
M"3P-INBKX<M/"]QI$>H>'!I*@C^S&T9R4:,* 1O5@%&<$GC\\_@S_P $H/V3
M/@IXAUGQ+H/@[5M2M[KQ=JWC6QTB\OHM,T^P;7-OEZ#)'H<D1UO0?#8;?;QR
M%25&VZ;Q/(VP '\S_P#P3]^)/A3PK_P5&T'XD:+I6G:)X.T[X:ZIX7TC5M5;
M6EU,Z6#G7-$;0\>$@WB ^'1K?_"%HZO'(I;QM*DD;LC87PM^)OP#LOV_O'6N
M?'OP>OQ'^&7BCQ'X]_X2'2M,T8Z?J7BUO'>B:^!K>BZ"&\'>&?$2_P#"28)
M8$@?\)P&!YK^LJV_X)O_ ++MIXM/BL>"9T4ZI]M/ARTN&L/#H?ABP96/B; \
M0AO$H!\4L?,P_P RCRWY75_^"6G[)FK^,+CQ1<^#=8MDN[[5KZ\T&TUKRM,O
M+_68P'=]9D\.GQ4V9P?$R[?%_ECQ@RN9#@;P#^3#]I;QAJOP?^+]OX__ ."7
ML]M;:/:ZQI?C3PUX(\)WG]I>.,_VU_R!1H?B$^+L_P#%1_VX,_\ "8?\5I_8
M&:^CI?V^OCK^T?\ &K]F'PM\;](U'PW8:=X$U/6[X^+++1LZAJFN#_A'QHNB
M:'_PC9SXB\5^(A@#'30/^$&P*_I ^ 7_  2^_9<_9Q^,-[\</ OAS6+CQ[>6
M>F6%GJGB&[?4I+%M$T;7M#UC7/WABV^(O%,6M%[CQ"5,C#0_#(213#BX]0^-
M?["G[/WQU^(?AWXE>//"M_<^(O#38L3I=V=/TV^#@KK9UJ-60SKXGT$KX;G.
M^+9!DY+8:@#^'G]D":^\-W7[=&A^'/"NI7-O=?&#5+V\M+NS_P"$;^P?\A_0
M?7_BG_\ A$_^)'X7Z$>"_P#D1J_9G_@DK^TCX2\&?L1_MF_";Q[-=>&;SPIX
MZ^*%G:6.JV.J^'-5U[6-;\'Q^!/'&CJS(S>'1X5U_0])AF'_  A^?!D<OR'Q
M<_SG^@7X)_L6_L_?L_ZOIVN?"WP&NA7^F/XH6T,^IZQJ3[M;N%B5<ZYD_P#%
M*Z &\(^#@' C\(!H<R+\]8WP:_84_9N^#VB>/M*\/?#W1-27XB^,/$GC76=4
MU[1]$U/4;'4/$&L:],-*T1GB8Z$GA?\ MAH(V@^7YY#N,BD0 '\2_P &K_\
MX3']@/\ X*S_ +.VA^#O%^I>.=2^-/@;Q_X/L_"7AYM1TG7_  'HNMQG7O&N
MB(/ET'P^/#B:&/&KL"R OXX4@.X/VO\  _\ ;G^%6G_\$?/$G[%'BR75]/\
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M4_8J^S?\,H_ 7[']F\C_ (5OX;V_9<;?]6<_\!Z]>?O8XQ7\H?CW1I_V&/\
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M$Z7KNL,FAZSHVLZ]X>\5B3PWXM1FPLFY/&;A)-N]%(_6-OVYK+1_#>F_$_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"M
M+"9?^6N/IC_'^GK61I^B:=I%I#8:59VNFV5K<F[6ULK1;"R!(^;"*" <@,2#
M@X!(PHKH** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH J^4/,\[$.>F<'ICUZ9QS_G-6J** "BBB@ HHHH **** *\T/F_
MY_G[=.]-$0C<'SC]#C/_ .H\=?PJU10 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MRVTCP[/>I_:6H?VYJW]D:*T29+DRW&Y"C$,2S."%PS>IU_$]\6_VL[[X6?\
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M1\(=6T+_ (13X._##Q-XJ\-'P[IAUI]2\0:8SG1-#UK7<D_\5$'.0.B\!0
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M$?PD_91\ ?M6^*?M&F^'OB)K'AC1=&\/W5V@U2]U77M<;0P@"C "+H>L8&T
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MOV;M3\#:'I4"LVE6>H:EXYUP[5\;:-X=\1^9LB,^D%/^$2E3_A+F<^6I#DH
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MSX1^ /@[HXOK35_$&K:UX=U74M,UO1"1XSUP &1ROB(:)X73PF-Q"Z\?'"@
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MC(/8$\5_ ?\  ?QMKF@_$OXD>!_"NJZWIVC^*,>&/$EY_P )(--U,:7KI_Y
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M>#5=2_MW50B.+;2]+T..ZG=\,) 4C VD%I,E=W\GW[37[./A3_@G%_P48_9
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MO]-ZC.A#PVI(\6'0Q_Q5 ()\%?\ %# C_D=:]P_X)W:!^S-:_P#!3KX[^(O
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MD)5C\J$'^C?XX?#^7XI_![XF?#F&[@M[CQUX&\4>%%NIR;0(VN:0]ON+*"0
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M)Y?\$[1^T?\ \$Q/@M!<?'W5-%\/^*? GB8:QXA717U/5,LVT'"^(_"6 /\
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MS-6TB6>*)HO$2R2M<IN8HS,(V)54G^)_A/\ \$</AGX4_9&\5?LG^./B'?\
MB6PU+64\2^&_%7AW2H_#6J^$_%<FDO#K&L'+@:Z99]9DMX_,"!_"7A[PS$I+
MAEH _)WQ@-)L_P#@A[HUP;&Z^TZG\=],O-7U:S)TT'5-#T5="SKNMYVZ ?E
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MSQM\2-4\2:7HNC^$[2\\9'^WM+_MK_D-:Y_T,'_%2?\ ,K ?\5H>U 'Z'_\
M!/[X/?LS>,/^"FWC#P/XI^'/@#6_AOI?C#XGWOANTU>RT8Z9_:>?^*&&,_\
M%09&0#S@D'!'%>P?M]?$/]FW3?VVE\ ?LZ6'A/0O&-KX:U31?$FJZ5>#=?:K
MH79O[>++N\)>).NTE<C@XP3^EO['O_!'27X"_'[P[^T]XB^*_B"Z\3:GK'BG
MQAXR^']U::7"]CJ.O2MJ^CZ-#KD ;0]>=-DI\8.L<8F95:";8?/7=_;S_P""
M$G[._P"W-\:M.^.EQ\1_%OP5\:QV7E^(_P#A -'TD#Q#JT92+1=>\P-X;?0=
M<29@MU,'G;Q2&S=XVNY /Y;OV/\ P?X5FT']M#0_%4&FZGX8_P"%P:I9:QX>
MNS_9NF?VIH6B_P#$]UK_ *E_Q'_PD?X>"\_\(-BOOS]@OX?> A_P3"_X**3>
M(K;P2=%\,>,/ HTGQ9JUCHV?#_\ Q.?#YUO1SKW_  CH\3>'AD;"FUG\&M('
M!5(Y,_=G@_\ X-?O@1X)OM7O]*_:?^,1_P"$@NQ?:KY>CZ59;]6.B'0QK8,>
MO'_B>8*XF^[D[<!@ WVQ\"/^"+OP4^!/[+WQT_9AT?XB^)-;T3XXOHM[<^.[
MOP[HVG^,O"OB;1F"G6=$EC2;$A5E>U7"KX6>778X9CY\GE@'\C_Q(T'X?WG[
M*&L>*K&^MKFWTO6-*LL6G_$RU.P_MW6O[>UW6O[#_F/?_A.? 5?VX?\ !+#Q
M!X/U']AG]GG0?#UYHA?P]\-M'D7P_:3:<'T+3WW:UI*"*)W\R(0ZQ"PUP1".
M>9BY_>Y8_G7>?\&ZGP'UWX ZM\"/$?QN^(.I0:KXH\->([SQ%:^']$5/^*?7
M']DG1/$(\7S>2\__ !4JR+XI)'B[_2"H3"G]&?\ @GQ_P3E^'/\ P3S^'4O@
M'P-XV\7>/9;FU^PR>(/%O]EB==._M/SUC$<2L"P5D+9=E(#(%9RM 'X$_P#!
MT)>2PGX,6.G7$5S<^*/#IT9K2:ZT5=9L,^,]>:/6M&'B!5<E8&U=4,N?"8C5
M%N6:X'A&OW6_8R^,OPY^&?\ P3\^ OC#Q3XO\.Z78Z#\']1O+MUU32],U*_;
MP^)I-7T?2-)UR:(2ZU&PTA'MG+ R2IOV+*C/YE_P4A_X)!?"#_@I/K.A>(OB
M!\1?&G@/Q!X7\)_\(7HE[X=TO2-5:QTL:Y+KTZB+7+4%$\2_VO-%XN(5C=-!
MX9+,C^%1+)\<3_\ !MS\!8=!UOPY9?M)_M#7&DZC;ZO8:/I_B+4-'\36.AQZ
MU/HZF5%@B\,*?.M;=_#WB]"X?QOX0(M)A!*'*@'Y:_L@?";Q_P#\%!O^"HG[
M0/QX\+>'+?Q=\)O"WQ(\4'_A-O$&3X:\)?VYHN?[%T+6E!/B$^+ -<\+_P#"
M4#/C4D8'_%"8%9O[%]WX5-E_P73A@U;P6-/\*W^F-K%U=6>N?V7X4&A?$K1-
M<UW66_X1TA?^$;\)9W#S T?@MO#R\>,O Y1E_L!_9+_9(^%G['?PB\/_  G^
M%>G6\%O9V6G'Q%XJ:TC7Q'XVU:,%6UK7I%+?O7WD?>*K&" $(<R?G[X-_P""
M(?[,O@O4/VL[W1/&/Q"TS_AK&^UB[\26VDOH&GKX3;6E,NM#1BOA]FUDRZYM
MF'VA80BNJM\S*& /QQ_X(B_#/X?_ +2G@?\ :QTR'0_!&M?$X?\ "+GX=>(O
M$=J-0TOP@@70#KS9T#C'BO&A9\5>%,#;EN=N#R'_  3;^$O[,_QG_:C_ &HO
MAE^V%XKT/0_%6A:OIGA?1?#^L>+]&\.ZCKNK'6O$ US1BH920#C*AE)' (-?
MT/\ _!/O_@EQ\%?^"=$OC*;X7>)_%'B.3QQI6E0>(CK]OIT>GOJ4$MN=:UHB
M!0Q,\VB:0D-ON=/#<46Q1-!<.$^*OVM_^#=']DK]J_XL^/?C$?B5\6_A-XH^
M)&N+XCUBV^'A\&QZ9:>*B&&N:W%$WAQF+.4:=8C(0GB8BY>;)$9 /Q+_ &__
M (<_LS?LC^)K?2_V9I?&_C/X<>%[UM9^)%S;:P-2\#Z@JZXRJ_!/A?7QX676
MQX:'B@X\&J&\3!PCAE']&_[&GQ]_8H^._P"SM^S!<>+_ !1\([CQ?X9N]3UO
MX=:#JVM:-_:MAJ^@ZWKJXT-,!>4!_P"*:W;AM4%6"J*]3^"G_!*OX&?"']DC
MQ+^R#?\ B'Q9\1-&\8Z1J.E>*_'WB^U\)7WBK4T;6SK&D.Y'AP)_HY=@8"EQ
M"SOK;B>-[B,Q?(7[+_\ P;J_LB_LL?&O1_C5X1^(WQA\5W&A:NVKZ-X+\7W?
M@_5/"Z2?VU_;:@Q_\(W&\B^9@$;H]P'# $&@#\5?A7X]^&4W_!53]LB>Q@_X
M1NXU[QAXGLO!^D^+/^);J=_I?]M?] /Q!_+'N37UK_P2L^.WPZ\%_P#!6S]M
M#2?&'BI/#5W\1?" .BWOB1#X>TO7-5!T#7M=;^VM?9"2/["(!# @X.3W_7+]
MH[_@C1^SI^TO\>1^T%XK\4>-M&\=!+YK5_#UIH4:V>HR<-*NKMH+S(BL"-LB
MA@055I2":P/BC_P0^_9%^*&J>']=GO\ Q_X>\3:'!J-B/$>D:AH-YJU]%)AU
M,FK3^'UDCEBUPBYEB;;(;57\%JJ^#/\ 00 ?SG?'SX>ZKK'_  4"_P""F^N?
M!;2].N_A_:KJ?B?Q(;;1MOAK4=+'PP_XGIT5=J_V_P"'CXBY*^$U7_A-"2,#
M&!^E'_!NKIGPSUKP1J%K_P (9HEUXU\(>'!>6WB(Z/H[+IJKK+./[&B7#:-K
M\CZRD,GB)2&F31&3(4DU^N'PO_X)4?L^?#_P%\4? .H7?B/Q7I_Q8\&ZMX*\
M3W>K'2]-U+[!K0/F:NCZ'#$&UT'A+@[4DZ; 171_L:_\$Y/A=^Q'XI\3>)?A
MOXR\::U9>)O#>G>&5\.>)VT>2PL734]";^U[?^R(+?=-(NAZ0@!51L5MS+N(
M4 _2/]W&.RC'Z#_/XX]J_E5_X+A>*M T?]MC]@\2:W;+J2^)?#%Y>:3_ ,)*
M#]C4:WX@"R?V$!A/,'S?\)*?]7DIV&?ZJ9(Q(,'_ #['OBORN_:0_P""3_[.
MO[3GQD'QU\9ZUXVTCQZ'\-3I-HM]HHTNR/AUE31?[&6;0#(CQD3*^7D9O[5E
M<X=XXV /U$LM1L=0MK:_LYTGM[NU6\MKA0=KVC[&W!L9P01UYSR<XS7\H?\
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M'^&+BW\7>,6TRZM5!333X153KXN'T9]',&OR1>(FUIH+Q?$,MXRG0@"4888
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MQIE_X+6ZCXY^(VA^)+;_ (2C1]3LKSQ!XK_XF7V_5-"\%Z!KVN8T+_F7R2<
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M'*U_*W_P58_8Q_;E;]M8?&_X'?!#6_BSH7B;5]*UK2M3\$Z0-3?33H1T)?\
MB?YR?#_S*ZJW*OM)5B.3_8I4<D8D&#_GV/?% '\57[0?P]_;T^*G[;GPF_:O
MUS]F7Q_IMO=>(_@YX9\1VG_"'^,?#>F?VGH1T#0<#^W\#P^/%?B(@#@\8R>I
M/JG_  4)_8I_;0_:%_X*B^)?%?P^^ 7C#4_A-KW@SP!HUG\0KZ[TK3/!6G_V
M)H0T/7 ^LS9\/J^#DI*/,4G#<BOZ^_LR_P"2?\*=##Y7^?\ /'7O0!_$7/\
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M^(/_  0.^+^O?LB?!KX2^ ?'G@_PYX[_ .%N7WQ"^(MMJBDZ7X4T_P 0:,_
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MK1'D9TULL/'VLZLNM)++-XF\4+'HF?$<7BN25FD\0H &D&/UQHH _D6\;?\
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M']CZ-KTLL@ [!=Q/ S@"OPB_X+B_M?:S\*O'W[,/[.:>,]9\._#;XWZAJ_\
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M_@X_^&$GCS5/!/A7]ECXN>+96N;R[T.Z7Q%I&FR7OAJ(L=(US7]_A][70%N
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M@^ /CZUTC5+P65C9W?B/2?[0O?+;=J^(_P#A']H$8P'"A0[#=\G"U^$OP?\
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M"(?BG1-3_8]FT2QF!FT'XD>*5O;7/_'BTC)$BGN1C1W/UQUK[I_:N_:%T_\
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M^'O@GI=QH]UXQ\7WAU9=.?PUK1DT+SI-<UR.-=#T'_A(Y-#V>)I%:WM]J_\
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M@_@GQ#:6VDO+9:J=;30U8Z/H$F_7="5M6@\NX8^$)?%\<06W:)A&_B[\I_\
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MG^SOHFHZC\,OV3O%&L>/_'7BP^%GE\3VG]N/HNBH076/'P_>(&3P7%&FSQ<
M?&<1>&!'H ZR'4-+\*?\%E_V@/&VM7__ !*/"VJ^%_$VK&]UG2+'#:%X)T
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M_+/_ (*$?M6^(_V@_$_B#2O'_P '?B3;:Q_;&J?V/XA\/>#_ .TS8>%]"_\
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MCQEH>L+);:5JWB'6M1TNR+:)Y8T<O_PD8&A/X236 I&XNJ+XC# *4SQ'Q?\
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MX2_&?X6:UX!%KX0;6='\/_$'PYK.FZEKQ4E=$!/(RK @@<^"B,$#M[Q\%/\
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MHV^MZQHGD:,VN@3,#_9/FJLOF']ZQ8B-P&_"_P#X+N?L]?MJ?M7>*_@'X!^
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M2Z9\+?B7X<T?PA\6?%/AZXT3P#KFKKX:M-?N[36--\-:?J>B:,VNZWHY7/\
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M1UTCQ#'IWAG6T^'^LZ&(M89W$47BP1J4B4X\9'_A&3N<N6K]R8_V"?!OC/\
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M^.Y^%FN:E_PB_P ;?B3JEGX[^R:/HOB4WW_$Z\0#0B!C_B?D>(CKHSR2,_\
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MQ%<:IINBS_$;PA\8[[PWJMK=Z-X<\,Z>=<8>(%;6QCPD/#_A[Q6P4@^$\?\
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M]!]?Z&J4-O9VXA$$<$ $ MK;R ,"/KM3"@;5*@@^N=QR: +NP>I_3_"OG/\
M:$_9O^#W[2O@35_A]\6O#%AX@TW4=,U"R@O&Q8ZKH1E=535M'U9&B>";P^90
M\1&\!A\Z$L4;Z/HH _F_^&__  ;Y_"WX8^-=,\:Z%^T9\0CXATW4/M/VL:'K
M8%Z3JQD&CON^(X*Q_P#"/+Y._H+DCQB<2Y4?O"/@Y\+Y? .O_"V?P1X<OOAW
MXGTG5-%\2>%?L*_V=K^F>(=/>+7DUI5<?VW_ &\C>7<R,A:5#EFWQL%]?HH
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M !H\V'U_4_XT ?&W[*_[(7A#]E'2_$FB>"=46[TK77TIK.RM]'?2A8'1(W5
MY779GUD$ORY5",;>0S*??OBU\(/ /QN\!^(/AI\3/#MMXK\&^)[3[%K&E7F"
MKH<8(.00>A'/'.<@C'J=% 'X)^-/^" O[&GBWQ9X?UZ['BR#1M &FV1TA65M
M5OM.4@&(ZX"8PP)*G_BDQA@1@C+#]C?#?P6^&?A#X<CX3^'/"&B:=\.1X?U+
MPVWA.WM ^F76EZW&8M935(V8C5C<*[[W?]Z1))'GYD,?K]% 'P#^R/\ \$^_
M@!^QTWQ&@^$>BSVVG_$2\U!)=*NE\G3]/\-R&!D\)JC3,VMQQYD+:],'DE!5
M"X"LL_S=J/\ P1-_8:?XT-\:=-\#ZUIOB"[^(VE_$"ZT&VU9CX6#:)'YB:/H
M>B95=%B_X2)D\3EH7.6RF1ABG['T4 >2>-/@]\,?'_PTU[X.^+O!6B:W\,?$
M6C?\(YJG@8VO]G>'I-&("_V.T.BB)XXP2I*QXYQ@C)#?F]\ ?^"0_P"R_P#L
M\:IJMWX8L=0U;POJ>F^([?5? ^J6L<?AH:OXBU^/5GUK0SHSQ^(=#:'0)#X9
MPLH:216\7*IN%PWZ^44 ?F?8?\$J?V.+3Q%>:_+X,\37]EJ@4ZUX7N_%>LOX
M;OS%-&-"$F8QXDV>'-LBQJGBI'NHV;_A-)/%+A)EK?#7_@E;^R9\(/B./BC\
M+]&\;>"_$J^(;_Q3';>'_%(CT>SU5SB2..%M$E=1@8$S/)XG7=_Q]R!)=GZ<
MT4 5>(H>Y^SC\P/S/3^7O7YB_P#!1+Q!\7_%GA/PS^SY\%M"\9V_BCXM7OV.
MZ\6:38ZF?#3:0=)\0:+K7A'6M>A)4QR,!-XR!577P<9'8L6R/U$IOR?[/Z4
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MCU] CD72+'5='TIQ'HL;JI.O36\VK:TTWB@[)?%&4N'V@)N^]:** /(_BO\
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M(Y@7Q+B+1ROEK(LAF_32/[B_2@!]%%% !562&&9QNP3CM_GWZ_XFIV<)UI]
M!15?S8?7]3_C5B@ HK@]6\=>"M&UO1O"FJ^+O#FB^)/$1=?#N@:KKFDV&K:W
ME<9T/2)9DEUH9R-D*2%&!.5/(_'O]D/_ (+(> ?VK?VLO$/[+\'P1^('PW^Q
M?\)S_P (9XK\5:PM_+XP/@5U+)KFBMX=2+0#/X=&M>) /^$O\68.A'##=\H!
M^X%%9WFG[/Y/G#[3MQ[YSGK]._7-?GC\!_VM?C;\7OVN/CC\"M<_9H\5_#3X
M2?!NU\4:?I'QMUN36-1TOXG>)]&\9IHFCG1"WACPQX>T1O$_AK5O^$L6".?Q
M5O2/RS.B*'4 _1^BJD4T7E0F24%B."3C)YQGZ#\..]0W<@EA_<3 ?3H?QQ^0
MH T:*_"_]AO_ (+#:%^UE^U;\2/V6O$?PNUKX<>*-".IW7@:\O4U97U]-#37
M-:UQ=9T?7$C?PZW_  CZ(X.7R2R  >28?W0H ***B:01@&0@>XZ?T_EZ=Z )
M:*9YB?WA3Z "BJ_FP^OZG_&K% !15;SH91\LP'? ./\ .<]<FI&DCC') 'M_
MG_/X4 2T5XCXC^)5IJ&D_$;1?A/JOA#Q]\5? VE%W^'*^,=#LM0L-7E0_P!A
M:+X@+&27PZ/$AC"QGQ$8D!D0E6C5RGY.?\$U_P#@J-\5/VV?VC/VH_@!\3O@
M78_!36/V?-0U2SL]FK:T-4?^PM;T#1M<T37]&UH1E-?#:PK.N5C\)*I@D64S
M!& /W1HJM%+F,'T'X?XX_4T?:K?_ )[C\O\ [&@"S15?S8?7]3_C1YL/K^I_
MQH L457\V'U_4_XT>=#_ ,]O_'C_ (4 6**K^=#_ ,]O_'C_ (4>;#Z_J?\
M&@"Q15?S8?7]3_C2?:X?4_D/\: +-%5OM5O_ ,]Q^7_V-'VJW_Y[C\O_ +&@
M"S17\_W_  6O_;,^.W[)&@? B_\ @_J5GX:M]>^(^C7>JZK:>(QINI:[J,>J
M"-=$UK0R%"^',-(-B1>*H_&6]PL(/A.267]=OV:?BAXC^-/P-^''Q5\2Z9IF
MC:OX]\,V^M7FDZ%-J\FFZ<S3>7B-];B610%W22*QE4KE5FU] +@@'T71110
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M4DD@*""*^_\ XR3>*=*_9]^+-QI4HU'QAIOPB\>MI%U9VK$:AXI3P;K@C?\
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MVVO-4^%/CRU)O+/[?8>4VDS?VL'C '1=X^8#YP25##Y0#A/V1?VV?AQ^T_\
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MXI_M!_%_X?\ [+OQ@UO3-9\+:K\!V\4^,/#VD#6!I9U;1#H&A/XVUS_A'O\
MBI\NQ/BHD\^#"Q\='_BA":]V_P"":OP"_;$_94_;,TKPUH_B?6;G]FKXL$>,
MS:^-]9.GB\D UW1=:$BHZ/XA\0X.LLT>Y3)XQ;_A.,A7'@P@']1_CWXG^"?A
MAI46O^//$^F>&M$NKP6"WFIW*JAU-DDD33(CSO,D>EZKN)^4/&P&>17\T/\
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M67C(R":]9_8;^+4W_!4C]N3]KJR^/WAJ]D^''@?P3%IG@+PDH4#PGJNC^-=
M4Z[H[OLC1/%/AP_\(VS%D9_!JB*!9KB7Q;XKF /Z6_%,6D?'?X0:Q;?#KXF:
MCH>G^._#>HVGAOXE_#W5U&J:<'+*NL:%K:E@"I3A@=O<$XR/@;]@?]E^V_91
MF^,B>*OVKM/^.6MZG?Z7=ZII_P#;&AZ7IO@+3/ Z-H>OMJ^B-K]PFA/!XD36
M= C2:,0^#?"<$/@DDF$[?Q8_86\?_&GX#_M[?\%#?V-/A=XOU[QWX&\"> _$
MFH^'M/\ %OB?5U;0?%.@ZT&_X2_1S&[KH'B >'M< D5)#'*/#_AE"TGC9F63
MY,^#/QF^*FI?"7_@IQ?:5??9OB!KWP'^*'AB\\;Z3K'_  C7B;PE_P 27Q!K
MW_(<\0?\B_QH?X?V_P#]#W0!_7SXC_;B_92\+7_A?2-=^-W@JSO?&FK:SHGA
MY6O-31;[4M&UE= UF)M5B5X]'6'7?]&;S7"A4!3S P9?'_\ @HQ^S/IG[3GP
MY^'ND:Y^T'=_LXZ1X.\>-XGOO%EE<[5UW3$\(:ZDFC'/B;PDH!+EPIE9V1&*
M*S BOY/O@_\ LW^./B1_P0XM_C]?_$?4;7Q3\,-8U2]T;_B<#.-!ZZU_;8_Y
MF$=/^Y@\49KT[QA\5/BWJ7_!%C]B?59_'_B2YU?_ (6G\3_]+_M<ZCJF="S_
M ,(+\WB [2/"?]N#"@ C!))WC !_2C\%?B%^S?\ L!_LQ?#GPWXS_:/NO'OA
M?5/'LGA7PUXU\2:@NH:IX@\3:Y(=;_L?1=&A:4JGAKPT!XM\8JJ[Q&/$WC><
MQ2.\*?1>C_MO?LM>(/B=H_P5T7XT>%=2^*.O6>EW&C>$H#J[:I>QZYI0UK1I
M4E303H*M<09>-C<LT8V&1!)F)OXQ?VQM7\;P_P#!.?\ X)[V.N7VF_9]>^/&
MEV7B3^R1K.I'7O%&N_\ "!:%_;7TP<^O/_0AU]T?\%?OV;K+]C(?L$>/O@CK
MTVB^*[C]H3PMHWC.R0 :KK!E_L&76=3TC6TE\,>(_P"PH];>'?X729EE+"94
MCBE\7J0#^H;XY_M-_!C]F[P[IWB;XP>,]-\)66K7AL/#UI<LUYJ/B#52.=+T
M6.,$239 &&9!M)PR@ '0^!_[0/PO_:*\-ZAXS^%>N#Q)H&FZ_?>&WU1;=[..
MZGBPS^5YBJ[(3@JQ5&;:&**S8K^;W]H;XR:9X(_;I\ ?%K]N^RF\5_ &[^!6
MDMI&E:78-XGTK0AKW@Y6E']A+XGC8,WB#7&57_X1 CQ@Y5RDBIY38_\ P3:^
M']S#_P %1O%WCGX!>/?'VM_L@ZMX#\27>DV5PTFJ:7>ZJS*KG6M%6/\ X1O0
M @)\,#Q644$>'_\ A!W,7CHLZ ']:E5YIO*_S_/VZ=JHVEW!-&8X;VVN6M3]
MDN6%P2PU!0NY&."<ELD#J2?E4E2*_&'_ (+I?'CQ9\$OV1M&C\$^(M2\)ZS\
M0_BII?@Z]O\ 1]773=1OO#$_A#Q,^OPJP^;*HL<SH^6QI"'."H4 ^B_$?_!4
M;]E7PG\6+_X/:EXJE;Q#:>(].\-#4=-1=0TPNP<Z[K)DCWF/0?"SL//F"3!L
M,4C&>?JWXM?M ?#;X+?#Y_B;XVUKR_"-W)I/V&_TL_VBVHKK2I(ATA(U&\+H
MBGQ$4+H'M][+*=PW_P J7PQ_92^$OCO_ ((X>)OC#8^*&TWXWZ%XDU7QI9^.
M;K6=8U+4K[5-!_Y /@ILL&);/_"4#:I'_": ^.6(&,_C!XV^)WQ4^,'["GPO
ML?''Q&\6ZEI]K\8-+T7^R;N\_LW^WO\ B=?\@77/\G_A-/\ D>: /[T_"7_!
M1+]E+QI\8]&^!_A7XBQZ[XQUKPX?$:7D6FZGIOAO3XF91I.C:UKFLK$B>(9U
M7(0 Y(4R8),<?IW[2?[5?PF_91\+6_C/XN:A?VMAJEWJEII-CI<']IZK>MI&
MEM<3B+35,996/D)\N0IU:)V!)VU_(-_P5$^"GAO]GOX2_LG_ !4^#OQ&U+PE
M\2/%'@/P'>ZQ_96L:,/^0&/#_/\ ;N/^$G/_  EN>H_Y'0@@\C \^TGXG_%/
M]JO]LS]G'P#\1OC1=6VC:EX";PU>ZK\0/$6CGPU8:5@LVM*NO!F=FY/_  E"
M@LQ_XH4 DT ?V0?LO?MI_ _]KG0=7UOX/Z]=:FF@WGV#5-)U4:;IVLHQSDMI
M?G,^T@$<^7V4MR ?GW_@J#_P4)\,?\$]O@EX?^(>M6MW<:SXF\9:9I&E(MN#
MIMCI.BZSHFL^-]7US;RD,?APND858VWZPIW$QMO_ #@_X)Y?\$\-*_8N_;'\
M+ZKJO[29\6>.->M/BA>_\*G\.WG]H^&CX7UO1O\ B1ZSKF1_R,+8_P"$G)'5
M3P1P1[I_P<7:?X5U3_@FGXXO?%,+-;:5X[\!WME>6UIHYU*QU(KK>TH_B ;=
M&5EY\S=N7HW))H _(W_@J)^VQ8_MW_\ !,BW^.$'ARZ\$ZQI?Q5\!V>CVATC
M6C]@\+Z\2?[:SSQGH.@' Q@ ?II_P3^_X*I_LL_"S]F_]FCX$?$WQ;XDM?&V
MF>#M(T6\\5W7AIAX)OM5US6R=%_XG^\* PUN,*%4%2KL6?>-GP?^WWX5^$_A
M#_@WV\-7VEW(MI?$^K?!B]\170N/[1U30/%3;AHFBMHQ<C0CP" J1A W_"<-
MO)^7@/C+^SO\)OAQ_P $!/AS\9_$=AIFM?$^>[\!:WX;\6:N1IVJV6[QH-"T
M#1P/#S?\3Y!X=#^)?F&YF#8PJ@R '[M_\%+_ (6_L>_%KX4:!\4?VF/'GBJV
M^&UGH#V7A2T^'NKZ1%J>MZGX@U?09-#UW0?E=9I/"\I#L T8"2L[.9$"2]WX
MH_;1_8__ &)O@C\&/#NA7^L-X*U_PJ#\(M TE9#JFIZ-&Q5"LGCBXM90[ZTS
M(#([B*5PPC=$*2?C!_P43^'1\8?\$:OV4OB%9:[J!_X1_P ,^%?#EWI%FV7U
MU=?SKH\S6CT#-H#_ /":,N1XV 8$ IE_GGXX_#2V^.'BW_@E%X(\0ZUH=IJ6
MK^'=+\&Z3=ZH-8U'3=$TW7/&2J&?1.-S?\) JH/%;'(5%7.% H _I0^ 7_!2
MS]G?X_>$OB%XPT2ZUSP]IWPQM6O?$?\ PD%FL?[LIQ#I+$.9=?X*_P#"-JHG
M7( R-[5_-S_P65_;8^#W[7UK\/M-^%GB7Q7I]M\+6UBSL6N;!]+/_"3:_)H3
MZX-'UW0I9GET+_B2Z(99W<R3R:"\O@7#NQ/T?_P6%_X0C]C0?LK? CP#8#X?
M_#CXMWFJ67Q(U7P[::UIPUX_VUH']O:UK9\/J/#&@?D/^0_S7B__  4]\'_L
MZ>&_V6OV:+_P1XWTS6M9\4:0W]L7=F21C)&N'.@*.3XBP2.QT @,?^$MR0#^
MG']A&[O;C]D#]F6ZU3Q$/%TY^#G@@OXD-S&RW@;1HLPL.&SX:W?\(V1R&\HE
MCC%5?@]^W'^SE\=M>\4^%/ WCW3I=?\ #/B=?#!TW4F32I-<431QQ:WHXF2?
MS] U_76.@12%F:6:$CRU=T!K_P#!/>RL=._8S_9_L+&>XN+:U\""SL[NZ^\<
M:SKHY/KD8/7C:.*_G6^#.O>%M,_X+P?M Z5XA\1/;V%S\7=5O;&TN?[%TVP/
MBG;_ ,2';_8N%WDZYQYI R?^$YD/_">9H _IC^''[5GP2^+?CSXI_#GP3XWT
MO6_$_P ';];7QU:>?%8C3&@;=K"[IF))\)W!_L+Q;E +><$%\%8V^6/'G_!5
MS]EGPAXD\8^%-+U/6_'NH>#/*36-6\*+H,OABTU!-)/B&YTB36FUU$6;0O#+
M'Q#<X5\1C=$R.05_GG\$Z#I5Y_P4Q_;HL8/'^-'U3P?X\_TN[\2:-_:>GZ7K
MNM<_\2/P\,$?\2/_ )FSO_R/O>I?^"1W[+W[/GQD_:-_;E\*>*+RYU2XO/".
MJV&LVA+C^SM*UV-]#&N9UY''+ZTOB;+F- -"\,X<^!@D4@!_6_\ "[]HSX._
M&7X>3_$SX=^-M%UWP=:V2ZGJ^I_;?L2Z%%)I']M$^(!(=VALL.'E$N\+\[+Y
MAW9_-RY_X+1_LUV/CN?PJ?"'Q$N_#-QXBT_0O#/Q$MX-";PSXL65W>36]#+>
M)"[:!<@K_P (LY?_ $IQY@$#-A?XS?&WBKQC^S3^T%^T!X ^&7C'Q_K?PVM3
MJGAC6+3_ (K+_A!O%WA?^VO^I?\ ^1@\.\''U[5_03XB^%G[(WQ._P""%_A/
MQAJ\VGVVN^#O GB?Q3H>L6UGHFF_$OQ;X[&K:WH#Z'K/_"-Q_P#"3:\GBMM=
M!7_A&I#/)X/;0"H$$,6X _?[]HG]M+X,?LW>"O 7C_QMJIO?#GQ,\3Z/X9\,
M7NB7.C_Z;_;D.^+6(QJ]Q;F2VC:31(]K-M9]=T2+YEE+#YP^'O\ P5I_9N\=
M_'.Y^"]S9>(_!=A< KX9^)OC3^R=*\%>+;\#*QZ)(TY9Y">=[,H+<E0<M7\?
MOQX\1>(?&'_!-#_@G1IGQ&O-9&M:;^T>+ OXA76!JK*AT(ZWK!/B ?\ ",E5
M\.NY4>%.%+^&B /'C'/ZO?\ !<#X6_!CX*^ ?V O$?AV]U"UC\=?%_2M$U7Q
M%X>;_A'7U'3QH^B:Y)\3M%4!D\/>( !&4/F'P=N\0R!TCVC< ?UO:IJMOI&F
M:AJFH$"VTVTU"^N?7[!$7<GGC)55_!".O7^4?]F#_@M?\7_C=_P4?^-F@6GP
MR^(,_P"S=H^DZIX.\->"3;2:GJFB'0E.N/\ %"4[PVC.ZLQ\<>&)C(?!GA B
M9@TBJU?TYZ#!80_!S0+?[9.-(M_ASIEH;K(!;2U\&JH<X')V@=>0=HSC!'\@
M_P#P2M\;?"#X5_\ !3/Q1X(3Q);Z9!KO@3QU:>)-6U^[7PZVI*K*VB:#K>A.
M0OAXR*#XD'A@D;2WAA@RX!H \ _87\:7'[*?_!3GX@ZGH?A?4_B-X?\  G@_
MXH7MIX4TB[4^)[#2M=.O:\=#PRNOA\,-</B9CMSC03MPV"/ZP/V2?^"CGP8_
M:H\&^)_$DGD?";4?!_B8>%]7TGXA>)-&TY+S5#I7FLVCZN98HY$_A)4&=1G:
M7WG'\X_[ UI\+/%/_!:/XT7^@M:Z9I%U:_';[9=VUD/#@;2M>^&8W*-#W+_Q
M3[^&_P"P_$T99L!BI(8 J?S*UZ\O_P#A:OBCPK\*X-;\2?\ %8:IQ]L_Y#P_
ML7_D"ZYH9X_G_P )IQTZT ?U8^,?^"Y_[/O@KQ[?Z+JOPY\??\*XL]6DT4?%
M@QL=)U)]VNM:OI>B'0//F_X2$Z&Y1!/&K;\Y#HKC]@OA?\6/!WQE^'W@[XF_
M#K55UOP?X]T<:WX=U95"B332!\Y7YB#N!X+$]R3@&OXXOV%]._8;^-?PE\4:
M'^UG\:-#\)^'_!OCOPQ]L\):PQ7Q+XMU7'B# R%;'ATG'A<_\4=_Q68/BCP0
M < 5_4G^Q9X7^!/AKX&Z'I_[-]EJ=E\)[S6=4N_#MYJ-M+NUHR#RWDBDC$9/
MA^%='T?PQ$[A%A_L#_A$BA:V"T ?SU?\'"7[17QO\->.O#WP>L-#URW^!]MX
M;\+^)[W5[6\_LW3;_P 4C6M?&UB0K$J/["0EQO\ D_XH7+#QH:^J?@/^R[_P
M3N^&7_!/WX4?M6_M3_L\?#W6]4T'PYJ?BCQ-XV\0:(VH>*]:U/6_&6N,D>A!
MO$,B^)!<-_91\&>'R\:1I$GC"& SF6Y3S_\ X+[3>')_'_P?LM4FTVX^R^'/
M#%[>VEY=;<Z8/&OB $X]"<D'G(.<X-=U_P %FYM*T;_@BUX9TG2K?3[<7/@[
MX%VFD6MK;SMI5AYG@\;=870]"'ER'_B<.S*&S:#;XUC41^%22 ?H?\;_ /@I
M+^R)^R1HWPATSQ/J]_96?Q(^'/AOQ+\*O#'A'2M(,MSX#:"2/0KJ"&XUSPS!
M'HT.@Y5%!-OX4BT>66=6*JDOSO\ !_\ X+?_ +-7Q.T#XO:IK'AGQ+X$UKX<
M:O)H?@_PMXAU.!-6^+)D*R:1/HA5%'AV6XDC4W*>*%6S\)L[^;XJ97>OPW_X
M*)^-?!WB/X[_ /!*_2?$>EVY\/W7[,GP<L[PWA_L[4[X:&WB#0O[#_MSQ!_S
M+?BO^W<+_P!#FH R2,U^T/\ P4#_ &$?V:?BQ\#OA1'\-=9^%?[/GB/4-<\,
MVOPV\9:_=ZYX2M=<TS1=)\0^(]*DUICHUS+-KA\[S?%NO>*(XI?%MN@MO&WC
M!A]G@ ![;:_\%5-%L_ 4WBSXA?LW?&#PCJVHVMY?> /#FF1Z/XG'C81+(FD&
M'6M?;P>BM-KNC:[",*HB&A/(?-&V*O@O_@B=_P %%?VGOVTOVM?VY_"GQYMM
M:TO1O =]I5_X1\$FQTJ7PY\)W&K[5\'Z/KJGS)Y#X>UN,N\CEW +.VX;A\^?
ML[?'[XF_\$XOVH])_9R_:8^#]U\3]/U4:;8>&OC-X;O-6\2Z=IS>.<K_ &WX
M%W*ZE_%7AX:)X7PZMXSRN&7P=X#X-?\ X(3_ !(\*P?\%'/^"C_A: V]J/B?
MXE&N>'/M5X.=4T+62#HC;NGB$>'/F.,$?\(\,'G% ']%W[3_ .W;^S;^R#%X
M>L/C'X\L]/\ &GC&V:Z\#_#722-3\<^+Q&7BE_L/1(VWOI,<D0C>5V0)DD*T
MB,E?)W[+'_!6?X-_M'?&#Q!\&]7\%^)_@GXW22^?PTWCK6M(U'2O%*6^NZ%H
M/AV&#RC&T&N>*(M>5(X1OM(YT_X15O%DMY-X8>[^/_\ @L-^V'^SK\#?VAOV
M>? 'Q,^!G@SQ[\0/$&EKI/AOXL:^-4U/Q-X!7QSKB:$T>A:'H,1ROAG8WBB1
MO%P;P@/-<1R(1XO9/P$^(4WPY^'O_!4JXOO _C__ (2WP_:^/-+^V7>/[-U.
MPTO^VO\ B>Z+Q_S,7_".=>OI_P CYB@#^LKQ%_P5\_9VTOX\?&']G3P+HWC/
MXG>/_@WX.\0>)-67PC8,NFWVH>'-(DUWQ!H8?6I+=@OA>!\>,?$G,5I,3(J3
M#*&]^S#_ ,%8O@7^U#X6^./]CZ/JOA#XE? +P)XD^(/COX8:G=E]5B\.:!IK
MS,^A:U)!X;BQ+YFBEI&6+RFUB"-6&\/%^)O_  3$N_"GCW_@MM^VQY,UMJFC
MZ]X0\3:Y9"[O2-3.F^.='\/,FL_V(.?#_P#Q3XUOPOCD$\$$&OE[]A+Q;X<^
M'7[<7_!47P[X/\.W5KX>\2?LY?&3PWI"W:ZKIXL]+70M"UW7-8;_ (2-&\4Z
M^%;11*I\4&-]^MH"Y0NC@'["Z5_P74L/'7@6RU[X.?!*3Q+KVB6G]N>/+F]\
M3 ^&-/\ #6A2-)K[:$V/,/B(^'#K/B0*SLD<4,21#Q@H8-]OS?\ !13]D7XX
M_L$^+_VIKNVL_&7P8U2R\3>"-8\!Z[;"^DU[QLEL\:_#8H+8PRR^)9GV1:](
M/LJ1R&Y!:15@7\._^"*6D> X/^"8'[9OQ-UGP+I=WXHN_AQX[T4W;:2WB/4[
M[2CH_CW^P]%&AK&_B88\0;V&[:&=4BR/^$5WQ^(?\$^?$>BZ=_P1V_:-T36K
M36M:O] ^)#7OA[1[Q<^&;+Q-M\0#7=:!\/LI5O%7P\T/6CN^9?&BGPTG@-,L
MCH ?J)\+?^"EVC?!S_@G7K_[2OP>_8WT/0_!7A_QUXG\,7=A\._$6CZ9X(L?
M'Y+A]:ET;>?$KQ%&T$+%Y0"NI\%,_A ^6(OLCX9?\%3_  '\0?V"]._;)N/!
MNIVMTVN:7X"G\%270TC^VOBA$NC_ -M:)I6LK<>*GT>W0/K"[/%3%TO-(D\)
M0?\ "43?9)_$?Q'_ ,$:/@Y;_%[_ ())_&#X-^)=*MA;^,OBE\9](T=CPJZE
MK6B^'AHFMDG !'B-@?< \\5_/1^PKXD^.'C;XM6'_!/7_A -2N;>U^*>J_V/
M=_8M9_LW_B1?V_\ \3G7/^@!_P (G_R*X\4 9\&=LX% ']A?QL_X*C?"GX3_
M  ]\,:A'H.H77QU\=:3IFK^&/@'JERNF:E8P:[H[>(EUO7->54\/0Z'_ ,(\
M8O$4J":;Q1)!JJ&.VM_.,<7SE^R1_P %H_"_Q U[P_\ "7]JKPC>_!OXO:[J
MFI6%EJ?A[2M;U3X:Z\T9UTJ4$S_\)-X?D*#145B_BV,LQ-RGA96 3\'_ /@M
M"/B!\ /^"LOPN^(_C+PMJ?AS]G _!_X8?#/2/B;:Z3OTS73HNCECH8; &@:^
MOB0[4)& H45]_?LY_M(_\$KM=^('PP'@^;XS^+OV@K;2!XTUCQ;H7A+P?J/A
MA?%!\&H->T?;X^1BWAWPCK^B2^*_ \?_  B"&1U3QJ9/%O@*1I8P#V7XB_\
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MF !]TP_\%D/A)X9^&FCZC\0_"_B>U^+EVNJ6%[\.-!L4.DWNIZ*49]<77->
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MWW@G2;S2_$?B/7&77];TF-]!1Y?"Z-+#/H.K-XI5HR;)$<6LOBQ!Y3_%C?\
M!?KPS;^ _B]XLUG]F#Q/&_PNUA?#)TG_ (6,JKKNJAS(PU9O$/PX\*W'AQ)/
M#N/$K)+X8G7R1Y0'5A^8/_!.?XRZ7^RG^R-^V_\ #GXBZ-JDWCCXBMXGM/"'
M@BRT;5]2U34=34Z_H/\ :^B:XZOA?"O]MGQ0Q7P<K@#Y64\U\P_!_P -^*M>
M_P"";O[='CCQ'X5TW3;BU\8?!NRO+OQ#I&LGQ-8:7KO]O_V[K7@?7/$'X_\
M";_]#I_U)O\ PB/_ !60!^L=C_P7;_:OU;X7V_[2GA[]@W5G_9XTNTTZ]\7^
M(FO_ !EJ&FZ>K$G7-7_X6I'X:3POH*Q@Z&J>&'\'/+C7@6=GRY^D]3_X.)?V
M3;#X/?L[^-8?#7B76_B?\=KNWM=8^"^EZP/[0^&^FKKK:%KVK:QXW30O^$>\
M0;&17\%?\(RNSQIYBA6\*YD6'Y"^ /[3?PA\5?\ !"$? +P!JNBZI\93\*M-
M^$W_  JBT_MA?$NLZGXY\9(HC_L,>']S%O#Q\0.0T+*W]@J6D0^)XE?\?/CC
M_P $LOVD?@U^SS^RC^U+>Z&;C2++QCJEC\2O"1LFTO4_AIGQF&T'7-;T/Q$/
M".]?%O\ 8@&Y<KX+\&AD)W>+&  /Z;O^"BG_  5&\<?L%_%_X">)-8^'4GC3
M]GSXO>$M-LK2QNM1_LG4M0\>?VT\._1=7BT*4:'KOAL:UHUQXR6[DG\(+X,E
MWL8YUQ'0^.O_  7<^&/@#XP:;\(_@5\(=6_:$@?1A>ZWXK?Q?JOPWL]-U%H/
M[;.B?V-K/PY\6>(%N!H1\YY?%*>$H@Q>.-2OERK^=G_!7'X]>%/V^/A'^R+\
M&OV;?#NJ?$CX@0?$G2K[Q)X?TK3-;/B3PCJ2:'H+?V/H:'"ZZVYG!;+DQK&N
M\>.(XXHOA7XP?LK_ !%_9+_:1\/_  D\53W/B3Q!_P (WX7O;S5;2S_M'PSG
M^Q?[>_L3^W/$(_XJ#W';_BI_>@#]WOAA_P %D?'^I?MT?#G]ECXM_L_Q_#;1
M?BAI'@;2-*U1;O7/^$GL?''CS1=(U_1M8U<:OY,PT(I-HGA9/#2>$&EWZW%X
M\_X3>3P0&9_Z"/)^UC]] 8".3GJ?;C'XU_)/^WI!XST+_@M9\'_B9X7^&/BS
MQ7H'@W2/@2NC6>CVS-IFO:CH.N'7$.AOX?7Q8P9TUP>&6QX.)1BRAW"AS_6]
M:_=G_P"OJ3^:4 ?RT?\ !!;4;^']KS_@I?HFN>(;C5=0'QB\27VD#5]9&HZF
M-*'CC727R3C]V-<T-P <DZY@<X!_/_X >/OVK?A[_P %8/\ @I;HO[*_A74O
M$?C;7_VC_C#97?V9O!FIZGI_AAO&FO:ZJ_V+X@\.,K>'B3H2@[F_X0UB,,W_
M  EX-??O_!(99_@K_P %"/V^O _Q,T/Q'X2\8?&[XP>*+_P%;:MI_P!C:]TS
M0-;U[Q"DNL1X;^PG\3Z %EC4*Y9D 4;F!'K7_!-#X%?$7P+_ ,%:O^"HOQ-\
M6^$-:T;PQXI\8^.8_#7B*[TG5DTW4M.U_P :^']=T';K<C*NX^'M#RJY)(X4
M,V 0#FO@%_P6P^+TGBS]HWP%\=?@#;W&K_LP_#K5[WQ+%X;U/0_!/C3Q!XL\
M#L=(UV671==\0;PRN)Y/&C>%O"8C\&>$])D\>.)/!+0;/C_QW_P6<_:,_:#M
MK'XC? _QE;_!S[/I&J&T\$>%&\'>)=+L#_;(&@ZUK6M^(O#A'C[Q!_PC8'RJ
M!X))RW_"#;F+'P#Q5^R[\:?CQ^UU_P %*+'PKX.N;G_A;-YX\LK/2M)\'ZSJ
M>F9_MK7\_P#,M?\ "3^'_P#D.=@/PKE_V"?%,_\ P3^E\7_"O]IG]B$^*_$&
ME:0+/X<:M\3-&\8?V9J _MH_VZI\#^(?#)\,>(/$)]1@_P#$@'_" X_XK.@#
M^LK_ ()O?M(_$O\ :R_94\#?&#XM>%=%\(>/=3UCQ1HVL:1X?;=IE^=!D_L9
M=8!9F94\4G/B=8QA%1ECC"HB*OY?_P#!6/\ X*>>/OV3_P!H#X??!?/B_P"%
MW@B[\,)XCUGXF:7;Z1)_PE@UEGP-%&]_$?A_0_"9T775GD4EY&&'=PB8_7C]
MB+7?B!XG_9S\%^(_B#\.M%^$NJ:Q?^)M1TCP+X7TC2= TG0?"VM:YJ^K:+MT
M30YU2WS%.V1"JN[DS;+AD?Q7=?E[_P %!;^W\?\ [2]SX'^-/P6L-4^'NB?#
M#QWX:^%_B,6!34=1\2Z]\-EUW0_&>B:YKP/AJ2;P?X\UO0HUD(0>$)(_$K%/
M%<;>7& ;WB3_ (*3ZI^R_P#\$YO!?[2/BF]L?C3JGB;QAK_AGPS=^(-6_LSQ
M'?Z=$_B&71-8^* D=XRNW0XE9XO%$93P9XA\,E+CQI.@_P"$H_&_QW_P5 _:
M#^)OQH\&_M7?"2]\6^$[^Y\-Z5HO_"/:7>ZUXG\$:AI870-;US1M%T9BQ;P_
MXM70O^$F;PRQ+$9\<DU\KQ?\$U?VZ_B;X)U?X ?"S3-0\6>$-"^)!\:^#K,M
MK'_"#G5-=T;7=<T+6M;UOQ!X<_X1C0.61?\ BJ_XF"_Q 'Z)^"<'[9GPX^#O
MC?X(:Y^PU;VWQ/N=7\,V/ARXL]NI>)=#.AG7?[<T?13X?4O_ ,))XI"GQ.OA
M8,J^-1H;>.75B$*@'[S_  Y_X*Y^$OCM^T1\+?@1\)O#(L+7XB>$=8^U^*O&
M'F/JOA/QRVE2R>']:/@G0)0GB'X?)_86J".1_%?A%_%ZZU(N[P?_ ,(N7\7?
M+&O?M2?\%&OV'_B+\3_C+^UEH6I_$7]G70O$GB72A=6MQHNF^"DTYM($V@:_
MHNL:/X78^'=#\T>:3-&9!+GP2V)<L/R=_:7_ &3O^"G'[&W[2_P*_:E\ ?!"
MV\6_\*X\._\ ">WMUH&K:SXC\,V.K>!]7$FNZ+XV_P"$!4>)7'BR/7=#\,>-
MRNY?&F&'@,[D<+^I?CGQ[^W3_P %6_V4G\&6/[-WA[P5X?O+S2QX\\0VWC#6
M/!2ZUXF;1_[!U_0_#R>/D"ZUX9 UO6!($'C!"L2^#)=TOFS, >P? O\ :0_;
M)_X*<:'\2/%OP<O;3]GCP'X,U/2=&\-W-UJWC/3]-UW4$1M;UGP5K?C7PX#X
MF3Q"5UO2/^$R\2>$%4>#O^$>\/F%#_PELN/EOX;_ /!:7X^2? W]J;1/$_AS
MPYK'QP^!_P -_#7_  JS5;$[4\8>*)#K[>(-:U]=?!4^(_\ A'_G#@?\(>&T
M!OF"R2K)YO\ L/>+/VA?^"2FM?'_ .!'Q4^&MAXSO]3'AC6?".K7'B55+KHF
MBZ\-#UDOX?0^'(_AW_Q.^/"\+1OX*.#NR 1Q'P5_X)9?&?Q%^SI^UM^T)XES
MX:U#XI>!-+N_@_I5IX-;QOJ/BTX_Y#+Z, ?$J>'6. I\7^$%#-CQNN? I (!
MK^'/&?\ P4)_:+_X)\^'_P!NG7/CW!!<?!SQSI?C;2O"EWJZZEI.NC0]:T$+
MK.B_V#X<'AEO$?A;Q'K6BKX''BE7QM\3[]@*D]CI_P#P6F_:1G_8,\#?%Z_L
M=3/Q'^(W[06J?"_2/C!:Z1\-#X6LM+T+1_#S:WHY30!C>GB36?E8>#@V"<YP
MNWZ-^ ?P4\?Z9_P0@_:+_9Y_X137+?QRW@WX^?#Z\\/G1M8U+4KW4]<VMKXT
M'1MA/B%V;6]9Q%YB!_&"R>"L,8@*_-SQ'_P2'_:N^&7_  27^$'@Z]LO%W_"
MX/A)^TCJGQ:\-_#&TT;1_$>J:?X$UWP7H UW^W-;\/\ _"7'P_QX'T(C_H3%
M*^",D,"0#Z[_ ."_'P5O8?A]^SC\<_&&HW5[K.H>/?A=\/KWP_XYL]&/BGP\
M7T4R:W%)KG@!1X8W>*=>;6/^$W_X15O!_A%E*OX' +AY/Z(OV%YYY_V2/@1+
M/;?9IF\ Z7FWR!CAL'^7/09^E?RT_M$ZY^V5_P % /V;OV3_ ( Z5\ =%NM?
M^'/QB^&.C7NK>%+76W\-?V7HG@PZ&?[<UUB?#/AX?\(Z=<_X351_Q1*+A4"J
M% _K+_9F^&M_\(?@)\+OAGJDUM<ZQX-\(:5HNL75L1A]50;]7(Y.,2-P< Y
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M76O[,\.7NDMN4-H>N AE\.>%"K!6&.=<\,_\)V<J2/[!/!'P4^%7PWNM8O/
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M4LHQH.L_V*RE\%E61]A*?*/D+8=L5^I_]FV'V[^U/L=K_:/V7[']K^SC[?\
M8-V?*W8WX\SG&W&/EQ_#5_RH?3]#_A0!_!]XW_86_;?^./[.?[/Y\ _#.Y\6
M?%#X7_&#P'HOCR[TF]&F:G8:4 2?^1@Z^'<:V3_U)8!/K7[BZ]<_'F7XGKX*
M_:M_9A\#>-?@VWP&T[X:67Q)N_"(_M1O$T;K_9#CQI_PCHX7Q+I*"3PROB_A
MY8O'/@8G<BG]^HK2"W_U40&?Z?7_  ^ONC6D$PS+"N?\X[_Y_D ?S>?\$D?V
M8/VF/@/\7+OQ#JNBW&B_!'Q1I'CJ.]&J7ND^)#KVK2:TI_MC1->AS)%GQ P9
MI0 ?%L9\]L1H6K]4_P#@I3\,?B+\8?V3/B!X!^%6ACQ)XUU6ZTD6.C]/MQ4N
M&X_X$H SQBONVWL[>UBB@@@AM[>WP+6. 8"@@\!=N!D=0,YZYXJVR!^M '\J
MWA#_ ()=?M/:O_P3\^+_ ,!]=N?^$<\=>(/$GA;QK8^!]4L]'?3M?U/0M'C3
M0SH>M(&/A_Q #I$>]R J*X\$N0@W#FO#7@K]OO2/V$[C]B?QM\*_$=UXW\57
MGA:T^#]K=6>BZ:++2M#UD:]XYT;/ .1CQ0/^A,'?&*_K)\J'T_0_X4>3#_SQ
M_P#'3_C0!_-A\;?^"<OQ \/_ /!&W4/V:/ 7@(ZC\=?&=AI-Q\1UTNQCU/4=
M;U@ZYX@;.LZ,J^;KQ\,#7525?#+F-BFO>.(%5S)YL7C7]BW]I[Q3_P $6/AE
M^SII7A$>)/CC\,? GB;0[WPWJ]KK'AO4KYQK&OG T/KK[,A4[,X\:##JH+,S
M?TJ>3#_SQ_\ '3_C1Y4/I^A_PH _E*^/'_!&KX[_ !O_ &6/V&+S1?%,'@GX
M\?LB?"W5+2QM5UC79-2U[4M<UC6M<.C:*2H2'_BGV $?BIFW+GP;_P ]O+C_
M &G/V4?V[/VN-+_9?^'/C'0]0\16_P .M9U/POXQ\0W=F!IGA+5FT;0<:SKF
M>N[P\=$QXIR<L3CD\_U<^5#Z?H?\*EV#U/Z?X4 ?BI^TG_P2FT/XK?L=^#O@
MSX6\272_%?X3Z,!X/\4EM5T_2];<:Y_;C:&VB)XD9/#^A>8QB\%()G7P68QY
M9/SFORQ\$_\ !!+QM\6OV1O"^C?%2:#P!\>;6\\3_8K75KO6=N@DZR[:%K1U
MSP]EE4!2#X995B+%?&JR-(2@_KT\J'T_0_X4>5#Z?H?\* /RT_8$_9 ^*/[+
M/[%,WP.N->3PW\63::LMCX@-ZOB73=$U0!O[%U?ON  )9>Q7D<5^*7[0G_!/
M?XT_M(2Z?JL^A_V;^T!\)=9\4>)_'MWI-GK/]IW_ /;NM#0="_YF3'B#_BG/
M[#\4'_H=/^9^]:_KX\J'T_0_X4W[);[\^2,]<]L_Y_'VQ0!^&]Y=?\%.?A7X
MN_9P\/>%?"=IXD^'-M9"Q\>VWV(>)&L O]A%1KFO?\C/A2[D G _L)L?>.?V
MOBMAJ^E"&^L?LXN[7;>:5=<XSZD9.-W4]N <&MORH?3]#_A3XHHH@1&H /H<
MT ?S*?%/]@_XW_LO?MS:]^V=^SWX+\/WO@!KS3=8OIY;O6+_ %?P]X:7^WE\
M0Z)KNAJ<-X<5^%FC+1>$/!.R:!Y/&TGBZ1_H+]MCXA?M6_M<_L]Z3X&_9!\$
MZ]X5NM7\?>%_#?Q+\7:P3J0LM.UX8U[2-"C!$43^&"-\OBGQ+'#'X/F;PY,8
MU>1C7[S>3#_SQ_\ '3_C5.#3+*T\]K>UMX/M5S]KN\  ,_\ >P!C)QQ_"/FQ
MUX /YFOVXO\ @DWX]B_X)V> _P!G#]ECPSX4\1_$7PG\1M.\:ZIX8;28=-TC
M42ASK*:"VOREI= \-Q++H$*^)ED_X3&#67>Y,#/$CZO[6O\ P3<_:6_:6_X)
M??##]F/2=,MO#?Q3^#7CL:RWAW5M:T<Z7XJ&A'^WU&BZV"5C\/MXC?Y0=K2@
M9&Y4^7^ESRH?3]#_ (4>3#_SQ_\ '3_C0!_(5^T5_P $=/VZK/QC\!_B[\"/
M&'@34O%'@+X+#PGK%E::_)X<?0=5T+2O)_X0W0]9">9K\7BR3DS%!"/%^;C?
M]G_>5]??L._LZ_\ !2(_'CPW\2OVNM1G\0_#[3?[/T.SM-2\21'5- U?P1I#
M:YHVM#07!B.@?\)26!'A=&4RDCP,K>!"WC.OZ-OLMO\ \\!^?_V5'V6W_P">
M _/_ .RH ^+OVY_V==<_:@^ 'B;X:>&[W3=.\3&]TSQ)X=.JSDZ;?ZMHB:PJ
M:/K&W.RV(U@[N67?M)8!"1_-:_\ P33_ ."C6J_LB_$#]GO1O"6@>&9]>\8&
M\N]*UG6]$72[_3-;C;1B-#/B$@96)&E)SQ'KS/\ \CT"1_9)Y4/I^A_PJ7RT
M_NB@#^6CQY_P3*_;1\5?\$@=._9&L+#PE;_&#0?B1X%\:6NEZKXET0K>:=H.
MB)H>N(^N9'AI697#*-N"H^9ER@?KOC%_P3Z_;'^)G_!,?0/V.K+P=X(MO%?@
MY?"NMZ1JVK7>C:GIM_J.AZ1MUQCH8\1$GQ CM_Q19^[&#N<JI!K^FGRT_NBC
MRT_NB@#^23X_?\$G?VQ_B%8_L^:#H>D^!-2TWX._#B+1+NZM)M-\.6&NZKX+
M9%31-'A_X2#S8O#OBHNI\&^8B_9TWO/Y:([+]Z_M9?\ !*_5OVP?V(/ ?PUO
MI=.^$W[1W@+X<CPKHVL66J-J.E#2_P"U=?E;P?K\NA%8V#;H_$B>)(P\@\:J
M7)9#((/WF\M/[HJ+RH?3]#_A0!_&)\0O^"=G_!2KX[?LH_"']BB?7?%>AZ#X
M-'VOQC=^+-&UG3?#FOZH@+A?[<'B/PCX:)'B)F95P3AR? (.37]/'["7P:\=
M_L^?LI?"#X0?$K4[;5/%?@SP]'87IM'-Z+$N[:J='#[1O,(=QA2>J@?-LQ]A
M^3#_ ,\?_'3_ (U-P@[]?Q)H _F3_:>_X)F_M2M_P4"G_;,^!^KZ5J-A=WFH
MWNC_ &.^73?$FAZGXB8KK$FLL"P,?AD_ZD@DM]WAU=!YS^R+_P $EOVGOAY^
MUKXR_:G_ &C?&^C^)-'N-0\2^+_$EIJVJ:6/$_BYGT36RNC)KO\ PD.-"C'F
MH&E\4[HD\&!U=U,<@3^JSRH?3]#_ (5PWCK2=6U;PAXETSPO_8UMX@U3P_J-
MKI%WKNEG4='_ +39/E.L:.%C%Q$6P2IQDELJ0%1@#^4O_@@_K^L3?\% ?^"B
M]C:QW%CX1U3QI?W>CV3WP0#4=%\<:XDND?V(5;)BA>1Q'@?\(@5\H,N_</I_
MP;_P1 U^R\!_M]Z7X[\<^!_$OBW]JO4?%%WX4!L]8_X1K0M2U[6F\<?VSK&O
M-+'XF5TG>-F+"3/C!)?&JQF9H\?9'["W_!,#_AD3XU?$SXV7OC/0]2UCXGV]
M_?>)/#_A?2=5T_PR?$^MZUK%QK[P+K332_V*D1T=[5?*#FXU;Q.PVQ&*63]A
MO*A]/T/^% '\R7@O_@FG^U]=?LG?$#]@S4/'NE>"?A+JEMJ6F^&VO-*7Q'X8
ML)'DT#6$CR3_ ,)-K^@/-_;D"^%"03,1XU^_A:Y7Q)_P0M^(6I:)^Q3;0>/O
M J^(?V>]5U&V\2WNEP3*E_X5\0Z5XBUE<2-&%8KXEC;PS,JLQ\6Q^(8Y9Q'%
MX7A>3^I?RH?3]#_A1Y4/I^A_PH _G]_X*'?\$A?B#^W!=_L<^)=-^/-O\-?$
M_P"S=9ZEI>K9FUOQ#IM]H^NI'&S:/\N[_A(8RNA&6254_P"$M70XUF* +G]V
MO#&A?\([X9T+1)[Y]3.A:-I.E-J5YL#W8T2%5&IN-QPQ*^8?F #8RVW!/4>5
M#Z?H?\*^8_VM/@7=_M%_"*^^'>E^,KGP!J%UJT6JV'BFPTQ=1OK#4=(TO6HX
MG6$NJ?>D"[P"VU2D88NJ, ?R,^-/^$<\>?\ !9W]J>^AU74KKPAH/Q'!\36N
MDZMK2Z83H7@K0-!UTZYK399?^*CS\OA0D@<$D@U^HW@#_@G?\6_V!?VO?C?^
MTE^S/!<^(_#7[06L-97OA+P_HPU >%=*UKQKX?UQM)UE0[_NFSK3 CPBQ\$A
MU7P(0_B[QHM?</[&G_!/V?\ 9Z\5Z_\ $WXDZAX1\6?$#575;*_TBWU:_3S5
MFBC34G/B".9P?#6AZ,D'@O;$?+1I6WQRB)'_ %;\F'_GC_XZ?\: /PW_ &+_
M /@F-XB^&G[0'Q__ &K?C#XWNM=\:?M!>'O$WAJZT;RC8ZG9GQOK+SZ]K&M_
M,J([1ZK((_#3N%CEV$Y;:C?/7A3_ ((@_$;P':?M)Z)X;^-WA0V'QU\,ZIX9
MM+G5;35#JFGOKJEO[6UW_BG]NON!KFM^%SN*K^\7QT'/CHL5_I1CC$8P/\^P
M[XI=@]3^G^% 'X9? W_@D[=?#;_@EIXH_8!U[XF0:QXF\9V7B6]O/'%M'K(\
M-^%/$NOZVFO"31M!QYNNQPM*5E\U8_\ A+#YKS*J8>OGR#_@B9\4Q^Q#\$?V
M5[SX_P"@/K'PI^+GBCQY>WB:.KZ9_P (SXRTS0XTT'1-:_L$^)E?PP^DNRDQ
MH/%ZI)]MEB*I&O\ 27Y4/I^A_P */*A]/T/^% '\[WQ,_P""*5YX]_8^^"W[
M/-U\5-.N/'GP:^-?AKXG:5XPO&U32M*T[PPK1:%K^BZ)_8>@HX\0>*8M%T?Q
M>Y$3+_PET;>"=Z^ Q&LWVG_P4+_X)YV7[;WPZ^"/@V\\6R:-K?P3^(/AKQGH
M_B'7DU74+^[;1DT?3Y+@R:'*I?796T=-?W*&(N,$HJ-*\7ZG>5#Z?H?\*/)A
M_P">/_CI_P : /X?_P!HK3=*^.__  4.N/@1KOQ-MO&VC_!OP'_PC'ANZ/\
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M4 >1?#;X*_"OX/VNKV?PR\#^'/!-KKVKG6M8MO#VD)IJZAJ1 (D;!&3QQMX
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M)<P:-%&JMN"[LH2  "Q'RGJH8?*_S_GCKWJQ10 4444 %%%% !1110 4444
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MLU/^Q?[<.AZ'K9\1O&^O!#D1NA0,,_>(=0#[WHKX<^.G[>_[-W[/>K:)X?\
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M0UL>&@+ZVAUS4?$]E_PD+^82^M1LGA0F-N8"$ \5  6PA48KZ?\ BM_P5?\
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MFK_M=?L=?"/XY^*]2@/B_P 56WBC_A+K1+?1[$V.HZ)XPUJ/!BT4"*$#P_\
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M ?*[JWBW[)O[3?\ P5H_;%\#_MKZII?QTN=%T[X=68\2>,-5NM5/@O4O"/\
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MI6/AW72VM,VD:-X>T'S)/$(BT?7/"L?B0Q?\)=&=WCUR9!!Y7YR_M<_\%/\
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M_P!N:T-<\0*1X!.XZ%CQ/X4*@!O#3 E@%\'\_P##?_@H_P#\% ?@E^P9\?\
MXT>*OB9;^+3_ ,+>\"?#'P?XL^(/_":>)/&^@+XX.NG^V=$/B#Y<CPYX'UO
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M6OQKTR\_X1ZT\":UJ.I:AI9*Z%_Q(Q_PCF/#_A[PGXC7@D$^"AD>/"O@(G<
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M?&G_ %(=>VG_ ()N_MY0?LS^'_C+^STWC[^RM5T8^*;/]FZT\=G4O^)3H&M
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M/_%-KK7BCPQXP_T1M+\2KXDU&_U37?!\:?VOKFM[@YT*3PWK["+:I7QJZ_\
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M?]H3XD_$W]I7_@LGXX_89\?_ !&\6>%/!'PXLO#&L^$"MYHHTLMXY_L#7M#
MT(D@'_A'@0/"K-_Q69_XKDG_ (I#_A#*_IK_ &>A\4X_A9X8TSXT:;!8^/\
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M?8^V7R]W@I(Y!&WC$@'S'^TI\-?",O\ P<)_LR^(?B+X=UK4XO$W@S2M8L]
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M[354?2EU[4M$+,FL?V[H6?[!?Q2@"R%6_P"*,=2_@-(@PC0 N?\ !6O]DO\
M9#^#7[.7[0GQD^'7AW2?A_\ &+QKXK^&EKXQN= UL"6R_M>36HSI&L>'AXC(
M>+Q7X=D)D\,[U;Q<VB01^!H@\N$^-/@IXD\)^%?^"$G[;OBB_BU#PU8Z#X T
M^TN]3M?$FB_V?J*C7$71-I//B"-2R>%WP/\ A-?&G@TQ^!BP\=C#?JM^Q]_P
M3,\2Q_!/QMI/[<VL6_Q#\?\ Q;O!=^)?#VCNFH>&] 9F 36E$I\5(_B':':0
M+*?!Z[4"12;\K^8/B[_@@S^V=I.F_&_X"_#+]HCPS<_LN?%I1:VEMX@OM6T_
M4=-5M6$F6T969!XAV$>&=^[:5(*MM8$@'P)XPU[0YOV*/V7]5\*S_P#(>T?5
M+W[7I.L?\?\ JG]M?V#_ ,2/_A(/^1?\1>$L?\C5G_J1LU^MO[4_A2X^(/\
MP;WV.N0ZYIGV?X8^ QKFKVMF,?;SH/C+7?#Y&BG_ )D#Q'_Q.P0Q;=X+!VX
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MA?58](DTV_.C:1X=\ :X[:#%XA;Q.J_\))HNN,\IC,/BQ= :>5?(C\'X\U^
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M&DC6%4B5H1%';JX.\F')R$P/PV_X*B?M:?LR^'/VFO#W[-&M?!UO%7[0M_\
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ML3M$OSP%A_PE.U;?:P577^,7_@CG9_M&?'+]HSPO^P_\:=#\27/PG^%^L?\
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MOH]S+HMR/[6US1[_ .Q:MH\A#ZNH/AEU,GBE2MOXO)=1>>&S]F(M RO5F/\
MX)(_LA+';_;])\6:C,;&PM+M[[6=&47FIQC']N./^$<.=>;EA("."@*Y.X@'
MX^?\%6_BQX0^+/\ P3@_9@^$O@^XTOQ+?7?AGX,C5[K["=1U;3]57P9HFA'1
M6?=AEPVM_P#":($4H1X;)=]X"?*O[;GASP4?B;_P33\;^$/%%MX:\;^%O@5X
M6T3Q!XB-VH_L/Q-_8,>AEM<*NQT#'A\Z.I+")LJ0$/CH++)_2OXC_P"":7[.
MGB71[;2M4G\9W5M;%OLF-9T<D;=<.M:$!CPT0S>$7!'@WYE$)V@YR"?Y:O\
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M^R)^S=\,;/Q-:>"/A%X3T2W\8Z4-$\16HLSJ*:CI10XTH_VU)./)8'*B3!!
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M !4V[E(!_!OXR\4Z5^R9^W5XA^.OQ%_9UM_BQ^S?\9?%_BGXM67B[5+S6/\
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M-YK.I9ZZ][_\5%V_]3T\5_H@?#/X(?"KX+:$OAWX8^"M&\&:65(N1HUF%O\
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MW^KECKEWX&\!>#_!FHZZ O(UJ7P_X?@_MD\;@[DC).WYA7K<,/E?Y_SQU[T
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M .P=X'_9MN_V>/')\7Z5\2]'\0>(7T?3/ ?BW5-#\&^/M?&N:XF@-_PDFO\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M=II^H_#D,(&\S6]$;=)'XA!U@+Y88*67<P?;&]>I_LA?M^:'X^_8,T7]J_\
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MCL@N+>-6D:)4N!N^:?\ @WEBTJ'_ ()Y6PT*"VM]('QL^*%I9BUO#J"D:&=
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M>%OB5#H7PU\':AX[T*_^'.E:YX:FO\^&[[4/'>NP+K7]@RB3<LS1>'QN\9:
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MJIBW_":#=XVQ_P )VY\%U])?ME_\%>?'/B/7M @\+?L>Z?HWPWM=(:^LKQO
M6K_\)UIXUYM!8+K>MJ%\+CPWXJ7Y%\+8+>-5 +LS98@'WE_P3,_X*G^*=0^*
ME_\ LZ?M9_$*[\4>.O'>K'5_AMK%C9+J?_"/Z4=%5ET?68]##^(&D\4,B&-Y
M89?+\9!U15$C$^+_ +1G_!3#]L[XT?M"ZQI/['?Q1T'X<_#CX(^/SX!^)7A:
M]\,Z)J>JZEK!C\EI-?/B$?\ "3G0GU_Y)'\) 'P:"V1XR\!$^,Z_'7]G#X@^
M%?!7_!2KX$?&#1/@A\?]:TXZN?&5Y:6?A#QF-4_X2@_\AW^PF7PYXM;7S@\,
MI!\9_P#(CYR/^$T'U#^TM\'_ (9>*]>^/'[7W[+VA_&/1/BQH/Q4_P"$GO?!
M'B&\_LW4_P"U/[:_YCFN>(?#?_"4?^IE_P (7_R(W>@#UK_@K1KWQ3M/VSO^
M"?GBOQOXHTJ_^)5W\#=-UFU'ADMI^EZ@5UG75#0_V [H(7C"/XU\40D(I\0L
M/ R1^#!.B_HUX?\ VZ/C?^RS^UW\%_@?^TI\3+SQ+X/_ &GK/PMXI\'74^M>
M#K[5M"TR/1U=5&B_\(['XGVLR >.59A%*OR>!@WCAF!_!OX_?%3]I/Q)\6OV
M/_%7QP^%?C^Y\0:7X#_X1CPW_9/@_6?^$9T YSKO]A\^+O\ BG?^Q3_X3'_A
M"_\ F0J_47_@J/X$^(GQ"_;'_P""9_Q-7X<>-]+T;PO\+=.7Q(+7P9I&E>&;
M#5M<<A]&VZ"/%GBC0!X4?6V8>&0-O@\$2(65@Q /ZZZ*_(Z]_P""H?A;3OVB
M/"7[/VJ?!GXHZ8=>_LG^U/&%WH[FPT!=8T0&-9=''A\23!9-YW;XW*-]_P X
M'PDWZU0_ZD?0_P J )Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#\P_
M^"E/_!/SP)^W;\)H]-;2O#UE\8O!1:^^%OC77)-<L;&PU=C$SZ%XRD\-L/$<
M_AC7T=U<PK/)X4E8^,8!]JM7@G^+?V8_^"8_[2,_@O3O#W[7WQ@U:\T?X8Z7
M%IWP?\)^&?$+:MIVG^*'E363XXU_0A_Q3*Q1%SX:F\->%<+XO0,['P8!@_T'
M44 ?@=\"O^"9/QK^!?[27C'XUZ-\4_#MOK_C.U$5]X_M-/?5=5!\02)"=^@:
MXDC:_KOA%M'0S3^+0;?Q?"?M,DB^- 91F^%?^".NK:OXJ\;^)OC)\6M.U+4_
M&7A?QMH,C>$M/UF<1ZCX\;6WD+ZQKDZ2K_PBWB!]!\1B0!SXJ>;Q%X0N86LU
M8M_0'10!_,#H_P#P0:\6P_#P?"[Q3\5? /C?PUH?B4^,_!]GJNC:SI@T'5%U
MN17T93H.W^P_#WBGP]&?$LBQ>8W@?QJR-X&58VWCH6_X(;>*Q\/H?A_;?$_P
M=8Z?I-_%J^D;;+QAJ']OZIHVN+KNB/K9E>,:$GB5'_X1SQX4/C(E0WC6$37"
M^17]+M% 'XI_&C_@FIXJ^.&C_!JP\<_$S2?%MK\+;31M$_LS7].UO5=)?3]&
MTK1H-#U70'4,K20-;L;OG;XJBQ/<M'XUW2+^*/\ P4CTV>7]L;19M#\!6_[,
M/Q!\ _#;2OAYX<=M874M.U'35UK&B>-FUQ%1 Q()\%>*$55SD>/%'0?VM5\L
M?M(?LD_ W]J_PW8>&_C-X0BU^UT^XCO+/5;/&F^(K,@S7!TL:S'MUQ=#N6N&
M:XT!"D4S! Y7RTV@'\POP.^''_!4B3QY;Z[\)OCQJ.M?#;[:%U?PG\-+/^S-
M+U[PQHA'A_0!_;G R6(4 <^#&( _XH0U]Y_M+?\ !$;0/BQXT/Q@^!?BW3O@
MKXQ\96BWWCJWU.RU54;Q-)-)KFNZP-:T&8R%O$FOB-[ABJ(P;="&;=#'^Q?[
M/7[)_P $?V8+&[T;X/\ A:X\.C5++2[75[RY\1:WXAU378M&\T1?VS+KLLV^
M11J[DLFPX9'58R-I^HZ /F[]FK]G;P-^S5\+](\ ^#[!/.-KIU[XN\0W/_(6
M\6>)2FW6=:UIF.UI9'RW0((VV$%EW-QW[7G[)?PO_:\^%&L?#7Q]I=N;UFFU
M#P1XJ6)6U7P-XJ<J(];T23S&?:2/^*L\.96#Q=:(UO<@2K')#]A44 ?B!^R5
M_P $J-<^"_C_ $?7/C-\1_#?Q.^&_A8IK?@/X4P6&LGPSX4\=*R_V. OB!E;
M7?#_ (2&Z/P4) KPR#,D9P%?[(_;E_8E^'_[;GP_\,^#_'%OIG]J^"_& \3^
M$M6U:U&I6%A*VS^VH]G&&="F%/S$Z)&-H&37WO10!XO\"/AEH_P8^%OA'X5:
M'?W.IV'@RP;3K74KO&^]661M:WG!.%)U9MIQDA6/; \^_:N_9,^#?[7_ ,,[
MOX=?&'P=HOB:TM2VJZ!<ZQ9)?G0M65<K/&"02-P*LH;E#E -F'^J:* /Q._8
M[_X(T?!3]FOQ9KOB[QG:^&_B9J-VZ/X<MU\.ZOI=CH0CD5Q"$EUJZ1X_#>TV
M_A%ML<D$$C2PNDRQR1]M^UG_ ,$N/AS\8==\.?$[X*3:+\%_B]X:4V=EXFLK
M35BM_I04%='8AQ_8(?\ A,:,N2"0%YK]>Z* /SW^"G["OPL^'OP5\4?"CQA8
M6WB_4?B':ZE9>/M?!<-KL4NM/K22Z(IB_P")#^_BT?Q*%#[!XN!N-YPBUT_P
M(_8M^$WP$\*_$?P1X:34=9\*_$ZS_L;6= U6ZD.G7WAM-(US0X]%_=LI=?[
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M;=B-[;-S96+=\:_LL? ;XE>/[CXG>,?AUIFH^.KKP\GAF]\0K?ZQI^I_V6'
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MN-'A(C1=R0 ;?G)+9<.S$#'7^6/+\OMC'ZY]:DHH \C\:?!/X3?$:\&H>.?
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MZR.,1C _S[#OBI** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M\0?L<V'Q"MQ\>?#EJMW?>$;RSU.Q^UK)HG]OMHVDZTQ1)==C\.X\121QOO:
M,T<A?&W[*WCT/Z?XT /HIF\>A_3_ !HWCT/Z?XT /HJ/S8O[Z_G2[QZ']/\
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M\4?#PQ1ZQ;JNS3[O>[&?^P9GN4;7CX:!6#Q:(V#V\SHV9$R(@#Z\JM%,9?\
MEECZX_P_KZ5R'C,:Q-X8\3P^&5-QK]QX>UE='M%OI-,']KOI3#2,ZPH T/\
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M[?M=J+J,O:#' 91DK]&VX]5Z4 :]%%95YJ-A8Q33WMY;6L%JIN;IKBY5?+0
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M'^(_@WQ/H/A_3")@=3UO6M UJXMM$B TG5T#SW"QXT>YDWQFW9: /;:*\O\
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M_#?Q#'AE=+N=;/A_^TV%BFL;O*\TLL6YF!X7:ZH[<D*"Y\@^+7_!0_\ 8P^
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MDM)&^CZW"\FR2%U60@HQ15:/< >T4444 %%%% !1110 4444 %%%% !1110
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MK]L/XA?M:?LC^/\ ]M'X$Z)ING>*/"'AB]T?^R;W1CJ8U3^V_P"WB-<T,_\
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MX9?\*Q^)&IZAXQ^!'CRR^&^DWGAK6=.^WZ9KNB?V[_Q//[ ]B1U[_P#"#>Q
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M^RCXEN]/\/:1IG]E?V1I#>'_  XNFG]X5USQO\S!B'4^-8QXOSX*4J$4+M
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MIC\:>-(G:3QXQ94CE_/#]GOQ1_P5]_X)N^./&G["W@WX2>)?B3X7TJY\,_\
M"+^+?#WA!_$>D_V5X^UK7=!T/7-#\:9'A4^)<*%61D\Q/&6A2+XZ95\*R*X!
M_2Q_P2K\3?M#^+OV0O!NI?M,Z#\0-.^)5TVDWK7'CV]UC4-8OM)N-(T++_\
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MKFLY\0>)1X8\/@%B0.0,_P#"##&:^K/V(OV9/^"IGP"_9'_:L^%NK?#FXNM
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M^.-<\<>/]<UOQ1:Z/JFM>&_^$>UC^TA8?V[QH7]A:)V[Y_Z'3V!K]+_V]_\
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M:WXR\.^!FT?7-'+;71U\1:QXF\9[!DR1Z"I8F-@OE/QP_P""(/\ P4F_9O\
MVDM>^(G_  2R^.^E_#SX9>/M9U.\U;2-6\::OX=U+16UW5A(PU<Y#.JY8?\
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M&@:R?#_ANPTMFT#^V]8.B !G\0H"%\QO!Y;_ (3+7?,F9F#R'^M&)O-MUDF
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MUY<:V/[2\?:UJ^M:^_C;2-<2-8X)6\PR^22#_P )<OAR90(HI?* /B3XS?\
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M>*]576)=$\>Z/KXT'Q&A'ASPIA/$JJC2NW@S001$D?BN:2O&/@;^V?JOQ/\
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MS2^!?"($D4=<+^RG_P $3/@5^SYJ7B#5_'OQ-^)_[1QU32=+T;2+7XG@6/\
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M1]*\/?VUJK>2)=7U9M$@B-QK+/&"URP!8C(*EL1X.O?"+X8^*KNYU/Q1\.?
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MC2A';C1DUQ[AT/F^;KSLP4M/JL[*JH-H^[H8?*_S_GCKWJQ10 4444 %%%%
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M>.?"O[;G@C]F>R\!76I>$/$&E^'+S5_%OE/I)T[^VYI%4HLVXN%P/+F ,-P
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MX8#?\5@J>0ZYA7'[/6MG#90PP6\-O;06XXM;6UPH)!QC!XX.<A>3WXX_%_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %,V#U/Z?X4^B@!FP>I_3_  I]
M%% !1110 4444 ,V#U/Z?X4;!ZG]/\*?10 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MF.BH-5U?0PZ>(-%0RG9&+BWB;+#(;C ![Q17GWCCXB^ ?AKHP\1?$/QSX3\
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M>C2/$-)US_A(_P#A%Y-?AFE>>!.%\7>$,/"J$8H _J1HK^8OQ3_P<)Z5X/\
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M:SX#LK6UT:RU<?86UK0QK7_"::[_ &\/^$7+)XB36H_^$I_Y$P>"D"_\CV@
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M:2ZZ=?>)]#8>7$NAZ]KZ>))0K)+*OAIYI+CQ8^BR",1I<C(!^W=%?RQ>//\
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M?!FC*_A^4./%+N_AJ-?#)D\8QN595!12/V&N-%T5K;4;)M+TTVNO,[:M ;1
MNH*YQJK:JP78X:-MI+-G><<@XK^5K_@W3\#>#=*\<?M?RW%C;7/B_0OB=X@.
MD:KYS7F=)'B'6]"*Z*R@EU\*@'PJT!^3PHI-L_R2L0 ;7QN_X*]?M9>'OV@I
M_ _A?0?#?A3POI6KZ=8^,/[9\.'5-+L5E_Y L>B[O#A\3MKS\9C?*>- J?\
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M;'_"0\!>#G_A,_[=!\!#Y00 ?UA4Q^@^O]#7\+/[/?P]_P""O_[4'[/GC_\
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MX-UC5-%O+O2/$FC::;#^P=:_Y@?_  C_ /S+I_YG?_A$_P#A,?\ A#/&F?\
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M\,!=J'P4I_X0?+!OE_J%_9-M])\,?LP?LW:'Y^G6Q'P4^%]G9VXL5\.F\/\
MPA.A+\FB-G:V."0I'KC<30!].U^5?[<O[ _PN_:GU'1/'WC7XO:_\+;S2?#7
M_",6DZZT%\.3WZZU)KFB:KY6L>(O#,3S0/K.M0*D<@20Z[+M(,0$GZI?P?\
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M&IW7B2$:?K>FE&!UB-BV!HA/5V<Q9(&_&YA_%=^R/\(/B+^VMX5^(6F?$_\
M:,^%_@G3O$_@WQ2U[JWC7Q=I'AUK#5%T0Z%H6B+H&O*SZ"?^$CR JAF/@S'C
M@*?'F!77?M_?L2?#']G/P?\ \$[OA.OQ:?QJ+SQYX8T;QWXL@^(FE7O@F_TK
M7=:U\:[HNBQRJDFO<CC>JGQK][QZ,<D _J TW_@K-^Q/JGQ*_P"%96?Q4,]R
MUU]BM?%:Z4[>!KUL#(77CM& 2>=B[NI':O<OA=^VI\ ?C!\4?%_P=\$^,K>[
M\9>%+/2=2-M=AK Z]I^LJ2C:)'K(B:< @9C"_O, !0:_E&_X+0_L1? K]FGQ
MW^Q!I7P2FN/!%S\1OC:;&]O+G6<K9:5G0-!&C@?\(YN'AUEP2IR?&1RNYP [
M9_[=WP;^'_[+/_!2;X?>%OV>?%>HZ)K!/P<UGQ+::J=9\2ZE8:L-<*L-=Z$^
M'O%?AX$,"%((P0/ @( !_6;X^_;;_9E^&OBCQ!X)\8?%WP=I?C+PSH[:W=^%
M#J6[5"5N3HD>E)'$'B/B&;Q#G0T\/F?[2)'3>BON"4?@)^U]\!_VE]$LO^$)
M\;Z<WBC4K'43=^")M:&F^)[1L8?RDT:0C6%5MV/$?A621!&5*2;MZC^5CQM\
M ?@#\</^"X'B'0OCWK5Q;>#M2U;[9=)X<U<:8/%OCL:SC04UO6R5 _XJ,<<J
M!T\!$#IU'B[P7H?[+_\ P75\8:'\,M4M_#5OI?PM\,^)M'L]*\.#_0?[;T?^
MW/[&_P")\6\+X;^VR5R=V" ZJX*@ _:7]FO]CK]CKX+?MN^-?%/P_P#%.H^+
M/C:? _B<-!KETNJ7WA'^V->T'1-<N/[9=W&N:Y(NKZUX<*'PKYT*:)XFC\<3
MFY6.0_AG\?OB'X<_:[_X+,_%#]F7XQ66I:E\+_!NK^*+*RM/!-WHW]I_VIX%
MT4?V[G6^/#/_  D7_".Z'SG'_"%]/'I%=O\ L(>.Y_$?_!>+$OQ%N/%=_KGP
MK^)^M>([,:MD#4ET77LKK2KC_F8?[=50 0IP=I'!QXM!^#VN_P#!S!\2? ][
M8:=='Q/HILM8\.K>:QIK'5==\%'7M<&M'0OESXL/ WD G[W!)(!^]?\ P3WT
M#]@+X%3^-_@M^Q[\0(-;UO4]3L]<\2Z'XCUO5;[Q DL4FN+#H>E?V[X?\,RI
M%X;#ZY*GAV.!C:)JTLEPT?F".OO6Z^-7@"P^)T'PKU+7M/LO'-];65_I.G-?
M1(NI+)_;!_LD_>SXB@MXEUO_ (1^98[D0ZUX?9<B=9:_E-_X*(?LP'_@EE^T
M-H'[<_PTO?$D_P $=3UEK*[\.AO[4_X1+QSO;7?#VC\A2-ZZ#GP3P4W!AXZ>
M5 LK_K!_P3A\):)^USX8\'_MV^([SQ';_%#5/%^IWUZU[::0JWVE'1CC1?[%
M*%= XUK1<@,64Z!&"H5PX /V\AE\Z,GO_/T_I7Y6?&O_ (*Z?LJ?!_Q9#X4L
M]5U+XK_8]8L;#Q9JWPPDT3Q)IWA=9=831&>9DUR-M9D\[=\MN[+\JR;V)$<?
MZ9Z[%IO_  CNM1>(=AT@Z+J@UGDX_LDZ4PU<\?P[3(3C)R1@5_ ?\>/$G[+W
MC#X<?M4:5_P3]\1W.B?\('XP\4?VQJWB&]Q]O[Y_MSK^'\_'F* /[>O%/[7O
M[-O@GX=:C\6O$7QH^'&E_#S2O#9\2WOB!O&.CE[32\*1(-)$ID S\HW#=P<C
M!4U\<W__  5X_94M/B#X(\&2ZEK5GH?C.VTAK7QWJ]@;+PY97^MZ<9Y8M9+R
M*4'A:(O'XOQ)_H3,KQF3RU!_B[LX?"OBK_@FG\>+CQ_XQ_MOQ1I?B3P'9:/:
M75G_ ,?^F?\ 0:[?]0/Z?V_GTK]8OVI_V<?V?_AO_P $4O@#\4?!W@ZQ?XB:
M]X,\"6NC^+5O-:\0^*X@=$\<ZYK",A+C1!X7==,\-&?,(0+'%X[BD(DE !_4
MM^T'^UA\-_V;_!,'B_Q1?P:S<ZE9B[\.^%-(O]*_M/7M,*J?[9T8>:=^AA A
M,K@M@I@D U_%[^W?\1_!WQ9_X*X_L?\ BGX2Z'XT\-W_ ,3_ !AIGVSX>W/B
M+6=0U$>)]<.@:\-9_P"$&T!B!_PE?B''B<^%\@>-2/\ A.L*#M&3XO\ CCXI
MUWXH_P#!*G1/'_B*UMOAAH5I\+O#/CV[\5V0'AJQ\,#6?#^N:[HVNGOX=VZV
M!D]@!T\(XK[%_P""W.O?!'Q+_P %$?\ @F=KGPS\??#C4=1_M<?VPO@G6-%U
M/35TDZUD:PQ\//(&91\K,'(9QX:8':10!_97#^]]NOZ?G_6OXAO^"A^@:3^S
M)_P5-^&'Q:/]B:=K]U^TX?B:0;S6=-U/7]+U[6M UW0\_P!@=?\ BH]<.?%'
M((_XH;-?W$P=_P ?Z5_(W_P7SLO!WBK]N/\ X)^Z5/J^BW=Q>>)-+\&ZQI1\
M2:0?L&EMXU+:\!H;Y;_A( ==T38#RJ;5Q\HH _9[]G__ (*F_L]?M ?'&_\
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MXFTO2=.OKSS]&'@AU\R(ZXVC_P!C_$+_ (1-S*- 9I%E!!^;:RMC-?S :/\
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MWV[Y/G+5^6G[&?Q(_9S^"?Q'^/'@"Q\8ZWK>H>,O'FJ:UH]W]C_M+[?C1?\
MB>YUSP_GPQV_GWH _;]_^"[GQM^(MKXWU;X!?!'X>>+++0+QO[&TS5G\9'5#
MIK.D@D?5V\1^$[?Q))&\:M"?#$+CQ9R(!&I*GH/V@_\ @M;\6H/@GX0^('P5
M^$$$&K:5:6%Y\6A]NTOQ'_PC^HRF/19!I0,S1Z1H9G61Q=/&LP20QEBS32S?
M)_\ P2VT?P/XJ_9O_P""F]CI6BZ;XLUC^R-,O-'L]6LQJ7V'2_[$\0' T,C.
M!_Q)&XP>,YP"#]??\$4O GAOQM\*_P!KWP?JVDZ-J8URTTSPSH^D^*M(THD>
M&==T/Q NN:(40$/X;_X2%M%)#DJK"-@I?#( ?H/\)OV]M?\ &O\ P3YUC]JN
M'0]%O_&OALMHUQI5T=2BTJ\U=]9T'0]'U35=BI/NF76M'GE8'?\ >97 !"?9
MO[*?Q=\3_'7X%>!OBGXNT71?#NK>+1K%R=*\/OJ<MA!::3KNKZ''A[@F02R+
MI)<(\C*5*+M.Z-6_C^_9NB_;2^%?[7/C_P#8$\4Z&+KPMJMYX#T6\TFSO ?#
M-^#TUK@_\5!X=\)_]39^&:_MF\#>$M$\$>%=!\'^&[.WT_0/#>EQZ18V=O\
M<B2()D+@<9.YCSG<Y[ 4 =E1110 4444 %%%% !1110 4444 %%%% !1110
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M1D@M7I7[</CSX,WG[!?["4'A_P &^"M#N->\/>&1JUI_9&B>'/'%BFA:(O\
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MFBZQIWAB_.O:UKV@:&VN:Y][P\P7<H*L!XS&A,? :MX\'C(#UCXX_P#!-O\
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MU?\ !#^Z\!_M"7'[0'[&&NVWAB^U3Q[I/B2]\(77B[7/#NHZ"[:R6UR/0/$
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M (2@AQ.OEGQEXE6,2>,,9EYE5(OVWIGEI_=% 'Y+_M@_\$H_A#^VIXN_9_\
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M0)HT/AB&/3<Z##X9\FZ-LTGBO[4LRK#\^?M/_P#!'7X1_&W]IL?M-^"-4L/
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MWX2_ W3H]7^*7C?0O"=O<748M;6Z>2ZU2^4/N;R]'C+R% 1QKIQ"0%W.H R
M>^T5\;>%_P!N?]F?QAX1UCQKI/Q)MF\/Z%<Z;::Q)=:3K<6I6#ZP5\E)M(&@
MFX.XDY98Y00CERN463N=<_:;^$F@_"N+XQ_\)=%J7@:>Q6\%[H5J?$VH6RN&
M^7^R-!,DC,I!#AOF!*GYE89 /;?$'B/1/#&E7.M>(]6TW1-(M(U:[U/5;Y=.
MT^T5N"9-3E"QH"00"2#D$$KC%-TOQ%I6OV-OJVB7MMK&D7BYLM3TJ[34;"[!
MX(W1L5Q[J6P>C&OBCXN_$O\ 9\_:2_8V^(OBCQ#XYN-,^#&K>$7U'Q3XAMUT
MIO$OA5- U:+6V&IZ*99%MM=631$*P'(.)/+4#=(?RIUG]O7]CS_@F3^RIH_B
M/X2:O\4OB?\ \+&;26\-7?BO1M7U(W^I*0=#0Z)H(\)@AP"K$!6"L1X[\<JX
M#T ?TI45^?'_  3W_;/\/?MP?L^>#/BII%PMUJ[Z/IH\5_8-'U;3=)N]6RK'
M5]"_X2#]X= F4N8Q*?\ A)4,2^<L;+&)OMOQ1XHTGPKIUQJNO:GINF:?;CYK
MF]OOL&"<9&23GG\.AQ@T =917P/\*?\ @H3^SK\5/%&O^#HO$NI?#_7O#U_J
MVC7=C\5;+1?!::EJ>B?+K/\ 8NMR>(9/#>M^5D$>3(B@@N?ERBW_ ([_ +>7
MP&_9^UBY\.>,?$-WJ&OVWAUO$K:/H%D=26STA=&;66UAM7SL,;QC]V2.596*
M@\$ ^Z:*^4OV6/VG/!?[6'PJT;XM?#RWUFPL-555O-*UBU;&FZB)4/E1:H D
M.MQ>4TB%U)8"*$RQ>&V!4U/VE_VS_P!GO]E*S\-W/QL\>VWA6?Q1>_8M(TN"
M%[W4KQ2)4?59(X23I'A^*3(EU^X\J$%MHD#QL  ?7%%?F5\,/^"J7[)?Q9^)
MVC?"GPOXM\1V_B;7@?[)/B#1]+TO3R>Q$AF9UQ@YY8\8STJA\:_^"L'[+'P/
M^('B#X5:SJOBOQ;\0/"XQK7AOP/X;&K:A8_4MX@0M^ ';((H _42BOROB_X*
MP_LUVO@+Q3XW\60>/O"A\,W?V*W\*7GAM]4\<>(B0P=-$T'0WD_XG1+$B#>%
M7D \FM#]CW_@J#\%?VN+M=,M]-U7X3^(+K1]*UC2- ^(5[I.GZGK::QK#Z*C
MZ+&&W3$2@*$&YV,G<;C0!^H%%?EM^W%_P5#^#_[$^D>%[BYT2_\ C'KNOZJE
ME_PC?@;Q)X2:70M/ .=:\07#2_\ $GC )"I) N.Y[5Z=\"?V_P#X%?&OX$:K
M\?9O%6D?#CPSX6@U23QUI?C;6](TW4_"::&51Q(-@A(VR&,1OO?_ (2]6\'(
MSW*9 !]]T5^&OPO_ ."W/[//Q#^*4?@_6O!?C'X7>!+LZE+#\5?B(VEVVD+<
M:'J6C12G5-$T!O$R>&C(TS^=+XF\3VW_  BT;: L\6;E_+^E/VN_^"C/PR_9
M;TSP^+6U@^*^O>(++6KVSTKP1KFD:E):+I6BR:_HX.5676!(6CF*Q-')%X2#
M>-5/E1J90#]-J\P^(_Q1^'GPBT&;Q7\2_&7AOX?>&K6]L+!O$/B[6=*\/:.-
M1U:4HB'5]:EC@#$'D9#85UPP!"? '[*/_!4G]GS]J>:_T:+Q+I/PU^(&D%9+
MWP1K_B3S"^F+HJ:ZVK/K9\/1^'C&0FL2,D<RM+X-@7QNQ,1DM_"WXG?\%K/^
M"@</[0'[.OCKX/\ PK^"7C_Q9\/- \8>%[K5?C0I8Z1I^HZVNM^'_#VMMH>A
M%S_8'BK^V6/@<^)_*3QJLA61/"3QK*0#^EKQ[^V1^S#\,_@U_P -!^./C?X
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MQS^)6J3?"R3P7=ZG_P )!X3;3-;U?6--\-#7&T/1"VE:*)I)_$$NX>8OAPS
M ?+CY0OQ%#_P7.^//BNYUC5/ /[+[:GX'NO&/Q3T7P#>7FB^+=2U/Q5I>B8'
M@147P]X@V+X@CA \0>-@!^\@^3P5YS9>@#^GC[2O^0?\:^:K/]JWX#ZI\>]9
M_9DL?B!:7/QQ\.VEC?:UX#MM*\5M=:;9:GHNB>,3--JZ: /#;1KX>UK0[KRS
M>&9$U[P[%/)#/XFMXV_F/_9'_P""KW_!0KXN_P#!5SXH?L[ZO\#/$G_"'Z7:
MZ0?$?P>N6;3-/\/[/![>(5U?_A.]?/\ PC7P_P!=7?)XF\DGR?&W@71)+=HV
M^.$CQ-]TZ?\ MLPZ%^W5^V!X;\._LD>#M3^._A?PWHY.JV?B6/4O'.H>*?#_
M (.;1-$)UWRO^$:\/^')O#C!)5!\')L4)XY\;1!O!^X _H<^TK_D'_&K5?Q
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M@F-2?':@D _7W]HW_@LE\#OV59O"$/Q5^"_QUT.X\9>'-1\;:(MYH^BV8NO
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MVG_#?PIXL6X.DZQK.B'X@R8\GQ)(7;P#'XN#I&7V>-A!$FV0 _JZFF\K_/\
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M7?#S>(] E\+.FM^%E/A-9)5&@_\ "9QR%#M/+_"#]J3_ (*%_L!?%/2?!?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "H
M)O\ 4GZ#^53TR3[C?2@#\W?VI?VIOB)\)?VFOV3_ ((>!],\)OI?QD\7K_PE
MVI:OJRMJ(TQ&?0_[*71 I?0M D8JQ\5L[ ^-4\*^"$57\7NTG6?\)[^W'/\
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M ()%^)_VLO!VA7'@+XT2> ?$^J6GV5=,L-,75/#NM*FNZWX'D\0AH-;)\/\
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MUH(8$_$1/#FC:P/^$9 _X0SQAX+T0 ,OCR0AKO[>7[2OBKXN_L)_LDZQ\/\
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M.;O3O$&G^,M3;XJC0/AP=3U/QWJHT)?'6W6<DA-?(76V\;HH"^-?!Q\-^//
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M@C7F_L%B-#"OX9/B,>&M<T3:H!\&/X-_X1;QOX"*@EE^!_ GQ7^/GA#XH_M
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M!-IUE>64]M>6T%U;:A;[;RTN1]M2[78.&W-B0;<?=7'(*A2 :^ M4_X)2?\
M!.O4IO$U]+^R/\)K6[\2(IU5]"T74O#@)*Y)T5?#]S;-X>ZGCPQ]DP>" >*
M/Y<? ?Q5_8&\;?\ !-];[XB_%KQGJ7QD^%]GIEEX1TJUTIEU8>/0,C6E381X
MA'_".XR2X(\%$G!\>#'@[Z(^&/[8O_!/K]K"S_9_UOXE?%_3 /V?O$Y\-?\
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M9VU$BZ\0,B^)IHG>!Y9+>1HY/H2[TC2]4LKW3-0LUU#3-2LQ97=I=[KZPO;
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M7_A&_P#A*->UK^W-<US7="\.A1X@\1>+O$@UTYQCQIX,T#PR    /Z[OB/\
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M,?ASX(UK4M/^'1TL>(]6TKPV!]A(UDG7L#/)_P"$;!) _P"1+ /CGUK^]/\
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MQ1UO5]=M!X,\!ZKX3\-KJ>E^!-5&BZ_H7CG6M=SG'_"5D:$1@C!P>0#7U/\
M\&_7[0-CXK^,/QX\)VVC^+(+OQN1?6FJ:N^KQ'4;[0M(3Q!-JVN:1H*_\(P
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M.GYRR*)T'[LY^7:1CH !0!_%C^R+_P %9/#O[$OQ$\?^&[SX2?$WXLV'Q/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M/X&\#QP2>,?&'AWPJ9[;4KVV_P"$BU?2M-^UV&B;'UB2-IG566)&W.(RQW8
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MM:_"3X]^,/"_A_5+3PSK?_"+::VBOX:T_5/[;\?_ -MZMKC +_PD*^)_#?\
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M-+.J@J,D_P!C[C( /8]"1CM5;XC_ !&\'?"7P7KWQ"^('B31/"7A#PS9M?\
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MQ/X>L_#.;3P+JNKVFK:;J>I'0]$UG7?$']MK(5A>7;"! WALLL)(B#^+[?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHJ";_4GZ#^5
M &#X@U[1/#.B:AXB\1ZMIOA_0M)L1?:MJNMWD>EZ=8V"*%>35-6N)##"J%OO
M/*/G(5O,WAF\T^#_ .T)\$_C[IOB#5/@Q\3?"7Q'T[PMK+>&/$EYX2U?^TTT
M3Q&H0-H\S>6HCEZD $*<< C.S\1OV^OVL?&.A?\ !1G]C/\ 9#G\3ZE;?"'X
MN>*-.M/BMH\4J^'_  YXA\,:R/#\(TC6-:$S>(-:CN%B69/$<7D1#S3X)D@@
MG>;QD/"_^"C7@K5_^"?W[1O[*OQA_9:\1Q> ="U*ZU-?$WPSAU;5O[.\0Z9H
M&MF,OKVB1*(CX?;P]XUT3PT?%'B@(/!0T(9C\7_\)AXR  /N;_@I9^WAXA^!
MWC?X0?L]_#?Q99^%O&'Q%UDW?B'Q4M_HSZH$#R?\(_X+T71%7Q7XE_X2+RC'
MXI\<1CP:5A\(_P#".HLDZ^+$\)2:G[*O[!/QW^#/QNO_ (V#]L_X@^-OASXX
M\42>,_$_P[O+G5M6TWQII^L:$%TO5O/URX6".X77WDMC+'X9*^+/!S3-(3XW
MMO"_C2/X=_X*]3?"+XA?'?\ 8:O=:\/%Y_'>FR^)C;7GAR7P5J0TW7I-"?0T
M\;>.I'\*>)R(\^4WA5&'C#P.Z-XT1(MABC_IA\.Z%I7AG0-(\/:' -.T;0M*
MT_2-+LR !:Z?HR+;Q)R<?+$JHQ/' 8]2  5O$OBKPYX2\/:AXI\1ZUINA^'=
M$M/MNKZOJETVGZ=8:< 2SR.?D4!0%7.23@ _=4?SY? W]I_2?VA_^"L&G>-_
MAG\6?$7B#X4>)_".H^'/#ND7OB/5=/TF\\->'_AKKLD9T+P3K\,*_P#"->(O
M$P3Q3',8D\<+XQA65O\ BA_%A8^EW7[34O[7'_!26^_9!\3LO@OX,? K5/$N
MM:KX8NFT9U^._B+1-FAMHOC+1H_^$L_XIR3Q"-<=?#/BK_A#O^$W\&#Q(S;E
M2-?&'YH?M-_!CP;^RQ^U[K$W[/.K:V+7P3<:9XF@TS4-8T*QU+PCJ4@_MTZ!
MI&MJ7\1>(SX34[?!GB?Q4TGC#P9\W@57D3#$ _J]^*?QO^%'P3TFPUOXJ>.-
M#\$:1JEZ=.LKO7KSRUO=2(.=*C&V3]YAONDA<@C/4G$^(/QU\!^"O@AXM^/"
M>+O#E_X"\/>$=5\3V7B)M8B/AO4<%H]%)UJ'*1Q7'B%(] 55<D/*/,570QG^
M:C]G#Q)XH_X**_M3ZU\.OCK)XK\:_#9;+QY?WFCW-CK0_P"$$TS6U_MQ5T/6
MT5FT _\ "1#05 7Q<[>"P/"RJK'Q< ?T5^&__!.OX9?LT_!?]J'2O'?QK\?_
M !<^']WX&^)VMW7P]\67>E2^!?"/A;6])_X2+^V6\&>'?#47B-_$?AC6=&U8
MAH'G@BN- T#QCX#\&>%?'D'[P ^%OA%\2]2_X++7&F#PW^UYXG^%_CCX8^)M
M4\?Z-I7PGT;QMX,_X0/PPNK-H>AZ[I<W_"1^%/[=U]=?U?1/^$*GF8;O!NO+
M'X\:2>2**3]A_A5^T#^SS^SAX'\%?LX?$+]J#P)JWQ2\!V7_  BVO7EYXGWB
MRU:&5CJ^DO''<^)U\/V_A:0KX?DB\3W$4GA>!(X;F2( P-^#/_!.G4?!VD?\
M$EOB'\1/#FH)X)^,'ACQ\VDZWXS\%>+O&'@SQU9^%-8_X1XKI'A_0O$+KX9U
MU_$\YU7PR/AB%\)>"?&7]@'QL4'C_P *12Q>N_LE?\$^/"7[>7[*@UOQ%\1X
M;&.T\6:5:Z3\1/#8/B;Q3?ZIH<NMZWKPUE0/"(?RH]=\&2^#?$W_  F7C"9U
M7Q*GC2*X=F6, _HA^(W[4/[/7PCM=!F^)OQJ^'7@B/Q=I7]K^&KCQ%XLTK21
MK^E;-K:QHQD)$\9W@AXP8]PVAF*M7A_P6_X*'?L@_M#?$>?X8_!SXS:3X]\2
M ZA96ESHEKK,FDZ[JF@Q:[J^L>']"UD+AM;BT#1CXN172*'Q?X0$MSX$D\6+
MX3\;GP?_ "S?M0_LT^ ?V?/VA_ 'P(A^,.N?%GQ#I>D:9HGB0:N1FPU,:Y@'
M0_[?)&#X;&ALN?& ;P5XS(W >!,@>W?M\?"_P;^S=^WE\)OAY\#OM/PD\/GX
M;-XE:YM+[0]/TU/%>MZX=;\0:JQC=_$GF>)W5HY/"J^$F"NK+X"/'_"%T ?T
M2?M4_P#!1?\ 9=_8TU'1?#OQD\8ZRWBC76#)X3\$Z(_C;Q1IVEJ HUO7M%T0
ME]#T$8/[Y@A<$,%&3N[/PC^VS^S/XZ^&6O?&+PI\5=*U+P/X7TD:SX@O+NQU
MK2M3T_2UU<>'P&T+7=#A\2R./$BGPT66(9\5));E1G+?S/?MM_LH?M3_  *^
M*;_$+X<^&8OVEOAU\0]7U+7+7XFZS<:1XU34-)?2)=<UHZU+_P )'X2A?Q(P
MB9VA60^$?%\;POX)CB\>>%HPWFGQ(_:*^&7CRT^$]C\,K'6_!.H6NC^%[+X\
M6EWK&C:;X&_X2C_D/:Z=<_Z%_P#XIPZ'_P (1C_H ?\ "#>/?^*\H _?;X3?
M\%H?V'OC%\4)OA79>./$/@KQ.%<V@\<^&=<\.Z??:<[0L DP>,_VYA&$\10G
MPKN!F8?O!-^JWBCQ#8>$_#.O>*-5%P+#P[I.IZQ>_9(-U\VGZ-')<2B,')8A
M$9QPH*L6  W$_@#X[_X)K?LU?M6? OX!?$3P3K?A?P5\:_ VGZ;K:^+/"FKK
MX<CULPB'^WM'U@QP?\4_XB\,&X<>"_$]SX8$O@PVP\$>-('C,TD?]!,&G16.
MD0:69KFZM[:TLK,7=T?MU]>*A"@RGDNQP#DJ0-S%5PH) /Y[OV>_^"^OPE_:
M(_:T'[/>G_#[Q/X7T&:^3PUX7U^<:KXA\1^+O$RN6?5'T+089?[!\+W*?N?"
M =9/^$S7$UOXVAN8X?"'B[\YOV0OVC_!/[+'_!4C_@HAXW\;:IXB/@"Z\9?$
M[Q/_ ,(_I5[_ ,)'M\3C1_#V==70SXAD&_Q1XAT/7/#2>)RO_"9LZKX$)3P%
MEU^DO^"4^E_#=_\ @IM^VC)XFL?"O]O6]J!X1M+C1=&T[4=/U1M:T +K6DJ"
MOBG0?'OBSP_M\3S("(_&R$^-_!1^S&8UYK^P[\(?AEXP_P""[G_!0"TU>X\.
M>*?#]JOCJT;P1JY3Q)IUX/'6B^'RVM,<F/'BKPWKAWD%A@'82=M ']'G[-G[
M97P,_:D^%\WQ5^'/C:V.CZ5::I=^+M)U\'PYK'@,Z*RMKR^-=$UX!_#Y\+LH
M>9FD" (9)3L5V7X;^)W_  6Y_8M^'_QI;X2_V[XA\90:9K6G:+XB^(6@6&?
M6@:B7G_MI5U9VDBUYO"<&E2:_/*BB6YC(/@5_%_RQI_,5H]F-!_;#_;(\#^%
M8-2\-^']!\-ZIHMF+3Q)K.FZ9_9?]B_\2+_B>#_BIQ_PB?\ R*__  E/'_"%
M_P#(C\5^N?\ P3M_9E_8-_:5_P""?6F>&OC?XH\%:?JNJ^//'MYK6L:1\4M#
M\$^.4;P*K,'+M*"$\)?VSKGB0JL3MX,DEB(8(LA !^MO[2O_  59_8]_9KT5
M=<\2?%.U\5W&6C@TCP"J>)9'O@FAZUM#Q/M4OH&MI,#R!&60QHY!3E/V?/\
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M'O'WQ:;PKXB\9V_P\\-:IXGNO"7A.U%_XGUZPT5/-DAT>+?EI=@\WE20A8\
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MO\./#3>%]'TKP^=9TC^T_B4VN'_A(%\::QH?A]CX:UM?$_A[!A\*KXRS%X,
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M\8-#USX<ZEINL?&[]K3PM^T%9VEIX/\ [-U/7O"^N_\ "??V%_[@_P#BEO\
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M/\:>(/+>)="&AZ3X@#IXZT#Q067PY'%XN"/-X-7_ (0CQLQ6"Z*?B)_P3O\
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M@ ZC_@J)>?M&?'[X&?LS^/\ Q_\ $WQ=K>L>%_$GV.S_ -,_XEE@?^0#KO\
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M/[2]I!X/\-^&+'Q%XJ\/ZR/&IU'2_' _L/P-HB:V3DX R1XK!_X7/XS&?'O
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M$_X7:!X.^"OBGQ/I_A+6+T?\(WX3?0D?^PQXUT,\_P#"2?V_K?B#Q1\OS?\
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M#IRP&H?\$P(+>:WMKBV7]HWX67-TMU<%$58]$\?$ 9'(RQ  P !P#R:^0_\
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MVA/VR_\ A _%'[-EO^T+\6M2\#^ ](U2]L])'CSQE_9E_P#\3H:[H1_L//\
MT,?_ !5'_%68_05^@G_!(;_@E=\?/CMX;_X:=/[3.JZ9XA\+^.?,\-L=?UT1
M#QUH1T+7M=S-X?\ $/\ PD(<?VUH9_X24OO"X;:%8$_:&K_\$4_BUX6_97U+
MQ?H:PZU\=_$^CK>>+_ %JN/$EEIIW:\577/^$EW>(?$:;03X8*B-BZHCNZNJ
M?KS_ ,$COV2OBU^R!\"_%/@CXN:+;:%K&N>+VUJTTJTUK1O$84,K#<=:T#*-
MCH/,&T8)YQ@@&W_P5WF^*%O^QIXH_P"%9:UXKT*ZO?$NE:-XOO?"6KKI6H2>
M"->T7Q'H<FA:SK)8O_87BKQ%JVA^&I01G&NJQ)*-M_'']E_]HWXZ^+_^"+'[
M8FL^)/B9XMU'QC\,/%TG@K1_$7]MZR/$GA/PR=:^'V@ZWX+.L^(?^0%H0\,*
MX3PSC=''K\J?=? _J$^*WP^T'XJ?#KQ3X \7Z)#KNA>+=!U71;VRF9E"23@1
MZ>%E>WUX:1J<;NTL/BC[/)+X;ECBNXT,L487^,;0_P!A[]O[X:_#7]I7]E'P
MA\-/BOH7PP^+GQ);Q'':VVD:OXC\-V6FZ#K'B&1T0D@^(2%B9_!:KGP9XT6/
MPTQ'_"=IX-P ?,'Q(\)_M!_&S]@SQ3XZ'[4_Q'T3P%\'/'?A6[TCP5=^(_&7
MB33CXFUL_$ Z!K&B:+C_ (1G0%4Z-KY49P#XA8^/!\Q%=1\0OV-?B;\)OV'/
MV4?VPO#GQV^('C7P_P#%GP$+[6+7Q;>:QJ(T/Q3KN->T/15_L @^(O\ A*LZ
MWN8#:#H84,W@4,J_6[?\$=OVR?AA^S5XV^#=C\.=3\?V%YX0U0:QJUGXZ\'Z
MIJ>NZI_;#^(-=.C:(/$9\3:XA$; >&I"B>-7Q'_PA.]E4^O^-_\ @GQ_P53\
M:_L&?#C]BG5O"^B7'A#X=:1'%I%GI?C/X;Z9J((D=/#^BZYXT;Q+_P )(A\+
M>']>UY _A)0TWR+N<+$% /F;XC_\%;OC9^T3HO\ P3X^"FE?%KQ)\,+_ ,9M
MI/PT^*?BKPKXEUK3]2^)/BG6]<_X09/[:UMO$I_M_9X?T(-XS'_+/QKKWB54
MVHB*N#_P6H_8UL?V7_BW^Q#?>%?B;XLNM7\3WVICQ%>W)TC3AX@U+0M84Z\W
M]A[5'A_P]_PCVNLN%9UX^]O+(GV1XA_X-^-;^)?[,?[+^K:+>O\ #C]HCX#>
M&=5URTM-3\6/(;_Q/H&->^%. GAIO#.@>).?^$8\;(H/@YADJK8./E_Q7_P3
M5_X*Q?MG:I\'O&'[4/@;Q)J%MX%M--O;/5O$'Q2^&O\ PDBG^V7E?2'T37O$
M?_"3>' <,6\,N54R,%W%W4, 9WQC_P""D/\ P4$^./[5MQ^S'\*=>U>+3=4\
M/>$O#FC:1H7B'5_#NEWTFK>$!H\,@##_ (28>)?$\VLI-$_BSQA_PAL<JK)X
MZ(< U\A:-^R]^V5\)M>\<CXF>%O&O@$ZEI']LZ3I'C8ZQINIWIQKS#63WU\_
M\)#HNM-C X(/((-?JW^U5_P0?_:+M_A];?&OX#_$N#Q'^T7H87^U?!6FW4FD
M^'=0\-:&7_L1/!6K21J^M^(E5493XOP7+XVC"EX?@W^P/_P46^.'P)\3>+OB
M=]K\)_%)[35=$N_!'Q U37/#WB7Q7J@5W!T9M=5EC5@FBA/%?C HK.!&I;P,
M54@'P[_P2I_X)%_&[]JGPMK_ ,>/%?[2/B?P:W@_XE1V&CZ[HOB/6-4DU[QS
MHNEQ:QK^EZ&N@>)E_P"$?A@,N@^&[CQ9R8X@S> @3A3_ &F?$'X67'B3]GGQ
M!\+O'%I/\8K^?X62^&KU-2;1/#FH^._%.D:*D<6M%]<;Q)X9T#6_%&OQR>((
M_$3PS#P?,]O<%6EL]Z_E-_P0\_8[^+W[(?PS^,&B?%OPQJGAU?'7BGP3XH\,
MC47TXZB;"/0O$D+K,MN?^$BT.*-==TI7CN@8DNQKP4+=#Q81^Y>OZ18Z[HM]
MHNJQ7<]CK5E?Z/J'V>[FLKY=/U='AG$4FDX<!XSY?F*R,0-SEMT@8 _E%_X(
M9:;I6O>#?^"B_AR?5L6]WI.I^&!X2M!K&FC4-+_L7Q!UUPX/_%)_VV?#(P<C
M^W2>1D'\IOV7O^"=WQ:_:4\'?MW>,/AG\:7\$ZS\$]9_X2>[\/"YUS3QXMP?
M'NN_V*S*I"9_X0G7/O, 1KY/16(^V/V8?V/?^"F_[/OCC]J#P=\*?A;XL\.Z
M?XSOO%2:SX@7_BG--O?#.@^-,LO@G7/$'.NGQ6/^1)'A;;_PF3'Q,I \"L%/
MK7[.O["W_!2SX,Z-^U?H?@#X=:C:ZQ\93_8GBX^(O'NB^&M,U\X)QH6N?\)(
M/^$A.W6]=/\ PE'/&O>)_ _0$@ M_P#!,SXP?&CXF_L5_MQ?![Q)\8/&MO;_
M  F_9^\4:MX1/A^]?3?$N@:D=#\0>(EUO0];7PR8]WBN6/6!XU;PP4"GQ"5C
M?S77QA)Y%^R#'_P4=\1?L4Z]XQ_9U^(OQ0\?#X.:/_PC%W\*_#_CU=,\2^+-
M6UXKK>M+X'T-B/#7_"2^%R^WQH%!!Y7P&1X];QB'Z7]E[]E#_@H;^SKK'[0W
M@'7?@'X_GU']H3P?J?PSU74[0:1XB\/-IGCI-#D"CQEX>\2#X;:"^R/Q!X9\
M;^)/^$M9O!8UQ_\ A D\';6QR7P#_9&_X*1?LU+J^A^$?AG\<O"<VE6NH_;#
MX*UC5R+]_,&@1Z+H>N:#D>('\S;Y??\ X0X#QROS8H ^8?@_\?KCP?\ %_X4
M>'/VK]=\?? GXP^#?BGX8UKQ?X4NQ_:?Q+&J_P#":<?V'K?B#'AGP_XB'AS7
M.GBPCICQZ1UK^^;1=3@UK2;+4["]T_4;74+5+JTU+2[G[;IMXC# DAE7 >-N
MF%)P0RY5E*C^)CP[_P $SOV^_P!LO]I6P\5_'[X<ZW\'?# \7Z5K?CSX@:J5
MTQM0W:U_;OCC6=#T-F7Q-X@/B\@A?"[%5+?\CZW&1_:#X!\'Z;\/O G@_P"'
MVBW&H76C^!O"?ASP=I-WK%Z]_JUUIGAW2+?0;;^U=7;_ %FLLL.9Y%<;ISNC
M"K(Z1 '\[/\ P5R^(%_^T]^T-\)/V /A[X;&M^-]!\2Z=XVN[F;7VTTWVH:W
MX-?Q NB!-=;POX:ET)O#CNQ9/%ZM(6 $*N"#^3G[:'[,'Q9_X)??MZ_LP_M7
MWL&AZW\(-(TG2]7?5/#U[J[:=>>*O @\/MK>B:]M;PEM+^(&T"10V&\:)(K,
MHS_PA5?L7^S-^R'^U9>?\%%M9^.OQO\ A:NA>&- \8>*=:TGQ5?ZKH_B34_^
M$4UO1_$(\$#1-:/B3Q8WB#Q"_B&/1QXS;D>#0IE1?"2>*R#]"?\ !:C]BCXK
M_MQ?L[^$/ 'PK\#:+XT\2:'XT;6]0M+SQA'X;\26.G.5VC07U[7X?ADZH,0^
M+SXM!E-ND?\ PA9^T%D !A?\%7_VF?%^K?\ !*C_ (7A^SSXSF\'VWQ8M/AF
M]WJNDW:ZAJI\#^/-(9O$7A!=94%?^$CF,I\-22!@[,[!QN9@/P=^+4_BO]KG
M]DS]GGX+?#KXW_',?&VYL=3^Q:5=VNM?\(/8-_;6A_V)X*\$:%X? \3:_P"(
M O\ ;6TAB23X9R%"@GN/C)X<^.O[+7_!/?5OV,/VH+*Y\)V^@^(_#'C/P#I5
MUXET?QKJ+:4QUW0B=#UOP]XD"^(L^(U!3PP03M/B<^.F"N<_*'P?_;>^-/[,
M?ASPOJOP!\'?"[6_BAI?@[5-%T?5O%FC_P!I:9H.J:[_ - /_H7_ !%_PCF.
MW_,?_P"A#H WOVXO^">GQW^!'PQ_8B3XM_%/Q-:ZS\3=8U+PQXQ\$G5]9_LK
MPI_8@T _VUK6O>'O^*7_ .$B\6?VX0R9#K@$J$\*>,&?OOVWOV&OC%_P33^&
M/@[XN^ ?C9XZ^)FD_&[Q>FBZWXGT(+XD\$QNVA>'F\#ZLVO:XTD,A\4%M<C=
MX/"DT/\ PAWAWPVGP_D8H:W/B:O_  47_P""G@^&WC#XI_".X75_ 5WJ=CHP
M^'?AKQB-+ T$ #61_P (\/%V/^*BUP8\4=@!QCBOWV^-'_!.ZX_;8_X)_?"S
MX5^.O%WQ ^'WQ;\)?#C0U\,WVN%-.TK0?$^D"5M$TGQO\+_^$>/A;0$CB$?A
MQ_%'A;P=#XR\%PN/(>YF\*QVS '\U,/[%O[=O[1/P1\#_%.'P?X_\-^%_AA>
MZIXS%WI/B36?#?V Z%HA.O:U_8?'_"0$@'L3@$UY]\0?VK/VK?&GQ,A_8UO?
MB7XUUG2/!^CZ5?\ AV\'CP>(]-;51HGA]=<.B^"/$'.@$>&M; \#GKX*"@?\
M(/\ \5;BOT_^"O\ P2#_ ."E7A_Q;X&^"WCKXD:9IG[,_@[6M)N;SQ9I/Q(.
MIB^TY@#K:Z+X(\/CPB-=+Y55_P"$N\( ,VAH@^9T\9M[3_P4J_X(9Z#J_P /
MK[XZ_LD^+OC1J_[0FA:KI4EYX5F\6O?IXO\ "C:WH>@:UI.A)X \.>%?$ZZ[
MX7"$P2&5DG"R-XX9U0F@#X1T?_@G7^T+^S>?BAKGQ;_L[P!<:I\*_'E[X/N]
M6\8:-_I_]A:+_;W_ !(_^*DQX@\1?\)'KFAGH?&O_":?\5SU_P"$SKP/]@;_
M ()QZY^U7^QO^U9\6]=^-UYKOB?X9^-/B?JWVW5 -3U+6SHFB-K^N:._((3Q
M;X?&M1@J&(>12PV;G7]5_ O_  3J_;K^*/P/\8W/Q.U77C?+X"\4>&/"'@CQ
MKX@DL/$WB#.L:!H@T1!KOB)SX#\/-X;_ +<51XHW,[Z#X6C4'P.RJ?I[]A7_
M ()J?&;X)_LY?M._L[>*=!L?!7AGXS6^J^,-'_MCQ;H]\/\ A: U43>!F!\"
MGQ4-#\-A-&4>./(\TA_^$<3P$NZ&?R@#^>[X;?LWS_\ #$?QX\8Z5\3?LVH?
M#GQYX7LKS2;O6/[-\3?V7XZ_XD/_ !(O^$@SC_D!Z'Z?\47_ ,4-QV[_ ,2?
MM6_M)?#W]@:Y^"/@;QO<:CX!M;O2K'6;S[7_ &D="TI22-$T0^(.?#_AQ?$A
M; Z Z$3U)K]QO!'_  1I\11_LE?&SX$>(O&/A_1];^(_CSPOXETJY%I!?:5=
MKX'T?7CHMQ/K>D-!(B^(O$/C1S*J^$O,5- EW6\C^*QY?IGPS_X(@_L]0?LD
M>/\ ]E[XT6[>+=0\8ZL=0TGXF^'_ !#K.F^.- 0:0%T,Z)KK-&4/A+Q'KFNL
MN<CQNB>'/^$Z21@  #\-/ G_  3<_:8_:#_9_P# WQFLKG3--\,^&+OQ3KGB
M*Y\/>,/!W@KQ18Z3X$/A_P =:)KFMC7_ !(3X 7Q5X>9?%'@L@?\)GX(\9LO
MCIL> CX+)^:?AO\ LTV/BK]M?]G_ , :I\1?$AU#Q1K'_"%WEU=ZQK/B33/[
M*UW^P#C7-#)QG)QSC_A-/^*8\<Y K]:OV1_^#?OXM_"KQ_XM?XI?'O7H/ T'
MAM=&\'W>E>.=<\9ZKKFHG5WD+'P^5\(>'= T +K) A2-IO,*!T12SI^BGA#_
M ((Z_#GP1^U1X)^-,/B_Q'K?@'P2RZU;Z7J_B76AXS'B8$'2-'$^@JL9\.Q>
M(1H_B@J=K>8A5E53NH _GIL_!.N?LN_M:?&#X$?\)3K>M^%_^$DU3X>^)+J\
M_MG_ (KS_B=?V\!KNA\C_F!Z)XH_[@'ABOL7_@BQH7AW2_\ @J%^TE<P?9?[
M17PSJUG\SF^U'IH)^9\':.,E@#MZXXK]-?B+_P $;])^(O[76N?M!ZM\1G?P
MSXH\7:IXR\268O-;L-4L6UK61KK:)HNC,\GA@'< I\5R2GYN'\%DY)W?V;O^
M"4S?LX_M\>*OVG/#'CZZUGP5K[WZ6NEZO=37_B-4D\&#0I='U>98BK2)KNN2
M&)@2@\)>'XHI60N!0!^@?[>YLS^QE^TK]NTNXUNW_P"%.>.BVDVNK-I3:@/[
M%D"J-6.##@X.X[LC<NW(##^1K]@K]H(_ _\ 8;_:=TSPWX?T\>/O'7AOQ5X8
M\.ZG97B_VCX&\+Z&-?&N:+HN5+'_ (2KJH5O!@R?^$Z(.!C^TSXT?#G3_C!\
M*?'7PMU2]N-/L/'GAK5_"UWJUD%#6(U?29%.K #:,1L=H);&6Y(!-?AU^S]_
MP0Z\#_#;Q%XRT+XA^([KQ+\*]4LM6&B_V3XNUJP\27VKZYJ^\:RQ!1/#V000
M'D\6[L[0X)! !\6_\$K/#7P\^.7_  2B_:Q\9>+]%\/6WCVVM/B#HDGBK56B
M\1>(]"TO0]"_M_P$7T'Q$C>'M!=64;/$\;QIXS#2/*24C5O<O^#>;Q_J=GIO
MQF^#5B+_ %'PII%VWB1+[6+P:CJG]IR:VF8]V"P23P_K418*069(R<E0*]]\
M+_\ !%W1_A3<>)?"'P'\?0>&O@Q\2;)[+QCX<\0WGC!]3CT[676*6&32(V>W
MUZ:/0F,1C$W@\NZ2"(^$1$Q'Z<?LB_L9?";]CCP=K'A7X:2ZS=3ZZVE?\)'J
MFNWQEDU#4]&TH1QS8"KM386=\;\+N&[Y&W 'V?1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %,D^XWTI]% 'XS_\%#_^"82?MI_$/X;_ !C^'OQ M_AE\5_A
MQI?BO0+#Q+JUGJ5Z+4:P(UTO7O#\ F,T.O65UHSV-Q!=)'X8\6>%=8EBEB;$
M<LVS\2/V ?C9\=;?X#CXR_M!MKM]\+-8TB]\2:I9>&M$34=;0Z28]?.AM)X<
M2-?$%OAF\&^)0V^)-<\4)X[B\9LT:-^O]% 'Y/?MH_L >,OVIOVA/@5\:?#7
MQ)T+X;0_!VTTHW%S_P (YK6I>.-4U0^,TUN-M%UZ+Q'X7/AY?"7R>)/!DF',
M?C!1*ZJGRK^I6F64FGZ;964][<ZC-;VGV9[V[VB_O&4<NY)&'."6^@/&-QUZ
M* /Y_OVU/^"+]Y\:/V@/!_[67[)7QDNOV9/CSIWCY_B%XPNC9*/#'B+Q(\GA
M\G6X_P"P%C\1Z)K?B>/28U\<,AE/C1,([^$YCND\[^$?_!#GQUI'[4VE_M&?
M&3]IOQ%XT\-ZGXC/C+XB_"F2YUOQ-'XJ\5LF5>3QKX@>(M&GB,AG \)H6\$@
M^ U=7QXUK^D6B@#^4[XZ_P#!OQ\9=5_:9^('QL_9>_;*NO@WX&^*&M:?=WOP
M^M?#6M^&-1\!Z9%NWZ-H6O:*OBD^(8_"H4MX#?;X-7PC%CP=#OMBLQ_7_P#9
M0_85\0? 3X9>-_AK\4?CKXL^/UU\1/A;X9^&7B7Q=?:(W@C4M/TO0M$\0>'W
MTGP\H\1>+CHOAU?#_B")/!GAE66+P6-%DQ,S^*98Q^F5% 'Y!_L;?\$I/AC^
MRM\+_B#\'?$7BBU^.O@+XEZ#J&B^*-"\6>#%L#>/)XOUS73*5G\1^*=N$GT>
M.412;W\6:$WC:*47$ABC_+"[_P"#=;XO>$/'NK7OP*_;Y\=?#3X6W?B_5?%&
MD^"W\-ZIJ C;7IEUC58Y(SXI_P"$>66[9B?&'B01,_C0J8YU@N"D3?UET4 ?
MS_:7_P $,O""_$[2OB+XN_:*^(GB^\M-9^W:Q92>%-'TG4-<TC^QI?\ B4R:
M]_PD#.NO_P#"0ZNX'BE(G)\' ^!L"(&8?2'[6'_!*_P+^U1\</#WQXUOXJ>,
M_#7B;0O#.G^&)])M-(T?4-(U#9'XATA-9S&OA8)KHCUI@TA&U?+ 2,AT6OUQ
MHH _!30_^"*GA^PD\+75]^U#\9=:NM"LM.LKRSN]/FT[PU>F.29';2-#.OA/
M#,$GAR+_ (1FT\.^%W5/"ZEC""%!?L+O_@BC^SG??LO?$+]G>;5-5M=?\<ZQ
MXLUD?&K2?#D&F^.-%.MR%$T<:0)&AU_P_/X;"^&O%\;31MXSCE7[2L<C;8?V
M[HH _FL_9U_X-V_ W[/7BL>(+']KWXU>-M(M8RVC>$?&WA[1M3\.V&J9 &MZ
MXG_"1_\ %0:^3D>82H##&WG(_I&$$R6ODB;SY@.)[A<Y)/4A1U ]./4]JNT4
M ?DFG_!(?]E+3OVD=2_:4T?3_%6A:_KNKRZ[XET#2M:*Z9>:EK']M'7UD8*_
MB >'_$QDT:*?PPERZ>9#N7&^2.W]%^$7_!-#]G3X-_'WXO?M$Z/H^L:SXZ^,
MND?V/XDO/$-Z-2U2Q36=''A_7MNLDDE6T +$QP!M9MC[C&3^D]% 'Y@> ?\
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MR^NX=7;3=8TK6UBD.BSG1I%D!&N:5%,Q^;",=V"8O-_1SX,^"+SX:_#7P)X
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MO#*R>'XBB-&B:M+)++%M0O\ O-']Q?I3Z* *LL$,W^NASCU_Q!Q_,T[R8?\
MGC_XZ?\ &LS4M1L-&LKC4]5O+6QTVRM;RZN[V[N18V5E81[6+RN0%&U-OSG#
M [BIW%%/S9^SY^V=^S5^U</$G_#/?Q9\.?$T>#[M;'Q(^D6NMZ>NF322ZM$D
M<JZWHENS%FTB4_)NCQ&69U8)'( ?5?EI_=%)Y47]Q?RJ2B@"OY,/_/'_ ,=/
M^-'DP_\ /'_QT_XU8HH K^3#_P \?_'3_C1Y,/\ SQ_\=/\ C5BB@"OY,/\
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MX5!#>0S?=./K],U:H K^5#Z?H?\ "CR8?^>/_CI_QHFF\K_/\_;IVKQ/Q?\
M'7X/^ O&O@_X<^-OB'X7\+>-_')!\(^'/$.L-8:GK[PW7]F;84F?RR6?*6RR
M2JOB"1=MNY0-0![CL'J?T_PH\M/[HKQ3X=_'#X4?%Z3Q2?AWXXT7Q</!^L-H
M'B0Z(\[BSO5V,DF[RU&J:)YTSI#XAM//\,73Q:R1=ND$WE>R1W<,LIA!^8#/
M/?']>_>@"?RT_NBC8/4_I_A3Z* "F;!ZG]/\*BFF\K_/\_;IVKGM>\2:1X9T
M35O$&NWZ:;I&@Z3JNKZKJ5T%1+'2]!1Y-9U-MH;"QQ@M@+R ' P=I .@,4$P
MSC\ <<=/?_)]ZLU\I_LS?M@_ O\ :Z\.:_XI^!7BRZ\3Z5X7U?\ L/6EOM$U
M7P_?V6IDSHL;0Z['&2,Z3JQ.,@K#ABI!DE^I(9O-_P _YXZ]J +%%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4R3[C?2GU5NO\ 4S_[J_S% '%7?CGPU;>)
MM/\ !MQXBT6V\3ZE9F]L_#UWK&F+J]]IX^\R:0661@0<*Z?>!P&*G%?.7C;]
MLKX0?#_]I_X:?LH^(;R[M_B%\4-$U/6M&NUT_=X;T[[.6>#0]5U=LHNO>)GY
MMX@NWH269F9_Y@_VWI_VFIO^#@/]G_PYX.^*GB3PWI_C*\TOPO9Z3=V>C?\
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M ?NE17\=GPT3_@LK^SG\6/#/P]\+>./%_P 6?!WBOP;X%T/6?'&IZ4_Q$?0
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MEM?V,/!W[27B/Q=\+O$'BGQCX$-[X>M+T^'/$]_I9UPZ'H>M9))'B$$_*O\
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M"HVI^#Y[']OS64\3>!+8:U_PKW5_$FL+J1T[1O&_]@>.AKFA^'\#P_\ $9]
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M)P3X,\:'0AX%51XZ\(>-2O[8?\%1_P!GCQ?^T_\ L;?$WX:^!?&P\!>)M/\
M[,\?V=^G]MR:9KC>!0\NKZ'KVN>'$;Q/'#Y2R-YGAAHO%PDT**.#S#,%3\4?
M^#9WQY\/O!GPT^.WPI\4^.[>P^)NL?&OQ5?Z?X4UW6M'TJ;Q!_8)71==U30=
M'&A6_B?^WII=6A\Z&206\X18_!*^7_PF;* >^_&?_@C]\>_"G@6?Q=\"?COX
MP\:_$G0O$O\ ;'AOP1_PD6M^&QKFF:]H6@:)K@T7QUK_ (C(\/>(&&A%1)DQ
M'P<##O\ -*HWZC?%;]M#X1_L*_"7X1:1^T5XNFC\>W/POT_[7:66-4U/4]5\
M$>#-_B+7=<QC9X>,^C2K)XG8$LRESC=BOLGXJ?&#X:?![PGJ_C'XF>+]&\)^
M'M#M#>7U[JU\-."!0<<L5;YCT"AL$Y; &3_&)^Q1\0O _P ;/^"I_@_5?VA-
M<'BZ#Q1=^*;WP==_$XZUXC\,:AIG_"%Z_H.A>"CH>OC_ )%PGGP1_P )8#_U
M/H/CP^#* /Z6?V9O^"HO[)'[5?A?Q=XQ^'?Q%@T[1O!EM%>ZPGB&:72M32-=
M,$NMF/0?-'B)/LY9F"B(A[=%\6;?)(%?(=Y_P<2_\$[K30O'VN'Q'\1+FW\"
M7K6DML/!TJMKS&,+B(>:1$&F'GGEE7P>!X\"-X+<W*_F5\6?"?P]_9__ ."\
M?[*7@C]G72+A/@OKOA/3= ^+G@GPIX/U[QMX(T35(M9$>C:0\?@2#Q*5'VA9
MO$T1\4A_%_A+Q8OB&Z\<2_\ " 7'@M(V?\$9/AK^SEXE^(W_  5=;Q]X5\*>
M-_ &D_&/Q0UE]IM7\1ZE_P ('H>L>(?'.A?\(5K2LHD4#12VSPMN4>-?#X?P
M /\ A!TC( /T]U+_ (.&_P#@G1X;\'>"O%/B3Q[XEM[SQ39?VW<>$O#_ (<D
M\2:MH%@9/-T5Y3'(B31^+B(U\$0[%/C91<GP5)<_\(_/M^@M'_X*\?L<2_LN
M']J_Q!\2KK0?AN-'&MWD>E:3JWBG5GTM]7BCT5]"AT2V:/6)/$XU.%H8;<IX
MF:;_ (HV2U/CQ!"?Y\/^":_PH^!MW'_P5<^(=G\./AWXN@A\:>)]#\,6OQ5\
M,>$OB5J.GOK:>!)O[%EU_P -J5\-1E8B"_A@I"[LGC+P&S2>%_%\<G$?LR^%
MOA9J_P#P3H_X*R6]]H5MXEM]#O\ PP-'M=6\2>#]2TS3_"_CKQB^AZZ3H85E
M\/YV@>-_^$6VKXT\%D>!O +?\)__ ,)@K 'ZWZ5_P<V?\$Z-:\'Z;XKB\2>+
M+>;79+[^R-'UO1SH>Z.W;STUI=:DPD.B?V((RTY6:0^,=93P0&6<I+#]^_$/
M_@JC^R/\./A%\(_C'?>-]0U[2?C!I&H7OAK0]$T4R^)]#TCPYI8D\:ZOX]T/
MS0_@;0/!OB!]'\+>+IIF=H/'>O\ AGP>5DD8[OQN^$W[//[(7C3_ ((=:O:7
MO@?X=W&L>$?!J>(])NO!.L>$_AW\2+'QUX?T/2-$T#;XU^(#>1;N/#S'PNWA
MW&9O!.SP!+N\>KXJ*?B-X#UC2O ?A?X#P>,(+G_1?[*_X4_=_8\:9KW]A?\
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MACPY\,K#X3:;X?N=9\!WMV=*UC1--U+PIX7(\/G0?!FM:XI)\0 $[?\ A%F
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M3PG9W>A?VD-+1FU]=:R%\T^'F\QN/"CGQ@H'RJO@5G+ '[(?\%H?C/=>"O\
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MRJ$PZ+_FN?$WP?8?!_6?^%M_LO:KXD\$ZA:^/-+OM'\/?\@W4]!U3_A--?\
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M=-US^PP1KAT+7&#*?$2Y_B5AX+/!!'% '[$Z9_P</_M$?$/]J7XN?LM_!O\
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M#?:G[*?[5%G^U5#X^\2^'/!.L>'/!'ACQ$-&T#Q+JUS'?CQ8QEU4SJL(A?\
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MQ!HYT[4O^$8Q_;VA:(I\0@'0 /#O]B?\(/XJ('_"&#!P#D5^BO[>?P>^+O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@HT@(D_X2./S=$?_ (2>;$:K+N\:\M<U_4A3/+3^Z* /RG_X)&_#+XB_"/\
M8ZT+PG\3_!_BOP'X@'BWQ!KZ>'O&EA-IFJ:=8:QI>BN6.E:Z_P#PD>B O'JP
M6W\3J)497\SS$FC5?RD_X+=_L8?M2:=\2+[]OO\ 9IF\6^/&\,>&O"^D^/\
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M>)/!NI>)M?TO^VO#^@#1?[#_ .$D_P"$8_X2+_A'!_R-/.?!8/7QX*_N8HH
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M>L/K$LGB#$:^)!H6ASHOB5N95'_"$Q8/BB4C]JZR-1TZPU2UFL-3LK?4;*Z
MWVEY9B_LC@8^:-D(.>3SC&?EQDY /YWOV2/'NI_\%+OV^?#O[>/@?PCJNB?L
MY?!3PCXH^#6B_P#"R_#2Z?K&H^)HVUUF.B #+:ZGB'7$\2.Q!?P8A1 [3O'O
M_HP@[_C_ $K.TO2=)T6T%CH^F6&FV8S<+;Z;9Q6%CN;!SL@41@G )PO0 D8K
M9H \/^-_P.^&_P"T/\.O$'PL^*_A^+Q%X.\3VZF]M79K-K74$,O]EZKI,C+N
MAUV!I T<N\^6X"R+M;RI/SP^$W_!&#]B3X%_$7P/X\\!^#O%P7P*VK_V+X8U
M_P 7S^)_"@OM:5%,LND:Y"\4;&>:+Q*(F=2?%>@>'+P.!;WEOXH_7^B@#XI_
M:Y_86_9R_;A^'D'P^^/7A>XUW2;6Z%]I.JZ%>C2?$FGD&0MI>E:]&CNN@RG+
M2^'V0Q,8\@(<EO-?V0O^"8O[-'[%>N:UXI^$@\<ZOXAUVW2U75_B%XATWQ/J
M&AJ+?^R$709%T"V_L<KH2_\ "/2^4626T1[=XPTC2+^D%% 'DOQ4^%7@;XQ>
M!?$'PR^(FC'Q'X*\46.GV^L^'FU;6-.74DBU5-857UK19H/$*?O],BE8PSQ"
M01! PWN4^&M,_P"".'_!-71K#Q!I6F?LJ^$].T[Q2!_PD.EVGB3XD+IU_P <
M[A_PE !)X^X%[@*.*_3;SH?,QGYNF<=_IU]_Z9I?.A_Y[?\ CQ_PH _.KPW_
M ,$I_P#@G[X3TCQCX;T;]EWP4/#WCS21X;\2:3>ZOXP\0Z7>Z0H!91I/B#Q%
M+%H0+#:/^$8%LY!R& ''<?"[_@GA^QO\&M \;>$/AU\!?"^A>$/B1X6?PKXW
M\-7DFN>)=*U_PW/*KZSI-S_PD>L^)95_X29(=(A\8Q1S1#Q?%H7AJ2]-S+X;
MLVMON6B@#\OO"O\ P1P_X)K>"=1&M^&OV7M$T[5/M?V[[7+\0/C!J$AU \>:
MHUKXB3HQ)^Z-@5NF%Q@_4NM?LH?L\Z[\.M1^$^M_"7PQJG@'4FUJXF\/W=D&
M2UDUZUCT35TT75U$7B#P^DOA]6\,^;X<N+%X_"X%G',(YP'^G** /@?]G'_@
MG/\ LJ?LLWT^L_"3P/J-MK;_ -K+9:OKGB76-4%AIFLA5GT+2=%$Z>%H-#1V
MF*11^%W91JDK"=VS&N#%_P $O?V'X-6U_4Y/@9IL4FNZOJ&H^39^(O&&FZ;8
MPZGHJ:'=:-I>D:-KUO;PZ',_G>(VMU7*^*-7GNXI(I7$=O\ HM10!\#_ /#L
MO]AK^S-9TK_A0>E_V?K]X=0U>U_X2_XD;;V_Z[W!\5AB."-RD#KE.!CG-._X
M)9?L%Z;HUKH=C^SUH5KI=L1=?V3'XJ^)C:?<,LGEL=4A/BMCK6[.7-TS?\)(
MRM]J66)6D7]&Z* /SST[_@EM^P1I/AZ?PK8_LY^$5T"XO=,U"[L9]6\7Z@)+
M[2-5.MQ&3SO$4K!TGR08V3/"NC\*<_4O^"5O_!/K5-+U'1+W]FCP/_9&IW>L
M75Y:6FH^-=-A,VNR0QZP@DT;Q+;!MS:9'Y0$B_\ ".!/,M3"A*O^CE% 'P%I
M7_!,[]A72?#/B'P7;?LU>"W\)^*2JZQI.J7_ (LU6%QLRSVYUKQ%+)H(W?+_
M ,4V]N,G/ XK0TO_ ()R?L5:1X<UKP?IGP,\.6OA?Q(;,ZWX=&L>+[W3+]%T
MK7=%B#K+XA9ABWUW6$:0.!B5W*JWEM']VTS>/0_I_C0!\G?!_P#8K_9;_9[L
M/$NE?!WX*>%/"6G^,=)7PYXEM =9\0KX@TD%RN@ZV?$<_B4G0F 7>DA,0'WT
M((#<!X$_X)K_ +$OPQ^+.G_'#P%\!M \)_%;3+DW]IXJT;6?&=AC4"#\PT7_
M (2,^''SU51:D$Y4G&6K[J^U6_\ SW'Y?_8U-O'H?T_QH \+^-'[.WP6_:#\
M+R>#OC)\-O#7Q%T"2UFMQ;^(=.S?V)VJQ?1M<B:/Q!H!D*X$GAVXMY"<C=C.
M?G?X'_\ !.K]D/\ 9WU5-<^&?P>TRWU*S\01ZQX>EUJZU+Q/_P (E+'L&D)I
M*:O<-*+CP[+YVNV_B7Q!#=>-(KG69F_X32Y7RX3][SS018\XX_#_ #_DTD4\
M,WW<9].G'X<4 2QQB,8'^?8=\5\4?%C_ ()\_L??'+QF?B)\5?@IHGB[QE]K
MTR_&M/K'B[3)O[1T<MY,C+H'B"WC0H>-AB;[NQBS;B?MNB@#YKNOV6/@/<_"
M;4/@&?AW86/PHU>+2CJ?A/1]1UKP^=:306TEH3K6JZ%K=MKVLM_Q)])2222=
MG=+>".:20[2OGEC^P'^QUIO@R'P79? /P-!H%OHHTB.T U?^TMO]HKK^XZUY
MO_"2'7_M +CQ2;O_ (3 1D#[9T%?:]5_.A_Y[?\ CQ_PH ^>O#7[+OP%\$_#
M.;X0>'OACX;_ .%8W%]_;#>$=6_M3Q/I1U8X+:GM\27'B0B8@*48X"]]P)%>
M$:;_ ,$SOV%-)U&XNM._9M^'MM+>:U_;MQYD6OW;-J/DE3;N\FO.@T+S ]X/
M#  \(GQ@J^,_L9\:YOG^_/-A]?U/^-'FP^OZG_&@#SS6OAI\/_$'@:[^&>O>
M%= UCX?76C+X;O/!=[9+?>'3H\;1KINER:.P*>6D?E #:APGW@/+9/"_@M^P
M_P#LF_L_6FO6'P@^!7@'P9#XHT34?#7BEK#1_M>H>*/#NM,)-:T/7-6UUY[G
M7=!GWQ[X))9(VC7802SQR?744L4H)C8$#T&*EH ^9_@O^R5^SC^SZ8I?A'\&
MO!7@:ZMXKRTMM4TJR^WZK963$%HO[=UMKC7@K[=K(EU*H!*L[1G>?IBBB@#Y
M0^+_ .Q;^S'\>O%>B>._B[\&?"7C7QCH-LUC:>(-8MI(-6^P?V1K>D-$)M'G
MB9T:'7+@8;F-2FS8L2QOK^!/V2OV<?AE_P ) / /P9^'_AS_ (2OPQJG@_Q&
M=/\ #L:'7?"^N,IU?P_J_F%A-X?FSAO#I*P,$("J6;;],44 ?-_PY_93_9]^
M$'BR_P#''PX^%GAWP?XHU/2AHMYJFC_VEODTP?\ +'+NZ@D?>QM;'W77K7F7
MC/\ 8'_8]^)/C_5/BKXS_9\^'6M?$'7ETZ[U7Q6FFOIVHWKIKTVLFYE;0IX_
M^)YN6,W&N1_Z3XEDS'<7#JV]/MVB@#(MM.L;*TM[*Q@@MK&VM#:6MI;J@L;1
M5!P J[0 ,A1A0>#G#-FOGKQ]^R-^S9\4?%NH>-_B+\(/"'BWQCJ=KI5I?:_K
M5B+[4[N+06B_L?>Y(7,,>EQLN "=NQMS%F'TY10!\9>%?V"?V2/!&I?VSX<^
M"GAV#4TOM(U:WEO-3U_7ULM3T,?\2::%=>UZX!9"?D1CL=@59U7#5Y+_ ,%1
M?VFOB=^R1^R7XQ^,7P@\ :WXV\=GQ#X8\$V5UX?TD:G'X)7Q%K!W^,=?C)Y\
M/IL'AD,01_PF'B+PT@ZO7Z3U4E%G)Q-Y#?[Q4_KP?\* /YKO^"5_PK_:D^/O
MQ6\/?MN_'J^N4;28_'&C:)J7C)GN_$OBG2$TG7? $6AZ'HT7AZ(1CPLP\OQC
MXC,D7VCQHKQ*?&4:S-'_ $LQ_<7Z5%YL/K^I_P :/.A_Y[?^/'_"@!)8(9OO
M8SZ]./QXKS*/X4?"V"Q\9:9_P@/@U=(\>:IJ6L^/=,/AW2#IOC'5M8S)K.K>
M-8O):'Q%+.K2&1_$44KX38 66 IZ;]KA]3^0_P :LT ?$J?\$^OV.[?QOX@^
M) ^!/@]/$_B9=VMW/DR6NG/DXPFAQ2)X=&.C$V[<],\5]5>%_!GA?P1X=T?P
MKX/TFT\.>%] LA8Z1H6DJ;#3;&P!R$6-?FVKRP)8$9(]6/844 <1I7@SPII&
MAR^&-$\-Z1H/AQK/4K-O#^D6&G:7I#1ZPY.KQKI6CI' I<,0ZH%R9&')Q)4?
M@+X?>$/AEX2T;P/X&T2U\.>&-!M!9:/I5FI"V*G/"\MST.<G)[8.*[/S8?7]
M3_C1YL/K^I_QH _/S4O^"8/["NK>.8_B-JW[-_A/4_&%I_91CO;S6O& TXC1
MM;_MB!?["77_ /A' Q95GNR]H!XM,C0^,TO0@8?H#%"81U,W;)QD?S_3GGFA
M;JWD^[,..>#C^E.\V'U_4_XT >5?%OX*_"OXZ^ ==^&7Q@\%Z)X^\!>)82NK
M>'/$5H\^FR@1JP*J<2:65QNW(Z/EF!)9F5N+^!W[+_P-_9IT[7=%^!_P]T_P
M%IGB:_76-:L+#5M;U.._E02#<RZ]JUS(H)=Y3NFVI-JFKA"JW$OF?2-% 'F]
MQ\,_ -YXYT[XF7?A?1;CX@Z5X='AG2O%T]FMWXBT[P\6UR8Z1I6KN1-#$[:Y
MK1D2-V:1+F3S58,'KO\ [)#Z'\Q_A5FB@#S7Q#\-_ ?BS6?#WB/Q+X+\-^(M
M<\(W+:AX1U?6O#^EZEJGA'4W6$2:KH$FKQR2:'*6TC2Y(I;4QR;X$QC+L(KC
MX;^!+A/#MC<>"?"ES9^#[CPU=>$;5_#VF&/PH/!C,WAU="@6VV:$_A9-1=?"
MW]@+ ]@&*0R;)93)Z?10!Q,?@OPDOBB?QFGAC0E\976E+I-SXM&CZ5_PDEYH
MZXV:0WB#R'UTZ.DN&6W9RFX)(&(5:\^^-/[/7P9_:'\.?\(I\9?A_HOC_0[6
MZ6[L;?68)$O]/DPVU]$UK19;;7]'&3F1H+B.1P%3@*K+[O10!Y!\)O@M\-O@
MMX1B\%_#'PI;^#_#2W,E\=(M-0UB^ OWV_O#J^MW%SKLA^4%'DF)0%R@4,RO
MZI]E/_/Q/_WT/_B:MT4 ?$W[2W[ G['_ .U[<Z1??M)_!#PW\4]3T&-;'1]3
MN[O7_#FJ"QDRXTI]6\.:_P"&IM5A?YMJRRLJ(JH A4[OH+X2?!KX:? OX<>#
M_A+\)_"NE^"OAUX"T8:'X1\*Z.FS3-%TQ=Q5(E9BQ&2Q&YVP6;:<$E?5Z* /
MG#X^_LM? ?\ :7T;0]%^.?PWTSQ_9>%[Y=:\./>WFK66IZ'J2J%:72-9T&XL
MO$$;="P2;!&#M)^5?0_ OPL\!_#30SX9^'WA'1/".ARW9O6L]!LUL(QJ.V%'
MU.1%)5WD_LG2@N,@^2"0Z8!]$\V'U_4_XTGVN'U/Y#_&@#D?#'@_PIX*T6Q\
M->%- T3PGX>TUBNE>'O#FD:5H.BV0$G]INNCZ-HD$44?S\M$@!.UW"L"2]VQ
MT#2]+A>'3+:/386N]2O6@T[R]/SJ&NZW<:]K6H??9BWB'7"TLH9F$AFD*-B6
M3'0^=#YGV?C.,^W3_(_^M5F@#\@_^"S+>-Y_V(_'WASP+^SMXN_:#UC7]6\/
M64NG>"['2-4U?X=:;%+_ &NOCA-':3_A)3%'_83^%W/A&-IG7Q'K;22PHJQ3
M?&W_  01_9)\:?"KX8?$3QO\>O@UXS^'_P 31X\TZQ\*I\3/ 6K^"M8L=*;P
M8(];U[0M'\0:-;F&/Q(=<D\.W!42.\4$D:%' 63^CWS8?7]3_C5B@#RKXA_"
M?X;?%?P\WA7XE^#O#OCGPPE]I^MC1_$>E1:C86^JZ,[&+5N4.-9C,A"R*RR*
M(@"& D$G$2_LN_L[7^F>"=$O/@S\/;K3OAPS#P)9W/AG2''AZ-2A(T;]WN32
M<. ("6& ,ID\_1E% 'F^A_#OP-X7OKJ_\->$?#.A7]S=:Q<W5UI&D:187CSZ
M[)H/]MEBD8<'Q$?#^@B;;,BNNBZ")%_T9"GF'QZ\2>)OA)\(OBY\3?@_\+T^
M(GQ8M=,36[+POHNG2+JOC/5K=X='TEM<;1K1M>UP^'-"20+;KNGGL-$/AFSN
MT(4Q?2]% '\N/[)_@_\ :._X*??$>7XP?M$:CK.A?"#X>^,],N[#1_$.DHNF
MGQ4R:++KW@SP-H)96T'/AJ+2';Q2@8JNN>')6 \<1RNO]&/Q8^%_A'XS_#?Q
M1\+_ !M'/=>&_&&FO8:C]AN_[/OD!9)EU32]@+QW U5XF0L51G926=&0/Z[1
M0!^;G_!.K]A*S_86\#^/="'B\>+M<^(WB./6M8N+2S_L[P]H>FZ-)K:Z#I&A
MH0"L446N2F0N.?F(4&/+?HU]DA]#^8_PJS10!\M^%?V0/V:? GB9O%_A+X)>
M ?#>O-JW_"4&_P!"T@Z<B^)M@+ZO#HR,- T>; 9D:&!.2% #K\WTYY'O^O\
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M2VTG0M!UGQ;K'CC0!XN\.Z/H$8T1/$*N(DD\*R+YGCNWB:80+_7=X$\%^%_
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MGB\N$QG[MUKQKX1\,26$'B3Q3X=T6^U.2TL[.UU?6-,TZ2]U Y9402N'9R0
M"H:,;<(!D$@':45X1X&_: ^"7CZ7Q-!X/^+7@KQ(?"&J/I.M?9/$>F,-.F4
M@2%+K$D!W$?VV"T4AWD28!8_.WB+_@I5^P[X:\2:OX;\0?M+_#JRUGPS<ZO9
MZO$=1U?^S8I- <1^(1_;,6AMX;UD>&U E\8FUN)3X.!D%T8)0/. /T HKYK^
M"/[5?[/?[2$NO1?!#XJ>&OB/+X8M=*N]>7P[_:3'2QKB%M&74VDB0EIHXVW*
MQ;Y1NPJJV/H>>[@@AEN)IH+:!1C[1.0J_B&*<#G )YQT/- %VBOC7QE^W-^R
MGX#?5+?7/CEX*,^@)8'6+73+QM4%EYA!42:SHV_0!@$_+YP *E&&-JI8U/\
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M5?C=X4NO@I.]C9CQ;HETNIO)JL\PTG^R(]'C?_A)1K@8F,120B4"-2WR[6F
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M_P )V@0LA /Z>*HSS06D,T]Q*(88 ;EWG/"C#$G).0 <@=2#C&<\_G!^Q/\
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MXLN?'>H:EH\;/I>F.#KJZ4FL7$<VO:%)$==#>-/^$:MYHO!; +X&B\;1ED8
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MPATO6="N]1T;6M'U7XH^"]/U30=5TKR_-T75]&G\1^;'K2,6$D3QQ3)L)V*
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ME^&]$N-ZZAJMEX71_':_V0=9#*SHLFBQ1N!E0VC('P61E /ZMZ*** "BBB@
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M'CGP$/\ A Z[#X,?V'\3OVN?V@-<L=<_XD_BCQAX\O;RTM-8_M+3/[4\=?\
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M,']E(:M\#?\ @G[^W_X=U70]2TWQ/KOQW\"CP?:7>DX.G^&-#.NZ"-:"@;=
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MOX?\":/_ ,)-\2+O^VCIVI:#J@T8_P!AC7-"Z>'B/^))X6\$^*>O@LC'7Q:
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MI>J:MK&N^-?$6AZNK*'77!H$3R R/-GP9HGBEOA_,WC<Q ?G+I'P+_X* _\
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MMZ,HV:\V@LJC0&)/_":@GQB/&FUB_@A.-W]=/EI_=%1>5#Z?H?\ "@#\1O\
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M.N:R_BX2SNQB?PRD:1VT/BUG_3[_ ()\_#KX@_"+]BG]G#X6?%O1[?PYX_\
MAUX'B\'>(=)6[&H#3DT!M:T/0UWC(?=X>CT8GD967:0!@G[?GA@EQYPS^/\
MG_(H\F'_ )X_^.G_ !H _E0_X)4_\$Q_VLOV3O\ @I9^T?\ '_XR>%K:[\ ?
M$BV^)=]9_$!?&6E:AJ=]J?CG7= \0J9=$A!98G\EUV^&-L'A,AK63<LI1O(/
MV4_^"+7Q9G_;>_; /[2&C:@/@1\6=:\<7E]XKT&[_LP^//#&OG6VT&+1$9_%
M1CFD\02:#XG02%2K:)XC9D<$(W]AWE0^GZ'_  H\J'T_0_X4 ?P]Q?\ !.G_
M (+G?LKIJ'[,/[*'CRP3]G:[UI]8LM5\ >+QX:T[4-3UK2-"C#ZWKFO>'?"?
MB;04DVCPWXR8,0\6A*_ 8"OZJ_\ @G3\(OBG\!?V+/@+\)/CA_9A^+7@[PYJ
MZ>/!I>LGQ%IX\2ZYXPU[Q%)Y6LXS.3_;,8.T-M)89&PJ/MGRH?3]#_A4W"#O
MU_$F@#\6/^"V'[%?QV_;G_94TWX8? F]\/W6O>'OB!IWC%?"?B"/2]/&MZQ'
M&^AZ'K.C>.-?R/#.O>%H]8USRF*1PLVNC]ZTWAJ)7^?_ -G_ /9@_P""J/P7
M_P""=WC#X.>$_'G@;X??';PUKUB?A=HMOJ^C>)5?PG&VMCQ!X/T37&_XI;X>
MQ^*/-T,>#&("^#?&6B^)69BGBL$?T0^5#Z?H?\*/*A]/T/\ A0!_+W^PS_P1
M[^*^L_'S6OVL_P#@HQ:VWC+XAZ7K>H77ASP/=^)=%\2-=ZE*YUA/$.N:MH+Q
M^&I_#*2:[K;MX1CD66?Q:LO_  F/G^"_)MYN!^"?_!)G]LGX6?\ !2[PA^TO
M?:;X(UOX9:!\:M3UPZ_I'B71/#>GKX!U_P#X2$:VQ\": <CQ"3K;!25QE2.=
MI%?U@_9;?_G@/S_^RI?*A]/T/^% '\UO_!'K]@/]JC]EC]I#XX?%KXW>";;P
MUX0^*&D>.O['-UX[T;5-3L-4UWQKX?\ $#*="\/@@;ET,C/& V1@XKX%_;O_
M ."/W_!0_P"&/[9/B;]I[_@F8VB6VA:MK&K?$X75KXPT7PWJNA>*-:VA]&.A
MZ^ OB$>$2R+X+=?D3P>PC+;BH/\ :7]EM_\ G@/S_P#LJ7RH?3]#_A0!_+!\
M!?\ @F9_P4-_;"\+LW_!5WXM?VG8Z3:*GA'PEI%QI7B9B-<UH/KRHOAOQ!X5
M\-Z)XC1-'+CQ,BL!_P 4USXPPY7X:MO^"9/_  <#?LL^-/&WPB_8B^,NB^'O
MV4=4\6ZI>^'4A^)'@K39(=+UX!GU;1=%UUG\1Z!M( =HY'\7DKE)'7!K^X3R
M8?\ GC_XZ?\ &D^RP^5Y.!MQ^./IZ?Y]J /Y%?V^?^".7[:O[2?[*'[)&B:!
MXOTGQ'\;O@WXT\0>(O'7A/7_ !K/+864GB68ZPG]AZOK<+^&1KJ>(]=1_'TV
M2GBJ'P]X>E\'_P#"4Q6\TGC#R']K'_@B#_P4'_:?^&'PW^-_C+XI>'M2_:V\
M/:3I>B_$'0?^$O72O$GB6_T(:-H.@W&D>.)'3PSK^MG0(&\1[_%*N?\ A#"O
M@PH/&0>X3^TGRH?3]#_A1Y4/I^A_PH _D3U[_@F9_P %'/VP?!/P6_9Y_:\O
MM.T_X0?"_6VT_1M73Q%X/;2M!T[P_H;Z$VL'P5X=4^)->VF-D\%,[*HDQ&6'
M@=E\9'W+XG_\$C/B+I'_  4U_90_:"_9X\%3Z;\%/@,/ MMXFU7QM\3](1;Q
M-$US0-?UI=%T022^)"_B:+18A.R>%2&\:GQ-<!889XQ7]/7DP_\ /'_QT_XT
M>5#Z?H?\* *]GV_X%7S7^UW^SS9?M3?L[?%O]G_4M7_L33_BCX>727U1;=2U
MAJ&DZSH>O:-(!D%D2?1DWGIM)=1E0I^HN$'?K^)-.H _D7_8O_X-Z9]'T+XS
M6/[56I6\MMJMIJ/@SX6Z9I.L:1XBU#04T8C^P?&L;B-UT3P^58LOA9?^*O&T
MB:: ;2?LS_@D#_P2,\8_\$[?B5\9O$7B_P 66>MZ/>C_ (1CP&=)O<G7](_M
MH:\=<UD#C0"<JO\ PB^0J[@QW !&_H4\J'T_0_X4>5#Z?H?\* /Y.?C1_P $
MNOVR+W_@IIXN_:$\$:3X;\0?#CXB_%;POX\T77VU81:9H>F+J^_7/^$S0M_P
MDY7PK$#(%4LWC% R>!MDD<B)]3:O_P $T_VE=6_X+%67[:]EXH\-Z)\(+%M)
MUIM5\/W0\.:G_9>A:2V@:Q\-=9T0%O$DGB+Q:R;O&?BE"_@[QEX-U[8RK,K1
MC^B#R8?^>/\ XZ?\:/)A_P">/_CI_P : /P!\<?\$P?B=XS_ ."UNC_MZ1:G
MH-M\+;?X=^"+O5;F:^B;49?%/@9VT5?!Z:%O3Q*#)!HFA7A\1M(?"0BW@-,Z
M-X/?]]OLG_3;]?\ Z]7?+3^Z*?0!_)C\6_\ @EK^W#\/O^"@R_M._LSQZ7<Q
M^&[K6-<\,ZY;>.]&\-2OJ'C9M;CED'A[Q#CPVT<;S:N/'?AK;L\9"6-F8+(A
M/MVD?\$G/C-^V'\2?B'\8O\ @H!-IGAG7;RSCL?#6D^%;GPAXAU)4;14\/JN
MLC0$7PN=!8Z/$GC2(E'\:DN(U\(/&?%[?TL>5#Z?H?\ "D^R0^A_,?X4 ?P^
M^%/^"7'_  7?_93^)WCFV_9!^(/A#1O!6HD:+X=\56?Q(\&-IUYX8T75RRZ,
M_@;Q_DIN0'_A!RVW_A#5( ZBOZG?V"?A]^TM\//@C'9_M=^+[;Q?\<M?\2:A
MXF\1WFG^+M:\3:;IRZWI/AP-H^D-KY\G0(D\0:5KCIX7\+%?!\*M(]N':0J/
MN;RH?3]#_A4D<8C&!_GV'?% 'X%_\%JOV#?VF_VW[G]G'_A2-KX;U#P]\)=<
M\5ZUX@TN[UO2?#WB5]1US1D4,Q\1@>&=:T'?HNAQO;OB194EVAU!:O*_^"AG
M_!,#]I+]KG]BC]C[X2>&+OX=W/Q-_9S70;CQ#HOBR=]0UF\D?1M'T(:3X,\?
M.^S08/#):.'Q<B0JGC'PG%<*)YYO#'@Z#Q5_295?RH?3]#_A0!_%;^T+_P $
M7O\ @IG!\4K76OA)/\+_ !_X9?PUIMGJXN_B.=.TRPU11R=$.OCPEXF4<@98
M@$D 9)%>!6'_  0__P""K&D_'FX^+5UHOPY&C_\ "-W^C#P_X=^+FE-J&H^<
MS! LFO(R:%M"/)X."L3;>+@+BX\J!A(W]ZFP>I_3_"HO*A]/T/\ A0!_-1_P
M2G_X)??M0_LL?"K]K_0?C#<^#= \4?'?PIXE\+^!=-T?Q<GB+2].U/6M#\YM
M9UPZ-X:VZ%%)XAUDP2- LDBC1&*^"8F1I?%N#_P3Y_X)G_ML?L]^ ?V]?"GB
M/4OAU\-[C]I8Z8?#EO=>)/\ A,TO/[>W)K>LZ]N\.^*_[#_X1;P[K?CGPJJH
MLO\ PFC:^DA7P6/"4;U_3KY,/_/'_P =/^-)]DA]#^8_PH _E4_9%_X(;?$N
M;X-_MD^"?VJ/$<&B:E\>+$>&O =KX?U72-1U#PENUI]?7QBNOZ  K2;4T;PT
M40LT:CQ,T@19(B_R+\(_^"8O_!?[]D'3Y_@!^S=\>_"L7[.&EQ^)WTJQT'QS
MX-\-B\U3QV%.O:OHLJ^&_"GQ'\ NA./!2I*__"%D,5)4%J_MF\J'T_0_X4>5
M#Z?H?\* /Y _CQ_P07_:PDT?X!?%3]GSX]^']+_:6\%ZUJ/B7Q=K'B&Z^PZ9
MX'U71?[=UWP*W@76HM[A%9QX5=G5"/&NNOX\8+$!)X/\?^-?_!'K_@M#^V5X
MG^%5C^TQ\=_A;J7A_P  C57M?%7C3Q'HWB75+#>S,3Y?ASX;%BSMN88&9&W$
M?\(>>O\ :YY4/I^A_P */*A]/T/^% '@_P"SSI/CW1O@E\-?#WQ4TZWT[XB^
M%?".E^&/$YM]5'B!+[5O#_\ Q(Y-=$H15D7Q5'H\?B/.2%.L,A<R)*5_EA_X
M*"_\$2?VU?B3^WA\4/VF?V;O'-C<_#_XH6A\2ZS::KXVTOP]XF_X2H:N9!HN
M=<C88\+#Y? OBH#;X/\ ".((RTQ$9_L6\J'T_0_X4>3#_P \?_'3_C0!_%U\
M)/\ @B1_P5<_9V\8Z5XX\'_'SX/:U>V@4:-I?A;Q?J_AO4_"OF#/]L:WK ^'
M/A*4.-VM*R>%_%J,2ZA0V:^C/B1_P1W_ &U?BWH.C^#?B)X]^"^J:;JEYJ=Z
M-5\/ZMXQAT[P(-H=\K<>'8=G_"3J=%\+RKX8\'^+6\8MX<\-^-?'X$B%*_JY
M\J'T_0_X5+L'J?T_PH \'_9U^'NL?"7X$_"3X6ZYJD>N:M\.?AEX&\$WFJQ(
M!IUUJ/A[P_:Z$S:8$T'PT+C2&,(>U/D0R);M' 41E,DGX1_\%'/^"3W[5?[7
M?[?7PM_:>^'GQ0^%^F_#KP%X.AL+/PG\0]6\9Z9J6A:OHY=8QHDGA_PQXKB#
M2R:PWB5<E 9&\2)A6FB5OZ5ZK^5#Z?H?\* /YE_V;_\ @D%\<_"7[87@']H3
MXO>*_!=WH7@+Q?J&M:QI&F>(M=BU.\?2-#W>'=7\%MH2'RI/^$A*M)$Z^#YH
MQHGB(O#F6)9.5_:5_P""+O[6_P </VD?%WQUL_CO\&IKC79[?4!JWB72?%EA
MXHO]4T:30(M'U=M#\.Z%)X:T%O$/AS^V?#5WX:^:()+&T4T[%@G]27DP_P#/
M'_QT_P"-'E0^GZ'_  H _DF^(/\ P1:_;U\>7^MV'CC]J+X8>/$\<QOX1-Q>
MZGXWTHZ)X33P@\>BZ1$3X8"S'PB^A+X9\&+$7=%GMI)%1?#ENWA+>^-G_!O!
MXY^(/[-7P?\ AUX'^/OAKP5\6_A-J^CZUHCW!\:/X;LM7T77&UYM:T7QJD9\
M3+KX'EL)?^$2((9RXC$89_ZN_*A]/T/^%2^6G]T4 ?QP?&#_ (("_P#!2+X\
M>-_A[XX^+?[9OPM\?:QX&&D[?$'B/Q+\2]0\4-_8GW?^)T?AN&!/( (SD$8&
M,5]B_LV?\$1OC/\ ";]MWPE^U#XY^./@#Q;HWAB?3M0NVTFU\:1^-]?U+0E)
MT)M;TG7-WAE,9/SH2ZCYU'0G^E7RH?3]#_A1Y4/I^A_PH _&O_@K?_P3"M_^
M"BGPFT+P[X+N? ?@#XL:#J]W=Z-\5->CUK3M3T/2Y$)\]=3\.J]UK D?S(WC
MG9A&NJE_E/G,_P G_L#?\$A_VOO@9JL'A#]KK]IOPA\??V<+5=4(^"6EZW\2
MM0TM=3_L3^PM#8MX@7PJ@VJ2P)5E+8&-IS7])E5_*A]/T/\ A0!_*5\1_P#@
M@5\;?AU\;OB)K'_!.;]I72/V2O@G\4M(!\2^$&U/XEOXE5]:.[6_!9:)KB'7
M_A]D)/'%XJFDF2(CP85"1R/']3?\$JO^"27QW_X)^?$SQ!XR^(?[0GA+Q_I/
MB>VU3^U=*\*66L:=_;NK:X^%DUS^W= 3*-X@/_"5X$BE_%SX(;?L/]!_E0^G
MZ'_"I?+3^Z* 'T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !17@W[0GQT^'W[-/PF\6?'#XJ:G/H_@'P(FE7/B+5+6PU75IK.PUK6]%T
M"*5=+T='ED?^VM8TQ2I5B8GE?(&6/*? +]JCX+_M/^%;KQ;\%/'ECXUTC3KJ
MWTK5Q9V$]A?Z'J/]CIJ\4;Z9J\$6'V3Q>1KQSX9G==MM-<+;32$ ^I**** .
M!T[PR+3Q5X@\4RZ[JU^^M)I=I::7J=Y'+I7A^PB=DE70XQD(NORJLC_-N\P+
M&I#*ROWU%<)X_P#B%X0^%GA'Q!X\\<ZUI_ASPEX6T?4=:UW5]2N1%#9Z=I";
MI)/FR6P#GC+!F ;DD@ [NBOP,\8?\'&?_!/7P3KUMX=U2W_:&NKNZLOM@O-
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MGP_I.HZWXBU+3=%TG2[+[?JFJ:I>)ING6&GHN-^JZQ.PB3;N)R649^\&W D
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M?A/]IK]GOQYK&G:+X,^-WPF\4:UJ-UJ-G8Z1I?C/1-1U+46AUHZ,G]DJFO2
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M&\"/0<Z/K8\5-O36]:6U3P]DW20*/'/G_P#"#YD;UGP5_P %8+7Q%^W!X/\
MV1/$GA7P_P#:O'-LNIZ+_P (Y+K6H^)K ZUHVN:_HBZTDA\I5\,IH#02\+_P
MFT,T_C;P$Z#PO+X-/Y6_\%';SX=']I7]E\Z5\.M.N_!]K\(?@]>:/JVE> -:
M0\2:%KNW7 0,^'!_Q(U5O%@_X3/P=XR ?QX6\!-N/;_MM>/O#>E?\%I_V9]7
M@L-<N+C2O@K\,D^U6ND#4M3O],UG2/B#K3:,-$^'Q.?#9\.J6\;9 .TC_A!%
M5MR@ _5+]IG_ (*H^&O@-^TKX<_9QM/A]JOB#Q-X@T;4Y=$%Q!K!OKS5=&U?
M1E+0Z-"D3/X:,4YC3Q4V5_X3**+P8$6<O*_QU\%_^"YV@>'_ (M:A\.OVGM$
M@T+4?%'B+Q*O@/2= MI'\;_V7&S/H+C06?'B#P YT?7Q+XN&)/"/C)AX%G=P
MB!?FG]J[XI>"/AW_ ,%ZOV5-3\2::]A ?%_BDWGB.WYT[3M+;X,;AK&656/B
M*/Q%H@3QJ9%/A ^"==!\$,_Q +NW!?MW^-;+X@_\%6/V=OC3\.O!%Q=:!\+[
MP?VR1HYTW4[\Z%U\:C6R25&=<UW:"6\%@''CTGQY_P 470!])_M%_P#!8;X^
M:)\0/'6M^!/ASJ7@#P#\"O$6JCQ-H'C^T_LI[S2]#T)M;.B?$^77 DWAWQ&H
M:0^-/#/A)A)X)+^&RC^,<\?3'C;_ (+5:1X/_9&N/V@[WX2ZM:Z\6>UM=+NX
M93X=;57TB230D,C$R#7?%7B671"GA)9%2+P3KR^-(_&JP@1U_.I^TU^VM_PV
M)!^W->?&'P?=:)?^ E&AV5IH'@;6_#NJZ^- UG^P-<\%Z]HS$MXB\/\ A/&?
M!7BOQ<Q;P8= SX_)\"<GD/!/[1>NZQ^Q1K'P6^'/@#6_$F;/^Q?M?B'X;ZSJ
M6F7^EZ[K?&M:'_PD'7_A%/#G_,K 9\%^-/\ BN? 6/ = 'ZY^.O^"G'_  4%
MM_@O\ /VC=4\,:7X)^&_CS1M5U@77A3^Q_$R^*M1;QEK?AXQZOK3>'"L4?A5
M8H_^$*CC"1>-F7S"I<LQ[?XH_P#!6[]HGP/J?PH^-&L#1/#GPG^*5IJ>BV>E
M"S \-V&QO[#36@VO!2OB*/Q)_;AC<$/'XV \$^.F'@<!J\J^,NN^(_ ?_!''
M]C+X6:'X<N=;\7^,O#7Q.6RTF[\(:WJ.I?\ $A\:>(-?_L37!H!*?\([EB?'
M'AE1_P 5L-!">!#^[4U]B>#/V>8_C]_P1.N_#/Q2^'%MJ?C[P?X!\?\ C;P/
M:6N1J5AXET$:_KNA:[X?UU$DW2>*- \I#%X7,*M'.W@M))&MVB(!]\?M9?M>
M:]X+M_AC/^SAXA\$>/[_ %3Q$J^+]*TF['B/4['2TET1E.N:(KDZ!X? UO6'
M\:DJOC6-CX9:,AF<)ZG\<OV3+']H[Q9X \0>-]3LM-\*^'['3GUC2K31)+#Q
M,Q65=8?1/[>(8G0Y)6_=HQ$OA>0NT G82LOX ?\ !O;\#_VKM<U:#XX?&F-;
M3P#X8&K:)HMKK-H A9=";1-#'@@D'Y2FM,7(Y\%)X?;P."" :_KKAA\K_/\
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MWP1^)/PD_M7PI\5_AU\+M+OK'X>ZNDNI?\)5I3IH,A.BRRN?$LOB#?H3>)O
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MZU)HVNH\.LNLBPM%).-WC,!O^$W!8FOGG]@/_@CG\??!GC;]HRP_:\DT*_\
MAUK$GB2Q^&ND:9K\DNJ:F-<97T?54UB/Q-XL?P_H36XD*\DQ -X.:*2*"1*
M/E3X3?\ !.?XM_\ !1G]GW_AJC0_CA=7/QPU3XO^*?#.L?\ "0ZP=4\,V'@,
M?V!KVNC0E'B0L6/B(:)_PFP\5 GQK@^.!_S)8KF/B/\ $7]N7XX_M.0_\$OO
MVD?C NA^$+WPYX7\&ZWXBLM6&F%]-UW6/#WA[<V/$@_X2%MB:TN?%W/QH5/$
MO@3P%@ 8W/AI^S-_P<?_ +&J^(_@!^QO\/\ X*WG[/VN>)O$_B.TU3XE:O\
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M[=?7'A[6='U"P&E:(TD:N="\/_O%U]VCT=? DH&UO!2L_CIF\=@D '[;Z?\
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M#6]GX#O=)6Z#S,-1E^)G@C0T9-&15&N:Q</JK^&X=#FQ'<'6_)P)V1$^2O\
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M@%1H6?#A306\+?V)HI\#,H'_  ARQNF6_P"$ED*@'XZ_MZ> _P!I#XL_ ?\
M98^)GQ\G^)_[3/\ PF'AS5;VTT>RT<>(],OVT36O#\FO9'A[HS>)&W_\(L>3
M_80;P$?F!/0?!_\ 9\_8O\2?\$Q?VS_B-X<UO6S\?O#'@+Q1>V?P2M/&.B^&
M]4T#Q3H6=?\ [;T7_A(2O_"0>(/%>-;48WL?!K?\B,OCI23^G_P@_8?_ ."R
M7[/?A7X4>$/A-\:OA<--^''ASQ1HH&L>(FU'3LAM 5<:#XB\->+O#;'Q<RZY
MY>%)\''!C#97-KP!_P $<_C-XD\%_MM3?'+6OA<WC7]HSP^FB^#+;2XYO^$&
M6_D6;6M:_P"$RT5?#!1]#6Y2(3(S>,/^$M\6>;X]EV'R@X!\:_L[?"+X:?%_
M_@W$74]5D@USQ-IG_%3Z1XML[U=2V^*3K.A$-H@+JP4>'=8V'PMXK5F+Z*A\
M> *LK+\'_$?X>Z9XJ_X) _\ !/&;Q5/;7/AT?M'?$[1O$?\ :WB+1],\,_V9
MKVMZ&&_L/1O$!/B;0?\ BH@OA8+M!3QID^/BW@-\)]K>!?\ @BU_P5V\&?LQ
M:A^QUI?QY^!.F?LXZK>:4K?#X>(M:;^SE5'D!EUY?AJ?[;B'B)7/C;PS*5C\
M:,?"Z!M_A55:^G_!#+_@H+K7P-^$'PV\4_%CX23Z[\#]6\,Z[X1NX-7-]IJ:
MEK99=>,B2>&E?7!X1:/1PWF*O_"9^#-<;P,0-IP ?07C[_@E9^Q;X!_8IN/C
MYI_C71_@;XQ\>VFE7O\ PD7Q U=?^$%UT:]H\?A]OAEKVBZ$W@]?$ \5#1]Y
M 8LWC)'$:OX&78?P#U[X8ZI\!_B#\%_^%<^#M$^SZIX\TO1?&'BR[L_[2TSQ
M=I9UK_BNO!?]A^'R/^$@\.?]#O\ C_P@5?U8?M&?\$[?VL_CO_P2^\.?LG:I
MX^\&/\</!WQ'TKQ'H^K1WCZ=I2^%=&?7M 72-&\:+X>QH.OLVMKXG281/Y:>
M9X)\Q8#(U?B%+_P;I?\ !2C6O#W@'2)OCU\/]-N? /B]=;\-V?\ PF&MZ:="
M&B:P9/#^N)K?A_PU^]5E5BOA>,,O@UHY4!+>*9 H!Z[^TY^S'!\8/^"JOP?\
M.?\ "'>&O#>C^,OAO\!]:L])\/6?]F_\AWP7X?T'73_;GB#Q'_Q4!Q_R._\
MT.G@OI_Q7G7R7XF?"31?^":?_!6KXSZ3^R98W'@K0;7]GGPO\0/#OA^SU;_A
M&=*L=6UW1<,=;UH^'7\,!6_XGI52[D# 8DU]U^ /^"(O[>$G[8?A3]H7XM?M
M7:1XVT?PA::;H=E<VNOZ]IFJ+I?A_1M$70VT;1/^$9*^'8V\20OY/ATL(/"0
M"^.H))?'3QE_H_X]_P#!&SXR_';_ (*-S_M2:E\8?!]M\&SX8\+>"9=#U:\\
M;>(O&^I>&-#T=41=:T..*7PUKNN1LR>%IG\4^*Y%\50G_A/I%7QPG(!\O?\
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MMKX^37SXK\->5KEO(NMLO@]PK7#VGV@^+?\ 3/(D4 _/;_@E9^RS^S1^VO\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5!-_J
M3]!_*IZ* /@[]HW]@;X%_M+2ZSJOC'0[C1O%^K0::4\:Z!>!-8L-1T*(:+H>
MK@'Y7D30B8\$HJ(,.Q=&9ZH_X)M_L=?\)YX!^)Q^"_AL^-OASX:'@W1]6:S
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MIMJ%E\*/#2R/??;Q:W6FO>^'1 VI#73"-&-S_P (Z-%/BLGQ<- 6W6%/%_\
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M.W.@:3<Z?=:1X>N=&TE](L3H[(\;:1I'E")&C&0H9<()#@[6VM^#O[?'A/\
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M4NP>I_3_  I]% !3/+3^Z*?10!'Y47]Q?RI=@]3^G^%/HH *9L'J?T_PI]%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MZ*^2_P!E3]KSX%?MB_#M?B9\ O$]_P")_"XO%TZX74=#UOP]JVG:F^E1ZO\
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MAX4UC5K+2[+3-<UB5K^*+]TYT30@GB?6M)%PA9D\+1W'BR6W2:+P@DLLP6,
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M3P\TD2M\K/N90?9?M</J?R'^- %FBJWG0^7G/R],8[_7I[?TQ7X=_P#!3?\
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MC=@= <\<GJ<=JN?:H?-\G(W8_#'T]/\ /M0!9HJM]KA]3^0_QI?-A]?U/^-
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_L/3O#EM\!O%X^)OAKPGXBM"WAJPQXT"Z$2S$^*/$1_YFCQQX78D^#/[?/\
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MK77R8V31P9]I& Q0;BI)C*N5H _"3_@A)_P5B^(W[9S>*/@!\=%_MGXI>#/
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M  J[_A//&']M>&O],UDG^RM=UK_B1=/^1@_X2SL?^:T?3PC0!_:#_P $_?\
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MXY\2W7Q'^(]IX.C^WWGAG6M'T1M$TE2(Q,7E$FM+())6C"P1^.8HXO'YF:4
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M _\ A"?^)5H0_MX?V'H?A_\ Y%__ (IS7/\ BM_"WA/_ +'GP%GQYF@#IO\
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MM?\ $\_Y&#CP_P#\QSQ1W_X0OGMXN-?L1_P3P^.W[6W[,O[;/[57_!-CQ?\
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M[*M/#?C'33?^%M".@?V[@#'_ !470>-O%/A/QA_PA8QX8\<^ CX-\>_\)H:
M/[B/V=%\86OP,^$=A\1;3^SO&VF?#SP18^)+5KB3>FJQ:!H<4BZN%B4P:WN;
M,FBEW"/)Y(.R6,Q_G/\ \%L_BJ?AA^QAK%O!XJM?#<_C+QAX;T>\M"KHVMZ/
MHLK^(M5B.LM&I\.[-<T;0@WB5BK0_*I0[MU>^_\ !.75_P!J#5/V;_!LW[3U
MO-:^)K?2/"]OH$^JVT47B>_TD:0#--K@*[71FD7_ (1,R-_PF?E8;QPOVAE#
M_A[^W=H7Q3_;M_X*=?!;X">-/@WXX\+_ +-_A7Q!JGPT\3^*]0TG6#X<US2Q
MXQU\_P!M2Z^/#LOA=G\5(H7P7X:$D@9E\,'QX2,4 ?SZ_%3XD_L3_LN_M.?L
M$?M4?LD^.-1UNXT&STOX@_'?2;/PW_9O]A>.]"UG^WM=T77=#. /#OBQM#(P
M">->'CK()(']NGQG_;X&N?\ !*OQU^W=\$].UK1KFY^'']M^&[6YL1J&H6M_
M_P )QI'@36AH<6YAK<Z&76#X1GC 6X:.-U6)6\B+\J_^"K'_  0__9"\ ?L'
M_%CQ-^SI\)-2\,_$GP+=/XVT2YM=6UCQ$6&LZXHU_2D82MXEEBD66)E,:D0Y
M"7#KX(D\8Q#\Y?V&_P!L3XQ:#_P2N_:0_9:_:N^#_B>UTC_A57CJQ^'(U;P+
MXS.E>(-3&LZ&-<&QBWB53X3,A\5>.'C"/X.VH/ I**$H \QU+X8?M&?M!_L,
M^-_^"B&D_M0W-M;:5K'A>]\2>'O$/B3_ (J:_P!3UW6O^)[P.?$'B+_B>?\
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M H(KW7]G'P#^WE_P2>_;D^-_AOX/? 'XE?%KX:ZIX1^)WAK2/%FO?"/QI?\
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MW_PA6CW-GXCUD#3]4T+1=  UG0AC_B?CQ8/[# _Z'3_F?:]=_;U_X)6_$/\
M9P_8B^ '[3E]\>/B1\6;+7M&\"F[LO%NLZ*&\*^)O'&S7M$=.[+XI\.R(CD?
M<<@-C<NZW^VC_P $\OVV/@UI?@?X ^#OV9O&VN?#[01I7Q"'BSP]H_\ PDFF
M7_BC7C_Q/-%_MSP]GPQ_PD7A/G_A-CT\:X/7%?MY^UM^RC^V=^UK_P $C?!/
MPSNOAG#I?QP^#>N^$=3LOA[JMEKO_";:AX8\$>$=$.[1-9UR$++XC7^V]<9_
M#7A?PI-_PE$*^&_!02U\;^%[GPA< 'PG^T)ILT/_  0P^"%E!XIU'4M'N_B_
MXF&[[9S8 :,VA8)ZD#.N[1V/B GC-?E?\8/V+OBI\-_^"8MA^UYX<^.WB[1)
M]!\=CPS9^";3^U]24ZJ=%T'7=HUP-_PC/A\C ))4*1H*[23N ^K_ (A^'_\
M@J=\0O\ @GG\-_V1/#G[(/Q0TW2?"WQ'TS65M?\ A6VLZEXG'B?1/!FO:^=$
MT(\GP\&_MO6B0./!A\/#P-R0,6/&OP=_X*\_$[_@F]XA_8HU7]E;Q]<M=W?A
M;QE::5=?#;QEINJV(!.AKK!/7P^/%?\ 8NO$>%<_\45EB.IR ?V(?\$K_B=X
MM^,O_!/C]E/XF>.];_X2/QAXF^%VG?V[K\R!7U&;1=7UG0_,R,981Z0"6//S
M MG:,?FK_P %H+SQEX;^,_[*_C/P[\8M<^&UOII\4$KX4\2:MIWB5=4.L^'Q
MH8718P!H2^+CGPT/%9RV=".=O")]#?\ !#'0_P!ISP/^PIX(^%G[2OPWUOX;
M7_PNNM0\'^!;#Q!9'PWXF3PW'(O]KZ/K>BHN?-\,^)VUF%?$;L6NE 6 'RY5
M?\G?^"U'[%?[8?Q*_;:\,_&_X1_"#QS\7_!">$_#::0O@NRUGQH-$_L'1_[$
MUS2]6T0/(F@ZW*KZU)&4E;_A,%<0RB*>.6&, ^)?V6OVZ/C%\+?VKOB^+?Q*
MWBKPQXGO_$OAJ[TOQ5XDU?4O#7BX:T^O:&R:YO\ $3^)@L@!\2.0 W@OQBS;
M&3P+M9?!_P!CO_@GGXA_;Y_:T_:F\'>"?CEJ/P)U'PUI'CSQ+="U/]I%]6 T
M'0]"T/61U/AX>(=:T5O' &<*I;P%A5)'0_L__P#!/_\ ;0\0?M!6]QK7[.GQ
M9^&%M\1?&6FZ':7GBKP)XQT[2[!E8HVL:[K@\.8\/^'D=6\3,/X?!H*D9%?4
M?A+]G#_@J3_P3B_:B^-_BO\ 9P^!7BGX@7OCNW&A7?Q#\*^!=7^(_A?7;#7I
M- U<:OH9_P"$< _L!I-%T2 IG/@XZ$82K;BA /*/V)/V_?C!^P!XP_;$_94\
M9:MXD^)_A#P3X<\4Z+::5\0/$49/A;QS_8;: -5T9M!1_#0C$A28#P>\;>-/
M!\,?S'QSO1_JG]B3]D_7?VR?V"_BM\=?''Q?^(/A3PM\,?$GQ0\4>!/!7AW6
M!J?A>]\4>!?!\6M?VRRZ\&ER1H^B.&$1B41N9Y?%@VL?IS]E;_@CS=_&/X<_
M%S]HK]HK0/%?@KX^?&7P=XJT?3?!?B.UF\,,GB;^Q<>'O&?C)==MI?$>C.WB
M;^W5:,^%8I%)3QTH<N%KX;^$ND_\%;OV,?A;\9?V2OAE^R5X[\8_"3QL?'7A
MK5/$5W\(/&'CC4;,ZYH@\$:UKGA_7?#Y\)>%_$1"J)5*Y/C0+O'W<T >!?!_
MQ9^V'^WW_P $^]7T+1/&7C6U^''[-?Q)\4^,KJS\$8U(Z&=!'B!B-;USCQ.?
M#P4:\V #@#Q0>@)KWSX=_P#!1KXD_M-?\$T= ^#*>-_$B_''PQ\;/ ]D=(L[
MP'Q+?_!S1M'UUY-'UH:!DZZ?"WB;0=#>01E5D=FD\#B3P/X15A^^'_!'_P#X
M)[W'[%?[(6J_"_XG:9IG_":_%G6-3UWQYI N9-1?3O#&M[QHW@_7921%_;:+
MKNMM*0\9B.MK"3*WA^)%_/C]AC_@B=\:_P!D;_@I7X3_ &CY+GP=<? :T\'?
M$Z\\26MGK[WT@\>^(1K>@^'S'H$T1,C#SX_%*HL4S>#WS#'XSEE#0T >,_\
M!1+]N_\ ;A^"?[4G[+_[,WPN\8^(K?XA>*/V9?AC?7?A[5-7.->\=_V,R^-_
M[;!)\,:_XD_M_ ;_ (2OY2VX@ 'GYD^#'PL_X+=^"/VS_P#A<7C#X:_&%$U;
M6]0T[Q'XCTS2A?>&+_699$CA57\0LI&@O,R)#XI\5$>#SX0;Q(/'/SE*_4'_
M (+<?\$[/V@_B]\2?A=^VA^RIX=N/&?Q4^'%J/!OB#PMIERT7B3^RVU4RZ/X
MNT+1Y)7_ .$HDB9=)\.2>&8ECACB=?&0#/;3D>P_\$V/B]_P53^+OQ;\.#]N
M3X?:U\.-*\ ^'/';ZREWX3U;X=^'/%VK^(9FC\/1!=%\/CPMX@\1>&IHWMXH
MR\0;P=N\:1O&R[O%X!^]^BS7]QH^E7&JVOV"^GTVP-Y9\/\ 8]0,:F6(8XPD
MK8 _AVA2>M;E?C%^RM\?O^"A'C#]K7XC_#?XW?"$Z%\$?#GCOXGV8\577A2>
MRL]%\+*DNN>!DT/QO'+_ &!XHED36O"!BR97;PHIG"23QFOV=H **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M'P9;#6?!]S=6L2:H%\0ZPVM^(/!^[0Q_PC0\G7C+/B)DD8:TRC(RIXKXX_\
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MV;QX/^+.L:FUQ>>(]5NO!OA75;73!J/A+PX</$DWDPS&/6B<^=H$BA;8:&A
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M_P#\+7^'.D>-AX:O-1O],?69-8T]85U4!9V\K198DUR(J%0>'/$"RQ/(6D9
MPW2 'XO?\$0/@GX2\>?LP?"SXF^)_#UE<_\ "&6O_",>!M'MQK>I^&M#70]7
M\1!=8T%M>8>6W]@Z['X9/ADI*/!B*T8CWNLD?W=^T-_P2]_9I^/&K^ /$\?A
M3PWX$\0^!'L[(7FA^%]+72==\*IKZ:_!H>MZ+*JQNWA36I=9D\%L) /!TFN3
MF .HVQ_>GPY^''@GX5^#O#W@'P!X?T_PSX7\,V(LM(TFS214LD6-F/(_Y"K%
MF.9'8M\H&XD*$])H ^"-+_X)V_L;Z=XI\8>,)O@AX4O]7\9Z@EWJQU1/[0L2
MR?V).Z!95<3H^O\ A]?$K#Q$LDA\7&::)T/E,GT7X"^ /P7^&&K:AK7PZ^'/
MA/P7K.K6AM-5U7P]I$>FZA?KF 89T4D8_LQ,8R2J @D9+^V44 ?"OC?]@C]G
M'QW\7=<^/,WA*_T'XB^)_P"S!XNU?PS>/H"^*_[!!T)WUR*W_>W$_B+PX'\+
MSZVABE;PBIM_/B#+<5Z<_P"R)^SA-\1%^+4_P=\#M\0AI'A31(/$C:.JZB-)
M\";CX)TPXE.$\,J/]'  VG[V5!"_3E% 'QC^T3^P[^RU^U5-%??''X1^&/'?
MB>U\/Q^&++QA>6C)XGL=".O#6CI=KK ,CHD6MQS2QQA'7PX^J2O:) DID;MM
M(_9(_9KT/P9;?#O1O@?\-].\%6FE66CVVDVOA/1PZZ;%JIU;R%U@0_\ "0LI
MGS(0]VN'!9691A/IBB@#Y9\-_LD? '03?J? 6E^(WN[O5+P?\)4#XG&G:=KF
MMP:T^A:2=>\Y8="$^F1JD&9"0A;S'5F"?2HM(1%Y)'VD_P#3T2?_ &4=_3FM
M&B@#A?"W@#P3X,6^7PAX1\-^$(M4(-W;>'=%TGP^EVZ_=<MHD<.=O;^+H>#S
M7!VG[/?P*T^2YCLO@_\ "FV@NI--N+F"T^'7@R,7;:'+)_8DTBIHFV0^'1JV
ML"V<Q,]NFL3[)H_M,R'W:B@#YLTW]F']G^PTK6-)A^#/PWNM+UV\-WJ^D:MX
M0TG6M,/FZLOB!(QI&N^;#H^A+XA8^)&\.0-]G$Y+)"LB"-/5_"_@+PGX(T>W
M\/>$?#FC>%?#]H;^Y@T'0-+TS3=-#ZM(9-4801IY>YY'W2NHA#@HC&6-41>\
MHH I16L,!G\H#$X#& D  XP<#.1G//3'ZUYMXB^$'PN\6WSZIXH^'?@/Q+J-
MS<Z?>FZ\1>$]'UV_>^THL8Y$FUJ*5U:)5VQLFQE&]V+-M:O5J* .#T/P'X-\
M*RZA-X9\+^'O#MWJ;:<=8NM TK2M+:^&B@_V.-5$4:-+Y2,1$P5I%!/SIP:Z
MF>PM;H 7$0G^87(SD?-V Y/X#@=:TZ* .$T3P+X0\.7^L:KH7A?P]HFK>)+O
M[9XBU32-%TO3=0UV_P!G+:W<0QH^KNV[=ND=MI7]V5/*]7]D'FYSVS[8_P#U
M]_US6A10!AQZ/913WT\2K#+J5X+Z]\C"F[<:2FD#<>@VHJ,IY(=%+'DX\]US
MX+_"7Q+X@O\ QEXB^&_@?Q#XHU:RTW2K[7/$/A/2-5U*^TS1Y3+I>DL^N12M
MMC=V\L_*C98';\I3UZB@#D(/"7A:'2(/#<.@Z&-"M5'V3P__ &/I?]D6*@$J
M!I7EJ@QEN ">3WKI?LW_ $T;\O\ Z]6J* .%\0>!_!OB==._X27PSH'B1M%N
MQ=Z.->T32M5>PDV@$Z2VK1RK"P&!YH;']T_*HKL?*/\ SV/Z?XU9HH K?9(?
M0_F/\*;]F'[W_;^[^7'_ -<_D:MT4 5/LD0'[D>0?5!@_EFDEMP>5F, ]L?S
M)':KE% #?X/^ _TJO]F7_)/^%6J* *OV9?\ )/\ A4/V0>5C/;/OC_\ 5W_7
M%:%% %7[,O\ DG_"C[)#YWGX'G8SN]_7&/U_3M5JB@"K]F_Z:-^7_P!>E\H_
M\]C^G^-6:* *\T7G1@=_Y^O]:_.7_@IU^SE\<_VHOV/?B/\ ![]GCXG3_"[X
ML:]_9>J^'-6 1?[;;099=9'A#^W2^?#ZW+*@3Q(NYXY %._+,OZ144 ?R-?#
M?_@G7_P6*^&_[,?B_P" GB/XQ^$_&VAB^?POX9\(Z7JND:9IITQ8D?1-=T#1
M"OA'POH'AE?$&D(C>'%)C$D@\9'P4)3LK]G/^"</_!.SP9^Q;X/O-?OO$?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !114$W^I/T'\J /A?]MO]M7P
MA^Q_X.\/ZU?:2?&?B_Q?JZ:-X:\$V7B*/2]1U '=G4U&UCY: +D@*3D;7RK
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M$A@><97I7\GV@?%3]HS_ ()>_M^_#[]FS5[>?Q;\*/C)JXLO#NK75INTK7?
MRD?\3G020IT#Q$KCCPN5\7GP61XG; \"5\P_#+P)^U#^W3^WU^UQ\%K@$^'_
M  ;XQ\=WGB_2?B98ZUX<TS0=+;7 -!R "< Z[H6?"_ \9C/CHD*"0 ?TT?\
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MT#\4_"MC^Q'_ ,%7?V,)_@Q;?$&TN/B-X%/Q!^-EUXBUG1AX:U[4]:\&^(-
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M-(T.PTS1=)M P/V33-$ AT=,'J56.,$'&<!< @UU%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MU?%'X(?%KPOXY\*66H> ?#FF:SXCMK75CX;\1GQYH(\/:'H6C#7U\-LNO?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MO;#%O;VX"H!@Y 7N.3U./4] )_-A]?U/^-6* "BBB@ HHHH ***K^?[?I_\
M7H L4444 %1R1B08/^?8]\5)10!7\J'T_0_X4>5#Z?H?\*L44 %%%% %?RH?
M3]#_ (58IF\>A_3_ !K"_MG3/[0_LC[=;_VK]B^V_P!F_:X_M_\ 9N_R_P"T
MO+^_C/?KGC=GB@#H**K?:X?4_D/\:7S_ &_3_P"O0!8K U34M/T2RO=3U6^@
MT_2=,M/M5[=WC?8M/L=/52&+/Z@(<DX P$ !VI7R-^U5^U3X#^ _A_7O#TNL
MZC'\3=4\$:KJ_@G1]'T!M>U3^T]6>70/#DJPQHR-N\01ZIXDVLZF6U\"^)O,
M<?98HI?SH^'_ , ?VDO^"AMIJGB']L:[^('P3^%\'AUM#\-^$OAAJK>##XNU
M0ZQ+*=<?1O$#>+ GAT^'P7:6?PD%\;NWAI-Q\$^%T'C0 T?B/^W7^T%^TG\2
MO$OP._8#T2S8Z/)JIUGXV:QI6EZUM\,:/IFA2Z]K6AZ/XC\1^$_#^A(/%'B#
M0_"\7A.5F\7>);<+XRLUMK2-E/LW["W_  3V3X4:=X?^*_[1"'QG^TAJ;)XH
MUFV?6#J?AKP'XE+'>NBKA8]>\3O%LG\9>)///A-/%S^?X(MP4'BJ?Z%_M3]D
MS_@GW\+-&\.:[XGTKX7^%;J^U2YN-6\0,+KQ+XJU)HUNM<\0:]_8&A-+K;$I
M'9^>+;_A&[9V\-^";2.WCD\(>%#\0?$[]HG]NGX_>,KZS_8G\#VNI_LUZK8:
M;X)O?BWJ^D2>&]1SX@TCQ!H\_C7P'K<GB?PKXGC_ .$8\4,?#;CPGX3:3P</
M#J>.'>1/$\>P _7GXD?%7X?_  :\):CX]^)GBO3/!7ABT(^W>(-6;&FCCC.W
M)&[G&>HS7XR?%_\ :J_X*!_M10:;XD_X)R>"#8_"O3[1#J_B_P 8:-\-['Q1
MXL\4PZIG7/!^C'Q_XD;PG!X;'AS5]'82!8/%JSZ,X0"XN7_X1+Z-_97_ ."<
M3_!SQ%9>-_C'\:_'_P ;]:AMI[NS\#>(+_5;GX9Z!XHU;28XM=UE](U625O'
M+P22!/"K/;>%;.WN(9_&$O@__A.&M[GPK^HNE:'I6B1S0:5I>FZ=!=737EY;
MZ;8QV"/J$C+YNHE5*@[PBY.TG &';Y@0#\1/V6_^"4GQ"^'O[<'CO]MW]I;X
M[V?QS\8^)?!WA2T\-^&[+2';PUH'CM9!KWC36##K@5Y(?"_B-&'P7A3YO"*)
M)XOA'A%W_P"$-7]U?*A]/T/^%6*XS4/%/ARQUC3/#M]K&EP:WX@L]5O]'T"Z
MO]/35M>TW1#;+K3Z/I6=VK)$VKZ1YZIO,<>LQ2DQM^[8 [.BO&M;F^)Y^(OA
M*31&\'W'PWN=/\56?C!+VVU]?&%CJC1V[>!]4T$1^(!X;U?P[^\U>/Q@LT*7
MT;+X=DAAD#W#^%:'Q;^&5O\ &#PU;^%Y_$GCSPII@OFGU"[\!^+)?#>HZSID
M]AJ^@:YH>L&,2QZ_X>\1^'M;NT2&6-S!.;;Q9:26GC#POX6GMP#VJ28^8(8L
M;L<]L'/3]#^.:_*N7_@K'^S4/C3I?PHM8?B#=6%SJVI>%=4^(&J>'9O!/A7P
M]XB\/:GH<.MKKUO\0)/">NZ%H'A8R^(7\=^*/$UM#'X/_L&WB>.5O$<,I_1_
MPGX2M/!OA3PMX-T:?4[K2?#'A[2?#-E=ZMJ,NH:N=,T/2(]%C?6M79I6UG6_
MW0#R.$1YT>3]V1\V+J?PU^'NOKIS:UX-\.7-S9:IJ>L6@N]#T?[=9ZIXAE5M
M??/=O%*(Z>, KE?%@D=[A9@R;0#^=+]NO_@I%^UG+\8=0\*_LHR7D_AOP/JF
MI"U'PW\)GXEZIXYTK0M$&OZ]XQ"CP_)#KGA_PIC6_-\+P<2^#$7QTS2!(R/E
MC]@7]J3_ (+2?M=_M)^ ?$UGXMBT_P" C>,-/UOXDQ>+O!BGPOHG@.3<)24\
M/KX2#>9_8^O+X,_XJ\_\)N9"&_X0[_A%#G^M;P9\)?AO\/;:TM? 7@3PIX1A
MTX:D;%?#OAW2-+:R.KL'<J8PK'(QN7.QU^4KM+!NWTW2K#P_9V^E:+IFGZ=I
M-JIV6EG:II]C:*!N+(B#:2>^U<  9/' !KP>?_RUQ^'X_P">/:K-%% !1507
M4$J$YXYX([]O\]J=]KA]3^0_QH LT5SVH:YI.GBV^W:G:V'VJ]%E9?:[R.Q^
MUZD=^S3!O7EC@9"[CTQNP<Z-E=VVH6L%]93P7%K=*MS:W%LPV7:%3\PSU!'!
M.YO?&,4 :%%%% !1110 4WAQWZ_B#3J* *_E0^GZ'_"CRH?3]#_A5BJWVN'U
M/Y#_ !H FV#U/Z?X5Q/BOP+X0\:V:Z7XN\+Z/XDL2<FTUK28M1L<)K6B>(%#
M12L(F'_"1Z'H>NC<&W3:1$Y"-$KIV/FP^OZG_&F_:X?,VYYZ9_7&/\_6@#XW
MD_X)Y_L12/?3-^S!\'W;4KG5+N]9O"5NIE?6SC66(0*H:ZY)554*>$5.M2R?
ML _L6'2/[#/[+_P5.G?;CK0_XH+1?[1_M Z5_8H)UX0'Q'DV^%R)R,?P^;7V
M;10!\$^ ?V#/@1\*_B9;_$SX7KXL\!ZG;>'-7\.+X=T'Q2K^'PVN:>^D1ZSG
M7AXH\2?VY# (H(T'B8^$P= 1V\(S3*9I/@;XQ_\ !&C6/C'\1-?^)VK?MU?&
MFU\0:_::3]K^U>'=&U,?VGHSF+6&R_B)#_PC<SAEA\,!=OA$_P"J9PP)_>^B
M@#^=71O^"%U[H>H6%X/VR?B1JD-I;I'=Z-K'@*6_T[4]4&L+-I.N0#_A8;G1
MS#:EO#BB 2++*C>,-\<BMM_5'PG\.OVL_ =EIEI'\??!GQB,]SIFG:G??$SX
M6MX8N-$\/(\RC6M!3P%XB77M>\1(?*D\3^'O&$S?\)I)I$N/&O@5A(9OMFB@
M#\$/CM^U9_P5N\!?%J3PYX _8\\(^.?!ZR:C8:7=>'=+UKQ!X=NI-#T+7IH=
M5FUQ/$D<PT+Q2US]KB%Q_P (?/'/I'A?P?&5E;QBU<)X;_;L_P""Q>IZO#IU
M[^P;H-MIUY?>'&L]7U?X>_$_P_LT_P 1:9Y^BOK1F^)4@5DE _X3#(QX 4"/
MQF($^6OZ*J* /AKX(_M?Z=X]^&'CCXC?%GPY;? L_#;Q%_87B_2-?UG[>_AY
M$_L717?7W70(VT/7CXHEUOPPOAHI).MQI#N\K"?,7F,__!7?_@G=9W$]O>_M
M*Z-:W%IC[9:GP-\3V-AZY/\ PKH,WXM7Z07EE!J-G<6%]!;W=O<VQMKNUNK<
M-970<8*LK DH3D8!; ((4LH-?&GC7]@3]COXA0Z3;^)?V=_AS%9:6VJ?9K+P
MKI[>!].O_P"WVT/5=8_M=? 3>%AKXDDT*+8?% DC<@MLS/0!<^!O[>O[*'[2
M6NV?A?X*?&+3/&>JW5B;ZUM#X:\9>'7OH53++I+>(_#WACSBHW992V5P O)S
M]I5\\>%_V:?@#X&UW1_%/@7X)_";P-XDT.\U.^T77?!?@#PCX8U:Q.M:3-HN
MLXU;0M @D_>IJDX96($JKELQ(X/R+^V'^P_\2OVA_&'AC7_AK\>?'/P@L;N#
M^Q_B3:V/C#Q6-.73-*E:32-:\&:%&([:/Q';R.R^5'<^&?"SP()9#/.[-( ?
MJ#17X9?"O]@3]N/X-WR>(O"O[65GK?B&"T\*$:3XK\1>,-3\+:A?OX4UZW\;
M3'2M>\/>+[;R_#'B'7?M'@2,^%?.DM\XA\'R?N3VG[47[0G_  4X^"MAX>U3
MP?\ LU?#SXI:/JGB?PQX>UH?"72/&/Q!U6S(TN*76-9?18?$,/BL^&_$OB&/
M6(!&WA+'@^V;RKSQM<;_ /A-6 /V9HK\)_@Y^VS_ ,%#?&FHW5WXJ_8QUVWT
MC2O#_CJ:ZT6S\)>,/#&G76IZ* "O]N:V/%;OKWAF6*3P[)X5\-F9O',K2_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MVZ5K?_"\-4_LN^\2?\)9HVL^)/$U_P"*-"_XGPT70_\ N7-#_P"*W_Z'7@>
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M6T?PCX?T)M:;4==TM)86UUMOB ,1/X/.M:%X=\6F)%*7&MKM>(,P?])O&?Q
M\&_#S1VU[QOXL\/>$M'-PEFNK>*-7TW2].%_*2(]*,\I1=YVL=JEI!MSEN0?
MD>3]E+4++XIS_$;P)\5]<^'>BC5?AKJ%E\/?A_X=A\.^'+/1/!6F+HNMZ+K.
ME)XB2'7DN(%=K-71(/";:QXE@N/"/BN3Q5(XZ/\ ;4ETR']G_P 7G4OAGK_Q
M8EGM)TTC1]*TU]1ET#5FTK6W_P"$U#M*#H \+*DS2N4/GL\7@T$#Q6PE /HC
MP1\1O!OQ&TIM=\#^)=$\6Z&UZUK_ &II%V+_ $\2>1#JR,DBXY$>KZ1G&"#(
M,!0BU^2_C+_@LU\#?AC^T1K?PA^*4&F^$_!VE^+V\,Q?$:#6M;U(1$ZZNB_V
MMK6AQ>'8RL3R(C7*JV[PJ%"SM*JJ%_-"^_8O_;*_:(_L?_A =+\6?!NWMCJN
MM6>K>+='_P"*9O\ ^P0="_YF#C7QXK\1#1#_ ,(MXM./&G_(\]?"7/YD?;/#
MGPVU3P/X5UWPYK?[2'Q0U2\TNR\-_P"F'Q)XGU[Q1KNM?\3SU_YF,ZYQT\:4
M ?W3^&?B]X=^)_@B[\;_  <UC1_B/MT?4[O2+.SU=-,6^U.19FTC2=8DDC-S
MX;EE">41XD\-;X@5F*C:QE_(R[_X+5_#&W@^*WA[XE?#OQ)\&_%'A72=1M-(
M6^U9M75=44S:#(^K"3P]X2>'1?#?B*<I/.7<N@Y7<Q>O@+_A6?[6MY\"#\9_
MAE^SG\2/"7BG0?$6J:-X:\)\^&]3OQ_8W]O?VWK?]@?\5-H'AT>'",^*!]WC
MP,?O#/R)^QC_ ,$WOVI?VYOB?XH\8_'G0_$GP<\ :5::0-8U/QKX/&FOK^K2
ML4UG1/ ^AD@+_P (NXUV-?##LB>#'XW#_A+N #Y(^-7_  4=_P""@_BV76/!
MWPP^*/Q8U#P_KUI(?]"\=>,?$7_%,2ZYOD.N'P]XC',GA_YW/A/[_@X[FRV3
M5K]D?P[^V'\:?'>HW/A[XD>/M0^+UG8ZK?\ @70&UG6-0U'7%49+:(<X"^$O
M#>3D\#G_ (3W'CSD?VN?!#]EG]FW]DKX:SRIIW@^WM-(T53XP\?>-K'1M,6S
MTS288I-89)-=62#P/X=7<WB0^&HKD6T;,YD+E(Y%_+WXN?M__LP_#CXC^"=2
M_8+\#_#3XA^/_&E[)8?%;Q!X>^&VM:>EEX59GU[0M%T0,/" _M_Q=K[+XG\G
MPJK?\)ASXU,LX E8 ^4M(_X*4_MM?L._#+3/@U^TS\-M&T.:TT9AX<\:>(++
M5?#GB/1O"QT4?\(^=&/B)&\-^(-A'_",QGQ0Z?\ "%G0F/C\,, <-^R;_P %
M%_\ @J+^T?\ $35?!OPFT0^//@Y8WJOJOQ7T;P_I&O:EH']L995/]N>'4#1C
MQ$I\+M$Q/C!O&(/CEU;P"#5SXR^([WX^?$KQ/\8?C1XJTWQ;/J9\+CPUX(NR
M=3\,Z#I??P7HFB'EO#Q)RQ))\:G7_$Y)))K]>OV9/%WQ0L?"N@_!7]F[]E@_
M 3X1W?AC2[KPU\0/$#:WJFEZ"FM:W)+KGQ*AU;Q#X=\)+X^D;PYK>B'P9X8C
M423&)/,)\ P1)" >V^-O W[+7P#O=#^(_P"U=\0]-\=>*]=4^#_#?B[X['1_
M$@5)"Z:QH_@?1F@,>@:(S:P[/$GG"+^W%,I*R1>9\B>._C[^V]^T+XRTKP%^
MR9\+3X$^"&K:SJFBZ7\8X'%AIFH:;X+UA/#GB!1XT&(_#?AOPZ5C+VW@Z-/%
MLUQ_PD_@SP#XQ-QX5=W]W^'G_!-;P!>:GXM\0_M,?$#Q1^TGXAURWELM)NO$
MD6N^&ET+3$UD:Q_:NE-H>N_\)(OB0SS+)#XEBN4D\)Q:YXC\'V\L]K)(#]\?
M"7QK\(M=T"#PO\*M<\/W-AX!M3X+/A;298TU3PBFAYT1='U;0BO]O:%Y)TGR
MT6[BC9_*WN9"B.P!\+?#S_@FM\/3XEU[Q1^T/X]\2_M3Z_J_V^SM++XB+K!\
M,:<LFBG03OT3Q'XD\5OK.O?\(V/$'A=9Y_%)"^#M;,?V>6<KXJ?]'_"G@_PY
MX+\+>&/!GA+2;30/"O@[0-*\-^%](TO_ )!VA^'/#^E+HFA:3I"$;DCM]#2.
M*$@N41%W%\J:Y;P9XOU'QA)/JI\&>+_#&A?V3I-]I%SXRLM)TG4[^367UQM9
MTU-!DE?Q%H(M4T719)(_%</AB6X?7(C'&S6ZQ5ZQ]JM_^>X_+_[&@#F-,\2:
M/>ZEJNC6NIZ7<ZAH%\FGZSIMG>?:KS0Y;O2AK.D+K$8._1&FT7;(!*A69ID,
M4C,Q)["OSB_:3_X*/?L9?LB^(M?\*?%WXM^'-"\>QZ,GC+5_"6@QC4/%4E@5
M?0M+EUMQL\,?V[(^C)X7C7Q;XFM'5X?#K!3!-"J?SB?\1.?QZ\;:_JVE_#+]
ME#3S;W-YXV_X1RS\7Z3XSF^QZ5;^-&T+PX-?UW1?$GA4YCT B;QM(GA!9?!D
MR*[.WS!@#^U27_5/_NFOESQ-\:/V=(=,U'X@:SX_^&6N6WPGO/&UX/$,>J:/
MK^L>$-0T;3-!T'QO+H2Z7))X@7Q%;P^.]$\+7:^%8Q=2KX\\.>"DB#^+;6"3
M^3'PW^QY_P %<?VM4MOV@Y_BI\7_ !?X%^*R^)/$MYI5W\4O"G@_3]0&OZW_
M ,(]K?@O0_!/B#Q'X4?0_#X.AYD\+EO"'@Y5_>>!R%.X_P! WPP_X)S?LP_"
MO]G;0]-_:"\.>#M;\1>&8=2^(/Q#\?W&L:KX'L+#56W'Q!*NMZ)KWA-(_ 'A
M)6Q ERZK-)#-XY>&+QKXFFN* /1/A;^TO\<OVC/$7C;PGX1_9\\;_ [X?64O
MBG1M/^/'C\:'>:E9:HLQT5(]#^%_B$@-XBAUPZYYH+>,_"'A+Q;X8G\%>.('
M8/'7Z ^'K?4+72].M]4U9M9U&VTG3[2]U0V0T_\ M&_  ?4SI.=L/F-L<8;C
M:RKG;\OX^Z-_P4Z_8C^#&E?#'X/_  ,NO%GQ7\.Z!9MH5S_PA6EL)-$TM=*F
MUW0M:"^.W\)KXY\0>+_$*P2K*DS23Q2>*?&=SXOA:)$\8;5O_P %BOV=C\2;
M[P;=Z!X^TKPRNC^&+[2?&[:+(ZZEJVML9=8T;^PUGCE$<4^/#(\1^<8F\6&6
MV*;71X@#[S_:G^*_Q*^"OPBUGQY\(_A?JOQ>\4Z7>:9CP3I%EK&J:F-,?4BF
MLZQ#HNA*^OZVT41:3R;8')597.QYEE_![Q=^TQ_P4I_X*%Q?!#PC^SG\+?'_
M .S/X!U[5O[9\=?&O0+OQ=X<\,ZUI>CZ])HLKIXZ\OPC,/#OAQ@#)X5\+2MX
MP\:"W0QI&4D\&-_25X%\5^'O'OA/0/&7A35;;6?#7B;1].U?1-7M1\FH:<R@
MH^0!D _)P.I=><9/D%]XR^+^F?%OPOX&\+_L^7M_\)A8@ZU\8(_B/\/-#T[0
MKU=,E6.UTCX;+<2^)_$&C C2HG9'\,>3,69(+B./$P!RG[*7[/GCG]G;P/K'
MA+QW^T#\4/VCM;U/5VUL^+/B??:YJ%_8A]."'1=#77/$WBV>+0FD42QZ&?$\
MD<)#NLA#%F^O9/N-]*HF*;RL0D#Z\>N2/\\^N17SS=^)/A?^SUI5Q+\6?CII
MNBQ>-/&'B37M-U7XX?$OPEIO_$TUC5_[<7P7X+DU]_"Z#0?"YDDA\&^'HP[>
M$[1A&S31HI !C>-?VROV;_AS?:K9>-_BIX>T/4-$\5GP9K-@8=8O;[3_ !4L
M8"Z(T,.@NQD<RA59!M/]K^'':1/^$GL//\N^+O[4GC#6_P!G73?C;^Q1X0TS
MX\M>>-O[*N+6X\.>,T%IX=CCUU=;UY/!:MX2\5:](NN+HMN(PR V6NOXM"2V
M< %?GW^U9_P5D_8?U_X9^(?#_P */%?A'XJ?%>3Q[X U_P 'Z'JG@W6!81:S
MH6NZ$TGQ,9O-\,>(-?'A=-#3PM*D8<"X;0?!?CKP@_@-_%[I\;1_\%R/CKX)
MMM:L_$/PT\&2Z#>>!4M/"/B3PYI&L:?IVA>)O#^M+H)U5=#E\12#6XG4$/X4
MB$9!?PY(A3P2[2T ?6&D?M9_\%@?%?Q%\8^%O^&7_A]HA\ MXHTC6[?1O#FL
MZEX;OG5=!U@NVOZ]XD_X1O7_ !(OAK6M%\1^"O#/A3QD/^$S7771CM5A7S]^
MWU^U+^TCJVFP? _]I+X;>%/A3;'P_)XIUC0+:RC\1F]!=MOB[0O&T4?BH>'5
MME&M6R>*/"OBTR!-:\2^!IVDG\R1]K_@F)_P4,^ GPF\$^-]%^*7B/XGW7B#
MQUXZ?Q.->;2&\1^&#IIT;PZT9R"WB4>(E;6=<_X3=C#(Z_V#E"IW"3[-^,?[
M5?[#_P"T?K/AFQL_A1\1?VF?&/AJ#Q6WA"R\$>#M<L3>IKT?_"/KH.LZ]O3Q
M+X>\/>*I-;5PWDJAC!C>)IF?PJX!_-=H7[$7_!0GXRZ_X6\<?"7PA\4-1^#%
MWX]U2\&K:4=%TS3#I9(T#7 /^$A_XJ?).B:WX6';P62!WY_MU_94\$W7P[_9
MU^"G@V_TNPT76=#^'/A:UU?3+/1='\.QVGB2/1X!KYUC1]'V0)XB?7&E?QB8
MV9)?%;7,T1+.SK^>/P7\5?M^>$/@1:>&OA[^RO\ #+3K&UL]-UOX5K/XNTO3
MM.LO#&MJ?$!\'OX?UOXC'Q./$:G5E,,WBWQ<I$H\1KXV</(B/U?P \=?\%0=
M5\<:-9?%WX3> [7P!?\ B671_$^JW<VD:)J>B:=X?U9M(U_6=&&B>)E\1BU<
M:&+?P6\OA?Q-!XT:>/Q=%=VW@N:W( /UO\T>;CMC'OC_ /7V_7%$TWE?Y_G[
M=.U?*?[0G[+/P^_:3TS3[#Q]+XLT.]TRT^Q67B;P3KI\/:NVD-J]OK6I:/=0
MRQ^(?#FIZ-=R:)HZ_8_$=G<Q;T+>;'))L;YW\'?\$M?V>/!=W8:G;:Q\8+W6
M=,@1;'59_B$8]31,:M"5D.@:%X6S(VAS-X?1@J@6S+$8R\33R@'Z9Q2YC!]!
M^'^./U-?.OQN_:4^''[/VAW&O?$F^U*S7[ ][8:9IWAS7-2.N2 'R]&T75E5
M/#DVN;OF:)[J(L. HR"/7O!GA;3_  1X2T+PCIMUK.IV&@V TJTN]?U0ZKJS
MV<2_>U75BH:614  ?[Q"Q*H^4[>UH _/?X%?M^?#/]H3XBZ?X%\'>"/BEI[:
MC:ZJ;+Q!XKT?0],\.2ZIH5K_ &MK>D>9X=\0^*'2YC#Z0(V>22-EE<.5S;MX
MF^XM4BU>72KQ-'N;'3=8NK:==-OM2LY=0TVUU*6/:LNHZ5'=^')]2C)"[4%Q
M#(2I;* ;9-2*UM+)#'!!!;J3=W&+>W51DMEV"J,!OWBY&/G("C &*_F5_P""
MG7_!?3P?^S%-!\'?@-X>\6W?Q>NKK2KW5=>\:^!&TS3M,\-F)=8>70/!FOE/
M$^N/XLB4I'_PD,5FJ>9,661Y R@'[)?&GP'^V-XJBMM9^#?Q]\&?#S4XH/#-
MLW@63X=Z/JGAQ2L9B\;2-X\U_P .^+_$<XEUDC_A#U3PIX4V_P!CJDZN)'8?
MG7]N_P""Q&L6NKZ;9:O+I^H2^(M)L;+4_$7A'X-6'V34M%T23Q!KF5/AP^&'
M\.NJZ1X9/BK#%_&:>'&\"$JOC4C\(M+_ ."_7[9_[2GBZR\+>!;VZ\(^%M8O
M?L;77A/P*VFZA_PE/]M: =#*ZRS'Q(GAUCEGV>+UWL3X);_A-&))_L ^./QH
M\0_"S]C[7_C;H5R_B3Q3HOPX\)ZOI%WK/AZ?PW+J'B+6_P#A']&BUO6O!9F+
MZ &?6E\2S^&GWGPJ8I(YMX7: #^.[XQ?\%2_^"S3>(M1^&-YXB\3?#C6-,UJ
M2T\2'3/A=X0E\3^$3HVNG16T/6CHGAUSKVO;L".-<1^+U5? 4:IXY1%']2'_
M  2FTK]N.'X 3:_^W7XMUG6_B#KVKW[>%?"_BOPWX?TWQMH/AC2-7\11C6O$
M6L>'Y!*WB+Q7'JT:R>%I(U7P;%H<8AD;_A*9/)^7/ O[8W[6O[2/AF]^(?P?
M_9:\%ZI=^"- \,Z3\5O$.KZ9IGB6_P!<U715C\;IH7A^&6;PKXCB CAB\3-\
M*X1XM\7^#KCQ#X?N%C26Z\)_\)K^V'Q0L/B'?>!_$-O\)=5\.Z)X_P#L+-X;
MU/Q38MJGAX:B, ?VQ#$ID=?= 6!((!'W0#T^BOQVOO"7_!7$:C?S6OQ&^$AT
MRZ9[VQM-)L/"!^POK9\Q]'SXB\,Y=O"Y'_".K(23.#YZ%PP<_:O[+WACX\>%
MOAA96/[0_B'_ (2CXC/XM\6ZM>ZI87EE<:>NE:UK$FIVZ VYBWP*9I%M[1XV
M7PB7C\)Z>P\%6D32 'UI7&>*O%?AKP7I$WB'Q;XCT;PEH.FI_IOB#Q#K&E:3
MI5B&ZF75M;98QN&5(;D\C/&*ZJ;=Y7[GU[8]??\ STS7S5\4OV1_@)\;-2N-
M<^)WPYMO$FMW$7V%M43Q)XQ\/7ZZ?Q\HDT#Q%#N(/ &(]PP6$?2@#<;]IC]G
MZ&!KV;XY_!NUL?M)L;/4+KXI>"UT^[U&1HAL1_[?*MQJVALRJVY1K-N&7YHG
M'JGA3Q?X7\:::-:\(^)]"\7:4\[6BZMX:UG2O$&FLR\E8]2T626'@$$Y?*%@
M2 "''Q'=_P#!,_\ 8RNQ\_PIFMQ_H+ VGC[XBCB.4K*./%1!&OJ=ER2.6 .0
M^4/UY\+?AIX/^#W@O2? 'P_T0>'O"OA]+M=-T<7FK:H(PS$DC5=:=[CYB3\K
MNZX^XY42%@#TZBBB@ K\[_%?[5_QA^'WC/XQ:?XA_9N\77/PU^&^G0W?A3XF
M#5M)\->&O$$L>E1RR2:SX@\4/X:\.KX;N/WXNO$WAM[F?PB'C \(^+9(VED_
M0V3[C?2OX1_^"F'_  6$U/\ :"^*OB+X(>%/%'BSX6_#B!O^$;TO2[,+IA=M
M=54&M^.BOB-0WB)45(PQSX-\%IKB GY1XT\9 '].O[,?_!4OX ?M*?$?Q3\+
M++5-%\ >+-,U+3K#PEI/BOQ1I/\ :OCK^VE?[/'%:HBIH7B'=+H[/X:AN/$M
MR!K%O&'FZI^HU?R!_P#!)7X&_P#!./4O$_@?XB^(OC/:P?M+> _$FF>)K3PG
M=:WH_@CPY_PDVA:QH/\ 8;+K@ 'B!\_V$J^%0?!N=_B=O^$)\8;?^$T/]2_Q
M@^,_PX^"W@N^\<?$CQ1IWAS0+/>@-W?*NHZAJ/ER;-'T/2-QEU_79&P$\/0J
M\C'YMA4,0 >RU6^R0^A_,?X5\D?#W]M?]EGXB:5J6IZ%\=?AU:6NEZWJVC7-
MOXJ\2:+X,OTET20;C_8^ORPW)T!4.5\1"-875%Q*&^5.OM?VG?V?-4UG^Q[+
MXX_"V:_EM=$N;1;7XA:-)I]^FO7%U_92Z5J*W#VNLZW(NDY&@6DLMR4F@%Q
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MN^&,", Q <]">WX_I0!Y1\-?#GCW1-)UFW^(7CFU\?7^I^)M3UC2;S3O"?\
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M?, #] ,_E5RB@"M]DA]#^8_PJS110 4444 %%%% !1110 4444 %?E+\<_\
M@B__ ,$Y/VA/&?C;XF?$;]G?2KKXI>/M6U+7?$GQ"TCQ9XUT[Q(_B763F?6T
M0>)/^$:25@ZHH/A6;& PC.'#?JU10!^8OPT_X)&_\$\?A&6G\#?LT>'M,O[F
M/3;>YN[O7_&>IZA?G0D/EEVUOQ-)N#2(65U*(PD^Q 'PL!:'W_QQ^Q;^S?\
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MI5FUS1$E270]$ 509Y5#8(*$MO% 'V3]I^?;Y3=.O&>N/R]O7VYK\\?VK?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MTCP?X&\/:;X4\+:%:FTTGP]H-G_9VFZ>@ZI$B!>F>"VYCU8O\H !^-'["O\
MP1\^''[.GB'7/B+\4?L7Q&\0:A:Z*/#GA?Q#&-2\+^!M5T.12-3CT.3'AB5O
M#)_T7P08E9D\(2[!B52%_:;P[X9T3PII]OI'A[2-&\/:5; XTS0M(ATRP!]0
ML*)'QGKMR>A) KIZ* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M8WIP,UZ[7\J?_!$W]H?X.^ ;CXG_  ^U77!H>LW.DZ5?W7AZ]U=M373SH/\
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MU_;^A:+_ &'X@SX8_P"$BR,?\(MT\:?V!_PG- ']YL?W%^E#.$ZU^1_[&O\
MP5,^'W[1NHMX#^(NCM\'/BI:Z1]OOM'U^-K'0+[]TVMEH_,:5/#^/#I218O$
MWBE#N5AMD+E&^+_VF/\ @N?H/PZ_:#D^&?PE\%S?$OX?^&KO3$UCX@6OA\ZA
MI6MQA=:3QNN@Z['XBCD;P^@B\Q/%TOA&7PFC:+*!.590H!^]GQ,^+7P^^#WA
M\>)_B=XST7P5X?:]BT:VU;7+X::M]JFL[UT?1]&25F&LZS,T:Q1Q0EI,AG'2
M8IQGP(_:$^$O[1FA7OB+X4>*[77K72KQ])UBR\Y?[3TEAK&LPI+J^F$!;=_$
M0T>:6-BIE="^TYC;/S3\1OC-^RO^T5^QA8_&CXJ06?BSX':[;:7K%W_9>J[=
M2T+Q*-9.B"1-;$GA5M#\1>%/$+ZO;MO:#$D4LRJ8V2-OSG_9_P#^"C7['?[+
MG[*>J_%7X=?#+Q$+;6OB1XGM-4M\:+I^L:W)H8\0(QUG6W4HA\*PZ-)$?#:_
MO-DS^-E*?\)>Q< _HXHK^=OPA_P7,@\3?$O6-+;]G'Q==?##_B;67AWQ7I9#
M)J>JZ+ =68OJS*8,F(_\)+E8UQX('_":#$+-&WEGBC_@X/DDT74?%_PY_9ZN
M]>^']KXETG1SXM<ZSJNF!D_Y'C1D!_X1%=;\1+U\#1Q!(_&!),:QL2: /Z=Z
M*_G[^,G_  7#\&^#_ WP_P#BS\.OADWC'X2W/_"-K\1_%6HZ\^G'0K_7I'9-
M#T-R$,853&T/B?Q,L;>)V#1VW@W826^Z?VDO^"@?@#X%?L?Z?^U+IVAWOBP>
M,?!VEZY\._!=J7.J:AK.N:+'K_\ 8FO-HS2MHB>%D91XT92WDB)XA(&^1 #]
M%HI8I03&P('H,5+7\^?["/\ P6K\-?M!_$[3_A!\;/"L/PO\4>(-'U*[\)ZY
M>P2:;'J*Z$ZNS:UH1+>5*WSF7R]B>%M_AI+O>?%\<L-CXN_\%P?!7A_XE^/_
M (.> OA;=ZGXV\%>)?$VCV&JZI>#Q#I?BMO#RD1'0]#\/?\ %2L/$K$3P*RX
MB\*@W"X?8(P#^@2BOQ9_X)I_\%8_#/[=VJ_$KX=>+O"<7PX^*O@;6EL[/PXQ
M3^S==L1H<6LZNT;MXB\7&,JZ:S,@&,>%DBF38ZD-^JGQ2^(FC?"7X;^./B9X
MCMBVD?#OP?XG\::Y;6>#J+Z7X?T5];UG^R2<EG"K@DC&X 'G9@ ]2HK^5.^_
MX.4O!6J?$7P!I6F_ SQ!X3\ ^)[(WFJ>)/B#L!A_L+7"VM^3K?A[Q#M7;X<)
M0A_!K_\ ")^+SY5Y]IC 4?:7[1W_  6_^!?P:U;X7:1X*\&^+?'\GQ0OM.?2
M=5N5?P[HY(_L9=5T(B5V)\1QPRZW#<3IY7A/PPL47C8R>++4&T(!^[5%?S^_
M!K_@N7X \1_M)>/_ (%?'GX7:]\ (=)UL:/X0U7Q&Q-_)J*<:W#KJ8VQQIA6
MB,"HR2+O;S%DN8_"GMW[;G_!5SPQ^SCXFMO@I\"O &K_ +27[0MS9I>W?@GP
M7;-JECX2TQ-"_P"$X76==DT)!/XA?Q/X="S1:!X6=KKS26\X X8 ^Y]0_;+_
M &8--^/'_#+U_P#&+P_:_'H1:7./AV]KK1U@+K;YT9UG&AMH ,X"E"UV63]V
MSG<&KZE\V'U_4_XU_!Q_P3R_::\;?M+_ /!?+PA\7_$GP>U3P1XN^(WPW\2^
M)+S0-6LIO#VG:?I;?#/7?#^N-H;QR>+)@RG1-<\5>>)%;Q>1_P (:T@V%J_K
MU_;B_:"MOV8_V:OB3\6GO&T[7=)T9K+PC-+8KJJ?\)3*BKHA.492T:;_ !&1
MXDE,.-%F616.T@ TOB/^W+^R1\(/B-:_"#XC_'/PCX:^)6I6SW-EX2G.M7NK
M"$J@WR_V+HDZ:3*QU6(*\LD<@1OX7#*?'O'G_!4?]B+X<>.](\ ^//CAI7AK
M4-=M[^\T;5K_ $W4TL-4U'1G*7&BZ/"RCQ'K&M1%OM"/!X9F\--"F%G$P\F3
M\#_^"'_[/?@+]NP?M0?M!_M2^'M9^)WB6#XO:=9^"=7UG5-9T!++3=8&O2-H
M"Q^'9H6T.7PK&-&:/PFL@_X0M=;DD/R^*F!_6W]N/_@C/^R_^TO\*[H>#_A[
MI_A+XS^#V?6?AGXN37M854U*)50Z)K_]N75V7\/W#I+<PL/+">+9H/&$B"ZB
MD,H!]LR?MK_LS_\ "X?A3\%+/XM>'M7^(7Q?LM:O/!UKH^LZ5JNG9T:.+7#H
MVLZNBM%HWB'Q-%&JVWAP0_:2NZ$^2TGA?[3]IU_GJ_MF:=XO_P""='_!0?\
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M&;P!XLL-#^%VE>*X=)TL>(-5U]XM?\;HVJ>'E,4OASPD=;T61?#I>.>V>,>
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MO"+'K[^:R1B0@ _KT\Z#/DY[8QCCKZ_7FC[5;_\ /<?E_P#8U_')^S=\2?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MIA%X>UKQ,/#;?\)0581^$/&#:^? K*K^+2*^.?V??A;^TC^W/\>_BSX1\/\
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M?YGVD&&NE^#/_!)__@H!\&OVH-0^/O@WXQ^$?#G]J:MI+WMG9:Q_:9OD.?\
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M/"T'C_7+;3?B1H/[0G@3PQH_]K:P--_L'P'_ &UG7?3_ (IW_A)/^96\)_\
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MKXP_X).?#>>#[-HFH:7^T)XHLOM=I>#4O[>TO^Q?'W_$E_MSKS_S)&<X&O\
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MSQ'X=UO3RF FM:+K44D=PHSEHVWQA@I<.0 @!_'1^QU_P5\_9N^.?BS]G/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** *_DP_\ /'_QT_XU8HHH **** "F>6G]T4^B@"OY,/\ SQ_\=/\ C4OE
MI_=%/HH 9Y:?W13Z** &>6G]T4>6G]T4^B@!FP>I_3_"C8/4_I_A3Z* &;!Z
MG]/\*/+3^Z*?10 S8/4_I_A1L'J?T_PI]% #-@]3^G^%&P>I_3_"GT4 5I,X
M'DXSCCTSVQG_ #T]Z^-=?_8*_9D\5?&VP^/VN_#33=1^(&EZ*=&LVNB/^$:4
M8^]_89!0D')&1M..A K[3HH BC@BA!\J,+G^[W_,U+110 4S8/4_I_A3Z* &
M>6G]T4^BB@ JO^Z_SMJC=ZA;V,5S<7TJVL%M:"[N[NYP+&S"@#YG)7G.6(!S
M@9!)R!^&'[3_ /P4N\5>+OC;;_L=_L47%IXO^*-VS6FL?$/2-$UCQ%X8T$'2
M2ZZ-HFM@GPP/$B#_ (JEF4^+U;P>7E"*7VJ ?>7[9W[>/P=_8Y\*7-_XKU@:
M[X_O;-U\(_#701]OUG7]27"1QN%#?V-'@O\ /*XXVD*^[</Q_P!(_9:_:[_X
M*>:KI\O[5'BOQ'X;_9:U2Z?QOX9T52OAO5FU-"/[$*Z#D9\1 OK()( \%'0U
MR?F'@L_0G[+/_!*F]E^)EM\?OVT)AXX^(&@WXN-(\*6NL'Q%X9OM7)13K>M[
M@JR*I8B0K(#XS<'QGX[#3'RQ^\L47DY (\G' _D2* /)O@G\&? ?P*^''A[X
M7?#G1;?1/"7ABS2TL;5=KWUTQ2)CJFL2^1'))K,C(6DD8%B3P4PJ1^P>6G]T
M4^B@!GEI_=%1>3#_ ,\?_'3_ (U8HH **** &;!ZG]/\*?110 4444 %%%%
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MNV)M;S1O$-H%DLW=2QU/1]90'7-#G5E(,L,N[*JA.S<S_P K_P 8O#W[6O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH ***@F_P!2?H/Y4 3T5^1W[>W[</Q(_9K^-7[)_P *_ ?A
M4ZC9_%GQ[IUUXZ\27?\ 8YT__A%=VN@>#]$\P$;W,:2^-_$Y4KX'\%D>,RK;
M"6]5_P""A'Q*_:E^#GP1UCXP?LR6'ASQ=<^#+>/4O$GAC4_#VN:_J:^&EUR-
MM9\8:)HOA^19=>'ACP^SYM@TD1AD?QA,#%X7\N4 _1*:=88VFF($..< Y /3
MTS_GI4/VS_EC_P M\=.<9]<_7W]J_+C_ ()]_MX>$?V_/A'KK7]IX9TWQQI]
MCJ-I\2O FA:RNI?8=*U_6_$6ARLNE2"6;^P]A*1>)OFB\:6Z)XMB2U1AX6A^
MA?V7_P!FW_AF?3/&NC0_%'QE\1]'\6>*DU?PQ?>*KQM0O] \-!#/%I$LD3@Z
M[K;2ZOK=LWBAO];X0T3PK T;1^&%W@'VE15#[59^=]G\X?:-OVG[/GY\8ZXQ
MCKVSUYJ?S8?7]3_C0!8HJOYT/_/;_P >/^%-^UP>5]H\U?)]<=\=/7/>@"U1
M7S_H7QZ^$_B?XFZG\*] \<:%KOB[2M*36YK+2-0TN_5#]YM'?;(%_MWRUCU\
M0I$"RK<&1VCT"Y5/=_M5O_SW'Y?_ &- %FBJ_G0_\]O_ !X_X4>;#Z_J?\:
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M3P#X'TOQWJVM> [DC6O$NEZCX7Q_Q(U.ACQ$WA@^'#T\$@*21_R/@/2OWO\
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MI'9W#1^6R!096< _HFHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "H)O]2?H
M/Y5/4$W^I/T'\J /YK?^"E]X++]NO]F>?Q3<7EOX8NK[3;*VU:71UU*70/"Y
M.=:UG1L!?#7RZZ=7$?GC[3_PEWE&YSX)+D_T3>);W2])T'6=5U1K==&TS2=2
MO-7XQG2TT@^8/HRKC/\ =Z8YK^:[_@J7\'_VV_BS^T!\,/%_PM_9TUCQ+X>^
M%GC[5;[2KOPW:+J8UW3]&T43Z(SA>CRB43,3AG\P>"C_ ,BID[VN_$K_ (*4
M?M[6L?[./BGX&7?[/'@CQH7M?&7Q!TBT\;>'O^)8=$#/_:VL L%\/2,@=TA1
M?-ESX)96E8L0#\_/V3!XW/[2W[:%]\.AJ/@KP?:^ ]3L]'\5^"/^*<\,W_AA
M=;U\ZX?[<T#_ (J?_A'E\2#0F\;$#@KGP"17U_\ L^^%_COXO_8+_:F\1>./
MVA?'^B^'_!_PX\3ZS>7>D7H&W5-!T7^WF\&8Y\,Z !X<T,>%_&__  B(.#X@
M'_"![?'.YQ^L/AO]C#2/V4OV'OB)\'O@1X>'B;XGWGPJU2RN_$]H5\/^*?B-
MXL31VC9EUJ)&9>9&B\(>&VF\N(QK&H!ED>OQ ^%?PV_;G\!_L^_&CPY?? 'X
MD:WX?\>> _%'@N\\)Z39^,N-4\=:+_R&_P"PQG_A'SX3\1^N/^$+Y\<_\5E_
MR)5 'C/['_["?QDU[]A33OV\/$7[9WQ<USQ=H-WXI^+=]X O+T:EIGA'2M"T
M0,FCJ#PZ9#>))/"RM_PB'C#P?K\/CIH3XWE\U?%-&_;H_P""G/[4_P -M:L_
M#6G_ !0\:^&=6\2CPS:WND7>BZCNU77-$P#HNB ?\)1XA\/!0%\#Y/\ Q68'
MB<>/< <_O'_P1_\ A/\ $7PG^QAXP_8T^/OPE\?>$K32['5C%K_B(Y_M_P ,
M_%8:\/['"_\ "/1C0/$/A-BJ\OXM5BZ^-3(GF@U^>.D_L\_MR_\ !'_]H\^%
MOV<M#\1_M#_LW_M 7_BBQTF[L_"6KZGXG^&9UPJZ:WKC1NW_ !4'A=#H$JAB
M&\;1:(F]%_X1,H "AX:_;4_:ETSX!_ 'X(?$SQ?\1_@GXGMO$OA:^L]?TF[U
M?_A)-=\-:YI#:-H7@\>-PO\ Q4.@-(QD\%,<G=_PC'@CQ[AMQ/ZX^*?^";OQ
M>OOCKXH^)FC_ +7OQ(L? WB?X>Z/X9N_![7NHG4[_5(=/70?[.UOS)1'_P (
MWXC*"\8AO/C1%\#I$?!@$%>)_P#!0+]@3XW?%G]B+X:1V7C?5=:^-7P+\7'X
MO3G5[ ^-O$K*NB:\?$/@SP0!EM<\11EM #-,OBP>-6T3Q(@+/XPQ7E_[$_QC
M_P""@W[4^B:1\+?BA<>-?@GH%MX2TTV?BJ/P='X9U0ZMX-TI3+H^M%_#J>)
M9)#YLH# RR: ?!(#RM_PFC 'GG[".F?\*L_;6^).M?$<:UXFT[P=9>*%TG5+
M7P?_ &DI&A\'6=='/]@?\(H">,#_ (0SID#Q>:^C/V=?VE?B[^VK^U1\5M0\
M'>,-9^'7@/2M'\4?#ZTT#[7_ &5\NBZ0K:/HNLA%D8?$3PGXBUK=XTC&X^#F
MUWQ(G@63),H^<O@G\/?VF?V9O^"E.K^%=;^$OB[Q]\/O$&KZ39CXB7/AP?\
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MAJGPK_X*=?&CP=JPN-%N/"WC#5+.S&KW?]G:G?G7-%U\ZX0!DD@C(_X2S/\
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M&:\(_$&@O!X?\+(->G\0,DOC$.WBZ4Q2*? L:-N0 '\__P#P;8?$WXF_$?\
MX+)^*/C#XGL+;Q7JWQ/LO'=KXE\5ZSH_]I:EH(.B:\ROH>MM@>'@5"^&0>A7
M;X''&#73:;^V5^U!\8/^"LW[?_PQ_9LOKKPGXG^+(^)_A>RN] O&U0_V8FM+
MH6N:VS-DZ!XD\5X4[B2?!9QX'SGD\/\ \&^O[%O[3/[2&D_%#XO?L[?&+4O
M.L_!SQ1IOA/6+71;S^P?$5@_CC0_$6ADF76?^$5B$7_".1L%\.%Q"YV!9"TD
M:MZS\(/^"5O[97P,_P""O'Q!^%?PS^+6B6_Q>C^%<GQ$L]7L;@6%AJ&EZZ%U
MU]#_ ':M+(?%?EX7Q)XKWX?>/'2;Y'W '[)?L^_\$[_B1^S=_P $T_VK-9^.
MOB?6V\7->:MK/PZMM5TC6-.U33=-&KZ"^MC74\0?\)<54^(AKG_"%.Q_XHIG
M\0^-E1O-9X?V*_X(UWNGR_L>&RAUJWUG4;7XA:R^M1?ZL:?J&KZ+X==HGTOK
M ) Q*R[A_P )AM?QX"&\6@UP*?L,_MO^,/V3_B[^SQ\9/VGO WC;Q)X\?3K?
MPQ>/HVJWWAO3]-14U9M+UC6YO#D?BMA_PD6EIX@\Z(./WPB+ 2!3W_\ P2__
M &'OB1^Q#X8\6^$_%OBC3_$VCZ^S7MDVF:GKB+ISQB-BIT*15\-A@',;2!&C
M@G5[?P0R>"P(6 )_^"W1LY/^"7'[8-O?RP6]O>> O#&G-=7=]+IJQ?V[\3/
M^B%BTN%N<G550>&2/,\:$GP8,)<MG\P?V3/V>_VP_'O_  1)^&UA^SG\;O&W
M@OXLZKX;TN^L])M%T5EUWP&FM@ZWHVB:[_Q2(_X2/Q7X>(V^*#\W_"&G_A"
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MQ#X*\(ZYKSQC( RZV^T'.1PY' P ?PS_ !<T:R_X+!_\'1%Q\$_'KG7?V?\
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MB*R2V\6?M(^._'GQ8UB]#*6O=-?7-7T/1-2<<^6T@T;4V7.&*R(_"D%OZ.Z
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 ?S0_P#!S]^PI8?M5?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%5I<PQ?N0![_\ U_\ /\Z
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M1].T;P1\3OASX6^'G@:"PL]&TO3;&3QG^S0/ .CCY0.#XGC9'4+A@64  XH
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M)6EI!:1K#;H(8 #BW &%SP<<D@?0\]Z )(8O)C([_P O3^E6*** "BF_Q_\
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M2?\ 9A_91\6:2(_ UAI.NG&A^,O&G@?Q &9O#^T,_@OPQXGCD;Q9$/#<[*?
MJPPS_P!B5KIUG86MO9642VUK:VQM+6VMSM$:#L"..,#EN <DG)H _@X_X/"/
MVKKGX6^*?V$?V7_ ]C:Z-?\ @VTU7]HY;NRLV/V!8]9_X0+P1HVBC&U6630_
M$ 8J,;%4DY&%S?\ @V:_9&^)OQ>_:%^)'_!7G]J_0K/1O!&G> ]7L/@EXT\1
MZR!ILFJ[&T/QWXR1?$15=#\/^%/#>@G_ (J8NBE=?9F=0O/]#W_!73_@E_\
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M^%/B9>:/XE\,^+F<+LT76M;"^$?["1@6S(.$VG=@*Y7^VK_5I_NC^O\ ]?\
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M0H%R"=S%=GZ-5^2O[(7B']G7_@G3_P $]?V5_A1\7OCE\,?A%I_PY^ G@/\
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M0K(A9O[<C\XZ"I1LJQ\-VUMAN/FP6'#'_@UY_P""<,%TM]H7BK]K+P4]L/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M'VS^5 %F64 ?KS_G\A^)K^0+]K+]HKQ+_P %?_\ @JW\'/\ @GQ\"X=;UO\
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M41:]GD_\N^??M0!_8'17\G3?\'@7_!-HVNH7"_#3]J"X:U)%A;VW@#1'.M9
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M[POX/TC3/#?AC1]+MDL-.T71]%TI-$T72(D0_-' C*L6WYB,*06(:0 _A?\
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M^!_A-X$\)?#;P?I0/V'PGX&\.:3X;\-V9/\ =T71(H(\G' R1GD]* /2(?\
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MD#DX  K\Y_\ @I7_ ,$GOV6O^"GOPGG\%?&GPN^@?$#3+346^'/Q?\*E-/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %,\M/[H
MI]% $4L44H D4$#U.*^"O$7[ GP(U;]H:^_:6T72KGP9\0M>M_[/\8#PI;1Z
M;IWC#4@Y;^W];"8#>)#:YT(>(U7S#&-H&_(K[ZHH ^+_ !+^QQ\)?&&N3ZYX
MQM/$7BQKJ\TK5VTSQ'JK:DO]LZ( J:S_ &OO$@W>'V3PUM9O]7_'SO'V-%%F
M+$L0SUQU_P#U&K5% $31QR#D CV_S_G\:=L'J?T_PI]% %?R8?\ GC_XZ?\
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MZOX@\)+H?A[PA&B>%O"+S333>*X-9+>.@OC!HFD_E._X*(?\$(?^"C&G?\%
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M%JNH?$R;]E_PE\+?BCJGB+4==\277P_\1^#_  SIFO!]<*ZYX+(;Q&/^*?#
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M^*_[-N;33;K=I.D_#/PYEETAE==%T7_A&R= ?Q7(65]S%O!DA;<=Q:H88O\
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M _A3_:>_X(O?\%;?BY\']0^/'Q)^/%QXX_:6_9]<^)_@IXAU/XD?VE\7[!O
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M ()7:!?VT^M7O[4/Q"T^U?[2WA_QK\;&?3;M\='7PWX:\)G@X!R5 )&2,YH
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MO"FMZ1J\ W>)Y)G1M7U37];4EM>EE;2- ,,3#_BDSHBJ@<2<_MC110 4444
M%51#"(SY,2^P P>/KS^M6J* /Y9O^#FO_@E?KW[='[-/AS]H/X&:)J^L_M+_
M ++/]N7_ (<TG1[6+4-2\=_#36[A-:\1:$RA@3-X5GT@^)O!VT'$^]'(=U#?
M$G_!"?\ X.//".K^#?#?[&O_  4/\3+\./BA\/K32_#/@?XU^+=FFZ9XRTP(
MD>AZ-X\^7&A>)1$HC#,%#JB(Q50 G]MDT/F_Y_G[=.]?A;_P4%_X-\O^"?O_
M  4$N-0\3^*O!FJ?!3XLRP@V7Q1^"AT?P[J3:HI5?[8U[P@^B-X<\0R!0=_G
M1AG+;O-W!B0#];]"^/?P7\3:'+XL\/?%_P"&.N^%;9=.-UXDT?QSX1U3PW9_
MVS@Z09M:AUO[-&9,[D#R*9RS") 00/EOX_\ _!4?_@GG^S/;VUQ\9_VO/@[X
M:R@NK6UTOQ%_PL35&VDC<V@?#^+Q5XESUP?)4,,8^3 K^2N7_@S&^*<5_-!H
M?_!1C3K;P\;K?]EN_@EK/]HA<9Y<?$@ISG(.[D#(/2OMG]F;_@T(_98\ ZSI
MWB/]J7X]?$']I.XM2UZ?"&DZ/_PK3P\^J#46G5=7UAO$?B[Q/X@T0L$3R+EK
M9@K/(S (!( ?/'[4G_!V+XV\:>+X?A#_ ,$T_P!ES5_B1XQ\47FI:+X:\9_$
M[1_%NJ:CK^/-_L+5O!/PN\/HDS:YF;2)53Q<\D<4@1(8_%D9V#SO]GS_ ((1
M_P#!1/\ X*K^.M*_:$_X+)_'WXX?#_PQH%[IQ\.?!N\?1(_&^N>&V82/H^C:
M)X>\2#PO\'?#SM)K18MX-;QJ3+O*Y;</[!/V9/V"_P!DO]C/P[-X;_9G^ 7P
MU^#^GWER;J^N_"7AT1^)M2?:&/\ :WC-P_B23?W#S-Y8^7+9?=]DPP^5_G_/
M'7O0!\U?LT_LN? /]D7X<Z?\*_V>OAGX:^&7@?2K;3!=:9X>L2LNM/H^D1Z%
M#JFOZKY;/KNOK#I*":5V60 ;F1/,7;]-;!ZG]/\ "GT4 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% %?RH?3]#_A1Y4/I^A_PJQ10 44
M44 %%%% !1110 4444 %%%% !1110 4444 ,\M/[HI]%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M7_!7M/B#XAN/!_A_]G:X\#VM[J@\.VM[>@:;?::NJ^9HGF$X\3HPA <[]N$
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BF;QZ']/\
M&GT %%,\Q/[PJ+SH?^>W_CQ_PH L444S>/0_I_C0 ^BF>8G]X4;QZ']/\: '
MT4S>/0_I_C4)E@A&,_B!GCK[?Y'M0!9HJOYT/_/;_P >/^%2^8G]X4 /HIGF
M)_>%1>;#Z_J?\: +%%5_-A]?U/\ C1YT/_/;_P >/^% %BBF;QZ']/\ &C>/
M0_I_C0 ^BF>8G]X5P$WQ,^'=M=SV%SX\\&V]]:W1LKNTN?$>C17UGJ##'E/
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MO!]-_:5_9TU26X@TKX]_!O4[FVM!>WEO9?%+P;J+6EB0/WDHC\0,(U..9&P
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MFVA?;W7.  ?M%17X)ZC_ ,%XO@196VI?8/AGXMN+BVLU-F;KQ'HVFZ=?[5V
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MG^P=J6EC74_:B^%]O9&'[4PU;6=3\.WJC)P!H^O06\Y!ZXVJH)^[D9KQ*_\
M^"+?_!.^_P!'GTB?X 6ENS@M%JND>)->T[4;!0 1I&DR)KS"W7&1EP4R!\Y)
MPO.2_P#!";_@G#+%;PGX/ZT5MON@>.=;!7/<\G.?95H ^L='_P""B7[#^OQ7
M\^B?M.?";4K;2QB^N;3Q&I6RSQ\Q*$GCT('U'%7(O^"A7[$TU]!I\/[4'P=:
M^N[K[':VG_"9Z2&=^.AW< XZ%^I ]2/B"?\ X($?\$U;A)H9?@_XJ1;D9:XM
MOBCXS9_P99@J_BK>OTYC4?\ @WG_ .";]Z]N;'P/\4O#1M;7:MUI?Q2UJ_9F
MSV'B0>*CG'/YX)H _2S4/VT?V4](U&#1=0_:)^"UKJ-T";6)?B/H5^['URD[
M)[<RXQU(%5KK]M+]DJTU.UTNZ_:3^":ZG=+MM%M/B5X1U" @9&/[46=X@"#W
M9CW).:_,*#_@W5_8#@FN9X-5_:%AN;K'VRX7XDZ&&N^.?,)^'F#SQ\H&,<9Z
MU2N_^#<S]@66Y^W1^)?VF+:Y'>S^*>BJ,?3_ (5TYS^/O0!^Q7AW]HOX"^,M
M3M]#\&?&WX3>*_$-RN+71_#GQ(\&>)-3<G^]I.A^()9& !P" #Z'CA;O]HS]
MG_3WN(+_ ..'P>TV?3V%O>VU]\4/!FG/9_+G$BOKP$9 P & 88Q\I! _#5/^
M#<G]E6.S\3L_QA^.=KK%Y<[_  ;K%CKB62>%0@!TB36=' "Z_K4995$OAC_A
M"2S9!C3Y ]K4O^#=;]GQ;7PS=>'_ (^_'73M4TK1M)M=8N]4N=)U22\U+1$4
MKK&A"(>%AHTAEWY'B<^, $9<!B S@'[W^#OB!X(^(-G<WW@?QEX3\;6NFW)M
M+N[\)^(M(\2V%AJ"C/ER2Z*[C=EOXRI^]M PS#N?/]OT_P#KU_-CK?\ P;G_
M  [U&2VGT?\ :T^.FG0V]I_I8O;4ZAJ&H:EQND,D?B+PN%7'*;@-QP"1DX\T
M^(/_  ;U?$Z'[-!\-/VMM:U*Q(_TT>*SK/@KL,X.@#Q:Q /&=HSUP#Q0!_4S
M#-YO^?\ /'7M22R@#]>?\_D/Q-?R77?_  0#_;*.C0:38_MM?9K==9_MDZ3:
M^(_&2^&<]@-#/AL ]<#&1SV.!6Y9?\$%/VM/!4=Q+X"_;K\4+J5UH&F1W=S_
M &MXQ\/DZI\W]M:2_DM*-;BD"ED\63F,X^5_ J/A0 ?U:?:5\S;CC_/.?KQC
M],T[S_;]/_KU_)!=_P#!&K_@IK%I6GZMX;_;4URWN;JUTT7GA'5?'/C;?9?V
MU(NL^('UF/\ X2'_ (1N37ED95\;R(K1>- =P?:=U8G_  Y[_P""O$(^W6/[
M:FH^?]DVYNOB3XR_M+=R,9Z9[=0>@H _KZ\T>7GOC'MC_P#5V_7-5_M?_3']
M/_K5_'K-_P $A_\ @LW_ ,2T6/[;>H6PM_\ CZ_XK[QB-V#_  ^N0>V>O>N_
MUC_@F)_P6VU+1K711^WKXD.GP?V2%TM?BCXTT_2FTO1<;=&_L5/$9&TX!W9V
MXQEAQ0!_6GY_M^G_ ->F0W(F\WMLZ=^W7\\<?CWK^0^]_P""5O\ P6BMXK@0
M_M;G6[D+OL[JZ^+WC73S_:63SA?$9/;@'GC@'FN?G_X)<_\ !:>ZAL-6U#]J
M/Q7<3@&S;2K;XV>,M+U'3P-8WG6FT70/B/\ \(NK!?G*D^,&VC=MQDT ?V)>
M:?\ GB?T_P *6:7R8P>_\O7^M?QZ6G_!/O\ X+S^!Y-2L_!'[2?BXVRY(NK/
MXU,S>("$W?NUU_Q&6D.TX \4#PB2<JH)XJ;5_P!B+_@X!U=-/-[\=O'NI/!=
MZ9>$ZI\=M%)T/5(<@ZOHK+\1^J%B C$$98*.&% ']@<,OFQ9F &?R/Y=.?\
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M_F_Z@_9\8SCGUZ=.G-6//]OT_P#KU_(Y<?\ !"__ (* ^(E@L_%?[:>IW5L
M;\BX^*?Q-U;3K'4B>JIKGAIG8'/&U6//YZ.C?\&^'[3-[XCL(/''[7EO;^#^
M/[8U;P]XD\9:EXE8$<8T3_A&O" /X>,?4^] ']:7G^WZ?_7KA/$GC_P;X3@^
MU^+O%7A_PK:&%KJ*\U[5M+TE4TY=6T71#JADU>7RUA37=<T"W$C+Y7GZWH,3
ML9KB.-OYJ-!_X-W-2OHA#XU_;"^)3Z:1IA_XI^RUJ]U:^ T>(2.=:G\21?)!
MXBES<DG/B]U/C+;X/N?W(Z>W_P"#;#X<&'R;_P#:\^,E^;FT"WUR?#B;KW/]
M[;XG*CC!'.[!Z'I0!_07J/QV^#NCVVA7^L_%'X;Z'8^)K+^V/#5UK'CWPAIB
M>(=+"9_M;0S)KS#78#E1O@#*2.F]2IS/^&H/V;?*\_\ X:!^"OD8^]_PM/P5
MG\O^$A]>,8K\$=!_X-JOV=X=04>.?VB_C]XK\/O;:CIUSI>@WR>&-1D+QK(&
MAUQF\6/H@_X2-AXE!1"3*=NW"NRZME_P;:?LM0R0PZO\:OV@M1\-VOB/Q;?)
MIEEXD;3_ !"='UC21'H>F'6Y6\3!=?Y$GCGQ+_PBI'C1?]3X.\**!(P!^X47
M[7W[*T\7G0_M-? (@_\ 58?AKS]?^*EZ >YQWKB==_;X_8U\.7!L-6_:@^!R
MW/V7[7_HGQ(T/5&*YP"3H;S KU/!#$#!4&ORRTG_ (-Q_P!B&SU.^O\ 4_&_
M[2&I6VY?[)M3\1M(L-3L4()(UG6T\.9U\_[3J%'/#5TMI_P;N_\ !/:SOK?5
M+P?'W6Y+8Y%EJWQ57^SKN(D@:9-'HGAV!_+##YE0LQZ*3U4 _16;_@HS^PU#
M"9O^&H_@\+<\Y/B2//YA?;^Z*S=1_P""E_["6F\7W[47PFM ;O[&1<ZWCYSU
MS\H&..O?CY:^'HO^" G_  3X.KS:O+X7^*]QI1_M''A^]^*6L-IEIO+?ZMQH
M0\3CY0I&?%C?[)?HO5P_\$%/^";?G07T_P (_$9N!SS\2?&@&3Z$>(2#^!)Y
MZ4 ?2>H_\%3_ /@GK8V<-[-^UE\*)K<O]F!TC5M2U7+^@_L6&8#&.NTD=%..
M#Q][_P %B/\ @FY:7]S82_M8> IKBWN?L326>E^,M4L%D)&535]$\,3PJ#SD
MEC@\ ,!NKRR7_@A1_P $YC_S2KQ>/K\4O&O\SXB'M],UT]K_ ,$4_P#@F_8W
MMA<_\,W:9<V]K:&RNM(N_%WC(Z;J6,DZOK*CQ+EY"%;"KDD\A2010!2G_P""
MV?\ P3GAU*.*U^.R:SHK6%_=W/BO2/!'C:3P[I^IG6?[$T;19"?#(UX>(?$D
MDCK;1+;NF$#&1#*RQ^9WO_!P)^P%:;/L]]\5]2V\7GV7P;I#'3N N=6_XJ?]
MR?\ =W<8X)&:]Z\/_P#!'7_@G-H6KW^JV/[,WAK-T!]EM+OQ'XTO]-T_@'.B
M(WB3<@/]UCD#@G@FNWLO^"7'[!6DWW]K6'[-GA(SFSU"SNC=:QXPU,%7V\_\
M3WQ-)GOE@%7I@[1O(!\:ZE_P<._\$]='E\C5=1^+EM/_ '?^$-T #_U8>?Y5
MQOBC_@XD_8UTM]-/AKP;\<?$4EYK6EVFI)-X7\'Z5_9WAB1D:37-)\SQ1-_P
MD5P-KE/#L310RFYD^U>*_"AB5I/TAU'_ ()R?L3ZCXHMO&K_ +-7PVM-;LX]
M+2.UT[1WT#PP#HF1"\W@?0I%^&\K87YBWA17E)<E]Y#+L7/_  3_ /V,YO%E
MCXXE_9L^&%OKVC(OV*VTOP\-.\-\ *I;P7HSIX6<]V>3PMN)^\23F@#\?9_^
M#CGX37.HR#PQ^SA\0-=T-3J#0:Q/XEDTK4)-.34A"=9_L&3X>3.L991((VFD
M;<!ODD;<[Y5[_P ''7@[]_/X;_93\<>([8 YNO\ A+M3T[[')QC2F+?#(GS5
M(W JRJ3U4X&/W^;]G7]GV:/18YO@5\'KA=!!_P"$;6X^%7@PKH'R_P#,'#>'
M"=$ ;E?)$;<$9-;G_"EO@^;F6\_X5=\.!J$UK]E:^'@?PG_:!LO[A?\ L3>8
M]QQY+J\9X!&0%H _G!U#_@XJU+[+<7&B_L>^)[I[NYTU;4KXGUW45T\R(%<Z
MKYGP[\*OJR\':L$J;>,LQ4$8VI?\'#_Q3@FU&QL/V4M%UJXMKO\ T.ZL_$?C
M#^S+[33P9 3X9)+]N21_LYZ_TUP_##X;VT7DP?#WP3%!_=@\)Z&B]?5+;<?R
M_/%.B^&/P]A'[KP#X(7_ '?">BY_,P_UH _EYU'_ (.!OVH+K3YQH?[">J?;
M[FSU+['=77_"87^F$QX )\M4&#@$@_*<  ;,J>0A_P""\?\ P40O(RUO^Q;X
M!$'V4L;O_A'?B;BQ;&,D'Q-CH!P1CBOZYX88+>/R888(+>#@+@;1W) XP0#U
M))/K5R@#^1'6/^"R_P#P5.U'1[5K?]D/P%X2L/%&D>)3X>\5W?@/XDZ<)!&I
M6/6-$'B+XC'PQKJ1MB55@_X2Q?,!8@AY%8@_X*Q?\%9/%/A"_P!,\-_LZ^!!
MJWA_2=^K>,M(\"^,M0\1:=I^A_V,?$.O:Z$\1^+?#>AF7S]$WI+X2DB5M;BD
MCCCD0N?ZZO*B_N+^55Q:01B?R885,X^8;0 QQ@D\'(YS@8_E@ _DIT#]LK_@
MO%X[\-:-XA^'_P );KQ)HVO#%GJ]K\+?![/8@="6/AS_ (1HG_:+$^IJ>[_:
M<_X."TC\J7X/>);?;I&FW?VNR^!7@[4M1W X<,J^'-I8,I'S#*-G&"6K^M?R
MHO[B_E2^6G]T4 ?R8WGQ!_X.&?&]UHT\_@WQ'X;MKBTXN])\->#/#>TXQG7-
M#['GJ.<$]S7.Z\O_  7TT[5H=!_X2+XG7-GJW]G?9M5M/#6B:DIW%O,W:WX?
M^7P_N8Z+OSU).X9)K^O.B@#^0,Z#_P ' -F_AVPN?'/Q?NKO4_[3O5NK;1_!
M9;3_ .Q&W+_;?_"/^&_^$9 9M7W#''C5HLCF/CT#P?\ !K_@O-XG$^KCXT?$
M>PFDN=3T>\;7[KP;X>6R08(_L+1=?\1^$E(.\%/%'_"($N"2@8!L?U<^6G]T
M4;!ZG]/\* /Y3KS]F;_@NOXF.JO??'3XB6]S9VQTI+>T^(W@OPYMD*:#K)=6
M\/\ Q(R',;M'N4Y,;,F=I(KG?#'[$7_!;OQ$WAV2_P#VI?C;X4TF?5_#GVJ^
MU/XXO+JJZ5K@#2ZQK6B1_$5V'A[PKM * CQM)(H1? S.H _K3\M/[HI/*B_N
M+^5 '\K.E?\ !//_ (+*^,[FX\.^(_VV/C)X+\/G2-2N[NZ\5_&'5]1TW4"[
M!%T4'P%XG\6>)3R<XSD@$*"Q /">,_\ @CE^WYI-WIVHQ?&6^^*VHW6GKI#3
MZ#\127\/:7HBC1-#T(CQX?"B2: GAPE?!0A:3_A"W!"EL@G^N'RHO[B_E4E
M'\BWA;_@C!^W#XCMM1FU/XU:-\.6L[L?8_"/BOQ:VH"_TYBH34VE\!CQ7#'H
MKLZ*L$LL<F=#3*A2&IFH_P#!$W]M>T\2^&+ _&G3=9T_4SJ5CK'BS2O&.KG2
MM")"$?VYHFO>'?"7B9?#I+[57PL?%[.P8HO@],.?Z[*9L'J?T_PH _D=\,_\
M$3OVO$\0ZOX=OOB]8:78Z;9Z5>VGCYO%^KKX<US5/D#Z+_8F@,/$CK$'^=_$
M_A+PDAP1&TAP#UND?\$+_P!I:"QUX>)/VF?"ESK#VI71KNV\2>,8SKNI#5U;
MS-;UB3X<I)H*C0)-7U]A&GC21;B5(V0?/XU7^K78/4_I_A3Z /Y;I?\ @A!\
M:88] _XR$\)ZU]I8_P#"7G5_^$Q(L1_;&=VA8)_M\?\ ".DCYO\ A##N#84C
M!9_B7_@A7\6UG\06FB_%CX=:Q8W5SJ#:/J6L6GB[PUJM\TAVKJNN:/X?\/\
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M].GKFM*S_P""%?PKTZ]T6_E^,_C6[;31%_;,X\/+ITE[_8NDB/1SHH3Q(Z:
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M>1C_ /56G_X)_P#[$\M@=+N/V9/@[<:9C(M+GP=I#:?GK]S9_P#%?3T^S**
M/B.[_P""<'["5]DWO[*'P,N?]+^V?-X!T<?-ZGY /J?N_P"Q5?\ X=K?L%=?
M^&2O@ALQG[/_ ,(+HW^&W_Q[&:^Y** /S+F_X(Z_\$T[B?[3+^R3\-Q<8X:U
MNO&-C['B+Q/SU]?I4[?\$@?^"<1@MX5_97\$+]FX'V35?&=CU[D1^)QGZ!NW
M7M7Z6T4 ?ECK7_!'+_@G;K&EW%G#^SSI/AV>]%BYU70/$7B]M0BV,0J(/$'B
M'Q-H9!.W[UM,3P _*M)SFD_\$3O^">-M>W%_J_P@U3Q%#<6P5[+5_'?B[3]-
MP>X3PS<>%MO!'5RPZ[,5^N-% 'XOW/\ P0@_X)^W*6YL?!GC?PV;,C[+_9'C
M%'*D]MNL^'K@@\'CD>N,"I)O^"$7["4R8-A\4//Q_P ?0\7Z1OZ^G_",#C'_
M .OM7[.44 ?A#=_\$ /V0IKF:XLO%_Q;TR!A?_Z):>)<*/-.W&[ SMQG[H)X
M^[DXP)O^#>']CR6\_M6'Q=\6K;5>3]M75]*9L_[@AQ_X^:_?VB@#\"S_ ,&_
M'[,^)?L_Q9^,5K<,1_I5M>Z0C#VV^6QSZYV]?>N1U;_@WK^"#7WGZ7\?OBS;
M0?9"#9ZI:Z-JH!!QU*IG'? SDD#/!K^B*B@#^=4_\$ _"L$0@TO]K3XIZ9_H
MFT?9?""=.FX?\5-R.P_B/9:SY?\ @@3<6LOVZP_;F^+-M<C'V:Z/@0ZB5SC&
M!_PL;D$]S@$9(]*_HZIFP>I_3_"@#^;[PK_P1 ^.[6DQ\0?\% /B%HM^RFT!
MT#P=_P )#]NTSC"R:T_B3PA*I;..(V*X.[!P"J?\$<?VH$TK439_MV:]<WUG
M=9T>UN;'6G.HZ7R"FM:PGB5I=!; !(">,>",$G('](=% '\W?A[_ ()0?\%
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A%% !1110 4444 %%%% !1110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>9
<FILENAME>gtbp-20220331.xsd
<DESCRIPTION>INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.13b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 96Mps7xRiXgen8uDanwsWaqIKbP9z5Z8KekhvWBzbalq3y0rYqBhdSvOy5E2MWIL -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:srt="http://fasb.org/srt/2022" xmlns:srt-types="http://fasb.org/srt-types/2022" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:GTBP="http://gtbiopharma.com/20220331" elementFormDefault="qualified" targetNamespace="http://gtbiopharma.com/20220331">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://gtbiopharma.com/role/Cover" id="Cover">
	  <link:definition>00000001 - Document - Cover</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://gtbiopharma.com/role/BalanceSheets" id="BalanceSheets">
	  <link:definition>00000002 - Statement - Condensed Consolidated Balance Sheets</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://gtbiopharma.com/role/BalanceSheetsParenthetical" id="BalanceSheetsParenthetical">
	  <link:definition>00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://gtbiopharma.com/role/StatementsOfOperations" id="StatementsOfOperations">
	  <link:definition>00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://gtbiopharma.com/role/StatementsOfOperationsParenthetical" id="StatementsOfOperationsParenthetical">
	  <link:definition>00000005 - Statement - Condensed Consolidated Statements of Operations (Unaudited) (Parenthetical)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://gtbiopharma.com/role/StatementsOfStockholdersEquityDeficit" id="StatementsOfStockholdersEquityDeficit">
	  <link:definition>00000006 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://gtbiopharma.com/role/StatementsOfCashFlows" id="StatementsOfCashFlows">
	  <link:definition>00000007 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://gtbiopharma.com/role/OrganizationAndOperations" id="OrganizationAndOperations">
	  <link:definition>00000008 - Disclosure - Organization and Operations</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://gtbiopharma.com/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
	  <link:definition>00000009 - Disclosure - Summary of Significant Accounting Policies</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://gtbiopharma.com/role/FairValueOfFinancialInstruments" id="FairValueOfFinancialInstruments">
	  <link:definition>00000010 - Disclosure - Fair Value of Financial Instruments</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://gtbiopharma.com/role/AccountsPayable" id="AccountsPayable">
	  <link:definition>00000011 - Disclosure - Accounts Payable</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://gtbiopharma.com/role/ConvertibleNotesPayable" id="ConvertibleNotesPayable">
	  <link:definition>00000012 - Disclosure - Convertible Notes Payable</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://gtbiopharma.com/role/DerivativeLiability" id="DerivativeLiability">
	  <link:definition>00000013 - Disclosure - Derivative Liability</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://gtbiopharma.com/role/StockholdersEquity" id="StockholdersEquity">
	  <link:definition>00000014 - Disclosure - Stockholders&#8217; Equity</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://gtbiopharma.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
	  <link:definition>00000015 - Disclosure - Commitments and Contingencies</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://gtbiopharma.com/role/SubsequentEvents" id="SubsequentEvents">
	  <link:definition>00000016 - Disclosure - Subsequent Events</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" id="SummaryOfSignificantAccountingPoliciesPolicies">
	  <link:definition>00000017 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesTables" id="SummaryOfSignificantAccountingPoliciesTables">
	  <link:definition>00000018 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://gtbiopharma.com/role/FairValueOfFinancialInstrumentsTables" id="FairValueOfFinancialInstrumentsTables">
	  <link:definition>00000019 - Disclosure - Fair Value of Financial Instruments (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://gtbiopharma.com/role/AccountsPayableTables" id="AccountsPayableTables">
	  <link:definition>00000020 - Disclosure - Accounts Payable (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://gtbiopharma.com/role/DerivativeLiabilityTables" id="DerivativeLiabilityTables">
	  <link:definition>00000021 - Disclosure - Derivative Liability (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://gtbiopharma.com/role/StockholdersEquityTables" id="StockholdersEquityTables">
	  <link:definition>00000022 - Disclosure - Stockholders&#8217; Equity (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://gtbiopharma.com/role/CommitmentsAndContingenciesTables" id="CommitmentsAndContingenciesTables">
	  <link:definition>00000023 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://gtbiopharma.com/role/ScheduleOfAnti-dilutiveSecuritiesDetails" id="ScheduleOfAnti-dilutiveSecuritiesDetails">
	  <link:definition>00000024 - Disclosure - Schedule of Anti-dilutive Securities (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" id="SummaryOfSignificantAccountingPoliciesDetailsNarrative">
	  <link:definition>00000025 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://gtbiopharma.com/role/ScheduleOfEstimatedFairValueOfFinancialInstrumentDetails" id="ScheduleOfEstimatedFairValueOfFinancialInstrumentDetails">
	  <link:definition>00000026 - Disclosure - Schedule of Estimated Fair Value of Financial Instrument (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://gtbiopharma.com/role/ScheduleOfFairValueHierarchyFinancialAssetsDetails" id="ScheduleOfFairValueHierarchyFinancialAssetsDetails">
	  <link:definition>00000027 - Disclosure - Schedule of Fair Value Hierarchy Financial Assets (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://gtbiopharma.com/role/ScheduleOfDerivativeLiabilityTransactionsDetails" id="ScheduleOfDerivativeLiabilityTransactionsDetails">
	  <link:definition>00000028 - Disclosure - Schedule of Derivative Liability Transactions (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://gtbiopharma.com/role/ScheduleOfAccountsPayableDetails" id="ScheduleOfAccountsPayableDetails">
	  <link:definition>00000029 - Disclosure - Schedule of Accounts Payable (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://gtbiopharma.com/role/AccountsPayableDetailsNarrative" id="AccountsPayableDetailsNarrative">
	  <link:definition>00000030 - Disclosure - Accounts Payable (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://gtbiopharma.com/role/ConvertibleNotesPayableDetailsNarrative" id="ConvertibleNotesPayableDetailsNarrative">
	  <link:definition>00000031 - Disclosure - Convertible Notes Payable (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://gtbiopharma.com/role/ScheduleOfDerivativeLiabilitiesAssumptionsDetails" id="ScheduleOfDerivativeLiabilitiesAssumptionsDetails">
	  <link:definition>00000032 - Disclosure - Schedule of Derivative Liabilities Assumptions (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://gtbiopharma.com/role/DerivativeLiabilityDetailsNarrative" id="DerivativeLiabilityDetailsNarrative">
	  <link:definition>00000033 - Disclosure - Derivative Liability (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://gtbiopharma.com/role/ScheduleOfWarrantActivityDetails" id="ScheduleOfWarrantActivityDetails">
	  <link:definition>00000034 - Disclosure - Schedule of Warrant Activity (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://gtbiopharma.com/role/ScheduleOfOptionsActivityDetails" id="ScheduleOfOptionsActivityDetails">
	  <link:definition>00000035 - Disclosure - Schedule of Options Activity (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative" id="StockholdersEquityDetailsNarrative">
	  <link:definition>00000036 - Disclosure - Stockholders&#8217; Equity (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://gtbiopharma.com/role/ScheduleOfOtherInformationRelatedLeasesUnderNon-cancellableDetails" id="ScheduleOfOtherInformationRelatedLeasesUnderNon-cancellableDetails">
	  <link:definition>00000037 - Disclosure - Schedule of Other Information Related Leases Under Non-Cancellable (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://gtbiopharma.com/role/ScheduleOfFutureMinimumLeasePaymentsDetails" id="ScheduleOfFutureMinimumLeasePaymentsDetails">
	  <link:definition>00000038 - Disclosure - Schedule of Future Minimum Lease Payments (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative" id="CommitmentsAndContingenciesDetailsNarrative">
	  <link:definition>00000039 - Disclosure - Commitments and Contingencies (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://gtbiopharma.com/role/SubsequentEventsDetailsNarrative" id="SubsequentEventsDetailsNarrative">
	  <link:definition>00000040 - Disclosure - Subsequent Events (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="gtbp-20220331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="gtbp-20220331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="gtbp-20220331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="gtbp-20220331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" />
    <import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd" />
    <import namespace="http://fasb.org/us-types/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd" />
    <import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd" />
    <import namespace="http://fasb.org/srt-types/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd" />
    <element id="GTBP_OfficersAndDirectorsMember" name="OfficersAndDirectorsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_CommonSharesIssuableMember" name="CommonSharesIssuableMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_OfficeSpaceAndEquipmentMember" name="OfficeSpaceAndEquipmentMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_OptionsToPurchaseCommonStockMember" name="OptionsToPurchaseCommonStockMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_WarrantsToPurchaseCommonStockMember" name="WarrantsToPurchaseCommonStockMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_UnvestedRestrictedCommonStockMember" name="UnvestedRestrictedCommonStockMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_ShortTermInvestmentMember" name="ShortTermInvestmentMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_CorporateNotesAndCommercialPaperMember" name="CorporateNotesAndCommercialPaperMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_VendorMember" name="VendorMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_AuguestOneTwentyEighteenAndJanuaryTwentySixTwentyTwentyOneMember" name="AuguestOneTwentyEighteenAndJanuaryTwentySixTwentyTwentyOneMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_NotesPayableIssuedForSettlementAgreementsMember" name="NotesPayableIssuedForSettlementAgreementsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_FiscalTwentyNinteenandTwentyTwentyMember" name="FiscalTwentyNinteenandTwentyTwentyMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_ForbearanceAgreementsMember" name="ForbearanceAgreementsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_NotesPayableIssuedForForbearanceAgreementMember" name="NotesPayableIssuedForForbearanceAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_ConsultingAgreementsMember" name="ConsultingAgreementsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_AdoptionofAsuTwentyTwentyZeroSixMember" name="AdoptionofAsuTwentyTwentyZeroSixMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_DuringTwentyTwentyMember" name="DuringTwentyTwentyMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_JanuaryOneTwentyTwentyOneMember" name="JanuaryOneTwentyTwentyOneMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_CommonStockIssuableMember" name="CommonStockIssuableMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_EmploymentAgreementsMember" name="EmploymentAgreementsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_EmployeesMember" name="EmployeesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_OfficersEmployeesAndBoardOfDirectorsMember" name="OfficersEmployeesAndBoardOfDirectorsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_ConsultingMember" name="ConsultingMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_SeriesCPreferredStocksMember" name="SeriesCPreferredStocksMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_SeriesKPreferredStocksMember" name="SeriesKPreferredStocksMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_MasterServicesAgreementMember" name="MasterServicesAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_CytovanceBiologicsIncMember" name="CytovanceBiologicsIncMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_TwoThousandSixteenPatentLicenseAgreementMember" name="TwoThousandSixteenPatentLicenseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_TwoThousandAndTwentyOnePatentLicenseAgreementMember" name="TwoThousandAndTwentyOnePatentLicenseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_AimmuneTherapeuticsIncMember" name="AimmuneTherapeuticsIncMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_CommonStockIssuable" name="CommonStockIssuable" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_CommonStockIssuableShares" name="CommonStockIssuableShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_StockIssuedDuringPeriodValueCancellation" name="StockIssuedDuringPeriodValueCancellation" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_StockIssuedDuringPeriodSharesCancellation" name="StockIssuedDuringPeriodSharesCancellation" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_StockIssuedDuringPeriodValueEquityCompensationToOfficersAndBoardOfDirectors" name="StockIssuedDuringPeriodValueEquityCompensationToOfficersAndBoardOfDirectors" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_StockIssuedDuringPeriodSharesEquityCompensationToOfficersAndBoardOfDirectors" name="StockIssuedDuringPeriodSharesEquityCompensationToOfficersAndBoardOfDirectors" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_ExtinguishmentOfDebtDiscountUponAdoptionOfAsu202006" name="ExtinguishmentOfDebtDiscountUponAdoptionOfAsu202006" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_StockIssuedDuringPeriodValueCommonSharesIssuedUponMandatoryConversionOfNotesPayableAndAccruedInterest" name="StockIssuedDuringPeriodValueCommonSharesIssuedUponMandatoryConversionOfNotesPayableAndAccruedInterest" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_StockIssuedDuringPeriodSharesCommonSharesIssuedUponMandatoryConversionOfNotesPayableAndAccruedInterest" name="StockIssuedDuringPeriodSharesCommonSharesIssuedUponMandatoryConversionOfNotesPayableAndAccruedInterest" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_StockIssuedDuringPeriodValueCommonSharesIssuedUponExerciseOfWarrants" name="StockIssuedDuringPeriodValueCommonSharesIssuedUponExerciseOfWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_StockIssuedDuringPeriodSharesCommonSharesIssuedUponExerciseOfWarrants" name="StockIssuedDuringPeriodSharesCommonSharesIssuedUponExerciseOfWarrants" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_StockIssuedDuringPeriodValueIssuanceOfCommonStockInPublicOfferingNetOfCost" name="StockIssuedDuringPeriodValueIssuanceOfCommonStockInPublicOfferingNetOfCost" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_StockIssuedDuringPeriodSharesIssuanceOfCommonStockInPublicOfferingNetOfCost" name="StockIssuedDuringPeriodSharesIssuanceOfCommonStockInPublicOfferingNetOfCost" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_StockIssuedDuringPeriodValueIssuanceOfCommonStockForResearchAndDevelopmentAgreement" name="StockIssuedDuringPeriodValueIssuanceOfCommonStockForResearchAndDevelopmentAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_StockIssuedDuringPeriodShareIssuanceOfCommonStockForResearchAndDevelopmentAgreement" name="StockIssuedDuringPeriodShareIssuanceOfCommonStockForResearchAndDevelopmentAgreement" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_StockBasedCompensationForServices" name="StockBasedCompensationForServices" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_StockBasedCompensationToOfficersAndBoardOfDirectors" name="StockBasedCompensationToOfficersAndBoardOfDirectors" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_ConvertibleNotesPayableIssuedForConsultingServices" name="ConvertibleNotesPayableIssuedForConsultingServices" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_IncreaseDecreaseInDeposit" name="IncreaseDecreaseInDeposit" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_CashPaidDuringYearFor" name="CashPaidDuringYearFor" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_RightofuseAssetsAndLeaseLiabilitiesRecognizedPursuantToLeaseAgreement" name="RightofuseAssetsAndLeaseLiabilitiesRecognizedPursuantToLeaseAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_ExtinguishmentOfUnamortizedDebtDiscountAndAdjustmentToAccumulatedDeficitUponAdoption" name="ExtinguishmentOfUnamortizedDebtDiscountAndAdjustmentToAccumulatedDeficitUponAdoption" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_DisclosureDerivativeLiabilityAbstract" name="DisclosureDerivativeLiabilityAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_LiquidityPolicyTextBlock" name="LiquidityPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_ScheduleOfOtherInformationRelatedLeasesUnderNOnCancellableTableTextBlock" name="ScheduleOfOtherInformationRelatedLeasesUnderNOnCancellableTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_CashOnHandAndShortTermInvestment" name="CashOnHandAndShortTermInvestment" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_WorkingCapital" name="WorkingCapital" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_ExtinguishmentOfWarrants" name="ExtinguishmentOfWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_ConvertibleNotesPayableIssuedInExchangeForConsultingServices" name="ConvertibleNotesPayableIssuedInExchangeForConsultingServices" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_AccruedInterestAmount" name="AccruedInterestAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_InterestExpenseDueAmortizationOfDebtDiscount" name="InterestExpenseDueAmortizationOfDebtDiscount" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_DerivativeLiabilityFairValueAssumptionsExpectedTerm1" name="DerivativeLiabilityFairValueAssumptionsExpectedTerm1" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeited" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeited" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionEquityInstrumentsExercised" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionEquityInstrumentsExercised" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_CommonStockSharesGrantedForConsultants" name="CommonStockSharesGrantedForConsultants" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_FairValueOfStockOptionsGrantedForConsultants" name="FairValueOfStockOptionsGrantedForConsultants" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedTounVestOutstandingNumber" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedTounVestOutstandingNumber" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToUnVestOutstandingAggregateIntrinsicValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToUnVestOutstandingAggregateIntrinsicValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_CommonStockConsultantToFairValue" name="CommonStockConsultantToFairValue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_NumberofsharesUnvestedOptions" name="NumberofsharesUnvestedOptions" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_NumberofValueUnvestedOptions" name="NumberofValueUnvestedOptions" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_ProjectFee" name="ProjectFee" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_RecordedExpenses" name="RecordedExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurred" name="ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurred" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_ResearchAndDevelopmentArrangementContractToPerformExpectedCostsIncurred" name="ResearchAndDevelopmentArrangementContractToPerformExpectedCostsIncurred" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_ProceedsFromUpfrontAmount" name="ProceedsFromUpfrontAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_AnnualMaintananceFee" name="AnnualMaintananceFee" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_RoyaltyFeePercentage" name="RoyaltyFeePercentage" nillable="true" xbrli:periodType="duration" type="xbrli:pureItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_AnnualRoyaltyPayments" name="AnnualRoyaltyPayments" nillable="true" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_PerformanceMilestonePayments" name="PerformanceMilestonePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_SalesMilestonePayments" name="SalesMilestonePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_GrossSales" name="GrossSales" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_SalesRevenue" name="SalesRevenue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_CummulativeGrossSales" name="CummulativeGrossSales" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_UpfrontLicenseFee" name="UpfrontLicenseFee" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_LicenseMaintenanceFeeReceivable" name="LicenseMaintenanceFeeReceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_NetSalesPercentage" name="NetSalesPercentage" nillable="true" xbrli:periodType="duration" type="xbrli:pureItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_MaintananceFee" name="MaintananceFee" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_CancellationOfCommonStockPreviouslyIssuedForServices" name="CancellationOfCommonStockPreviouslyIssuedForServices" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_StockIssuedDuringPeriodCancellationOfCommonStockPreviouslyIssuedForServices" name="StockIssuedDuringPeriodCancellationOfCommonStockPreviouslyIssuedForServices" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_StockBasedCompensationConsultantsAndResearchAndDevelopment" name="StockBasedCompensationConsultantsAndResearchAndDevelopment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_RightOfUseAssetExchangeForFinanceLeaseLiability" name="RightOfUseAssetExchangeForFinanceLeaseLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_RightOfUseAssetsExchangeForFinanceLeaseLiability" name="RightOfUseAssetsExchangeForFinanceLeaseLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_CashPaidAmountsForLeaseLiabilities" name="CashPaidAmountsForLeaseLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_ShortTermInvestment" name="ShortTermInvestment" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_NotesPayableIssuedForCashMember" name="NotesPayableIssuedForCashMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_JanuaryTwentyTwentyOneMember" name="JanuaryTwentyTwentyOneMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_NotesPayableIssuedForForbearanceAgreementsMember" name="NotesPayableIssuedForForbearanceAgreementsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_JuneTwentyThreeTwentyTwentyMember" name="JuneTwentyThreeTwentyTwentyMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_NotesPayableIssuedForConsultingAgreementMember" name="NotesPayableIssuedForConsultingAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_InternalControlConsiderationsTextBlock" name="InternalControlConsiderationsTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_NumberOfSharesCancellationOfCommonStock" name="NumberOfSharesCancellationOfCommonStock" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_NumberOfSharesCancellationOfCommonStockValue" name="NumberOfSharesCancellationOfCommonStockValue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo" name="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_CancellationOfCommonStockPreviouslyIssuedWithoutProperApproval" name="CancellationOfCommonStockPreviouslyIssuedWithoutProperApproval" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_StockIssuedDuringPeriodSharesCancellationOfCommonStockPreviouslyIssuedWithoutProperApproval" name="StockIssuedDuringPeriodSharesCancellationOfCommonStockPreviouslyIssuedWithoutProperApproval" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_StockIssuedDuringPeriodValueCancellationOfCommonStockPreviouslyIssuedWithoutProperApproval" name="StockIssuedDuringPeriodValueCancellationOfCommonStockPreviouslyIssuedWithoutProperApproval" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_CancelationOfCommonStockPreviouslyIssued" name="CancelationOfCommonStockPreviouslyIssued" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_CancellationOfCommonStock" name="CancellationOfCommonStock" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_AdjustmentToCancelShareBasedCompensationExpense" name="AdjustmentToCancelShareBasedCompensationExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>10
<FILENAME>gtbp-20220331_cal.xml
<DESCRIPTION>INLINE XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.13b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://gtbiopharma.com/role/Cover" xlink:href="gtbp-20220331.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/BalanceSheets" xlink:href="gtbp-20220331.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/BalanceSheetsParenthetical" xlink:href="gtbp-20220331.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/StatementsOfOperations" xlink:href="gtbp-20220331.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/StatementsOfOperationsParenthetical" xlink:href="gtbp-20220331.xsd#StatementsOfOperationsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/StatementsOfStockholdersEquityDeficit" xlink:href="gtbp-20220331.xsd#StatementsOfStockholdersEquityDeficit" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/StatementsOfCashFlows" xlink:href="gtbp-20220331.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/OrganizationAndOperations" xlink:href="gtbp-20220331.xsd#OrganizationAndOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="gtbp-20220331.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/FairValueOfFinancialInstruments" xlink:href="gtbp-20220331.xsd#FairValueOfFinancialInstruments" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/AccountsPayable" xlink:href="gtbp-20220331.xsd#AccountsPayable" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/ConvertibleNotesPayable" xlink:href="gtbp-20220331.xsd#ConvertibleNotesPayable" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/DerivativeLiability" xlink:href="gtbp-20220331.xsd#DerivativeLiability" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/StockholdersEquity" xlink:href="gtbp-20220331.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/CommitmentsAndContingencies" xlink:href="gtbp-20220331.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/SubsequentEvents" xlink:href="gtbp-20220331.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="gtbp-20220331.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="gtbp-20220331.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/FairValueOfFinancialInstrumentsTables" xlink:href="gtbp-20220331.xsd#FairValueOfFinancialInstrumentsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/AccountsPayableTables" xlink:href="gtbp-20220331.xsd#AccountsPayableTables" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/DerivativeLiabilityTables" xlink:href="gtbp-20220331.xsd#DerivativeLiabilityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/StockholdersEquityTables" xlink:href="gtbp-20220331.xsd#StockholdersEquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/CommitmentsAndContingenciesTables" xlink:href="gtbp-20220331.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/ScheduleOfAnti-dilutiveSecuritiesDetails" xlink:href="gtbp-20220331.xsd#ScheduleOfAnti-dilutiveSecuritiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="gtbp-20220331.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/ScheduleOfEstimatedFairValueOfFinancialInstrumentDetails" xlink:href="gtbp-20220331.xsd#ScheduleOfEstimatedFairValueOfFinancialInstrumentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/ScheduleOfFairValueHierarchyFinancialAssetsDetails" xlink:href="gtbp-20220331.xsd#ScheduleOfFairValueHierarchyFinancialAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/ScheduleOfDerivativeLiabilityTransactionsDetails" xlink:href="gtbp-20220331.xsd#ScheduleOfDerivativeLiabilityTransactionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/ScheduleOfAccountsPayableDetails" xlink:href="gtbp-20220331.xsd#ScheduleOfAccountsPayableDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/AccountsPayableDetailsNarrative" xlink:href="gtbp-20220331.xsd#AccountsPayableDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/ConvertibleNotesPayableDetailsNarrative" xlink:href="gtbp-20220331.xsd#ConvertibleNotesPayableDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/ScheduleOfDerivativeLiabilitiesAssumptionsDetails" xlink:href="gtbp-20220331.xsd#ScheduleOfDerivativeLiabilitiesAssumptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/DerivativeLiabilityDetailsNarrative" xlink:href="gtbp-20220331.xsd#DerivativeLiabilityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/ScheduleOfWarrantActivityDetails" xlink:href="gtbp-20220331.xsd#ScheduleOfWarrantActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/ScheduleOfOptionsActivityDetails" xlink:href="gtbp-20220331.xsd#ScheduleOfOptionsActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative" xlink:href="gtbp-20220331.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/ScheduleOfOtherInformationRelatedLeasesUnderNon-cancellableDetails" xlink:href="gtbp-20220331.xsd#ScheduleOfOtherInformationRelatedLeasesUnderNon-cancellableDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/ScheduleOfFutureMinimumLeasePaymentsDetails" xlink:href="gtbp-20220331.xsd#ScheduleOfFutureMinimumLeasePaymentsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="gtbp-20220331.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/SubsequentEventsDetailsNarrative" xlink:href="gtbp-20220331.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/BalanceSheets" xlink:title="00000002 - Statement - Condensed Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashEquivalentsAtCarryingValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCashEquivalentsAtCarryingValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments" xlink:label="loc_us-gaapShortTermInvestments" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapShortTermInvestments" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="loc_us-gaapDepositsAssetsNoncurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapDepositsAssetsNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaapDerivativeLiabilitiesCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapDerivativeLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_CommonStockIssuable" xlink:label="loc_GTBPCommonStockIssuable" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_GTBPCommonStockIssuable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapRevenues" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpense" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebtExcludingAmortization" xlink:label="loc_us-gaapInterestExpenseDebtExcludingAmortization" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapInterestExpenseDebtExcludingAmortization" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaapDerivativeGainLossOnDerivativeNet" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapDerivativeGainLossOnDerivativeNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:label="loc_us-gaapMarketableSecuritiesUnrealizedGainLoss" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapMarketableSecuritiesUnrealizedGainLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/StatementsOfOperationsParenthetical" xlink:title="00000005 - Statement - Condensed Consolidated Statements of Operations (Unaudited) (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/StatementsOfStockholdersEquityDeficit" xlink:title="00000006 - Statement - Condensed Consolidated Statements of Stockholders&apos; Equity (Deficit) (Unaudited)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/StatementsOfCashFlows" xlink:title="00000007 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapProfitLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_StockBasedCompensationForServices" xlink:label="loc_GTBPStockBasedCompensationForServices" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_GTBPStockBasedCompensationForServices" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_StockBasedCompensationToOfficersAndBoardOfDirectors" xlink:label="loc_GTBPStockBasedCompensationToOfficersAndBoardOfDirectors" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_GTBPStockBasedCompensationToOfficersAndBoardOfDirectors" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_ConvertibleNotesPayableIssuedForConsultingServices" xlink:label="loc_GTBPConvertibleNotesPayableIssuedForConsultingServices" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_GTBPConvertibleNotesPayableIssuedForConsultingServices" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaapDerivativeGainLossOnDerivativeNet" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDerivativeGainLossOnDerivativeNet" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAssetAmortizationExpense" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:label="loc_us-gaapMarketableSecuritiesUnrealizedGainLoss" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapMarketableSecuritiesUnrealizedGainLoss" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpense" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_IncreaseDecreaseInDeposit" xlink:label="loc_GTBPIncreaseDecreaseInDeposit" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_GTBPIncreaseDecreaseInDeposit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" />
      <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:label="loc_us-gaapIncreaseDecreaseInInterestPayableNet" />
      <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInInterestPayableNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSalesOfAssetsInvestingActivities" xlink:label="loc_us-gaapProceedsFromSalesOfAssetsInvestingActivities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapProceedsFromSalesOfAssetsInvestingActivities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromWarrantExercises" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfMediumTermNotes" xlink:label="loc_us-gaapProceedsFromIssuanceOfMediumTermNotes" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfMediumTermNotes" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/OrganizationAndOperations" xlink:title="00000008 - Disclosure - Organization and Operations" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="00000009 - Disclosure - Summary of Significant Accounting Policies" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/FairValueOfFinancialInstruments" xlink:title="00000010 - Disclosure - Fair Value of Financial Instruments" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/AccountsPayable" xlink:title="00000011 - Disclosure - Accounts Payable" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ConvertibleNotesPayable" xlink:title="00000012 - Disclosure - Convertible Notes Payable" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/DerivativeLiability" xlink:title="00000013 - Disclosure - Derivative Liability" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/StockholdersEquity" xlink:title="00000014 - Disclosure - Stockholders&#8217; Equity" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/CommitmentsAndContingencies" xlink:title="00000015 - Disclosure - Commitments and Contingencies" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/SubsequentEvents" xlink:title="00000016 - Disclosure - Subsequent Events" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000017 - Disclosure - Summary of Significant Accounting Policies (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="00000018 - Disclosure - Summary of Significant Accounting Policies (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/FairValueOfFinancialInstrumentsTables" xlink:title="00000019 - Disclosure - Fair Value of Financial Instruments (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/AccountsPayableTables" xlink:title="00000020 - Disclosure - Accounts Payable (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/DerivativeLiabilityTables" xlink:title="00000021 - Disclosure - Derivative Liability (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/StockholdersEquityTables" xlink:title="00000022 - Disclosure - Stockholders&#8217; Equity (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/CommitmentsAndContingenciesTables" xlink:title="00000023 - Disclosure - Commitments and Contingencies (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfAnti-dilutiveSecuritiesDetails" xlink:title="00000024 - Disclosure - Schedule of Anti-dilutive Securities (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000025 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfEstimatedFairValueOfFinancialInstrumentDetails" xlink:title="00000026 - Disclosure - Schedule of Estimated Fair Value of Financial Instrument (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfFairValueHierarchyFinancialAssetsDetails" xlink:title="00000027 - Disclosure - Schedule of Fair Value Hierarchy Financial Assets (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfDerivativeLiabilityTransactionsDetails" xlink:title="00000028 - Disclosure - Schedule of Derivative Liability Transactions (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfAccountsPayableDetails" xlink:title="00000029 - Disclosure - Schedule of Accounts Payable (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:label="loc_us-gaapAccountsPayableRelatedPartiesCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccountsPayableCurrent" xlink:to="loc_us-gaapAccountsPayableRelatedPartiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:label="loc_us-gaapAccountsPayableOtherCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccountsPayableCurrent" xlink:to="loc_us-gaapAccountsPayableOtherCurrent" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/AccountsPayableDetailsNarrative" xlink:title="00000030 - Disclosure - Accounts Payable (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ConvertibleNotesPayableDetailsNarrative" xlink:title="00000031 - Disclosure - Convertible Notes Payable (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfDerivativeLiabilitiesAssumptionsDetails" xlink:title="00000032 - Disclosure - Schedule of Derivative Liabilities Assumptions (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/DerivativeLiabilityDetailsNarrative" xlink:title="00000033 - Disclosure - Derivative Liability (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfWarrantActivityDetails" xlink:title="00000034 - Disclosure - Schedule of Warrant Activity (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfOptionsActivityDetails" xlink:title="00000035 - Disclosure - Schedule of Options Activity (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative" xlink:title="00000036 - Disclosure - Stockholders&#8217; Equity (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfOtherInformationRelatedLeasesUnderNon-cancellableDetails" xlink:title="00000037 - Disclosure - Schedule of Other Information Related Leases Under Non-Cancellable (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfFutureMinimumLeasePaymentsDetails" xlink:title="00000038 - Disclosure - Schedule of Future Minimum Lease Payments (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingLeaseLiability" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingLeaseLiability" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingLeaseLiability" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingLeaseLiability" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000039 - Disclosure - Commitments and Contingencies (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/SubsequentEventsDetailsNarrative" xlink:title="00000040 - Disclosure - Subsequent Events (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>11
<FILENAME>gtbp-20220331_def.xml
<DESCRIPTION>INLINE XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.13b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://gtbiopharma.com/role/Cover" xlink:href="gtbp-20220331.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/BalanceSheets" xlink:href="gtbp-20220331.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/BalanceSheetsParenthetical" xlink:href="gtbp-20220331.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/StatementsOfOperations" xlink:href="gtbp-20220331.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/StatementsOfOperationsParenthetical" xlink:href="gtbp-20220331.xsd#StatementsOfOperationsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/StatementsOfStockholdersEquityDeficit" xlink:href="gtbp-20220331.xsd#StatementsOfStockholdersEquityDeficit" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/StatementsOfCashFlows" xlink:href="gtbp-20220331.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/OrganizationAndOperations" xlink:href="gtbp-20220331.xsd#OrganizationAndOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="gtbp-20220331.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/FairValueOfFinancialInstruments" xlink:href="gtbp-20220331.xsd#FairValueOfFinancialInstruments" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/AccountsPayable" xlink:href="gtbp-20220331.xsd#AccountsPayable" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/ConvertibleNotesPayable" xlink:href="gtbp-20220331.xsd#ConvertibleNotesPayable" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/DerivativeLiability" xlink:href="gtbp-20220331.xsd#DerivativeLiability" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/StockholdersEquity" xlink:href="gtbp-20220331.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/CommitmentsAndContingencies" xlink:href="gtbp-20220331.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/SubsequentEvents" xlink:href="gtbp-20220331.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="gtbp-20220331.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="gtbp-20220331.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/FairValueOfFinancialInstrumentsTables" xlink:href="gtbp-20220331.xsd#FairValueOfFinancialInstrumentsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/AccountsPayableTables" xlink:href="gtbp-20220331.xsd#AccountsPayableTables" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/DerivativeLiabilityTables" xlink:href="gtbp-20220331.xsd#DerivativeLiabilityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/StockholdersEquityTables" xlink:href="gtbp-20220331.xsd#StockholdersEquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/CommitmentsAndContingenciesTables" xlink:href="gtbp-20220331.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/ScheduleOfAnti-dilutiveSecuritiesDetails" xlink:href="gtbp-20220331.xsd#ScheduleOfAnti-dilutiveSecuritiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="gtbp-20220331.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/ScheduleOfEstimatedFairValueOfFinancialInstrumentDetails" xlink:href="gtbp-20220331.xsd#ScheduleOfEstimatedFairValueOfFinancialInstrumentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/ScheduleOfFairValueHierarchyFinancialAssetsDetails" xlink:href="gtbp-20220331.xsd#ScheduleOfFairValueHierarchyFinancialAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/ScheduleOfDerivativeLiabilityTransactionsDetails" xlink:href="gtbp-20220331.xsd#ScheduleOfDerivativeLiabilityTransactionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/ScheduleOfAccountsPayableDetails" xlink:href="gtbp-20220331.xsd#ScheduleOfAccountsPayableDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/AccountsPayableDetailsNarrative" xlink:href="gtbp-20220331.xsd#AccountsPayableDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/ConvertibleNotesPayableDetailsNarrative" xlink:href="gtbp-20220331.xsd#ConvertibleNotesPayableDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/ScheduleOfDerivativeLiabilitiesAssumptionsDetails" xlink:href="gtbp-20220331.xsd#ScheduleOfDerivativeLiabilitiesAssumptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/DerivativeLiabilityDetailsNarrative" xlink:href="gtbp-20220331.xsd#DerivativeLiabilityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/ScheduleOfWarrantActivityDetails" xlink:href="gtbp-20220331.xsd#ScheduleOfWarrantActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/ScheduleOfOptionsActivityDetails" xlink:href="gtbp-20220331.xsd#ScheduleOfOptionsActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative" xlink:href="gtbp-20220331.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/ScheduleOfOtherInformationRelatedLeasesUnderNon-cancellableDetails" xlink:href="gtbp-20220331.xsd#ScheduleOfOtherInformationRelatedLeasesUnderNon-cancellableDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/ScheduleOfFutureMinimumLeasePaymentsDetails" xlink:href="gtbp-20220331.xsd#ScheduleOfFutureMinimumLeasePaymentsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="gtbp-20220331.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/SubsequentEventsDetailsNarrative" xlink:href="gtbp-20220331.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/BalanceSheets" xlink:title="00000002 - Statement - Condensed Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaapSeriesCPreferredStockMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesCPreferredStockMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssetsAbstract_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_50" xlink:to="loc_us-gaapAssetsCurrentAbstract_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashEquivalentsAtCarryingValue_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_50" xlink:to="loc_us-gaapCashEquivalentsAtCarryingValue_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments" xlink:label="loc_us-gaapShortTermInvestments_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_50" xlink:to="loc_us-gaapShortTermInvestments_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrent_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_50" xlink:to="loc_us-gaapPrepaidExpenseCurrent_50" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_50" xlink:to="loc_us-gaapAssetsCurrent_50" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_50" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset_50" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="loc_us-gaapDepositsAssetsNoncurrent_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_50" xlink:to="loc_us-gaapDepositsAssetsNoncurrent_50" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_50" xlink:to="loc_us-gaapAssets_50" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_50" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_50" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract_50" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_50" xlink:to="loc_us-gaapAccountsPayableCurrent_50" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_50" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent_50" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_50" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent_50" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaapDerivativeLiabilitiesCurrent_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_50" xlink:to="loc_us-gaapDerivativeLiabilitiesCurrent_50" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_50" xlink:to="loc_us-gaapLiabilitiesCurrent_50" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_50" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent_50" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_50" xlink:to="loc_us-gaapLiabilities_50" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_50" xlink:to="loc_us-gaapStockholdersEquityAbstract_50" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_50" xlink:to="loc_us-gaapPreferredStockValue_50" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_50" xlink:to="loc_us-gaapCommonStockValue_50" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_CommonStockIssuable" xlink:label="loc_GTBPCommonStockIssuable_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_50" xlink:to="loc_GTBPCommonStockIssuable_50" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_50" xlink:to="loc_us-gaapAdditionalPaidInCapital_50" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_50" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit_50" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_50" xlink:to="loc_us-gaapStockholdersEquity_50" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_50" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity_50" xlink:type="arc" order="25" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaapSeriesCPreferredStockMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesCPreferredStockMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized_70" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued_70" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding_70" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_CommonStockIssuableShares" xlink:label="loc_GTBPCommonStockIssuableShares_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GTBPCommonStockIssuableShares_70" xlink:type="arc" order="8" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/StatementsOfOperationsParenthetical" xlink:title="00000005 - Statement - Condensed Consolidated Statements of Operations (Unaudited) (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:label="loc_us-gaapDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xlink:label="loc_us-gaapScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="loc_us-gaapScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_OfficersAndDirectorsMember" xlink:label="loc_GTBPOfficersAndDirectorsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_GTBPOfficersAndDirectorsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense_30" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/StatementsOfStockholdersEquityDeficit" xlink:title="00000006 - Statement - Condensed Consolidated Statements of Stockholders&apos; Equity (Deficit) (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaapPreferredStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapPreferredStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_CommonSharesIssuableMember" xlink:label="loc_GTBPCommonSharesIssuableMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_GTBPCommonSharesIssuableMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_StockIssuedDuringPeriodValueCancellation" xlink:label="loc_GTBPStockIssuedDuringPeriodValueCancellation_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GTBPStockIssuedDuringPeriodValueCancellation_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_StockIssuedDuringPeriodSharesCancellation" xlink:label="loc_GTBPStockIssuedDuringPeriodSharesCancellation_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GTBPStockIssuedDuringPeriodSharesCancellation_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther_70" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther_70" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_70" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_StockIssuedDuringPeriodValueEquityCompensationToOfficersAndBoardOfDirectors" xlink:label="loc_GTBPStockIssuedDuringPeriodValueEquityCompensationToOfficersAndBoardOfDirectors_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GTBPStockIssuedDuringPeriodValueEquityCompensationToOfficersAndBoardOfDirectors_70" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_StockIssuedDuringPeriodSharesEquityCompensationToOfficersAndBoardOfDirectors" xlink:label="loc_GTBPStockIssuedDuringPeriodSharesEquityCompensationToOfficersAndBoardOfDirectors_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GTBPStockIssuedDuringPeriodSharesEquityCompensationToOfficersAndBoardOfDirectors_70" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_70" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_70" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_ExtinguishmentOfDebtDiscountUponAdoptionOfAsu202006" xlink:label="loc_GTBPExtinguishmentOfDebtDiscountUponAdoptionOfAsu202006_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GTBPExtinguishmentOfDebtDiscountUponAdoptionOfAsu202006_70" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_70" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_70" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_StockIssuedDuringPeriodValueCommonSharesIssuedUponMandatoryConversionOfNotesPayableAndAccruedInterest" xlink:label="loc_GTBPStockIssuedDuringPeriodValueCommonSharesIssuedUponMandatoryConversionOfNotesPayableAndAccruedInterest_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GTBPStockIssuedDuringPeriodValueCommonSharesIssuedUponMandatoryConversionOfNotesPayableAndAccruedInterest_70" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_StockIssuedDuringPeriodSharesCommonSharesIssuedUponMandatoryConversionOfNotesPayableAndAccruedInterest" xlink:label="loc_GTBPStockIssuedDuringPeriodSharesCommonSharesIssuedUponMandatoryConversionOfNotesPayableAndAccruedInterest_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GTBPStockIssuedDuringPeriodSharesCommonSharesIssuedUponMandatoryConversionOfNotesPayableAndAccruedInterest_70" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_StockIssuedDuringPeriodValueCommonSharesIssuedUponExerciseOfWarrants" xlink:label="loc_GTBPStockIssuedDuringPeriodValueCommonSharesIssuedUponExerciseOfWarrants_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GTBPStockIssuedDuringPeriodValueCommonSharesIssuedUponExerciseOfWarrants_70" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_StockIssuedDuringPeriodSharesCommonSharesIssuedUponExerciseOfWarrants" xlink:label="loc_GTBPStockIssuedDuringPeriodSharesCommonSharesIssuedUponExerciseOfWarrants_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GTBPStockIssuedDuringPeriodSharesCommonSharesIssuedUponExerciseOfWarrants_70" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_StockIssuedDuringPeriodValueIssuanceOfCommonStockInPublicOfferingNetOfCost" xlink:label="loc_GTBPStockIssuedDuringPeriodValueIssuanceOfCommonStockInPublicOfferingNetOfCost_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GTBPStockIssuedDuringPeriodValueIssuanceOfCommonStockInPublicOfferingNetOfCost_70" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_StockIssuedDuringPeriodSharesIssuanceOfCommonStockInPublicOfferingNetOfCost" xlink:label="loc_GTBPStockIssuedDuringPeriodSharesIssuanceOfCommonStockInPublicOfferingNetOfCost_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GTBPStockIssuedDuringPeriodSharesIssuanceOfCommonStockInPublicOfferingNetOfCost_70" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_StockIssuedDuringPeriodValueIssuanceOfCommonStockForResearchAndDevelopmentAgreement" xlink:label="loc_GTBPStockIssuedDuringPeriodValueIssuanceOfCommonStockForResearchAndDevelopmentAgreement_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GTBPStockIssuedDuringPeriodValueIssuanceOfCommonStockForResearchAndDevelopmentAgreement_70" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_StockIssuedDuringPeriodShareIssuanceOfCommonStockForResearchAndDevelopmentAgreement" xlink:label="loc_GTBPStockIssuedDuringPeriodShareIssuanceOfCommonStockForResearchAndDevelopmentAgreement_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GTBPStockIssuedDuringPeriodShareIssuanceOfCommonStockForResearchAndDevelopmentAgreement_70" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProfitLoss_70" xlink:type="arc" order="23" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/StatementsOfCashFlows" xlink:title="00000007 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/OrganizationAndOperations" xlink:title="00000008 - Disclosure - Organization and Operations" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="00000009 - Disclosure - Summary of Significant Accounting Policies" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/FairValueOfFinancialInstruments" xlink:title="00000010 - Disclosure - Fair Value of Financial Instruments" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/AccountsPayable" xlink:title="00000011 - Disclosure - Accounts Payable" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ConvertibleNotesPayable" xlink:title="00000012 - Disclosure - Convertible Notes Payable" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/DerivativeLiability" xlink:title="00000013 - Disclosure - Derivative Liability" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/StockholdersEquity" xlink:title="00000014 - Disclosure - Stockholders&#8217; Equity" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/CommitmentsAndContingencies" xlink:title="00000015 - Disclosure - Commitments and Contingencies" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/SubsequentEvents" xlink:title="00000016 - Disclosure - Subsequent Events" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000017 - Disclosure - Summary of Significant Accounting Policies (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="00000018 - Disclosure - Summary of Significant Accounting Policies (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/FairValueOfFinancialInstrumentsTables" xlink:title="00000019 - Disclosure - Fair Value of Financial Instruments (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/AccountsPayableTables" xlink:title="00000020 - Disclosure - Accounts Payable (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/DerivativeLiabilityTables" xlink:title="00000021 - Disclosure - Derivative Liability (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/StockholdersEquityTables" xlink:title="00000022 - Disclosure - Stockholders&#8217; Equity (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/CommitmentsAndContingenciesTables" xlink:title="00000023 - Disclosure - Commitments and Contingencies (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfAnti-dilutiveSecuritiesDetails" xlink:title="00000024 - Disclosure - Schedule of Anti-dilutive Securities (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_OptionsToPurchaseCommonStockMember" xlink:label="loc_GTBPOptionsToPurchaseCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_GTBPOptionsToPurchaseCommonStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_WarrantsToPurchaseCommonStockMember" xlink:label="loc_GTBPWarrantsToPurchaseCommonStockMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_GTBPWarrantsToPurchaseCommonStockMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_UnvestedRestrictedCommonStockMember" xlink:label="loc_GTBPUnvestedRestrictedCommonStockMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_GTBPUnvestedRestrictedCommonStockMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_90" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000025 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_OfficeSpaceAndEquipmentMember" xlink:label="loc_GTBPOfficeSpaceAndEquipmentMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_GTBPOfficeSpaceAndEquipmentMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapNetIncomeLoss_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_CashOnHandAndShortTermInvestment" xlink:label="loc_GTBPCashOnHandAndShortTermInvestment_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_GTBPCashOnHandAndShortTermInvestment_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_WorkingCapital" xlink:label="loc_GTBPWorkingCapital_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_GTBPWorkingCapital_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapStockholdersEquity_50" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsAndCash" xlink:label="loc_us-gaapInvestmentsAndCash_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapInvestmentsAndCash_50" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="loc_us-gaapCashCashEquivalentsAndShortTermInvestments_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapCashCashEquivalentsAndShortTermInvestments_50" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments" xlink:label="loc_us-gaapShortTermInvestments_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapShortTermInvestments_50" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaapDerivativeLiabilitiesCurrent_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapDerivativeLiabilitiesCurrent_50" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset_50" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapOperatingLeaseLiability_50" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="loc_us-gaapCashFDICInsuredAmount_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapCashFDICInsuredAmount_50" xlink:type="arc" order="11" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfEstimatedFairValueOfFinancialInstrumentDetails" xlink:title="00000026 - Disclosure - Schedule of Estimated Fair Value of Financial Instrument (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLineItems" xlink:label="loc_us-gaapFairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareTable" xlink:label="loc_us-gaapFairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLineItems" xlink:to="loc_us-gaapFairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaapInvestmentTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareTable" xlink:to="loc_us-gaapInvestmentTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaapInvestmentTypeCategorizationMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapInvestmentTypeAxis" xlink:to="loc_us-gaapInvestmentTypeCategorizationMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaapInvestmentTypeCategorizationMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapInvestmentTypeAxis" xlink:to="loc_us-gaapInvestmentTypeCategorizationMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsMember" xlink:label="loc_us-gaapCashAndCashEquivalentsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapInvestmentTypeCategorizationMember" xlink:to="loc_us-gaapCashAndCashEquivalentsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_ShortTermInvestmentMember" xlink:label="loc_GTBPShortTermInvestmentMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapInvestmentTypeCategorizationMember" xlink:to="loc_GTBPShortTermInvestmentMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaapAvailableForSaleDebtSecuritiesAmortizedCostBasis_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLineItems" xlink:to="loc_us-gaapAvailableForSaleDebtSecuritiesAmortizedCostBasis_130" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:label="loc_us-gaapDebtSecuritiesAvailableForSaleRealizedGain_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLineItems" xlink:to="loc_us-gaapDebtSecuritiesAvailableForSaleRealizedGain_130" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:label="loc_us-gaapDebtSecuritiesAvailableForSaleRealizedLoss_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLineItems" xlink:to="loc_us-gaapDebtSecuritiesAvailableForSaleRealizedLoss_130" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:label="loc_us-gaapDebtSecuritiesAvailableForSaleRealizedGainLoss_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLineItems" xlink:to="loc_us-gaapDebtSecuritiesAvailableForSaleRealizedGainLoss_130" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfFairValueHierarchyFinancialAssetsDetails" xlink:title="00000027 - Disclosure - Schedule of Fair Value Hierarchy Financial Assets (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLineItems" xlink:label="loc_us-gaapFairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareTable" xlink:label="loc_us-gaapFairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLineItems" xlink:to="loc_us-gaapFairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaapInvestmentTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareTable" xlink:to="loc_us-gaapInvestmentTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaapInvestmentTypeCategorizationMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapInvestmentTypeAxis" xlink:to="loc_us-gaapInvestmentTypeCategorizationMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaapInvestmentTypeCategorizationMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapInvestmentTypeAxis" xlink:to="loc_us-gaapInvestmentTypeCategorizationMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaapMoneyMarketFundsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapInvestmentTypeCategorizationMember" xlink:to="loc_us-gaapMoneyMarketFundsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_CorporateNotesAndCommercialPaperMember" xlink:label="loc_GTBPCorporateNotesAndCommercialPaperMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapInvestmentTypeCategorizationMember" xlink:to="loc_GTBPCorporateNotesAndCommercialPaperMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaapFairValueInputsLevel1Member_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel1Member_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaapFairValueInputsLevel2Member_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel2Member_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueNetAssetLiability" xlink:label="loc_us-gaapFairValueNetAssetLiability_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLineItems" xlink:to="loc_us-gaapFairValueNetAssetLiability_250" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfDerivativeLiabilityTransactionsDetails" xlink:title="00000028 - Disclosure - Schedule of Derivative Liability Transactions (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfAccountsPayableDetails" xlink:title="00000029 - Disclosure - Schedule of Accounts Payable (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/AccountsPayableDetailsNarrative" xlink:title="00000030 - Disclosure - Accounts Payable (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaapRelatedPartyTransactionAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapRelatedPartyTransactionAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaapRelatedPartyTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionAxis" xlink:to="loc_us-gaapRelatedPartyTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaapRelatedPartyTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionAxis" xlink:to="loc_us-gaapRelatedPartyTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_VendorMember" xlink:label="loc_GTBPVendorMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionDomain" xlink:to="loc_GTBPVendorMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapAccountsPayableCurrent_20" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ConvertibleNotesPayableDetailsNarrative" xlink:title="00000031 - Disclosure - Convertible Notes Payable (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaapShortTermDebtLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaapScheduleOfShortTermDebtTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapScheduleOfShortTermDebtTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateAxis" xlink:label="loc_us-gaapAwardDateAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapAwardDateAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaapAwardDateDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardDateAxis" xlink:to="loc_us-gaapAwardDateDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaapAwardDateDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardDateAxis" xlink:to="loc_us-gaapAwardDateDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_AuguestOneTwentyEighteenAndJanuaryTwentySixTwentyTwentyOneMember" xlink:label="loc_GTBPAuguestOneTwentyEighteenAndJanuaryTwentySixTwentyTwentyOneMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_GTBPAuguestOneTwentyEighteenAndJanuaryTwentySixTwentyTwentyOneMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_FiscalTwentyNinteenandTwentyTwentyMember" xlink:label="loc_GTBPFiscalTwentyNinteenandTwentyTwentyMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_GTBPFiscalTwentyNinteenandTwentyTwentyMember_50" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_DuringTwentyTwentyMember" xlink:label="loc_GTBPDuringTwentyTwentyMember_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_GTBPDuringTwentyTwentyMember_150" xlink:type="arc" order="152" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_JanuaryOneTwentyTwentyOneMember" xlink:label="loc_GTBPJanuaryOneTwentyTwentyOneMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_GTBPJanuaryOneTwentyTwentyOneMember_160" xlink:type="arc" order="162" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapDebtInstrumentAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_NotesPayableIssuedForSettlementAgreementsMember" xlink:label="loc_GTBPNotesPayableIssuedForSettlementAgreementsMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_GTBPNotesPayableIssuedForSettlementAgreementsMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_NotesPayableIssuedForForbearanceAgreementMember" xlink:label="loc_GTBPNotesPayableIssuedForForbearanceAgreementMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_GTBPNotesPayableIssuedForForbearanceAgreementMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_AdoptionofAsuTwentyTwentyZeroSixMember" xlink:label="loc_GTBPAdoptionofAsuTwentyTwentyZeroSixMember_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_GTBPAdoptionofAsuTwentyTwentyZeroSixMember_150" xlink:type="arc" order="151" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_ForbearanceAgreementsMember" xlink:label="loc_GTBPForbearanceAgreementsMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_GTBPForbearanceAgreementsMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_ConsultingAgreementsMember" xlink:label="loc_GTBPConsultingAgreementsMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_GTBPConsultingAgreementsMember_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="loc_us-gaapConvertibleNotesPayableCurrent_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapConvertibleNotesPayableCurrent_200" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaapDebtInstrumentConvertibleConversionPrice1_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleConversionPrice1_200" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaapDebtConversionConvertedInstrumentSharesIssued1_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtConversionConvertedInstrumentSharesIssued1_200" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="loc_us-gaapConvertibleNotesPayable_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapConvertibleNotesPayable_200" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount_200" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaapNotesPayable_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapNotesPayable_200" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="loc_us-gaapDebtConversionConvertedInstrumentAmount1_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtConversionConvertedInstrumentAmount1_200" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_ConvertibleNotesPayableIssuedInExchangeForConsultingServices" xlink:label="loc_GTBPConvertibleNotesPayableIssuedInExchangeForConsultingServices_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_GTBPConvertibleNotesPayableIssuedInExchangeForConsultingServices_200" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_AccruedInterestAmount" xlink:label="loc_GTBPAccruedInterestAmount_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_GTBPAccruedInterestAmount_200" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentRate" xlink:label="loc_us-gaapDebtConversionConvertedInstrumentRate_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtConversionConvertedInstrumentRate_200" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaapConversionOfStockSharesConverted1_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapConversionOfStockSharesConverted1_200" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:label="loc_us-gaapDebtInstrumentConvertibleBeneficialConversionFeature_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleBeneficialConversionFeature_200" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_InterestExpenseDueAmortizationOfDebtDiscount" xlink:label="loc_GTBPInterestExpenseDueAmortizationOfDebtDiscount_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_GTBPInterestExpenseDueAmortizationOfDebtDiscount_200" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaapDebtInstrumentUnamortizedDiscount_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentUnamortizedDiscount_200" xlink:type="arc" order="13" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfDerivativeLiabilitiesAssumptionsDetails" xlink:title="00000032 - Disclosure - Schedule of Derivative Liabilities Assumptions (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaapMeasurementInputTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapMeasurementInputTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaapMeasurementInputRiskFreeInterestRateMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputRiskFreeInterestRateMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaapMeasurementInputPriceVolatilityMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputPriceVolatilityMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaapMeasurementInputExpectedTermMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExpectedTermMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="loc_us-gaapMeasurementInputExpectedDividendRateMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExpectedDividendRateMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapSharePrice_130" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilityMeasurementInput" xlink:label="loc_us-gaapDerivativeLiabilityMeasurementInput_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapDerivativeLiabilityMeasurementInput_130" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_DerivativeLiabilityFairValueAssumptionsExpectedTerm1" xlink:label="loc_GTBPDerivativeLiabilityFairValueAssumptionsExpectedTerm1_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_GTBPDerivativeLiabilityFairValueAssumptionsExpectedTerm1_130" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants_130" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/DerivativeLiabilityDetailsNarrative" xlink:title="00000033 - Disclosure - Derivative Liability (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfWarrantActivityDetails" xlink:title="00000034 - Disclosure - Schedule of Warrant Activity (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfOptionsActivityDetails" xlink:title="00000035 - Disclosure - Schedule of Options Activity (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative" xlink:title="00000036 - Disclosure - Stockholders&#8217; Equity (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_CommonStockIssuableMember" xlink:label="loc_GTBPCommonStockIssuableMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_GTBPCommonStockIssuableMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="loc_srtChiefExecutiveOfficerMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtChiefExecutiveOfficerMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ChiefFinancialOfficerMember" xlink:label="loc_srtChiefFinancialOfficerMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtChiefFinancialOfficerMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_DirectorMember" xlink:label="loc_srtDirectorMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtDirectorMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_EmployeesMember" xlink:label="loc_GTBPEmployeesMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_GTBPEmployeesMember_110" xlink:type="arc" order="111" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_OfficersEmployeesAndBoardOfDirectorsMember" xlink:label="loc_GTBPOfficersEmployeesAndBoardOfDirectorsMember_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_GTBPOfficersEmployeesAndBoardOfDirectorsMember_130" xlink:type="arc" order="131" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_ConsultingMember" xlink:label="loc_GTBPConsultingMember_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_GTBPConsultingMember_190" xlink:type="arc" order="191" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_EmploymentAgreementsMember" xlink:label="loc_GTBPEmploymentAgreementsMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_GTBPEmploymentAgreementsMember_60" xlink:type="arc" order="62" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_80" xlink:type="arc" order="83" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_90" xlink:type="arc" order="93" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_SeriesCPreferredStocksMember" xlink:label="loc_GTBPSeriesCPreferredStocksMember_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_GTBPSeriesCPreferredStocksMember_210" xlink:type="arc" order="211" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_SeriesKPreferredStocksMember" xlink:label="loc_GTBPSeriesKPreferredStocksMember_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_GTBPSeriesKPreferredStocksMember_230" xlink:type="arc" order="231" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized_280" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_280" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized_280" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare_280" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="loc_us-gaapDebtConversionConvertedInstrumentAmount1_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapDebtConversionConvertedInstrumentAmount1_280" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaapDebtConversionConvertedInstrumentSharesIssued1_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapDebtConversionConvertedInstrumentSharesIssued1_280" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaapSharesIssued_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSharesIssued_280" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_280" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:label="loc_us-gaapStockRepurchasedAndRetiredDuringPeriodShares_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockRepurchasedAndRetiredDuringPeriodShares_280" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_280" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_280" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_280" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_CommonStockSharesGrantedForConsultants" xlink:label="loc_GTBPCommonStockSharesGrantedForConsultants_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_GTBPCommonStockSharesGrantedForConsultants_280" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_FairValueOfStockOptionsGrantedForConsultants" xlink:label="loc_GTBPFairValueOfStockOptionsGrantedForConsultants_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_GTBPFairValueOfStockOptionsGrantedForConsultants_280" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensation_280" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedTounVestOutstandingNumber" xlink:label="loc_GTBPShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedTounVestOutstandingNumber_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_GTBPShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedTounVestOutstandingNumber_280" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToUnVestOutstandingAggregateIntrinsicValue" xlink:label="loc_GTBPShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToUnVestOutstandingAggregateIntrinsicValue_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_GTBPShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToUnVestOutstandingAggregateIntrinsicValue_280" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_CommonStockConsultantToFairValue" xlink:label="loc_GTBPCommonStockConsultantToFairValue_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_GTBPCommonStockConsultantToFairValue_280" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_280" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_280" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensation_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensation_280" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_280" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued_280" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding_280" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_280" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockConvertibleSharesIssuable" xlink:label="loc_us-gaapPreferredStockConvertibleSharesIssuable_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPreferredStockConvertibleSharesIssuable_280" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_NumberofsharesUnvestedOptions" xlink:label="loc_GTBPNumberofsharesUnvestedOptions_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_GTBPNumberofsharesUnvestedOptions_280" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_NumberofValueUnvestedOptions" xlink:label="loc_GTBPNumberofValueUnvestedOptions_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_GTBPNumberofValueUnvestedOptions_280" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_280" xlink:type="arc" order="28" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfOtherInformationRelatedLeasesUnderNon-cancellableDetails" xlink:title="00000037 - Disclosure - Schedule of Other Information Related Leases Under Non-Cancellable (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfFutureMinimumLeasePaymentsDetails" xlink:title="00000038 - Disclosure - Schedule of Future Minimum Lease Payments (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000039 - Disclosure - Commitments and Contingencies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaapLossContingenciesLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaapLossContingenciesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapLossContingenciesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_MasterServicesAgreementMember" xlink:label="loc_GTBPMasterServicesAgreementMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_GTBPMasterServicesAgreementMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_TwoThousandSixteenPatentLicenseAgreementMember" xlink:label="loc_GTBPTwoThousandSixteenPatentLicenseAgreementMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_GTBPTwoThousandSixteenPatentLicenseAgreementMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_TwoThousandAndTwentyOnePatentLicenseAgreementMember" xlink:label="loc_GTBPTwoThousandAndTwentyOnePatentLicenseAgreementMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_GTBPTwoThousandAndTwentyOnePatentLicenseAgreementMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_CytovanceBiologicsIncMember" xlink:label="loc_GTBPCytovanceBiologicsIncMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_GTBPCytovanceBiologicsIncMember_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srtCounterpartyNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_srtCounterpartyNameAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srtRepurchaseAgreementCounterpartyNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtCounterpartyNameAxis" xlink:to="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srtRepurchaseAgreementCounterpartyNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtCounterpartyNameAxis" xlink:to="loc_srtRepurchaseAgreementCounterpartyNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_AimmuneTherapeuticsIncMember" xlink:label="loc_GTBPAimmuneTherapeuticsIncMember_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:to="loc_GTBPAimmuneTherapeuticsIncMember_130" xlink:type="arc" order="131" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementExpense" xlink:label="loc_us-gaapLitigationSettlementExpense_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapLitigationSettlementExpense_160" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_ProjectFee" xlink:label="loc_GTBPProjectFee_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GTBPProjectFee_160" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_RecordedExpenses" xlink:label="loc_GTBPRecordedExpenses_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GTBPRecordedExpenses_160" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsDescription" xlink:label="loc_us-gaapOtherCommitmentsDescription_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapOtherCommitmentsDescription_160" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurred" xlink:label="loc_GTBPResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurred_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GTBPResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurred_160" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" xlink:label="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross_160" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_ResearchAndDevelopmentArrangementContractToPerformExpectedCostsIncurred" xlink:label="loc_GTBPResearchAndDevelopmentArrangementContractToPerformExpectedCostsIncurred_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GTBPResearchAndDevelopmentArrangementContractToPerformExpectedCostsIncurred_160" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_ProceedsFromUpfrontAmount" xlink:label="loc_GTBPProceedsFromUpfrontAmount_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GTBPProceedsFromUpfrontAmount_160" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_AnnualMaintananceFee" xlink:label="loc_GTBPAnnualMaintananceFee_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GTBPAnnualMaintananceFee_160" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_RoyaltyFeePercentage" xlink:label="loc_GTBPRoyaltyFeePercentage_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GTBPRoyaltyFeePercentage_160" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_AnnualRoyaltyPayments" xlink:label="loc_GTBPAnnualRoyaltyPayments_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GTBPAnnualRoyaltyPayments_160" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_PerformanceMilestonePayments" xlink:label="loc_GTBPPerformanceMilestonePayments_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GTBPPerformanceMilestonePayments_160" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_SalesMilestonePayments" xlink:label="loc_GTBPSalesMilestonePayments_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GTBPSalesMilestonePayments_160" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_GrossSales" xlink:label="loc_GTBPGrossSales_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GTBPGrossSales_160" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_SalesRevenue" xlink:label="loc_GTBPSalesRevenue_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GTBPSalesRevenue_160" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_CummulativeGrossSales" xlink:label="loc_GTBPCummulativeGrossSales_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GTBPCummulativeGrossSales_160" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_UpfrontLicenseFee" xlink:label="loc_GTBPUpfrontLicenseFee_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GTBPUpfrontLicenseFee_160" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_LicenseMaintenanceFeeReceivable" xlink:label="loc_GTBPLicenseMaintenanceFeeReceivable_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GTBPLicenseMaintenanceFeeReceivable_160" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_NetSalesPercentage" xlink:label="loc_GTBPNetSalesPercentage_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GTBPNetSalesPercentage_160" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_MaintananceFee" xlink:label="loc_GTBPMaintananceFee_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GTBPMaintananceFee_160" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AreaOfLand" xlink:label="loc_us-gaapAreaOfLand_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapAreaOfLand_160" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingSubleaseOptionToExtend" xlink:label="loc_us-gaapLesseeOperatingSubleaseOptionToExtend_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapLesseeOperatingSubleaseOptionToExtend_160" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRent" xlink:label="loc_us-gaapPaymentsForRent_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapPaymentsForRent_160" xlink:type="arc" order="22" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/SubsequentEventsDetailsNarrative" xlink:title="00000040 - Disclosure - Subsequent Events (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaapSubsequentEventLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaapSubsequentEventTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSubsequentEventTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="loc_srtChiefExecutiveOfficerMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtChiefExecutiveOfficerMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="loc_us-gaapStockRepurchasedDuringPeriodShares_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapStockRepurchasedDuringPeriodShares_20" xlink:type="arc" order="0" />
    </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>12
<FILENAME>gtbp-20220331_lab.xml
<DESCRIPTION>INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.13b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="us-gaap_SeriesCPreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesCPreferredStockMember" xlink:to="us-gaap_SeriesCPreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesCPreferredStockMember_lbl" xml:lang="en-US">Series C Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title of Individual [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_OfficersAndDirectorsMember" xlink:label="GTBP_OfficersAndDirectorsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_OfficersAndDirectorsMember" xlink:to="GTBP_OfficersAndDirectorsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_OfficersAndDirectorsMember_lbl" xml:lang="en-US">Officers and Directors [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockMember_lbl" xml:lang="en-US">Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_CommonSharesIssuableMember" xlink:label="GTBP_CommonSharesIssuableMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_CommonSharesIssuableMember" xlink:to="GTBP_CommonSharesIssuableMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_CommonSharesIssuableMember_lbl" xml:lang="en-US">Common Shares Issuable [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_OfficeSpaceAndEquipmentMember" xlink:label="GTBP_OfficeSpaceAndEquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_OfficeSpaceAndEquipmentMember" xlink:to="GTBP_OfficeSpaceAndEquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_OfficeSpaceAndEquipmentMember_lbl" xml:lang="en-US">Office Space And Equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_OptionsToPurchaseCommonStockMember" xlink:label="GTBP_OptionsToPurchaseCommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_OptionsToPurchaseCommonStockMember" xlink:to="GTBP_OptionsToPurchaseCommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_OptionsToPurchaseCommonStockMember_lbl" xml:lang="en-US">Options to Purchase Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_WarrantsToPurchaseCommonStockMember" xlink:label="GTBP_WarrantsToPurchaseCommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_WarrantsToPurchaseCommonStockMember" xlink:to="GTBP_WarrantsToPurchaseCommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_WarrantsToPurchaseCommonStockMember_lbl" xml:lang="en-US">Warrants to Purchase Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_UnvestedRestrictedCommonStockMember" xlink:label="GTBP_UnvestedRestrictedCommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_UnvestedRestrictedCommonStockMember" xlink:to="GTBP_UnvestedRestrictedCommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_UnvestedRestrictedCommonStockMember_lbl" xml:lang="en-US">Unvested Restricted Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xml:lang="en-US">Investment Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsMember" xlink:label="us-gaap_CashAndCashEquivalentsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsMember" xlink:to="us-gaap_CashAndCashEquivalentsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsMember_lbl" xml:lang="en-US">Cash and Cash Equivalents [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_ShortTermInvestmentMember" xlink:label="GTBP_ShortTermInvestmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ShortTermInvestmentMember" xlink:to="GTBP_ShortTermInvestmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_ShortTermInvestmentMember_lbl" xml:lang="en-US">Short-Term Investments [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xml:lang="en-US">Money Market Funds [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_CorporateNotesAndCommercialPaperMember" xlink:label="GTBP_CorporateNotesAndCommercialPaperMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_CorporateNotesAndCommercialPaperMember" xlink:to="GTBP_CorporateNotesAndCommercialPaperMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_CorporateNotesAndCommercialPaperMember_lbl" xml:lang="en-US">Corporate Notes and Commercial Paper [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_VendorMember" xlink:label="GTBP_VendorMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_VendorMember" xlink:to="GTBP_VendorMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_VendorMember_lbl" xml:lang="en-US">Vendor [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateAxis" xlink:label="us-gaap_AwardDateAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardDateAxis_lbl" xml:lang="en-US">Award Date [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_AuguestOneTwentyEighteenAndJanuaryTwentySixTwentyTwentyOneMember" xlink:label="GTBP_AuguestOneTwentyEighteenAndJanuaryTwentySixTwentyTwentyOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_AuguestOneTwentyEighteenAndJanuaryTwentySixTwentyTwentyOneMember" xlink:to="GTBP_AuguestOneTwentyEighteenAndJanuaryTwentySixTwentyTwentyOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_AuguestOneTwentyEighteenAndJanuaryTwentySixTwentyTwentyOneMember_lbl" xml:lang="en-US">August 1, 2018 and January 26, 2021 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US">Debt Instrument [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_NotesPayableIssuedForSettlementAgreementsMember" xlink:label="GTBP_NotesPayableIssuedForSettlementAgreementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_NotesPayableIssuedForSettlementAgreementsMember" xlink:to="GTBP_NotesPayableIssuedForSettlementAgreementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_NotesPayableIssuedForSettlementAgreementsMember_lbl" xml:lang="en-US">Notes Payable Issued For Settlement Agreements [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_FiscalTwentyNinteenandTwentyTwentyMember" xlink:label="GTBP_FiscalTwentyNinteenandTwentyTwentyMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_FiscalTwentyNinteenandTwentyTwentyMember" xlink:to="GTBP_FiscalTwentyNinteenandTwentyTwentyMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_FiscalTwentyNinteenandTwentyTwentyMember_lbl" xml:lang="en-US">Fiscal 2019 and 2020 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_ForbearanceAgreementsMember" xlink:label="GTBP_ForbearanceAgreementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ForbearanceAgreementsMember" xlink:to="GTBP_ForbearanceAgreementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_ForbearanceAgreementsMember_lbl" xml:lang="en-US">Forbearance Agreements [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_NotesPayableIssuedForForbearanceAgreementMember" xlink:label="GTBP_NotesPayableIssuedForForbearanceAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_NotesPayableIssuedForForbearanceAgreementMember" xlink:to="GTBP_NotesPayableIssuedForForbearanceAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_NotesPayableIssuedForForbearanceAgreementMember_lbl" xml:lang="en-US">Notes Payable Issued For Forbearance Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_ConsultingAgreementsMember" xlink:label="GTBP_ConsultingAgreementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ConsultingAgreementsMember" xlink:to="GTBP_ConsultingAgreementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_ConsultingAgreementsMember_lbl" xml:lang="en-US">Consulting Agreements [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_AdoptionofAsuTwentyTwentyZeroSixMember" xlink:label="GTBP_AdoptionofAsuTwentyTwentyZeroSixMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_AdoptionofAsuTwentyTwentyZeroSixMember" xlink:to="GTBP_AdoptionofAsuTwentyTwentyZeroSixMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_AdoptionofAsuTwentyTwentyZeroSixMember_lbl" xml:lang="en-US">Adoption of ASU 2020-06 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_DuringTwentyTwentyMember" xlink:label="GTBP_DuringTwentyTwentyMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_DuringTwentyTwentyMember" xlink:to="GTBP_DuringTwentyTwentyMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_DuringTwentyTwentyMember_lbl" xml:lang="en-US">During 2020 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_JanuaryOneTwentyTwentyOneMember" xlink:label="GTBP_JanuaryOneTwentyTwentyOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_JanuaryOneTwentyTwentyOneMember" xlink:to="GTBP_JanuaryOneTwentyTwentyOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_JanuaryOneTwentyTwentyOneMember_lbl" xml:lang="en-US">January 1, 2021 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputTypeAxis_lbl" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xml:lang="en-US">Measurement Input, Risk Free Interest Rate [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xml:lang="en-US">Measurement Input, Price Volatility [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedTermMember" xlink:to="us-gaap_MeasurementInputExpectedTermMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputExpectedTermMember_lbl" xml:lang="en-US">Measurement Input, Expected Term [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember_lbl" xml:lang="en-US">Measurement Input, Expected Dividend Rate [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_CommonStockIssuableMember" xlink:label="GTBP_CommonStockIssuableMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_CommonStockIssuableMember" xlink:to="GTBP_CommonStockIssuableMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_CommonStockIssuableMember_lbl" xml:lang="en-US">Common Stock Issuable [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefExecutiveOfficerMember" xlink:to="srt_ChiefExecutiveOfficerMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ChiefExecutiveOfficerMember_lbl" xml:lang="en-US">Chief Executive Officer [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_EmploymentAgreementsMember" xlink:label="GTBP_EmploymentAgreementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_EmploymentAgreementsMember" xlink:to="GTBP_EmploymentAgreementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_EmploymentAgreementsMember_lbl" xml:lang="en-US">Employment Agreements [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ChiefFinancialOfficerMember" xlink:label="srt_ChiefFinancialOfficerMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefFinancialOfficerMember" xlink:to="srt_ChiefFinancialOfficerMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ChiefFinancialOfficerMember_lbl" xml:lang="en-US">Chief Financial Officer [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_DirectorMember" xlink:to="srt_DirectorMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_DirectorMember_lbl" xml:lang="en-US">Director [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_EmployeesMember" xlink:label="GTBP_EmployeesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_EmployeesMember" xlink:to="GTBP_EmployeesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_EmployeesMember_lbl" xml:lang="en-US">Employees [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_OfficersEmployeesAndBoardOfDirectorsMember" xlink:label="GTBP_OfficersEmployeesAndBoardOfDirectorsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_OfficersEmployeesAndBoardOfDirectorsMember" xlink:to="GTBP_OfficersEmployeesAndBoardOfDirectorsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_OfficersEmployeesAndBoardOfDirectorsMember_lbl" xml:lang="en-US">Officers Employees And Board Of Directors [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_ConsultingMember" xlink:label="GTBP_ConsultingMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ConsultingMember" xlink:to="GTBP_ConsultingMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_ConsultingMember_lbl" xml:lang="en-US">Consultings [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_SeriesCPreferredStocksMember" xlink:label="GTBP_SeriesCPreferredStocksMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_SeriesCPreferredStocksMember" xlink:to="GTBP_SeriesCPreferredStocksMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_SeriesCPreferredStocksMember_lbl" xml:lang="en-US">Series C Preferred Stocks [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_SeriesKPreferredStocksMember" xlink:label="GTBP_SeriesKPreferredStocksMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_SeriesKPreferredStocksMember" xlink:to="GTBP_SeriesKPreferredStocksMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_SeriesKPreferredStocksMember_lbl" xml:lang="en-US">Series K Preferred Stocks [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_MasterServicesAgreementMember" xlink:label="GTBP_MasterServicesAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_MasterServicesAgreementMember" xlink:to="GTBP_MasterServicesAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_MasterServicesAgreementMember_lbl" xml:lang="en-US">Master Services Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_CytovanceBiologicsIncMember" xlink:label="GTBP_CytovanceBiologicsIncMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_CytovanceBiologicsIncMember" xlink:to="GTBP_CytovanceBiologicsIncMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_CytovanceBiologicsIncMember_lbl" xml:lang="en-US">Cytovance Biologics, Inc. [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_TwoThousandSixteenPatentLicenseAgreementMember" xlink:label="GTBP_TwoThousandSixteenPatentLicenseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_TwoThousandSixteenPatentLicenseAgreementMember" xlink:to="GTBP_TwoThousandSixteenPatentLicenseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_TwoThousandSixteenPatentLicenseAgreementMember_lbl" xml:lang="en-US">2016 Patent License Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_TwoThousandAndTwentyOnePatentLicenseAgreementMember" xlink:label="GTBP_TwoThousandAndTwentyOnePatentLicenseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_TwoThousandAndTwentyOnePatentLicenseAgreementMember" xlink:to="GTBP_TwoThousandAndTwentyOnePatentLicenseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_TwoThousandAndTwentyOnePatentLicenseAgreementMember_lbl" xml:lang="en-US">2021 Patent License Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CounterpartyNameAxis_lbl" xml:lang="en-US">Counterparty Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_AimmuneTherapeuticsIncMember" xlink:label="GTBP_AimmuneTherapeuticsIncMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_AimmuneTherapeuticsIncMember" xlink:to="GTBP_AimmuneTherapeuticsIncMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_AimmuneTherapeuticsIncMember_lbl" xml:lang="en-US">Aimmune Therapeutics Inc [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashEquivalentsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashEquivalentsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermInvestments" xlink:to="us-gaap_ShortTermInvestments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermInvestments_lbl" xml:lang="en-US">Short-term investments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating lease right-of-use asset</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="us-gaap_DepositsAssetsNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositsAssetsNoncurrent" xlink:to="us-gaap_DepositsAssetsNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepositsAssetsNoncurrent_lbl" xml:lang="en-US">Deposits</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">TOTAL ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Current operating lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="us-gaap_DerivativeLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilitiesCurrent" xlink:to="us-gaap_DerivativeLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeLiabilitiesCurrent_lbl" xml:lang="en-US">Derivative liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Non-current operating lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders&#8217; equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Convertible Preferred stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, par value $0.001, 750,000,000 shares authorized, 32,345,717 shares and 32,061,989 shares issued and outstanding as of March 31, 2022 and December 31, 2021, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_CommonStockIssuable" xlink:label="GTBP_CommonStockIssuable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_CommonStockIssuable" xlink:to="GTBP_CommonStockIssuable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_CommonStockIssuable_lbl" xml:lang="en-US">Common stock issuable 0 shares and 327,298 shares at March 31, 2022 and December 31, 2021, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">TOTAL LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_CommonStockIssuableShares" xlink:label="GTBP_CommonStockIssuableShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_CommonStockIssuableShares" xlink:to="GTBP_CommonStockIssuableShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_CommonStockIssuableShares_lbl" xml:lang="en-US">Common stock issuable, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">Revenues</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating Expenses:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">Selling, general and administrative (including $447 and $14,296 expense from stock compensation granted to officers, employees and directors during the three months ended March 31, 2022 and 2021, respectively)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Loss from Operations</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Other (Income) Expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US">Interest income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebtExcludingAmortization" xlink:label="us-gaap_InterestExpenseDebtExcludingAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebtExcludingAmortization" xlink:to="us-gaap_InterestExpenseDebtExcludingAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseDebtExcludingAmortization_lbl" xml:lang="en-US">Interest expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeGainLossOnDerivativeNet" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_lbl" xml:lang="en-US">Change in fair value of derivative liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:label="us-gaap_MarketableSecuritiesUnrealizedGainLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:to="us-gaap_MarketableSecuritiesUnrealizedGainLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_MarketableSecuritiesUnrealizedGainLoss_lbl" xml:lang="en-US">Unrealized loss on marketable securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Total Other (Income) Expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net Loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Net loss per share - basic and diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted average common shares outstanding - basic and diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xlink:label="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xlink:to="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable_lbl" xml:lang="en-US">Schedule of Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits, by Title of Individual and by Type of Deferred Compensation [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems_lbl" xml:lang="en-US">Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Beginning balance, value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Beginning balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_StockIssuedDuringPeriodValueCancellation" xlink:label="GTBP_StockIssuedDuringPeriodValueCancellation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_StockIssuedDuringPeriodValueCancellation" xlink:to="GTBP_StockIssuedDuringPeriodValueCancellation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_StockIssuedDuringPeriodValueCancellation_lbl" xml:lang="en-US">Cancellation of common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_StockIssuedDuringPeriodSharesCancellation" xlink:label="GTBP_StockIssuedDuringPeriodSharesCancellation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_StockIssuedDuringPeriodSharesCancellation" xlink:to="GTBP_StockIssuedDuringPeriodSharesCancellation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_StockIssuedDuringPeriodSharesCancellation_lbl" xml:lang="en-US">Cancellation of common stock, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xml:lang="en-US">Issuance of common shares for common shares issuable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xml:lang="en-US">Issuance of common shares as equity, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_StockIssuedDuringPeriodValueEquityCompensationToOfficersAndBoardOfDirectors" xlink:label="GTBP_StockIssuedDuringPeriodValueEquityCompensationToOfficersAndBoardOfDirectors" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_StockIssuedDuringPeriodValueEquityCompensationToOfficersAndBoardOfDirectors" xlink:to="GTBP_StockIssuedDuringPeriodValueEquityCompensationToOfficersAndBoardOfDirectors_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_StockIssuedDuringPeriodValueEquityCompensationToOfficersAndBoardOfDirectors_lbl" xml:lang="en-US">Equity compensation to officers and board of directors</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_StockIssuedDuringPeriodSharesEquityCompensationToOfficersAndBoardOfDirectors" xlink:label="GTBP_StockIssuedDuringPeriodSharesEquityCompensationToOfficersAndBoardOfDirectors" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_StockIssuedDuringPeriodSharesEquityCompensationToOfficersAndBoardOfDirectors" xlink:to="GTBP_StockIssuedDuringPeriodSharesEquityCompensationToOfficersAndBoardOfDirectors_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_StockIssuedDuringPeriodSharesEquityCompensationToOfficersAndBoardOfDirectors_lbl" xml:lang="en-US">Equity compensation to officers and board of directors, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xml:lang="en-US">Issuance of common stock for services</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xml:lang="en-US">Issuance of common stock for services, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_ExtinguishmentOfDebtDiscountUponAdoptionOfAsu202006" xlink:label="GTBP_ExtinguishmentOfDebtDiscountUponAdoptionOfAsu202006" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ExtinguishmentOfDebtDiscountUponAdoptionOfAsu202006" xlink:to="GTBP_ExtinguishmentOfDebtDiscountUponAdoptionOfAsu202006_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_ExtinguishmentOfDebtDiscountUponAdoptionOfAsu202006_lbl" xml:lang="en-US">Extinguishment of debt discount upon adoption of ASU 2020-06</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Conversion of Preferred Series J-1 to common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Conversion of Preferred Series J-1 to common stock, Shares</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_StockIssuedDuringPeriodValueCommonSharesIssuedUponMandatoryConversionOfNotesPayableAndAccruedInterest" xlink:label="GTBP_StockIssuedDuringPeriodValueCommonSharesIssuedUponMandatoryConversionOfNotesPayableAndAccruedInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_StockIssuedDuringPeriodValueCommonSharesIssuedUponMandatoryConversionOfNotesPayableAndAccruedInterest" xlink:to="GTBP_StockIssuedDuringPeriodValueCommonSharesIssuedUponMandatoryConversionOfNotesPayableAndAccruedInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_StockIssuedDuringPeriodValueCommonSharesIssuedUponMandatoryConversionOfNotesPayableAndAccruedInterest_lbl" xml:lang="en-US">Common shares issued upon mandatory conversion of notes payable and accrued interest</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_StockIssuedDuringPeriodSharesCommonSharesIssuedUponMandatoryConversionOfNotesPayableAndAccruedInterest" xlink:label="GTBP_StockIssuedDuringPeriodSharesCommonSharesIssuedUponMandatoryConversionOfNotesPayableAndAccruedInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_StockIssuedDuringPeriodSharesCommonSharesIssuedUponMandatoryConversionOfNotesPayableAndAccruedInterest" xlink:to="GTBP_StockIssuedDuringPeriodSharesCommonSharesIssuedUponMandatoryConversionOfNotesPayableAndAccruedInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_StockIssuedDuringPeriodSharesCommonSharesIssuedUponMandatoryConversionOfNotesPayableAndAccruedInterest_lbl" xml:lang="en-US">Common shares issued upon mandatory conversion of notes payable and accrued interest, Shares</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_StockIssuedDuringPeriodValueCommonSharesIssuedUponExerciseOfWarrants" xlink:label="GTBP_StockIssuedDuringPeriodValueCommonSharesIssuedUponExerciseOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_StockIssuedDuringPeriodValueCommonSharesIssuedUponExerciseOfWarrants" xlink:to="GTBP_StockIssuedDuringPeriodValueCommonSharesIssuedUponExerciseOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_StockIssuedDuringPeriodValueCommonSharesIssuedUponExerciseOfWarrants_lbl" xml:lang="en-US">Common shares issued upon exercise of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_StockIssuedDuringPeriodSharesCommonSharesIssuedUponExerciseOfWarrants" xlink:label="GTBP_StockIssuedDuringPeriodSharesCommonSharesIssuedUponExerciseOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_StockIssuedDuringPeriodSharesCommonSharesIssuedUponExerciseOfWarrants" xlink:to="GTBP_StockIssuedDuringPeriodSharesCommonSharesIssuedUponExerciseOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_StockIssuedDuringPeriodSharesCommonSharesIssuedUponExerciseOfWarrants_lbl" xml:lang="en-US">Common shares issued upon exercise of warrants, Shares</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_StockIssuedDuringPeriodValueIssuanceOfCommonStockInPublicOfferingNetOfCost" xlink:label="GTBP_StockIssuedDuringPeriodValueIssuanceOfCommonStockInPublicOfferingNetOfCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_StockIssuedDuringPeriodValueIssuanceOfCommonStockInPublicOfferingNetOfCost" xlink:to="GTBP_StockIssuedDuringPeriodValueIssuanceOfCommonStockInPublicOfferingNetOfCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_StockIssuedDuringPeriodValueIssuanceOfCommonStockInPublicOfferingNetOfCost_lbl" xml:lang="en-US">Issuance of common stock in public offering, net of cost</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_StockIssuedDuringPeriodSharesIssuanceOfCommonStockInPublicOfferingNetOfCost" xlink:label="GTBP_StockIssuedDuringPeriodSharesIssuanceOfCommonStockInPublicOfferingNetOfCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_StockIssuedDuringPeriodSharesIssuanceOfCommonStockInPublicOfferingNetOfCost" xlink:to="GTBP_StockIssuedDuringPeriodSharesIssuanceOfCommonStockInPublicOfferingNetOfCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_StockIssuedDuringPeriodSharesIssuanceOfCommonStockInPublicOfferingNetOfCost_lbl" xml:lang="en-US">Issuance of common stock in public offering, net of cost, Shares</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_StockIssuedDuringPeriodValueIssuanceOfCommonStockForResearchAndDevelopmentAgreement" xlink:label="GTBP_StockIssuedDuringPeriodValueIssuanceOfCommonStockForResearchAndDevelopmentAgreement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_StockIssuedDuringPeriodValueIssuanceOfCommonStockForResearchAndDevelopmentAgreement" xlink:to="GTBP_StockIssuedDuringPeriodValueIssuanceOfCommonStockForResearchAndDevelopmentAgreement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_StockIssuedDuringPeriodValueIssuanceOfCommonStockForResearchAndDevelopmentAgreement_lbl" xml:lang="en-US">Issuance of common stock for research and development agreement</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_StockIssuedDuringPeriodShareIssuanceOfCommonStockForResearchAndDevelopmentAgreement" xlink:label="GTBP_StockIssuedDuringPeriodShareIssuanceOfCommonStockForResearchAndDevelopmentAgreement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_StockIssuedDuringPeriodShareIssuanceOfCommonStockForResearchAndDevelopmentAgreement" xlink:to="GTBP_StockIssuedDuringPeriodShareIssuanceOfCommonStockForResearchAndDevelopmentAgreement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_StockIssuedDuringPeriodShareIssuanceOfCommonStockForResearchAndDevelopmentAgreement_lbl" xml:lang="en-US">Issuance of common stock for research and development agreement, Shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US">Net loss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_3_lbl" xml:lang="en-US">Ending balance, value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_2_lbl" xml:lang="en-US">Ending balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash (used in) operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_StockBasedCompensationForServices" xlink:label="GTBP_StockBasedCompensationForServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_StockBasedCompensationForServices" xlink:to="GTBP_StockBasedCompensationForServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_StockBasedCompensationForServices_lbl" xml:lang="en-US">Stock based compensation for services</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_StockBasedCompensationToOfficersAndBoardOfDirectors" xlink:label="GTBP_StockBasedCompensationToOfficersAndBoardOfDirectors" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_StockBasedCompensationToOfficersAndBoardOfDirectors" xlink:to="GTBP_StockBasedCompensationToOfficersAndBoardOfDirectors_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_StockBasedCompensationToOfficersAndBoardOfDirectors_lbl" xml:lang="en-US">Stock based compensation to officers, employees and board of directors</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_ConvertibleNotesPayableIssuedForConsultingServices" xlink:label="GTBP_ConvertibleNotesPayableIssuedForConsultingServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ConvertibleNotesPayableIssuedForConsultingServices" xlink:to="GTBP_ConvertibleNotesPayableIssuedForConsultingServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_ConvertibleNotesPayableIssuedForConsultingServices_lbl" xml:lang="en-US">Convertible notes payable issued for consulting services</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xml:lang="en-US">Change in operating lease right-of-use assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xml:lang="en-US">(Increase) decrease in prepaid expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_IncreaseDecreaseInDeposit" xlink:label="GTBP_IncreaseDecreaseInDeposit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_IncreaseDecreaseInDeposit" xlink:to="GTBP_IncreaseDecreaseInDeposit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_IncreaseDecreaseInDeposit_lbl" xml:lang="en-US">Increase in deposits</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Increase (decrease) in accounts payable and accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xml:lang="en-US">(Decrease) in operating lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:to="us-gaap_IncreaseDecreaseInInterestPayableNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet_lbl" xml:lang="en-US">Increase in accrued interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net Cash (Used in) Operating Activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSalesOfAssetsInvestingActivities" xlink:label="us-gaap_ProceedsFromSalesOfAssetsInvestingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSalesOfAssetsInvestingActivities" xlink:to="us-gaap_ProceedsFromSalesOfAssetsInvestingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSalesOfAssetsInvestingActivities_lbl" xml:lang="en-US">Sale of investments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net Cash Provided by Investing Activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from issuance of common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US">Proceeds from exercise of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfMediumTermNotes" xlink:label="us-gaap_ProceedsFromIssuanceOfMediumTermNotes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfMediumTermNotes" xlink:to="us-gaap_ProceedsFromIssuanceOfMediumTermNotes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfMediumTermNotes_lbl" xml:lang="en-US">Proceeds from issuance of notes payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net Cash Provided by Financing Activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Net Increase (Decrease) in Cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash at Beginning of Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2_lbl" xml:lang="en-US">Cash at End of Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_CashPaidDuringYearFor" xlink:label="GTBP_CashPaidDuringYearFor" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_CashPaidDuringYearFor" xlink:to="GTBP_CashPaidDuringYearFor_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_CashPaidDuringYearFor_lbl" xml:lang="en-US">Cash paid during the year for:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaid" xlink:label="us-gaap_InterestPaid" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaid" xlink:to="us-gaap_InterestPaid_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaid_lbl" xml:lang="en-US">Interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxesPaidNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xml:lang="en-US">Income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US">SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING ACTIVITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_RightofuseAssetsAndLeaseLiabilitiesRecognizedPursuantToLeaseAgreement" xlink:label="GTBP_RightofuseAssetsAndLeaseLiabilitiesRecognizedPursuantToLeaseAgreement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_RightofuseAssetsAndLeaseLiabilitiesRecognizedPursuantToLeaseAgreement" xlink:to="GTBP_RightofuseAssetsAndLeaseLiabilitiesRecognizedPursuantToLeaseAgreement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_RightofuseAssetsAndLeaseLiabilitiesRecognizedPursuantToLeaseAgreement_lbl" xml:lang="en-US">Right-of-use assets and lease liabilities recognized pursuant to lease agreement</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_ExtinguishmentOfUnamortizedDebtDiscountAndAdjustmentToAccumulatedDeficitUponAdoption" xlink:label="GTBP_ExtinguishmentOfUnamortizedDebtDiscountAndAdjustmentToAccumulatedDeficitUponAdoption" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ExtinguishmentOfUnamortizedDebtDiscountAndAdjustmentToAccumulatedDeficitUponAdoption" xlink:to="GTBP_ExtinguishmentOfUnamortizedDebtDiscountAndAdjustmentToAccumulatedDeficitUponAdoption_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_ExtinguishmentOfUnamortizedDebtDiscountAndAdjustmentToAccumulatedDeficitUponAdoption_lbl" xml:lang="en-US">Extinguishment of unamortized debt discount and adjustment to accumulated deficit upon adoption of ASU 2020-06</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssued1" xlink:label="us-gaap_StockIssued1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssued1" xlink:to="us-gaap_StockIssued1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssued1_lbl" xml:lang="en-US">Common stock issued upon conversion of notes payable and accrued interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesIssued1" xlink:label="us-gaap_NotesIssued1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesIssued1" xlink:to="us-gaap_NotesIssued1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesIssued1_lbl" xml:lang="en-US">Convertible notes payable issued for accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Organization and Operations</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US">Accounts Payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US">Convertible Notes Payable</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_DisclosureDerivativeLiabilityAbstract" xlink:label="GTBP_DisclosureDerivativeLiabilityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_DisclosureDerivativeLiabilityAbstract" xlink:to="GTBP_DisclosureDerivativeLiabilityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_DisclosureDerivativeLiabilityAbstract_lbl" xml:lang="en-US">Derivative Liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativesAndFairValueTextBlock" xlink:label="us-gaap_DerivativesAndFairValueTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativesAndFairValueTextBlock" xlink:to="us-gaap_DerivativesAndFairValueTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DerivativesAndFairValueTextBlock_lbl" xml:lang="en-US">Derivative Liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">Equity [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Stockholders&#8217; Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">Commitments and Contingencies</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">Subsequent Events</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Basis of Presentation and Principles of Consolidation</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_LiquidityPolicyTextBlock" xlink:label="GTBP_LiquidityPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_LiquidityPolicyTextBlock" xlink:to="GTBP_LiquidityPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_LiquidityPolicyTextBlock_lbl" xml:lang="en-US">Liquidity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnusualRisksAndUncertaintiesTextBlock" xlink:label="us-gaap_UnusualRisksAndUncertaintiesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnusualRisksAndUncertaintiesTextBlock" xlink:to="us-gaap_UnusualRisksAndUncertaintiesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnusualRisksAndUncertaintiesTextBlock_lbl" xml:lang="en-US">COVID-19</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Accounting Estimates</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash Equivalents and Short-Term Investments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="us-gaap_DerivativesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativesPolicyTextBlock" xlink:to="us-gaap_DerivativesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativesPolicyTextBlock_lbl" xml:lang="en-US">Derivative Financial Instruments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xml:lang="en-US">Stock-Based Compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development Costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US">Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Net Earnings (Loss) Per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US">Concentration</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Segments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US">Schedule of Anti-dilutive Securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_lbl" xml:lang="en-US">Schedule of Estimated Fair Value of Financial Instrument</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl" xml:lang="en-US">Schedule of Fair Value Hierarchy Financial Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:label="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:to="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_lbl" xml:lang="en-US">Schedule of Derivative Liability Transactions</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Accounts Payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xml:lang="en-US">Schedule of Derivative Liabilities Assumptions</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US">Schedule of Warrant Activity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of Options Activity</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_ScheduleOfOtherInformationRelatedLeasesUnderNOnCancellableTableTextBlock" xlink:label="GTBP_ScheduleOfOtherInformationRelatedLeasesUnderNOnCancellableTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ScheduleOfOtherInformationRelatedLeasesUnderNOnCancellableTableTextBlock" xlink:to="GTBP_ScheduleOfOtherInformationRelatedLeasesUnderNOnCancellableTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_ScheduleOfOtherInformationRelatedLeasesUnderNOnCancellableTableTextBlock_lbl" xml:lang="en-US">Schedule of Other Information Related Leases Under Non-Cancellable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">Schedule of Future Minimum Lease Payments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Total anti-dilutive securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_CashOnHandAndShortTermInvestment" xlink:label="GTBP_CashOnHandAndShortTermInvestment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_CashOnHandAndShortTermInvestment" xlink:to="GTBP_CashOnHandAndShortTermInvestment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_CashOnHandAndShortTermInvestment_lbl" xml:lang="en-US">[custom:CashOnHandAndShortTermInvestment-0]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_WorkingCapital" xlink:label="GTBP_WorkingCapital" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_WorkingCapital" xlink:to="GTBP_WorkingCapital_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_WorkingCapital_lbl" xml:lang="en-US">[custom:WorkingCapital-0]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_4_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsAndCash" xlink:label="us-gaap_InvestmentsAndCash" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsAndCash" xlink:to="us-gaap_InvestmentsAndCash_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentsAndCash_lbl" xml:lang="en-US">Investments and Cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xml:lang="en-US">Total cash equivalents</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermInvestments" xlink:to="us-gaap_ShortTermInvestments_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShortTermInvestments_2_lbl" xml:lang="en-US">Short term investment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_2_lbl" xml:lang="en-US">Operating lease, right-of-use asset</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Operating lease,liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="us-gaap_CashFDICInsuredAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFDICInsuredAmount" xlink:to="us-gaap_CashFDICInsuredAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFDICInsuredAmount_lbl" xml:lang="en-US">FDIC amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareTable" xlink:label="us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareTable" xlink:to="us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareTable_lbl" xml:lang="en-US">Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLineItems" xlink:label="us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLineItems" xlink:to="us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLineItems_lbl" xml:lang="en-US">Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xml:lang="en-US">Cost</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_lbl" xml:lang="en-US">Unrealized gains</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_lbl" xml:lang="en-US">Unrealized losses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_lbl" xml:lang="en-US">Fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueNetAssetLiability" xlink:label="us-gaap_FairValueNetAssetLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueNetAssetLiability" xlink:to="us-gaap_FairValueNetAssetLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueNetAssetLiability_lbl" xml:lang="en-US">Total financial assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilitiesCurrent" xlink:to="us-gaap_DerivativeLiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_DerivativeLiabilitiesCurrent_2_lbl" xml:lang="en-US">Beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl" xml:lang="en-US">Fair value upon issuance of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:label="us-gaap_IncreaseDecreaseInDerivativeLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:to="us-gaap_IncreaseDecreaseInDerivativeLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDerivativeLiabilities_lbl" xml:lang="en-US">Change in fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_ExtinguishmentOfWarrants" xlink:label="GTBP_ExtinguishmentOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ExtinguishmentOfWarrants" xlink:to="GTBP_ExtinguishmentOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_ExtinguishmentOfWarrants_lbl" xml:lang="en-US">Extinguishment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilitiesCurrent" xlink:to="us-gaap_DerivativeLiabilitiesCurrent_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_DerivativeLiabilitiesCurrent_3_lbl" xml:lang="en-US">Ending balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:label="us-gaap_AccountsPayableRelatedPartiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:to="us-gaap_AccountsPayableRelatedPartiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableRelatedPartiesCurrent_lbl" xml:lang="en-US">Accounts payable to a third-party manufacturer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:label="us-gaap_AccountsPayableOtherCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableOtherCurrent" xlink:to="us-gaap_AccountsPayableOtherCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableOtherCurrent_lbl" xml:lang="en-US">Other accounts payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccountsPayableCurrent_2_lbl" xml:lang="en-US">Total accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_lbl" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedBenefitPlanDisclosureLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems_lbl" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccountsPayableCurrent_3_lbl" xml:lang="en-US">Accounts payable current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="us-gaap_ScheduleOfShortTermDebtTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShortTermDebtTable" xlink:to="us-gaap_ScheduleOfShortTermDebtTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShortTermDebtTable_lbl" xml:lang="en-US">Schedule of Short-Term Debt [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="us-gaap_ShortTermDebtLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_ShortTermDebtLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtLineItems_lbl" xml:lang="en-US">Short-Term Debt [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="us-gaap_ConvertibleNotesPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayableCurrent" xlink:to="us-gaap_ConvertibleNotesPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleNotesPayableCurrent_lbl" xml:lang="en-US">Convertible notes payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xml:lang="en-US">Conversion price per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl" xml:lang="en-US">Converted conversion of common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="us-gaap_ConvertibleNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayable" xlink:to="us-gaap_ConvertibleNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ConvertibleNotesPayable_lbl" xml:lang="en-US">Convertible notes payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US">Debt instrument, face amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayable" xlink:label="us-gaap_NotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayable" xlink:to="us-gaap_NotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayable_lbl" xml:lang="en-US">Notes payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl" xml:lang="en-US">Debt converted amount</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_ConvertibleNotesPayableIssuedInExchangeForConsultingServices" xlink:label="GTBP_ConvertibleNotesPayableIssuedInExchangeForConsultingServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ConvertibleNotesPayableIssuedInExchangeForConsultingServices" xlink:to="GTBP_ConvertibleNotesPayableIssuedInExchangeForConsultingServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_ConvertibleNotesPayableIssuedInExchangeForConsultingServices_lbl" xml:lang="en-US">Notes payable in exchange of consulting services</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_AccruedInterestAmount" xlink:label="GTBP_AccruedInterestAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_AccruedInterestAmount" xlink:to="GTBP_AccruedInterestAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_AccruedInterestAmount_lbl" xml:lang="en-US">Accrued interest amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentRate" xlink:label="us-gaap_DebtConversionConvertedInstrumentRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentRate" xlink:to="us-gaap_DebtConversionConvertedInstrumentRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionConvertedInstrumentRate_lbl" xml:lang="en-US">Debt conversion rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesConverted1" xlink:to="us-gaap_ConversionOfStockSharesConverted1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl" xml:lang="en-US">Conversion of common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:label="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:to="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_lbl" xml:lang="en-US">Beneficial conversion feature</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_InterestExpenseDueAmortizationOfDebtDiscount" xlink:label="GTBP_InterestExpenseDueAmortizationOfDebtDiscount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_InterestExpenseDueAmortizationOfDebtDiscount" xlink:to="GTBP_InterestExpenseDueAmortizationOfDebtDiscount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_InterestExpenseDueAmortizationOfDebtDiscount_lbl" xml:lang="en-US">Interest expense due amortization of debt discount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xml:lang="en-US">Unamortized debt discount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US">Stock Price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilityMeasurementInput" xlink:label="us-gaap_DerivativeLiabilityMeasurementInput" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilityMeasurementInput" xlink:to="us-gaap_DerivativeLiabilityMeasurementInput_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeLiabilityMeasurementInput_lbl" xml:lang="en-US">Expected dividend yield</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_DerivativeLiabilityFairValueAssumptionsExpectedTerm1" xlink:label="GTBP_DerivativeLiabilityFairValueAssumptionsExpectedTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_DerivativeLiabilityFairValueAssumptionsExpectedTerm1" xlink:to="GTBP_DerivativeLiabilityFairValueAssumptionsExpectedTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_DerivativeLiabilityFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected life (in years)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xml:lang="en-US">Fair value of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeGainOnDerivative" xlink:label="us-gaap_DerivativeGainOnDerivative" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeGainOnDerivative" xlink:to="us-gaap_DerivativeGainOnDerivative_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeGainOnDerivative_lbl" xml:lang="en-US">Derivative, Gain on Derivative</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xml:lang="en-US">Warrants Outstanding,Beginning Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" xlink:label="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" xlink:to="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Beginning Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" xml:lang="en-US">Number of Warrants, Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue_lbl" xml:lang="en-US">Weighted Average Exercise Price, Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeited" xlink:label="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeited" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeited" xlink:to="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeited_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeited_lbl" xml:lang="en-US">Number of Warrants, Forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue_lbl" xml:lang="en-US">Weighted Average Exercise Price, Forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xml:lang="en-US">Number of Warrants, Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="GTBP_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="GTBP_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Exercised</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2_lbl" xml:lang="en-US">Warrants Outstanding, Ending Balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" xlink:to="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted Average Exercise Price, Ending Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable" xlink:label="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable" xlink:to="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable_lbl" xml:lang="en-US">Warrants Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice" xlink:label="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice" xlink:to="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Options outstanding, beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Exercise Price of Warrants or Rights</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xml:lang="en-US">Number of Options, Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_lbl" xml:lang="en-US">Number of Options, Forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionEquityInstrumentsExercised" xlink:label="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionEquityInstrumentsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionEquityInstrumentsExercised" xlink:to="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionEquityInstrumentsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionEquityInstrumentsExercised_lbl" xml:lang="en-US">Number of Options, Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Exercised</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xml:lang="en-US">Options outstanding, Ending</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Exercise Price of Warrants or Rights</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Options exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Options Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_lbl" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_lbl" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1_2_lbl" xml:lang="en-US">Debt Conversion, Converted Instrument, Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_2_lbl" xml:lang="en-US">Debt Conversion, Converted Instrument, Shares Issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssued_lbl" xml:lang="en-US">Shares issued</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_2_lbl" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:label="us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:to="us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_lbl" xml:lang="en-US">Common shares cancelled and returned</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US">Vested period</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_CommonStockSharesGrantedForConsultants" xlink:label="GTBP_CommonStockSharesGrantedForConsultants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_CommonStockSharesGrantedForConsultants" xlink:to="GTBP_CommonStockSharesGrantedForConsultants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_CommonStockSharesGrantedForConsultants_lbl" xml:lang="en-US">Common stock shares granted for consultants</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_FairValueOfStockOptionsGrantedForConsultants" xlink:label="GTBP_FairValueOfStockOptionsGrantedForConsultants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_FairValueOfStockOptionsGrantedForConsultants" xlink:to="GTBP_FairValueOfStockOptionsGrantedForConsultants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_FairValueOfStockOptionsGrantedForConsultants_lbl" xml:lang="en-US">Fair value of stock options granted f0r consultants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Share based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedTounVestOutstandingNumber" xlink:label="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedTounVestOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedTounVestOutstandingNumber" xlink:to="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedTounVestOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedTounVestOutstandingNumber_lbl" xml:lang="en-US">[custom:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedTounVestOutstandingNumber-0]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToUnVestOutstandingAggregateIntrinsicValue" xlink:label="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToUnVestOutstandingAggregateIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToUnVestOutstandingAggregateIntrinsicValue" xlink:to="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToUnVestOutstandingAggregateIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToUnVestOutstandingAggregateIntrinsicValue_lbl" xml:lang="en-US">[custom:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToUnVestOutstandingAggregateIntrinsicValue-0]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_CommonStockConsultantToFairValue" xlink:label="GTBP_CommonStockConsultantToFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_CommonStockConsultantToFairValue" xlink:to="GTBP_CommonStockConsultantToFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_CommonStockConsultantToFairValue_lbl" xml:lang="en-US">Common stock consultant to fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US">Vested shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xml:lang="en-US">Remaining vested shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xml:lang="en-US">Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockSharesIssued_2_lbl" xml:lang="en-US">Preferred stock, shares issued</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_2_lbl" xml:lang="en-US">Preferred stock, shares outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xml:lang="en-US">Preferred stock shares designated</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockConvertibleSharesIssuable" xlink:label="us-gaap_PreferredStockConvertibleSharesIssuable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockConvertibleSharesIssuable" xlink:to="us-gaap_PreferredStockConvertibleSharesIssuable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockConvertibleSharesIssuable_lbl" xml:lang="en-US">Convertible shares issuable</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_NumberofsharesUnvestedOptions" xlink:label="GTBP_NumberofsharesUnvestedOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_NumberofsharesUnvestedOptions" xlink:to="GTBP_NumberofsharesUnvestedOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_NumberofsharesUnvestedOptions_lbl" xml:lang="en-US">Number of shares unvested</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_NumberofValueUnvestedOptions" xlink:label="GTBP_NumberofValueUnvestedOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_NumberofValueUnvestedOptions" xlink:to="GTBP_NumberofValueUnvestedOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_NumberofValueUnvestedOptions_lbl" xml:lang="en-US">Number of shares unvested, value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Options outstanding intrinsic value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US">Operating cash flows from operating leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US">Right of use assets operating leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Weighted average remaining lease term operating leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Weighted average discount rate operating leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" xml:lang="en-US">Within one year</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">After one year and within two years</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">After two years and within three years</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xml:lang="en-US">Thereafter</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingLeaseLiability_2_lbl" xml:lang="en-US">Total future minimum lease payments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US">Less &#8211; discount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LossContingenciesTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingenciesTable_lbl" xml:lang="en-US">Loss Contingencies [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingenciesLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingenciesLineItems_lbl" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementExpense" xlink:label="us-gaap_LitigationSettlementExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LitigationSettlementExpense" xlink:to="us-gaap_LitigationSettlementExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LitigationSettlementExpense_lbl" xml:lang="en-US">Litigation settlement expense</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_ProjectFee" xlink:label="GTBP_ProjectFee" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ProjectFee" xlink:to="GTBP_ProjectFee_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_ProjectFee_lbl" xml:lang="en-US">Project fees</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_RecordedExpenses" xlink:label="GTBP_RecordedExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_RecordedExpenses" xlink:to="GTBP_RecordedExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_RecordedExpenses_lbl" xml:lang="en-US">Recorded expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsDescription" xlink:label="us-gaap_OtherCommitmentsDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsDescription" xlink:to="us-gaap_OtherCommitmentsDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCommitmentsDescription_lbl" xml:lang="en-US">Other commitments, description</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurred" xlink:label="GTBP_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurred" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurred" xlink:to="GTBP_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurred_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurred_lbl" xml:lang="en-US">Commitment amount for services, total</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross_lbl" xml:lang="en-US">Commitment cost incurred</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_ResearchAndDevelopmentArrangementContractToPerformExpectedCostsIncurred" xlink:label="GTBP_ResearchAndDevelopmentArrangementContractToPerformExpectedCostsIncurred" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ResearchAndDevelopmentArrangementContractToPerformExpectedCostsIncurred" xlink:to="GTBP_ResearchAndDevelopmentArrangementContractToPerformExpectedCostsIncurred_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_ResearchAndDevelopmentArrangementContractToPerformExpectedCostsIncurred_lbl" xml:lang="en-US">Compensation cost expected to be incurred in future</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_ProceedsFromUpfrontAmount" xlink:label="GTBP_ProceedsFromUpfrontAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ProceedsFromUpfrontAmount" xlink:to="GTBP_ProceedsFromUpfrontAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_ProceedsFromUpfrontAmount_lbl" xml:lang="en-US">Received upfront payment</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_AnnualMaintananceFee" xlink:label="GTBP_AnnualMaintananceFee" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_AnnualMaintananceFee" xlink:to="GTBP_AnnualMaintananceFee_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_AnnualMaintananceFee_lbl" xml:lang="en-US">Annual maintanance fee</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_RoyaltyFeePercentage" xlink:label="GTBP_RoyaltyFeePercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_RoyaltyFeePercentage" xlink:to="GTBP_RoyaltyFeePercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_RoyaltyFeePercentage_lbl" xml:lang="en-US">[custom:RoyaltyFeePercentage]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_AnnualRoyaltyPayments" xlink:label="GTBP_AnnualRoyaltyPayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_AnnualRoyaltyPayments" xlink:to="GTBP_AnnualRoyaltyPayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_AnnualRoyaltyPayments_lbl" xml:lang="en-US">Annual royalty payments</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_PerformanceMilestonePayments" xlink:label="GTBP_PerformanceMilestonePayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_PerformanceMilestonePayments" xlink:to="GTBP_PerformanceMilestonePayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_PerformanceMilestonePayments_lbl" xml:lang="en-US">Performance milestone payments</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_SalesMilestonePayments" xlink:label="GTBP_SalesMilestonePayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_SalesMilestonePayments" xlink:to="GTBP_SalesMilestonePayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_SalesMilestonePayments_lbl" xml:lang="en-US">Sales milestone payments</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_GrossSales" xlink:label="GTBP_GrossSales" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_GrossSales" xlink:to="GTBP_GrossSales_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_GrossSales_lbl" xml:lang="en-US">Gross sales</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_SalesRevenue" xlink:label="GTBP_SalesRevenue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_SalesRevenue" xlink:to="GTBP_SalesRevenue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_SalesRevenue_lbl" xml:lang="en-US">Sales revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_CummulativeGrossSales" xlink:label="GTBP_CummulativeGrossSales" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_CummulativeGrossSales" xlink:to="GTBP_CummulativeGrossSales_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_CummulativeGrossSales_lbl" xml:lang="en-US">Cummulative gross sales</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_UpfrontLicenseFee" xlink:label="GTBP_UpfrontLicenseFee" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_UpfrontLicenseFee" xlink:to="GTBP_UpfrontLicenseFee_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_UpfrontLicenseFee_lbl" xml:lang="en-US">Upfront license fee</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_LicenseMaintenanceFeeReceivable" xlink:label="GTBP_LicenseMaintenanceFeeReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_LicenseMaintenanceFeeReceivable" xlink:to="GTBP_LicenseMaintenanceFeeReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_LicenseMaintenanceFeeReceivable_lbl" xml:lang="en-US">License maintenance fee, receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_NetSalesPercentage" xlink:label="GTBP_NetSalesPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_NetSalesPercentage" xlink:to="GTBP_NetSalesPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_NetSalesPercentage_lbl" xml:lang="en-US">Net sales percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_MaintananceFee" xlink:label="GTBP_MaintananceFee" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_MaintananceFee" xlink:to="GTBP_MaintananceFee_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_MaintananceFee_lbl" xml:lang="en-US">Maintanance fee</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AreaOfLand" xlink:label="us-gaap_AreaOfLand" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AreaOfLand" xlink:to="us-gaap_AreaOfLand_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AreaOfLand_lbl" xml:lang="en-US">Area of land</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingSubleaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingSubleaseOptionToExtend" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingSubleaseOptionToExtend" xlink:to="us-gaap_LesseeOperatingSubleaseOptionToExtend_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingSubleaseOptionToExtend_lbl" xml:lang="en-US">Commencement date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRent" xlink:label="us-gaap_PaymentsForRent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRent" xlink:to="us-gaap_PaymentsForRent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForRent_lbl" xml:lang="en-US">Rent expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US">Subsequent Event [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchasedDuringPeriodShares" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares_lbl" xml:lang="en-US">Number of shares received</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_CommonStockIssuable" xlink:to="GTBP_CommonStockIssuable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_CommonStockIssuable_doc" xml:lang="en-US">Common Stock Issuable.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_CommonStockIssuableShares" xlink:to="GTBP_CommonStockIssuableShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_CommonStockIssuableShares_doc" xml:lang="en-US">Common Stock Issuable, Shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_OfficersAndDirectorsMember" xlink:to="GTBP_OfficersAndDirectorsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_OfficersAndDirectorsMember_doc" xml:lang="en-US">Officers and Directors [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_CommonSharesIssuableMember" xlink:to="GTBP_CommonSharesIssuableMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_CommonSharesIssuableMember_doc" xml:lang="en-US">Common Shares Issuable [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_CancellationOfCommonStockPreviouslyIssuedForServices" xlink:label="GTBP_CancellationOfCommonStockPreviouslyIssuedForServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_CancellationOfCommonStockPreviouslyIssuedForServices" xlink:to="GTBP_CancellationOfCommonStockPreviouslyIssuedForServices_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_CancellationOfCommonStockPreviouslyIssuedForServices_doc" xml:lang="en-US">Cancellation of common stock previously issued for services</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_StockIssuedDuringPeriodValueEquityCompensationToOfficersAndBoardOfDirectors" xlink:to="GTBP_StockIssuedDuringPeriodValueEquityCompensationToOfficersAndBoardOfDirectors_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_StockIssuedDuringPeriodValueEquityCompensationToOfficersAndBoardOfDirectors_doc" xml:lang="en-US">Equity compensation to officers and board of directors.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ExtinguishmentOfDebtDiscountUponAdoptionOfAsu202006" xlink:to="GTBP_ExtinguishmentOfDebtDiscountUponAdoptionOfAsu202006_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_ExtinguishmentOfDebtDiscountUponAdoptionOfAsu202006_doc" xml:lang="en-US">Extinguishment of debt discount upon adoption of ASU 2020-06.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_StockIssuedDuringPeriodValueCommonSharesIssuedUponMandatoryConversionOfNotesPayableAndAccruedInterest" xlink:to="GTBP_StockIssuedDuringPeriodValueCommonSharesIssuedUponMandatoryConversionOfNotesPayableAndAccruedInterest_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_StockIssuedDuringPeriodValueCommonSharesIssuedUponMandatoryConversionOfNotesPayableAndAccruedInterest_doc" xml:lang="en-US">Common shares issued upon mandatory conversion of notes payable and accrued interest.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_StockIssuedDuringPeriodValueCommonSharesIssuedUponExerciseOfWarrants" xlink:to="GTBP_StockIssuedDuringPeriodValueCommonSharesIssuedUponExerciseOfWarrants_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_StockIssuedDuringPeriodValueCommonSharesIssuedUponExerciseOfWarrants_doc" xml:lang="en-US">Common shares issued upon exercise of warrants.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_StockIssuedDuringPeriodValueIssuanceOfCommonStockInPublicOfferingNetOfCost" xlink:to="GTBP_StockIssuedDuringPeriodValueIssuanceOfCommonStockInPublicOfferingNetOfCost_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_StockIssuedDuringPeriodValueIssuanceOfCommonStockInPublicOfferingNetOfCost_doc" xml:lang="en-US">Issuance of common stock in public offering, net of cost.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_StockIssuedDuringPeriodValueIssuanceOfCommonStockForResearchAndDevelopmentAgreement" xlink:to="GTBP_StockIssuedDuringPeriodValueIssuanceOfCommonStockForResearchAndDevelopmentAgreement_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_StockIssuedDuringPeriodValueIssuanceOfCommonStockForResearchAndDevelopmentAgreement_doc" xml:lang="en-US">Issuance of common stock for research and development agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_StockIssuedDuringPeriodSharesCommonSharesIssuedUponMandatoryConversionOfNotesPayableAndAccruedInterest" xlink:to="GTBP_StockIssuedDuringPeriodSharesCommonSharesIssuedUponMandatoryConversionOfNotesPayableAndAccruedInterest_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_StockIssuedDuringPeriodSharesCommonSharesIssuedUponMandatoryConversionOfNotesPayableAndAccruedInterest_doc" xml:lang="en-US">Common shares issued upon mandatory conversion of notes payable and accrued interest, shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_StockIssuedDuringPeriodSharesCommonSharesIssuedUponExerciseOfWarrants" xlink:to="GTBP_StockIssuedDuringPeriodSharesCommonSharesIssuedUponExerciseOfWarrants_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_StockIssuedDuringPeriodSharesCommonSharesIssuedUponExerciseOfWarrants_doc" xml:lang="en-US">Common shares issued upon exercise of warrants, shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_StockIssuedDuringPeriodSharesIssuanceOfCommonStockInPublicOfferingNetOfCost" xlink:to="GTBP_StockIssuedDuringPeriodSharesIssuanceOfCommonStockInPublicOfferingNetOfCost_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_StockIssuedDuringPeriodSharesIssuanceOfCommonStockInPublicOfferingNetOfCost_doc" xml:lang="en-US">Issuance of common stock in public offering, net of cost, shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_StockIssuedDuringPeriodShareIssuanceOfCommonStockForResearchAndDevelopmentAgreement" xlink:to="GTBP_StockIssuedDuringPeriodShareIssuanceOfCommonStockForResearchAndDevelopmentAgreement_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_StockIssuedDuringPeriodShareIssuanceOfCommonStockForResearchAndDevelopmentAgreement_doc" xml:lang="en-US">Issuance of common stock for research and development agreement, shares.</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_StockIssuedDuringPeriodCancellationOfCommonStockPreviouslyIssuedForServices" xlink:label="GTBP_StockIssuedDuringPeriodCancellationOfCommonStockPreviouslyIssuedForServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_StockIssuedDuringPeriodCancellationOfCommonStockPreviouslyIssuedForServices" xlink:to="GTBP_StockIssuedDuringPeriodCancellationOfCommonStockPreviouslyIssuedForServices_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_StockIssuedDuringPeriodCancellationOfCommonStockPreviouslyIssuedForServices_doc" xml:lang="en-US">Stock issued during period cancellation of common stock previously issued for services</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_StockIssuedDuringPeriodSharesEquityCompensationToOfficersAndBoardOfDirectors" xlink:to="GTBP_StockIssuedDuringPeriodSharesEquityCompensationToOfficersAndBoardOfDirectors_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_StockIssuedDuringPeriodSharesEquityCompensationToOfficersAndBoardOfDirectors_doc" xml:lang="en-US">Stock issued during period shares equity compensation to officers and board of directors</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_StockBasedCompensationConsultantsAndResearchAndDevelopment" xlink:label="GTBP_StockBasedCompensationConsultantsAndResearchAndDevelopment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_StockBasedCompensationConsultantsAndResearchAndDevelopment" xlink:to="GTBP_StockBasedCompensationConsultantsAndResearchAndDevelopment_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_StockBasedCompensationConsultantsAndResearchAndDevelopment_doc" xml:lang="en-US">Stock based compensation consultants and research and development.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_StockBasedCompensationForServices" xlink:to="GTBP_StockBasedCompensationForServices_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_StockBasedCompensationForServices_doc" xml:lang="en-US">Stock based compensation for services</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_StockBasedCompensationToOfficersAndBoardOfDirectors" xlink:to="GTBP_StockBasedCompensationToOfficersAndBoardOfDirectors_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_StockBasedCompensationToOfficersAndBoardOfDirectors_doc" xml:lang="en-US">Stock based compensation to officers and board of directors.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ConvertibleNotesPayableIssuedForConsultingServices" xlink:to="GTBP_ConvertibleNotesPayableIssuedForConsultingServices_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_ConvertibleNotesPayableIssuedForConsultingServices_doc" xml:lang="en-US">Convertible notes payable issued for consulting services.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_CashPaidDuringYearFor" xlink:to="GTBP_CashPaidDuringYearFor_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_CashPaidDuringYearFor_doc" xml:lang="en-US">Cash paid during the year for [Abstract]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ExtinguishmentOfUnamortizedDebtDiscountAndAdjustmentToAccumulatedDeficitUponAdoption" xlink:to="GTBP_ExtinguishmentOfUnamortizedDebtDiscountAndAdjustmentToAccumulatedDeficitUponAdoption_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_ExtinguishmentOfUnamortizedDebtDiscountAndAdjustmentToAccumulatedDeficitUponAdoption_doc" xml:lang="en-US">Extinguishment of unamortized debt discount and adjustment to accumulated deficit upon adoption of ASU 2020-06.</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_RightOfUseAssetExchangeForFinanceLeaseLiability" xlink:label="GTBP_RightOfUseAssetExchangeForFinanceLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_RightOfUseAssetExchangeForFinanceLeaseLiability" xlink:to="GTBP_RightOfUseAssetExchangeForFinanceLeaseLiability_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_RightOfUseAssetExchangeForFinanceLeaseLiability_doc" xml:lang="en-US">Right of use asset exchange for finance lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_RightOfUseAssetsExchangeForFinanceLeaseLiability" xlink:label="GTBP_RightOfUseAssetsExchangeForFinanceLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_RightOfUseAssetsExchangeForFinanceLeaseLiability" xlink:to="GTBP_RightOfUseAssetsExchangeForFinanceLeaseLiability_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_RightOfUseAssetsExchangeForFinanceLeaseLiability_doc" xml:lang="en-US">Right of use assets exchange for finance lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_CashPaidAmountsForLeaseLiabilities" xlink:label="GTBP_CashPaidAmountsForLeaseLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_CashPaidAmountsForLeaseLiabilities" xlink:to="GTBP_CashPaidAmountsForLeaseLiabilities_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_CashPaidAmountsForLeaseLiabilities_doc" xml:lang="en-US">Cash paid amounts for lease liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_LiquidityPolicyTextBlock" xlink:to="GTBP_LiquidityPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_LiquidityPolicyTextBlock_doc" xml:lang="en-US">Liquidity Policy [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_WorkingCapital" xlink:to="GTBP_WorkingCapital_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_WorkingCapital_doc" xml:lang="en-US">Working capital</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_ShortTermInvestment" xlink:label="GTBP_ShortTermInvestment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ShortTermInvestment" xlink:to="GTBP_ShortTermInvestment_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_ShortTermInvestment_doc" xml:lang="en-US">Short term investment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_CashOnHandAndShortTermInvestment" xlink:to="GTBP_CashOnHandAndShortTermInvestment_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_CashOnHandAndShortTermInvestment_doc" xml:lang="en-US">Cash on hand and short term investment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_OptionsToPurchaseCommonStockMember" xlink:to="GTBP_OptionsToPurchaseCommonStockMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_OptionsToPurchaseCommonStockMember_doc" xml:lang="en-US">Options to Purchase Common Stock [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_WarrantsToPurchaseCommonStockMember" xlink:to="GTBP_WarrantsToPurchaseCommonStockMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_WarrantsToPurchaseCommonStockMember_doc" xml:lang="en-US">Warrants to Purchase Common Stock [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ShortTermInvestmentMember" xlink:to="GTBP_ShortTermInvestmentMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_ShortTermInvestmentMember_doc" xml:lang="en-US">Short-Term Investments [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_CorporateNotesAndCommercialPaperMember" xlink:to="GTBP_CorporateNotesAndCommercialPaperMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_CorporateNotesAndCommercialPaperMember_doc" xml:lang="en-US">Corporate Notes and Commercial Paper [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_NotesPayableIssuedForCashMember" xlink:label="GTBP_NotesPayableIssuedForCashMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_NotesPayableIssuedForCashMember" xlink:to="GTBP_NotesPayableIssuedForCashMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_NotesPayableIssuedForCashMember_doc" xml:lang="en-US">Notes Payables Issued For Cash [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_JanuaryTwentyTwentyOneMember" xlink:label="GTBP_JanuaryTwentyTwentyOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_JanuaryTwentyTwentyOneMember" xlink:to="GTBP_JanuaryTwentyTwentyOneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_JanuaryTwentyTwentyOneMember_doc" xml:lang="en-US">January 2021 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_NotesPayableIssuedForSettlementAgreementsMember" xlink:to="GTBP_NotesPayableIssuedForSettlementAgreementsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_NotesPayableIssuedForSettlementAgreementsMember_doc" xml:lang="en-US">Notes Payable Issued For Settlement Agreements [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_FiscalTwentyNinteenandTwentyTwentyMember" xlink:to="GTBP_FiscalTwentyNinteenandTwentyTwentyMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_FiscalTwentyNinteenandTwentyTwentyMember_doc" xml:lang="en-US">Fiscal 2019 and 2020 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_NotesPayableIssuedForForbearanceAgreementsMember" xlink:label="GTBP_NotesPayableIssuedForForbearanceAgreementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_NotesPayableIssuedForForbearanceAgreementsMember" xlink:to="GTBP_NotesPayableIssuedForForbearanceAgreementsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_NotesPayableIssuedForForbearanceAgreementsMember_doc" xml:lang="en-US">Notes Payable Issued For Forbearance Agreements [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_AuguestOneTwentyEighteenAndJanuaryTwentySixTwentyTwentyOneMember" xlink:to="GTBP_AuguestOneTwentyEighteenAndJanuaryTwentySixTwentyTwentyOneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_AuguestOneTwentyEighteenAndJanuaryTwentySixTwentyTwentyOneMember_doc" xml:lang="en-US">August 1, 2018 and January 26, 2021 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_JuneTwentyThreeTwentyTwentyMember" xlink:label="GTBP_JuneTwentyThreeTwentyTwentyMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_JuneTwentyThreeTwentyTwentyMember" xlink:to="GTBP_JuneTwentyThreeTwentyTwentyMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_JuneTwentyThreeTwentyTwentyMember_doc" xml:lang="en-US">June 23, 2020 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_NotesPayableIssuedForConsultingAgreementMember" xlink:label="GTBP_NotesPayableIssuedForConsultingAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_NotesPayableIssuedForConsultingAgreementMember" xlink:to="GTBP_NotesPayableIssuedForConsultingAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_NotesPayableIssuedForConsultingAgreementMember_doc" xml:lang="en-US">Notes Payables Issued for Consulting Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_DerivativeLiabilityFairValueAssumptionsExpectedTerm1" xlink:to="GTBP_DerivativeLiabilityFairValueAssumptionsExpectedTerm1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_DerivativeLiabilityFairValueAssumptionsExpectedTerm1_doc" xml:lang="en-US">Derivative liability fair value assumptions expected term 1.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_SeriesCPreferredStocksMember" xlink:to="GTBP_SeriesCPreferredStocksMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_SeriesCPreferredStocksMember_doc" xml:lang="en-US">Series C Preferred Stocks [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_SeriesKPreferredStocksMember" xlink:to="GTBP_SeriesKPreferredStocksMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_SeriesKPreferredStocksMember_doc" xml:lang="en-US">Series K Preferred Stocks [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" xlink:to="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_doc" xml:lang="en-US">Share based compensation arrangements by share based payment award non options outstanding weighted average exercise price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="GTBP_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice_doc" xml:lang="en-US">Share Based Compensation Arrangements By Share Based Paymen tAward Non Options Exercises In Period Weighted Average Exercise Price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice" xlink:to="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_doc" xml:lang="en-US">Share Based Compensation Arrangement By ShareBased Payment Award Non Options Exercisable Weighted Average Exercise Price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable" xlink:to="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable_doc" xml:lang="en-US">Share Based Compensation Arrangements By Share Based Payment Award Non Options Equity Instruments Exercisable.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeited" xlink:to="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeited_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeited_doc" xml:lang="en-US">Share Based Compensation Arrangements By Share Based Payment Award Non Options Equity Instruments Forfeited</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionEquityInstrumentsExercised" xlink:to="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionEquityInstrumentsExercised_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionEquityInstrumentsExercised_doc" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Option Equity Instruments Exercised.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ProjectFee" xlink:to="GTBP_ProjectFee_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_ProjectFee_doc" xml:lang="en-US">Project fee.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_RecordedExpenses" xlink:to="GTBP_RecordedExpenses_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_RecordedExpenses_doc" xml:lang="en-US">Recorded expenses.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurred" xlink:to="GTBP_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurred_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurred_doc" xml:lang="en-US">Research and development arrangement contract to perform for others costs incurred.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_MasterServicesAgreementMember" xlink:to="GTBP_MasterServicesAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_MasterServicesAgreementMember_doc" xml:lang="en-US">Master Services Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_CytovanceBiologicsIncMember" xlink:to="GTBP_CytovanceBiologicsIncMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_CytovanceBiologicsIncMember_doc" xml:lang="en-US">Cytovance Biologics, Inc. [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ResearchAndDevelopmentArrangementContractToPerformExpectedCostsIncurred" xlink:to="GTBP_ResearchAndDevelopmentArrangementContractToPerformExpectedCostsIncurred_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_ResearchAndDevelopmentArrangementContractToPerformExpectedCostsIncurred_doc" xml:lang="en-US">Compensation cost expected to be incurred in future.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ProceedsFromUpfrontAmount" xlink:to="GTBP_ProceedsFromUpfrontAmount_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_ProceedsFromUpfrontAmount_doc" xml:lang="en-US">Received upfront payment.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_AnnualMaintananceFee" xlink:to="GTBP_AnnualMaintananceFee_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_AnnualMaintananceFee_doc" xml:lang="en-US">Annual maintanance fee.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_RoyaltyFeePercentage" xlink:to="GTBP_RoyaltyFeePercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_RoyaltyFeePercentage_doc" xml:lang="en-US">Royalty fee percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_AnnualRoyaltyPayments" xlink:to="GTBP_AnnualRoyaltyPayments_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_AnnualRoyaltyPayments_doc" xml:lang="en-US">Annual royalty payments.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_PerformanceMilestonePayments" xlink:to="GTBP_PerformanceMilestonePayments_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_PerformanceMilestonePayments_doc" xml:lang="en-US">Performance milestone payments.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_SalesMilestonePayments" xlink:to="GTBP_SalesMilestonePayments_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_SalesMilestonePayments_doc" xml:lang="en-US">Sales milestone payments.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_GrossSales" xlink:to="GTBP_GrossSales_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_GrossSales_doc" xml:lang="en-US">Gross sales.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_SalesRevenue" xlink:to="GTBP_SalesRevenue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_SalesRevenue_doc" xml:lang="en-US">Sales revenue.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_CummulativeGrossSales" xlink:to="GTBP_CummulativeGrossSales_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_CummulativeGrossSales_doc" xml:lang="en-US">Cummulative gross sales.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_UpfrontLicenseFee" xlink:to="GTBP_UpfrontLicenseFee_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_UpfrontLicenseFee_doc" xml:lang="en-US">Upfront license fee.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_LicenseMaintenanceFeeReceivable" xlink:to="GTBP_LicenseMaintenanceFeeReceivable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_LicenseMaintenanceFeeReceivable_doc" xml:lang="en-US">License maintenance fee, receivable.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_NetSalesPercentage" xlink:to="GTBP_NetSalesPercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_NetSalesPercentage_doc" xml:lang="en-US">Net sales percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_MaintananceFee" xlink:to="GTBP_MaintananceFee_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_MaintananceFee_doc" xml:lang="en-US">Maintanance fee.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_AimmuneTherapeuticsIncMember" xlink:to="GTBP_AimmuneTherapeuticsIncMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_AimmuneTherapeuticsIncMember_doc" xml:lang="en-US">Aimmune Therapeutics Inc [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_InternalControlConsiderationsTextBlock" xlink:label="GTBP_InternalControlConsiderationsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_InternalControlConsiderationsTextBlock" xlink:to="GTBP_InternalControlConsiderationsTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_InternalControlConsiderationsTextBlock_doc" xml:lang="en-US">Internal Control Considerations [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_TwoThousandAndTwentyOnePatentLicenseAgreementMember" xlink:to="GTBP_TwoThousandAndTwentyOnePatentLicenseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_TwoThousandAndTwentyOnePatentLicenseAgreementMember_doc" xml:lang="en-US">2021 Patent License Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_TwoThousandSixteenPatentLicenseAgreementMember" xlink:to="GTBP_TwoThousandSixteenPatentLicenseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_TwoThousandSixteenPatentLicenseAgreementMember_doc" xml:lang="en-US">2016  Patent License Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ConsultingAgreementsMember" xlink:to="GTBP_ConsultingAgreementsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_ConsultingAgreementsMember_doc" xml:lang="en-US">Consulting Agreements [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_NumberOfSharesCancellationOfCommonStock" xlink:label="GTBP_NumberOfSharesCancellationOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_NumberOfSharesCancellationOfCommonStock" xlink:to="GTBP_NumberOfSharesCancellationOfCommonStock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_NumberOfSharesCancellationOfCommonStock_doc" xml:lang="en-US">Number of shares cancellation of common stock.</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_NumberOfSharesCancellationOfCommonStockValue" xlink:label="GTBP_NumberOfSharesCancellationOfCommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_NumberOfSharesCancellationOfCommonStockValue" xlink:to="GTBP_NumberOfSharesCancellationOfCommonStockValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_NumberOfSharesCancellationOfCommonStockValue_doc" xml:lang="en-US">Number of shares cancellation of common stock value.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_CommonStockIssuableMember" xlink:to="GTBP_CommonStockIssuableMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_CommonStockIssuableMember_doc" xml:lang="en-US">Common Stock Issuable [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo" xlink:label="GTBP_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo" xlink:to="GTBP_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo_doc" xml:lang="en-US">Lessee operating lease liability payments due after year two.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ScheduleOfOtherInformationRelatedLeasesUnderNOnCancellableTableTextBlock" xlink:to="GTBP_ScheduleOfOtherInformationRelatedLeasesUnderNOnCancellableTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_ScheduleOfOtherInformationRelatedLeasesUnderNOnCancellableTableTextBlock_doc" xml:lang="en-US">Schedule of Other Information Related Leases Under Non Cancellable [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_VendorMember" xlink:to="GTBP_VendorMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_VendorMember_doc" xml:lang="en-US">Vendor [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ForbearanceAgreementsMember" xlink:to="GTBP_ForbearanceAgreementsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_ForbearanceAgreementsMember_doc" xml:lang="en-US">Forbearance Agreements [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_OfficersEmployeesAndBoardOfDirectorsMember" xlink:to="GTBP_OfficersEmployeesAndBoardOfDirectorsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_OfficersEmployeesAndBoardOfDirectorsMember_doc" xml:lang="en-US">Officers Employees And Board Of Directors [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedTounVestOutstandingNumber" xlink:to="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedTounVestOutstandingNumber_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedTounVestOutstandingNumber_doc" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected to unvest Outstanding Number.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToUnVestOutstandingAggregateIntrinsicValue" xlink:to="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToUnVestOutstandingAggregateIntrinsicValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToUnVestOutstandingAggregateIntrinsicValue_doc" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To unvest Outstanding Aggregate Intrinsic Value.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ConsultingMember" xlink:to="GTBP_ConsultingMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_ConsultingMember_doc" xml:lang="en-US">Consultings [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_NumberofsharesUnvestedOptions" xlink:to="GTBP_NumberofsharesUnvestedOptions_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_NumberofsharesUnvestedOptions_doc" xml:lang="en-US">Number of shares unvested options.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_NumberofValueUnvestedOptions" xlink:to="GTBP_NumberofValueUnvestedOptions_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_NumberofValueUnvestedOptions_doc" xml:lang="en-US">Number of value unvested options.</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_CancellationOfCommonStockPreviouslyIssuedWithoutProperApproval" xlink:label="GTBP_CancellationOfCommonStockPreviouslyIssuedWithoutProperApproval" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_CancellationOfCommonStockPreviouslyIssuedWithoutProperApproval" xlink:to="GTBP_CancellationOfCommonStockPreviouslyIssuedWithoutProperApproval_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_CancellationOfCommonStockPreviouslyIssuedWithoutProperApproval_doc" xml:lang="en-US">Cancellation of common stock previously issued without proper approval.</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_StockIssuedDuringPeriodSharesCancellationOfCommonStockPreviouslyIssuedWithoutProperApproval" xlink:label="GTBP_StockIssuedDuringPeriodSharesCancellationOfCommonStockPreviouslyIssuedWithoutProperApproval" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_StockIssuedDuringPeriodSharesCancellationOfCommonStockPreviouslyIssuedWithoutProperApproval" xlink:to="GTBP_StockIssuedDuringPeriodSharesCancellationOfCommonStockPreviouslyIssuedWithoutProperApproval_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_StockIssuedDuringPeriodSharesCancellationOfCommonStockPreviouslyIssuedWithoutProperApproval_doc" xml:lang="en-US">Stock issued during period shares cancellation of common stock previously issued without proper approval.</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_StockIssuedDuringPeriodValueCancellationOfCommonStockPreviouslyIssuedWithoutProperApproval" xlink:label="GTBP_StockIssuedDuringPeriodValueCancellationOfCommonStockPreviouslyIssuedWithoutProperApproval" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_StockIssuedDuringPeriodValueCancellationOfCommonStockPreviouslyIssuedWithoutProperApproval" xlink:to="GTBP_StockIssuedDuringPeriodValueCancellationOfCommonStockPreviouslyIssuedWithoutProperApproval_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_StockIssuedDuringPeriodValueCancellationOfCommonStockPreviouslyIssuedWithoutProperApproval_doc" xml:lang="en-US">Stock issued during period value cancellation of common stock previously issued without proper approval.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_AdoptionofAsuTwentyTwentyZeroSixMember" xlink:to="GTBP_AdoptionofAsuTwentyTwentyZeroSixMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_AdoptionofAsuTwentyTwentyZeroSixMember_doc" xml:lang="en-US">Adoption of ASU 2020-06 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_DuringTwentyTwentyMember" xlink:to="GTBP_DuringTwentyTwentyMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_DuringTwentyTwentyMember_doc" xml:lang="en-US">During 2020 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_JanuaryOneTwentyTwentyOneMember" xlink:to="GTBP_JanuaryOneTwentyTwentyOneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_JanuaryOneTwentyTwentyOneMember_doc" xml:lang="en-US">January 1, 2021 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_InterestExpenseDueAmortizationOfDebtDiscount" xlink:to="GTBP_InterestExpenseDueAmortizationOfDebtDiscount_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_InterestExpenseDueAmortizationOfDebtDiscount_doc" xml:lang="en-US">Interest expense due amortization of debt discount.</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_CancelationOfCommonStockPreviouslyIssued" xlink:label="GTBP_CancelationOfCommonStockPreviouslyIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_CancelationOfCommonStockPreviouslyIssued" xlink:to="GTBP_CancelationOfCommonStockPreviouslyIssued_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_CancelationOfCommonStockPreviouslyIssued_doc" xml:lang="en-US">Cancelation of common stock previously issued.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_RightofuseAssetsAndLeaseLiabilitiesRecognizedPursuantToLeaseAgreement" xlink:to="GTBP_RightofuseAssetsAndLeaseLiabilitiesRecognizedPursuantToLeaseAgreement_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_RightofuseAssetsAndLeaseLiabilitiesRecognizedPursuantToLeaseAgreement_doc" xml:lang="en-US">Rightof use assets and lease liabilities recognized pursuant to lease agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_OfficeSpaceAndEquipmentMember" xlink:to="GTBP_OfficeSpaceAndEquipmentMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_OfficeSpaceAndEquipmentMember_doc" xml:lang="en-US">Office Space And Equipment [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_NotesPayableIssuedForForbearanceAgreementMember" xlink:to="GTBP_NotesPayableIssuedForForbearanceAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_NotesPayableIssuedForForbearanceAgreementMember_doc" xml:lang="en-US">Notes Payable Issued For Forbearance Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ConvertibleNotesPayableIssuedInExchangeForConsultingServices" xlink:to="GTBP_ConvertibleNotesPayableIssuedInExchangeForConsultingServices_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_ConvertibleNotesPayableIssuedInExchangeForConsultingServices_doc" xml:lang="en-US">Convertible notes payable issued in exchange for consulting services.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_AccruedInterestAmount" xlink:to="GTBP_AccruedInterestAmount_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_AccruedInterestAmount_doc" xml:lang="en-US">Accrued interest amount.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_EmploymentAgreementsMember" xlink:to="GTBP_EmploymentAgreementsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_EmploymentAgreementsMember_doc" xml:lang="en-US">Employment Agreements [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_CommonStockSharesGrantedForConsultants" xlink:to="GTBP_CommonStockSharesGrantedForConsultants_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_CommonStockSharesGrantedForConsultants_doc" xml:lang="en-US">Common stock shares granted for consultants.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_FairValueOfStockOptionsGrantedForConsultants" xlink:to="GTBP_FairValueOfStockOptionsGrantedForConsultants_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_FairValueOfStockOptionsGrantedForConsultants_doc" xml:lang="en-US">Fair Value Of Stock Options Granted For Consultants.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_CommonStockConsultantToFairValue" xlink:to="GTBP_CommonStockConsultantToFairValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_CommonStockConsultantToFairValue_doc" xml:lang="en-US">Common Stock Consultant To Fair Value.</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_CancellationOfCommonStock" xlink:label="GTBP_CancellationOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_CancellationOfCommonStock" xlink:to="GTBP_CancellationOfCommonStock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_CancellationOfCommonStock_doc" xml:lang="en-US">Cancellation Of Common Stock.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_EmployeesMember" xlink:to="GTBP_EmployeesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_EmployeesMember_doc" xml:lang="en-US">Employees [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_IncreaseDecreaseInDeposit" xlink:to="GTBP_IncreaseDecreaseInDeposit_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_IncreaseDecreaseInDeposit_doc" xml:lang="en-US">Increase decrease in deposit</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_AdjustmentToCancelShareBasedCompensationExpense" xlink:label="GTBP_AdjustmentToCancelShareBasedCompensationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_AdjustmentToCancelShareBasedCompensationExpense" xlink:to="GTBP_AdjustmentToCancelShareBasedCompensationExpense_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_AdjustmentToCancelShareBasedCompensationExpense_doc" xml:lang="en-US">Adjustment to cancel share based compensation expense.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_2_lbl" xml:lang="en-US">Assets, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_2_lbl" xml:lang="en-US">Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_2_lbl" xml:lang="en-US">Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_2_lbl" xml:lang="en-US">Operating Income (Loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_2_lbl" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeGainLossOnDerivativeNet" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_2_lbl" xml:lang="en-US">Derivative, Gain (Loss) on Derivative, Net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:to="us-gaap_MarketableSecuritiesUnrealizedGainLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecuritiesUnrealizedGainLoss_2_lbl" xml:lang="en-US">Marketable Securities, Unrealized Gain (Loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_2_lbl" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_3_lbl" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_3_lbl" xml:lang="en-US">Shares, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_2_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_3_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativesAndFairValueTextBlock" xlink:to="us-gaap_DerivativesAndFairValueTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativesAndFairValueTextBlock_2_lbl" xml:lang="en-US">Derivatives and Fair Value [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_2_lbl" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayable" xlink:to="us-gaap_ConvertibleNotesPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleNotesPayable_2_lbl" xml:lang="en-US">Convertible Notes Payable [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" xlink:to="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_4_lbl" xml:lang="en-US">Share Based Compensation Arrangements By Share Based Payment Award Non Options Outstanding Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeited" xlink:to="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeited_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeited_3_lbl" xml:lang="en-US">Share Based Compensation Arrangements By Share Based Payment Award Non Options Equity Instruments Forfeited</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>13
<FILENAME>gtbp-20220331_pre.xml
<DESCRIPTION>INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.13b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://gtbiopharma.com/role/Cover" xlink:href="gtbp-20220331.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/BalanceSheets" xlink:href="gtbp-20220331.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/BalanceSheetsParenthetical" xlink:href="gtbp-20220331.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/StatementsOfOperations" xlink:href="gtbp-20220331.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/StatementsOfOperationsParenthetical" xlink:href="gtbp-20220331.xsd#StatementsOfOperationsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/StatementsOfStockholdersEquityDeficit" xlink:href="gtbp-20220331.xsd#StatementsOfStockholdersEquityDeficit" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/StatementsOfCashFlows" xlink:href="gtbp-20220331.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/OrganizationAndOperations" xlink:href="gtbp-20220331.xsd#OrganizationAndOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="gtbp-20220331.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/FairValueOfFinancialInstruments" xlink:href="gtbp-20220331.xsd#FairValueOfFinancialInstruments" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/AccountsPayable" xlink:href="gtbp-20220331.xsd#AccountsPayable" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/ConvertibleNotesPayable" xlink:href="gtbp-20220331.xsd#ConvertibleNotesPayable" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/DerivativeLiability" xlink:href="gtbp-20220331.xsd#DerivativeLiability" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/StockholdersEquity" xlink:href="gtbp-20220331.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/CommitmentsAndContingencies" xlink:href="gtbp-20220331.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/SubsequentEvents" xlink:href="gtbp-20220331.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="gtbp-20220331.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="gtbp-20220331.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/FairValueOfFinancialInstrumentsTables" xlink:href="gtbp-20220331.xsd#FairValueOfFinancialInstrumentsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/AccountsPayableTables" xlink:href="gtbp-20220331.xsd#AccountsPayableTables" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/DerivativeLiabilityTables" xlink:href="gtbp-20220331.xsd#DerivativeLiabilityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/StockholdersEquityTables" xlink:href="gtbp-20220331.xsd#StockholdersEquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/CommitmentsAndContingenciesTables" xlink:href="gtbp-20220331.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/ScheduleOfAnti-dilutiveSecuritiesDetails" xlink:href="gtbp-20220331.xsd#ScheduleOfAnti-dilutiveSecuritiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="gtbp-20220331.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/ScheduleOfEstimatedFairValueOfFinancialInstrumentDetails" xlink:href="gtbp-20220331.xsd#ScheduleOfEstimatedFairValueOfFinancialInstrumentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/ScheduleOfFairValueHierarchyFinancialAssetsDetails" xlink:href="gtbp-20220331.xsd#ScheduleOfFairValueHierarchyFinancialAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/ScheduleOfDerivativeLiabilityTransactionsDetails" xlink:href="gtbp-20220331.xsd#ScheduleOfDerivativeLiabilityTransactionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/ScheduleOfAccountsPayableDetails" xlink:href="gtbp-20220331.xsd#ScheduleOfAccountsPayableDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/AccountsPayableDetailsNarrative" xlink:href="gtbp-20220331.xsd#AccountsPayableDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/ConvertibleNotesPayableDetailsNarrative" xlink:href="gtbp-20220331.xsd#ConvertibleNotesPayableDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/ScheduleOfDerivativeLiabilitiesAssumptionsDetails" xlink:href="gtbp-20220331.xsd#ScheduleOfDerivativeLiabilitiesAssumptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/DerivativeLiabilityDetailsNarrative" xlink:href="gtbp-20220331.xsd#DerivativeLiabilityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/ScheduleOfWarrantActivityDetails" xlink:href="gtbp-20220331.xsd#ScheduleOfWarrantActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/ScheduleOfOptionsActivityDetails" xlink:href="gtbp-20220331.xsd#ScheduleOfOptionsActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative" xlink:href="gtbp-20220331.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/ScheduleOfOtherInformationRelatedLeasesUnderNon-cancellableDetails" xlink:href="gtbp-20220331.xsd#ScheduleOfOtherInformationRelatedLeasesUnderNon-cancellableDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/ScheduleOfFutureMinimumLeasePaymentsDetails" xlink:href="gtbp-20220331.xsd#ScheduleOfFutureMinimumLeasePaymentsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="gtbp-20220331.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/SubsequentEventsDetailsNarrative" xlink:href="gtbp-20220331.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/BalanceSheets" xlink:title="00000002 - Statement - Condensed Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaapSeriesCPreferredStockMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesCPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments" xlink:label="loc_us-gaapShortTermInvestments" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapShortTermInvestments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPrepaidExpenseCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="loc_us-gaapDepositsAssetsNoncurrent" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapDepositsAssetsNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaapDerivativeLiabilitiesCurrent" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapDerivativeLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_CommonStockIssuable" xlink:label="loc_GTBPCommonStockIssuable" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_GTBPCommonStockIssuable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaapSeriesCPreferredStockMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesCPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_CommonStockIssuableShares" xlink:label="loc_GTBPCommonStockIssuableShares" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GTBPCommonStockIssuableShares" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapRevenues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpense" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaapNonoperatingIncomeExpenseAbstract" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpense" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebtExcludingAmortization" xlink:label="loc_us-gaapInterestExpenseDebtExcludingAmortization" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapInterestExpenseDebtExcludingAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaapDerivativeGainLossOnDerivativeNet" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapDerivativeGainLossOnDerivativeNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:label="loc_us-gaapMarketableSecuritiesUnrealizedGainLoss" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapMarketableSecuritiesUnrealizedGainLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/StatementsOfOperationsParenthetical" xlink:title="00000005 - Statement - Condensed Consolidated Statements of Operations (Unaudited) (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xlink:label="loc_us-gaapScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:label="loc_us-gaapDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xlink:to="loc_us-gaapDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xlink:to="loc_srtTitleOfIndividualAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_OfficersAndDirectorsMember" xlink:label="loc_GTBPOfficersAndDirectorsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_GTBPOfficersAndDirectorsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/StatementsOfStockholdersEquityDeficit" xlink:title="00000006 - Statement - Condensed Consolidated Statements of Stockholders&apos; Equity (Deficit) (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaapPreferredStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_CommonSharesIssuableMember" xlink:label="loc_GTBPCommonSharesIssuableMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_GTBPCommonSharesIssuableMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_StockIssuedDuringPeriodValueCancellation" xlink:label="loc_GTBPStockIssuedDuringPeriodValueCancellation" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GTBPStockIssuedDuringPeriodValueCancellation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_StockIssuedDuringPeriodSharesCancellation" xlink:label="loc_GTBPStockIssuedDuringPeriodSharesCancellation" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GTBPStockIssuedDuringPeriodSharesCancellation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_StockIssuedDuringPeriodValueEquityCompensationToOfficersAndBoardOfDirectors" xlink:label="loc_GTBPStockIssuedDuringPeriodValueEquityCompensationToOfficersAndBoardOfDirectors" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GTBPStockIssuedDuringPeriodValueEquityCompensationToOfficersAndBoardOfDirectors" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_StockIssuedDuringPeriodSharesEquityCompensationToOfficersAndBoardOfDirectors" xlink:label="loc_GTBPStockIssuedDuringPeriodSharesEquityCompensationToOfficersAndBoardOfDirectors" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GTBPStockIssuedDuringPeriodSharesEquityCompensationToOfficersAndBoardOfDirectors" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_ExtinguishmentOfDebtDiscountUponAdoptionOfAsu202006" xlink:label="loc_GTBPExtinguishmentOfDebtDiscountUponAdoptionOfAsu202006" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GTBPExtinguishmentOfDebtDiscountUponAdoptionOfAsu202006" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_StockIssuedDuringPeriodValueCommonSharesIssuedUponMandatoryConversionOfNotesPayableAndAccruedInterest" xlink:label="loc_GTBPStockIssuedDuringPeriodValueCommonSharesIssuedUponMandatoryConversionOfNotesPayableAndAccruedInterest" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GTBPStockIssuedDuringPeriodValueCommonSharesIssuedUponMandatoryConversionOfNotesPayableAndAccruedInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_StockIssuedDuringPeriodSharesCommonSharesIssuedUponMandatoryConversionOfNotesPayableAndAccruedInterest" xlink:label="loc_GTBPStockIssuedDuringPeriodSharesCommonSharesIssuedUponMandatoryConversionOfNotesPayableAndAccruedInterest" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GTBPStockIssuedDuringPeriodSharesCommonSharesIssuedUponMandatoryConversionOfNotesPayableAndAccruedInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_StockIssuedDuringPeriodValueCommonSharesIssuedUponExerciseOfWarrants" xlink:label="loc_GTBPStockIssuedDuringPeriodValueCommonSharesIssuedUponExerciseOfWarrants" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GTBPStockIssuedDuringPeriodValueCommonSharesIssuedUponExerciseOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_StockIssuedDuringPeriodSharesCommonSharesIssuedUponExerciseOfWarrants" xlink:label="loc_GTBPStockIssuedDuringPeriodSharesCommonSharesIssuedUponExerciseOfWarrants" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GTBPStockIssuedDuringPeriodSharesCommonSharesIssuedUponExerciseOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_StockIssuedDuringPeriodValueIssuanceOfCommonStockInPublicOfferingNetOfCost" xlink:label="loc_GTBPStockIssuedDuringPeriodValueIssuanceOfCommonStockInPublicOfferingNetOfCost" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GTBPStockIssuedDuringPeriodValueIssuanceOfCommonStockInPublicOfferingNetOfCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_StockIssuedDuringPeriodSharesIssuanceOfCommonStockInPublicOfferingNetOfCost" xlink:label="loc_GTBPStockIssuedDuringPeriodSharesIssuanceOfCommonStockInPublicOfferingNetOfCost" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GTBPStockIssuedDuringPeriodSharesIssuanceOfCommonStockInPublicOfferingNetOfCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_StockIssuedDuringPeriodValueIssuanceOfCommonStockForResearchAndDevelopmentAgreement" xlink:label="loc_GTBPStockIssuedDuringPeriodValueIssuanceOfCommonStockForResearchAndDevelopmentAgreement" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GTBPStockIssuedDuringPeriodValueIssuanceOfCommonStockForResearchAndDevelopmentAgreement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_StockIssuedDuringPeriodShareIssuanceOfCommonStockForResearchAndDevelopmentAgreement" xlink:label="loc_GTBPStockIssuedDuringPeriodShareIssuanceOfCommonStockForResearchAndDevelopmentAgreement" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GTBPStockIssuedDuringPeriodShareIssuanceOfCommonStockForResearchAndDevelopmentAgreement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProfitLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_2" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_2" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/StatementsOfCashFlows" xlink:title="00000007 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapProfitLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_StockBasedCompensationForServices" xlink:label="loc_GTBPStockBasedCompensationForServices" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_GTBPStockBasedCompensationForServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_StockBasedCompensationToOfficersAndBoardOfDirectors" xlink:label="loc_GTBPStockBasedCompensationToOfficersAndBoardOfDirectors" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_GTBPStockBasedCompensationToOfficersAndBoardOfDirectors" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_ConvertibleNotesPayableIssuedForConsultingServices" xlink:label="loc_GTBPConvertibleNotesPayableIssuedForConsultingServices" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_GTBPConvertibleNotesPayableIssuedForConsultingServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaapDerivativeGainLossOnDerivativeNet" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDerivativeGainLossOnDerivativeNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAssetAmortizationExpense" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:label="loc_us-gaapMarketableSecuritiesUnrealizedGainLoss" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapMarketableSecuritiesUnrealizedGainLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpense" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_IncreaseDecreaseInDeposit" xlink:label="loc_GTBPIncreaseDecreaseInDeposit" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_GTBPIncreaseDecreaseInDeposit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:label="loc_us-gaapIncreaseDecreaseInInterestPayableNet" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInInterestPayableNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSalesOfAssetsInvestingActivities" xlink:label="loc_us-gaapProceedsFromSalesOfAssetsInvestingActivities" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromSalesOfAssetsInvestingActivities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromWarrantExercises" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfMediumTermNotes" xlink:label="loc_us-gaapProceedsFromIssuanceOfMediumTermNotes" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfMediumTermNotes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaapSupplementalCashFlowInformationAbstract" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_CashPaidDuringYearFor" xlink:label="loc_GTBPCashPaidDuringYearFor" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_GTBPCashPaidDuringYearFor" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaid" xlink:label="loc_us-gaapInterestPaid" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPCashPaidDuringYearFor" xlink:to="loc_us-gaapInterestPaid" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="loc_us-gaapIncomeTaxesPaidNet" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPCashPaidDuringYearFor" xlink:to="loc_us-gaapIncomeTaxesPaidNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_RightofuseAssetsAndLeaseLiabilitiesRecognizedPursuantToLeaseAgreement" xlink:label="loc_GTBPRightofuseAssetsAndLeaseLiabilitiesRecognizedPursuantToLeaseAgreement" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_GTBPRightofuseAssetsAndLeaseLiabilitiesRecognizedPursuantToLeaseAgreement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_ExtinguishmentOfUnamortizedDebtDiscountAndAdjustmentToAccumulatedDeficitUponAdoption" xlink:label="loc_GTBPExtinguishmentOfUnamortizedDebtDiscountAndAdjustmentToAccumulatedDeficitUponAdoption" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_GTBPExtinguishmentOfUnamortizedDebtDiscountAndAdjustmentToAccumulatedDeficitUponAdoption" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssued1" xlink:label="loc_us-gaapStockIssued1" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_us-gaapStockIssued1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesIssued1" xlink:label="loc_us-gaapNotesIssued1" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_us-gaapNotesIssued1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/OrganizationAndOperations" xlink:title="00000008 - Disclosure - Organization and Operations">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="00000009 - Disclosure - Summary of Significant Accounting Policies">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapSignificantAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSignificantAccountingPoliciesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/FairValueOfFinancialInstruments" xlink:title="00000010 - Disclosure - Fair Value of Financial Instruments">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaapFairValueDisclosuresTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapFairValueDisclosuresTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/AccountsPayable" xlink:title="00000011 - Disclosure - Accounts Payable">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ConvertibleNotesPayable" xlink:title="00000012 - Disclosure - Convertible Notes Payable">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaapDebtDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapDebtDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/DerivativeLiability" xlink:title="00000013 - Disclosure - Derivative Liability">
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_DisclosureDerivativeLiabilityAbstract" xlink:label="loc_GTBPDisclosureDerivativeLiabilityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativesAndFairValueTextBlock" xlink:label="loc_us-gaapDerivativesAndFairValueTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDisclosureDerivativeLiabilityAbstract" xlink:to="loc_us-gaapDerivativesAndFairValueTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/StockholdersEquity" xlink:title="00000014 - Disclosure - Stockholders&#8217; Equity">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/CommitmentsAndContingencies" xlink:title="00000015 - Disclosure - Commitments and Contingencies">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/SubsequentEvents" xlink:title="00000016 - Disclosure - Subsequent Events">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaapSubsequentEventsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000017 - Disclosure - Summary of Significant Accounting Policies (Policies)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapBasisOfPresentationAndSignificantAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapBasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_LiquidityPolicyTextBlock" xlink:label="loc_GTBPLiquidityPolicyTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_GTBPLiquidityPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnusualRisksAndUncertaintiesTextBlock" xlink:label="loc_us-gaapUnusualRisksAndUncertaintiesTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapUnusualRisksAndUncertaintiesTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapUseOfEstimates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="loc_us-gaapDerivativesPolicyTextBlock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapDerivativesPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="loc_us-gaapCompensationRelatedCostsPolicyTextBlock" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCompensationRelatedCostsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaapResearchAndDevelopmentExpensePolicy" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpensePolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaapLesseeLeasesPolicyTextBlock" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapLesseeLeasesPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaapEarningsPerSharePolicyTextBlock" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapEarningsPerSharePolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaapConcentrationRiskCreditRisk" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapConcentrationRiskCreditRisk" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaapSegmentReportingPolicyPolicyTextBlock" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSegmentReportingPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="00000018 - Disclosure - Summary of Significant Accounting Policies (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/FairValueOfFinancialInstrumentsTables" xlink:title="00000019 - Disclosure - Fair Value of Financial Instruments (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:label="loc_us-gaapDebtSecuritiesAvailableForSaleTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapDebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:label="loc_us-gaapScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/AccountsPayableTables" xlink:title="00000020 - Disclosure - Accounts Payable (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/DerivativeLiabilityTables" xlink:title="00000021 - Disclosure - Derivative Liability (Tables)">
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_DisclosureDerivativeLiabilityAbstract" xlink:label="loc_GTBPDisclosureDerivativeLiabilityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDisclosureDerivativeLiabilityAbstract" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/StockholdersEquityTables" xlink:title="00000022 - Disclosure - Stockholders&#8217; Equity (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/CommitmentsAndContingenciesTables" xlink:title="00000023 - Disclosure - Commitments and Contingencies (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_ScheduleOfOtherInformationRelatedLeasesUnderNOnCancellableTableTextBlock" xlink:label="loc_GTBPScheduleOfOtherInformationRelatedLeasesUnderNOnCancellableTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_GTBPScheduleOfOtherInformationRelatedLeasesUnderNOnCancellableTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfAnti-dilutiveSecuritiesDetails" xlink:title="00000024 - Disclosure - Schedule of Anti-dilutive Securities (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_OptionsToPurchaseCommonStockMember" xlink:label="loc_GTBPOptionsToPurchaseCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_GTBPOptionsToPurchaseCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_WarrantsToPurchaseCommonStockMember" xlink:label="loc_GTBPWarrantsToPurchaseCommonStockMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_GTBPWarrantsToPurchaseCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_UnvestedRestrictedCommonStockMember" xlink:label="loc_GTBPUnvestedRestrictedCommonStockMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_GTBPUnvestedRestrictedCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000025 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_OfficeSpaceAndEquipmentMember" xlink:label="loc_GTBPOfficeSpaceAndEquipmentMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_GTBPOfficeSpaceAndEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_CashOnHandAndShortTermInvestment" xlink:label="loc_GTBPCashOnHandAndShortTermInvestment" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_GTBPCashOnHandAndShortTermInvestment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_WorkingCapital" xlink:label="loc_GTBPWorkingCapital" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_GTBPWorkingCapital" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsAndCash" xlink:label="loc_us-gaapInvestmentsAndCash" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapInvestmentsAndCash" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="loc_us-gaapCashCashEquivalentsAndShortTermInvestments" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapCashCashEquivalentsAndShortTermInvestments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments" xlink:label="loc_us-gaapShortTermInvestments" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapShortTermInvestments" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaapDerivativeLiabilitiesCurrent" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapDerivativeLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapOperatingLeaseLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="loc_us-gaapCashFDICInsuredAmount" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapCashFDICInsuredAmount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfEstimatedFairValueOfFinancialInstrumentDetails" xlink:title="00000026 - Disclosure - Schedule of Estimated Fair Value of Financial Instrument (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareTable" xlink:label="loc_us-gaapFairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapFairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLineItems" xlink:label="loc_us-gaapFairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareTable" xlink:to="loc_us-gaapFairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaapInvestmentTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareTable" xlink:to="loc_us-gaapInvestmentTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaapInvestmentTypeCategorizationMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentTypeAxis" xlink:to="loc_us-gaapInvestmentTypeCategorizationMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsMember" xlink:label="loc_us-gaapCashAndCashEquivalentsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentTypeCategorizationMember" xlink:to="loc_us-gaapCashAndCashEquivalentsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_ShortTermInvestmentMember" xlink:label="loc_GTBPShortTermInvestmentMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentTypeCategorizationMember" xlink:to="loc_GTBPShortTermInvestmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaapAvailableForSaleDebtSecuritiesAmortizedCostBasis" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLineItems" xlink:to="loc_us-gaapAvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:label="loc_us-gaapDebtSecuritiesAvailableForSaleRealizedGain" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLineItems" xlink:to="loc_us-gaapDebtSecuritiesAvailableForSaleRealizedGain" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:label="loc_us-gaapDebtSecuritiesAvailableForSaleRealizedLoss" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLineItems" xlink:to="loc_us-gaapDebtSecuritiesAvailableForSaleRealizedLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:label="loc_us-gaapDebtSecuritiesAvailableForSaleRealizedGainLoss" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLineItems" xlink:to="loc_us-gaapDebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfFairValueHierarchyFinancialAssetsDetails" xlink:title="00000027 - Disclosure - Schedule of Fair Value Hierarchy Financial Assets (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareTable" xlink:label="loc_us-gaapFairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapFairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLineItems" xlink:label="loc_us-gaapFairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareTable" xlink:to="loc_us-gaapFairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaapInvestmentTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareTable" xlink:to="loc_us-gaapInvestmentTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaapInvestmentTypeCategorizationMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentTypeAxis" xlink:to="loc_us-gaapInvestmentTypeCategorizationMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaapMoneyMarketFundsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentTypeCategorizationMember" xlink:to="loc_us-gaapMoneyMarketFundsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_CorporateNotesAndCommercialPaperMember" xlink:label="loc_GTBPCorporateNotesAndCommercialPaperMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentTypeCategorizationMember" xlink:to="loc_GTBPCorporateNotesAndCommercialPaperMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaapFairValueInputsLevel1Member" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaapFairValueInputsLevel2Member" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel2Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueNetAssetLiability" xlink:label="loc_us-gaapFairValueNetAssetLiability" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLineItems" xlink:to="loc_us-gaapFairValueNetAssetLiability" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfDerivativeLiabilityTransactionsDetails" xlink:title="00000028 - Disclosure - Schedule of Derivative Liability Transactions (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaapDerivativeLiabilitiesCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapDerivativeLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInDerivativeLiabilities" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInDerivativeLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_ExtinguishmentOfWarrants" xlink:label="loc_GTBPExtinguishmentOfWarrants" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_GTBPExtinguishmentOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaapDerivativeLiabilitiesCurrent_2" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapDerivativeLiabilitiesCurrent_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfAccountsPayableDetails" xlink:title="00000029 - Disclosure - Schedule of Accounts Payable (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:label="loc_us-gaapAccountsPayableRelatedPartiesCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccountsPayableRelatedPartiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:label="loc_us-gaapAccountsPayableOtherCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccountsPayableOtherCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/AccountsPayableDetailsNarrative" xlink:title="00000030 - Disclosure - Accounts Payable (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaapRelatedPartyTransactionAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapRelatedPartyTransactionAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaapRelatedPartyTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionAxis" xlink:to="loc_us-gaapRelatedPartyTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_VendorMember" xlink:label="loc_GTBPVendorMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionDomain" xlink:to="loc_GTBPVendorMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ConvertibleNotesPayableDetailsNarrative" xlink:title="00000031 - Disclosure - Convertible Notes Payable (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaapScheduleOfShortTermDebtTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfShortTermDebtTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaapShortTermDebtLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapShortTermDebtLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateAxis" xlink:label="loc_us-gaapAwardDateAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapAwardDateAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaapAwardDateDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateAxis" xlink:to="loc_us-gaapAwardDateDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_AuguestOneTwentyEighteenAndJanuaryTwentySixTwentyTwentyOneMember" xlink:label="loc_GTBPAuguestOneTwentyEighteenAndJanuaryTwentySixTwentyTwentyOneMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_GTBPAuguestOneTwentyEighteenAndJanuaryTwentySixTwentyTwentyOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_FiscalTwentyNinteenandTwentyTwentyMember" xlink:label="loc_GTBPFiscalTwentyNinteenandTwentyTwentyMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_GTBPFiscalTwentyNinteenandTwentyTwentyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_DuringTwentyTwentyMember" xlink:label="loc_GTBPDuringTwentyTwentyMember" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_GTBPDuringTwentyTwentyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_JanuaryOneTwentyTwentyOneMember" xlink:label="loc_GTBPJanuaryOneTwentyTwentyOneMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_GTBPJanuaryOneTwentyTwentyOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapDebtInstrumentAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_NotesPayableIssuedForSettlementAgreementsMember" xlink:label="loc_GTBPNotesPayableIssuedForSettlementAgreementsMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_GTBPNotesPayableIssuedForSettlementAgreementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_NotesPayableIssuedForForbearanceAgreementMember" xlink:label="loc_GTBPNotesPayableIssuedForForbearanceAgreementMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_GTBPNotesPayableIssuedForForbearanceAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_AdoptionofAsuTwentyTwentyZeroSixMember" xlink:label="loc_GTBPAdoptionofAsuTwentyTwentyZeroSixMember" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_GTBPAdoptionofAsuTwentyTwentyZeroSixMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_ForbearanceAgreementsMember" xlink:label="loc_GTBPForbearanceAgreementsMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_GTBPForbearanceAgreementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_ConsultingAgreementsMember" xlink:label="loc_GTBPConsultingAgreementsMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_GTBPConsultingAgreementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="loc_us-gaapConvertibleNotesPayableCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapConvertibleNotesPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaapDebtInstrumentConvertibleConversionPrice1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleConversionPrice1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaapDebtConversionConvertedInstrumentSharesIssued1" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtConversionConvertedInstrumentSharesIssued1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="loc_us-gaapConvertibleNotesPayable" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapConvertibleNotesPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaapNotesPayable" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapNotesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="loc_us-gaapDebtConversionConvertedInstrumentAmount1" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtConversionConvertedInstrumentAmount1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_ConvertibleNotesPayableIssuedInExchangeForConsultingServices" xlink:label="loc_GTBPConvertibleNotesPayableIssuedInExchangeForConsultingServices" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_GTBPConvertibleNotesPayableIssuedInExchangeForConsultingServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_AccruedInterestAmount" xlink:label="loc_GTBPAccruedInterestAmount" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_GTBPAccruedInterestAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentRate" xlink:label="loc_us-gaapDebtConversionConvertedInstrumentRate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtConversionConvertedInstrumentRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaapConversionOfStockSharesConverted1" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapConversionOfStockSharesConverted1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:label="loc_us-gaapDebtInstrumentConvertibleBeneficialConversionFeature" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleBeneficialConversionFeature" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_InterestExpenseDueAmortizationOfDebtDiscount" xlink:label="loc_GTBPInterestExpenseDueAmortizationOfDebtDiscount" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_GTBPInterestExpenseDueAmortizationOfDebtDiscount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaapDebtInstrumentUnamortizedDiscount" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentUnamortizedDiscount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfDerivativeLiabilitiesAssumptionsDetails" xlink:title="00000032 - Disclosure - Schedule of Derivative Liabilities Assumptions (Details)">
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_DisclosureDerivativeLiabilityAbstract" xlink:label="loc_GTBPDisclosureDerivativeLiabilityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDisclosureDerivativeLiabilityAbstract" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaapMeasurementInputTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapMeasurementInputTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaapMeasurementInputRiskFreeInterestRateMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputRiskFreeInterestRateMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaapMeasurementInputPriceVolatilityMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputPriceVolatilityMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaapMeasurementInputExpectedTermMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExpectedTermMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="loc_us-gaapMeasurementInputExpectedDividendRateMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExpectedDividendRateMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapSharePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilityMeasurementInput" xlink:label="loc_us-gaapDerivativeLiabilityMeasurementInput" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapDerivativeLiabilityMeasurementInput" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_DerivativeLiabilityFairValueAssumptionsExpectedTerm1" xlink:label="loc_GTBPDerivativeLiabilityFairValueAssumptionsExpectedTerm1" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_GTBPDerivativeLiabilityFairValueAssumptionsExpectedTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/DerivativeLiabilityDetailsNarrative" xlink:title="00000033 - Disclosure - Derivative Liability (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_DisclosureDerivativeLiabilityAbstract" xlink:label="loc_GTBPDisclosureDerivativeLiabilityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeGainOnDerivative" xlink:label="loc_us-gaapDerivativeGainOnDerivative" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDisclosureDerivativeLiabilityAbstract" xlink:to="loc_us-gaapDerivativeGainOnDerivative" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfWarrantActivityDetails" xlink:title="00000034 - Disclosure - Schedule of Warrant Activity (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_GTBPShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_GTBPShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeited" xlink:label="loc_GTBPShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeited" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_GTBPShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeited" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_GTBPShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_GTBPShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_GTBPShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_GTBPShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable" xlink:label="loc_GTBPShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_GTBPShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_GTBPShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_GTBPShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfOptionsActivityDetails" xlink:title="00000035 - Disclosure - Schedule of Options Activity (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionEquityInstrumentsExercised" xlink:label="loc_GTBPShareBasedCompensationArrangementByShareBasedPaymentAwardOptionEquityInstrumentsExercised" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_GTBPShareBasedCompensationArrangementByShareBasedPaymentAwardOptionEquityInstrumentsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative" xlink:title="00000036 - Disclosure - Stockholders&#8217; Equity (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_CommonStockIssuableMember" xlink:label="loc_GTBPCommonStockIssuableMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_GTBPCommonStockIssuableMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_srtTitleOfIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="loc_srtChiefExecutiveOfficerMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtChiefExecutiveOfficerMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ChiefFinancialOfficerMember" xlink:label="loc_srtChiefFinancialOfficerMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtChiefFinancialOfficerMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_DirectorMember" xlink:label="loc_srtDirectorMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtDirectorMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_EmployeesMember" xlink:label="loc_GTBPEmployeesMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_GTBPEmployeesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_OfficersEmployeesAndBoardOfDirectorsMember" xlink:label="loc_GTBPOfficersEmployeesAndBoardOfDirectorsMember" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_GTBPOfficersEmployeesAndBoardOfDirectorsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_ConsultingMember" xlink:label="loc_GTBPConsultingMember" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_GTBPConsultingMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_EmploymentAgreementsMember" xlink:label="loc_GTBPEmploymentAgreementsMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_GTBPEmploymentAgreementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_srtRangeAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_SeriesCPreferredStocksMember" xlink:label="loc_GTBPSeriesCPreferredStocksMember" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_GTBPSeriesCPreferredStocksMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_SeriesKPreferredStocksMember" xlink:label="loc_GTBPSeriesKPreferredStocksMember" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_GTBPSeriesKPreferredStocksMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="loc_us-gaapDebtConversionConvertedInstrumentAmount1" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapDebtConversionConvertedInstrumentAmount1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaapDebtConversionConvertedInstrumentSharesIssued1" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapDebtConversionConvertedInstrumentSharesIssued1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaapSharesIssued" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:label="loc_us-gaapStockRepurchasedAndRetiredDuringPeriodShares" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockRepurchasedAndRetiredDuringPeriodShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_CommonStockSharesGrantedForConsultants" xlink:label="loc_GTBPCommonStockSharesGrantedForConsultants" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_GTBPCommonStockSharesGrantedForConsultants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_FairValueOfStockOptionsGrantedForConsultants" xlink:label="loc_GTBPFairValueOfStockOptionsGrantedForConsultants" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_GTBPFairValueOfStockOptionsGrantedForConsultants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedTounVestOutstandingNumber" xlink:label="loc_GTBPShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedTounVestOutstandingNumber" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_GTBPShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedTounVestOutstandingNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToUnVestOutstandingAggregateIntrinsicValue" xlink:label="loc_GTBPShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToUnVestOutstandingAggregateIntrinsicValue" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_GTBPShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToUnVestOutstandingAggregateIntrinsicValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_CommonStockConsultantToFairValue" xlink:label="loc_GTBPCommonStockConsultantToFairValue" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_GTBPCommonStockConsultantToFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensation" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockConvertibleSharesIssuable" xlink:label="loc_us-gaapPreferredStockConvertibleSharesIssuable" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPreferredStockConvertibleSharesIssuable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_NumberofsharesUnvestedOptions" xlink:label="loc_GTBPNumberofsharesUnvestedOptions" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_GTBPNumberofsharesUnvestedOptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_NumberofValueUnvestedOptions" xlink:label="loc_GTBPNumberofValueUnvestedOptions" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_GTBPNumberofValueUnvestedOptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfOtherInformationRelatedLeasesUnderNon-cancellableDetails" xlink:title="00000037 - Disclosure - Schedule of Other Information Related Leases Under Non-Cancellable (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaapOperatingLeasePayments" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOperatingLeasePayments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="loc_us-gaapRightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapRightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfFutureMinimumLeasePaymentsDetails" xlink:title="00000038 - Disclosure - Schedule of Future Minimum Lease Payments (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOperatingLeaseLiability" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000039 - Disclosure - Commitments and Contingencies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaapLossContingenciesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLossContingenciesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaapLossContingenciesLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapLossContingenciesLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_MasterServicesAgreementMember" xlink:label="loc_GTBPMasterServicesAgreementMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_GTBPMasterServicesAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_TwoThousandSixteenPatentLicenseAgreementMember" xlink:label="loc_GTBPTwoThousandSixteenPatentLicenseAgreementMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_GTBPTwoThousandSixteenPatentLicenseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_TwoThousandAndTwentyOnePatentLicenseAgreementMember" xlink:label="loc_GTBPTwoThousandAndTwentyOnePatentLicenseAgreementMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_GTBPTwoThousandAndTwentyOnePatentLicenseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_deiLegalEntityAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_CytovanceBiologicsIncMember" xlink:label="loc_GTBPCytovanceBiologicsIncMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_GTBPCytovanceBiologicsIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_srtRangeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srtCounterpartyNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_srtCounterpartyNameAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srtRepurchaseAgreementCounterpartyNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtCounterpartyNameAxis" xlink:to="loc_srtRepurchaseAgreementCounterpartyNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_AimmuneTherapeuticsIncMember" xlink:label="loc_GTBPAimmuneTherapeuticsIncMember" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:to="loc_GTBPAimmuneTherapeuticsIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementExpense" xlink:label="loc_us-gaapLitigationSettlementExpense" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapLitigationSettlementExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_ProjectFee" xlink:label="loc_GTBPProjectFee" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GTBPProjectFee" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_RecordedExpenses" xlink:label="loc_GTBPRecordedExpenses" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GTBPRecordedExpenses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsDescription" xlink:label="loc_us-gaapOtherCommitmentsDescription" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapOtherCommitmentsDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurred" xlink:label="loc_GTBPResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurred" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GTBPResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurred" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" xlink:label="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_ResearchAndDevelopmentArrangementContractToPerformExpectedCostsIncurred" xlink:label="loc_GTBPResearchAndDevelopmentArrangementContractToPerformExpectedCostsIncurred" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GTBPResearchAndDevelopmentArrangementContractToPerformExpectedCostsIncurred" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_ProceedsFromUpfrontAmount" xlink:label="loc_GTBPProceedsFromUpfrontAmount" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GTBPProceedsFromUpfrontAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_AnnualMaintananceFee" xlink:label="loc_GTBPAnnualMaintananceFee" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GTBPAnnualMaintananceFee" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_RoyaltyFeePercentage" xlink:label="loc_GTBPRoyaltyFeePercentage" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GTBPRoyaltyFeePercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_AnnualRoyaltyPayments" xlink:label="loc_GTBPAnnualRoyaltyPayments" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GTBPAnnualRoyaltyPayments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_PerformanceMilestonePayments" xlink:label="loc_GTBPPerformanceMilestonePayments" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GTBPPerformanceMilestonePayments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_SalesMilestonePayments" xlink:label="loc_GTBPSalesMilestonePayments" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GTBPSalesMilestonePayments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_GrossSales" xlink:label="loc_GTBPGrossSales" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GTBPGrossSales" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_SalesRevenue" xlink:label="loc_GTBPSalesRevenue" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GTBPSalesRevenue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_CummulativeGrossSales" xlink:label="loc_GTBPCummulativeGrossSales" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GTBPCummulativeGrossSales" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_UpfrontLicenseFee" xlink:label="loc_GTBPUpfrontLicenseFee" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GTBPUpfrontLicenseFee" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_LicenseMaintenanceFeeReceivable" xlink:label="loc_GTBPLicenseMaintenanceFeeReceivable" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GTBPLicenseMaintenanceFeeReceivable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_NetSalesPercentage" xlink:label="loc_GTBPNetSalesPercentage" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GTBPNetSalesPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20220331.xsd#GTBP_MaintananceFee" xlink:label="loc_GTBPMaintananceFee" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GTBPMaintananceFee" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AreaOfLand" xlink:label="loc_us-gaapAreaOfLand" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapAreaOfLand" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingSubleaseOptionToExtend" xlink:label="loc_us-gaapLesseeOperatingSubleaseOptionToExtend" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapLesseeOperatingSubleaseOptionToExtend" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRent" xlink:label="loc_us-gaapPaymentsForRent" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapPaymentsForRent" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/SubsequentEventsDetailsNarrative" xlink:title="00000040 - Disclosure - Subsequent Events (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaapSubsequentEventTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaapSubsequentEventLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_srtTitleOfIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="loc_srtChiefExecutiveOfficerMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtChiefExecutiveOfficerMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="loc_us-gaapStockRepurchasedDuringPeriodShares" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapStockRepurchasedDuringPeriodShares" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140447026044904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>May 16, 2022</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-40023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">GT
BIOPHARMA, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000109657<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">94-1620407<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">8000
Marina Blvd<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Brisbane<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94005<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">415<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">919-4040<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common
    Stock, $0.001 par value per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">GTBP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,500,717<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140447029334872">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 7,286<span></span>
</td>
<td class="nump">$ 8,968<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">19,454<span></span>
</td>
<td class="nump">23,011<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">453<span></span>
</td>
<td class="nump">190<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">27,193<span></span>
</td>
<td class="nump">32,169<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset</a></td>
<td class="nump">237<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepositsAssetsNoncurrent', window );">Deposits</a></td>
<td class="nump">9<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">TOTAL ASSETS</a></td>
<td class="nump">27,439<span></span>
</td>
<td class="nump">32,169<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">8,113<span></span>
</td>
<td class="nump">8,220<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">1,170<span></span>
</td>
<td class="nump">1,901<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current operating lease liability</a></td>
<td class="nump">100<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Derivative liability</a></td>
<td class="nump">120<span></span>
</td>
<td class="nump">138<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">9,503<span></span>
</td>
<td class="nump">10,259<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Non-current operating lease liability</a></td>
<td class="nump">147<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">9,650<span></span>
</td>
<td class="nump">10,259<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Convertible Preferred stock</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, par value $0.001, 750,000,000 shares authorized, 32,345,717 shares and 32,061,989 shares issued and outstanding as of March 31, 2022 and December 31, 2021, respectively</a></td>
<td class="nump">32<span></span>
</td>
<td class="nump">32<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_GTBP_CommonStockIssuable', window );">Common stock issuable 0 shares and 327,298 shares at March 31, 2022 and December 31, 2021, respectively</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,113<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid in capital</a></td>
<td class="nump">676,780<span></span>
</td>
<td class="nump">674,348<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(659,024)<span></span>
</td>
<td class="num">(653,584)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">17,789<span></span>
</td>
<td class="nump">21,910<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">TOTAL LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</a></td>
<td class="nump">27,439<span></span>
</td>
<td class="nump">32,169<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Convertible Preferred stock</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_CommonStockIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common Stock Issuable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_CommonStockIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositsAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126905020&amp;loc=d3e5879-108316<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140447025989336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">15,000,000<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">750,000,000<span></span>
</td>
<td class="nump">750,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">32,345,717<span></span>
</td>
<td class="nump">32,061,989<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">32,345,717<span></span>
</td>
<td class="nump">32,061,989<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_GTBP_CommonStockIssuableShares', window );">Common stock issuable, shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">327,298<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred Stock, Shares Issued</a></td>
<td class="nump">96,230<span></span>
</td>
<td class="nump">96,230<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred Stock, Shares Outstanding</a></td>
<td class="nump">96,230<span></span>
</td>
<td class="nump">96,230<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_CommonStockIssuableShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common Stock Issuable, Shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_CommonStockIssuableShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140447029362184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating Expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">2,087<span></span>
</td>
<td class="nump">1,640<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative (including $447 and $14,296 expense from stock compensation granted to officers, employees and directors during the three months ended March 31, 2022 and 2021, respectively)</a></td>
<td class="nump">3,355<span></span>
</td>
<td class="nump">27,362<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from Operations</a></td>
<td class="nump">5,442<span></span>
</td>
<td class="nump">29,002<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other (Income) Expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Interest income</a></td>
<td class="num">(8)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebtExcludingAmortization', window );">Interest expense</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">696<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Change in fair value of derivative liability</a></td>
<td class="num">(18)<span></span>
</td>
<td class="num">(21)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss', window );">Unrealized loss on marketable securities</a></td>
<td class="nump">24<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total Other (Income) Expense</a></td>
<td class="num">(2)<span></span>
</td>
<td class="nump">675<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="num">$ (5,440)<span></span>
</td>
<td class="num">$ (29,677)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share - basic and diluted</a></td>
<td class="num">$ (0.17)<span></span>
</td>
<td class="num">$ (1.83)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares outstanding - basic and diluted</a></td>
<td class="nump">32,486,116<span></span>
</td>
<td class="nump">16,239,938<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebtExcludingAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebtExcludingAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140447026043496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations (Unaudited) (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=GTBP_OfficersAndDirectorsMember', window );">Officers and Directors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems', window );"><strong>Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-Based Payment Arrangement, Expense</a></td>
<td class="nump">$ 447<span></span>
</td>
<td class="nump">$ 14,296<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=GTBP_OfficersAndDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=GTBP_OfficersAndDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140447027217272">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Preferred Stock [Member]</div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Common Shares Issuable [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Dec. 31, 2020</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 566,356<span></span>
</td>
<td class="num">$ (595,797)<span></span>
</td>
<td class="num">$ (29,433)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares at Dec. 31, 2020</a></td>
<td class="nump">2,450,000<span></span>
</td>
<td class="nump">5,218,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_GTBP_StockIssuedDuringPeriodValueEquityCompensationToOfficersAndBoardOfDirectors', window );">Equity compensation to officers and board of directors</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">14,292<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">14,296<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_GTBP_StockIssuedDuringPeriodSharesEquityCompensationToOfficersAndBoardOfDirectors', window );">Equity compensation to officers and board of directors, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,641,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of common stock for services</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">8,450<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">8,452<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of common stock for services, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,957,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_GTBP_ExtinguishmentOfDebtDiscountUponAdoptionOfAsu202006', window );">Extinguishment of debt discount upon adoption of ASU 2020-06</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(4,745)<span></span>
</td>
<td class="nump">226<span></span>
</td>
<td class="num">(4,519)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Conversion of Preferred Series J-1 to common stock</a></td>
<td class="num">$ (2)<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Conversion of Preferred Series J-1 to common stock, Shares</a></td>
<td class="num">(2,354,000)<span></span>
</td>
<td class="nump">692,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_GTBP_StockIssuedDuringPeriodValueCommonSharesIssuedUponMandatoryConversionOfNotesPayableAndAccruedInterest', window );">Common shares issued upon mandatory conversion of notes payable and accrued interest</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">$ 25,956<span></span>
</td>
<td class="nump">12,846<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">38,806<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_GTBP_StockIssuedDuringPeriodSharesCommonSharesIssuedUponMandatoryConversionOfNotesPayableAndAccruedInterest', window );">Common shares issued upon mandatory conversion of notes payable and accrued interest, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,779,000<span></span>
</td>
<td class="nump">7,634,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_GTBP_StockIssuedDuringPeriodValueCommonSharesIssuedUponExerciseOfWarrants', window );">Common shares issued upon exercise of warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">58<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">58<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_GTBP_StockIssuedDuringPeriodSharesCommonSharesIssuedUponExerciseOfWarrants', window );">Common shares issued upon exercise of warrants, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_GTBP_StockIssuedDuringPeriodValueIssuanceOfCommonStockInPublicOfferingNetOfCost', window );">Issuance of common stock in public offering, net of cost</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">24,674<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">24,679<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_GTBP_StockIssuedDuringPeriodSharesIssuanceOfCommonStockInPublicOfferingNetOfCost', window );">Issuance of common stock in public offering, net of cost, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,945,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_GTBP_StockIssuedDuringPeriodValueIssuanceOfCommonStockForResearchAndDevelopmentAgreement', window );">Issuance of common stock for research and development agreement</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,355<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,355<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_GTBP_StockIssuedDuringPeriodShareIssuanceOfCommonStockForResearchAndDevelopmentAgreement', window );">Issuance of common stock for research and development agreement, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">190,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(29,677)<span></span>
</td>
<td class="num">(29,677)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Mar. 31, 2021</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 21<span></span>
</td>
<td class="nump">$ 25,956<span></span>
</td>
<td class="nump">623,287<span></span>
</td>
<td class="num">(625,248)<span></span>
</td>
<td class="nump">24,017<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Mar. 31, 2021</a></td>
<td class="nump">96,000<span></span>
</td>
<td class="nump">20,517,000<span></span>
</td>
<td class="nump">7,634,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Dec. 31, 2021</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 32<span></span>
</td>
<td class="nump">$ 1,113<span></span>
</td>
<td class="nump">674,348<span></span>
</td>
<td class="num">(653,584)<span></span>
</td>
<td class="nump">21,910<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares at Dec. 31, 2021</a></td>
<td class="nump">96,000<span></span>
</td>
<td class="nump">32,062<span></span>
</td>
<td class="nump">327,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_GTBP_StockIssuedDuringPeriodValueCancellation', window );">Cancellation of common stock</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_GTBP_StockIssuedDuringPeriodSharesCancellation', window );">Cancellation of common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(291)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Issuance of common shares for common shares issuable</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">$ (1,113)<span></span>
</td>
<td class="nump">1,113<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Issuance of common shares as equity, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">327<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Stock Issued During Period, Shares, Conversion of Convertible Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(327,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_GTBP_StockIssuedDuringPeriodValueEquityCompensationToOfficersAndBoardOfDirectors', window );">Equity compensation to officers and board of directors</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">447<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">447<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_GTBP_StockIssuedDuringPeriodSharesEquityCompensationToOfficersAndBoardOfDirectors', window );">Equity compensation to officers and board of directors, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of common stock for services</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">872<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">872<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of common stock for services, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">163,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,440)<span></span>
</td>
<td class="num">(5,440)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Mar. 31, 2022</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 32<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 676,780<span></span>
</td>
<td class="num">$ (659,024)<span></span>
</td>
<td class="nump">$ 17,789<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Mar. 31, 2022</a></td>
<td class="nump">96,000<span></span>
</td>
<td class="nump">32,346,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_ExtinguishmentOfDebtDiscountUponAdoptionOfAsu202006">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Extinguishment of debt discount upon adoption of ASU 2020-06.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_ExtinguishmentOfDebtDiscountUponAdoptionOfAsu202006</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_StockIssuedDuringPeriodShareIssuanceOfCommonStockForResearchAndDevelopmentAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock for research and development agreement, shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_StockIssuedDuringPeriodShareIssuanceOfCommonStockForResearchAndDevelopmentAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_StockIssuedDuringPeriodSharesCancellation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_StockIssuedDuringPeriodSharesCancellation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_StockIssuedDuringPeriodSharesCommonSharesIssuedUponExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common shares issued upon exercise of warrants, shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_StockIssuedDuringPeriodSharesCommonSharesIssuedUponExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_StockIssuedDuringPeriodSharesCommonSharesIssuedUponMandatoryConversionOfNotesPayableAndAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common shares issued upon mandatory conversion of notes payable and accrued interest, shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_StockIssuedDuringPeriodSharesCommonSharesIssuedUponMandatoryConversionOfNotesPayableAndAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_StockIssuedDuringPeriodSharesEquityCompensationToOfficersAndBoardOfDirectors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares equity compensation to officers and board of directors</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_StockIssuedDuringPeriodSharesEquityCompensationToOfficersAndBoardOfDirectors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_StockIssuedDuringPeriodSharesIssuanceOfCommonStockInPublicOfferingNetOfCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock in public offering, net of cost, shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_StockIssuedDuringPeriodSharesIssuanceOfCommonStockInPublicOfferingNetOfCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_StockIssuedDuringPeriodValueCancellation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_StockIssuedDuringPeriodValueCancellation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_StockIssuedDuringPeriodValueCommonSharesIssuedUponExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common shares issued upon exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_StockIssuedDuringPeriodValueCommonSharesIssuedUponExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_StockIssuedDuringPeriodValueCommonSharesIssuedUponMandatoryConversionOfNotesPayableAndAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common shares issued upon mandatory conversion of notes payable and accrued interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_StockIssuedDuringPeriodValueCommonSharesIssuedUponMandatoryConversionOfNotesPayableAndAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_StockIssuedDuringPeriodValueEquityCompensationToOfficersAndBoardOfDirectors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity compensation to officers and board of directors.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_StockIssuedDuringPeriodValueEquityCompensationToOfficersAndBoardOfDirectors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_StockIssuedDuringPeriodValueIssuanceOfCommonStockForResearchAndDevelopmentAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock for research and development agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_StockIssuedDuringPeriodValueIssuanceOfCommonStockForResearchAndDevelopmentAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_StockIssuedDuringPeriodValueIssuanceOfCommonStockInPublicOfferingNetOfCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock in public offering, net of cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_StockIssuedDuringPeriodValueIssuanceOfCommonStockInPublicOfferingNetOfCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140447028311096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (5,440)<span></span>
</td>
<td class="num">$ (29,677)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash (used in) operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_GTBP_StockBasedCompensationForServices', window );">Stock based compensation for services</a></td>
<td class="nump">872<span></span>
</td>
<td class="nump">9,807<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_GTBP_StockBasedCompensationToOfficersAndBoardOfDirectors', window );">Stock based compensation to officers, employees and board of directors</a></td>
<td class="nump">447<span></span>
</td>
<td class="nump">14,296<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_GTBP_ConvertibleNotesPayableIssuedForConsultingServices', window );">Convertible notes payable issued for consulting services</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">720<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Change in fair value of derivative liability</a></td>
<td class="num">(18)<span></span>
</td>
<td class="num">(21)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Change in operating lease right-of-use assets</a></td>
<td class="nump">23<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss', window );">Unrealized loss on marketable securities</a></td>
<td class="nump">24<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">(Increase) decrease in prepaid expenses</a></td>
<td class="num">(263)<span></span>
</td>
<td class="nump">276<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_GTBP_IncreaseDecreaseInDeposit', window );">Increase in deposits</a></td>
<td class="num">(9)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities', window );">Increase (decrease) in accounts payable and accrued expenses</a></td>
<td class="num">(838)<span></span>
</td>
<td class="nump">219<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">(Decrease) in operating lease liability</a></td>
<td class="num">(13)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInterestPayableNet', window );">Increase in accrued interest</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">696<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net Cash (Used in) Operating Activities</a></td>
<td class="num">(5,215)<span></span>
</td>
<td class="num">(3,684)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSalesOfAssetsInvestingActivities', window );">Sale of investments</a></td>
<td class="nump">3,533<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net Cash Provided by Investing Activities</a></td>
<td class="nump">3,533<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">24,679<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">58<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfMediumTermNotes', window );">Proceeds from issuance of notes payable</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,205<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net Cash Provided by Financing Activities</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">25,942<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net Increase (Decrease) in Cash</a></td>
<td class="num">(1,682)<span></span>
</td>
<td class="nump">22,258<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash at Beginning of Period</a></td>
<td class="nump">8,968<span></span>
</td>
<td class="nump">5,297<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash at End of Period</a></td>
<td class="nump">7,286<span></span>
</td>
<td class="nump">27,555<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Interest</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Income taxes</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_GTBP_RightofuseAssetsAndLeaseLiabilitiesRecognizedPursuantToLeaseAgreement', window );">Right-of-use assets and lease liabilities recognized pursuant to lease agreement</a></td>
<td class="nump">260<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_GTBP_ExtinguishmentOfUnamortizedDebtDiscountAndAdjustmentToAccumulatedDeficitUponAdoption', window );">Extinguishment of unamortized debt discount and adjustment to accumulated deficit upon adoption of ASU 2020-06</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">4,519<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Common stock issued upon conversion of notes payable and accrued interest</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">38,806<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesIssued1', window );">Convertible notes payable issued for accrued expenses</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1,525<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_ConvertibleNotesPayableIssuedForConsultingServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Convertible notes payable issued for consulting services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_ConvertibleNotesPayableIssuedForConsultingServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_ExtinguishmentOfUnamortizedDebtDiscountAndAdjustmentToAccumulatedDeficitUponAdoption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Extinguishment of unamortized debt discount and adjustment to accumulated deficit upon adoption of ASU 2020-06.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_ExtinguishmentOfUnamortizedDebtDiscountAndAdjustmentToAccumulatedDeficitUponAdoption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_IncreaseDecreaseInDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in deposit</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_IncreaseDecreaseInDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_RightofuseAssetsAndLeaseLiabilitiesRecognizedPursuantToLeaseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rightof use assets and lease liabilities recognized pursuant to lease agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_RightofuseAssetsAndLeaseLiabilitiesRecognizedPursuantToLeaseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_StockBasedCompensationForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock based compensation for services</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_StockBasedCompensationForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_StockBasedCompensationToOfficersAndBoardOfDirectors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock based compensation to officers and board of directors.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_StockBasedCompensationToOfficersAndBoardOfDirectors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInterestPayableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in interest payable, which represents the amount owed to note holders, bond holders, and other parties for interest earned on loans or credit extended to the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInterestPayableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, including, but not limited to, capitalized interest and payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount; classified as operating and investing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of notes issued in noncash investing and financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfMediumTermNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt funding received on a regular basis with maturities ranging from 5-10 years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfMediumTermNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSalesOfAssetsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate cash proceeds received from a combination of transactions that are classified as investing activities in which assets, which may include one or more investments, are sold to third-party buyers. This element can be used by entities to aggregate proceeds from all asset sales that are classified as investing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSalesOfAssetsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of stock issued in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140447028088760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Operations<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">Organization and Operations</a></td>
<td class="text"><p id="xdx_80C_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_zTytNuG4E3N5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
1 &#8211; <span id="xdx_828_z33dYldWWUKi">Organization and Operations</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
1965, the corporate predecessor of GT Biopharma Inc. (Company), Diagnostic Data, Inc. was incorporated in the State of California. Diagnostic
Data changed its incorporation to the State of Delaware in 1972 and changed its name to DDI Pharmaceuticals, Inc. in 1985. In 1994, DDI
Pharmaceuticals merged with International BioClinical, Inc. and Bioxytech S.A. and changed its name to OXIS International, Inc. In July
2017, the Company changed its name to GT Biopharma, Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">The
Company is a clinical stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products
based on our proprietary Tri-specific Killer Engager (TriKE<sup>&#174;</sup>) fusion protein immune cell engager technology platform.
The Company&#8217;s TriKE<sup>&#174;</sup> platform generates proprietary therapeutics designed to harness and enhance the cancer killing
abilities of a patient&#8217;s own natural killer cells, or NK cells. Once bound to an NK cell, our moieties are designed to enhance
the NK cell, and precisely direct it to one or more specifically targeted proteins expressed on a specific type of cancer cell or virus
infected cell, resulting in the targeted cell&#8217;s death. TriKE<sup>&#174;</sup>s can be designed to target any number of tumor antigens
on hematologic malignancies or solid tumors and do not require patient-specific customization.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI https://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140447028514488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><p id="xdx_800_eus-gaap--SignificantAccountingPoliciesTextBlock_zd3oRPjYPGv1" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Note
2 &#8211; <span><span id="xdx_827_z9CGeKu4Kdkg">Summary of Significant Accounting Policies</span></span></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p id="xdx_84C_eus-gaap--BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_ziwXdnXm6Eo" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86C_zZA5OqiTgsti">Basis
of Presentation and Principles of Consolidation</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Oxis Biotech, Inc. and
Georgetown Translational Pharmaceuticals, Inc. All intercompany transactions and balances have been eliminated in consolidation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying condensed consolidated financial statements are unaudited. These unaudited interim condensed consolidated financial statements
have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) and
applicable rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;) regarding interim financial reporting.
Certain information and note disclosures normally included in the financial statements prepared in accordance with GAAP have been condensed
or omitted pursuant to such rules and regulations. Accordingly, these interim condensed consolidated financial statements should be read
in conjunction with the consolidated financial statements and notes thereto contained in the Company&#8217;s Annual Report on Form 10-K
for the fiscal year ended December 31, 2021 filed with the SEC on March 28, 2022 (the &#8220;2021 Annual Report&#8221;). The consolidated
balance sheet as of December 31, 2021 included herein was derived from the audited consolidated financial statements as of that date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the opinion of management, the accompanying unaudited condensed consolidated financial statements contain all adjustments necessary to
fairly present the Company&#8217;s financial position and results of operations for the interim periods reflected. Except as noted, all
adjustments contained herein are of a normal recurring nature. Results of operations for the fiscal periods presented herein are not
necessarily indicative of fiscal year-end results.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_844_ecustom--LiquidityPolicyTextBlock_zp3rOnYqS4E4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span style="text-decoration: underline">Liquidity</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The accompanying consolidated financial statements
have been prepared under the assumption that the Company will continue as a going concern. Such assumption contemplates the realization
of assets and satisfaction of liabilities in the normal course of business. For the quarter ended March 31, 2022, the Company recorded
a net loss of $<span id="xdx_90D_eus-gaap--NetIncomeLoss_iN_pn5n6_di_c20220101__20220331_zvWfIejSWSJ3">5.4</span> million  and
used cash in operations of $<span id="xdx_902_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pn5n6_di_c20220101__20220331_zCZSXuW8NNIa">5.2
</span>million. As of March 31, 2022, the Company had a cash and short-term investments balance of $<span id="xdx_904_ecustom--CashOnHandAndShortTermInvestment_c20220331_pn5n6">26.7
</span>million, working capital of $<span id="xdx_904_ecustom--WorkingCapital_iI_pn5n6_c20220331_zg4BIqqFLElb">17.7</span> million and
stockholders&#8217; equity of $<span id="xdx_90E_eus-gaap--StockholdersEquity_iI_pn5n6_c20220331_zDxGAycIXqF2">17.8</span> million.
Management anticipates that the $<span id="xdx_902_eus-gaap--InvestmentsAndCash_c20220331_pn5n6">26.7</span> million of cash and
cash equivalents, and short-term investments are adequate to satisfy the liquidity needs of the Company for at least one year from the
date the Company&#8217;s condensed consolidated financial statements for the quarter ended March 31, 2022 were issued.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Historically, the Company has financed its operations
through public and private sales of common stock, issuance of preferred and common stock, issuance of convertible debt instruments, and
strategic collaborations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p id="xdx_842_eus-gaap--UnusualRisksAndUncertaintiesTextBlock_z1InoGYI4SHf" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_860_zdJ9LQtHssS4">COVID-19</span></span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2020, the World Health Organization declared coronavirus COVID-19 a global pandemic. This contagious disease outbreak, which has
continued to spread, has adversely affected workforces, customers, economies, and financial markets globally. It has also disrupted the
normal operations of many businesses. This outbreak could adversely affect the Company&#8217;s operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
the pandemic has impacted the Company&#8217;s operations, during the three months ended March 31, 2022, the Company believes the COVID-19
pandemic had limited impact on its operating results. The Company has not observed any impairments of its assets or a significant change
in the fair value of its assets due to the COVID-19 pandemic. At this time, it is not possible for the Company to predict the duration
or magnitude of the adverse results of the outbreak and its effects on the Company&#8217;s business or results of operations, financial
condition, or liquidity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has been following the recommendations of health authorities to minimize exposure risk for its team members, including having team members work remotely. Most vendors have transitioned to electronic submission of invoices
and payments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_845_eus-gaap--UseOfEstimates_zaQpHjiWj2Ug" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_86F_z6Y0sUxBSbdi">Accounting
Estimates</span></span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of financial statements in conformity with GAAP requires management
to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and
liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual
results could differ from those estimates. Significant estimates include accruals for potential liabilities, assumptions used in deriving
the fair value of derivative liabilities, valuation of equity instruments issued for services and realization of deferred tax assets.
Actual results could differ from those estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_846_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zvf7AVWQ7JVl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_868_zNZM9POImGMb">Cash
Equivalents and Short-Term Investments</span></span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company considers highly liquid investments with maturities of three months or less at the date of acquisition as cash equivalents in
the accompanying condensed consolidated financial statements. As of March 31, 2022 total cash and cash equivalents, which consist
of cash and money market funds, amounted to approximately $<span id="xdx_90D_eus-gaap--CashCashEquivalentsAndShortTermInvestments_iI_pn5n6_c20220331_zHe7zv78whkk" title="Total cash equivalents">7.3
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company also invested its excess cash in commercial paper and corporate notes and bonds. Management generally determines the appropriate
classification of its investments at the time of purchase. We classify these investments as short-term investments, as part of current
assets, based upon our ability and intent to use any and all of these investments as necessary to satisfy liquidity requirements that
may arise from our businesses. Investments are carried at fair value with the unrealized holding gains and losses reported in the accompanying
condensed consolidated statements of operations. As of March 31, 2022 total short-term investments amounted to approximately $<span id="xdx_90D_eus-gaap--ShortTermInvestments_iI_pn5n6_c20220331_zbFVx4slt7Dd" title="Short term investment">19.5</span> million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84C_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zGMqlOyhVRBe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_86E_zeQcKVhcvrEf">Fair
Value of Financial Instruments</span></span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
Accounting Standards Board (&#8220;FASB&#8221;)</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
Accounting Standards Codification (&#8220;ASC&#8221;) 820-10 requires entities to disclose the fair value of financial instruments, both
assets and liabilities recognized and not recognized on the balance sheet for which it is practicable to estimate fair value. ASC 820-10
defines the fair value of a financial instrument as the amount at which the instrument could be exchanged in a current transaction between
willing parties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
three levels of the fair value hierarchy are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Valuations
    based on unadjusted quoted prices in active markets for identical assets or liabilities that the entity has the ability to access.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Valuations
    based on quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are
    observable or can be corroborated by observable data for substantially the full term of the assets or liabilities.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Valuations
    based on inputs that are unobservable, supported by little or no market activity and that are significant to the fair value of the
    assets or liabilities.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.05pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
carrying amount of the Company&#8217;s derivative liability of $<span id="xdx_907_eus-gaap--DerivativeLiabilitiesCurrent_iI_pn3d_c20220331_zARRNOM8kcxd" title="Derivative liability">120,000</span> at March 31, 2022 and $<span id="xdx_90A_eus-gaap--DerivativeLiabilitiesCurrent_iI_pn3d_c20211231_ztYMVWP5ezf5" title="Derivative liability">138,000</span> at December 31, 2021 was based
on Level 2 measurements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
carrying amounts of the Company&#8217;s other financial assets and liabilities, such as cash, prepaid expense, accounts payable and accrued
expenses approximate their fair values because of the short maturity of these instruments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84F_eus-gaap--DerivativesPolicyTextBlock_zDqDJqg4m6qg" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_86B_z4YndwtpjxUh">Derivative
Financial Instruments</span></span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded
derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded
at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the consolidated statements
of operations. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or
as equity, is evaluated at the end of each reporting period. Derivative instrument liabilities are classified in the balance sheet as
current or non-current based on whether or not net-cash settlement of the derivative instrument could be required within 12 months of
the balance sheet date. The fair value of the embedded derivatives is determined using a Binomial valuation method at inception
and on subsequent valuation dates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p id="xdx_845_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zT4axtXtmrMa" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_86D_zqacO57IIn6l">Stock-Based
Compensation</span></span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for share-based awards to employees, nonemployees and consultants in accordance with the provisions of ASC 718, <i>Compensation-Stock
Compensation</i>. Stock-based compensation cost is measured at fair value on the grant date and that fair value is recognized as expense
over the requisite service, or vesting period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company values its equity awards using the Black-Scholes option pricing model, and accounts for forfeitures when they occur. Use of the
Black-Scholes option pricing model requires the input of subjective assumptions including expected volatility, expected term, and a risk-free
interest rate. The Company estimates volatility using a its own historical stock price volatility. The expected term of the instrument
is estimated by using the simplified method to estimate expected term. The risk-free interest rate is estimated using comparable published
federal funds rates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84C_eus-gaap--ResearchAndDevelopmentExpensePolicy_zNdiKDWMACGc" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_86A_z0CP2o2xfAB7">Research
and Development Costs</span></span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Costs
incurred for research and development are expensed as incurred. The salaries, benefits, and overhead costs of personnel conducting research
and development of the Company&#8217;s products are included in research and development expenses. Purchased materials that do not have
an alternative future use are also expensed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p id="xdx_84B_eus-gaap--LesseeLeasesPolicyTextBlock_zIyeYy38CWhl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_86A_zNrwgdvKJgdf">Leases</span></span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for its leases in accordance with Accounting Standards Update (&#8220;ASU&#8221;) No. 2016-02, <i>Leases</i> (Topic
842) (&#8220;ASC 842&#8221;). ASC 842 requires lessees to (i) recognize a right of use asset (&#8220;ROU asset&#8221;) and a lease liability
that is measured at the present value of the remaining lease payments, on the consolidated balance sheets, (ii) recognize a single lease
cost, calculated over the lease term on a straight-line basis and (iii) classify lease related cash payments within operating and financing
activities. The Company has made an accounting policy election to not recognize short-term leases on the consolidated balance sheets
and all non-lease components, such as common area maintenance, were excluded. At any given time during the lease term, the lease liability
represents the present value of the remaining lease payments, and the ROU asset is measured as the amount of the lease liability, adjusted
for pre-paid rent, unamortized initial direct costs, and the remaining balance of lease incentives received. Both the lease ROU asset
and liability are reduced to zero at the end of the lease term.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 16.95pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company leases office space and equipment. At the lease inception date, the Company determines if an arrangement is, or contains a lease.
Some of the Company&#8217;s leases include options to renew at similar terms. The Company assesses these options to determine if the
Company is reasonably certain of exercising these options based on relevant economic and financial factors. Options that meet these criteria
are included in the lease term at the lease commencement date</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">During the period ended March 31, 2022, the Company
executed lease agreements for its office space and equipment and as a result, recorded operating lease right-of-use assets and the related
lease liabilities of $<span id="xdx_902_eus-gaap--OperatingLeaseRightOfUseAsset_iI_c20220331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeSpaceAndEquipmentMember_zGG1pfSFWhBk" title="Operating lease, right-of-use asset"><span id="xdx_903_eus-gaap--OperatingLeaseLiability_iI_c20220331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeSpaceAndEquipmentMember_z2hZmOW2i1ih" title="Operating lease,liability">260,000</span></span> pursuant to ASC 842,&#160;<i>Leases</i> (see Note 8).</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p id="xdx_840_eus-gaap--EarningsPerSharePolicyTextBlock_zk2Uix3Jq2id" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_863_zAq2AuhKN4Yd" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Net
Earnings (Loss) Per Share</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
earnings (loss) per share is computed using the weighted-average number of common shares outstanding during the period. Common stock
issuable is included in our calculation as of the date of the underlying agreement. Diluted earnings (loss) per share is computed using
the weighted-average number of common shares and the dilutive effect of contingent shares outstanding during the period. Potentially
dilutive contingent shares, which primarily consist of convertible notes, stock issuable for the exercise of stock options and warrants
have been excluded from the diluted loss per share calculation because their effect is anti-dilutive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89C_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_z08jlg8yBhpd" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
following common stock equivalents were excluded in the computation of the net loss per share because their effect is anti-dilutive:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BC_z2TePbqZshn8" style="display: none">Schedule of Anti-dilutive Securities</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20220101__20220331_zmOg4YGJwO1a" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>March 31</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Unaudited)</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_494_20210101__20210331_zL4A4uv6tP1l" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>March 31</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2021<br/> (Unaudited)</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--OptionsToPurchaseCommonStockMember_z4SQlSsT7MUl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Options to purchase common stock</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">302,500</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0602">&#160;</span></td><td style="width: 14%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsToPurchaseCommonStockMember_znsSoEx839G3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Warrants to purchase common stock</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">2,337,274</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">5,319</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--UnvestedRestrictedCommonStockMember_zpEB40CpS4Wi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Unvested restricted common stock</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">681,270</p></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">1.596,659</p></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_zMyj6yomOmDf" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total anti-dilutive
securities</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,321,044</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,601,978</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A3_zPgPEvpU3XJ6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i/></span><i>&#160;</i></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/>

<p id="xdx_845_eus-gaap--ConcentrationRiskCreditRisk_zRl8PF0gepF4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_86E_zmpEwVyRDgAc">Concentration</span></span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
is deposited in one financial institution. The balances held at this financial institution at times may be in excess of Federal Deposit
Insurance Corporation (&#8220;FDIC&#8221;) insurance limits of up to $<span id="xdx_904_eus-gaap--CashFDICInsuredAmount_iI_c20220331_zOTm1zFRT8fi" title="FDIC amount">250,000</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has a significant concentration of expenses incurred and accounts payable from a single vendor. Please see Note 4 for further
information.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_848_eus-gaap--SegmentReportingPolicyPolicyTextBlock_z5E8YT2mMjc1" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_860_zfA0RxfMt3ze">Segments</span></span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company determined its reporting units in accordance with ASC 280, &#8220;Segment Reporting&#8221; (&#8220;ASC 280&#8221;). Management
evaluates a reporting unit by first identifying its&#8217; operating segments under ASC 280. The Company then evaluates each operating
segment to determine if it includes one or more components that constitute a business. If there are components within an operating segment
that meet the definition of a business, the Company evaluates those components to determine if they must be aggregated into one or more
reporting units. If applicable, when determining if it is appropriate to aggregate different operating segments, the Company determines
if the segments are economically similar and, if so, the operating segments are aggregated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
has determined that the Company has one  operating segment. The Company&#8217;s reporting segment reflects the manner in
which its chief operating decision maker reviews results and allocates resources. The Company&#8217;s reporting segment meets the definition
of an operating segment and does not include the aggregation of multiple operating segments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84B_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zDJDSg8lipo4" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_86D_z8QXODnl6JKc" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Recent
Accounting Pronouncements</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2021, the FASB issued ASU 2021-04, <i>Earnings Per Share (Topic 260), Debt-Modifications and Extinguishments (Subtopic 470-50), Compensation-Stock
Compensation (Topic 718), and Derivatives and Hedging-Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Issuer&#8217;s Accounting
for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options</i>. ASU 2021-04 provides clarification
and reduces diversity in an issuer&#8217;s accounting for modifications or exchanges of freestanding equity-classified written call options
(such as warrants) that remain equity classified after modification or exchange. An issuer measures the effect of a modification or exchange
as the difference between the fair value of the modified or exchanged warrant and the fair value of that warrant immediately before modification
or exchange. ASU 2021-04 introduces a recognition model that comprises four categories of transactions and the corresponding accounting
treatment for each category (equity issuance, debt origination, debt modification, and modifications unrelated to equity issuance and
debt origination or modification). ASU 2021-04 is effective for all entities for fiscal years beginning after December 15, 2021, including
interim periods within those fiscal years. An entity should apply the guidance provided in ASU 2021-04 prospectively to modifications
or exchanges occurring on or after the effective date. Early adoption is permitted for all entities, including adoption in an interim
period. Effective January 1, 2022, we adopted ASU 2021-04 using a prospective approach. It did not have a material impact on the Company&#8217;s
financial statements or disclosures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public
Accountants, and the Securities and Exchange Commission (the &#8220;SEC&#8221;) did not or are not believed by management to have a material
impact on the Company&#8217;s present or future consolidated financial statements.</span></p>

<p id="xdx_85F_z41n7ayvdc97" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140447028074168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><p id="xdx_807_eus-gaap--FairValueDisclosuresTextBlock_zX5FPsfe1pc5" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
3 &#8211; <span id="xdx_82B_z9In1tIzB1l8">Fair Value of Financial Instruments</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89B_eus-gaap--DebtSecuritiesAvailableForSaleTableTextBlock_zeQohQiV5KW6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
estimated fair values of financial instruments outstanding were (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B0_zINi0pXAkORk" style="display: none">Schedule of Estimated Fair Value of Financial Instrument</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31, 2022 (Unaudited)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Unrealized</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Unrealized</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Fair</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Cost</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Gains</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Losses</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%; text-align: left">Cash and cash equivalents</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pn3n3_c20220331__us-gaap--InvestmentTypeAxis__us-gaap--CashAndCashEquivalentsMember_zNHpxSJr3vjc" style="width: 12%; text-align: right" title="Cost">7,286</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--DebtSecuritiesAvailableForSaleRealizedGain_pn3n3_c20220101__20220331__us-gaap--InvestmentTypeAxis__us-gaap--CashAndCashEquivalentsMember_zA0l0WnF7X5j" style="width: 12%; text-align: right" title="Unrealized gains">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl0627">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--DebtSecuritiesAvailableForSaleRealizedLoss_pn3n3_c20220101__20220331__us-gaap--InvestmentTypeAxis__us-gaap--CashAndCashEquivalentsMember_zzWNzM114vD7" style="width: 12%; text-align: right" title="Unrealized losses">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl0629">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--DebtSecuritiesAvailableForSaleRealizedGainLoss_pn3n3_c20220101__20220331__us-gaap--InvestmentTypeAxis__us-gaap--CashAndCashEquivalentsMember_zI5kxS58pm1b" style="width: 12%; text-align: right" title="Fair value">7,286</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Short-term investments</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pn3n3_c20220331__us-gaap--InvestmentTypeAxis__custom--ShortTermInvestmentMember_zp1sJ9jJAp6c" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cost">19,496</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--DebtSecuritiesAvailableForSaleRealizedGain_pn3n3_c20220101__20220331__us-gaap--InvestmentTypeAxis__custom--ShortTermInvestmentMember_z6JcJF0hjsqj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Unrealized gains"><span style="-sec-ix-hidden: xdx2ixbrl0635">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--DebtSecuritiesAvailableForSaleRealizedLoss_pn3n3_c20220101__20220331__us-gaap--InvestmentTypeAxis__custom--ShortTermInvestmentMember_zc4BCyBuHV2c" style="border-bottom: Black 1.5pt solid; text-align: right" title="Unrealized losses">(42</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--DebtSecuritiesAvailableForSaleRealizedGainLoss_pn3n3_c20220101__20220331__us-gaap--InvestmentTypeAxis__custom--ShortTermInvestmentMember_zObPMSK74Ywc" style="border-bottom: Black 1.5pt solid; text-align: right" title="Fair value">19,454</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pn3n3_c20220331_zpr5X2NKUd03" style="border-bottom: Black 2.5pt double; text-align: right" title="Cost">26,782</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--DebtSecuritiesAvailableForSaleRealizedGain_pn3n3_c20220101__20220331_zfY6KFcS6X0g" style="border-bottom: Black 2.5pt double; text-align: right" title="Unrealized gains"><span style="-sec-ix-hidden: xdx2ixbrl0643">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--DebtSecuritiesAvailableForSaleRealizedLoss_pn3n3_c20220101__20220331_zAugk9I5CE9g" style="border-bottom: Black 2.5pt double; text-align: right" title="Unrealized losses">(42</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--DebtSecuritiesAvailableForSaleRealizedGainLoss_pn3n3_c20220101__20220331_zrbNMYLOql2j" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value">26,740</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Unrealized</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Unrealized</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Fair</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Cost</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Gains</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Losses</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%; text-align: left">Cash and cash equivalents</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pn3n3_c20211231__us-gaap--InvestmentTypeAxis__us-gaap--CashAndCashEquivalentsMember_zUlswoZLTXe5" style="width: 12%; text-align: right" title="Cost">8,968</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--DebtSecuritiesAvailableForSaleRealizedGain_pn3n3_c20210101__20211231__us-gaap--InvestmentTypeAxis__us-gaap--CashAndCashEquivalentsMember_zGH3sKl27OWa" style="width: 12%; text-align: right" title="Unrealized gains">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl0651">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--DebtSecuritiesAvailableForSaleRealizedLoss_pn3n3_c20210101__20211231__us-gaap--InvestmentTypeAxis__us-gaap--CashAndCashEquivalentsMember_zdjO2Rrzkb99" style="width: 12%; text-align: right" title="Unrealized losses">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl0653">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--DebtSecuritiesAvailableForSaleRealizedGainLoss_c20210101__20211231__us-gaap--InvestmentTypeAxis__us-gaap--CashAndCashEquivalentsMember_pn3n3" style="width: 12%; text-align: right" title="Fair value">8,968</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Short-term investments</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_c20211231__us-gaap--InvestmentTypeAxis__custom--ShortTermInvestmentMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cost">23,040</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--DebtSecuritiesAvailableForSaleRealizedGain_pn3n3_c20210101__20211231__us-gaap--InvestmentTypeAxis__custom--ShortTermInvestmentMember_zWVQ6LMxERjj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Unrealized gains"><span style="-sec-ix-hidden: xdx2ixbrl0659">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--DebtSecuritiesAvailableForSaleRealizedLoss_c20210101__20211231__us-gaap--InvestmentTypeAxis__custom--ShortTermInvestmentMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Unrealized losses">(29</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--DebtSecuritiesAvailableForSaleRealizedGainLoss_c20210101__20211231__us-gaap--InvestmentTypeAxis__custom--ShortTermInvestmentMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Fair value">23,011</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_c20211231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Cost">32,008</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--DebtSecuritiesAvailableForSaleRealizedGain_pn3n3_c20210101__20211231_zBqd78pn4Eta" style="border-bottom: Black 2.5pt double; text-align: right" title="Unrealized gains"><span style="-sec-ix-hidden: xdx2ixbrl0667">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--DebtSecuritiesAvailableForSaleRealizedLoss_c20210101__20211231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Unrealized losses">(29</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--DebtSecuritiesAvailableForSaleRealizedGainLoss_pn3n3_c20210101__20211231_zGnGlqfREVqk" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value">31,979</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A2_zzIrpHtCC3R8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89E_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_zI3PgrbzMN11" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table represents the Company&#8217;s fair value hierarchy for its financial assets (cash equivalents and investments) (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B5_zDbwwi6g3JC5" style="display: none">Schedule
of Fair Value Hierarchy Financial Assets</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_499_20220331_zxeNbTSQqHAb" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20220331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zEjdov4Uo7Ij" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_492_20220331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z66fYX6UdRsg" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20220331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zLGe7PBAqEml" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31, 2022 (Unaudited)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--FairValueNetAssetLiability_iI_pn3n3_hus-gaap--InvestmentTypeAxis__us-gaap--MoneyMarketFundsMember_zlEFJ7v5qpFe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%; text-align: left">Money market funds</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">6,299</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">6,299</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl0677">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl0678">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--FairValueNetAssetLiability_iI_pn3n3_hus-gaap--InvestmentTypeAxis__custom--CorporateNotesAndCommercialPaperMember_zJ2eGfprqtr1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Corporate notes and commercial paper</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">19,454</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0681">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">19,454</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0683">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--FairValueNetAssetLiability_iI_pn3n3_zbgzUE5eDvBi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt; text-align: left; padding-bottom: 2.5pt">Total financial assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">25,753</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">6,299</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">19,454</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0688">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20211231_zG2l7AhYYoMd" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_493_20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z80spwcHx7p8" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_495_20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zF69jgkUQ4jg" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zqoqfxEs4uib" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--FairValueNetAssetLiability_iI_pn3n3_hus-gaap--InvestmentTypeAxis__us-gaap--MoneyMarketFundsMember_z29ohChGhUsc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%; text-align: left">Money market funds</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">5,484</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">5,484</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl0692">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl0693">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--FairValueNetAssetLiability_iI_pn3n3_hus-gaap--InvestmentTypeAxis__custom--CorporateNotesAndCommercialPaperMember_ztq6kmtGIfi3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Corporate notes and commercial paper</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">23,011</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0696">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">23,011</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0698">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--FairValueNetAssetLiability_iI_pn3n3_zC0E2xpy5qe7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt; text-align: left; padding-bottom: 2.5pt">Total financial assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">28,495</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,484</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">23,011</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0703">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A0_zvfqBGDcB504" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/>

<p id="xdx_89C_eus-gaap--ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_zmExvcUrhL6b" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of March 31, 2022, the fair value of the derivative liability amounted
to $<span id="xdx_900_eus-gaap--DerivativeLiabilitiesCurrent_iI_pn3d_c20220331_z4SbKAkbsnCc"><span id="xdx_905_eus-gaap--DerivativeLiabilitiesCurrent_iI_pn3d_c20210331_zyuayTJ2ZRJb">120,000</span></span>. The details of derivative liability transactions for the three months ended March 31, 2022 and 2021, are as follows:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;<span id="xdx_8B9_zhINUzne4oz7" style="display: none">Schedule
of Derivative Liability Transactions</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b/></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_499_20220101__20220331_zG55aeY08pz1" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_496_20210101__20210331_zeB1f8gQSmw2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Unaudited)</b></span></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Unaudited)</b></span></td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DerivativeLiabilitiesCurrent_iS_pn3d_z0EuE0GkcdC2" style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: left">Beginning balance</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">138,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">383,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--IssuanceOfStockAndWarrantsForServicesOrClaims_pn3d_zIvGR25VX2kk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Fair value upon issuance of warrants</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0710">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0711">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--IncreaseDecreaseInDerivativeLiabilities_pn3d_zuaXPbmfw0h8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Change in fair value</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(18,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(21,000</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_408_ecustom--ExtinguishmentOfWarrants_pn3d_z8LLtwMnJ73a" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Extinguishment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0716">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0717">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--DerivativeLiabilitiesCurrent_iE_pn3d_zW8Qm6sz2bQe" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Ending balance</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">120,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">362,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A0_zIwPi0plFWu8" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140447028154312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Payable<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accounts Payable</a></td>
<td class="text"><p id="xdx_801_eus-gaap--AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_zmXy4sUY5Yw7" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
4 &#8211; <span id="xdx_824_zKdifaVeu57g">Accounts Payable</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p id="xdx_89A_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zijFJvpzXUa2" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts
payable consisted of the following (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BA_zhJHGZcTSXc8" style="display: none">Schedule of Accounts Payable</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49C_20220331_zOJxegZvtWFl" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">March 31, <br/>
2022 </td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_498_20211231_zJq5UyUkUPZ1" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><p style="margin-top: 0; margin-bottom: 0">December 31, <br/>
2021</p>
                                                                  <p style="margin-top: 0; margin-bottom: 0"/></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">(Unaudited)</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AccountsPayableRelatedPartiesCurrent_iI_pn3n3_maAPCz7ta_zgaOSxvWmmzg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Accounts payable to a third-party manufacturer</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">7,423</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">6,335</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AccountsPayableOtherCurrent_iI_pn3n3_maAPCz7ta_zzkEUsbFKf46" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left">Other accounts payable</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">690</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,885</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--AccountsPayableCurrent_iTI_pn3n3_mtAPCz7ta_z00cLDEcrAJ3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-align: left">Total accounts payable</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">8,113</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">8,220</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AD_zt5bRxPkVhNc" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company relies on a third-party contract manufacturing operation to produce and/or test our compounds used in our potential product candidates.
As of March 31, 2022 the Company was indebted $<span id="xdx_908_eus-gaap--AccountsPayableCurrent_iI_pn5n6_c20220331__us-gaap--RelatedPartyTransactionAxis__custom--VendorMember_zGLvHbeTpDU7" title="Accounts payable current">7.4</span> million of accounts payable to this vendor.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140447028119160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Notes Payable<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Convertible Notes Payable</a></td>
<td class="text"><p id="xdx_80A_eus-gaap--DebtDisclosureTextBlock_zsWSV5fQgRmk" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
5 &#8211; <span id="xdx_826_zIhcg88MHJI4">Convertible Notes Payable</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Notes
Payable Issued for Cash</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
part of the Company&#8217;s financing activities, the Company issued convertible notes payable totaling $<span id="xdx_906_eus-gaap--ConvertibleNotesPayableCurrent_iI_pn5n6_c20220331__us-gaap--AwardDateAxis__custom--AuguestOneTwentyEighteenAndJanuaryTwentySixTwentyTwentyOneMember_zLkEk8aFX2va" title="Convertible notes payable">25.3</span> million between August
1, 2018 and January 26, 2021. On February 16, 2021, in accordance with the terms of the note agreements upon completion of the equity
offering, these notes were mandatorily converted at a conversion rate of $<span id="xdx_907_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20210216__us-gaap--AwardDateAxis__custom--AuguestOneTwentyEighteenAndJanuaryTwentySixTwentyTwentyOneMember_zNDMRAtkkkbf" title="Conversion rate">3.40</span> per share into <span id="xdx_90C_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_pid_c20210215__20210216__us-gaap--AwardDateAxis__custom--AuguestOneTwentyEighteenAndJanuaryTwentySixTwentyTwentyOneMember_zS3KLaRWWsZh" title="Converted conversion of common stock">7,438,235</span> shares of the Company&#8217;s
common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Notes
Pa</span>y<span style="text-decoration: underline">able Issued for Settlement Agreements</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
fiscal 2019 and 2020, the Company issued its convertible notes payable in the amount of $<span id="xdx_905_eus-gaap--ConvertibleNotesPayable_iI_pn5n6_c20191231_zS5UymwT9Tv1" title="Convertible notes payable"><span id="xdx_90B_eus-gaap--ConvertibleNotesPayable_iI_pn5n6_c20201231_zhTdbi2bppr8" title="Convertible notes payable">2.5</span></span> million to resolve claims and disputes
pertaining to certain debt and equity instruments issued by the Company in prior years. On February 16, 2021 in accordance with the note
agreements upon completion of the equity offering, these notes were mandatorily converted at a conversion rate of $<span id="xdx_906_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20210216__us-gaap--DebtInstrumentAxis__custom--NotesPayableIssuedForSettlementAgreementsMember__us-gaap--AwardDateAxis__custom--FiscalTwentyNinteenandTwentyTwentyMember_zja1C7zWAJt3">3.40
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share into <span id="xdx_909_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_pid_c20210215__20210216__us-gaap--DebtInstrumentAxis__custom--NotesPayableIssuedForSettlementAgreementsMember__us-gaap--AwardDateAxis__custom--FiscalTwentyNinteenandTwentyTwentyMember_zFWn4AyITj38">743,529
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of the Company&#8217;s common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Notes
Pa</span>y<span style="text-decoration: underline">able Issued for Forbearance Agreements</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 23, 2020, the Company entered into Standstill and Forbearance Agreements (collectively, the &#8220;Forbearance Agreements&#8221;)
with the holders of $<span id="xdx_907_eus-gaap--DebtInstrumentFaceAmount_iI_pn5n6_c20200623__us-gaap--TypeOfArrangementAxis__custom--ForbearanceAgreementsMember_zRYIyVEPQps8" title="Debt instrument, face amount">13.2</span> million aggregate principal amount of the Convertible Notes (the &#8220;Default Notes&#8221;), which were in
default. Pursuant to the Forbearance Agreements, the holders of the Default Notes agreed to forbear from exercising their rights and
remedies under the Default Notes (including declaring such Default Notes (together with any default amounts and accrued and unpaid interest)
immediately due and payable) until the earlier of (i) the date that the Company completes a future financing in the amount of $<span id="xdx_905_eus-gaap--NotesPayable_iI_pn6n6_c20200623__us-gaap--TypeOfArrangementAxis__custom--ForbearanceAgreementsMember_zsZ8XwSJoOr2" title="Notes payable">15</span> million
and, in connection therewith, commences listing on NASDAQ (collectively, the &#8220;New Financing&#8221;) or (ii) January 31, 2021 (the
&#8220;Termination Date&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 16, 2021 in accordance with the note agreements upon completion of the equity offering, these notes, in the amount of $<span id="xdx_902_eus-gaap--DebtConversionConvertedInstrumentAmount1_pn5n6_c20210215__20210216__us-gaap--DebtInstrumentAxis__custom--NotesPayableIssuedForForbearanceAgreementMember_zKh7JHSyEsV8" title="Debt Conversion, Converted Instrument, Amount">3.8</span>
million, were mandatorily converted at a conversion rate of $<span id="xdx_90F_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20210216__us-gaap--TypeOfArrangementAxis__custom--ForbearanceAgreementsMember_zZDKE7U4rnx5">3.40
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share into <span id="xdx_902_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_pid_c20210215__20210216__us-gaap--TypeOfArrangementAxis__custom--ForbearanceAgreementsMember_zChZkLtWCY41">1,132,059
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of the Company&#8217;s common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Notes
Pa</span>y<span style="text-decoration: underline">able issued for Consulting Agreements</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
prior years, the Company issued its convertible notes payable in exchange for consulting services in the amount of $<span id="xdx_903_ecustom--ConvertibleNotesPayableIssuedInExchangeForConsultingServices_pn5n6_c20220101__20220331_ze3buae1LZsc" title="Notes payable in exchange of consulting services">1.6</span> million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 16, 2021 in accordance with the note agreements upon completion of the equity offering, these notes in the aggregate amount
of $<span id="xdx_906_eus-gaap--DebtConversionConvertedInstrumentAmount1_pn5n6_c20210215__20210216__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementsMember_zUIqzoh61lzd" title="Debt converted amount">1.6</span> million were mandatorily converted at a conversion rate of $<span id="xdx_900_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20210216__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementsMember_zT9AIRK5PY54" title="Conversion price per share">3.40</span> per share into <span id="xdx_90A_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_pid_c20210215__20210216__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementsMember_zgvys8tqU6ph" title="Converted conversion of common stock">472,059</span> shares of the Company&#8217;s common
stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline">Notes Payable issued for Accrued
Interest</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In prior years, the Company recorded accrued interest
of $<span id="xdx_90F_ecustom--AccruedInterestAmount_pn5n6_c20220101__20220331_zRHUntFo7Z5h" title="Accrued interest amount">5.6</span> million related to all notes payable. On February 16, 2021, in accordance with the note agreements upon completion of the equity
offering, the accrued interest was mandatorily converted at a conversion rate of $<span id="xdx_907_eus-gaap--DebtConversionConvertedInstrumentRate_pid_dp_uPure_c20210215__20210216_zZ6BZf04p37c" title="Debt conversion rate">3.40</span> per share into <span id="xdx_904_eus-gaap--ConversionOfStockSharesConverted1_pid_c20210215__20210216_ze6kBBBndOO9" title="Conversion of common stock">1,627,440</span> shares of the Company&#8217;s
common stock.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 9.5pt 0pt 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Adoption
of ASU 2020-<span style="letter-spacing: -0.25pt">06</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 9.5pt 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 9.5pt 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
fiscal 2020, the Company recorded a note/debt discount of $<span id="xdx_907_eus-gaap--DebtInstrumentConvertibleBeneficialConversionFeature_pn5n6_c20200101__20201231__us-gaap--DebtInstrumentAxis__custom--AdoptionofAsuTwentyTwentyZeroSixMember__us-gaap--AwardDateAxis__custom--DuringTwentyTwentyMember_zdu21bJnGmzf" title="Beneficial conversion feature">4.7</span> million&#160;to account for the beneficial conversion feature that existed
on the date of issuance for the above convertible notes payable. The debt discount was being amortized to interest expense over the term
of the corresponding convertible notes payable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 9.5pt 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 9.5pt 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 1, 2021 the Company chose to adopt ASU 2020-06, Debt-Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives
and Hedging-Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#8217;s
Own Equity. As a result of the adoption of ASU 2020-06, the Company extinguished the previously recorded debt discount of $<span id="xdx_900_eus-gaap--DebtInstrumentConvertibleBeneficialConversionFeature_pn5n6_c20220101__20220331__us-gaap--DebtInstrumentAxis__custom--AdoptionofAsuTwentyTwentyZeroSixMember__us-gaap--AwardDateAxis__custom--JanuaryOneTwentyTwentyOneMember_z4OGDfn5vSqh">4.7</span> million&#160;by
charging the opening additional paid in capital at January 1, 2021. In addition, the Company also adjusted accumulated deficit to account
for the derecognition of the $<span id="xdx_90A_ecustom--InterestExpenseDueAmortizationOfDebtDiscount_iI_pn5n6_c20220331__us-gaap--DebtInstrumentAxis__custom--AdoptionofAsuTwentyTwentyZeroSixMember__us-gaap--AwardDateAxis__custom--DuringTwentyTwentyMember_zleabVONGvu4" title="Interest expense due amortization of debt discount">0.2</span> million&#160;interest expense due</span> to the amortization of the debt discount that was recorded
in fiscal 2020.<b>&#160;</b>As a result of these adjustments, the unamortized debt discount of $<span id="xdx_902_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_pn5n6_c20220331__us-gaap--DebtInstrumentAxis__custom--AdoptionofAsuTwentyTwentyZeroSixMember__us-gaap--AwardDateAxis__custom--JanuaryOneTwentyTwentyOneMember_zByyCyiGm7Ne" title="Unamortized debt discount">4.5</span> million&#160;was extinguished.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI https://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140447028226664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Liability<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_GTBP_DisclosureDerivativeLiabilityAbstract', window );"><strong>Derivative Liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesAndFairValueTextBlock', window );">Derivative Liability</a></td>
<td class="text"><p id="xdx_80D_eus-gaap--DerivativesAndFairValueTextBlock_zuWnNIcIGt1" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Note
6 &#8211; <span id="xdx_82C_zV8MNW9ikHj1">Derivative Liability</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2020, the Company issued certain warrants that contained a fundamental transaction provision that could give
rise to an obligation to pay cash to the warrant holder upon occurrence of certain change in control type events. In accordance with
ASC 480, the fair value of these warrants is classified as a liability in the Condensed Consolidated Balance Sheet and will be
re- measured at the end of every reporting period with the change in value reported in the statement of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89F_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_zYcz0vlKIxW" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
derivative liabilities were valued using a Binomial pricing model with the following average assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B2_zdAyouL0Qnn4" style="display: none">Schedule
of Derivative Liabilities Assumptions</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">March 31</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December 31</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b/></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">2021</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0"/></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; text-align: center"><b>(Unaudited)</b></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%">Stock Price</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><span id="xdx_904_eus-gaap--SharePrice_iI_pid_c20220331_zTYm3dbo2xX6" title="Stock Price">2.88</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><span id="xdx_90B_eus-gaap--SharePrice_iI_pid_c20211231_z4R4jSPSkTu5" title="Stock Price">3.05</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Risk-free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_909_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20220331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zlyRpeVCVeh1" title="Risk-free interest rate">2.42</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90C_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zVp6pQCz6Owc" title="Risk-free interest rate">1.26</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90A_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20220331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zJ73JYTImDci" title="Expected volatility">127</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90D_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zL20lNqzqNd1" title="Expected volatility">129</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected life (in years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90B_ecustom--DerivativeLiabilityFairValueAssumptionsExpectedTerm1_dtY_c20220101__20220331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zGvKIoyzrawk" title="Expected life (in years)">3.3</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90E_ecustom--DerivativeLiabilityFairValueAssumptionsExpectedTerm1_dtY_c20210101__20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zE2HmJRBFaC1" title="Expected life (in years)">3.6</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Expected dividend yield</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_dp_uPure_c20220331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zfp6Vho0rCQ3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Expected dividend yield"><span style="-sec-ix-hidden: xdx2ixbrl0800">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_dp_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_z4ounqs98iX1" style="border-bottom: Black 1.5pt solid; text-align: right" title="Expected dividend yield"><span style="-sec-ix-hidden: xdx2ixbrl0802">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Fair Value of Warrants</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--FairValueAdjustmentOfWarrants_c20220101__20220331_zVo4G5kPuZi3" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value of warrants">120,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--FairValueAdjustmentOfWarrants_c20210101__20211231_zUYPRxq3FoNh" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value of warrants">138,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A9_z9WGbVISiQU3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
risk-free interest rate was based on rates established by the Federal Reserve Bank. The Company uses the historical volatility of its
common stock to estimate the future volatility for its common stock. The expected life of the derivative securities was determined by
the remaining contractual life of the derivative instrument. The expected dividend yield was based on the fact that the Company has not paid dividends to its common stockholders in the past
and does not expect to pay dividends to its common stockholders in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the three months ended March 31, 2022, the Company recognized a gain of $<span id="xdx_900_eus-gaap--DerivativeGainOnDerivative_c20220101__20220331_zXEqobUxBWpd">18,000
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">to account for the change in fair value of the
derivative liability between the reporting periods in accordance with ASC 842.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_DisclosureDerivativeLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_DisclosureDerivativeLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesAndFairValueTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for derivatives and fair value of assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -URI https://asc.fasb.org/topic&amp;trid=2155941<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -URI https://asc.fasb.org/topic&amp;trid=2229140<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesAndFairValueTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140447028181400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders&#8217; Equity</a></td>
<td class="text"><p id="xdx_808_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zWMlWuj3AF94" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Note
7 &#8211; <span id="xdx_82F_zZ5QpLyKnDk9">Stockholders&#8217; Equity</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: normal 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-style: normal; font-weight: normal">The
Company&#8217;s authorized capital as of March 31, 2022 was <span id="xdx_904_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20220331_zCSijIPSZLW5" title="Common stock, shares authorized">750,000,000</span> shares of common stock, par value $<span id="xdx_909_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20220331_zvptnkaRREgg" title="Common stock, par value">0.001</span> per share, and <span id="xdx_908_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20220331_z1Npg8AXpNuj" title="Preferred stock, shares authorized">15,000,000</span>
shares of preferred stock, par value $<span id="xdx_90F_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20220331_zQqazY9UOWD1" title="Preferred stock, par value">0.01</span> per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Common
Stock</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Common
Stock Issuable</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 16, 2021, as a result of the mandatory conversion of the notes payable and accrued interest in the aggregate amount of $<span id="xdx_909_eus-gaap--DebtConversionConvertedInstrumentAmount1_pn5n6_c20210215__20210216_zb8R93AKulg4">38.8
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million, the Company issued a total of <span id="xdx_904_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_pid_c20210215__20210216_zI09xAIu2Jp9">11,413,322
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock to the respective noteholders,
of which <span id="xdx_907_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_pid_c20210101__20211231_zib2HLgLrT1j">11,086,024
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">were already issued as of December 31,
2021.</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> The remaining <span id="xdx_90B_eus-gaap--SharesIssued_iI_pid_c20211231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockIssuableMember_z6EOaou8B1L8">327,298
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">common </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares
issuable at December 31, 2021 valued at $<span id="xdx_900_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn5n6_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__custom--CommonStockIssuableMember_z5aJXUB7Wzx5">1.1
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million,</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
were issued during the three months period ended March 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i><span style="text-decoration: underline">Cancellation of common stock</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the period ended March 31, 2022, the Company
cancelled and returned to authorized capital <span id="xdx_90D_eus-gaap--StockRepurchasedAndRetiredDuringPeriodShares_pid_c20220101__20220331_zh28nJx1ouJ5" title="Common shares cancelled and returned">290,999</span> previously issued shares of common stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Equity
compensation to officers, employees, and board of directors</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As part of employment agreements with its former
CEO and its former CFO (&#8220;Officers&#8221;), the Officers received a fully vested stock grant equal to an aggregate of&#160;<span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_pid_dp_uPure_c20220101__20220331__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementsMember_zVMp8m7L5jf1" title="Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum">10</span>% and&#160;<span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_pid_dp_uPure_c20220101__20220331__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementsMember_zmRVBIY3Qjf9" title="Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum">1.5</span>%
of the fully diluted shares of common stock of the Company (calculated with the inclusion of the current stock holdings of the CEO) upon
conversion of options, warrants and Convertible Notes in association with a national markets qualified financing as consideration for
entering into the Agreement (with such stock to vest and be delivered within 30 days after the national markets qualified financing).
In addition, the Company also granted similar equity compensation to members of the Company&#8217;s board of directors wherein these
directors received stock grants equal to&#160;<span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_pid_dp_uPure_c20220101__20220331__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementsMember__srt--RangeAxis__srt--MinimumMember_zewLcFpVZw1g" title="Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum">1</span>% and&#160;<span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_pid_dp_uPure_c20220101__20220331__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementsMember__srt--RangeAxis__srt--MaximumMember_z3xzAnQe2pcb" title="Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum">1.25</span>% of the fully diluted shares of common stock of the Company.&#160;<span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_c20220101__20220331__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementsMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zXGci5T8VxFi" title="Share-based Compensation Arrangement by Share-based Payment Award, Description">Pursuant
to the agreement, approximately 33% of the common stock to be issued vested immediately while the remaining</span>&#160;67% will vest over a
period of <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dc_c20220101__20220331_z3JB7VLGxlPf" title="Vesting period">two years</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On February 16, 2021, the Company completed its
equity offering and listed its shares of common stock on the Nasdaq Capital Market. As such,&#160;<span id="xdx_900_ecustom--CommonStockSharesGrantedForConsultants_pid_c20210215__20210216_zpRJqgSrMxR9" title="Common stock shares granted for consultants">4,379,407</span>&#160;shares of its common
stock were granted to these Officers, employees and board of directors, which had a fair value of $<span id="xdx_90E_ecustom--FairValueOfStockOptionsGrantedForConsultants_pn5n6_c20210215__20210216_zoQX27lrTJqa" title="Fair value of stock options granted f0r consultants">18.6</span>&#160;million. Since the grant
of the common stock is subject to milestone or performance conditions, the Company measured the fair value of the common stock on the
respective date of the agreement, and such awards were recorded as compensation expense as the milestone or performance condition is
met and in accordance with its vesting terms.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the period ended March 31, 2021, the Company
recognized $<span id="xdx_906_eus-gaap--ShareBasedCompensation_pn5n6_c20210101__20210331__srt--TitleOfIndividualAxis__custom--EmployeesMember_z5IwEMH2Ti0f">14.3</span> million of stock compensation expense related to vesting of shares to officers, employees and board of directors.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the period ended March 31, 2022, the Company
recognized $<span id="xdx_90B_eus-gaap--ShareBasedCompensation_c20220101__20220331__srt--TitleOfIndividualAxis__custom--EmployeesMember_zU9rwNamXxH5">447,000</span> of stock compensation expense related to vesting of shares to officers, employees and board of directors. <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of the remaining <span id="xdx_901_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedTounVestOutstandingNumber_iI_pid_c20220331__srt--TitleOfIndividualAxis__custom--OfficersEmployeesAndBoardOfDirectorsMember_z6bAYGFzRKnk">291,700
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">unvested shares of common stock to officers,
employees and board of directors at March 31, 2022 was $<span id="xdx_90A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToUnVestOutstandingAggregateIntrinsicValue_iI_pn5n6_c20220331__srt--TitleOfIndividualAxis__custom--OfficersEmployeesAndBoardOfDirectorsMember_zk4fysE53Xuj">1.4
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million and will be recognized as stock compensation
expense in future periods. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Issuance
of common shares for services</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As part of consulting agreements with certain
consultants, the Company agreed to grant these consultants common stock equal to&#160;<span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_pid_dp_uPure_c20210215__20210215__srt--RangeAxis__srt--MinimumMember_zE2MJgbn1Si8" title="Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum">1</span>% and&#160;<span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_pid_dp_uPure_c20210215__20210215__srt--RangeAxis__srt--MaximumMember_z9q3JquBztld" title="Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum">3</span>% of the fully diluted shares of common
stock of the Company upon conversion of options, warrants and Convertible Notes in association with a national markets qualified financing
as consideration for entering into the Agreement (with such stock to vest and be delivered within 30 days after the national markets
qualified financing).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On February 16, 2021, the Company completed its
equity offering and listed its shares of common stock on the Nasdaq Capital Market. As a result of this offering, the Company agreed
to issue to these consultants&#160;<span id="xdx_90C_eus-gaap--SharesIssued_iI_pid_c20210216_zIN88rZ4JMJe" title="Shares issued">2,850,090</span>&#160;shares of common stock with a grant date fair value of $<span id="xdx_905_ecustom--CommonStockConsultantToFairValue_pn5n6_c20210215__20210216_zp3b2HWXjAlc" title="Common stock consultant to fair value">10.7</span>&#160;million,&#160;of
which&#160;<span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_pid_c20210216_zWAkJfHVFz21" title="Vested shares">1,934,817</span>&#160;shares of common stock vested immediately while the remaining&#160;<span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pid_c20210215__20210216_zFJQBqsHU237" title="Remaining vested shares">915,273</span>,&#160;shares of&#160;common stock
vests over <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dc_c20210215__20210216_z96yp33tIXV8" title="Vested period">two years</span>. Pursuant to current accounting guidelines, as the grant of the common stock is subject to milestone or performance
conditions, the Company measured the fair value of the common stock on the respective date of the agreement, and then such award is being
recorded as compensation expense based upon the vesting term of the grant.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the period ended March 31, 2021, the Company
recognized $<span id="xdx_90E_eus-gaap--ShareBasedCompensation_pn5n6_c20210101__20210331_zYxaVnBQydD9" title="Share based compensation">8.5</span> million of stock compensation expense related to the issuance of <span id="xdx_90C_eus-gaap--SharesIssued_iI_pid_c20210331_zOGACsz92y6b" title="Shares issued">1,957,374</span> shares of common stock and the vesting of
shares to these consultants.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the period ended March 31, 2022, the</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> Company recognized
$<span id="xdx_906_eus-gaap--ShareBasedCompensation_c20220101__20220331__srt--TitleOfIndividualAxis__custom--ConsultingMember_zirSHx53TV9e">872,000
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of stock compensation expense related to the
issuance of <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensation_pid_c20220101__20220331__srt--TitleOfIndividualAxis__custom--ConsultingMember_zoOlMvkfQDji">46,500
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock and the vesting of <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_pid_c20220101__20220331__srt--TitleOfIndividualAxis__custom--ConsultingMember_znxlirzZpaAb">116,247
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock issued to consultants
for services in fiscal 2022. The fair value of the <span id="xdx_902_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedTounVestOutstandingNumber_iI_pid_c20220331__srt--TitleOfIndividualAxis__custom--ConsultingMember_zT64upi4Mp95">389,570
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">unvested shares of common stock to consultants
at March 31, 2022 was $<span id="xdx_90D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToUnVestOutstandingAggregateIntrinsicValue_iI_pn5n6_c20220331__srt--TitleOfIndividualAxis__custom--ConsultingMember_zO40t43rDWsj">1.3
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million and will be recognized as stock compensation
expense in future periods. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Preferred
Stock</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Series
C Preferred Stock</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
March 31, 2022 and March 31, 2021, there were <span id="xdx_906_eus-gaap--PreferredStockSharesIssued_iI_c20220331__us-gaap--StatementClassOfStockAxis__custom--SeriesCPreferredStocksMember_zciSKlx8pGyb"><span id="xdx_90F_eus-gaap--PreferredStockSharesOutstanding_iI_c20220331__us-gaap--StatementClassOfStockAxis__custom--SeriesCPreferredStocksMember_zOzrPHLcdFi1"><span id="xdx_904_eus-gaap--PreferredStockSharesIssued_iI_c20210331__us-gaap--StatementClassOfStockAxis__custom--SeriesCPreferredStocksMember_zLQ9x9K2aSa2" title="Preferred stock, shares issued"><span id="xdx_908_eus-gaap--PreferredStockSharesOutstanding_iI_c20210331__us-gaap--StatementClassOfStockAxis__custom--SeriesCPreferredStocksMember_z5HX6ZLlhZb9" title="Preferred stock, shares outstanding">96,230</span></span></span>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of series C preferred stock, par value
$<span id="xdx_90F_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20220331__us-gaap--StatementClassOfStockAxis__custom--SeriesCPreferredStocksMember_zsYsghFFToT6"><span id="xdx_90B_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20210331__us-gaap--StatementClassOfStockAxis__custom--SeriesCPreferredStocksMember_zex8msIzdNQ6" title="Preferred stock, par value">0.01</span>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share (the &#8220;Series C Preferred Stock&#8221;)
issued and outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of reverse stock splits in previous years and the agreement terms for adjusting the rights of the related shares, the <span id="xdx_90D_eus-gaap--PreferredStockSharesIssued_iI_c20220331__us-gaap--StatementClassOfStockAxis__custom--SeriesCPreferredStocksMember_zuzkAd5Hlyvk">96,230</span>
shares of Series C Preferred Stock are not currently convertible, have no voting rights, and in the event of liquidation, the holders
of the Series C Preferred Stock would not participate in any distribution of the assets or surplus funds of the Company. The holders
of Series C Preferred Stock also are not currently entitled to any dividends if and when declared by the Company&#8217;s board of directors
(the &#8220;Board&#8221;). No dividends to holders of the Series C Preferred Stock were issued or unpaid through March 31, 2022 and 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Series
K Preferred Stock</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 16, 2021, the Board designated <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20210215__20210216__us-gaap--StatementClassOfStockAxis__custom--SeriesKPreferredStocksMember_zFZKJ6mz6gJh" title="Preferred stock shares designated">115,000</span> shares of Series K preferred stock, par value $<span id="xdx_904_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20210216__us-gaap--StatementClassOfStockAxis__custom--SeriesKPreferredStocksMember_zsR1NQ5Ho7ak" title="Preferred stock, par value">.01</span>. (the &#8220;Series K Preferred Stock&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
of the Series K Preferred Stock are convertible at any time, at the option of the holders, into shares of the Company&#8217;s common
stock at an effective conversion rate of <span id="xdx_90C_eus-gaap--PreferredStockConvertibleSharesIssuable_iI_c20210216__us-gaap--StatementClassOfStockAxis__custom--SeriesKPreferredStocksMember_zLXCxZzoLJz2" title="Convertible shares issuable">100
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock for each share of Series
K Preferred. Shares of the Series K Preferred Stock have the same voting rights as the shares of the Company&#8217;s common stock,
with the holders of the Series K Preferred Stock entitled to vote on an as-converted-to-common stock basis, subject to the beneficial
ownership limitation, together with the holders of the Company&#8217;s common stock on all matters presented to the Company&#8217;s stockholders.
The Series K Preferred Stock are not entitled to any dividends (unless specifically declared by the Board) but will participate on an
as-converted-to-common-stock basis in any dividends to the holders of the Company&#8217;s common stock. In the event of the Company&#8217;s
dissolution, liquidation or winding up, the holders of the Series K Preferred Stock will be on parity with the holders of the Company&#8217;s
common stock and will participate, on a on an as-converted-to-common stock basis, in any distribution to holders of the Company&#8217;s
common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 31, 2022 and December 31, 2021, there were <span id="xdx_90C_eus-gaap--PreferredStockSharesOutstanding_iI_pid_do_c20220331__us-gaap--StatementClassOfStockAxis__custom--SeriesKPreferredStocksMember_zT5m1bkb3zR6" title="Preferred stock, shares outstanding"><span id="xdx_905_eus-gaap--PreferredStockSharesIssued_iI_pid_do_c20220331__us-gaap--StatementClassOfStockAxis__custom--SeriesKPreferredStocksMember_zSAFXILRmPX5" title="Preferred stock, shares issued"><span id="xdx_902_eus-gaap--PreferredStockSharesOutstanding_iI_pid_do_c20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesKPreferredStocksMember_zDbF8m0J4eDc" title="Preferred stock, shares outstanding"><span id="xdx_90B_eus-gaap--PreferredStockSharesIssued_iI_pid_do_c20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesKPreferredStocksMember_zhOunByS1yXf" title="Preferred stock, shares issued">no</span></span></span></span> shares of Series K Preferred stock issued and outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Warrants
and Options</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Common
Stock Warrants</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p id="xdx_894_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_z1QoQDPZe3W6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock
warrant transactions for the three months ended March 31, 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BF_zL76BPA8JD5d" style="display: none">Schedule
of  Warrant Activity</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Weighted Average</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Warrants
</b></span></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Exercise Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%">Outstanding at December 31, 2021:</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20220101__20220331_zmsj6DS0orD9" style="width: 16%; text-align: right" title="Warrants Outstanding,Beginning Balance">2,337,274</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20220101__20220331_z4mRwCIdZ5oh" style="width: 16%; text-align: right" title="Weighted Average Exercise Price, Beginning Balance">5.30</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20220101__20220331_zbM6PbxiHEng" style="text-align: right" title="Number of Warrants, Granted"><span style="-sec-ix-hidden: xdx2ixbrl0899">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue_pid_c20220101__20220331_zWMlhOOt7pG9" style="text-align: right" title="Weighted Average Exercise Price, Granted"><span style="-sec-ix-hidden: xdx2ixbrl0901">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Forfeited/canceled</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeited_iN_pid_di_c20220101__20220331_zJcvJ1Sr3zF5" style="text-align: right" title="Number of Warrants, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl0903">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue_pid_c20220101__20220331_zHF7dlCWyH6b" style="text-align: right" title="Weighted Average Exercise Price, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl0905">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Exercised</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20220101__20220331_zEoGKelxWMke" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Warrants, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl0907">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20220101__20220331_zJhvs1KP25ji" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl0909">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Warrants outstanding at March 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20220101__20220331_zNxAOaFzLKi4" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants Outstanding, Ending Balance">2,337,274</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20220101__20220331_zOiOMdTfCkzf" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Ending Balance">5.30</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Warrants exercisable at March 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable_iI_pid_c20220331_zZkuBvyoStr2" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants Exercisable">2,337,274</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20220331_zXXcxag5t8Eb" style="border-bottom: Black 2.5pt double; text-align: right" title="Exercisable">5.30</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AE_zgZCApjehyrk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 31, 2022, all issued and outstanding warrants are fully vested, and have no intrinsic value as the exercise price of
these warrants was greater than the market price.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Common
Stock Options</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p id="xdx_89C_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zoV3yKJSBuWf" style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock option transactions for the three
months ended March 31, 2022:</span></p>



<p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B9_zbXKwz9p29kb" style="display: none">Schedule
of Options Activity</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Weighted Average</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Exercise Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%">Options outstanding at December 31, 2021:</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20220101__20220331_zgPtBAAs4vk7" style="width: 16%; text-align: right" title="Options outstanding, beginning">302,500</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20220101__20220331_zE8is2UMksP7" style="width: 16%; text-align: right" title="Exercise Price of Warrants or Rights">3.05</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20220101__20220331_zWfdsNbefRzg" style="text-align: right" title="Number of Options, Granted"><span style="-sec-ix-hidden: xdx2ixbrl0925">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20220101__20220331_zCzO2SX6nm6f" style="text-align: right" title="Weighted Average Exercise Price, Granted"><span style="-sec-ix-hidden: xdx2ixbrl0927">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Forfeited/canceled</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_pid_c20220101__20220331_zSaLArFlb7P8" style="text-align: right" title="Number of Options, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl0929">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20220101__20220331_zqEnKSqrIMnh" style="text-align: right" title="Weighted Average Exercise Price, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl0931">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Exercised</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionEquityInstrumentsExercised_pid_c20220101__20220331_zwky8LS3Vypk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Options, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl0933">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20220101__20220331_zqYEMfzBiDXc" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl0935">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Options outstanding at March 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20220101__20220331_zhwZPBmMv7s9" style="border-bottom: Black 2.5pt double; text-align: right" title="Options outstanding, Ending">302,500</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20220101__20220331_zBa7eB8VWFWa" style="border-bottom: Black 2.5pt double; text-align: right" title="Exercise Price of Warrants or Rights">3.05</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Options exercisable at March 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20220331_zkSnJVkHaEY5" style="border-bottom: Black 2.5pt double; text-align: right" title="Options exercisable">111,215</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20220331_zHow2t57AW68" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Exercisable">3.05</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A8_zMLgyvdFhbj7" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
March 31, 2022, there were <span id="xdx_90B_ecustom--NumberofsharesUnvestedOptions_c20220101__20220331_zmrp065Zosng" title="Number of shares unvested">191,285</span> unvested options with a grant date fair value of $<span id="xdx_90D_ecustom--NumberofValueUnvestedOptions_c20220101__20220331_zNXH7h0vhBKl" title="Number of shares unvested, value">511,115</span> which will be recognized as stock compensation
in future periods based upon the remaining vesting term of the applicable grants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
was <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_do_c20220331_zwK3tFSJaAE6" title="Options outstanding intrinsic value">no
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">intrinsic value of the outstanding options as
of March 31, 2022 as the exercise price of these options was greater than the market price.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140447028163032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p id="xdx_800_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zkNEWs4XXv5" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Note
8 &#8211; <span id="xdx_829_z5ILQcczdnc9">Commitments and Contingencies</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.7pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Litigation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> involved in certain legal proceedings
that arise from time to time in the ordinary course of our business. Except for income tax contingencies, we record accruals for contingencies
to the extent that our management concludes that the occurrence is probable and that the related amounts of loss can be reasonably estimated.
Legal expenses associated with the contingency are expensed as incurred. There is no current or pending litigation of any significance
with the exception of the matters that have arisen under, and are being handled in, the normal course of business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On
August 28, 2019, a complaint was filed in the Superior Court of California, County of Los Angeles, West Judicial District, Santa Monica
Courthouse, Unlimited Civil Division by Jeffrey Lion, an individual (&#8220;Lion&#8221;), and by Daniel Vallera, an individual (&#8220;Vallera&#8221;).
Lion and Vallera are referred to jointly as the &#8220;Plaintiffs.&#8221; The complaint was filed against GT Biopharma, Inc. and its
subsidiary Oxis Biotech, Inc. (either of them or jointly, the &#8220;Company&#8221;). The Plaintiffs alleged breach of a license agreement
between the Plaintiffs and the Company entered into on or about September 3, 2015. A settlement of the case was reached on February 7,
2022 in the amount of $<span id="xdx_90B_eus-gaap--LitigationSettlementExpense_c20220206__20220207_zNoVfISTexhd" title="Litigation settlement expense">425,000</span>. This amount was fully accrued at December 31, 2021. The settlement amount was subsequently paid on March
4, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Significant Agreements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and Development Agreements</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is a party to a scientific research agreement with the Regents of the University of Minnesota, effective June 16, 2021. This
scientific research agreement aims to work with the Company with three major goals in mind: (1) support the Company&#8217;s TriKE<sup>&#174;
</sup>product development and GMP manufacturing efforts; (2) TriKE<sup>&#174;</sup> pharmacokinetics optimization in humans; and (3) investigation
of the patient&#8217;s native NK cell population based on insights obtained from the analysis of the human data generated during our
GTB-3550 clinical trial. The major deliverables proposed here are: (1) creation of IND enabling data for TriKE<sup>&#174;</sup> constructs
in support of our product development and GMP manufacturing efforts; (2) TriKE<sup>&#174;</sup> platform drug delivery changes to allow
transition to alternative drug delivery means and extended PK in humans; and (3) gain an increased understanding of changes in the patient&#8217;s
native NK cell population as a result of TriKE<sup>&#174; </sup>therapy. Most studies will use TriKE<sup>&#174;</sup> DNA/amino acid sequences
created by us under current UMN/GTB licensing terms. The term of this agreement shall expire on June 30, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
University of Minnesota shall use reasonable efforts to complete the project for a fixed sum of $<span id="xdx_903_ecustom--ProjectFee_pn5n6_c20220101__20220331_zdoinf8BizIf" title="Project fees">2.1</span> million. The Company recorded expense
of $<span id="xdx_90B_ecustom--RecordedExpenses_pn5n6_c20220101__20220331_zqI1cqtO9sb9" title="Recorded expenses">1.1</span> million through March 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--OtherCommitmentsDescription_c20201001__20201005_z25qPgmWY3Lg" title="Other commitments, description">On
October 5, 2020, GT Biopharma entered into a Master Services Agreement with a third-party product manufacturer to perform biologic development
and manufacturing services on behalf of the Company. Associated with this, the Company has subsequently signed five Statements of Work
for the research and development of products for use in clinical trials. At March 31 2022, the Company&#8217;s commitments in relation
to these Statements of Work and any related Change Orders totaled approximately $<span id="xdx_905_ecustom--ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurred_pn5n6_c20220101__20220331__us-gaap--TypeOfArrangementAxis__custom--MasterServicesAgreementMember__dei--LegalEntityAxis__custom--CytovanceBiologicsIncMember_z4IqnhIZpFF4" title="Commitment amount for services, total">13.0</span> million, of which $<span id="xdx_908_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross_pn5n6_c20220101__20220331__us-gaap--TypeOfArrangementAxis__custom--MasterServicesAgreementMember__dei--LegalEntityAxis__custom--CytovanceBiologicsIncMember_z2invhO1hb5" title="Commitment cost incurred">8.4</span> million was incurred at
that date and an additional $<span id="xdx_90D_ecustom--ResearchAndDevelopmentArrangementContractToPerformExpectedCostsIncurred_pn5n6_c20220101__20220331__us-gaap--TypeOfArrangementAxis__custom--MasterServicesAgreementMember__dei--LegalEntityAxis__custom--CytovanceBiologicsIncMember_z8h1UDfF6TIg" title="Compensation cost expected to be incurred in future">4.6</span> million is in process during fiscal year 2022</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patent
and License Agreements</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>2016
Exclusive Patent License Agreement</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is party to an exclusive worldwide license agreement with the Regents of the University of Minnesota, (&#8220;UofMN&#8221;),
to further develop and commercialize cancer therapies using TriKE<sup>&#174;</sup> technology developed by researchers at the UofMN to
target NK cells to cancer. Under the terms of the 2016 agreement, the Company receives exclusive rights to conduct research and to develop,
make, use, sell, and import TriKE<sup>&#174;</sup> technology worldwide for the treatment of any disease, state, or condition in humans.
The Company is responsible for obtaining all permits, licenses, authorizations, registrations, and regulatory approvals required or granted
by any governmental authority anywhere in the world that is responsible for the regulation of products such as the TriKE<sup>&#174;</sup>
technology, including without limitation the FDA and the European Agency for the Evaluation of Medicinal Products in the European Union.
Under the agreement, the UofMN received an upfront payment of $<span id="xdx_903_ecustom--ProceedsFromUpfrontAmount_iI_pn5n6_c20220331__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_z9K1qR4xc8R4">0.2
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million, and an annual License Maintenance fee
of $<span id="xdx_90C_ecustom--AnnualMaintananceFee_pn5n6_c20220101__20220331__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zGmFyuGQglu6">0.1
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million beginning in 2021. The agreement also
includes <span id="xdx_903_ecustom--RoyaltyFeePercentage_pid_dp_uPure_c20220101__20220331__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zKl4mAtYvDkf">4%
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">royalty fees, (not to exceed 6%) under
subsequent license agreements or amendments to this agreement or minimum annual royalty payments ranging from $<span id="xdx_90E_ecustom--AnnualRoyaltyPayments_pn4n6_c20220101__20220331__srt--RangeAxis__srt--MinimumMember__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_ztyoCtKLY0Ll">0.25
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million to $<span id="xdx_905_ecustom--AnnualRoyaltyPayments_pn5n6_c20220101__20220331__srt--RangeAxis__srt--MaximumMember__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zgaQhcCqFhM8">5.0
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million. The agreement also includes certain
performance milestone payments totaling $<span id="xdx_907_ecustom--PerformanceMilestonePayments_pn5n6_c20220101__20220331__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zrwhEO0YkQh9">3.1
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million, and one-time sales milestone payments
of $<span id="xdx_907_ecustom--SalesMilestonePayments_pn5n6_c20220101__20220331__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zPuMtqyAwnWl">1.0
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million upon reaching $<span id="xdx_901_ecustom--GrossSales_pn6n6_c20220101__20220331__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_z6mqku6t5Pif">250
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million in gross sales, and $<span id="xdx_905_ecustom--SalesRevenue_pn5n6_c20220101__20220331__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zMy56DuChP9">5.0
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million upon reaching $<span id="xdx_900_ecustom--CummulativeGrossSales_pn6n6_c20220101__20220331__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zOhmnnYP5Qt1">500
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million dollars in cumulative gross sales of
Licensed Products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>2021
Patent License Agreement</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 26, 2021, the Company signed an agreement specific to the B7H3 targeted TriKE<sup>&#174;</sup>. Under the agreement, the UofMN received
an upfront license fee of $<span id="xdx_90A_ecustom--UpfrontLicenseFee_c20210325__20210326__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_zgyPliO9g329" title="Upfront license fee">20,000</span> and will receive an annual License Maintenance fee of $<span id="xdx_902_ecustom--LicenseMaintenanceFeeReceivable_iI_c20220331__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_z4DarsZtep43" title="License maintenance fee, receivable">5,000</span> beginning in 2022, <span id="xdx_906_ecustom--NetSalesPercentage_pid_dp_uPure_c20220101__20220331__srt--RangeAxis__srt--MinimumMember__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_zycDcOcLhsG3" title="Net sales percentage">2.5%</span> to <span id="xdx_904_ecustom--NetSalesPercentage_pid_dp_uPure_c20220101__20220331__srt--RangeAxis__srt--MaximumMember__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_zncDE4bb855f" title="Net sales percentage">5%</span> royalty
fees, or minimum annual royalty payments of $<span id="xdx_900_ecustom--AnnualRoyaltyPayments_pn4n6_c20220101__20220331__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_zhR2MH5smYl" title="Annual royalty payments">0.25</span> million beginning in the year after the first commercial sales of Licensed Product,
and $<span id="xdx_906_ecustom--MaintananceFee_pn5n6_c20220101__20220331__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_zNZRerpobAgl" title="Maintanance fee">2.0</span> million beginning in the fifth year after the first commercial sale of such Licensed Product. The agreement also includes certain
performance milestone payments totaling $<span id="xdx_909_ecustom--PerformanceMilestonePayments_pn5n6_c20220101__20220331__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_zfkyZl5G4bl8" title="Performance milestone payments">3.1</span> million-, and one-time sales milestone payments of $<span id="xdx_904_ecustom--SalesMilestonePayments_pn5n6_c20220101__20220331__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_zXmlmRHF5E69" title="Sales milestone payments">1.0</span> million upon reaching $<span id="xdx_901_ecustom--GrossSales_pn6n6_c20220101__20220331__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_zx4cZYsF6EF1" title="Gross sales">250</span> million
in gross sales, and $<span id="xdx_90C_ecustom--SalesRevenue_pn5n6_c20220101__20220331__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_zOOXqVYoN219" title="Sales revenue">5.0</span> million upon reaching $<span id="xdx_907_ecustom--CummulativeGrossSales_pn6n6_c20220101__20220331__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_zs18T8hPDJtd" title="Cummulative gross sales">500</span> million dollars in cumulative gross sales of Licensed Products. There is no double
payment intended; if one of the milestone payments has been paid under the 2016 agreement no further payment is due for the corresponding
milestone above.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lease
Agreements</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 16.95pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 19, 2021 the Company entered into a sublease with Aimmune Therapeutics, Inc. for <span id="xdx_900_eus-gaap--AreaOfLand_iI_uSqft_c20211119__srt--CounterpartyNameAxis__custom--AimmuneTherapeuticsIncMember_zjcfzQNqhB9d" title="Area of land">4,500
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">square feet of office space located in Brisbane,
California having a <span id="xdx_90E_eus-gaap--LesseeOperatingSubleaseOptionToExtend_c20211118__20211119__srt--CounterpartyNameAxis__custom--AimmuneTherapeuticsIncMember_zIoZsJGUss27" title="Commencement date">commencement
date of January 1, 2022 and maturing on June 30, 2024</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
Additionally, on February 8, 2022, the Company entered into a lease of a photocopier, which matures on February 7, 2025. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Rent expense related to these leases reflected
on the Company&#8217;s Condensed Consolidated Statements of Operations totaled $<span id="xdx_90A_eus-gaap--PaymentsForRent_c20220101__20220331_zBCFA3X6efk7" title="Rent expense">29,000</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_891_ecustom--ScheduleOfOtherInformationRelatedLeasesUnderNOnCancellableTableTextBlock_zLGVnlqeHhB2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
information related to leases and future minimum lease payments under non-cancellable operating leases were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span><span><span id="xdx_8B1_zfme6KpWNgD8" style="display: none">Schedule of Other Information Related Leases Under Non-Cancellable</span></span>&#160;</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>March 31, 2022</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Unaudited)</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-style: normal; font-weight: normal; text-align: left">Cash paid for amounts included in the measurement of lease liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 82%; text-align: left">Operating cash flows from operating leases</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--OperatingLeasePayments_c20220101__20220331_zOvD28bx9yKi" style="width: 14%; text-align: right" title="Operating cash flows from operating leases">20,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-style: normal; font-weight: normal; text-align: left">Right-of-use assets obtained in exchange for lease liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Operating leases</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_c20220101__20220331_zrJwZZ6jXZO1" style="text-align: right" title="Right of use assets operating leases">260,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-style: normal; font-weight: normal; text-align: left">Weighted-average remaining lease term (in years):</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Operating leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90E_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20220331_ziwy9rtDmqjj" title="Weighted average remaining lease term operating leases">2.5</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-style: normal; font-weight: normal; text-align: left">Weighted-average discount rate:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Operating leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_900_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20220331_zDW9dVBUYrN2" title="Weighted average discount rate operating leases">10</span></td><td style="text-align: left">%</td></tr>
  </table>

<p id="xdx_8AF_zec0kjqf9Sa8" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_897_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zgOezNxtO318" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future
minimum lease payments under non-cancellable operating leases were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B0_zJPDTRAHFnQc" style="display: none">Schedule
of Future Minimum Lease Payments</span>&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_491_20220331_z6qXdtgac6aa" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>March 31, 2022</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Unaudited)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b/></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_maOLLzd8y_zLQ1XYQeq8Nc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 82%; text-align: left">Within one year</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">90,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maOLLzd8y_zPfQgTZaLSF7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">After one year and within two years</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">122,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maOLLzd8y_zwEDGHHMoiG5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">After two years and within three years</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">65,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_iI_maOLLzd8y_zW30AWZmxwJ3" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Thereafter</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl1023">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--OperatingLeaseLiability_iTI_mtOLLzd8y_zHteqIgSavc2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total future minimum lease payments</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">277,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_zPnXSc3irq71" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Less &#8211; discount</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(30,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_zRs1RhF2rN3i" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Lease liability</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">247,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140447028104712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p id="xdx_809_eus-gaap--SubsequentEventsTextBlock_z3ofp2iCfzj7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note
9 - <span id="xdx_824_zyRotnA9YbJ8">Subsequent Events</span></b></p>

<p style="font: normal 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-style: normal; font-weight: normal">&#160;</span></p>

<p style="font: normal 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-style: normal; font-weight: normal">On
April 29, 2022, the Company entered into a settlement agreement with its former Chief Executive Officer (&#8220;Officer&#8221;) and received
<span id="xdx_902_eus-gaap--StockRepurchasedDuringPeriodShares_pid_c20220428__20220429__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_ztJetsFNl71d" title="Number of shares received">1,845,000</span> shares of its common stock in full and final settlement of all its claims against the Officer. The common stock certificates
were received by the Company on May 2, 2022 and the common shares were subsequently cancelled.</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI https://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140447029174424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Basis of Presentation and Principles of Consolidation</a></td>
<td class="text"><p id="xdx_84C_eus-gaap--BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_ziwXdnXm6Eo" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86C_zZA5OqiTgsti">Basis
of Presentation and Principles of Consolidation</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Oxis Biotech, Inc. and
Georgetown Translational Pharmaceuticals, Inc. All intercompany transactions and balances have been eliminated in consolidation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying condensed consolidated financial statements are unaudited. These unaudited interim condensed consolidated financial statements
have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) and
applicable rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;) regarding interim financial reporting.
Certain information and note disclosures normally included in the financial statements prepared in accordance with GAAP have been condensed
or omitted pursuant to such rules and regulations. Accordingly, these interim condensed consolidated financial statements should be read
in conjunction with the consolidated financial statements and notes thereto contained in the Company&#8217;s Annual Report on Form 10-K
for the fiscal year ended December 31, 2021 filed with the SEC on March 28, 2022 (the &#8220;2021 Annual Report&#8221;). The consolidated
balance sheet as of December 31, 2021 included herein was derived from the audited consolidated financial statements as of that date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the opinion of management, the accompanying unaudited condensed consolidated financial statements contain all adjustments necessary to
fairly present the Company&#8217;s financial position and results of operations for the interim periods reflected. Except as noted, all
adjustments contained herein are of a normal recurring nature. Results of operations for the fiscal periods presented herein are not
necessarily indicative of fiscal year-end results.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_GTBP_LiquidityPolicyTextBlock', window );">Liquidity</a></td>
<td class="text"><p id="xdx_844_ecustom--LiquidityPolicyTextBlock_zp3rOnYqS4E4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span style="text-decoration: underline">Liquidity</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The accompanying consolidated financial statements
have been prepared under the assumption that the Company will continue as a going concern. Such assumption contemplates the realization
of assets and satisfaction of liabilities in the normal course of business. For the quarter ended March 31, 2022, the Company recorded
a net loss of $<span id="xdx_90D_eus-gaap--NetIncomeLoss_iN_pn5n6_di_c20220101__20220331_zvWfIejSWSJ3">5.4</span> million  and
used cash in operations of $<span id="xdx_902_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pn5n6_di_c20220101__20220331_zCZSXuW8NNIa">5.2
</span>million. As of March 31, 2022, the Company had a cash and short-term investments balance of $<span id="xdx_904_ecustom--CashOnHandAndShortTermInvestment_c20220331_pn5n6">26.7
</span>million, working capital of $<span id="xdx_904_ecustom--WorkingCapital_iI_pn5n6_c20220331_zg4BIqqFLElb">17.7</span> million and
stockholders&#8217; equity of $<span id="xdx_90E_eus-gaap--StockholdersEquity_iI_pn5n6_c20220331_zDxGAycIXqF2">17.8</span> million.
Management anticipates that the $<span id="xdx_902_eus-gaap--InvestmentsAndCash_c20220331_pn5n6">26.7</span> million of cash and
cash equivalents, and short-term investments are adequate to satisfy the liquidity needs of the Company for at least one year from the
date the Company&#8217;s condensed consolidated financial statements for the quarter ended March 31, 2022 were issued.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Historically, the Company has financed its operations
through public and private sales of common stock, issuance of preferred and common stock, issuance of convertible debt instruments, and
strategic collaborations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnusualRisksAndUncertaintiesTextBlock', window );">COVID-19</a></td>
<td class="text"><p id="xdx_842_eus-gaap--UnusualRisksAndUncertaintiesTextBlock_z1InoGYI4SHf" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_860_zdJ9LQtHssS4">COVID-19</span></span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2020, the World Health Organization declared coronavirus COVID-19 a global pandemic. This contagious disease outbreak, which has
continued to spread, has adversely affected workforces, customers, economies, and financial markets globally. It has also disrupted the
normal operations of many businesses. This outbreak could adversely affect the Company&#8217;s operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
the pandemic has impacted the Company&#8217;s operations, during the three months ended March 31, 2022, the Company believes the COVID-19
pandemic had limited impact on its operating results. The Company has not observed any impairments of its assets or a significant change
in the fair value of its assets due to the COVID-19 pandemic. At this time, it is not possible for the Company to predict the duration
or magnitude of the adverse results of the outbreak and its effects on the Company&#8217;s business or results of operations, financial
condition, or liquidity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has been following the recommendations of health authorities to minimize exposure risk for its team members, including having team members work remotely. Most vendors have transitioned to electronic submission of invoices
and payments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Accounting Estimates</a></td>
<td class="text"><p id="xdx_845_eus-gaap--UseOfEstimates_zaQpHjiWj2Ug" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_86F_z6Y0sUxBSbdi">Accounting
Estimates</span></span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of financial statements in conformity with GAAP requires management
to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and
liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual
results could differ from those estimates. Significant estimates include accruals for potential liabilities, assumptions used in deriving
the fair value of derivative liabilities, valuation of equity instruments issued for services and realization of deferred tax assets.
Actual results could differ from those estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash Equivalents and Short-Term Investments</a></td>
<td class="text"><p id="xdx_846_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zvf7AVWQ7JVl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_868_zNZM9POImGMb">Cash
Equivalents and Short-Term Investments</span></span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company considers highly liquid investments with maturities of three months or less at the date of acquisition as cash equivalents in
the accompanying condensed consolidated financial statements. As of March 31, 2022 total cash and cash equivalents, which consist
of cash and money market funds, amounted to approximately $<span id="xdx_90D_eus-gaap--CashCashEquivalentsAndShortTermInvestments_iI_pn5n6_c20220331_zHe7zv78whkk" title="Total cash equivalents">7.3
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company also invested its excess cash in commercial paper and corporate notes and bonds. Management generally determines the appropriate
classification of its investments at the time of purchase. We classify these investments as short-term investments, as part of current
assets, based upon our ability and intent to use any and all of these investments as necessary to satisfy liquidity requirements that
may arise from our businesses. Investments are carried at fair value with the unrealized holding gains and losses reported in the accompanying
condensed consolidated statements of operations. As of March 31, 2022 total short-term investments amounted to approximately $<span id="xdx_90D_eus-gaap--ShortTermInvestments_iI_pn5n6_c20220331_zbFVx4slt7Dd" title="Short term investment">19.5</span> million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><p id="xdx_84C_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zGMqlOyhVRBe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_86E_zeQcKVhcvrEf">Fair
Value of Financial Instruments</span></span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
Accounting Standards Board (&#8220;FASB&#8221;)</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
Accounting Standards Codification (&#8220;ASC&#8221;) 820-10 requires entities to disclose the fair value of financial instruments, both
assets and liabilities recognized and not recognized on the balance sheet for which it is practicable to estimate fair value. ASC 820-10
defines the fair value of a financial instrument as the amount at which the instrument could be exchanged in a current transaction between
willing parties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
three levels of the fair value hierarchy are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Valuations
    based on unadjusted quoted prices in active markets for identical assets or liabilities that the entity has the ability to access.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Valuations
    based on quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are
    observable or can be corroborated by observable data for substantially the full term of the assets or liabilities.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Valuations
    based on inputs that are unobservable, supported by little or no market activity and that are significant to the fair value of the
    assets or liabilities.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.05pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
carrying amount of the Company&#8217;s derivative liability of $<span id="xdx_907_eus-gaap--DerivativeLiabilitiesCurrent_iI_pn3d_c20220331_zARRNOM8kcxd" title="Derivative liability">120,000</span> at March 31, 2022 and $<span id="xdx_90A_eus-gaap--DerivativeLiabilitiesCurrent_iI_pn3d_c20211231_ztYMVWP5ezf5" title="Derivative liability">138,000</span> at December 31, 2021 was based
on Level 2 measurements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
carrying amounts of the Company&#8217;s other financial assets and liabilities, such as cash, prepaid expense, accounts payable and accrued
expenses approximate their fair values because of the short maturity of these instruments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Derivative Financial Instruments</a></td>
<td class="text"><p id="xdx_84F_eus-gaap--DerivativesPolicyTextBlock_zDqDJqg4m6qg" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_86B_z4YndwtpjxUh">Derivative
Financial Instruments</span></span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded
derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded
at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the consolidated statements
of operations. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or
as equity, is evaluated at the end of each reporting period. Derivative instrument liabilities are classified in the balance sheet as
current or non-current based on whether or not net-cash settlement of the derivative instrument could be required within 12 months of
the balance sheet date. The fair value of the embedded derivatives is determined using a Binomial valuation method at inception
and on subsequent valuation dates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><p id="xdx_845_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zT4axtXtmrMa" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_86D_zqacO57IIn6l">Stock-Based
Compensation</span></span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for share-based awards to employees, nonemployees and consultants in accordance with the provisions of ASC 718, <i>Compensation-Stock
Compensation</i>. Stock-based compensation cost is measured at fair value on the grant date and that fair value is recognized as expense
over the requisite service, or vesting period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company values its equity awards using the Black-Scholes option pricing model, and accounts for forfeitures when they occur. Use of the
Black-Scholes option pricing model requires the input of subjective assumptions including expected volatility, expected term, and a risk-free
interest rate. The Company estimates volatility using a its own historical stock price volatility. The expected term of the instrument
is estimated by using the simplified method to estimate expected term. The risk-free interest rate is estimated using comparable published
federal funds rates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text"><p id="xdx_84C_eus-gaap--ResearchAndDevelopmentExpensePolicy_zNdiKDWMACGc" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_86A_z0CP2o2xfAB7">Research
and Development Costs</span></span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Costs
incurred for research and development are expensed as incurred. The salaries, benefits, and overhead costs of personnel conducting research
and development of the Company&#8217;s products are included in research and development expenses. Purchased materials that do not have
an alternative future use are also expensed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p id="xdx_84B_eus-gaap--LesseeLeasesPolicyTextBlock_zIyeYy38CWhl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_86A_zNrwgdvKJgdf">Leases</span></span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for its leases in accordance with Accounting Standards Update (&#8220;ASU&#8221;) No. 2016-02, <i>Leases</i> (Topic
842) (&#8220;ASC 842&#8221;). ASC 842 requires lessees to (i) recognize a right of use asset (&#8220;ROU asset&#8221;) and a lease liability
that is measured at the present value of the remaining lease payments, on the consolidated balance sheets, (ii) recognize a single lease
cost, calculated over the lease term on a straight-line basis and (iii) classify lease related cash payments within operating and financing
activities. The Company has made an accounting policy election to not recognize short-term leases on the consolidated balance sheets
and all non-lease components, such as common area maintenance, were excluded. At any given time during the lease term, the lease liability
represents the present value of the remaining lease payments, and the ROU asset is measured as the amount of the lease liability, adjusted
for pre-paid rent, unamortized initial direct costs, and the remaining balance of lease incentives received. Both the lease ROU asset
and liability are reduced to zero at the end of the lease term.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 16.95pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company leases office space and equipment. At the lease inception date, the Company determines if an arrangement is, or contains a lease.
Some of the Company&#8217;s leases include options to renew at similar terms. The Company assesses these options to determine if the
Company is reasonably certain of exercising these options based on relevant economic and financial factors. Options that meet these criteria
are included in the lease term at the lease commencement date</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">During the period ended March 31, 2022, the Company
executed lease agreements for its office space and equipment and as a result, recorded operating lease right-of-use assets and the related
lease liabilities of $<span id="xdx_902_eus-gaap--OperatingLeaseRightOfUseAsset_iI_c20220331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeSpaceAndEquipmentMember_zGG1pfSFWhBk" title="Operating lease, right-of-use asset"><span id="xdx_903_eus-gaap--OperatingLeaseLiability_iI_c20220331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeSpaceAndEquipmentMember_z2hZmOW2i1ih" title="Operating lease,liability">260,000</span></span> pursuant to ASC 842,&#160;<i>Leases</i> (see Note 8).</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Earnings (Loss) Per Share</a></td>
<td class="text"><p id="xdx_840_eus-gaap--EarningsPerSharePolicyTextBlock_zk2Uix3Jq2id" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_863_zAq2AuhKN4Yd" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Net
Earnings (Loss) Per Share</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
earnings (loss) per share is computed using the weighted-average number of common shares outstanding during the period. Common stock
issuable is included in our calculation as of the date of the underlying agreement. Diluted earnings (loss) per share is computed using
the weighted-average number of common shares and the dilutive effect of contingent shares outstanding during the period. Potentially
dilutive contingent shares, which primarily consist of convertible notes, stock issuable for the exercise of stock options and warrants
have been excluded from the diluted loss per share calculation because their effect is anti-dilutive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89C_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_z08jlg8yBhpd" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
following common stock equivalents were excluded in the computation of the net loss per share because their effect is anti-dilutive:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BC_z2TePbqZshn8" style="display: none">Schedule of Anti-dilutive Securities</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20220101__20220331_zmOg4YGJwO1a" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>March 31</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Unaudited)</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_494_20210101__20210331_zL4A4uv6tP1l" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>March 31</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2021<br/> (Unaudited)</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--OptionsToPurchaseCommonStockMember_z4SQlSsT7MUl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Options to purchase common stock</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">302,500</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0602">&#160;</span></td><td style="width: 14%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsToPurchaseCommonStockMember_znsSoEx839G3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Warrants to purchase common stock</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">2,337,274</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">5,319</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--UnvestedRestrictedCommonStockMember_zpEB40CpS4Wi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Unvested restricted common stock</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">681,270</p></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">1.596,659</p></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_zMyj6yomOmDf" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total anti-dilutive
securities</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,321,044</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,601,978</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A3_zPgPEvpU3XJ6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i/></span><i>&#160;</i></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration</a></td>
<td class="text"><p id="xdx_845_eus-gaap--ConcentrationRiskCreditRisk_zRl8PF0gepF4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_86E_zmpEwVyRDgAc">Concentration</span></span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
is deposited in one financial institution. The balances held at this financial institution at times may be in excess of Federal Deposit
Insurance Corporation (&#8220;FDIC&#8221;) insurance limits of up to $<span id="xdx_904_eus-gaap--CashFDICInsuredAmount_iI_c20220331_zOTm1zFRT8fi" title="FDIC amount">250,000</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has a significant concentration of expenses incurred and accounts payable from a single vendor. Please see Note 4 for further
information.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segments</a></td>
<td class="text"><p id="xdx_848_eus-gaap--SegmentReportingPolicyPolicyTextBlock_z5E8YT2mMjc1" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_860_zfA0RxfMt3ze">Segments</span></span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company determined its reporting units in accordance with ASC 280, &#8220;Segment Reporting&#8221; (&#8220;ASC 280&#8221;). Management
evaluates a reporting unit by first identifying its&#8217; operating segments under ASC 280. The Company then evaluates each operating
segment to determine if it includes one or more components that constitute a business. If there are components within an operating segment
that meet the definition of a business, the Company evaluates those components to determine if they must be aggregated into one or more
reporting units. If applicable, when determining if it is appropriate to aggregate different operating segments, the Company determines
if the segments are economically similar and, if so, the operating segments are aggregated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
has determined that the Company has one  operating segment. The Company&#8217;s reporting segment reflects the manner in
which its chief operating decision maker reviews results and allocates resources. The Company&#8217;s reporting segment meets the definition
of an operating segment and does not include the aggregation of multiple operating segments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><p id="xdx_84B_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zDJDSg8lipo4" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_86D_z8QXODnl6JKc" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Recent
Accounting Pronouncements</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2021, the FASB issued ASU 2021-04, <i>Earnings Per Share (Topic 260), Debt-Modifications and Extinguishments (Subtopic 470-50), Compensation-Stock
Compensation (Topic 718), and Derivatives and Hedging-Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Issuer&#8217;s Accounting
for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options</i>. ASU 2021-04 provides clarification
and reduces diversity in an issuer&#8217;s accounting for modifications or exchanges of freestanding equity-classified written call options
(such as warrants) that remain equity classified after modification or exchange. An issuer measures the effect of a modification or exchange
as the difference between the fair value of the modified or exchanged warrant and the fair value of that warrant immediately before modification
or exchange. ASU 2021-04 introduces a recognition model that comprises four categories of transactions and the corresponding accounting
treatment for each category (equity issuance, debt origination, debt modification, and modifications unrelated to equity issuance and
debt origination or modification). ASU 2021-04 is effective for all entities for fiscal years beginning after December 15, 2021, including
interim periods within those fiscal years. An entity should apply the guidance provided in ASU 2021-04 prospectively to modifications
or exchanges occurring on or after the effective date. Early adoption is permitted for all entities, including adoption in an interim
period. Effective January 1, 2022, we adopted ASU 2021-04 using a prospective approach. It did not have a material impact on the Company&#8217;s
financial statements or disclosures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public
Accountants, and the Securities and Exchange Commission (the &#8220;SEC&#8221;) did not or are not believed by management to have a material
impact on the Company&#8217;s present or future consolidated financial statements.</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_LiquidityPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liquidity Policy [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_LiquidityPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941378&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41620-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41638-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41675-113959<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(n))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579240-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13279-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnusualRisksAndUncertaintiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the nature of the unusual risk or uncertainty, if estimable, such as the threat of expropriation of its assets by a foreign government, rapid technological obsolescence in the industry, risk of natural disaster from earthquake or weather events, and availability of or continuation of a labor force at a reasonable cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnusualRisksAndUncertaintiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140447028129688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Anti-dilutive Securities</a></td>
<td class="text"><p id="xdx_89C_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_z08jlg8yBhpd" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
following common stock equivalents were excluded in the computation of the net loss per share because their effect is anti-dilutive:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BC_z2TePbqZshn8" style="display: none">Schedule of Anti-dilutive Securities</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20220101__20220331_zmOg4YGJwO1a" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>March 31</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Unaudited)</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_494_20210101__20210331_zL4A4uv6tP1l" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>March 31</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2021<br/> (Unaudited)</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--OptionsToPurchaseCommonStockMember_z4SQlSsT7MUl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Options to purchase common stock</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">302,500</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0602">&#160;</span></td><td style="width: 14%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsToPurchaseCommonStockMember_znsSoEx839G3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Warrants to purchase common stock</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">2,337,274</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">5,319</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--UnvestedRestrictedCommonStockMember_zpEB40CpS4Wi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Unvested restricted common stock</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">681,270</p></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">1.596,659</p></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_zMyj6yomOmDf" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total anti-dilutive
securities</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,321,044</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,601,978</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140447028356488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Schedule of Estimated Fair Value of Financial Instrument</a></td>
<td class="text"><p id="xdx_89B_eus-gaap--DebtSecuritiesAvailableForSaleTableTextBlock_zeQohQiV5KW6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
estimated fair values of financial instruments outstanding were (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B0_zINi0pXAkORk" style="display: none">Schedule of Estimated Fair Value of Financial Instrument</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31, 2022 (Unaudited)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Unrealized</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Unrealized</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Fair</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Cost</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Gains</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Losses</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%; text-align: left">Cash and cash equivalents</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pn3n3_c20220331__us-gaap--InvestmentTypeAxis__us-gaap--CashAndCashEquivalentsMember_zNHpxSJr3vjc" style="width: 12%; text-align: right" title="Cost">7,286</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--DebtSecuritiesAvailableForSaleRealizedGain_pn3n3_c20220101__20220331__us-gaap--InvestmentTypeAxis__us-gaap--CashAndCashEquivalentsMember_zA0l0WnF7X5j" style="width: 12%; text-align: right" title="Unrealized gains">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl0627">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--DebtSecuritiesAvailableForSaleRealizedLoss_pn3n3_c20220101__20220331__us-gaap--InvestmentTypeAxis__us-gaap--CashAndCashEquivalentsMember_zzWNzM114vD7" style="width: 12%; text-align: right" title="Unrealized losses">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl0629">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--DebtSecuritiesAvailableForSaleRealizedGainLoss_pn3n3_c20220101__20220331__us-gaap--InvestmentTypeAxis__us-gaap--CashAndCashEquivalentsMember_zI5kxS58pm1b" style="width: 12%; text-align: right" title="Fair value">7,286</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Short-term investments</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pn3n3_c20220331__us-gaap--InvestmentTypeAxis__custom--ShortTermInvestmentMember_zp1sJ9jJAp6c" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cost">19,496</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--DebtSecuritiesAvailableForSaleRealizedGain_pn3n3_c20220101__20220331__us-gaap--InvestmentTypeAxis__custom--ShortTermInvestmentMember_z6JcJF0hjsqj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Unrealized gains"><span style="-sec-ix-hidden: xdx2ixbrl0635">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--DebtSecuritiesAvailableForSaleRealizedLoss_pn3n3_c20220101__20220331__us-gaap--InvestmentTypeAxis__custom--ShortTermInvestmentMember_zc4BCyBuHV2c" style="border-bottom: Black 1.5pt solid; text-align: right" title="Unrealized losses">(42</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--DebtSecuritiesAvailableForSaleRealizedGainLoss_pn3n3_c20220101__20220331__us-gaap--InvestmentTypeAxis__custom--ShortTermInvestmentMember_zObPMSK74Ywc" style="border-bottom: Black 1.5pt solid; text-align: right" title="Fair value">19,454</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pn3n3_c20220331_zpr5X2NKUd03" style="border-bottom: Black 2.5pt double; text-align: right" title="Cost">26,782</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--DebtSecuritiesAvailableForSaleRealizedGain_pn3n3_c20220101__20220331_zfY6KFcS6X0g" style="border-bottom: Black 2.5pt double; text-align: right" title="Unrealized gains"><span style="-sec-ix-hidden: xdx2ixbrl0643">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--DebtSecuritiesAvailableForSaleRealizedLoss_pn3n3_c20220101__20220331_zAugk9I5CE9g" style="border-bottom: Black 2.5pt double; text-align: right" title="Unrealized losses">(42</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--DebtSecuritiesAvailableForSaleRealizedGainLoss_pn3n3_c20220101__20220331_zrbNMYLOql2j" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value">26,740</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Unrealized</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Unrealized</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Fair</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Cost</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Gains</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Losses</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%; text-align: left">Cash and cash equivalents</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pn3n3_c20211231__us-gaap--InvestmentTypeAxis__us-gaap--CashAndCashEquivalentsMember_zUlswoZLTXe5" style="width: 12%; text-align: right" title="Cost">8,968</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--DebtSecuritiesAvailableForSaleRealizedGain_pn3n3_c20210101__20211231__us-gaap--InvestmentTypeAxis__us-gaap--CashAndCashEquivalentsMember_zGH3sKl27OWa" style="width: 12%; text-align: right" title="Unrealized gains">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl0651">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--DebtSecuritiesAvailableForSaleRealizedLoss_pn3n3_c20210101__20211231__us-gaap--InvestmentTypeAxis__us-gaap--CashAndCashEquivalentsMember_zdjO2Rrzkb99" style="width: 12%; text-align: right" title="Unrealized losses">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl0653">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--DebtSecuritiesAvailableForSaleRealizedGainLoss_c20210101__20211231__us-gaap--InvestmentTypeAxis__us-gaap--CashAndCashEquivalentsMember_pn3n3" style="width: 12%; text-align: right" title="Fair value">8,968</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Short-term investments</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_c20211231__us-gaap--InvestmentTypeAxis__custom--ShortTermInvestmentMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cost">23,040</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--DebtSecuritiesAvailableForSaleRealizedGain_pn3n3_c20210101__20211231__us-gaap--InvestmentTypeAxis__custom--ShortTermInvestmentMember_zWVQ6LMxERjj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Unrealized gains"><span style="-sec-ix-hidden: xdx2ixbrl0659">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--DebtSecuritiesAvailableForSaleRealizedLoss_c20210101__20211231__us-gaap--InvestmentTypeAxis__custom--ShortTermInvestmentMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Unrealized losses">(29</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--DebtSecuritiesAvailableForSaleRealizedGainLoss_c20210101__20211231__us-gaap--InvestmentTypeAxis__custom--ShortTermInvestmentMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Fair value">23,011</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_c20211231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Cost">32,008</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--DebtSecuritiesAvailableForSaleRealizedGain_pn3n3_c20210101__20211231_zBqd78pn4Eta" style="border-bottom: Black 2.5pt double; text-align: right" title="Unrealized gains"><span style="-sec-ix-hidden: xdx2ixbrl0667">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--DebtSecuritiesAvailableForSaleRealizedLoss_c20210101__20211231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Unrealized losses">(29</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--DebtSecuritiesAvailableForSaleRealizedGainLoss_pn3n3_c20210101__20211231_zGnGlqfREVqk" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value">31,979</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Schedule of Fair Value Hierarchy Financial Assets</a></td>
<td class="text"><p id="xdx_89E_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_zI3PgrbzMN11" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table represents the Company&#8217;s fair value hierarchy for its financial assets (cash equivalents and investments) (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B5_zDbwwi6g3JC5" style="display: none">Schedule
of Fair Value Hierarchy Financial Assets</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_499_20220331_zxeNbTSQqHAb" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20220331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zEjdov4Uo7Ij" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_492_20220331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z66fYX6UdRsg" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20220331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zLGe7PBAqEml" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31, 2022 (Unaudited)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--FairValueNetAssetLiability_iI_pn3n3_hus-gaap--InvestmentTypeAxis__us-gaap--MoneyMarketFundsMember_zlEFJ7v5qpFe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%; text-align: left">Money market funds</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">6,299</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">6,299</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl0677">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl0678">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--FairValueNetAssetLiability_iI_pn3n3_hus-gaap--InvestmentTypeAxis__custom--CorporateNotesAndCommercialPaperMember_zJ2eGfprqtr1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Corporate notes and commercial paper</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">19,454</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0681">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">19,454</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0683">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--FairValueNetAssetLiability_iI_pn3n3_zbgzUE5eDvBi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt; text-align: left; padding-bottom: 2.5pt">Total financial assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">25,753</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">6,299</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">19,454</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0688">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20211231_zG2l7AhYYoMd" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_493_20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z80spwcHx7p8" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_495_20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zF69jgkUQ4jg" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zqoqfxEs4uib" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--FairValueNetAssetLiability_iI_pn3n3_hus-gaap--InvestmentTypeAxis__us-gaap--MoneyMarketFundsMember_z29ohChGhUsc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%; text-align: left">Money market funds</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">5,484</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">5,484</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl0692">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl0693">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--FairValueNetAssetLiability_iI_pn3n3_hus-gaap--InvestmentTypeAxis__custom--CorporateNotesAndCommercialPaperMember_ztq6kmtGIfi3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Corporate notes and commercial paper</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">23,011</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0696">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">23,011</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0698">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--FairValueNetAssetLiability_iI_pn3n3_zC0E2xpy5qe7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt; text-align: left; padding-bottom: 2.5pt">Total financial assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">28,495</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,484</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">23,011</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0703">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock', window );">Schedule of Derivative Liability Transactions</a></td>
<td class="text"><p id="xdx_89C_eus-gaap--ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_zmExvcUrhL6b" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of March 31, 2022, the fair value of the derivative liability amounted
to $<span id="xdx_900_eus-gaap--DerivativeLiabilitiesCurrent_iI_pn3d_c20220331_z4SbKAkbsnCc"><span id="xdx_905_eus-gaap--DerivativeLiabilitiesCurrent_iI_pn3d_c20210331_zyuayTJ2ZRJb">120,000</span></span>. The details of derivative liability transactions for the three months ended March 31, 2022 and 2021, are as follows:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;<span id="xdx_8B9_zhINUzne4oz7" style="display: none">Schedule
of Derivative Liability Transactions</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b/></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_499_20220101__20220331_zG55aeY08pz1" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_496_20210101__20210331_zeB1f8gQSmw2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Unaudited)</b></span></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Unaudited)</b></span></td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DerivativeLiabilitiesCurrent_iS_pn3d_z0EuE0GkcdC2" style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: left">Beginning balance</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">138,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">383,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--IssuanceOfStockAndWarrantsForServicesOrClaims_pn3d_zIvGR25VX2kk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Fair value upon issuance of warrants</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0710">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0711">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--IncreaseDecreaseInDerivativeLiabilities_pn3d_zuaXPbmfw0h8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Change in fair value</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(18,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(21,000</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_408_ecustom--ExtinguishmentOfWarrants_pn3d_z8LLtwMnJ73a" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Extinguishment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0716">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0717">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--DerivativeLiabilitiesCurrent_iE_pn3d_zW8Qm6sz2bQe" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Ending balance</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">120,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">362,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI https://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19279-110258<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2C<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=SL7498348-110258<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of derivative liabilities at fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140447028104712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Payable (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of Accounts Payable</a></td>
<td class="text"><p id="xdx_89A_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zijFJvpzXUa2" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts
payable consisted of the following (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BA_zhJHGZcTSXc8" style="display: none">Schedule of Accounts Payable</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49C_20220331_zOJxegZvtWFl" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">March 31, <br/>
2022 </td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_498_20211231_zJq5UyUkUPZ1" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><p style="margin-top: 0; margin-bottom: 0">December 31, <br/>
2021</p>
                                                                  <p style="margin-top: 0; margin-bottom: 0"/></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">(Unaudited)</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AccountsPayableRelatedPartiesCurrent_iI_pn3n3_maAPCz7ta_zgaOSxvWmmzg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Accounts payable to a third-party manufacturer</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">7,423</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">6,335</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AccountsPayableOtherCurrent_iI_pn3n3_maAPCz7ta_zzkEUsbFKf46" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left">Other accounts payable</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">690</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,885</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--AccountsPayableCurrent_iTI_pn3n3_mtAPCz7ta_z00cLDEcrAJ3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-align: left">Total accounts payable</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">8,113</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">8,220</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140447028163032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Liability (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_GTBP_DisclosureDerivativeLiabilityAbstract', window );"><strong>Derivative Liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Schedule of Derivative Liabilities Assumptions</a></td>
<td class="text"><p id="xdx_89F_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_zYcz0vlKIxW" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
derivative liabilities were valued using a Binomial pricing model with the following average assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B2_zdAyouL0Qnn4" style="display: none">Schedule
of Derivative Liabilities Assumptions</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">March 31</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December 31</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b/></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">2021</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0"/></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; text-align: center"><b>(Unaudited)</b></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%">Stock Price</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><span id="xdx_904_eus-gaap--SharePrice_iI_pid_c20220331_zTYm3dbo2xX6" title="Stock Price">2.88</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><span id="xdx_90B_eus-gaap--SharePrice_iI_pid_c20211231_z4R4jSPSkTu5" title="Stock Price">3.05</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Risk-free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_909_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20220331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zlyRpeVCVeh1" title="Risk-free interest rate">2.42</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90C_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zVp6pQCz6Owc" title="Risk-free interest rate">1.26</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90A_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20220331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zJ73JYTImDci" title="Expected volatility">127</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90D_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zL20lNqzqNd1" title="Expected volatility">129</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected life (in years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90B_ecustom--DerivativeLiabilityFairValueAssumptionsExpectedTerm1_dtY_c20220101__20220331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zGvKIoyzrawk" title="Expected life (in years)">3.3</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90E_ecustom--DerivativeLiabilityFairValueAssumptionsExpectedTerm1_dtY_c20210101__20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zE2HmJRBFaC1" title="Expected life (in years)">3.6</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Expected dividend yield</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_dp_uPure_c20220331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zfp6Vho0rCQ3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Expected dividend yield"><span style="-sec-ix-hidden: xdx2ixbrl0800">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_dp_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_z4ounqs98iX1" style="border-bottom: Black 1.5pt solid; text-align: right" title="Expected dividend yield"><span style="-sec-ix-hidden: xdx2ixbrl0802">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Fair Value of Warrants</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--FairValueAdjustmentOfWarrants_c20220101__20220331_zVo4G5kPuZi3" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value of warrants">120,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--FairValueAdjustmentOfWarrants_c20210101__20211231_zUYPRxq3FoNh" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value of warrants">138,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_DisclosureDerivativeLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_DisclosureDerivativeLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140447028184056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of Warrant Activity</a></td>
<td class="text"><p id="xdx_894_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_z1QoQDPZe3W6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock
warrant transactions for the three months ended March 31, 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BF_zL76BPA8JD5d" style="display: none">Schedule
of  Warrant Activity</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Weighted Average</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Warrants
</b></span></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Exercise Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%">Outstanding at December 31, 2021:</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20220101__20220331_zmsj6DS0orD9" style="width: 16%; text-align: right" title="Warrants Outstanding,Beginning Balance">2,337,274</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20220101__20220331_z4mRwCIdZ5oh" style="width: 16%; text-align: right" title="Weighted Average Exercise Price, Beginning Balance">5.30</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20220101__20220331_zbM6PbxiHEng" style="text-align: right" title="Number of Warrants, Granted"><span style="-sec-ix-hidden: xdx2ixbrl0899">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue_pid_c20220101__20220331_zWMlhOOt7pG9" style="text-align: right" title="Weighted Average Exercise Price, Granted"><span style="-sec-ix-hidden: xdx2ixbrl0901">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Forfeited/canceled</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeited_iN_pid_di_c20220101__20220331_zJcvJ1Sr3zF5" style="text-align: right" title="Number of Warrants, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl0903">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue_pid_c20220101__20220331_zHF7dlCWyH6b" style="text-align: right" title="Weighted Average Exercise Price, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl0905">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Exercised</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20220101__20220331_zEoGKelxWMke" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Warrants, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl0907">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20220101__20220331_zJhvs1KP25ji" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl0909">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Warrants outstanding at March 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20220101__20220331_zNxAOaFzLKi4" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants Outstanding, Ending Balance">2,337,274</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20220101__20220331_zOiOMdTfCkzf" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Ending Balance">5.30</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Warrants exercisable at March 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable_iI_pid_c20220331_zZkuBvyoStr2" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants Exercisable">2,337,274</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20220331_zXXcxag5t8Eb" style="border-bottom: Black 2.5pt double; text-align: right" title="Exercisable">5.30</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Options Activity</a></td>
<td class="text"><p id="xdx_89C_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zoV3yKJSBuWf" style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock option transactions for the three
months ended March 31, 2022:</span></p>



<p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B9_zbXKwz9p29kb" style="display: none">Schedule
of Options Activity</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Weighted Average</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Exercise Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%">Options outstanding at December 31, 2021:</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20220101__20220331_zgPtBAAs4vk7" style="width: 16%; text-align: right" title="Options outstanding, beginning">302,500</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20220101__20220331_zE8is2UMksP7" style="width: 16%; text-align: right" title="Exercise Price of Warrants or Rights">3.05</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20220101__20220331_zWfdsNbefRzg" style="text-align: right" title="Number of Options, Granted"><span style="-sec-ix-hidden: xdx2ixbrl0925">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20220101__20220331_zCzO2SX6nm6f" style="text-align: right" title="Weighted Average Exercise Price, Granted"><span style="-sec-ix-hidden: xdx2ixbrl0927">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Forfeited/canceled</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_pid_c20220101__20220331_zSaLArFlb7P8" style="text-align: right" title="Number of Options, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl0929">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20220101__20220331_zqEnKSqrIMnh" style="text-align: right" title="Weighted Average Exercise Price, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl0931">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Exercised</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionEquityInstrumentsExercised_pid_c20220101__20220331_zwky8LS3Vypk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Options, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl0933">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20220101__20220331_zqYEMfzBiDXc" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl0935">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Options outstanding at March 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20220101__20220331_zhwZPBmMv7s9" style="border-bottom: Black 2.5pt double; text-align: right" title="Options outstanding, Ending">302,500</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20220101__20220331_zBa7eB8VWFWa" style="border-bottom: Black 2.5pt double; text-align: right" title="Exercise Price of Warrants or Rights">3.05</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Options exercisable at March 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20220331_zkSnJVkHaEY5" style="border-bottom: Black 2.5pt double; text-align: right" title="Options exercisable">111,215</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20220331_zHow2t57AW68" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Exercisable">3.05</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section S99<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140447028499832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_GTBP_ScheduleOfOtherInformationRelatedLeasesUnderNOnCancellableTableTextBlock', window );">Schedule of Other Information Related Leases Under Non-Cancellable</a></td>
<td class="text"><p id="xdx_891_ecustom--ScheduleOfOtherInformationRelatedLeasesUnderNOnCancellableTableTextBlock_zLGVnlqeHhB2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
information related to leases and future minimum lease payments under non-cancellable operating leases were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span><span><span id="xdx_8B1_zfme6KpWNgD8" style="display: none">Schedule of Other Information Related Leases Under Non-Cancellable</span></span>&#160;</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>March 31, 2022</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Unaudited)</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-style: normal; font-weight: normal; text-align: left">Cash paid for amounts included in the measurement of lease liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 82%; text-align: left">Operating cash flows from operating leases</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--OperatingLeasePayments_c20220101__20220331_zOvD28bx9yKi" style="width: 14%; text-align: right" title="Operating cash flows from operating leases">20,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-style: normal; font-weight: normal; text-align: left">Right-of-use assets obtained in exchange for lease liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Operating leases</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_c20220101__20220331_zrJwZZ6jXZO1" style="text-align: right" title="Right of use assets operating leases">260,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-style: normal; font-weight: normal; text-align: left">Weighted-average remaining lease term (in years):</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Operating leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90E_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20220331_ziwy9rtDmqjj" title="Weighted average remaining lease term operating leases">2.5</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-style: normal; font-weight: normal; text-align: left">Weighted-average discount rate:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Operating leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_900_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20220331_zDW9dVBUYrN2" title="Weighted average discount rate operating leases">10</span></td><td style="text-align: left">%</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Future Minimum Lease Payments</a></td>
<td class="text"><p id="xdx_897_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zgOezNxtO318" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future
minimum lease payments under non-cancellable operating leases were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B0_zJPDTRAHFnQc" style="display: none">Schedule
of Future Minimum Lease Payments</span>&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_491_20220331_z6qXdtgac6aa" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>March 31, 2022</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Unaudited)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b/></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_maOLLzd8y_zLQ1XYQeq8Nc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 82%; text-align: left">Within one year</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">90,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maOLLzd8y_zPfQgTZaLSF7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">After one year and within two years</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">122,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maOLLzd8y_zwEDGHHMoiG5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">After two years and within three years</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">65,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_iI_maOLLzd8y_zW30AWZmxwJ3" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Thereafter</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl1023">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--OperatingLeaseLiability_iTI_mtOLLzd8y_zHteqIgSavc2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total future minimum lease payments</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">277,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_zPnXSc3irq71" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Less &#8211; discount</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(30,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_zRs1RhF2rN3i" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Lease liability</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">247,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_ScheduleOfOtherInformationRelatedLeasesUnderNOnCancellableTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of Other Information Related Leases Under Non Cancellable [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_ScheduleOfOtherInformationRelatedLeasesUnderNOnCancellableTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140447025891176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Anti-dilutive Securities (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total anti-dilutive securities</a></td>
<td class="nump">3,321,044<span></span>
</td>
<td class="nump">1,601,978<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=GTBP_OptionsToPurchaseCommonStockMember', window );">Options to Purchase Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total anti-dilutive securities</a></td>
<td class="nump">302,500<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=GTBP_WarrantsToPurchaseCommonStockMember', window );">Warrants to Purchase Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total anti-dilutive securities</a></td>
<td class="nump">2,337,274<span></span>
</td>
<td class="nump">5,319<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=GTBP_UnvestedRestrictedCommonStockMember', window );">Unvested Restricted Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total anti-dilutive securities</a></td>
<td class="nump">681,270<span></span>
</td>
<td class="nump">1,596.659<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=GTBP_OptionsToPurchaseCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=GTBP_OptionsToPurchaseCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=GTBP_WarrantsToPurchaseCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=GTBP_WarrantsToPurchaseCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=GTBP_UnvestedRestrictedCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=GTBP_UnvestedRestrictedCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140447028316008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss) Attributable to Parent</a></td>
<td class="nump">$ 5,440,000<span></span>
</td>
<td class="nump">$ 29,677,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net Cash Provided by (Used in) Operating Activities</a></td>
<td class="nump">5,215,000<span></span>
</td>
<td class="nump">3,684,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_GTBP_CashOnHandAndShortTermInvestment', window );">[custom:CashOnHandAndShortTermInvestment-0]</a></td>
<td class="nump">26,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_GTBP_WorkingCapital', window );">[custom:WorkingCapital-0]</a></td>
<td class="nump">17,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' Equity Attributable to Parent</a></td>
<td class="nump">17,789,000<span></span>
</td>
<td class="nump">24,017,000<span></span>
</td>
<td class="nump">$ 21,910,000<span></span>
</td>
<td class="num">$ (29,433,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsAndCash', window );">Investments and Cash</a></td>
<td class="nump">26,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Total cash equivalents</a></td>
<td class="nump">7,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short term investment</a></td>
<td class="nump">19,454,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,011,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Derivative liability</a></td>
<td class="nump">120,000<span></span>
</td>
<td class="nump">$ 362,000<span></span>
</td>
<td class="nump">138,000<span></span>
</td>
<td class="nump">$ 383,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease, right-of-use asset</a></td>
<td class="nump">237,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease,liability</a></td>
<td class="nump">277,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFDICInsuredAmount', window );">FDIC amount</a></td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=GTBP_OfficeSpaceAndEquipmentMember', window );">Office Space And Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease, right-of-use asset</a></td>
<td class="nump">260,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease,liability</a></td>
<td class="nump">$ 260,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_CashOnHandAndShortTermInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash on hand and short term investment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_CashOnHandAndShortTermInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_WorkingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Working capital</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_WorkingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFDICInsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFDICInsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAndCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of investments and unrestricted cash as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.1,2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAndCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=GTBP_OfficeSpaceAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=GTBP_OfficeSpaceAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140447026239096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Estimated Fair Value of Financial Instrument (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLineItems', window );"><strong>Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">$ 26,782<span></span>
</td>
<td class="nump">$ 32,008<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain', window );">Unrealized gains</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss', window );">Unrealized losses</a></td>
<td class="num">(42)<span></span>
</td>
<td class="num">(29)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss', window );">Fair value</a></td>
<td class="nump">26,740<span></span>
</td>
<td class="nump">31,979<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CashAndCashEquivalentsMember', window );">Cash and Cash Equivalents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLineItems', window );"><strong>Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">7,286<span></span>
</td>
<td class="nump">8,968<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain', window );">Unrealized gains</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss', window );">Unrealized losses</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss', window );">Fair value</a></td>
<td class="nump">7,286<span></span>
</td>
<td class="nump">8,968<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=GTBP_ShortTermInvestmentMember', window );">Short-Term Investments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLineItems', window );"><strong>Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">19,496<span></span>
</td>
<td class="nump">23,040<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain', window );">Unrealized gains</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss', window );">Unrealized losses</a></td>
<td class="num">(42)<span></span>
</td>
<td class="num">(29)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss', window );">Fair value</a></td>
<td class="nump">$ 19,454<span></span>
</td>
<td class="nump">$ 23,011<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleRealizedGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=GTBP_ShortTermInvestmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=GTBP_ShortTermInvestmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140447029280984">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Fair Value Hierarchy Financial Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLineItems', window );"><strong>Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiability', window );">Total financial assets</a></td>
<td class="nump">$ 25,753<span></span>
</td>
<td class="nump">$ 28,495<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLineItems', window );"><strong>Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiability', window );">Total financial assets</a></td>
<td class="nump">6,299<span></span>
</td>
<td class="nump">5,484<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLineItems', window );"><strong>Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiability', window );">Total financial assets</a></td>
<td class="nump">19,454<span></span>
</td>
<td class="nump">23,011<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLineItems', window );"><strong>Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiability', window );">Total financial assets</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLineItems', window );"><strong>Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiability', window );">Total financial assets</a></td>
<td class="nump">6,299<span></span>
</td>
<td class="nump">5,484<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Funds [Member] | Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLineItems', window );"><strong>Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiability', window );">Total financial assets</a></td>
<td class="nump">6,299<span></span>
</td>
<td class="nump">5,484<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Funds [Member] | Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLineItems', window );"><strong>Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiability', window );">Total financial assets</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Funds [Member] | Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLineItems', window );"><strong>Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiability', window );">Total financial assets</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=GTBP_CorporateNotesAndCommercialPaperMember', window );">Corporate Notes and Commercial Paper [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLineItems', window );"><strong>Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiability', window );">Total financial assets</a></td>
<td class="nump">19,454<span></span>
</td>
<td class="nump">23,011<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=GTBP_CorporateNotesAndCommercialPaperMember', window );">Corporate Notes and Commercial Paper [Member] | Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLineItems', window );"><strong>Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiability', window );">Total financial assets</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=GTBP_CorporateNotesAndCommercialPaperMember', window );">Corporate Notes and Commercial Paper [Member] | Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLineItems', window );"><strong>Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiability', window );">Total financial assets</a></td>
<td class="nump">19,454<span></span>
</td>
<td class="nump">23,011<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=GTBP_CorporateNotesAndCommercialPaperMember', window );">Corporate Notes and Commercial Paper [Member] | Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLineItems', window );"><strong>Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiability', window );">Total financial assets</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueNetAssetLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of asset after deduction of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueNetAssetLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=GTBP_CorporateNotesAndCommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=GTBP_CorporateNotesAndCommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140447029179144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Derivative Liability Transactions (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Beginning balance</a></td>
<td class="nump">$ 138<span></span>
</td>
<td class="nump">$ 383<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims', window );">Fair value upon issuance of warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDerivativeLiabilities', window );">Change in fair value</a></td>
<td class="num">(18)<span></span>
</td>
<td class="num">(21)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_GTBP_ExtinguishmentOfWarrants', window );">Extinguishment</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Ending balance</a></td>
<td class="nump">$ 120<span></span>
</td>
<td class="nump">$ 362<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_ExtinguishmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_ExtinguishmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the carrying value of derivative instruments reported as liabilities that are due to be disposed of within one year (or the normal operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140447029227320">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Accounts Payable (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableRelatedPartiesCurrent', window );">Accounts payable to a third-party manufacturer</a></td>
<td class="nump">$ 7,423<span></span>
</td>
<td class="nump">$ 6,335<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableOtherCurrent', window );">Other accounts payable</a></td>
<td class="nump">690<span></span>
</td>
<td class="nump">1,885<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Total accounts payable</a></td>
<td class="nump">$ 8,113<span></span>
</td>
<td class="nump">$ 8,220<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableOtherCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableOtherCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount for accounts payable to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140447028692184">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accounts Payable (Details Narrative) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable current</a></td>
<td class="nump">$ 8,113<span></span>
</td>
<td class="nump">$ 8,220<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=GTBP_VendorMember', window );">Vendor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable current</a></td>
<td class="nump">$ 7,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=GTBP_VendorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=GTBP_VendorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140447023345464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Notes Payable (Details Narrative) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 16, 2021</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jun. 23, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Converted conversion of common stock</a></td>
<td class="nump">11,413,322<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,086,024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayable', window );">Convertible notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Debt converted amount</a></td>
<td class="nump">$ 38.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_GTBP_ConvertibleNotesPayableIssuedInExchangeForConsultingServices', window );">Notes payable in exchange of consulting services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_GTBP_AccruedInterestAmount', window );">Accrued interest amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentRate', window );">Debt conversion rate</a></td>
<td class="nump">3.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Conversion of common stock</a></td>
<td class="nump">1,627,440<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=GTBP_ForbearanceAgreementsMember', window );">Forbearance Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price per share</a></td>
<td class="nump">$ 3.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Converted conversion of common stock</a></td>
<td class="nump">1,132,059<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=GTBP_ConsultingAgreementsMember', window );">Consulting Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price per share</a></td>
<td class="nump">$ 3.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Converted conversion of common stock</a></td>
<td class="nump">472,059<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Debt converted amount</a></td>
<td class="nump">$ 1.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=GTBP_NotesPayableIssuedForForbearanceAgreementMember', window );">Notes Payable Issued For Forbearance Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Debt converted amount</a></td>
<td class="nump">$ 3.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardDateAxis=GTBP_AuguestOneTwentyEighteenAndJanuaryTwentySixTwentyTwentyOneMember', window );">August 1, 2018 and January 26, 2021 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayableCurrent', window );">Convertible notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price per share</a></td>
<td class="nump">$ 3.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Converted conversion of common stock</a></td>
<td class="nump">7,438,235<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardDateAxis=GTBP_FiscalTwentyNinteenandTwentyTwentyMember', window );">Fiscal 2019 and 2020 [Member] | Notes Payable Issued For Settlement Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price per share</a></td>
<td class="nump">$ 3.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Converted conversion of common stock</a></td>
<td class="nump">743,529<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardDateAxis=GTBP_DuringTwentyTwentyMember', window );">During 2020 [Member] | Adoption of ASU 2020-06 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature', window );">Beneficial conversion feature</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_GTBP_InterestExpenseDueAmortizationOfDebtDiscount', window );">Interest expense due amortization of debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardDateAxis=GTBP_JanuaryOneTwentyTwentyOneMember', window );">January 1, 2021 [Member] | Adoption of ASU 2020-06 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature', window );">Beneficial conversion feature</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Unamortized debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_AccruedInterestAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued interest amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_AccruedInterestAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_ConvertibleNotesPayableIssuedInExchangeForConsultingServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Convertible notes payable issued in exchange for consulting services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_ConvertibleNotesPayableIssuedInExchangeForConsultingServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_InterestExpenseDueAmortizationOfDebtDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest expense due amortization of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_InterestExpenseDueAmortizationOfDebtDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120401414&amp;loc=d3e603758-122996<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleNotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Dividend or interest rate associated with the financial instrument issued in exchange for the original debt being converted in a noncash or part noncash transaction. Noncash are transactions that affect recognized assets or liabilities but that do not result in cash receipts or cash payments. Part noncash refers to that portion of the transaction not resulting in cash receipts or cash payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of a favorable spread to a debt holder between the amount of debt being converted and the value of the securities received upon conversion. This is an embedded conversion feature of convertible debt issued that is in-the-money at the commitment date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21538-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031898-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=GTBP_ForbearanceAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=GTBP_ForbearanceAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=GTBP_ConsultingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=GTBP_ConsultingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=GTBP_NotesPayableIssuedForForbearanceAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=GTBP_NotesPayableIssuedForForbearanceAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=GTBP_AuguestOneTwentyEighteenAndJanuaryTwentySixTwentyTwentyOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=GTBP_AuguestOneTwentyEighteenAndJanuaryTwentySixTwentyTwentyOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=GTBP_FiscalTwentyNinteenandTwentyTwentyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=GTBP_FiscalTwentyNinteenandTwentyTwentyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=GTBP_NotesPayableIssuedForSettlementAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=GTBP_NotesPayableIssuedForSettlementAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=GTBP_DuringTwentyTwentyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=GTBP_DuringTwentyTwentyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=GTBP_AdoptionofAsuTwentyTwentyZeroSixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=GTBP_AdoptionofAsuTwentyTwentyZeroSixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=GTBP_JanuaryOneTwentyTwentyOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=GTBP_JanuaryOneTwentyTwentyOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140447027110168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Derivative Liabilities Assumptions (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Stock Price | $ / shares</a></td>
<td class="nump">$ 2.88<span></span>
</td>
<td class="nump">$ 3.05<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value of warrants | $</a></td>
<td class="nump">$ 120,000<span></span>
</td>
<td class="nump">$ 138,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Measurement Input, Risk Free Interest Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Expected dividend yield</a></td>
<td class="nump">2.42<span></span>
</td>
<td class="nump">1.26<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Measurement Input, Price Volatility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Expected dividend yield</a></td>
<td class="nump">127<span></span>
</td>
<td class="nump">129<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Measurement Input, Expected Term [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_GTBP_DerivativeLiabilityFairValueAssumptionsExpectedTerm1', window );">Expected life (in years)</a></td>
<td class="text">3 years 3 months 18 days<span></span>
</td>
<td class="text">3 years 7 months 6 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember', window );">Measurement Input, Expected Dividend Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Expected dividend yield</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_DerivativeLiabilityFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Derivative liability fair value assumptions expected term 1.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_DerivativeLiabilityFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure derivative liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140447028086520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Liability (Details Narrative)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_GTBP_DisclosureDerivativeLiabilityAbstract', window );"><strong>Derivative Liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainOnDerivative', window );">Derivative, Gain on Derivative</a></td>
<td class="nump">$ 18,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_DisclosureDerivativeLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_DisclosureDerivativeLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainOnDerivative">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainOnDerivative</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140447029222904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Warrant Activity (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Warrants Outstanding,Beginning Balance | shares</a></td>
<td class="nump">2,337,274<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Beginning Balance | $ / shares</a></td>
<td class="nump">$ 5.30<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Number of Warrants, Granted | shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue', window );">Weighted Average Exercise Price, Granted | $ / shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeited', window );">Number of Warrants, Forfeited | shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue', window );">Weighted Average Exercise Price, Forfeited | $ / shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Number of Warrants, Exercised | shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_GTBP_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercised | $ / shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Warrants Outstanding, Ending Balance | shares</a></td>
<td class="nump">2,337,274<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Ending Balance | $ / shares</a></td>
<td class="nump">$ 5.30<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable', window );">Warrants Exercisable | shares</a></td>
<td class="nump">2,337,274<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable | $ / shares</a></td>
<td class="nump">$ 5.30<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangements By Share Based Payment Award Non Options Equity Instruments Exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangements By Share Based Payment Award Non Options Equity Instruments Forfeited</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By ShareBased Payment Award Non Options Exercisable Weighted Average Exercise Price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangements by share based payment award non options outstanding weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangements By Share Based Paymen tAward Non Options Exercises In Period Weighted Average Exercise Price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average intrinsic value of award forfeited under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average intrinsic value of award granted under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of non-option equity instruments exercised by participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of non-option equity instruments granted to participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of equity instruments other than options outstanding, including both vested and non-vested instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140447026011736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Options Activity (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding, beginning | shares</a></td>
<td class="nump">302,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise Price of Warrants or Rights | $ / shares</a></td>
<td class="nump">$ 3.05<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Number of Options, Granted | shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Granted | $ / shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares', window );">Number of Options, Forfeited | shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Forfeited | $ / shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionEquityInstrumentsExercised', window );">Number of Options, Exercised | shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercised | $ / shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding, Ending | shares</a></td>
<td class="nump">302,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise Price of Warrants or Rights | $ / shares</a></td>
<td class="nump">$ 3.05<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options exercisable | shares</a></td>
<td class="nump">111,215<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Options Exercisable | $ / shares</a></td>
<td class="nump">$ 3.05<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionEquityInstrumentsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award Option Equity Instruments Exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionEquityInstrumentsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140447022154952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 16, 2021</div></th>
<th class="th"><div>Feb. 15, 2021</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">750,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">750,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Debt Conversion, Converted Instrument, Amount</a></td>
<td class="nump">$ 38,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Debt Conversion, Converted Instrument, Shares Issued</a></td>
<td class="nump">11,413,322<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,086,024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Shares issued</a></td>
<td class="nump">2,850,090<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,957,374<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock Issued During Period, Value, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Common shares cancelled and returned</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">290,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vested period</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_GTBP_CommonStockSharesGrantedForConsultants', window );">Common stock shares granted for consultants</a></td>
<td class="nump">4,379,407<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_GTBP_FairValueOfStockOptionsGrantedForConsultants', window );">Fair value of stock options granted f0r consultants</a></td>
<td class="nump">$ 18,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_GTBP_CommonStockConsultantToFairValue', window );">Common stock consultant to fair value</a></td>
<td class="nump">$ 10,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested shares</a></td>
<td class="nump">1,934,817<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Remaining vested shares</a></td>
<td class="nump">915,273<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_GTBP_NumberofsharesUnvestedOptions', window );">Number of shares unvested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">191,285<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_GTBP_NumberofValueUnvestedOptions', window );">Number of shares unvested, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">511,115<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Options outstanding intrinsic value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=GTBP_SeriesCPreferredStocksMember', window );">Series C Preferred Stocks [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96,230<span></span>
</td>
<td class="nump">96,230<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96,230<span></span>
</td>
<td class="nump">96,230<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=GTBP_SeriesKPreferredStocksMember', window );">Series K Preferred Stocks [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Preferred stock shares designated</a></td>
<td class="nump">115,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleSharesIssuable', window );">Convertible shares issuable</a></td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember', window );">Chief Executive Officer [Member] | Employment Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_ChiefFinancialOfficerMember', window );">Chief Financial Officer [Member] | Employment Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_DirectorMember', window );">Director [Member] | Employment Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription', window );">Share-based Compensation Arrangement by Share-based Payment Award, Description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Pursuant
to the agreement, approximately 33% of the common stock to be issued vested immediately while the remaining<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_DirectorMember', window );">Director [Member] | Employment Agreements [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_DirectorMember', window );">Director [Member] | Employment Agreements [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=GTBP_EmployeesMember', window );">Employees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 447,000<span></span>
</td>
<td class="nump">$ 14,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=GTBP_OfficersEmployeesAndBoardOfDirectorsMember', window );">Officers Employees And Board Of Directors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedTounVestOutstandingNumber', window );">[custom:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedTounVestOutstandingNumber-0]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">291,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToUnVestOutstandingAggregateIntrinsicValue', window );">[custom:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToUnVestOutstandingAggregateIntrinsicValue-0]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=GTBP_ConsultingMember', window );">Consultings [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 872,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedTounVestOutstandingNumber', window );">[custom:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedTounVestOutstandingNumber-0]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">389,570<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToUnVestOutstandingAggregateIntrinsicValue', window );">[custom:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToUnVestOutstandingAggregateIntrinsicValue-0]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">116,247<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=GTBP_CommonStockIssuableMember', window );">Common Stock Issuable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">327,298<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock Issued During Period, Value, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_CommonStockConsultantToFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common Stock Consultant To Fair Value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_CommonStockConsultantToFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_CommonStockSharesGrantedForConsultants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock shares granted for consultants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_CommonStockSharesGrantedForConsultants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_FairValueOfStockOptionsGrantedForConsultants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value Of Stock Options Granted For Consultants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_FairValueOfStockOptionsGrantedForConsultants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_NumberofValueUnvestedOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of value unvested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_NumberofValueUnvestedOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_NumberofsharesUnvestedOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares unvested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_NumberofsharesUnvestedOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToUnVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To unvest Outstanding Aggregate Intrinsic Value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToUnVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedTounVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected to unvest Outstanding Number.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedTounVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConvertibleSharesIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common shares issuable upon conversion of preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConvertibleSharesIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of terms of share-based payment arrangement. Includes, but is not limited to, type of award or grantee and reason for issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased and retired during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=GTBP_SeriesCPreferredStocksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=GTBP_SeriesCPreferredStocksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=GTBP_SeriesKPreferredStocksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=GTBP_SeriesKPreferredStocksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=GTBP_EmploymentAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=GTBP_EmploymentAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefFinancialOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefFinancialOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=GTBP_EmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=GTBP_EmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=GTBP_OfficersEmployeesAndBoardOfDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=GTBP_OfficersEmployeesAndBoardOfDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=GTBP_ConsultingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=GTBP_ConsultingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=GTBP_CommonStockIssuableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=GTBP_CommonStockIssuableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140447026077048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Other Information Related Leases Under Non-Cancellable (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows from operating leases</a></td>
<td class="nump">$ 20,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right of use assets operating leases</a></td>
<td class="nump">$ 260,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term operating leases</a></td>
<td class="text">2 years 6 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate operating leases</a></td>
<td class="nump">10.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140447025908408">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Future Minimum Lease Payments (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">Within one year</a></td>
<td class="nump">$ 90,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">After one year and within two years</a></td>
<td class="nump">122,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">After two years and within three years</a></td>
<td class="nump">65,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total future minimum lease payments</a></td>
<td class="nump">277,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less &#8211; discount</a></td>
<td class="num">(30,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Lease liability</a></td>
<td class="nump">$ 247,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140447023197064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details Narrative)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Feb. 07, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 19, 2021 </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Mar. 26, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Oct. 05, 2020</div></th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">Litigation settlement expense</a></td>
<td class="nump">$ 425,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_GTBP_ProjectFee', window );">Project fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,100,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_GTBP_RecordedExpenses', window );">Recorded expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsDescription', window );">Other commitments, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">On
October 5, 2020, GT Biopharma entered into a Master Services Agreement with a third-party product manufacturer to perform biologic development
and manufacturing services on behalf of the Company. Associated with this, the Company has subsequently signed five Statements of Work
for the research and development of products for use in clinical trials. At March 31 2022, the Company&#8217;s commitments in relation
to these Statements of Work and any related Change Orders totaled approximately $13.0 million, of which $8.4 million was incurred at
that date and an additional $4.6 million is in process during fiscal year 2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRent', window );">Rent expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=GTBP_AimmuneTherapeuticsIncMember', window );">Aimmune Therapeutics Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfLand', window );">Area of land | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingSubleaseOptionToExtend', window );">Commencement date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">commencement
date of January 1, 2022 and maturing on June 30, 2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=GTBP_MasterServicesAgreementMember', window );">Master Services Agreement [Member] | Cytovance Biologics, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_GTBP_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurred', window );">Commitment amount for services, total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,000,000.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross', window );">Commitment cost incurred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,400,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_GTBP_ResearchAndDevelopmentArrangementContractToPerformExpectedCostsIncurred', window );">Compensation cost expected to be incurred in future</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,600,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=GTBP_TwoThousandSixteenPatentLicenseAgreementMember', window );">2016 Patent License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_GTBP_ProceedsFromUpfrontAmount', window );">Received upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_GTBP_AnnualMaintananceFee', window );">Annual maintanance fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_GTBP_RoyaltyFeePercentage', window );">[custom:RoyaltyFeePercentage]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.04<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_GTBP_PerformanceMilestonePayments', window );">Performance milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,100,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_GTBP_SalesMilestonePayments', window );">Sales milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_GTBP_GrossSales', window );">Gross sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_GTBP_SalesRevenue', window );">Sales revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_GTBP_CummulativeGrossSales', window );">Cummulative gross sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=GTBP_TwoThousandSixteenPatentLicenseAgreementMember', window );">2016 Patent License Agreement [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_GTBP_AnnualRoyaltyPayments', window );">Annual royalty payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=GTBP_TwoThousandSixteenPatentLicenseAgreementMember', window );">2016 Patent License Agreement [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_GTBP_AnnualRoyaltyPayments', window );">Annual royalty payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=GTBP_TwoThousandAndTwentyOnePatentLicenseAgreementMember', window );">2021 Patent License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_GTBP_AnnualRoyaltyPayments', window );">Annual royalty payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_GTBP_PerformanceMilestonePayments', window );">Performance milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,100,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_GTBP_SalesMilestonePayments', window );">Sales milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_GTBP_GrossSales', window );">Gross sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_GTBP_SalesRevenue', window );">Sales revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_GTBP_CummulativeGrossSales', window );">Cummulative gross sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_GTBP_UpfrontLicenseFee', window );">Upfront license fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_GTBP_LicenseMaintenanceFeeReceivable', window );">License maintenance fee, receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_GTBP_MaintananceFee', window );">Maintanance fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=GTBP_TwoThousandAndTwentyOnePatentLicenseAgreementMember', window );">2021 Patent License Agreement [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_GTBP_NetSalesPercentage', window );">Net sales percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.025<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=GTBP_TwoThousandAndTwentyOnePatentLicenseAgreementMember', window );">2021 Patent License Agreement [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_GTBP_NetSalesPercentage', window );">Net sales percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.05<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_AnnualMaintananceFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Annual maintanance fee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_AnnualMaintananceFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_AnnualRoyaltyPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Annual royalty payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_AnnualRoyaltyPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_CummulativeGrossSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cummulative gross sales.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_CummulativeGrossSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_GrossSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross sales.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_GrossSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_LicenseMaintenanceFeeReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License maintenance fee, receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_LicenseMaintenanceFeeReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_MaintananceFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maintanance fee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_MaintananceFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_NetSalesPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net sales percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_NetSalesPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_PerformanceMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Performance milestone payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_PerformanceMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_ProceedsFromUpfrontAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Received upfront payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_ProceedsFromUpfrontAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_ProjectFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Project fee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_ProjectFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_RecordedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Recorded expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_RecordedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_ResearchAndDevelopmentArrangementContractToPerformExpectedCostsIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Compensation cost expected to be incurred in future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_ResearchAndDevelopmentArrangementContractToPerformExpectedCostsIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and development arrangement contract to perform for others costs incurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_RoyaltyFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty fee percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_RoyaltyFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_SalesMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sales milestone payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_SalesMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_SalesRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sales revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_SalesRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_UpfrontLicenseFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront license fee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_UpfrontLicenseFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfLand">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area of land held.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfLand</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingSubleaseOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of terms and conditions of option to extend operating sublease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingSubleaseOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the nature and terms of commitment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash payments to lessor's for use of assets under operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of costs incurred under a research and development arrangement accounted for as a contract to perform research and development for others.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23221-108380<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23199-108380<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=GTBP_AimmuneTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=GTBP_AimmuneTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=GTBP_MasterServicesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=GTBP_MasterServicesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=GTBP_CytovanceBiologicsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=GTBP_CytovanceBiologicsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=GTBP_TwoThousandSixteenPatentLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=GTBP_TwoThousandSixteenPatentLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=GTBP_TwoThousandAndTwentyOnePatentLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=GTBP_TwoThousandAndTwentyOnePatentLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140447028209656">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Subsequent Events (Details Narrative)<br></strong></div></th>
<th class="th">
<div>Apr. 29, 2022 </div>
<div>shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Chief Executive Officer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Number of shares received</a></td>
<td class="nump">1,845,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>form10-q_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:GTBP="http://gtbiopharma.com/20220331"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="gtbp-20220331.xsd" xlink:type="simple"/>
    <context id="From2022-01-01to2022-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-05-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
        </entity>
        <period>
            <instant>2022-05-16</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_SeriesCPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_SeriesCPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2021-01-012021-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_custom_OfficersAndDirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">GTBP:OfficersAndDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-03-31_custom_OfficersAndDirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">GTBP:OfficersAndDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_CommonSharesIssuableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GTBP:CommonSharesIssuableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_CommonSharesIssuableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GTBP:CommonSharesIssuableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_custom_CommonSharesIssuableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GTBP:CommonSharesIssuableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-03-31_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-03-31_custom_CommonSharesIssuableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GTBP:CommonSharesIssuableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_custom_CommonSharesIssuableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GTBP:CommonSharesIssuableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31_custom_CommonSharesIssuableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GTBP:CommonSharesIssuableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_custom_OfficeSpaceAndEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">GTBP:OfficeSpaceAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_custom_OptionsToPurchaseCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">GTBP:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-03-31_custom_OptionsToPurchaseCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">GTBP:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_custom_WarrantsToPurchaseCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">GTBP:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-03-31_custom_WarrantsToPurchaseCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">GTBP:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_custom_UnvestedRestrictedCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">GTBP:UnvestedRestrictedCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-03-31_custom_UnvestedRestrictedCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">GTBP:UnvestedRestrictedCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_CashAndCashEquivalentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_us-gaap_CashAndCashEquivalentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-03-31_custom_ShortTermInvestmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">GTBP:ShortTermInvestmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_custom_ShortTermInvestmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">GTBP:ShortTermInvestmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_CashAndCashEquivalentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_CashAndCashEquivalentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_ShortTermInvestmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">GTBP:ShortTermInvestmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_ShortTermInvestmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">GTBP:ShortTermInvestmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_MoneyMarketFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_FairValueInputsLevel1Member_us-gaap_MoneyMarketFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_FairValueInputsLevel2Member_us-gaap_MoneyMarketFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_FairValueInputsLevel3Member_us-gaap_MoneyMarketFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_custom_CorporateNotesAndCommercialPaperMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">GTBP:CorporateNotesAndCommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_FairValueInputsLevel1Member_custom_CorporateNotesAndCommercialPaperMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">GTBP:CorporateNotesAndCommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_FairValueInputsLevel2Member_custom_CorporateNotesAndCommercialPaperMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">GTBP:CorporateNotesAndCommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_FairValueInputsLevel3Member_custom_CorporateNotesAndCommercialPaperMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">GTBP:CorporateNotesAndCommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_MoneyMarketFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_MoneyMarketFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_MoneyMarketFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_MoneyMarketFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_CorporateNotesAndCommercialPaperMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">GTBP:CorporateNotesAndCommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel1Member_custom_CorporateNotesAndCommercialPaperMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">GTBP:CorporateNotesAndCommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel2Member_custom_CorporateNotesAndCommercialPaperMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">GTBP:CorporateNotesAndCommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_custom_CorporateNotesAndCommercialPaperMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">GTBP:CorporateNotesAndCommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_custom_VendorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">GTBP:VendorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_custom_AuguestOneTwentyEighteenAndJanuaryTwentySixTwentyTwentyOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">GTBP:AuguestOneTwentyEighteenAndJanuaryTwentySixTwentyTwentyOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-02-16_custom_AuguestOneTwentyEighteenAndJanuaryTwentySixTwentyTwentyOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">GTBP:AuguestOneTwentyEighteenAndJanuaryTwentySixTwentyTwentyOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-16</instant>
        </period>
    </context>
    <context id="From2021-02-152021-02-16_custom_AuguestOneTwentyEighteenAndJanuaryTwentySixTwentyTwentyOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">GTBP:AuguestOneTwentyEighteenAndJanuaryTwentySixTwentyTwentyOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-15</startDate>
            <endDate>2021-02-16</endDate>
        </period>
    </context>
    <context id="AsOf2019-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-02-16_custom_NotesPayableIssuedForSettlementAgreementsMember_custom_FiscalTwentyNinteenandTwentyTwentyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">GTBP:FiscalTwentyNinteenandTwentyTwentyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:NotesPayableIssuedForSettlementAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-16</instant>
        </period>
    </context>
    <context id="From2021-02-152021-02-16_custom_NotesPayableIssuedForSettlementAgreementsMember_custom_FiscalTwentyNinteenandTwentyTwentyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">GTBP:FiscalTwentyNinteenandTwentyTwentyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:NotesPayableIssuedForSettlementAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-15</startDate>
            <endDate>2021-02-16</endDate>
        </period>
    </context>
    <context id="AsOf2020-06-23_custom_ForbearanceAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:ForbearanceAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-23</instant>
        </period>
    </context>
    <context id="From2021-02-152021-02-16_custom_NotesPayableIssuedForForbearanceAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:NotesPayableIssuedForForbearanceAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-15</startDate>
            <endDate>2021-02-16</endDate>
        </period>
    </context>
    <context id="AsOf2021-02-16_custom_ForbearanceAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:ForbearanceAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-16</instant>
        </period>
    </context>
    <context id="From2021-02-152021-02-16_custom_ForbearanceAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:ForbearanceAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-15</startDate>
            <endDate>2021-02-16</endDate>
        </period>
    </context>
    <context id="From2021-02-152021-02-16_custom_ConsultingAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:ConsultingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-15</startDate>
            <endDate>2021-02-16</endDate>
        </period>
    </context>
    <context id="AsOf2021-02-16_custom_ConsultingAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:ConsultingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-16</instant>
        </period>
    </context>
    <context id="From2021-02-152021-02-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
        </entity>
        <period>
            <startDate>2021-02-15</startDate>
            <endDate>2021-02-16</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_AdoptionofAsuTwentyTwentyZeroSixMember_custom_DuringTwentyTwentyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">GTBP:DuringTwentyTwentyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:AdoptionofAsuTwentyTwentyZeroSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_custom_AdoptionofAsuTwentyTwentyZeroSixMember_custom_JanuaryOneTwentyTwentyOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">GTBP:JanuaryOneTwentyTwentyOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:AdoptionofAsuTwentyTwentyZeroSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-03-31_custom_AdoptionofAsuTwentyTwentyZeroSixMember_custom_DuringTwentyTwentyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">GTBP:DuringTwentyTwentyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:AdoptionofAsuTwentyTwentyZeroSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_custom_AdoptionofAsuTwentyTwentyZeroSixMember_custom_JanuaryOneTwentyTwentyOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">GTBP:JanuaryOneTwentyTwentyOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:AdoptionofAsuTwentyTwentyZeroSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_MeasurementInputRiskFreeInterestRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_MeasurementInputPriceVolatilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_MeasurementInputPriceVolatilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_us-gaap_MeasurementInputExpectedTermMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_MeasurementInputExpectedTermMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_MeasurementInputExpectedDividendRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_MeasurementInputExpectedDividendRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_CommonStockIssuableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GTBP:CommonStockIssuableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_custom_CommonStockIssuableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GTBP:CommonStockIssuableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_srt_ChiefExecutiveOfficerMember_custom_EmploymentAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:EmploymentAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_srt_ChiefFinancialOfficerMember_custom_EmploymentAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:EmploymentAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_srt_DirectorMember_custom_EmploymentAgreementsMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:EmploymentAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_srt_DirectorMember_custom_EmploymentAgreementsMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:EmploymentAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_custom_EmploymentAgreementsMember_srt_DirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:EmploymentAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-03-31_custom_EmployeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">GTBP:EmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_custom_EmployeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">GTBP:EmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-03-31_custom_OfficersEmployeesAndBoardOfDirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">GTBP:OfficersEmployeesAndBoardOfDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="From2021-02-152021-02-15_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-15</startDate>
            <endDate>2021-02-15</endDate>
        </period>
    </context>
    <context id="From2021-02-152021-02-15_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-15</startDate>
            <endDate>2021-02-15</endDate>
        </period>
    </context>
    <context id="AsOf2021-02-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
        </entity>
        <period>
            <instant>2021-02-16</instant>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_custom_ConsultingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">GTBP:ConsultingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-03-31_custom_ConsultingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">GTBP:ConsultingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_custom_SeriesCPreferredStocksMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">GTBP:SeriesCPreferredStocksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31_custom_SeriesCPreferredStocksMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">GTBP:SeriesCPreferredStocksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="From2021-02-152021-02-16_custom_SeriesKPreferredStocksMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">GTBP:SeriesKPreferredStocksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-15</startDate>
            <endDate>2021-02-16</endDate>
        </period>
    </context>
    <context id="AsOf2021-02-16_custom_SeriesKPreferredStocksMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">GTBP:SeriesKPreferredStocksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-16</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_custom_SeriesKPreferredStocksMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">GTBP:SeriesKPreferredStocksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_SeriesKPreferredStocksMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">GTBP:SeriesKPreferredStocksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2022-02-062022-02-07">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
        </entity>
        <period>
            <startDate>2022-02-06</startDate>
            <endDate>2022-02-07</endDate>
        </period>
    </context>
    <context id="From2020-10-012020-10-05">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-05</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_custom_MasterServicesAgreementMember_custom_CytovanceBiologicsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:MasterServicesAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">GTBP:CytovanceBiologicsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-03-31_custom_TwoThousandSixteenPatentLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandSixteenPatentLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_custom_TwoThousandSixteenPatentLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandSixteenPatentLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_srt_MinimumMember_custom_TwoThousandSixteenPatentLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandSixteenPatentLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_srt_MaximumMember_custom_TwoThousandSixteenPatentLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandSixteenPatentLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2021-03-252021-03-26_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandAndTwentyOnePatentLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-25</startDate>
            <endDate>2021-03-26</endDate>
        </period>
    </context>
    <context id="AsOf2022-03-31_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandAndTwentyOnePatentLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_srt_MinimumMember_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandAndTwentyOnePatentLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_srt_MaximumMember_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandAndTwentyOnePatentLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandAndTwentyOnePatentLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-11-19_custom_AimmuneTherapeuticsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">GTBP:AimmuneTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-19</instant>
        </period>
    </context>
    <context id="From2021-11-182021-11-19_custom_AimmuneTherapeuticsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">GTBP:AimmuneTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-18</startDate>
            <endDate>2021-11-19</endDate>
        </period>
    </context>
    <context id="From2022-04-282022-04-29_us-gaap_SubsequentEventMember_srt_ChiefExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-28</startDate>
            <endDate>2022-04-29</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <unit id="Sqft">
        <measure>utr:sqft</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2022-01-01to2022-03-31">0000109657</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2022-01-01to2022-03-31">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus contextRef="From2022-01-01to2022-03-31">2022</dei:DocumentFiscalYearFocus>
    <dei:CurrentFiscalYearEndDate contextRef="From2022-01-01to2022-03-31">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalPeriodFocus contextRef="From2022-01-01to2022-03-31">Q1</dei:DocumentFiscalPeriodFocus>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2021-12-31"
      id="xdx2ixbrl0060"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DepositsAssetsNoncurrent
      contextRef="AsOf2021-12-31"
      id="xdx2ixbrl0063"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2021-12-31"
      id="xdx2ixbrl0081"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2021-12-31"
      id="xdx2ixbrl0090"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2022-03-31"
      id="xdx2ixbrl0113"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2021-12-31"
      id="xdx2ixbrl0114"
      unitRef="USD"
      xsi:nil="true"/>
    <GTBP:CommonStockIssuable
      contextRef="AsOf2022-03-31"
      id="xdx2ixbrl0133"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:Revenues
      contextRef="From2022-01-01to2022-03-31"
      id="xdx2ixbrl0152"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:Revenues
      contextRef="From2021-01-012021-03-31"
      id="xdx2ixbrl0153"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2021-01-012021-03-31"
      id="xdx2ixbrl0173"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InterestExpenseDebtExcludingAmortization
      contextRef="From2022-01-01to2022-03-31"
      id="xdx2ixbrl0175"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="From2021-01-012021-03-31"
      id="xdx2ixbrl0182"
      unitRef="USD"
      xsi:nil="true"/>
    <GTBP:StockIssuedDuringPeriodValueCancellation
      contextRef="From2022-01-012022-03-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0209"
      unitRef="USD"
      xsi:nil="true"/>
    <GTBP:StockIssuedDuringPeriodValueCancellation
      contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0210"
      unitRef="USD"
      xsi:nil="true"/>
    <GTBP:StockIssuedDuringPeriodValueCancellation
      contextRef="From2022-01-012022-03-31_custom_CommonSharesIssuableMember"
      id="xdx2ixbrl0211"
      unitRef="USD"
      xsi:nil="true"/>
    <GTBP:StockIssuedDuringPeriodValueCancellation
      contextRef="From2022-01-012022-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0212"
      unitRef="USD"
      xsi:nil="true"/>
    <GTBP:StockIssuedDuringPeriodValueCancellation
      contextRef="From2022-01-012022-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0213"
      unitRef="USD"
      xsi:nil="true"/>
    <GTBP:StockIssuedDuringPeriodValueCancellation
      contextRef="From2022-01-01to2022-03-31"
      id="xdx2ixbrl0214"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2022-01-012022-03-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0218"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0219"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2022-01-012022-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0222"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2022-01-01to2022-03-31"
      id="xdx2ixbrl0223"
      unitRef="USD"
      xsi:nil="true"/>
    <GTBP:StockIssuedDuringPeriodValueEquityCompensationToOfficersAndBoardOfDirectors
      contextRef="From2022-01-012022-03-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0228"
      unitRef="USD"
      xsi:nil="true"/>
    <GTBP:StockIssuedDuringPeriodValueEquityCompensationToOfficersAndBoardOfDirectors
      contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0229"
      unitRef="USD"
      xsi:nil="true"/>
    <GTBP:StockIssuedDuringPeriodValueEquityCompensationToOfficersAndBoardOfDirectors
      contextRef="From2022-01-012022-03-31_custom_CommonSharesIssuableMember"
      id="xdx2ixbrl0230"
      unitRef="USD"
      xsi:nil="true"/>
    <GTBP:StockIssuedDuringPeriodValueEquityCompensationToOfficersAndBoardOfDirectors
      contextRef="From2022-01-012022-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0232"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2022-01-012022-03-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0237"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0238"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2022-01-012022-03-31_custom_CommonSharesIssuableMember"
      id="xdx2ixbrl0239"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2022-01-012022-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0241"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2022-01-012022-03-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0323"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0324"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2022-01-012022-03-31_custom_CommonSharesIssuableMember"
      id="xdx2ixbrl0325"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-03-31_custom_CommonSharesIssuableMember"
      id="xdx2ixbrl0332"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-03-31_custom_CommonSharesIssuableMember"
      id="xdx2ixbrl0341"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_custom_CommonSharesIssuableMember"
      id="xdx2ixbrl0345"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2020-12-31_custom_CommonSharesIssuableMember"
      id="xdx2ixbrl0352"
      unitRef="Shares"
      xsi:nil="true"/>
    <GTBP:ExtinguishmentOfDebtDiscountUponAdoptionOfAsu202006
      contextRef="From2021-01-012021-03-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0354"
      unitRef="USD"
      xsi:nil="true"/>
    <GTBP:ExtinguishmentOfDebtDiscountUponAdoptionOfAsu202006
      contextRef="From2021-01-012021-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0355"
      unitRef="USD"
      xsi:nil="true"/>
    <GTBP:ExtinguishmentOfDebtDiscountUponAdoptionOfAsu202006
      contextRef="From2021-01-012021-03-31_custom_CommonSharesIssuableMember"
      id="xdx2ixbrl0356"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2021-01-012021-03-31_custom_CommonSharesIssuableMember"
      id="xdx2ixbrl0363"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2021-01-012021-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0365"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2021-01-012021-03-31"
      id="xdx2ixbrl0366"
      unitRef="USD"
      xsi:nil="true"/>
    <GTBP:StockIssuedDuringPeriodValueCommonSharesIssuedUponMandatoryConversionOfNotesPayableAndAccruedInterest
      contextRef="From2021-01-012021-03-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0372"
      unitRef="USD"
      xsi:nil="true"/>
    <GTBP:StockIssuedDuringPeriodValueCommonSharesIssuedUponMandatoryConversionOfNotesPayableAndAccruedInterest
      contextRef="From2021-01-012021-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0376"
      unitRef="USD"
      xsi:nil="true"/>
    <GTBP:StockIssuedDuringPeriodValueCommonSharesIssuedUponExerciseOfWarrants
      contextRef="From2021-01-012021-03-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0382"
      unitRef="USD"
      xsi:nil="true"/>
    <GTBP:StockIssuedDuringPeriodValueCommonSharesIssuedUponExerciseOfWarrants
      contextRef="From2021-01-012021-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0383"
      unitRef="USD"
      xsi:nil="true"/>
    <GTBP:StockIssuedDuringPeriodValueCommonSharesIssuedUponExerciseOfWarrants
      contextRef="From2021-01-012021-03-31_custom_CommonSharesIssuableMember"
      id="xdx2ixbrl0384"
      unitRef="USD"
      xsi:nil="true"/>
    <GTBP:StockIssuedDuringPeriodValueCommonSharesIssuedUponExerciseOfWarrants
      contextRef="From2021-01-012021-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0386"
      unitRef="USD"
      xsi:nil="true"/>
    <GTBP:StockIssuedDuringPeriodValueIssuanceOfCommonStockInPublicOfferingNetOfCost
      contextRef="From2021-01-012021-03-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0391"
      unitRef="USD"
      xsi:nil="true"/>
    <GTBP:StockIssuedDuringPeriodValueIssuanceOfCommonStockInPublicOfferingNetOfCost
      contextRef="From2021-01-012021-03-31_custom_CommonSharesIssuableMember"
      id="xdx2ixbrl0393"
      unitRef="USD"
      xsi:nil="true"/>
    <GTBP:StockIssuedDuringPeriodValueIssuanceOfCommonStockInPublicOfferingNetOfCost
      contextRef="From2021-01-012021-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0395"
      unitRef="USD"
      xsi:nil="true"/>
    <GTBP:StockIssuedDuringPeriodValueIssuanceOfCommonStockForResearchAndDevelopmentAgreement
      contextRef="From2021-01-012021-03-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0400"
      unitRef="USD"
      xsi:nil="true"/>
    <GTBP:StockIssuedDuringPeriodValueIssuanceOfCommonStockForResearchAndDevelopmentAgreement
      contextRef="From2021-01-012021-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0401"
      unitRef="USD"
      xsi:nil="true"/>
    <GTBP:StockIssuedDuringPeriodValueIssuanceOfCommonStockForResearchAndDevelopmentAgreement
      contextRef="From2021-01-012021-03-31_custom_CommonSharesIssuableMember"
      id="xdx2ixbrl0402"
      unitRef="USD"
      xsi:nil="true"/>
    <GTBP:StockIssuedDuringPeriodValueIssuanceOfCommonStockForResearchAndDevelopmentAgreement
      contextRef="From2021-01-012021-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0404"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2021-01-012021-03-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0409"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2021-01-012021-03-31_custom_CommonSharesIssuableMember"
      id="xdx2ixbrl0411"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2021-01-012021-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0413"
      unitRef="USD"
      xsi:nil="true"/>
    <GTBP:StockIssuedDuringPeriodValueEquityCompensationToOfficersAndBoardOfDirectors
      contextRef="From2021-01-012021-03-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0418"
      unitRef="USD"
      xsi:nil="true"/>
    <GTBP:StockIssuedDuringPeriodValueEquityCompensationToOfficersAndBoardOfDirectors
      contextRef="From2021-01-012021-03-31_custom_CommonSharesIssuableMember"
      id="xdx2ixbrl0420"
      unitRef="USD"
      xsi:nil="true"/>
    <GTBP:StockIssuedDuringPeriodValueEquityCompensationToOfficersAndBoardOfDirectors
      contextRef="From2021-01-012021-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0422"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2021-01-012021-03-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0427"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2021-01-012021-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0428"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2021-01-012021-03-31_custom_CommonSharesIssuableMember"
      id="xdx2ixbrl0429"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2021-01-012021-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0430"
      unitRef="USD"
      xsi:nil="true"/>
    <GTBP:ConvertibleNotesPayableIssuedForConsultingServices
      contextRef="From2022-01-01to2022-03-31"
      id="xdx2ixbrl0462"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="From2021-01-012021-03-31"
      id="xdx2ixbrl0469"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="From2021-01-012021-03-31"
      id="xdx2ixbrl0472"
      unitRef="USD"
      xsi:nil="true"/>
    <GTBP:IncreaseDecreaseInDeposit
      contextRef="From2021-01-012021-03-31"
      id="xdx2ixbrl0481"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="From2021-01-012021-03-31"
      id="xdx2ixbrl0487"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInInterestPayableNet
      contextRef="From2022-01-01to2022-03-31"
      id="xdx2ixbrl0489"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromSalesOfAssetsInvestingActivities
      contextRef="From2021-01-012021-03-31"
      id="xdx2ixbrl0499"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2021-01-012021-03-31"
      id="xdx2ixbrl0502"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2022-01-01to2022-03-31"
      id="xdx2ixbrl0507"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2022-01-01to2022-03-31"
      id="xdx2ixbrl0510"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfMediumTermNotes
      contextRef="From2022-01-01to2022-03-31"
      id="xdx2ixbrl0513"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2022-01-01to2022-03-31"
      id="xdx2ixbrl0516"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InterestPaid
      contextRef="From2022-01-01to2022-03-31"
      id="xdx2ixbrl0534"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InterestPaid
      contextRef="From2021-01-012021-03-31"
      id="xdx2ixbrl0535"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="From2022-01-01to2022-03-31"
      id="xdx2ixbrl0537"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="From2021-01-012021-03-31"
      id="xdx2ixbrl0538"
      unitRef="USD"
      xsi:nil="true"/>
    <GTBP:RightofuseAssetsAndLeaseLiabilitiesRecognizedPursuantToLeaseAgreement
      contextRef="From2021-01-012021-03-31"
      id="xdx2ixbrl0544"
      unitRef="USD"
      xsi:nil="true"/>
    <GTBP:ExtinguishmentOfUnamortizedDebtDiscountAndAdjustmentToAccumulatedDeficitUponAdoption
      contextRef="From2022-01-01to2022-03-31"
      id="xdx2ixbrl0546"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssued1
      contextRef="From2022-01-01to2022-03-31"
      id="xdx2ixbrl0549"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NotesIssued1
      contextRef="From2022-01-01to2022-03-31"
      id="xdx2ixbrl0552"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2021-01-012021-03-31_custom_OptionsToPurchaseCommonStockMember"
      id="xdx2ixbrl0602"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGain
      contextRef="From2022-01-012022-03-31_us-gaap_CashAndCashEquivalentsMember"
      id="xdx2ixbrl0627"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss
      contextRef="From2022-01-012022-03-31_us-gaap_CashAndCashEquivalentsMember"
      id="xdx2ixbrl0629"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGain
      contextRef="From2022-01-012022-03-31_custom_ShortTermInvestmentMember"
      id="xdx2ixbrl0635"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGain
      contextRef="From2022-01-01to2022-03-31"
      id="xdx2ixbrl0643"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGain
      contextRef="From2021-01-012021-12-31_us-gaap_CashAndCashEquivalentsMember"
      id="xdx2ixbrl0651"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss
      contextRef="From2021-01-012021-12-31_us-gaap_CashAndCashEquivalentsMember"
      id="xdx2ixbrl0653"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGain
      contextRef="From2021-01-012021-12-31_custom_ShortTermInvestmentMember"
      id="xdx2ixbrl0659"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGain
      contextRef="From2021-01-012021-12-31"
      id="xdx2ixbrl0667"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueNetAssetLiability
      contextRef="AsOf2022-03-31_us-gaap_FairValueInputsLevel2Member_us-gaap_MoneyMarketFundsMember"
      id="xdx2ixbrl0677"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueNetAssetLiability
      contextRef="AsOf2022-03-31_us-gaap_FairValueInputsLevel3Member_us-gaap_MoneyMarketFundsMember"
      id="xdx2ixbrl0678"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueNetAssetLiability
      contextRef="AsOf2022-03-31_us-gaap_FairValueInputsLevel1Member_custom_CorporateNotesAndCommercialPaperMember"
      id="xdx2ixbrl0681"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueNetAssetLiability
      contextRef="AsOf2022-03-31_us-gaap_FairValueInputsLevel3Member_custom_CorporateNotesAndCommercialPaperMember"
      id="xdx2ixbrl0683"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueNetAssetLiability
      contextRef="AsOf2022-03-31_us-gaap_FairValueInputsLevel3Member"
      id="xdx2ixbrl0688"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueNetAssetLiability
      contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_MoneyMarketFundsMember"
      id="xdx2ixbrl0692"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueNetAssetLiability
      contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_MoneyMarketFundsMember"
      id="xdx2ixbrl0693"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueNetAssetLiability
      contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel1Member_custom_CorporateNotesAndCommercialPaperMember"
      id="xdx2ixbrl0696"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueNetAssetLiability
      contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_custom_CorporateNotesAndCommercialPaperMember"
      id="xdx2ixbrl0698"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueNetAssetLiability
      contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member"
      id="xdx2ixbrl0703"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="From2022-01-01to2022-03-31"
      id="xdx2ixbrl0710"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="From2021-01-012021-03-31"
      id="xdx2ixbrl0711"
      unitRef="USD"
      xsi:nil="true"/>
    <GTBP:ExtinguishmentOfWarrants
      contextRef="From2022-01-01to2022-03-31"
      id="xdx2ixbrl0716"
      unitRef="USD"
      xsi:nil="true"/>
    <GTBP:ExtinguishmentOfWarrants
      contextRef="From2021-01-012021-03-31"
      id="xdx2ixbrl0717"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="AsOf2022-03-31_us-gaap_MeasurementInputExpectedDividendRateMember"
      id="xdx2ixbrl0800"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="AsOf2021-12-31_us-gaap_MeasurementInputExpectedDividendRateMember"
      id="xdx2ixbrl0802"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="From2022-01-01to2022-03-31"
      id="xdx2ixbrl0899"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue
      contextRef="From2022-01-01to2022-03-31"
      id="xdx2ixbrl0901"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeited
      contextRef="From2022-01-01to2022-03-31"
      id="xdx2ixbrl0903"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue
      contextRef="From2022-01-01to2022-03-31"
      id="xdx2ixbrl0905"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="From2022-01-01to2022-03-31"
      id="xdx2ixbrl0907"
      unitRef="Shares"
      xsi:nil="true"/>
    <GTBP:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2022-01-01to2022-03-31"
      id="xdx2ixbrl0909"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="From2022-01-01to2022-03-31"
      id="xdx2ixbrl0925"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2022-01-01to2022-03-31"
      id="xdx2ixbrl0927"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares
      contextRef="From2022-01-01to2022-03-31"
      id="xdx2ixbrl0929"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="From2022-01-01to2022-03-31"
      id="xdx2ixbrl0931"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionEquityInstrumentsExercised
      contextRef="From2022-01-01to2022-03-31"
      id="xdx2ixbrl0933"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2022-01-01to2022-03-31"
      id="xdx2ixbrl0935"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="AsOf2022-03-31"
      id="xdx2ixbrl1023"
      unitRef="USD"
      xsi:nil="true"/>
    <dei:DocumentType contextRef="From2022-01-01to2022-03-31">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="From2022-01-01to2022-03-31">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="From2022-01-01to2022-03-31">2022-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="From2022-01-01to2022-03-31">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="From2022-01-01to2022-03-31">001-40023</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="From2022-01-01to2022-03-31">GT BIOPHARMA, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2022-01-01to2022-03-31">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="From2022-01-01to2022-03-31">94-1620407</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2022-01-01to2022-03-31">8000 Marina Blvd</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2022-01-01to2022-03-31">Suite 100</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2022-01-01to2022-03-31">Brisbane</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2022-01-01to2022-03-31">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2022-01-01to2022-03-31">94005</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2022-01-01to2022-03-31">415</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2022-01-01to2022-03-31">919-4040</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="From2022-01-01to2022-03-31">Common     Stock, $0.001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2022-01-01to2022-03-31">GTBP</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2022-01-01to2022-03-31">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="From2022-01-01to2022-03-31">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="From2022-01-01to2022-03-31">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="From2022-01-01to2022-03-31">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2022-01-01to2022-03-31">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2022-01-01to2022-03-31">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="From2022-01-01to2022-03-31">false</dei:EntityShellCompany>
    <dei:EntityShellCompany contextRef="From2022-01-01to2022-03-31">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding contextRef="AsOf2022-05-16" decimals="INF" unitRef="Shares">30500717</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashEquivalentsAtCarryingValue contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">7286000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">8968000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">19454000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">23011000</us-gaap:ShortTermInvestments>
    <us-gaap:PrepaidExpenseCurrent contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">453000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">190000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">27193000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">32169000</us-gaap:AssetsCurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">237000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:DepositsAssetsNoncurrent contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">9000</us-gaap:DepositsAssetsNoncurrent>
    <us-gaap:Assets contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">27439000</us-gaap:Assets>
    <us-gaap:Assets contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">32169000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">8113000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">8220000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">1170000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">1901000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">100000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">120000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">138000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">9503000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">10259000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">147000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">9650000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">10259000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2022-03-31"
      decimals="INF"
      unitRef="USDPShares">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2021-12-31"
      decimals="INF"
      unitRef="USDPShares">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2022-03-31" decimals="0" unitRef="Shares">15000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2021-12-31" decimals="0" unitRef="Shares">15000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2022-03-31_us-gaap_SeriesCPreferredStockMember"
      decimals="0"
      unitRef="Shares">96230</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2022-03-31_us-gaap_SeriesCPreferredStockMember"
      decimals="0"
      unitRef="Shares">96230</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2021-12-31_us-gaap_SeriesCPreferredStockMember"
      decimals="0"
      unitRef="Shares">96230</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2021-12-31_us-gaap_SeriesCPreferredStockMember"
      decimals="0"
      unitRef="Shares">96230</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2022-03-31_us-gaap_SeriesCPreferredStockMember"
      decimals="-3"
      unitRef="USD">1000</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2021-12-31_us-gaap_SeriesCPreferredStockMember"
      decimals="-3"
      unitRef="USD">1000</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2022-03-31"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2021-12-31"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2022-03-31" decimals="0" unitRef="Shares">750000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2021-12-31" decimals="0" unitRef="Shares">750000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2022-03-31" decimals="0" unitRef="Shares">32345717</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2022-03-31" decimals="0" unitRef="Shares">32345717</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2021-12-31" decimals="0" unitRef="Shares">32061989</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2021-12-31" decimals="0" unitRef="Shares">32061989</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">32000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">32000</us-gaap:CommonStockValue>
    <GTBP:CommonStockIssuableShares
      contextRef="From2022-01-01to2022-03-31"
      decimals="0"
      unitRef="Shares">0</GTBP:CommonStockIssuableShares>
    <GTBP:CommonStockIssuableShares
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="Shares">327298</GTBP:CommonStockIssuableShares>
    <GTBP:CommonStockIssuable contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">1113000</GTBP:CommonStockIssuable>
    <us-gaap:AdditionalPaidInCapital contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">676780000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">674348000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">-659024000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">-653584000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">17789000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">21910000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">27439000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">32169000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-01-01to2022-03-31"
      decimals="-3"
      unitRef="USD">2087000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2021-01-012021-03-31"
      decimals="-3"
      unitRef="USD">1640000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2022-01-012022-03-31_custom_OfficersAndDirectorsMember"
      decimals="-3"
      unitRef="USD">447000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2021-01-012021-03-31_custom_OfficersAndDirectorsMember"
      decimals="-3"
      unitRef="USD">14296000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="From2022-01-01to2022-03-31"
      decimals="-3"
      unitRef="USD">3355000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="From2021-01-012021-03-31"
      decimals="-3"
      unitRef="USD">27362000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2022-01-01to2022-03-31"
      decimals="-3"
      unitRef="USD">-5442000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2021-01-012021-03-31"
      decimals="-3"
      unitRef="USD">-29002000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2022-01-01to2022-03-31"
      decimals="-3"
      unitRef="USD">8000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:InterestExpenseDebtExcludingAmortization
      contextRef="From2021-01-012021-03-31"
      decimals="-3"
      unitRef="USD">696000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="From2022-01-01to2022-03-31"
      decimals="-3"
      unitRef="USD">18000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="From2021-01-012021-03-31"
      decimals="-3"
      unitRef="USD">21000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="From2022-01-01to2022-03-31"
      decimals="-3"
      unitRef="USD">-24000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2022-01-01to2022-03-31"
      decimals="-3"
      unitRef="USD">2000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2021-01-012021-03-31"
      decimals="-3"
      unitRef="USD">-675000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-01to2022-03-31"
      decimals="-3"
      unitRef="USD">-5440000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-012021-03-31"
      decimals="-3"
      unitRef="USD">-29677000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2022-01-01to2022-03-31"
      decimals="INF"
      unitRef="USDPShares">-0.17</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2021-01-012021-03-31"
      decimals="INF"
      unitRef="USDPShares">-1.83</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2022-01-01to2022-03-31"
      decimals="INF"
      unitRef="Shares">32486116</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2021-01-012021-03-31"
      decimals="INF"
      unitRef="Shares">16239938</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember"
      decimals="-3"
      unitRef="Shares">96000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember"
      decimals="-3"
      unitRef="USD">1000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">32062</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="USD">32000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-12-31_custom_CommonSharesIssuableMember"
      decimals="-3"
      unitRef="Shares">327000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_custom_CommonSharesIssuableMember"
      decimals="-3"
      unitRef="USD">1113000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">674348000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      unitRef="USD">-653584000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">21910000</us-gaap:StockholdersEquity>
    <GTBP:StockIssuedDuringPeriodSharesCancellation
      contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">-291</GTBP:StockIssuedDuringPeriodSharesCancellation>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">327</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="From2022-01-012022-03-31_custom_CommonSharesIssuableMember"
      decimals="-3"
      unitRef="Shares">-327000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2022-01-012022-03-31_custom_CommonSharesIssuableMember"
      decimals="-3"
      unitRef="USD">-1113000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2022-01-012022-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">1113000</us-gaap:StockIssuedDuringPeriodValueOther>
    <GTBP:StockIssuedDuringPeriodSharesEquityCompensationToOfficersAndBoardOfDirectors
      contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="Shares">85000</GTBP:StockIssuedDuringPeriodSharesEquityCompensationToOfficersAndBoardOfDirectors>
    <GTBP:StockIssuedDuringPeriodValueEquityCompensationToOfficersAndBoardOfDirectors
      contextRef="From2022-01-012022-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">447000</GTBP:StockIssuedDuringPeriodValueEquityCompensationToOfficersAndBoardOfDirectors>
    <GTBP:StockIssuedDuringPeriodValueEquityCompensationToOfficersAndBoardOfDirectors
      contextRef="From2022-01-01to2022-03-31"
      decimals="-3"
      unitRef="USD">447000</GTBP:StockIssuedDuringPeriodValueEquityCompensationToOfficersAndBoardOfDirectors>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="Shares">163000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2022-01-012022-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">872000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2022-01-01to2022-03-31"
      decimals="-3"
      unitRef="USD">872000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:ProfitLoss
      contextRef="From2022-01-012022-03-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      unitRef="USD">-5440000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2022-01-01to2022-03-31"
      decimals="-3"
      unitRef="USD">-5440000</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-03-31_us-gaap_PreferredStockMember"
      decimals="-3"
      unitRef="Shares">96000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-03-31_us-gaap_PreferredStockMember"
      decimals="-3"
      unitRef="USD">1000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-03-31_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="Shares">32346000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-03-31_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="USD">32000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">676780000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-03-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      unitRef="USD">-659024000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">17789000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2020-12-31_us-gaap_PreferredStockMember"
      decimals="-3"
      unitRef="Shares">2450000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_us-gaap_PreferredStockMember"
      decimals="-3"
      unitRef="USD">3000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2020-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="Shares">5218000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="USD">5000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">566356000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      unitRef="USD">-595797000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">-29433000</us-gaap:StockholdersEquity>
    <GTBP:ExtinguishmentOfDebtDiscountUponAdoptionOfAsu202006
      contextRef="From2021-01-012021-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">-4745000</GTBP:ExtinguishmentOfDebtDiscountUponAdoptionOfAsu202006>
    <GTBP:ExtinguishmentOfDebtDiscountUponAdoptionOfAsu202006
      contextRef="From2021-01-012021-03-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      unitRef="USD">226000</GTBP:ExtinguishmentOfDebtDiscountUponAdoptionOfAsu202006>
    <GTBP:ExtinguishmentOfDebtDiscountUponAdoptionOfAsu202006
      contextRef="From2021-01-012021-03-31"
      decimals="-3"
      unitRef="USD">-4519000</GTBP:ExtinguishmentOfDebtDiscountUponAdoptionOfAsu202006>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2021-01-012021-03-31_us-gaap_PreferredStockMember"
      decimals="-3"
      unitRef="Shares">-2354000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2021-01-012021-03-31_us-gaap_PreferredStockMember"
      decimals="-3"
      unitRef="USD">-2000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2021-01-012021-03-31_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="Shares">692000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2021-01-012021-03-31_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="USD">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2021-01-012021-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <GTBP:StockIssuedDuringPeriodSharesCommonSharesIssuedUponMandatoryConversionOfNotesPayableAndAccruedInterest
      contextRef="From2021-01-012021-03-31_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="Shares">3779000</GTBP:StockIssuedDuringPeriodSharesCommonSharesIssuedUponMandatoryConversionOfNotesPayableAndAccruedInterest>
    <GTBP:StockIssuedDuringPeriodValueCommonSharesIssuedUponMandatoryConversionOfNotesPayableAndAccruedInterest
      contextRef="From2021-01-012021-03-31_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="USD">4000</GTBP:StockIssuedDuringPeriodValueCommonSharesIssuedUponMandatoryConversionOfNotesPayableAndAccruedInterest>
    <GTBP:StockIssuedDuringPeriodSharesCommonSharesIssuedUponMandatoryConversionOfNotesPayableAndAccruedInterest
      contextRef="From2021-01-012021-03-31_custom_CommonSharesIssuableMember"
      decimals="-3"
      unitRef="Shares">7634000</GTBP:StockIssuedDuringPeriodSharesCommonSharesIssuedUponMandatoryConversionOfNotesPayableAndAccruedInterest>
    <GTBP:StockIssuedDuringPeriodValueCommonSharesIssuedUponMandatoryConversionOfNotesPayableAndAccruedInterest
      contextRef="From2021-01-012021-03-31_custom_CommonSharesIssuableMember"
      decimals="-3"
      unitRef="USD">25956000</GTBP:StockIssuedDuringPeriodValueCommonSharesIssuedUponMandatoryConversionOfNotesPayableAndAccruedInterest>
    <GTBP:StockIssuedDuringPeriodValueCommonSharesIssuedUponMandatoryConversionOfNotesPayableAndAccruedInterest
      contextRef="From2021-01-012021-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">12846000</GTBP:StockIssuedDuringPeriodValueCommonSharesIssuedUponMandatoryConversionOfNotesPayableAndAccruedInterest>
    <GTBP:StockIssuedDuringPeriodValueCommonSharesIssuedUponMandatoryConversionOfNotesPayableAndAccruedInterest
      contextRef="From2021-01-012021-03-31"
      decimals="-3"
      unitRef="USD">38806000</GTBP:StockIssuedDuringPeriodValueCommonSharesIssuedUponMandatoryConversionOfNotesPayableAndAccruedInterest>
    <GTBP:StockIssuedDuringPeriodSharesCommonSharesIssuedUponExerciseOfWarrants
      contextRef="From2021-01-012021-03-31_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="Shares">95000</GTBP:StockIssuedDuringPeriodSharesCommonSharesIssuedUponExerciseOfWarrants>
    <GTBP:StockIssuedDuringPeriodValueCommonSharesIssuedUponExerciseOfWarrants
      contextRef="From2021-01-012021-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">58000</GTBP:StockIssuedDuringPeriodValueCommonSharesIssuedUponExerciseOfWarrants>
    <GTBP:StockIssuedDuringPeriodValueCommonSharesIssuedUponExerciseOfWarrants
      contextRef="From2021-01-012021-03-31"
      decimals="-3"
      unitRef="USD">58000</GTBP:StockIssuedDuringPeriodValueCommonSharesIssuedUponExerciseOfWarrants>
    <GTBP:StockIssuedDuringPeriodSharesIssuanceOfCommonStockInPublicOfferingNetOfCost
      contextRef="From2021-01-012021-03-31_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="Shares">4945000</GTBP:StockIssuedDuringPeriodSharesIssuanceOfCommonStockInPublicOfferingNetOfCost>
    <GTBP:StockIssuedDuringPeriodValueIssuanceOfCommonStockInPublicOfferingNetOfCost
      contextRef="From2021-01-012021-03-31_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="USD">5000</GTBP:StockIssuedDuringPeriodValueIssuanceOfCommonStockInPublicOfferingNetOfCost>
    <GTBP:StockIssuedDuringPeriodValueIssuanceOfCommonStockInPublicOfferingNetOfCost
      contextRef="From2021-01-012021-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">24674000</GTBP:StockIssuedDuringPeriodValueIssuanceOfCommonStockInPublicOfferingNetOfCost>
    <GTBP:StockIssuedDuringPeriodValueIssuanceOfCommonStockInPublicOfferingNetOfCost
      contextRef="From2021-01-012021-03-31"
      decimals="-3"
      unitRef="USD">24679000</GTBP:StockIssuedDuringPeriodValueIssuanceOfCommonStockInPublicOfferingNetOfCost>
    <GTBP:StockIssuedDuringPeriodShareIssuanceOfCommonStockForResearchAndDevelopmentAgreement
      contextRef="From2021-01-012021-03-31_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="Shares">190000</GTBP:StockIssuedDuringPeriodShareIssuanceOfCommonStockForResearchAndDevelopmentAgreement>
    <GTBP:StockIssuedDuringPeriodValueIssuanceOfCommonStockForResearchAndDevelopmentAgreement
      contextRef="From2021-01-012021-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">1355000</GTBP:StockIssuedDuringPeriodValueIssuanceOfCommonStockForResearchAndDevelopmentAgreement>
    <GTBP:StockIssuedDuringPeriodValueIssuanceOfCommonStockForResearchAndDevelopmentAgreement
      contextRef="From2021-01-012021-03-31"
      decimals="-3"
      unitRef="USD">1355000</GTBP:StockIssuedDuringPeriodValueIssuanceOfCommonStockForResearchAndDevelopmentAgreement>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2021-01-012021-03-31_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="Shares">1957000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2021-01-012021-03-31_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="USD">2000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2021-01-012021-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">8450000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2021-01-012021-03-31"
      decimals="-3"
      unitRef="USD">8452000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <GTBP:StockIssuedDuringPeriodSharesEquityCompensationToOfficersAndBoardOfDirectors
      contextRef="From2021-01-012021-03-31_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="Shares">3641000</GTBP:StockIssuedDuringPeriodSharesEquityCompensationToOfficersAndBoardOfDirectors>
    <GTBP:StockIssuedDuringPeriodValueEquityCompensationToOfficersAndBoardOfDirectors
      contextRef="From2021-01-012021-03-31_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="USD">4000</GTBP:StockIssuedDuringPeriodValueEquityCompensationToOfficersAndBoardOfDirectors>
    <GTBP:StockIssuedDuringPeriodValueEquityCompensationToOfficersAndBoardOfDirectors
      contextRef="From2021-01-012021-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">14292000</GTBP:StockIssuedDuringPeriodValueEquityCompensationToOfficersAndBoardOfDirectors>
    <GTBP:StockIssuedDuringPeriodValueEquityCompensationToOfficersAndBoardOfDirectors
      contextRef="From2021-01-012021-03-31"
      decimals="-3"
      unitRef="USD">14296000</GTBP:StockIssuedDuringPeriodValueEquityCompensationToOfficersAndBoardOfDirectors>
    <us-gaap:ProfitLoss
      contextRef="From2021-01-012021-03-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      unitRef="USD">-29677000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2021-01-012021-03-31"
      decimals="-3"
      unitRef="USD">-29677000</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-03-31_us-gaap_PreferredStockMember"
      decimals="-3"
      unitRef="Shares">96000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-03-31_us-gaap_PreferredStockMember"
      decimals="-3"
      unitRef="USD">1000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-03-31_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="Shares">20517000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-03-31_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="USD">21000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-03-31_custom_CommonSharesIssuableMember"
      decimals="-3"
      unitRef="Shares">7634000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-03-31_custom_CommonSharesIssuableMember"
      decimals="-3"
      unitRef="USD">25956000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">623287000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-03-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      unitRef="USD">-625248000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2021-03-31" decimals="-3" unitRef="USD">24017000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="From2022-01-01to2022-03-31"
      decimals="-3"
      unitRef="USD">-5440000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2021-01-012021-03-31"
      decimals="-3"
      unitRef="USD">-29677000</us-gaap:ProfitLoss>
    <GTBP:StockBasedCompensationForServices
      contextRef="From2022-01-01to2022-03-31"
      decimals="-3"
      unitRef="USD">872000</GTBP:StockBasedCompensationForServices>
    <GTBP:StockBasedCompensationForServices
      contextRef="From2021-01-012021-03-31"
      decimals="-3"
      unitRef="USD">9807000</GTBP:StockBasedCompensationForServices>
    <GTBP:StockBasedCompensationToOfficersAndBoardOfDirectors
      contextRef="From2022-01-01to2022-03-31"
      decimals="-3"
      unitRef="USD">447000</GTBP:StockBasedCompensationToOfficersAndBoardOfDirectors>
    <GTBP:StockBasedCompensationToOfficersAndBoardOfDirectors
      contextRef="From2021-01-012021-03-31"
      decimals="-3"
      unitRef="USD">14296000</GTBP:StockBasedCompensationToOfficersAndBoardOfDirectors>
    <GTBP:ConvertibleNotesPayableIssuedForConsultingServices
      contextRef="From2021-01-012021-03-31"
      decimals="-3"
      unitRef="USD">720000</GTBP:ConvertibleNotesPayableIssuedForConsultingServices>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="From2022-01-01to2022-03-31"
      decimals="-3"
      unitRef="USD">18000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="From2021-01-012021-03-31"
      decimals="-3"
      unitRef="USD">21000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="From2022-01-01to2022-03-31"
      decimals="-3"
      unitRef="USD">23000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="From2022-01-01to2022-03-31"
      decimals="-3"
      unitRef="USD">-24000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="From2022-01-01to2022-03-31"
      decimals="-3"
      unitRef="USD">263000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="From2021-01-012021-03-31"
      decimals="-3"
      unitRef="USD">-276000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <GTBP:IncreaseDecreaseInDeposit
      contextRef="From2022-01-01to2022-03-31"
      decimals="-3"
      unitRef="USD">-9000</GTBP:IncreaseDecreaseInDeposit>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
      contextRef="From2022-01-01to2022-03-31"
      decimals="-3"
      unitRef="USD">-838000</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
      contextRef="From2021-01-012021-03-31"
      decimals="-3"
      unitRef="USD">219000</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="From2022-01-01to2022-03-31"
      decimals="-3"
      unitRef="USD">-13000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInInterestPayableNet
      contextRef="From2021-01-012021-03-31"
      decimals="-3"
      unitRef="USD">696000</us-gaap:IncreaseDecreaseInInterestPayableNet>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2022-01-01to2022-03-31"
      decimals="-3"
      unitRef="USD">-5215000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2021-01-012021-03-31"
      decimals="-3"
      unitRef="USD">-3684000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromSalesOfAssetsInvestingActivities
      contextRef="From2022-01-01to2022-03-31"
      decimals="-3"
      unitRef="USD">3533000</us-gaap:ProceedsFromSalesOfAssetsInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2022-01-01to2022-03-31"
      decimals="-3"
      unitRef="USD">3533000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2021-01-012021-03-31"
      decimals="-3"
      unitRef="USD">24679000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2021-01-012021-03-31"
      decimals="-3"
      unitRef="USD">58000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromIssuanceOfMediumTermNotes
      contextRef="From2021-01-012021-03-31"
      decimals="-3"
      unitRef="USD">1205000</us-gaap:ProceedsFromIssuanceOfMediumTermNotes>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2021-01-012021-03-31"
      decimals="-3"
      unitRef="USD">25942000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2022-01-01to2022-03-31"
      decimals="-3"
      unitRef="USD">-1682000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2021-01-012021-03-31"
      decimals="-3"
      unitRef="USD">22258000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">8968000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">5297000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">7286000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="AsOf2021-03-31" decimals="-3" unitRef="USD">27555000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <GTBP:RightofuseAssetsAndLeaseLiabilitiesRecognizedPursuantToLeaseAgreement
      contextRef="From2022-01-01to2022-03-31"
      decimals="-3"
      unitRef="USD">260000</GTBP:RightofuseAssetsAndLeaseLiabilitiesRecognizedPursuantToLeaseAgreement>
    <GTBP:ExtinguishmentOfUnamortizedDebtDiscountAndAdjustmentToAccumulatedDeficitUponAdoption
      contextRef="From2021-01-012021-03-31"
      decimals="-3"
      unitRef="USD">4519000</GTBP:ExtinguishmentOfUnamortizedDebtDiscountAndAdjustmentToAccumulatedDeficitUponAdoption>
    <us-gaap:StockIssued1
      contextRef="From2021-01-012021-03-31"
      decimals="-3"
      unitRef="USD">38806000</us-gaap:StockIssued1>
    <us-gaap:NotesIssued1
      contextRef="From2021-01-012021-03-31"
      decimals="-3"
      unitRef="USD">1525000</us-gaap:NotesIssued1>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock contextRef="From2022-01-01to2022-03-31">&lt;p id="xdx_80C_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_zTytNuG4E3N5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
1 &#x2013; &lt;span id="xdx_828_z33dYldWWUKi"&gt;Organization and Operations&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
1965, the corporate predecessor of GT Biopharma Inc. (Company), Diagnostic Data, Inc. was incorporated in the State of California. Diagnostic
Data changed its incorporation to the State of Delaware in 1972 and changed its name to DDI Pharmaceuticals, Inc. in 1985. In 1994, DDI
Pharmaceuticals merged with International BioClinical, Inc. and Bioxytech S.A. and changed its name to OXIS International, Inc. In July
2017, the Company changed its name to GT Biopharma, Inc.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;The
Company is a clinical stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products
based on our proprietary Tri-specific Killer Engager (TriKE&lt;sup&gt;&#xae;&lt;/sup&gt;) fusion protein immune cell engager technology platform.
The Company&#x2019;s TriKE&lt;sup&gt;&#xae;&lt;/sup&gt; platform generates proprietary therapeutics designed to harness and enhance the cancer killing
abilities of a patient&#x2019;s own natural killer cells, or NK cells. Once bound to an NK cell, our moieties are designed to enhance
the NK cell, and precisely direct it to one or more specifically targeted proteins expressed on a specific type of cancer cell or virus
infected cell, resulting in the targeted cell&#x2019;s death. TriKE&lt;sup&gt;&#xae;&lt;/sup&gt;s can be designed to target any number of tumor antigens
on hematologic malignancies or solid tumors and do not require patient-specific customization.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="From2022-01-01to2022-03-31">&lt;p id="xdx_800_eus-gaap--SignificantAccountingPoliciesTextBlock_zd3oRPjYPGv1" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Note
2 &#x2013; &lt;span&gt;&lt;span id="xdx_827_z9CGeKu4Kdkg"&gt;Summary of Significant Accounting Policies&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84C_eus-gaap--BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_ziwXdnXm6Eo" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_86C_zZA5OqiTgsti"&gt;Basis
of Presentation and Principles of Consolidation&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Oxis Biotech, Inc. and
Georgetown Translational Pharmaceuticals, Inc. All intercompany transactions and balances have been eliminated in consolidation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
accompanying condensed consolidated financial statements are unaudited. These unaudited interim condensed consolidated financial statements
have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;) and
applicable rules and regulations of the Securities and Exchange Commission (&#x201c;SEC&#x201d;) regarding interim financial reporting.
Certain information and note disclosures normally included in the financial statements prepared in accordance with GAAP have been condensed
or omitted pursuant to such rules and regulations. Accordingly, these interim condensed consolidated financial statements should be read
in conjunction with the consolidated financial statements and notes thereto contained in the Company&#x2019;s Annual Report on Form 10-K
for the fiscal year ended December 31, 2021 filed with the SEC on March 28, 2022 (the &#x201c;2021 Annual Report&#x201d;). The consolidated
balance sheet as of December 31, 2021 included herein was derived from the audited consolidated financial statements as of that date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
the opinion of management, the accompanying unaudited condensed consolidated financial statements contain all adjustments necessary to
fairly present the Company&#x2019;s financial position and results of operations for the interim periods reflected. Except as noted, all
adjustments contained herein are of a normal recurring nature. Results of operations for the fiscal periods presented herein are not
necessarily indicative of fiscal year-end results.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_844_ecustom--LiquidityPolicyTextBlock_zp3rOnYqS4E4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Liquidity&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The accompanying consolidated financial statements
have been prepared under the assumption that the Company will continue as a going concern. Such assumption contemplates the realization
of assets and satisfaction of liabilities in the normal course of business. For the quarter ended March 31, 2022, the Company recorded
a net loss of $&lt;span id="xdx_90D_eus-gaap--NetIncomeLoss_iN_pn5n6_di_c20220101__20220331_zvWfIejSWSJ3"&gt;5.4&lt;/span&gt; million  and
used cash in operations of $&lt;span id="xdx_902_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pn5n6_di_c20220101__20220331_zCZSXuW8NNIa"&gt;5.2
&lt;/span&gt;million. As of March 31, 2022, the Company had a cash and short-term investments balance of $&lt;span id="xdx_904_ecustom--CashOnHandAndShortTermInvestment_c20220331_pn5n6"&gt;26.7
&lt;/span&gt;million, working capital of $&lt;span id="xdx_904_ecustom--WorkingCapital_iI_pn5n6_c20220331_zg4BIqqFLElb"&gt;17.7&lt;/span&gt; million and
stockholders&#x2019; equity of $&lt;span id="xdx_90E_eus-gaap--StockholdersEquity_iI_pn5n6_c20220331_zDxGAycIXqF2"&gt;17.8&lt;/span&gt; million.
Management anticipates that the $&lt;span id="xdx_902_eus-gaap--InvestmentsAndCash_c20220331_pn5n6"&gt;26.7&lt;/span&gt; million of cash and
cash equivalents, and short-term investments are adequate to satisfy the liquidity needs of the Company for at least one year from the
date the Company&#x2019;s condensed consolidated financial statements for the quarter ended March 31, 2022 were issued.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Historically, the Company has financed its operations
through public and private sales of common stock, issuance of preferred and common stock, issuance of convertible debt instruments, and
strategic collaborations.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_842_eus-gaap--UnusualRisksAndUncertaintiesTextBlock_z1InoGYI4SHf" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_860_zdJ9LQtHssS4"&gt;COVID-19&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
March 2020, the World Health Organization declared coronavirus COVID-19 a global pandemic. This contagious disease outbreak, which has
continued to spread, has adversely affected workforces, customers, economies, and financial markets globally. It has also disrupted the
normal operations of many businesses. This outbreak could adversely affect the Company&#x2019;s operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;While
the pandemic has impacted the Company&#x2019;s operations, during the three months ended March 31, 2022, the Company believes the COVID-19
pandemic had limited impact on its operating results. The Company has not observed any impairments of its assets or a significant change
in the fair value of its assets due to the COVID-19 pandemic. At this time, it is not possible for the Company to predict the duration
or magnitude of the adverse results of the outbreak and its effects on the Company&#x2019;s business or results of operations, financial
condition, or liquidity.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has been following the recommendations of health authorities to minimize exposure risk for its team members, including having team members work remotely. Most vendors have transitioned to electronic submission of invoices
and payments.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_845_eus-gaap--UseOfEstimates_zaQpHjiWj2Ug" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86F_z6Y0sUxBSbdi"&gt;Accounting
Estimates&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
preparation of financial statements in conformity with GAAP requires management
to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and
liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual
results could differ from those estimates. Significant estimates include accruals for potential liabilities, assumptions used in deriving
the fair value of derivative liabilities, valuation of equity instruments issued for services and realization of deferred tax assets.
Actual results could differ from those estimates.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_846_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zvf7AVWQ7JVl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_868_zNZM9POImGMb"&gt;Cash
Equivalents and Short-Term Investments&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company considers highly liquid investments with maturities of three months or less at the date of acquisition as cash equivalents in
the accompanying condensed consolidated financial statements. As of March 31, 2022 total cash and cash equivalents, which consist
of cash and money market funds, amounted to approximately $&lt;span id="xdx_90D_eus-gaap--CashCashEquivalentsAndShortTermInvestments_iI_pn5n6_c20220331_zHe7zv78whkk" title="Total cash equivalents"&gt;7.3
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company also invested its excess cash in commercial paper and corporate notes and bonds. Management generally determines the appropriate
classification of its investments at the time of purchase. We classify these investments as short-term investments, as part of current
assets, based upon our ability and intent to use any and all of these investments as necessary to satisfy liquidity requirements that
may arise from our businesses. Investments are carried at fair value with the unrealized holding gains and losses reported in the accompanying
condensed consolidated statements of operations. As of March 31, 2022 total short-term investments amounted to approximately $&lt;span id="xdx_90D_eus-gaap--ShortTermInvestments_iI_pn5n6_c20220331_zbFVx4slt7Dd" title="Short term investment"&gt;19.5&lt;/span&gt; million.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84C_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zGMqlOyhVRBe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86E_zeQcKVhcvrEf"&gt;Fair
Value of Financial Instruments&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial
Accounting Standards Board (&#x201c;FASB&#x201d;)&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;
Accounting Standards Codification (&#x201c;ASC&#x201d;) 820-10 requires entities to disclose the fair value of financial instruments, both
assets and liabilities recognized and not recognized on the balance sheet for which it is practicable to estimate fair value. ASC 820-10
defines the fair value of a financial instrument as the amount at which the instrument could be exchanged in a current transaction between
willing parties.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
three levels of the fair value hierarchy are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    1&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Valuations
    based on unadjusted quoted prices in active markets for identical assets or liabilities that the entity has the ability to access.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    2&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Valuations
    based on quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are
    observable or can be corroborated by observable data for substantially the full term of the assets or liabilities.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    3&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Valuations
    based on inputs that are unobservable, supported by little or no market activity and that are significant to the fair value of the
    assets or liabilities.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.05pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
carrying amount of the Company&#x2019;s derivative liability of $&lt;span id="xdx_907_eus-gaap--DerivativeLiabilitiesCurrent_iI_pn3d_c20220331_zARRNOM8kcxd" title="Derivative liability"&gt;120,000&lt;/span&gt; at March 31, 2022 and $&lt;span id="xdx_90A_eus-gaap--DerivativeLiabilitiesCurrent_iI_pn3d_c20211231_ztYMVWP5ezf5" title="Derivative liability"&gt;138,000&lt;/span&gt; at December 31, 2021 was based
on Level 2 measurements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
carrying amounts of the Company&#x2019;s other financial assets and liabilities, such as cash, prepaid expense, accounts payable and accrued
expenses approximate their fair values because of the short maturity of these instruments.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84F_eus-gaap--DerivativesPolicyTextBlock_zDqDJqg4m6qg" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86B_z4YndwtpjxUh"&gt;Derivative
Financial Instruments&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded
derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded
at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the consolidated statements
of operations. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or
as equity, is evaluated at the end of each reporting period. Derivative instrument liabilities are classified in the balance sheet as
current or non-current based on whether or not net-cash settlement of the derivative instrument could be required within 12 months of
the balance sheet date. The fair value of the embedded derivatives is determined using a Binomial valuation method at inception
and on subsequent valuation dates.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_845_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zT4axtXtmrMa" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86D_zqacO57IIn6l"&gt;Stock-Based
Compensation&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for share-based awards to employees, nonemployees and consultants in accordance with the provisions of ASC 718, &lt;i&gt;Compensation-Stock
Compensation&lt;/i&gt;. Stock-based compensation cost is measured at fair value on the grant date and that fair value is recognized as expense
over the requisite service, or vesting period.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company values its equity awards using the Black-Scholes option pricing model, and accounts for forfeitures when they occur. Use of the
Black-Scholes option pricing model requires the input of subjective assumptions including expected volatility, expected term, and a risk-free
interest rate. The Company estimates volatility using a its own historical stock price volatility. The expected term of the instrument
is estimated by using the simplified method to estimate expected term. The risk-free interest rate is estimated using comparable published
federal funds rates.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84C_eus-gaap--ResearchAndDevelopmentExpensePolicy_zNdiKDWMACGc" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86A_z0CP2o2xfAB7"&gt;Research
and Development Costs&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Costs
incurred for research and development are expensed as incurred. The salaries, benefits, and overhead costs of personnel conducting research
and development of the Company&#x2019;s products are included in research and development expenses. Purchased materials that do not have
an alternative future use are also expensed.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84B_eus-gaap--LesseeLeasesPolicyTextBlock_zIyeYy38CWhl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86A_zNrwgdvKJgdf"&gt;Leases&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for its leases in accordance with Accounting Standards Update (&#x201c;ASU&#x201d;) No. 2016-02, &lt;i&gt;Leases&lt;/i&gt; (Topic
842) (&#x201c;ASC 842&#x201d;). ASC 842 requires lessees to (i) recognize a right of use asset (&#x201c;ROU asset&#x201d;) and a lease liability
that is measured at the present value of the remaining lease payments, on the consolidated balance sheets, (ii) recognize a single lease
cost, calculated over the lease term on a straight-line basis and (iii) classify lease related cash payments within operating and financing
activities. The Company has made an accounting policy election to not recognize short-term leases on the consolidated balance sheets
and all non-lease components, such as common area maintenance, were excluded. At any given time during the lease term, the lease liability
represents the present value of the remaining lease payments, and the ROU asset is measured as the amount of the lease liability, adjusted
for pre-paid rent, unamortized initial direct costs, and the remaining balance of lease incentives received. Both the lease ROU asset
and liability are reduced to zero at the end of the lease term.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 16.95pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company leases office space and equipment. At the lease inception date, the Company determines if an arrangement is, or contains a lease.
Some of the Company&#x2019;s leases include options to renew at similar terms. The Company assesses these options to determine if the
Company is reasonably certain of exercising these options based on relevant economic and financial factors. Options that meet these criteria
are included in the lease term at the lease commencement date&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/&gt;

&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;During the period ended March 31, 2022, the Company
executed lease agreements for its office space and equipment and as a result, recorded operating lease right-of-use assets and the related
lease liabilities of $&lt;span id="xdx_902_eus-gaap--OperatingLeaseRightOfUseAsset_iI_c20220331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeSpaceAndEquipmentMember_zGG1pfSFWhBk" title="Operating lease, right-of-use asset"&gt;&lt;span id="xdx_903_eus-gaap--OperatingLeaseLiability_iI_c20220331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeSpaceAndEquipmentMember_z2hZmOW2i1ih" title="Operating lease,liability"&gt;260,000&lt;/span&gt;&lt;/span&gt; pursuant to ASC 842,&#160;&lt;i&gt;Leases&lt;/i&gt; (see Note 8).&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i/&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_840_eus-gaap--EarningsPerSharePolicyTextBlock_zk2Uix3Jq2id" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_863_zAq2AuhKN4Yd" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Net
Earnings (Loss) Per Share&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Basic
earnings (loss) per share is computed using the weighted-average number of common shares outstanding during the period. Common stock
issuable is included in our calculation as of the date of the underlying agreement. Diluted earnings (loss) per share is computed using
the weighted-average number of common shares and the dilutive effect of contingent shares outstanding during the period. Potentially
dilutive contingent shares, which primarily consist of convertible notes, stock issuable for the exercise of stock options and warrants
have been excluded from the diluted loss per share calculation because their effect is anti-dilutive.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89C_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_z08jlg8yBhpd" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;These
following common stock equivalents were excluded in the computation of the net loss per share because their effect is anti-dilutive:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BC_z2TePbqZshn8" style="display: none"&gt;Schedule of Anti-dilutive Securities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20220101__20220331_zmOg4YGJwO1a" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;March 31&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2022&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(Unaudited)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20210101__20210331_zL4A4uv6tP1l" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;March 31&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2021&lt;br/&gt; (Unaudited)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--OptionsToPurchaseCommonStockMember_z4SQlSsT7MUl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Options to purchase common stock&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;302,500&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0602"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;-&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsToPurchaseCommonStockMember_znsSoEx839G3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Warrants to purchase common stock&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;2,337,274&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;5,319&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--UnvestedRestrictedCommonStockMember_zpEB40CpS4Wi" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Unvested restricted common stock&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;681,270&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;1.596,659&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_zMyj6yomOmDf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total anti-dilutive
securities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;3,321,044&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,601,978&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A3_zPgPEvpU3XJ6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i/&gt;&lt;/span&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/&gt;

&lt;p id="xdx_845_eus-gaap--ConcentrationRiskCreditRisk_zRl8PF0gepF4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86E_zmpEwVyRDgAc"&gt;Concentration&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cash
is deposited in one financial institution. The balances held at this financial institution at times may be in excess of Federal Deposit
Insurance Corporation (&#x201c;FDIC&#x201d;) insurance limits of up to $&lt;span id="xdx_904_eus-gaap--CashFDICInsuredAmount_iI_c20220331_zOTm1zFRT8fi" title="FDIC amount"&gt;250,000&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has a significant concentration of expenses incurred and accounts payable from a single vendor. Please see Note 4 for further
information.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_848_eus-gaap--SegmentReportingPolicyPolicyTextBlock_z5E8YT2mMjc1" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_860_zfA0RxfMt3ze"&gt;Segments&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company determined its reporting units in accordance with ASC 280, &#x201c;Segment Reporting&#x201d; (&#x201c;ASC 280&#x201d;). Management
evaluates a reporting unit by first identifying its&#x2019; operating segments under ASC 280. The Company then evaluates each operating
segment to determine if it includes one or more components that constitute a business. If there are components within an operating segment
that meet the definition of a business, the Company evaluates those components to determine if they must be aggregated into one or more
reporting units. If applicable, when determining if it is appropriate to aggregate different operating segments, the Company determines
if the segments are economically similar and, if so, the operating segments are aggregated.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Management
has determined that the Company has one  operating segment. The Company&#x2019;s reporting segment reflects the manner in
which its chief operating decision maker reviews results and allocates resources. The Company&#x2019;s reporting segment meets the definition
of an operating segment and does not include the aggregation of multiple operating segments.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84B_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zDJDSg8lipo4" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_86D_z8QXODnl6JKc" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Recent
Accounting Pronouncements&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
May 2021, the FASB issued ASU 2021-04, &lt;i&gt;Earnings Per Share (Topic 260), Debt-Modifications and Extinguishments (Subtopic 470-50), Compensation-Stock
Compensation (Topic 718), and Derivatives and Hedging-Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40): Issuer&#x2019;s Accounting
for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options&lt;/i&gt;. ASU 2021-04 provides clarification
and reduces diversity in an issuer&#x2019;s accounting for modifications or exchanges of freestanding equity-classified written call options
(such as warrants) that remain equity classified after modification or exchange. An issuer measures the effect of a modification or exchange
as the difference between the fair value of the modified or exchanged warrant and the fair value of that warrant immediately before modification
or exchange. ASU 2021-04 introduces a recognition model that comprises four categories of transactions and the corresponding accounting
treatment for each category (equity issuance, debt origination, debt modification, and modifications unrelated to equity issuance and
debt origination or modification). ASU 2021-04 is effective for all entities for fiscal years beginning after December 15, 2021, including
interim periods within those fiscal years. An entity should apply the guidance provided in ASU 2021-04 prospectively to modifications
or exchanges occurring on or after the effective date. Early adoption is permitted for all entities, including adoption in an interim
period. Effective January 1, 2022, we adopted ASU 2021-04 using a prospective approach. It did not have a material impact on the Company&#x2019;s
financial statements or disclosures.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Other
recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public
Accountants, and the Securities and Exchange Commission (the &#x201c;SEC&#x201d;) did not or are not believed by management to have a material
impact on the Company&#x2019;s present or future consolidated financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_85F_z41n7ayvdc97" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock contextRef="From2022-01-01to2022-03-31">&lt;p id="xdx_84C_eus-gaap--BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_ziwXdnXm6Eo" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_86C_zZA5OqiTgsti"&gt;Basis
of Presentation and Principles of Consolidation&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Oxis Biotech, Inc. and
Georgetown Translational Pharmaceuticals, Inc. All intercompany transactions and balances have been eliminated in consolidation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
accompanying condensed consolidated financial statements are unaudited. These unaudited interim condensed consolidated financial statements
have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;) and
applicable rules and regulations of the Securities and Exchange Commission (&#x201c;SEC&#x201d;) regarding interim financial reporting.
Certain information and note disclosures normally included in the financial statements prepared in accordance with GAAP have been condensed
or omitted pursuant to such rules and regulations. Accordingly, these interim condensed consolidated financial statements should be read
in conjunction with the consolidated financial statements and notes thereto contained in the Company&#x2019;s Annual Report on Form 10-K
for the fiscal year ended December 31, 2021 filed with the SEC on March 28, 2022 (the &#x201c;2021 Annual Report&#x201d;). The consolidated
balance sheet as of December 31, 2021 included herein was derived from the audited consolidated financial statements as of that date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
the opinion of management, the accompanying unaudited condensed consolidated financial statements contain all adjustments necessary to
fairly present the Company&#x2019;s financial position and results of operations for the interim periods reflected. Except as noted, all
adjustments contained herein are of a normal recurring nature. Results of operations for the fiscal periods presented herein are not
necessarily indicative of fiscal year-end results.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <GTBP:LiquidityPolicyTextBlock contextRef="From2022-01-01to2022-03-31">&lt;p id="xdx_844_ecustom--LiquidityPolicyTextBlock_zp3rOnYqS4E4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Liquidity&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The accompanying consolidated financial statements
have been prepared under the assumption that the Company will continue as a going concern. Such assumption contemplates the realization
of assets and satisfaction of liabilities in the normal course of business. For the quarter ended March 31, 2022, the Company recorded
a net loss of $&lt;span id="xdx_90D_eus-gaap--NetIncomeLoss_iN_pn5n6_di_c20220101__20220331_zvWfIejSWSJ3"&gt;5.4&lt;/span&gt; million  and
used cash in operations of $&lt;span id="xdx_902_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pn5n6_di_c20220101__20220331_zCZSXuW8NNIa"&gt;5.2
&lt;/span&gt;million. As of March 31, 2022, the Company had a cash and short-term investments balance of $&lt;span id="xdx_904_ecustom--CashOnHandAndShortTermInvestment_c20220331_pn5n6"&gt;26.7
&lt;/span&gt;million, working capital of $&lt;span id="xdx_904_ecustom--WorkingCapital_iI_pn5n6_c20220331_zg4BIqqFLElb"&gt;17.7&lt;/span&gt; million and
stockholders&#x2019; equity of $&lt;span id="xdx_90E_eus-gaap--StockholdersEquity_iI_pn5n6_c20220331_zDxGAycIXqF2"&gt;17.8&lt;/span&gt; million.
Management anticipates that the $&lt;span id="xdx_902_eus-gaap--InvestmentsAndCash_c20220331_pn5n6"&gt;26.7&lt;/span&gt; million of cash and
cash equivalents, and short-term investments are adequate to satisfy the liquidity needs of the Company for at least one year from the
date the Company&#x2019;s condensed consolidated financial statements for the quarter ended March 31, 2022 were issued.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Historically, the Company has financed its operations
through public and private sales of common stock, issuance of preferred and common stock, issuance of convertible debt instruments, and
strategic collaborations.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

</GTBP:LiquidityPolicyTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-01to2022-03-31"
      decimals="-5"
      unitRef="USD">-5400000</us-gaap:NetIncomeLoss>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2022-01-01to2022-03-31"
      decimals="-5"
      unitRef="USD">-5200000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <GTBP:CashOnHandAndShortTermInvestment contextRef="AsOf2022-03-31" decimals="-5" unitRef="USD">26700000</GTBP:CashOnHandAndShortTermInvestment>
    <GTBP:WorkingCapital contextRef="AsOf2022-03-31" decimals="-5" unitRef="USD">17700000</GTBP:WorkingCapital>
    <us-gaap:StockholdersEquity contextRef="AsOf2022-03-31" decimals="-5" unitRef="USD">17800000</us-gaap:StockholdersEquity>
    <us-gaap:InvestmentsAndCash contextRef="AsOf2022-03-31" decimals="-5" unitRef="USD">26700000</us-gaap:InvestmentsAndCash>
    <us-gaap:UnusualRisksAndUncertaintiesTextBlock contextRef="From2022-01-01to2022-03-31">&lt;p id="xdx_842_eus-gaap--UnusualRisksAndUncertaintiesTextBlock_z1InoGYI4SHf" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_860_zdJ9LQtHssS4"&gt;COVID-19&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
March 2020, the World Health Organization declared coronavirus COVID-19 a global pandemic. This contagious disease outbreak, which has
continued to spread, has adversely affected workforces, customers, economies, and financial markets globally. It has also disrupted the
normal operations of many businesses. This outbreak could adversely affect the Company&#x2019;s operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;While
the pandemic has impacted the Company&#x2019;s operations, during the three months ended March 31, 2022, the Company believes the COVID-19
pandemic had limited impact on its operating results. The Company has not observed any impairments of its assets or a significant change
in the fair value of its assets due to the COVID-19 pandemic. At this time, it is not possible for the Company to predict the duration
or magnitude of the adverse results of the outbreak and its effects on the Company&#x2019;s business or results of operations, financial
condition, or liquidity.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has been following the recommendations of health authorities to minimize exposure risk for its team members, including having team members work remotely. Most vendors have transitioned to electronic submission of invoices
and payments.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:UnusualRisksAndUncertaintiesTextBlock>
    <us-gaap:UseOfEstimates contextRef="From2022-01-01to2022-03-31">&lt;p id="xdx_845_eus-gaap--UseOfEstimates_zaQpHjiWj2Ug" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86F_z6Y0sUxBSbdi"&gt;Accounting
Estimates&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
preparation of financial statements in conformity with GAAP requires management
to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and
liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual
results could differ from those estimates. Significant estimates include accruals for potential liabilities, assumptions used in deriving
the fair value of derivative liabilities, valuation of equity instruments issued for services and realization of deferred tax assets.
Actual results could differ from those estimates.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="From2022-01-01to2022-03-31">&lt;p id="xdx_846_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zvf7AVWQ7JVl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_868_zNZM9POImGMb"&gt;Cash
Equivalents and Short-Term Investments&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company considers highly liquid investments with maturities of three months or less at the date of acquisition as cash equivalents in
the accompanying condensed consolidated financial statements. As of March 31, 2022 total cash and cash equivalents, which consist
of cash and money market funds, amounted to approximately $&lt;span id="xdx_90D_eus-gaap--CashCashEquivalentsAndShortTermInvestments_iI_pn5n6_c20220331_zHe7zv78whkk" title="Total cash equivalents"&gt;7.3
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company also invested its excess cash in commercial paper and corporate notes and bonds. Management generally determines the appropriate
classification of its investments at the time of purchase. We classify these investments as short-term investments, as part of current
assets, based upon our ability and intent to use any and all of these investments as necessary to satisfy liquidity requirements that
may arise from our businesses. Investments are carried at fair value with the unrealized holding gains and losses reported in the accompanying
condensed consolidated statements of operations. As of March 31, 2022 total short-term investments amounted to approximately $&lt;span id="xdx_90D_eus-gaap--ShortTermInvestments_iI_pn5n6_c20220331_zbFVx4slt7Dd" title="Short term investment"&gt;19.5&lt;/span&gt; million.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments contextRef="AsOf2022-03-31" decimals="-5" unitRef="USD">7300000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:ShortTermInvestments contextRef="AsOf2022-03-31" decimals="-5" unitRef="USD">19500000</us-gaap:ShortTermInvestments>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="From2022-01-01to2022-03-31">&lt;p id="xdx_84C_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zGMqlOyhVRBe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86E_zeQcKVhcvrEf"&gt;Fair
Value of Financial Instruments&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial
Accounting Standards Board (&#x201c;FASB&#x201d;)&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;
Accounting Standards Codification (&#x201c;ASC&#x201d;) 820-10 requires entities to disclose the fair value of financial instruments, both
assets and liabilities recognized and not recognized on the balance sheet for which it is practicable to estimate fair value. ASC 820-10
defines the fair value of a financial instrument as the amount at which the instrument could be exchanged in a current transaction between
willing parties.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
three levels of the fair value hierarchy are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    1&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Valuations
    based on unadjusted quoted prices in active markets for identical assets or liabilities that the entity has the ability to access.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    2&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Valuations
    based on quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are
    observable or can be corroborated by observable data for substantially the full term of the assets or liabilities.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    3&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Valuations
    based on inputs that are unobservable, supported by little or no market activity and that are significant to the fair value of the
    assets or liabilities.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.05pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
carrying amount of the Company&#x2019;s derivative liability of $&lt;span id="xdx_907_eus-gaap--DerivativeLiabilitiesCurrent_iI_pn3d_c20220331_zARRNOM8kcxd" title="Derivative liability"&gt;120,000&lt;/span&gt; at March 31, 2022 and $&lt;span id="xdx_90A_eus-gaap--DerivativeLiabilitiesCurrent_iI_pn3d_c20211231_ztYMVWP5ezf5" title="Derivative liability"&gt;138,000&lt;/span&gt; at December 31, 2021 was based
on Level 2 measurements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
carrying amounts of the Company&#x2019;s other financial assets and liabilities, such as cash, prepaid expense, accounts payable and accrued
expenses approximate their fair values because of the short maturity of these instruments.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:DerivativeLiabilitiesCurrent contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">120000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">138000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativesPolicyTextBlock contextRef="From2022-01-01to2022-03-31">&lt;p id="xdx_84F_eus-gaap--DerivativesPolicyTextBlock_zDqDJqg4m6qg" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86B_z4YndwtpjxUh"&gt;Derivative
Financial Instruments&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded
derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded
at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the consolidated statements
of operations. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or
as equity, is evaluated at the end of each reporting period. Derivative instrument liabilities are classified in the balance sheet as
current or non-current based on whether or not net-cash settlement of the derivative instrument could be required within 12 months of
the balance sheet date. The fair value of the embedded derivatives is determined using a Binomial valuation method at inception
and on subsequent valuation dates.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:DerivativesPolicyTextBlock>
    <us-gaap:CompensationRelatedCostsPolicyTextBlock contextRef="From2022-01-01to2022-03-31">&lt;p id="xdx_845_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zT4axtXtmrMa" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86D_zqacO57IIn6l"&gt;Stock-Based
Compensation&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for share-based awards to employees, nonemployees and consultants in accordance with the provisions of ASC 718, &lt;i&gt;Compensation-Stock
Compensation&lt;/i&gt;. Stock-based compensation cost is measured at fair value on the grant date and that fair value is recognized as expense
over the requisite service, or vesting period.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company values its equity awards using the Black-Scholes option pricing model, and accounts for forfeitures when they occur. Use of the
Black-Scholes option pricing model requires the input of subjective assumptions including expected volatility, expected term, and a risk-free
interest rate. The Company estimates volatility using a its own historical stock price volatility. The expected term of the instrument
is estimated by using the simplified method to estimate expected term. The risk-free interest rate is estimated using comparable published
federal funds rates.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CompensationRelatedCostsPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="From2022-01-01to2022-03-31">&lt;p id="xdx_84C_eus-gaap--ResearchAndDevelopmentExpensePolicy_zNdiKDWMACGc" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86A_z0CP2o2xfAB7"&gt;Research
and Development Costs&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Costs
incurred for research and development are expensed as incurred. The salaries, benefits, and overhead costs of personnel conducting research
and development of the Company&#x2019;s products are included in research and development expenses. Purchased materials that do not have
an alternative future use are also expensed.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="From2022-01-01to2022-03-31">&lt;p id="xdx_84B_eus-gaap--LesseeLeasesPolicyTextBlock_zIyeYy38CWhl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86A_zNrwgdvKJgdf"&gt;Leases&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for its leases in accordance with Accounting Standards Update (&#x201c;ASU&#x201d;) No. 2016-02, &lt;i&gt;Leases&lt;/i&gt; (Topic
842) (&#x201c;ASC 842&#x201d;). ASC 842 requires lessees to (i) recognize a right of use asset (&#x201c;ROU asset&#x201d;) and a lease liability
that is measured at the present value of the remaining lease payments, on the consolidated balance sheets, (ii) recognize a single lease
cost, calculated over the lease term on a straight-line basis and (iii) classify lease related cash payments within operating and financing
activities. The Company has made an accounting policy election to not recognize short-term leases on the consolidated balance sheets
and all non-lease components, such as common area maintenance, were excluded. At any given time during the lease term, the lease liability
represents the present value of the remaining lease payments, and the ROU asset is measured as the amount of the lease liability, adjusted
for pre-paid rent, unamortized initial direct costs, and the remaining balance of lease incentives received. Both the lease ROU asset
and liability are reduced to zero at the end of the lease term.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 16.95pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company leases office space and equipment. At the lease inception date, the Company determines if an arrangement is, or contains a lease.
Some of the Company&#x2019;s leases include options to renew at similar terms. The Company assesses these options to determine if the
Company is reasonably certain of exercising these options based on relevant economic and financial factors. Options that meet these criteria
are included in the lease term at the lease commencement date&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/&gt;

&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;During the period ended March 31, 2022, the Company
executed lease agreements for its office space and equipment and as a result, recorded operating lease right-of-use assets and the related
lease liabilities of $&lt;span id="xdx_902_eus-gaap--OperatingLeaseRightOfUseAsset_iI_c20220331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeSpaceAndEquipmentMember_zGG1pfSFWhBk" title="Operating lease, right-of-use asset"&gt;&lt;span id="xdx_903_eus-gaap--OperatingLeaseLiability_iI_c20220331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeSpaceAndEquipmentMember_z2hZmOW2i1ih" title="Operating lease,liability"&gt;260,000&lt;/span&gt;&lt;/span&gt; pursuant to ASC 842,&#160;&lt;i&gt;Leases&lt;/i&gt; (see Note 8).&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i/&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2022-03-31_custom_OfficeSpaceAndEquipmentMember"
      decimals="0"
      unitRef="USD">260000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="AsOf2022-03-31_custom_OfficeSpaceAndEquipmentMember"
      decimals="0"
      unitRef="USD">260000</us-gaap:OperatingLeaseLiability>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2022-01-01to2022-03-31">&lt;p id="xdx_840_eus-gaap--EarningsPerSharePolicyTextBlock_zk2Uix3Jq2id" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_863_zAq2AuhKN4Yd" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Net
Earnings (Loss) Per Share&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Basic
earnings (loss) per share is computed using the weighted-average number of common shares outstanding during the period. Common stock
issuable is included in our calculation as of the date of the underlying agreement. Diluted earnings (loss) per share is computed using
the weighted-average number of common shares and the dilutive effect of contingent shares outstanding during the period. Potentially
dilutive contingent shares, which primarily consist of convertible notes, stock issuable for the exercise of stock options and warrants
have been excluded from the diluted loss per share calculation because their effect is anti-dilutive.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89C_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_z08jlg8yBhpd" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;These
following common stock equivalents were excluded in the computation of the net loss per share because their effect is anti-dilutive:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BC_z2TePbqZshn8" style="display: none"&gt;Schedule of Anti-dilutive Securities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20220101__20220331_zmOg4YGJwO1a" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;March 31&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2022&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(Unaudited)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20210101__20210331_zL4A4uv6tP1l" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;March 31&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2021&lt;br/&gt; (Unaudited)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--OptionsToPurchaseCommonStockMember_z4SQlSsT7MUl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Options to purchase common stock&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;302,500&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0602"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;-&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsToPurchaseCommonStockMember_znsSoEx839G3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Warrants to purchase common stock&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;2,337,274&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;5,319&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--UnvestedRestrictedCommonStockMember_zpEB40CpS4Wi" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Unvested restricted common stock&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;681,270&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;1.596,659&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_zMyj6yomOmDf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total anti-dilutive
securities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;3,321,044&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,601,978&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A3_zPgPEvpU3XJ6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i/&gt;&lt;/span&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/&gt;

</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="From2022-01-01to2022-03-31">&lt;p id="xdx_89C_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_z08jlg8yBhpd" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;These
following common stock equivalents were excluded in the computation of the net loss per share because their effect is anti-dilutive:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BC_z2TePbqZshn8" style="display: none"&gt;Schedule of Anti-dilutive Securities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20220101__20220331_zmOg4YGJwO1a" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;March 31&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2022&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(Unaudited)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20210101__20210331_zL4A4uv6tP1l" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;March 31&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2021&lt;br/&gt; (Unaudited)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--OptionsToPurchaseCommonStockMember_z4SQlSsT7MUl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Options to purchase common stock&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;302,500&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0602"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;-&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsToPurchaseCommonStockMember_znsSoEx839G3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Warrants to purchase common stock&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;2,337,274&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;5,319&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--UnvestedRestrictedCommonStockMember_zpEB40CpS4Wi" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Unvested restricted common stock&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;681,270&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;1.596,659&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_zMyj6yomOmDf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total anti-dilutive
securities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;3,321,044&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,601,978&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-01-012022-03-31_custom_OptionsToPurchaseCommonStockMember"
      decimals="INF"
      unitRef="Shares">302500</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-01-012022-03-31_custom_WarrantsToPurchaseCommonStockMember"
      decimals="INF"
      unitRef="Shares">2337274</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2021-01-012021-03-31_custom_WarrantsToPurchaseCommonStockMember"
      decimals="INF"
      unitRef="Shares">5319</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-01-012022-03-31_custom_UnvestedRestrictedCommonStockMember"
      decimals="INF"
      unitRef="Shares">681270</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2021-01-012021-03-31_custom_UnvestedRestrictedCommonStockMember"
      decimals="INF"
      unitRef="Shares">1596.659</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-01-01to2022-03-31"
      decimals="INF"
      unitRef="Shares">3321044</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2021-01-012021-03-31"
      decimals="INF"
      unitRef="Shares">1601978</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="From2022-01-01to2022-03-31">&lt;p id="xdx_845_eus-gaap--ConcentrationRiskCreditRisk_zRl8PF0gepF4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86E_zmpEwVyRDgAc"&gt;Concentration&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cash
is deposited in one financial institution. The balances held at this financial institution at times may be in excess of Federal Deposit
Insurance Corporation (&#x201c;FDIC&#x201d;) insurance limits of up to $&lt;span id="xdx_904_eus-gaap--CashFDICInsuredAmount_iI_c20220331_zOTm1zFRT8fi" title="FDIC amount"&gt;250,000&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has a significant concentration of expenses incurred and accounts payable from a single vendor. Please see Note 4 for further
information.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:CashFDICInsuredAmount contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">250000</us-gaap:CashFDICInsuredAmount>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="From2022-01-01to2022-03-31">&lt;p id="xdx_848_eus-gaap--SegmentReportingPolicyPolicyTextBlock_z5E8YT2mMjc1" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_860_zfA0RxfMt3ze"&gt;Segments&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company determined its reporting units in accordance with ASC 280, &#x201c;Segment Reporting&#x201d; (&#x201c;ASC 280&#x201d;). Management
evaluates a reporting unit by first identifying its&#x2019; operating segments under ASC 280. The Company then evaluates each operating
segment to determine if it includes one or more components that constitute a business. If there are components within an operating segment
that meet the definition of a business, the Company evaluates those components to determine if they must be aggregated into one or more
reporting units. If applicable, when determining if it is appropriate to aggregate different operating segments, the Company determines
if the segments are economically similar and, if so, the operating segments are aggregated.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Management
has determined that the Company has one  operating segment. The Company&#x2019;s reporting segment reflects the manner in
which its chief operating decision maker reviews results and allocates resources. The Company&#x2019;s reporting segment meets the definition
of an operating segment and does not include the aggregation of multiple operating segments.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2022-01-01to2022-03-31">&lt;p id="xdx_84B_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zDJDSg8lipo4" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_86D_z8QXODnl6JKc" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Recent
Accounting Pronouncements&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
May 2021, the FASB issued ASU 2021-04, &lt;i&gt;Earnings Per Share (Topic 260), Debt-Modifications and Extinguishments (Subtopic 470-50), Compensation-Stock
Compensation (Topic 718), and Derivatives and Hedging-Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40): Issuer&#x2019;s Accounting
for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options&lt;/i&gt;. ASU 2021-04 provides clarification
and reduces diversity in an issuer&#x2019;s accounting for modifications or exchanges of freestanding equity-classified written call options
(such as warrants) that remain equity classified after modification or exchange. An issuer measures the effect of a modification or exchange
as the difference between the fair value of the modified or exchanged warrant and the fair value of that warrant immediately before modification
or exchange. ASU 2021-04 introduces a recognition model that comprises four categories of transactions and the corresponding accounting
treatment for each category (equity issuance, debt origination, debt modification, and modifications unrelated to equity issuance and
debt origination or modification). ASU 2021-04 is effective for all entities for fiscal years beginning after December 15, 2021, including
interim periods within those fiscal years. An entity should apply the guidance provided in ASU 2021-04 prospectively to modifications
or exchanges occurring on or after the effective date. Early adoption is permitted for all entities, including adoption in an interim
period. Effective January 1, 2022, we adopted ASU 2021-04 using a prospective approach. It did not have a material impact on the Company&#x2019;s
financial statements or disclosures.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Other
recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public
Accountants, and the Securities and Exchange Commission (the &#x201c;SEC&#x201d;) did not or are not believed by management to have a material
impact on the Company&#x2019;s present or future consolidated financial statements.&lt;/span&gt;&lt;/p&gt;

</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="From2022-01-01to2022-03-31">&lt;p id="xdx_807_eus-gaap--FairValueDisclosuresTextBlock_zX5FPsfe1pc5" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
3 &#x2013; &lt;span id="xdx_82B_z9In1tIzB1l8"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89B_eus-gaap--DebtSecuritiesAvailableForSaleTableTextBlock_zeQohQiV5KW6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
estimated fair values of financial instruments outstanding were (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B0_zINi0pXAkORk" style="display: none"&gt;Schedule of Estimated Fair Value of Financial Instrument&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;March 31, 2022 (Unaudited)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Unrealized&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Unrealized&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Fair&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Cost&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Gains&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Losses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 36%; text-align: left"&gt;Cash and cash equivalents&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pn3n3_c20220331__us-gaap--InvestmentTypeAxis__us-gaap--CashAndCashEquivalentsMember_zNHpxSJr3vjc" style="width: 12%; text-align: right" title="Cost"&gt;7,286&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--DebtSecuritiesAvailableForSaleRealizedGain_pn3n3_c20220101__20220331__us-gaap--InvestmentTypeAxis__us-gaap--CashAndCashEquivalentsMember_zA0l0WnF7X5j" style="width: 12%; text-align: right" title="Unrealized gains"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;span style="-sec-ix-hidden: xdx2ixbrl0627"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--DebtSecuritiesAvailableForSaleRealizedLoss_pn3n3_c20220101__20220331__us-gaap--InvestmentTypeAxis__us-gaap--CashAndCashEquivalentsMember_zzWNzM114vD7" style="width: 12%; text-align: right" title="Unrealized losses"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;span style="-sec-ix-hidden: xdx2ixbrl0629"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--DebtSecuritiesAvailableForSaleRealizedGainLoss_pn3n3_c20220101__20220331__us-gaap--InvestmentTypeAxis__us-gaap--CashAndCashEquivalentsMember_zI5kxS58pm1b" style="width: 12%; text-align: right" title="Fair value"&gt;7,286&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Short-term investments&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pn3n3_c20220331__us-gaap--InvestmentTypeAxis__custom--ShortTermInvestmentMember_zp1sJ9jJAp6c" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cost"&gt;19,496&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--DebtSecuritiesAvailableForSaleRealizedGain_pn3n3_c20220101__20220331__us-gaap--InvestmentTypeAxis__custom--ShortTermInvestmentMember_z6JcJF0hjsqj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Unrealized gains"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0635"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--DebtSecuritiesAvailableForSaleRealizedLoss_pn3n3_c20220101__20220331__us-gaap--InvestmentTypeAxis__custom--ShortTermInvestmentMember_zc4BCyBuHV2c" style="border-bottom: Black 1.5pt solid; text-align: right" title="Unrealized losses"&gt;(42&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--DebtSecuritiesAvailableForSaleRealizedGainLoss_pn3n3_c20220101__20220331__us-gaap--InvestmentTypeAxis__custom--ShortTermInvestmentMember_zObPMSK74Ywc" style="border-bottom: Black 1.5pt solid; text-align: right" title="Fair value"&gt;19,454&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pn3n3_c20220331_zpr5X2NKUd03" style="border-bottom: Black 2.5pt double; text-align: right" title="Cost"&gt;26,782&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--DebtSecuritiesAvailableForSaleRealizedGain_pn3n3_c20220101__20220331_zfY6KFcS6X0g" style="border-bottom: Black 2.5pt double; text-align: right" title="Unrealized gains"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0643"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--DebtSecuritiesAvailableForSaleRealizedLoss_pn3n3_c20220101__20220331_zAugk9I5CE9g" style="border-bottom: Black 2.5pt double; text-align: right" title="Unrealized losses"&gt;(42&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--DebtSecuritiesAvailableForSaleRealizedGainLoss_pn3n3_c20220101__20220331_zrbNMYLOql2j" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value"&gt;26,740&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Unrealized&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Unrealized&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Fair&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Cost&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Gains&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Losses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 36%; text-align: left"&gt;Cash and cash equivalents&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pn3n3_c20211231__us-gaap--InvestmentTypeAxis__us-gaap--CashAndCashEquivalentsMember_zUlswoZLTXe5" style="width: 12%; text-align: right" title="Cost"&gt;8,968&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--DebtSecuritiesAvailableForSaleRealizedGain_pn3n3_c20210101__20211231__us-gaap--InvestmentTypeAxis__us-gaap--CashAndCashEquivalentsMember_zGH3sKl27OWa" style="width: 12%; text-align: right" title="Unrealized gains"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;span style="-sec-ix-hidden: xdx2ixbrl0651"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--DebtSecuritiesAvailableForSaleRealizedLoss_pn3n3_c20210101__20211231__us-gaap--InvestmentTypeAxis__us-gaap--CashAndCashEquivalentsMember_zdjO2Rrzkb99" style="width: 12%; text-align: right" title="Unrealized losses"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;span style="-sec-ix-hidden: xdx2ixbrl0653"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--DebtSecuritiesAvailableForSaleRealizedGainLoss_c20210101__20211231__us-gaap--InvestmentTypeAxis__us-gaap--CashAndCashEquivalentsMember_pn3n3" style="width: 12%; text-align: right" title="Fair value"&gt;8,968&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Short-term investments&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_c20211231__us-gaap--InvestmentTypeAxis__custom--ShortTermInvestmentMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cost"&gt;23,040&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--DebtSecuritiesAvailableForSaleRealizedGain_pn3n3_c20210101__20211231__us-gaap--InvestmentTypeAxis__custom--ShortTermInvestmentMember_zWVQ6LMxERjj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Unrealized gains"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0659"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--DebtSecuritiesAvailableForSaleRealizedLoss_c20210101__20211231__us-gaap--InvestmentTypeAxis__custom--ShortTermInvestmentMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Unrealized losses"&gt;(29&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--DebtSecuritiesAvailableForSaleRealizedGainLoss_c20210101__20211231__us-gaap--InvestmentTypeAxis__custom--ShortTermInvestmentMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Fair value"&gt;23,011&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_c20211231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Cost"&gt;32,008&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--DebtSecuritiesAvailableForSaleRealizedGain_pn3n3_c20210101__20211231_zBqd78pn4Eta" style="border-bottom: Black 2.5pt double; text-align: right" title="Unrealized gains"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0667"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--DebtSecuritiesAvailableForSaleRealizedLoss_c20210101__20211231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Unrealized losses"&gt;(29&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--DebtSecuritiesAvailableForSaleRealizedGainLoss_pn3n3_c20210101__20211231_zGnGlqfREVqk" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value"&gt;31,979&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A2_zzIrpHtCC3R8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89E_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_zI3PgrbzMN11" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table represents the Company&#x2019;s fair value hierarchy for its financial assets (cash equivalents and investments) (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B5_zDbwwi6g3JC5" style="display: none"&gt;Schedule
of Fair Value Hierarchy Financial Assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20220331_zxeNbTSQqHAb" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Fair Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20220331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zEjdov4Uo7Ij" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20220331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z66fYX6UdRsg" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20220331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zLGe7PBAqEml" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;March 31, 2022 (Unaudited)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Fair Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--FairValueNetAssetLiability_iI_pn3n3_hus-gaap--InvestmentTypeAxis__us-gaap--MoneyMarketFundsMember_zlEFJ7v5qpFe" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 36%; text-align: left"&gt;Money market funds&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;6,299&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;6,299&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&lt;span style="-sec-ix-hidden: xdx2ixbrl0677"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;span style="-sec-ix-hidden: xdx2ixbrl0678"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--FairValueNetAssetLiability_iI_pn3n3_hus-gaap--InvestmentTypeAxis__custom--CorporateNotesAndCommercialPaperMember_zJ2eGfprqtr1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Corporate notes and commercial paper&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;19,454&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0681"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;19,454&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0683"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--FairValueNetAssetLiability_iI_pn3n3_zbgzUE5eDvBi" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0pt; text-align: left; padding-bottom: 2.5pt"&gt;Total financial assets&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;25,753&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;6,299&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;19,454&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0688"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20211231_zG2l7AhYYoMd" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Fair Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z80spwcHx7p8" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zF69jgkUQ4jg" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zqoqfxEs4uib" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Fair Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--FairValueNetAssetLiability_iI_pn3n3_hus-gaap--InvestmentTypeAxis__us-gaap--MoneyMarketFundsMember_z29ohChGhUsc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 36%; text-align: left"&gt;Money market funds&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;5,484&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;5,484&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;span style="-sec-ix-hidden: xdx2ixbrl0692"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;span style="-sec-ix-hidden: xdx2ixbrl0693"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--FairValueNetAssetLiability_iI_pn3n3_hus-gaap--InvestmentTypeAxis__custom--CorporateNotesAndCommercialPaperMember_ztq6kmtGIfi3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Corporate notes and commercial paper&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;23,011&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0696"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;23,011&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0698"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--FairValueNetAssetLiability_iI_pn3n3_zC0E2xpy5qe7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0pt; text-align: left; padding-bottom: 2.5pt"&gt;Total financial assets&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;28,495&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;5,484&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;23,011&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0703"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A0_zvfqBGDcB504" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/&gt;

&lt;p id="xdx_89C_eus-gaap--ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_zmExvcUrhL6b" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As of March 31, 2022, the fair value of the derivative liability amounted
to $&lt;span id="xdx_900_eus-gaap--DerivativeLiabilitiesCurrent_iI_pn3d_c20220331_z4SbKAkbsnCc"&gt;&lt;span id="xdx_905_eus-gaap--DerivativeLiabilitiesCurrent_iI_pn3d_c20210331_zyuayTJ2ZRJb"&gt;120,000&lt;/span&gt;&lt;/span&gt;. The details of derivative liability transactions for the three months ended March 31, 2022 and 2021, are as follows:&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;span id="xdx_8B9_zhINUzne4oz7" style="display: none"&gt;Schedule
of Derivative Liability Transactions&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b/&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20220101__20220331_zG55aeY08pz1" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;March 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20210101__20210331_zeB1f8gQSmw2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;March 31, 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(Unaudited)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(Unaudited)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--DerivativeLiabilitiesCurrent_iS_pn3d_z0EuE0GkcdC2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Beginning balance&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;138,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;383,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--IssuanceOfStockAndWarrantsForServicesOrClaims_pn3d_zIvGR25VX2kk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Fair value upon issuance of warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0710"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0711"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--IncreaseDecreaseInDerivativeLiabilities_pn3d_zuaXPbmfw0h8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Change in fair value&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(18,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(21,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_ecustom--ExtinguishmentOfWarrants_pn3d_z8LLtwMnJ73a" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Extinguishment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0716"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0717"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--DerivativeLiabilitiesCurrent_iE_pn3d_zW8Qm6sz2bQe" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Ending balance&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;120,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;362,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A0_zIwPi0plFWu8" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock contextRef="From2022-01-01to2022-03-31">&lt;p id="xdx_89B_eus-gaap--DebtSecuritiesAvailableForSaleTableTextBlock_zeQohQiV5KW6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
estimated fair values of financial instruments outstanding were (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B0_zINi0pXAkORk" style="display: none"&gt;Schedule of Estimated Fair Value of Financial Instrument&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;March 31, 2022 (Unaudited)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Unrealized&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Unrealized&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Fair&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Cost&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Gains&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Losses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 36%; text-align: left"&gt;Cash and cash equivalents&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pn3n3_c20220331__us-gaap--InvestmentTypeAxis__us-gaap--CashAndCashEquivalentsMember_zNHpxSJr3vjc" style="width: 12%; text-align: right" title="Cost"&gt;7,286&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--DebtSecuritiesAvailableForSaleRealizedGain_pn3n3_c20220101__20220331__us-gaap--InvestmentTypeAxis__us-gaap--CashAndCashEquivalentsMember_zA0l0WnF7X5j" style="width: 12%; text-align: right" title="Unrealized gains"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;span style="-sec-ix-hidden: xdx2ixbrl0627"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--DebtSecuritiesAvailableForSaleRealizedLoss_pn3n3_c20220101__20220331__us-gaap--InvestmentTypeAxis__us-gaap--CashAndCashEquivalentsMember_zzWNzM114vD7" style="width: 12%; text-align: right" title="Unrealized losses"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;span style="-sec-ix-hidden: xdx2ixbrl0629"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--DebtSecuritiesAvailableForSaleRealizedGainLoss_pn3n3_c20220101__20220331__us-gaap--InvestmentTypeAxis__us-gaap--CashAndCashEquivalentsMember_zI5kxS58pm1b" style="width: 12%; text-align: right" title="Fair value"&gt;7,286&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Short-term investments&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pn3n3_c20220331__us-gaap--InvestmentTypeAxis__custom--ShortTermInvestmentMember_zp1sJ9jJAp6c" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cost"&gt;19,496&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--DebtSecuritiesAvailableForSaleRealizedGain_pn3n3_c20220101__20220331__us-gaap--InvestmentTypeAxis__custom--ShortTermInvestmentMember_z6JcJF0hjsqj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Unrealized gains"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0635"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--DebtSecuritiesAvailableForSaleRealizedLoss_pn3n3_c20220101__20220331__us-gaap--InvestmentTypeAxis__custom--ShortTermInvestmentMember_zc4BCyBuHV2c" style="border-bottom: Black 1.5pt solid; text-align: right" title="Unrealized losses"&gt;(42&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--DebtSecuritiesAvailableForSaleRealizedGainLoss_pn3n3_c20220101__20220331__us-gaap--InvestmentTypeAxis__custom--ShortTermInvestmentMember_zObPMSK74Ywc" style="border-bottom: Black 1.5pt solid; text-align: right" title="Fair value"&gt;19,454&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pn3n3_c20220331_zpr5X2NKUd03" style="border-bottom: Black 2.5pt double; text-align: right" title="Cost"&gt;26,782&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--DebtSecuritiesAvailableForSaleRealizedGain_pn3n3_c20220101__20220331_zfY6KFcS6X0g" style="border-bottom: Black 2.5pt double; text-align: right" title="Unrealized gains"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0643"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--DebtSecuritiesAvailableForSaleRealizedLoss_pn3n3_c20220101__20220331_zAugk9I5CE9g" style="border-bottom: Black 2.5pt double; text-align: right" title="Unrealized losses"&gt;(42&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--DebtSecuritiesAvailableForSaleRealizedGainLoss_pn3n3_c20220101__20220331_zrbNMYLOql2j" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value"&gt;26,740&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Unrealized&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Unrealized&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Fair&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Cost&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Gains&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Losses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 36%; text-align: left"&gt;Cash and cash equivalents&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pn3n3_c20211231__us-gaap--InvestmentTypeAxis__us-gaap--CashAndCashEquivalentsMember_zUlswoZLTXe5" style="width: 12%; text-align: right" title="Cost"&gt;8,968&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--DebtSecuritiesAvailableForSaleRealizedGain_pn3n3_c20210101__20211231__us-gaap--InvestmentTypeAxis__us-gaap--CashAndCashEquivalentsMember_zGH3sKl27OWa" style="width: 12%; text-align: right" title="Unrealized gains"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;span style="-sec-ix-hidden: xdx2ixbrl0651"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--DebtSecuritiesAvailableForSaleRealizedLoss_pn3n3_c20210101__20211231__us-gaap--InvestmentTypeAxis__us-gaap--CashAndCashEquivalentsMember_zdjO2Rrzkb99" style="width: 12%; text-align: right" title="Unrealized losses"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;span style="-sec-ix-hidden: xdx2ixbrl0653"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--DebtSecuritiesAvailableForSaleRealizedGainLoss_c20210101__20211231__us-gaap--InvestmentTypeAxis__us-gaap--CashAndCashEquivalentsMember_pn3n3" style="width: 12%; text-align: right" title="Fair value"&gt;8,968&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Short-term investments&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_c20211231__us-gaap--InvestmentTypeAxis__custom--ShortTermInvestmentMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cost"&gt;23,040&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--DebtSecuritiesAvailableForSaleRealizedGain_pn3n3_c20210101__20211231__us-gaap--InvestmentTypeAxis__custom--ShortTermInvestmentMember_zWVQ6LMxERjj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Unrealized gains"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0659"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--DebtSecuritiesAvailableForSaleRealizedLoss_c20210101__20211231__us-gaap--InvestmentTypeAxis__custom--ShortTermInvestmentMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Unrealized losses"&gt;(29&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--DebtSecuritiesAvailableForSaleRealizedGainLoss_c20210101__20211231__us-gaap--InvestmentTypeAxis__custom--ShortTermInvestmentMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Fair value"&gt;23,011&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_c20211231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Cost"&gt;32,008&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--DebtSecuritiesAvailableForSaleRealizedGain_pn3n3_c20210101__20211231_zBqd78pn4Eta" style="border-bottom: Black 2.5pt double; text-align: right" title="Unrealized gains"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0667"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--DebtSecuritiesAvailableForSaleRealizedLoss_c20210101__20211231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Unrealized losses"&gt;(29&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--DebtSecuritiesAvailableForSaleRealizedGainLoss_pn3n3_c20210101__20211231_zGnGlqfREVqk" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value"&gt;31,979&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="AsOf2022-03-31_us-gaap_CashAndCashEquivalentsMember"
      decimals="-3"
      unitRef="USD">7286000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss
      contextRef="From2022-01-012022-03-31_us-gaap_CashAndCashEquivalentsMember"
      decimals="-3"
      unitRef="USD">7286000</us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="AsOf2022-03-31_custom_ShortTermInvestmentMember"
      decimals="-3"
      unitRef="USD">19496000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss
      contextRef="From2022-01-012022-03-31_custom_ShortTermInvestmentMember"
      decimals="-3"
      unitRef="USD">-42000</us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss
      contextRef="From2022-01-012022-03-31_custom_ShortTermInvestmentMember"
      decimals="-3"
      unitRef="USD">19454000</us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">26782000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss
      contextRef="From2022-01-01to2022-03-31"
      decimals="-3"
      unitRef="USD">-42000</us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss
      contextRef="From2022-01-01to2022-03-31"
      decimals="-3"
      unitRef="USD">26740000</us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="AsOf2021-12-31_us-gaap_CashAndCashEquivalentsMember"
      decimals="-3"
      unitRef="USD">8968000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss
      contextRef="From2021-01-012021-12-31_us-gaap_CashAndCashEquivalentsMember"
      decimals="-3"
      unitRef="USD">8968000</us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="AsOf2021-12-31_custom_ShortTermInvestmentMember"
      decimals="-3"
      unitRef="USD">23040000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss
      contextRef="From2021-01-012021-12-31_custom_ShortTermInvestmentMember"
      decimals="-3"
      unitRef="USD">-29000</us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss
      contextRef="From2021-01-012021-12-31_custom_ShortTermInvestmentMember"
      decimals="-3"
      unitRef="USD">23011000</us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">32008000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">-29000</us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">31979000</us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock contextRef="From2022-01-01to2022-03-31">&lt;p id="xdx_89E_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_zI3PgrbzMN11" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table represents the Company&#x2019;s fair value hierarchy for its financial assets (cash equivalents and investments) (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B5_zDbwwi6g3JC5" style="display: none"&gt;Schedule
of Fair Value Hierarchy Financial Assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20220331_zxeNbTSQqHAb" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Fair Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20220331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zEjdov4Uo7Ij" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20220331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z66fYX6UdRsg" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20220331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zLGe7PBAqEml" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;March 31, 2022 (Unaudited)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Fair Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--FairValueNetAssetLiability_iI_pn3n3_hus-gaap--InvestmentTypeAxis__us-gaap--MoneyMarketFundsMember_zlEFJ7v5qpFe" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 36%; text-align: left"&gt;Money market funds&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;6,299&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;6,299&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&lt;span style="-sec-ix-hidden: xdx2ixbrl0677"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;span style="-sec-ix-hidden: xdx2ixbrl0678"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--FairValueNetAssetLiability_iI_pn3n3_hus-gaap--InvestmentTypeAxis__custom--CorporateNotesAndCommercialPaperMember_zJ2eGfprqtr1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Corporate notes and commercial paper&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;19,454&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0681"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;19,454&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0683"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--FairValueNetAssetLiability_iI_pn3n3_zbgzUE5eDvBi" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0pt; text-align: left; padding-bottom: 2.5pt"&gt;Total financial assets&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;25,753&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;6,299&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;19,454&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0688"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20211231_zG2l7AhYYoMd" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Fair Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z80spwcHx7p8" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zF69jgkUQ4jg" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zqoqfxEs4uib" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Fair Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--FairValueNetAssetLiability_iI_pn3n3_hus-gaap--InvestmentTypeAxis__us-gaap--MoneyMarketFundsMember_z29ohChGhUsc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 36%; text-align: left"&gt;Money market funds&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;5,484&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;5,484&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;span style="-sec-ix-hidden: xdx2ixbrl0692"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;span style="-sec-ix-hidden: xdx2ixbrl0693"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--FairValueNetAssetLiability_iI_pn3n3_hus-gaap--InvestmentTypeAxis__custom--CorporateNotesAndCommercialPaperMember_ztq6kmtGIfi3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Corporate notes and commercial paper&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;23,011&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0696"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;23,011&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0698"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--FairValueNetAssetLiability_iI_pn3n3_zC0E2xpy5qe7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0pt; text-align: left; padding-bottom: 2.5pt"&gt;Total financial assets&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;28,495&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;5,484&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;23,011&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0703"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:FairValueNetAssetLiability
      contextRef="AsOf2022-03-31_us-gaap_MoneyMarketFundsMember"
      decimals="-3"
      unitRef="USD">6299000</us-gaap:FairValueNetAssetLiability>
    <us-gaap:FairValueNetAssetLiability
      contextRef="AsOf2022-03-31_us-gaap_FairValueInputsLevel1Member_us-gaap_MoneyMarketFundsMember"
      decimals="-3"
      unitRef="USD">6299000</us-gaap:FairValueNetAssetLiability>
    <us-gaap:FairValueNetAssetLiability
      contextRef="AsOf2022-03-31_custom_CorporateNotesAndCommercialPaperMember"
      decimals="-3"
      unitRef="USD">19454000</us-gaap:FairValueNetAssetLiability>
    <us-gaap:FairValueNetAssetLiability
      contextRef="AsOf2022-03-31_us-gaap_FairValueInputsLevel2Member_custom_CorporateNotesAndCommercialPaperMember"
      decimals="-3"
      unitRef="USD">19454000</us-gaap:FairValueNetAssetLiability>
    <us-gaap:FairValueNetAssetLiability contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">25753000</us-gaap:FairValueNetAssetLiability>
    <us-gaap:FairValueNetAssetLiability
      contextRef="AsOf2022-03-31_us-gaap_FairValueInputsLevel1Member"
      decimals="-3"
      unitRef="USD">6299000</us-gaap:FairValueNetAssetLiability>
    <us-gaap:FairValueNetAssetLiability
      contextRef="AsOf2022-03-31_us-gaap_FairValueInputsLevel2Member"
      decimals="-3"
      unitRef="USD">19454000</us-gaap:FairValueNetAssetLiability>
    <us-gaap:FairValueNetAssetLiability
      contextRef="AsOf2021-12-31_us-gaap_MoneyMarketFundsMember"
      decimals="-3"
      unitRef="USD">5484000</us-gaap:FairValueNetAssetLiability>
    <us-gaap:FairValueNetAssetLiability
      contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_MoneyMarketFundsMember"
      decimals="-3"
      unitRef="USD">5484000</us-gaap:FairValueNetAssetLiability>
    <us-gaap:FairValueNetAssetLiability
      contextRef="AsOf2021-12-31_custom_CorporateNotesAndCommercialPaperMember"
      decimals="-3"
      unitRef="USD">23011000</us-gaap:FairValueNetAssetLiability>
    <us-gaap:FairValueNetAssetLiability
      contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel2Member_custom_CorporateNotesAndCommercialPaperMember"
      decimals="-3"
      unitRef="USD">23011000</us-gaap:FairValueNetAssetLiability>
    <us-gaap:FairValueNetAssetLiability contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">28495000</us-gaap:FairValueNetAssetLiability>
    <us-gaap:FairValueNetAssetLiability
      contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel1Member"
      decimals="-3"
      unitRef="USD">5484000</us-gaap:FairValueNetAssetLiability>
    <us-gaap:FairValueNetAssetLiability
      contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel2Member"
      decimals="-3"
      unitRef="USD">23011000</us-gaap:FairValueNetAssetLiability>
    <us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock contextRef="From2022-01-01to2022-03-31">&lt;p id="xdx_89C_eus-gaap--ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_zmExvcUrhL6b" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As of March 31, 2022, the fair value of the derivative liability amounted
to $&lt;span id="xdx_900_eus-gaap--DerivativeLiabilitiesCurrent_iI_pn3d_c20220331_z4SbKAkbsnCc"&gt;&lt;span id="xdx_905_eus-gaap--DerivativeLiabilitiesCurrent_iI_pn3d_c20210331_zyuayTJ2ZRJb"&gt;120,000&lt;/span&gt;&lt;/span&gt;. The details of derivative liability transactions for the three months ended March 31, 2022 and 2021, are as follows:&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;span id="xdx_8B9_zhINUzne4oz7" style="display: none"&gt;Schedule
of Derivative Liability Transactions&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b/&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20220101__20220331_zG55aeY08pz1" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;March 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20210101__20210331_zeB1f8gQSmw2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;March 31, 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(Unaudited)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(Unaudited)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--DerivativeLiabilitiesCurrent_iS_pn3d_z0EuE0GkcdC2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Beginning balance&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;138,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;383,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--IssuanceOfStockAndWarrantsForServicesOrClaims_pn3d_zIvGR25VX2kk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Fair value upon issuance of warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0710"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0711"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--IncreaseDecreaseInDerivativeLiabilities_pn3d_zuaXPbmfw0h8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Change in fair value&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(18,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(21,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_ecustom--ExtinguishmentOfWarrants_pn3d_z8LLtwMnJ73a" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Extinguishment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0716"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0717"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--DerivativeLiabilitiesCurrent_iE_pn3d_zW8Qm6sz2bQe" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Ending balance&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;120,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;362,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock>
    <us-gaap:DerivativeLiabilitiesCurrent contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">138000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">383000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:IncreaseDecreaseInDerivativeLiabilities
      contextRef="From2022-01-01to2022-03-31"
      decimals="-3"
      unitRef="USD">-18000</us-gaap:IncreaseDecreaseInDerivativeLiabilities>
    <us-gaap:IncreaseDecreaseInDerivativeLiabilities
      contextRef="From2021-01-012021-03-31"
      decimals="-3"
      unitRef="USD">-21000</us-gaap:IncreaseDecreaseInDerivativeLiabilities>
    <us-gaap:DerivativeLiabilitiesCurrent contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">120000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent contextRef="AsOf2021-03-31" decimals="-3" unitRef="USD">362000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="From2022-01-01to2022-03-31">&lt;p id="xdx_801_eus-gaap--AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_zmXy4sUY5Yw7" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
4 &#x2013; &lt;span id="xdx_824_zKdifaVeu57g"&gt;Accounts Payable&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89A_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zijFJvpzXUa2" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accounts
payable consisted of the following (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BA_zhJHGZcTSXc8" style="display: none"&gt;Schedule of Accounts Payable&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20220331_zOJxegZvtWFl" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;March 31, &lt;br/&gt;
2022 &lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20211231_zJq5UyUkUPZ1" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;December 31, &lt;br/&gt;
2021&lt;/p&gt;
                                                                  &lt;p style="margin-top: 0; margin-bottom: 0"/&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;(Unaudited)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--AccountsPayableRelatedPartiesCurrent_iI_pn3n3_maAPCz7ta_zgaOSxvWmmzg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Accounts payable to a third-party manufacturer&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;7,423&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;6,335&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--AccountsPayableOtherCurrent_iI_pn3n3_maAPCz7ta_zzkEUsbFKf46" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;Other accounts payable&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;690&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,885&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--AccountsPayableCurrent_iTI_pn3n3_mtAPCz7ta_z00cLDEcrAJ3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;Total accounts payable&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;8,113&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;8,220&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AD_zt5bRxPkVhNc" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company relies on a third-party contract manufacturing operation to produce and/or test our compounds used in our potential product candidates.
As of March 31, 2022 the Company was indebted $&lt;span id="xdx_908_eus-gaap--AccountsPayableCurrent_iI_pn5n6_c20220331__us-gaap--RelatedPartyTransactionAxis__custom--VendorMember_zGLvHbeTpDU7" title="Accounts payable current"&gt;7.4&lt;/span&gt; million of accounts payable to this vendor.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock contextRef="From2022-01-01to2022-03-31">&lt;p id="xdx_89A_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zijFJvpzXUa2" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accounts
payable consisted of the following (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BA_zhJHGZcTSXc8" style="display: none"&gt;Schedule of Accounts Payable&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20220331_zOJxegZvtWFl" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;March 31, &lt;br/&gt;
2022 &lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20211231_zJq5UyUkUPZ1" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;December 31, &lt;br/&gt;
2021&lt;/p&gt;
                                                                  &lt;p style="margin-top: 0; margin-bottom: 0"/&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;(Unaudited)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--AccountsPayableRelatedPartiesCurrent_iI_pn3n3_maAPCz7ta_zgaOSxvWmmzg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Accounts payable to a third-party manufacturer&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;7,423&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;6,335&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--AccountsPayableOtherCurrent_iI_pn3n3_maAPCz7ta_zzkEUsbFKf46" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;Other accounts payable&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;690&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,885&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--AccountsPayableCurrent_iTI_pn3n3_mtAPCz7ta_z00cLDEcrAJ3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;Total accounts payable&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;8,113&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;8,220&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccountsPayableRelatedPartiesCurrent contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">7423000</us-gaap:AccountsPayableRelatedPartiesCurrent>
    <us-gaap:AccountsPayableRelatedPartiesCurrent contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">6335000</us-gaap:AccountsPayableRelatedPartiesCurrent>
    <us-gaap:AccountsPayableOtherCurrent contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">690000</us-gaap:AccountsPayableOtherCurrent>
    <us-gaap:AccountsPayableOtherCurrent contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">1885000</us-gaap:AccountsPayableOtherCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">8113000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">8220000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2022-03-31_custom_VendorMember"
      decimals="-5"
      unitRef="USD">7400000</us-gaap:AccountsPayableCurrent>
    <us-gaap:DebtDisclosureTextBlock contextRef="From2022-01-01to2022-03-31">&lt;p id="xdx_80A_eus-gaap--DebtDisclosureTextBlock_zsWSV5fQgRmk" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
5 &#x2013; &lt;span id="xdx_826_zIhcg88MHJI4"&gt;Convertible Notes Payable&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;Notes
Payable Issued for Cash&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
part of the Company&#x2019;s financing activities, the Company issued convertible notes payable totaling $&lt;span id="xdx_906_eus-gaap--ConvertibleNotesPayableCurrent_iI_pn5n6_c20220331__us-gaap--AwardDateAxis__custom--AuguestOneTwentyEighteenAndJanuaryTwentySixTwentyTwentyOneMember_zLkEk8aFX2va" title="Convertible notes payable"&gt;25.3&lt;/span&gt; million between August
1, 2018 and January 26, 2021. On February 16, 2021, in accordance with the terms of the note agreements upon completion of the equity
offering, these notes were mandatorily converted at a conversion rate of $&lt;span id="xdx_907_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20210216__us-gaap--AwardDateAxis__custom--AuguestOneTwentyEighteenAndJanuaryTwentySixTwentyTwentyOneMember_zNDMRAtkkkbf" title="Conversion rate"&gt;3.40&lt;/span&gt; per share into &lt;span id="xdx_90C_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_pid_c20210215__20210216__us-gaap--AwardDateAxis__custom--AuguestOneTwentyEighteenAndJanuaryTwentySixTwentyTwentyOneMember_zS3KLaRWWsZh" title="Converted conversion of common stock"&gt;7,438,235&lt;/span&gt; shares of the Company&#x2019;s
common stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;Notes
Pa&lt;/span&gt;y&lt;span style="text-decoration: underline"&gt;able Issued for Settlement Agreements&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
fiscal 2019 and 2020, the Company issued its convertible notes payable in the amount of $&lt;span id="xdx_905_eus-gaap--ConvertibleNotesPayable_iI_pn5n6_c20191231_zS5UymwT9Tv1" title="Convertible notes payable"&gt;&lt;span id="xdx_90B_eus-gaap--ConvertibleNotesPayable_iI_pn5n6_c20201231_zhTdbi2bppr8" title="Convertible notes payable"&gt;2.5&lt;/span&gt;&lt;/span&gt; million to resolve claims and disputes
pertaining to certain debt and equity instruments issued by the Company in prior years. On February 16, 2021 in accordance with the note
agreements upon completion of the equity offering, these notes were mandatorily converted at a conversion rate of $&lt;span id="xdx_906_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20210216__us-gaap--DebtInstrumentAxis__custom--NotesPayableIssuedForSettlementAgreementsMember__us-gaap--AwardDateAxis__custom--FiscalTwentyNinteenandTwentyTwentyMember_zja1C7zWAJt3"&gt;3.40
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;per share into &lt;span id="xdx_909_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_pid_c20210215__20210216__us-gaap--DebtInstrumentAxis__custom--NotesPayableIssuedForSettlementAgreementsMember__us-gaap--AwardDateAxis__custom--FiscalTwentyNinteenandTwentyTwentyMember_zFWn4AyITj38"&gt;743,529
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares of the Company&#x2019;s common stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;Notes
Pa&lt;/span&gt;y&lt;span style="text-decoration: underline"&gt;able Issued for Forbearance Agreements&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
June 23, 2020, the Company entered into Standstill and Forbearance Agreements (collectively, the &#x201c;Forbearance Agreements&#x201d;)
with the holders of $&lt;span id="xdx_907_eus-gaap--DebtInstrumentFaceAmount_iI_pn5n6_c20200623__us-gaap--TypeOfArrangementAxis__custom--ForbearanceAgreementsMember_zRYIyVEPQps8" title="Debt instrument, face amount"&gt;13.2&lt;/span&gt; million aggregate principal amount of the Convertible Notes (the &#x201c;Default Notes&#x201d;), which were in
default. Pursuant to the Forbearance Agreements, the holders of the Default Notes agreed to forbear from exercising their rights and
remedies under the Default Notes (including declaring such Default Notes (together with any default amounts and accrued and unpaid interest)
immediately due and payable) until the earlier of (i) the date that the Company completes a future financing in the amount of $&lt;span id="xdx_905_eus-gaap--NotesPayable_iI_pn6n6_c20200623__us-gaap--TypeOfArrangementAxis__custom--ForbearanceAgreementsMember_zsZ8XwSJoOr2" title="Notes payable"&gt;15&lt;/span&gt; million
and, in connection therewith, commences listing on NASDAQ (collectively, the &#x201c;New Financing&#x201d;) or (ii) January 31, 2021 (the
&#x201c;Termination Date&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
February 16, 2021 in accordance with the note agreements upon completion of the equity offering, these notes, in the amount of $&lt;span id="xdx_902_eus-gaap--DebtConversionConvertedInstrumentAmount1_pn5n6_c20210215__20210216__us-gaap--DebtInstrumentAxis__custom--NotesPayableIssuedForForbearanceAgreementMember_zKh7JHSyEsV8" title="Debt Conversion, Converted Instrument, Amount"&gt;3.8&lt;/span&gt;
million, were mandatorily converted at a conversion rate of $&lt;span id="xdx_90F_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20210216__us-gaap--TypeOfArrangementAxis__custom--ForbearanceAgreementsMember_zZDKE7U4rnx5"&gt;3.40
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;per share into &lt;span id="xdx_902_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_pid_c20210215__20210216__us-gaap--TypeOfArrangementAxis__custom--ForbearanceAgreementsMember_zChZkLtWCY41"&gt;1,132,059
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares of the Company&#x2019;s common stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;Notes
Pa&lt;/span&gt;y&lt;span style="text-decoration: underline"&gt;able issued for Consulting Agreements&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
prior years, the Company issued its convertible notes payable in exchange for consulting services in the amount of $&lt;span id="xdx_903_ecustom--ConvertibleNotesPayableIssuedInExchangeForConsultingServices_pn5n6_c20220101__20220331_ze3buae1LZsc" title="Notes payable in exchange of consulting services"&gt;1.6&lt;/span&gt; million.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
February 16, 2021 in accordance with the note agreements upon completion of the equity offering, these notes in the aggregate amount
of $&lt;span id="xdx_906_eus-gaap--DebtConversionConvertedInstrumentAmount1_pn5n6_c20210215__20210216__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementsMember_zUIqzoh61lzd" title="Debt converted amount"&gt;1.6&lt;/span&gt; million were mandatorily converted at a conversion rate of $&lt;span id="xdx_900_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20210216__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementsMember_zT9AIRK5PY54" title="Conversion price per share"&gt;3.40&lt;/span&gt; per share into &lt;span id="xdx_90A_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_pid_c20210215__20210216__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementsMember_zgvys8tqU6ph" title="Converted conversion of common stock"&gt;472,059&lt;/span&gt; shares of the Company&#x2019;s common
stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;Notes Payable issued for Accrued
Interest&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In prior years, the Company recorded accrued interest
of $&lt;span id="xdx_90F_ecustom--AccruedInterestAmount_pn5n6_c20220101__20220331_zRHUntFo7Z5h" title="Accrued interest amount"&gt;5.6&lt;/span&gt; million related to all notes payable. On February 16, 2021, in accordance with the note agreements upon completion of the equity
offering, the accrued interest was mandatorily converted at a conversion rate of $&lt;span id="xdx_907_eus-gaap--DebtConversionConvertedInstrumentRate_pid_dp_uPure_c20210215__20210216_zZ6BZf04p37c" title="Debt conversion rate"&gt;3.40&lt;/span&gt; per share into &lt;span id="xdx_904_eus-gaap--ConversionOfStockSharesConverted1_pid_c20210215__20210216_ze6kBBBndOO9" title="Conversion of common stock"&gt;1,627,440&lt;/span&gt; shares of the Company&#x2019;s
common stock.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 9.5pt 0pt 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;Adoption
of ASU 2020-&lt;span style="letter-spacing: -0.25pt"&gt;06&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 9.5pt 0pt 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 9.5pt 0pt 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
fiscal 2020, the Company recorded a note/debt discount of $&lt;span id="xdx_907_eus-gaap--DebtInstrumentConvertibleBeneficialConversionFeature_pn5n6_c20200101__20201231__us-gaap--DebtInstrumentAxis__custom--AdoptionofAsuTwentyTwentyZeroSixMember__us-gaap--AwardDateAxis__custom--DuringTwentyTwentyMember_zdu21bJnGmzf" title="Beneficial conversion feature"&gt;4.7&lt;/span&gt; million&#160;to account for the beneficial conversion feature that existed
on the date of issuance for the above convertible notes payable. The debt discount was being amortized to interest expense over the term
of the corresponding convertible notes payable.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 9.5pt 0pt 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 9.5pt 0pt 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
January 1, 2021 the Company chose to adopt ASU 2020-06, Debt-Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives
and Hedging-Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#x2019;s
Own Equity. As a result of the adoption of ASU 2020-06, the Company extinguished the previously recorded debt discount of $&lt;span id="xdx_900_eus-gaap--DebtInstrumentConvertibleBeneficialConversionFeature_pn5n6_c20220101__20220331__us-gaap--DebtInstrumentAxis__custom--AdoptionofAsuTwentyTwentyZeroSixMember__us-gaap--AwardDateAxis__custom--JanuaryOneTwentyTwentyOneMember_z4OGDfn5vSqh"&gt;4.7&lt;/span&gt; million&#160;by
charging the opening additional paid in capital at January 1, 2021. In addition, the Company also adjusted accumulated deficit to account
for the derecognition of the $&lt;span id="xdx_90A_ecustom--InterestExpenseDueAmortizationOfDebtDiscount_iI_pn5n6_c20220331__us-gaap--DebtInstrumentAxis__custom--AdoptionofAsuTwentyTwentyZeroSixMember__us-gaap--AwardDateAxis__custom--DuringTwentyTwentyMember_zleabVONGvu4" title="Interest expense due amortization of debt discount"&gt;0.2&lt;/span&gt; million&#160;interest expense due&lt;/span&gt; to the amortization of the debt discount that was recorded
in fiscal 2020.&lt;b&gt;&#160;&lt;/b&gt;As a result of these adjustments, the unamortized debt discount of $&lt;span id="xdx_902_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_pn5n6_c20220331__us-gaap--DebtInstrumentAxis__custom--AdoptionofAsuTwentyTwentyZeroSixMember__us-gaap--AwardDateAxis__custom--JanuaryOneTwentyTwentyOneMember_zByyCyiGm7Ne" title="Unamortized debt discount"&gt;4.5&lt;/span&gt; million&#160;was extinguished.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ConvertibleNotesPayableCurrent
      contextRef="AsOf2022-03-31_custom_AuguestOneTwentyEighteenAndJanuaryTwentySixTwentyTwentyOneMember"
      decimals="-5"
      unitRef="USD">25300000</us-gaap:ConvertibleNotesPayableCurrent>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="AsOf2021-02-16_custom_AuguestOneTwentyEighteenAndJanuaryTwentySixTwentyTwentyOneMember"
      decimals="INF"
      unitRef="USDPShares">3.40</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="From2021-02-152021-02-16_custom_AuguestOneTwentyEighteenAndJanuaryTwentySixTwentyTwentyOneMember"
      decimals="INF"
      unitRef="Shares">7438235</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:ConvertibleNotesPayable contextRef="AsOf2019-12-31" decimals="-5" unitRef="USD">2500000</us-gaap:ConvertibleNotesPayable>
    <us-gaap:ConvertibleNotesPayable contextRef="AsOf2020-12-31" decimals="-5" unitRef="USD">2500000</us-gaap:ConvertibleNotesPayable>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="AsOf2021-02-16_custom_NotesPayableIssuedForSettlementAgreementsMember_custom_FiscalTwentyNinteenandTwentyTwentyMember"
      decimals="INF"
      unitRef="USDPShares">3.40</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="From2021-02-152021-02-16_custom_NotesPayableIssuedForSettlementAgreementsMember_custom_FiscalTwentyNinteenandTwentyTwentyMember"
      decimals="INF"
      unitRef="Shares">743529</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2020-06-23_custom_ForbearanceAgreementsMember"
      decimals="-5"
      unitRef="USD">13200000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:NotesPayable
      contextRef="AsOf2020-06-23_custom_ForbearanceAgreementsMember"
      decimals="-6"
      unitRef="USD">15000000</us-gaap:NotesPayable>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="From2021-02-152021-02-16_custom_NotesPayableIssuedForForbearanceAgreementMember"
      decimals="-5"
      unitRef="USD">3800000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="AsOf2021-02-16_custom_ForbearanceAgreementsMember"
      decimals="INF"
      unitRef="USDPShares">3.40</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="From2021-02-152021-02-16_custom_ForbearanceAgreementsMember"
      decimals="INF"
      unitRef="Shares">1132059</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <GTBP:ConvertibleNotesPayableIssuedInExchangeForConsultingServices
      contextRef="From2022-01-01to2022-03-31"
      decimals="-5"
      unitRef="USD">1600000</GTBP:ConvertibleNotesPayableIssuedInExchangeForConsultingServices>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="From2021-02-152021-02-16_custom_ConsultingAgreementsMember"
      decimals="-5"
      unitRef="USD">1600000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="AsOf2021-02-16_custom_ConsultingAgreementsMember"
      decimals="INF"
      unitRef="USDPShares">3.40</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="From2021-02-152021-02-16_custom_ConsultingAgreementsMember"
      decimals="INF"
      unitRef="Shares">472059</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <GTBP:AccruedInterestAmount
      contextRef="From2022-01-01to2022-03-31"
      decimals="-5"
      unitRef="USD">5600000</GTBP:AccruedInterestAmount>
    <us-gaap:DebtConversionConvertedInstrumentRate
      contextRef="From2021-02-152021-02-16"
      decimals="INF"
      unitRef="Pure">0.0340</us-gaap:DebtConversionConvertedInstrumentRate>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="From2021-02-152021-02-16"
      decimals="INF"
      unitRef="Shares">1627440</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature
      contextRef="From2020-01-012020-12-31_custom_AdoptionofAsuTwentyTwentyZeroSixMember_custom_DuringTwentyTwentyMember"
      decimals="-5"
      unitRef="USD">4700000</us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature>
    <us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature
      contextRef="From2022-01-012022-03-31_custom_AdoptionofAsuTwentyTwentyZeroSixMember_custom_JanuaryOneTwentyTwentyOneMember"
      decimals="-5"
      unitRef="USD">4700000</us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature>
    <GTBP:InterestExpenseDueAmortizationOfDebtDiscount
      contextRef="AsOf2022-03-31_custom_AdoptionofAsuTwentyTwentyZeroSixMember_custom_DuringTwentyTwentyMember"
      decimals="-5"
      unitRef="USD">200000</GTBP:InterestExpenseDueAmortizationOfDebtDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="AsOf2022-03-31_custom_AdoptionofAsuTwentyTwentyZeroSixMember_custom_JanuaryOneTwentyTwentyOneMember"
      decimals="-5"
      unitRef="USD">4500000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DerivativesAndFairValueTextBlock contextRef="From2022-01-01to2022-03-31">&lt;p id="xdx_80D_eus-gaap--DerivativesAndFairValueTextBlock_zuWnNIcIGt1" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Note
6 &#x2013; &lt;span id="xdx_82C_zV8MNW9ikHj1"&gt;Derivative Liability&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the year ended December 31, 2020, the Company issued certain warrants that contained a fundamental transaction provision that could give
rise to an obligation to pay cash to the warrant holder upon occurrence of certain change in control type events. In accordance with
ASC 480, the fair value of these warrants is classified as a liability in the Condensed Consolidated Balance Sheet and will be
re- measured at the end of every reporting period with the change in value reported in the statement of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89F_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_zYcz0vlKIxW" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
derivative liabilities were valued using a Binomial pricing model with the following average assumptions:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B2_zdAyouL0Qnn4" style="display: none"&gt;Schedule
of Derivative Liabilities Assumptions&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;March 31&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December 31&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2022&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b/&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;2021&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"/&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="padding-bottom: 1.5pt; text-align: center"&gt;&lt;b&gt;(Unaudited)&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%"&gt;Stock Price&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--SharePrice_iI_pid_c20220331_zTYm3dbo2xX6" title="Stock Price"&gt;2.88&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--SharePrice_iI_pid_c20211231_z4R4jSPSkTu5" title="Stock Price"&gt;3.05&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Risk-free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20220331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zlyRpeVCVeh1" title="Risk-free interest rate"&gt;2.42&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zVp6pQCz6Owc" title="Risk-free interest rate"&gt;1.26&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expected volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20220331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zJ73JYTImDci" title="Expected volatility"&gt;127&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zL20lNqzqNd1" title="Expected volatility"&gt;129&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected life (in years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_ecustom--DerivativeLiabilityFairValueAssumptionsExpectedTerm1_dtY_c20220101__20220331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zGvKIoyzrawk" title="Expected life (in years)"&gt;3.3&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90E_ecustom--DerivativeLiabilityFairValueAssumptionsExpectedTerm1_dtY_c20210101__20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zE2HmJRBFaC1" title="Expected life (in years)"&gt;3.6&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Expected dividend yield&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_dp_uPure_c20220331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zfp6Vho0rCQ3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Expected dividend yield"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0800"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_dp_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_z4ounqs98iX1" style="border-bottom: Black 1.5pt solid; text-align: right" title="Expected dividend yield"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0802"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Fair Value of Warrants&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--FairValueAdjustmentOfWarrants_c20220101__20220331_zVo4G5kPuZi3" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value of warrants"&gt;120,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--FairValueAdjustmentOfWarrants_c20210101__20211231_zUYPRxq3FoNh" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value of warrants"&gt;138,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A9_z9WGbVISiQU3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
risk-free interest rate was based on rates established by the Federal Reserve Bank. The Company uses the historical volatility of its
common stock to estimate the future volatility for its common stock. The expected life of the derivative securities was determined by
the remaining contractual life of the derivative instrument. The expected dividend yield was based on the fact that the Company has not paid dividends to its common stockholders in the past
and does not expect to pay dividends to its common stockholders in the future.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the three months ended March 31, 2022, the Company recognized a gain of $&lt;span id="xdx_900_eus-gaap--DerivativeGainOnDerivative_c20220101__20220331_zXEqobUxBWpd"&gt;18,000
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;to account for the change in fair value of the
derivative liability between the reporting periods in accordance with ASC 842.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:DerivativesAndFairValueTextBlock>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock contextRef="From2022-01-01to2022-03-31">&lt;p id="xdx_89F_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_zYcz0vlKIxW" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
derivative liabilities were valued using a Binomial pricing model with the following average assumptions:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B2_zdAyouL0Qnn4" style="display: none"&gt;Schedule
of Derivative Liabilities Assumptions&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;March 31&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December 31&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2022&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b/&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;2021&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"/&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="padding-bottom: 1.5pt; text-align: center"&gt;&lt;b&gt;(Unaudited)&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%"&gt;Stock Price&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--SharePrice_iI_pid_c20220331_zTYm3dbo2xX6" title="Stock Price"&gt;2.88&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--SharePrice_iI_pid_c20211231_z4R4jSPSkTu5" title="Stock Price"&gt;3.05&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Risk-free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20220331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zlyRpeVCVeh1" title="Risk-free interest rate"&gt;2.42&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zVp6pQCz6Owc" title="Risk-free interest rate"&gt;1.26&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expected volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20220331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zJ73JYTImDci" title="Expected volatility"&gt;127&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zL20lNqzqNd1" title="Expected volatility"&gt;129&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected life (in years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_ecustom--DerivativeLiabilityFairValueAssumptionsExpectedTerm1_dtY_c20220101__20220331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zGvKIoyzrawk" title="Expected life (in years)"&gt;3.3&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90E_ecustom--DerivativeLiabilityFairValueAssumptionsExpectedTerm1_dtY_c20210101__20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zE2HmJRBFaC1" title="Expected life (in years)"&gt;3.6&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Expected dividend yield&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_dp_uPure_c20220331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zfp6Vho0rCQ3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Expected dividend yield"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0800"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_dp_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_z4ounqs98iX1" style="border-bottom: Black 1.5pt solid; text-align: right" title="Expected dividend yield"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0802"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Fair Value of Warrants&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--FairValueAdjustmentOfWarrants_c20220101__20220331_zVo4G5kPuZi3" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value of warrants"&gt;120,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--FairValueAdjustmentOfWarrants_c20210101__20211231_zUYPRxq3FoNh" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value of warrants"&gt;138,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:SharePrice
      contextRef="AsOf2022-03-31"
      decimals="INF"
      unitRef="USDPShares">2.88</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="AsOf2021-12-31"
      decimals="INF"
      unitRef="USDPShares">3.05</us-gaap:SharePrice>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="AsOf2022-03-31_us-gaap_MeasurementInputRiskFreeInterestRateMember"
      decimals="INF"
      unitRef="Pure">2.42</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="AsOf2021-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember"
      decimals="INF"
      unitRef="Pure">1.26</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="AsOf2022-03-31_us-gaap_MeasurementInputPriceVolatilityMember"
      decimals="INF"
      unitRef="Pure">127</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="AsOf2021-12-31_us-gaap_MeasurementInputPriceVolatilityMember"
      decimals="INF"
      unitRef="Pure">129</us-gaap:DerivativeLiabilityMeasurementInput>
    <GTBP:DerivativeLiabilityFairValueAssumptionsExpectedTerm1 contextRef="From2022-01-012022-03-31_us-gaap_MeasurementInputExpectedTermMember">P3Y3M18D</GTBP:DerivativeLiabilityFairValueAssumptionsExpectedTerm1>
    <GTBP:DerivativeLiabilityFairValueAssumptionsExpectedTerm1 contextRef="From2021-01-012021-12-31_us-gaap_MeasurementInputExpectedTermMember">P3Y7M6D</GTBP:DerivativeLiabilityFairValueAssumptionsExpectedTerm1>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2022-01-01to2022-03-31"
      decimals="-3"
      unitRef="USD">120000000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">138000000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:DerivativeGainOnDerivative
      contextRef="From2022-01-01to2022-03-31"
      decimals="0"
      unitRef="USD">18000</us-gaap:DerivativeGainOnDerivative>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2022-01-01to2022-03-31">&lt;p id="xdx_808_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zWMlWuj3AF94" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Note
7 &#x2013; &lt;span id="xdx_82F_zZ5QpLyKnDk9"&gt;Stockholders&#x2019; Equity&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: normal 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-style: normal; font-weight: normal"&gt;The
Company&#x2019;s authorized capital as of March 31, 2022 was &lt;span id="xdx_904_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20220331_zCSijIPSZLW5" title="Common stock, shares authorized"&gt;750,000,000&lt;/span&gt; shares of common stock, par value $&lt;span id="xdx_909_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20220331_zvptnkaRREgg" title="Common stock, par value"&gt;0.001&lt;/span&gt; per share, and &lt;span id="xdx_908_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20220331_z1Npg8AXpNuj" title="Preferred stock, shares authorized"&gt;15,000,000&lt;/span&gt;
shares of preferred stock, par value $&lt;span id="xdx_90F_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20220331_zQqazY9UOWD1" title="Preferred stock, par value"&gt;0.01&lt;/span&gt; per share.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;Common
Stock&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Common
Stock Issuable&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
February 16, 2021, as a result of the mandatory conversion of the notes payable and accrued interest in the aggregate amount of $&lt;span id="xdx_909_eus-gaap--DebtConversionConvertedInstrumentAmount1_pn5n6_c20210215__20210216_zb8R93AKulg4"&gt;38.8
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million, the Company issued a total of &lt;span id="xdx_904_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_pid_c20210215__20210216_zI09xAIu2Jp9"&gt;11,413,322
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares of common stock to the respective noteholders,
of which &lt;span id="xdx_907_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_pid_c20210101__20211231_zib2HLgLrT1j"&gt;11,086,024
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;were already issued as of December 31,
2021.&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt; The remaining &lt;span id="xdx_90B_eus-gaap--SharesIssued_iI_pid_c20211231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockIssuableMember_z6EOaou8B1L8"&gt;327,298
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;common &lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares
issuable at December 31, 2021 valued at $&lt;span id="xdx_900_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn5n6_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__custom--CommonStockIssuableMember_z5aJXUB7Wzx5"&gt;1.1
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million,&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;
were issued during the three months period ended March 31, 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Cancellation of common stock&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;During the period ended March 31, 2022, the Company
cancelled and returned to authorized capital &lt;span id="xdx_90D_eus-gaap--StockRepurchasedAndRetiredDuringPeriodShares_pid_c20220101__20220331_zh28nJx1ouJ5" title="Common shares cancelled and returned"&gt;290,999&lt;/span&gt; previously issued shares of common stock.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Equity
compensation to officers, employees, and board of directors&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As part of employment agreements with its former
CEO and its former CFO (&#x201c;Officers&#x201d;), the Officers received a fully vested stock grant equal to an aggregate of&#160;&lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_pid_dp_uPure_c20220101__20220331__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementsMember_zVMp8m7L5jf1" title="Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum"&gt;10&lt;/span&gt;% and&#160;&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_pid_dp_uPure_c20220101__20220331__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementsMember_zmRVBIY3Qjf9" title="Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum"&gt;1.5&lt;/span&gt;%
of the fully diluted shares of common stock of the Company (calculated with the inclusion of the current stock holdings of the CEO) upon
conversion of options, warrants and Convertible Notes in association with a national markets qualified financing as consideration for
entering into the Agreement (with such stock to vest and be delivered within 30 days after the national markets qualified financing).
In addition, the Company also granted similar equity compensation to members of the Company&#x2019;s board of directors wherein these
directors received stock grants equal to&#160;&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_pid_dp_uPure_c20220101__20220331__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementsMember__srt--RangeAxis__srt--MinimumMember_zewLcFpVZw1g" title="Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum"&gt;1&lt;/span&gt;% and&#160;&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_pid_dp_uPure_c20220101__20220331__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementsMember__srt--RangeAxis__srt--MaximumMember_z3xzAnQe2pcb" title="Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum"&gt;1.25&lt;/span&gt;% of the fully diluted shares of common stock of the Company.&#160;&lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_c20220101__20220331__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementsMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zXGci5T8VxFi" title="Share-based Compensation Arrangement by Share-based Payment Award, Description"&gt;Pursuant
to the agreement, approximately 33% of the common stock to be issued vested immediately while the remaining&lt;/span&gt;&#160;67% will vest over a
period of &lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dc_c20220101__20220331_z3JB7VLGxlPf" title="Vesting period"&gt;two years&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On February 16, 2021, the Company completed its
equity offering and listed its shares of common stock on the Nasdaq Capital Market. As such,&#160;&lt;span id="xdx_900_ecustom--CommonStockSharesGrantedForConsultants_pid_c20210215__20210216_zpRJqgSrMxR9" title="Common stock shares granted for consultants"&gt;4,379,407&lt;/span&gt;&#160;shares of its common
stock were granted to these Officers, employees and board of directors, which had a fair value of $&lt;span id="xdx_90E_ecustom--FairValueOfStockOptionsGrantedForConsultants_pn5n6_c20210215__20210216_zoQX27lrTJqa" title="Fair value of stock options granted f0r consultants"&gt;18.6&lt;/span&gt;&#160;million. Since the grant
of the common stock is subject to milestone or performance conditions, the Company measured the fair value of the common stock on the
respective date of the agreement, and such awards were recorded as compensation expense as the milestone or performance condition is
met and in accordance with its vesting terms.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;During the period ended March 31, 2021, the Company
recognized $&lt;span id="xdx_906_eus-gaap--ShareBasedCompensation_pn5n6_c20210101__20210331__srt--TitleOfIndividualAxis__custom--EmployeesMember_z5IwEMH2Ti0f"&gt;14.3&lt;/span&gt; million of stock compensation expense related to vesting of shares to officers, employees and board of directors.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;During the period ended March 31, 2022, the Company
recognized $&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensation_c20220101__20220331__srt--TitleOfIndividualAxis__custom--EmployeesMember_zU9rwNamXxH5"&gt;447,000&lt;/span&gt; of stock compensation expense related to vesting of shares to officers, employees and board of directors. &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
fair value of the remaining &lt;span id="xdx_901_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedTounVestOutstandingNumber_iI_pid_c20220331__srt--TitleOfIndividualAxis__custom--OfficersEmployeesAndBoardOfDirectorsMember_z6bAYGFzRKnk"&gt;291,700
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;unvested shares of common stock to officers,
employees and board of directors at March 31, 2022 was $&lt;span id="xdx_90A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToUnVestOutstandingAggregateIntrinsicValue_iI_pn5n6_c20220331__srt--TitleOfIndividualAxis__custom--OfficersEmployeesAndBoardOfDirectorsMember_zk4fysE53Xuj"&gt;1.4
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million and will be recognized as stock compensation
expense in future periods. &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Issuance
of common shares for services&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As part of consulting agreements with certain
consultants, the Company agreed to grant these consultants common stock equal to&#160;&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_pid_dp_uPure_c20210215__20210215__srt--RangeAxis__srt--MinimumMember_zE2MJgbn1Si8" title="Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum"&gt;1&lt;/span&gt;% and&#160;&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_pid_dp_uPure_c20210215__20210215__srt--RangeAxis__srt--MaximumMember_z9q3JquBztld" title="Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum"&gt;3&lt;/span&gt;% of the fully diluted shares of common
stock of the Company upon conversion of options, warrants and Convertible Notes in association with a national markets qualified financing
as consideration for entering into the Agreement (with such stock to vest and be delivered within 30 days after the national markets
qualified financing).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On February 16, 2021, the Company completed its
equity offering and listed its shares of common stock on the Nasdaq Capital Market. As a result of this offering, the Company agreed
to issue to these consultants&#160;&lt;span id="xdx_90C_eus-gaap--SharesIssued_iI_pid_c20210216_zIN88rZ4JMJe" title="Shares issued"&gt;2,850,090&lt;/span&gt;&#160;shares of common stock with a grant date fair value of $&lt;span id="xdx_905_ecustom--CommonStockConsultantToFairValue_pn5n6_c20210215__20210216_zp3b2HWXjAlc" title="Common stock consultant to fair value"&gt;10.7&lt;/span&gt;&#160;million,&#160;of
which&#160;&lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_pid_c20210216_zWAkJfHVFz21" title="Vested shares"&gt;1,934,817&lt;/span&gt;&#160;shares of common stock vested immediately while the remaining&#160;&lt;span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pid_c20210215__20210216_zFJQBqsHU237" title="Remaining vested shares"&gt;915,273&lt;/span&gt;,&#160;shares of&#160;common stock
vests over &lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dc_c20210215__20210216_z96yp33tIXV8" title="Vested period"&gt;two years&lt;/span&gt;. Pursuant to current accounting guidelines, as the grant of the common stock is subject to milestone or performance
conditions, the Company measured the fair value of the common stock on the respective date of the agreement, and then such award is being
recorded as compensation expense based upon the vesting term of the grant.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;During the period ended March 31, 2021, the Company
recognized $&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensation_pn5n6_c20210101__20210331_zYxaVnBQydD9" title="Share based compensation"&gt;8.5&lt;/span&gt; million of stock compensation expense related to the issuance of &lt;span id="xdx_90C_eus-gaap--SharesIssued_iI_pid_c20210331_zOGACsz92y6b" title="Shares issued"&gt;1,957,374&lt;/span&gt; shares of common stock and the vesting of
shares to these consultants.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the period ended March 31, 2022, the&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt; Company recognized
$&lt;span id="xdx_906_eus-gaap--ShareBasedCompensation_c20220101__20220331__srt--TitleOfIndividualAxis__custom--ConsultingMember_zirSHx53TV9e"&gt;872,000
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;of stock compensation expense related to the
issuance of &lt;span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensation_pid_c20220101__20220331__srt--TitleOfIndividualAxis__custom--ConsultingMember_zoOlMvkfQDji"&gt;46,500
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares of common stock and the vesting of &lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_pid_c20220101__20220331__srt--TitleOfIndividualAxis__custom--ConsultingMember_znxlirzZpaAb"&gt;116,247
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares of common stock issued to consultants
for services in fiscal 2022. The fair value of the &lt;span id="xdx_902_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedTounVestOutstandingNumber_iI_pid_c20220331__srt--TitleOfIndividualAxis__custom--ConsultingMember_zT64upi4Mp95"&gt;389,570
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;unvested shares of common stock to consultants
at March 31, 2022 was $&lt;span id="xdx_90D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToUnVestOutstandingAggregateIntrinsicValue_iI_pn5n6_c20220331__srt--TitleOfIndividualAxis__custom--ConsultingMember_zO40t43rDWsj"&gt;1.3
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million and will be recognized as stock compensation
expense in future periods. &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;Preferred
Stock&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;Series
C Preferred Stock&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
March 31, 2022 and March 31, 2021, there were &lt;span id="xdx_906_eus-gaap--PreferredStockSharesIssued_iI_c20220331__us-gaap--StatementClassOfStockAxis__custom--SeriesCPreferredStocksMember_zciSKlx8pGyb"&gt;&lt;span id="xdx_90F_eus-gaap--PreferredStockSharesOutstanding_iI_c20220331__us-gaap--StatementClassOfStockAxis__custom--SeriesCPreferredStocksMember_zOzrPHLcdFi1"&gt;&lt;span id="xdx_904_eus-gaap--PreferredStockSharesIssued_iI_c20210331__us-gaap--StatementClassOfStockAxis__custom--SeriesCPreferredStocksMember_zLQ9x9K2aSa2" title="Preferred stock, shares issued"&gt;&lt;span id="xdx_908_eus-gaap--PreferredStockSharesOutstanding_iI_c20210331__us-gaap--StatementClassOfStockAxis__custom--SeriesCPreferredStocksMember_z5HX6ZLlhZb9" title="Preferred stock, shares outstanding"&gt;96,230&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares of series C preferred stock, par value
$&lt;span id="xdx_90F_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20220331__us-gaap--StatementClassOfStockAxis__custom--SeriesCPreferredStocksMember_zsYsghFFToT6"&gt;&lt;span id="xdx_90B_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20210331__us-gaap--StatementClassOfStockAxis__custom--SeriesCPreferredStocksMember_zex8msIzdNQ6" title="Preferred stock, par value"&gt;0.01&lt;/span&gt;
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;per share (the &#x201c;Series C Preferred Stock&#x201d;)
issued and outstanding.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
a result of reverse stock splits in previous years and the agreement terms for adjusting the rights of the related shares, the &lt;span id="xdx_90D_eus-gaap--PreferredStockSharesIssued_iI_c20220331__us-gaap--StatementClassOfStockAxis__custom--SeriesCPreferredStocksMember_zuzkAd5Hlyvk"&gt;96,230&lt;/span&gt;
shares of Series C Preferred Stock are not currently convertible, have no voting rights, and in the event of liquidation, the holders
of the Series C Preferred Stock would not participate in any distribution of the assets or surplus funds of the Company. The holders
of Series C Preferred Stock also are not currently entitled to any dividends if and when declared by the Company&#x2019;s board of directors
(the &#x201c;Board&#x201d;). No dividends to holders of the Series C Preferred Stock were issued or unpaid through March 31, 2022 and 2021.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;Series
K Preferred Stock&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
February 16, 2021, the Board designated &lt;span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20210215__20210216__us-gaap--StatementClassOfStockAxis__custom--SeriesKPreferredStocksMember_zFZKJ6mz6gJh" title="Preferred stock shares designated"&gt;115,000&lt;/span&gt; shares of Series K preferred stock, par value $&lt;span id="xdx_904_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20210216__us-gaap--StatementClassOfStockAxis__custom--SeriesKPreferredStocksMember_zsR1NQ5Ho7ak" title="Preferred stock, par value"&gt;.01&lt;/span&gt;. (the &#x201c;Series K Preferred Stock&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Shares
of the Series K Preferred Stock are convertible at any time, at the option of the holders, into shares of the Company&#x2019;s common
stock at an effective conversion rate of &lt;span id="xdx_90C_eus-gaap--PreferredStockConvertibleSharesIssuable_iI_c20210216__us-gaap--StatementClassOfStockAxis__custom--SeriesKPreferredStocksMember_zLXCxZzoLJz2" title="Convertible shares issuable"&gt;100
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares of common stock for each share of Series
K Preferred. Shares of the Series K Preferred Stock have the same voting rights as the shares of the Company&#x2019;s common stock,
with the holders of the Series K Preferred Stock entitled to vote on an as-converted-to-common stock basis, subject to the beneficial
ownership limitation, together with the holders of the Company&#x2019;s common stock on all matters presented to the Company&#x2019;s stockholders.
The Series K Preferred Stock are not entitled to any dividends (unless specifically declared by the Board) but will participate on an
as-converted-to-common-stock basis in any dividends to the holders of the Company&#x2019;s common stock. In the event of the Company&#x2019;s
dissolution, liquidation or winding up, the holders of the Series K Preferred Stock will be on parity with the holders of the Company&#x2019;s
common stock and will participate, on a on an as-converted-to-common stock basis, in any distribution to holders of the Company&#x2019;s
common stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of March 31, 2022 and December 31, 2021, there were &lt;span id="xdx_90C_eus-gaap--PreferredStockSharesOutstanding_iI_pid_do_c20220331__us-gaap--StatementClassOfStockAxis__custom--SeriesKPreferredStocksMember_zT5m1bkb3zR6" title="Preferred stock, shares outstanding"&gt;&lt;span id="xdx_905_eus-gaap--PreferredStockSharesIssued_iI_pid_do_c20220331__us-gaap--StatementClassOfStockAxis__custom--SeriesKPreferredStocksMember_zSAFXILRmPX5" title="Preferred stock, shares issued"&gt;&lt;span id="xdx_902_eus-gaap--PreferredStockSharesOutstanding_iI_pid_do_c20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesKPreferredStocksMember_zDbF8m0J4eDc" title="Preferred stock, shares outstanding"&gt;&lt;span id="xdx_90B_eus-gaap--PreferredStockSharesIssued_iI_pid_do_c20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesKPreferredStocksMember_zhOunByS1yXf" title="Preferred stock, shares issued"&gt;no&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt; shares of Series K Preferred stock issued and outstanding.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;Warrants
and Options&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Common
Stock Warrants&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_894_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_z1QoQDPZe3W6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Stock
warrant transactions for the three months ended March 31, 2022:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BF_zL76BPA8JD5d" style="display: none"&gt;Schedule
of  Warrant Activity&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Number of&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Weighted Average&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Warrants
&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Exercise Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%"&gt;Outstanding at December 31, 2021:&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20220101__20220331_zmsj6DS0orD9" style="width: 16%; text-align: right" title="Warrants Outstanding,Beginning Balance"&gt;2,337,274&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20220101__20220331_z4mRwCIdZ5oh" style="width: 16%; text-align: right" title="Weighted Average Exercise Price, Beginning Balance"&gt;5.30&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20220101__20220331_zbM6PbxiHEng" style="text-align: right" title="Number of Warrants, Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0899"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue_pid_c20220101__20220331_zWMlhOOt7pG9" style="text-align: right" title="Weighted Average Exercise Price, Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0901"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Forfeited/canceled&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeited_iN_pid_di_c20220101__20220331_zJcvJ1Sr3zF5" style="text-align: right" title="Number of Warrants, Forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0903"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue_pid_c20220101__20220331_zHF7dlCWyH6b" style="text-align: right" title="Weighted Average Exercise Price, Forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0905"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Exercised&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20220101__20220331_zEoGKelxWMke" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Warrants, Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0907"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20220101__20220331_zJhvs1KP25ji" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0909"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Warrants outstanding at March 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20220101__20220331_zNxAOaFzLKi4" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants Outstanding, Ending Balance"&gt;2,337,274&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20220101__20220331_zOiOMdTfCkzf" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Ending Balance"&gt;5.30&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Warrants exercisable at March 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable_iI_pid_c20220331_zZkuBvyoStr2" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants Exercisable"&gt;2,337,274&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20220331_zXXcxag5t8Eb" style="border-bottom: Black 2.5pt double; text-align: right" title="Exercisable"&gt;5.30&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AE_zgZCApjehyrk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of March 31, 2022, all issued and outstanding warrants are fully vested, and have no intrinsic value as the exercise price of
these warrants was greater than the market price.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Common
Stock Options&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89C_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zoV3yKJSBuWf" style="margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Stock option transactions for the three
months ended March 31, 2022:&lt;/span&gt;&lt;/p&gt;



&lt;p style="margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B9_zbXKwz9p29kb" style="display: none"&gt;Schedule
of Options Activity&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Number of&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Weighted Average&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Options&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Exercise Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%"&gt;Options outstanding at December 31, 2021:&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20220101__20220331_zgPtBAAs4vk7" style="width: 16%; text-align: right" title="Options outstanding, beginning"&gt;302,500&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20220101__20220331_zE8is2UMksP7" style="width: 16%; text-align: right" title="Exercise Price of Warrants or Rights"&gt;3.05&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20220101__20220331_zWfdsNbefRzg" style="text-align: right" title="Number of Options, Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0925"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20220101__20220331_zCzO2SX6nm6f" style="text-align: right" title="Weighted Average Exercise Price, Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0927"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Forfeited/canceled&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_pid_c20220101__20220331_zSaLArFlb7P8" style="text-align: right" title="Number of Options, Forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0929"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20220101__20220331_zqEnKSqrIMnh" style="text-align: right" title="Weighted Average Exercise Price, Forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0931"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Exercised&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionEquityInstrumentsExercised_pid_c20220101__20220331_zwky8LS3Vypk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Options, Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0933"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20220101__20220331_zqYEMfzBiDXc" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0935"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Options outstanding at March 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20220101__20220331_zhwZPBmMv7s9" style="border-bottom: Black 2.5pt double; text-align: right" title="Options outstanding, Ending"&gt;302,500&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20220101__20220331_zBa7eB8VWFWa" style="border-bottom: Black 2.5pt double; text-align: right" title="Exercise Price of Warrants or Rights"&gt;3.05&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Options exercisable at March 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20220331_zkSnJVkHaEY5" style="border-bottom: Black 2.5pt double; text-align: right" title="Options exercisable"&gt;111,215&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20220331_zHow2t57AW68" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Exercisable"&gt;3.05&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A8_zMLgyvdFhbj7" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
March 31, 2022, there were &lt;span id="xdx_90B_ecustom--NumberofsharesUnvestedOptions_c20220101__20220331_zmrp065Zosng" title="Number of shares unvested"&gt;191,285&lt;/span&gt; unvested options with a grant date fair value of $&lt;span id="xdx_90D_ecustom--NumberofValueUnvestedOptions_c20220101__20220331_zNXH7h0vhBKl" title="Number of shares unvested, value"&gt;511,115&lt;/span&gt; which will be recognized as stock compensation
in future periods based upon the remaining vesting term of the applicable grants.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;There
was &lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_do_c20220331_zwK3tFSJaAE6" title="Options outstanding intrinsic value"&gt;no
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;intrinsic value of the outstanding options as
of March 31, 2022 as the exercise price of these options was greater than the market price.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2022-03-31" decimals="INF" unitRef="Shares">750000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2022-03-31"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2022-03-31" decimals="INF" unitRef="Shares">15000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2022-03-31"
      decimals="INF"
      unitRef="USDPShares">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="From2021-02-152021-02-16"
      decimals="-5"
      unitRef="USD">38800000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="From2021-02-152021-02-16"
      decimals="INF"
      unitRef="Shares">11413322</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="From2021-01-012021-12-31"
      decimals="INF"
      unitRef="Shares">11086024</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:SharesIssued
      contextRef="AsOf2021-12-31_custom_CommonStockIssuableMember"
      decimals="INF"
      unitRef="Shares">327298</us-gaap:SharesIssued>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-01-012022-03-31_custom_CommonStockIssuableMember"
      decimals="-5"
      unitRef="USD">1100000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="From2022-01-01to2022-03-31"
      decimals="INF"
      unitRef="Shares">290999</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum
      contextRef="From2022-01-012022-03-31_srt_ChiefExecutiveOfficerMember_custom_EmploymentAgreementsMember"
      decimals="INF"
      unitRef="Pure">0.10</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum
      contextRef="From2022-01-012022-03-31_srt_ChiefFinancialOfficerMember_custom_EmploymentAgreementsMember"
      decimals="INF"
      unitRef="Pure">0.015</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum
      contextRef="From2022-01-012022-03-31_srt_DirectorMember_custom_EmploymentAgreementsMember_srt_MinimumMember"
      decimals="INF"
      unitRef="Pure">0.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum
      contextRef="From2022-01-012022-03-31_srt_DirectorMember_custom_EmploymentAgreementsMember_srt_MaximumMember"
      decimals="INF"
      unitRef="Pure">0.0125</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription contextRef="From2022-01-012022-03-31_custom_EmploymentAgreementsMember_srt_DirectorMember">Pursuant
to the agreement, approximately 33% of the common stock to be issued vested immediately while the remaining</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="From2022-01-01to2022-03-31">P2Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <GTBP:CommonStockSharesGrantedForConsultants
      contextRef="From2021-02-152021-02-16"
      decimals="INF"
      unitRef="Shares">4379407</GTBP:CommonStockSharesGrantedForConsultants>
    <GTBP:FairValueOfStockOptionsGrantedForConsultants
      contextRef="From2021-02-152021-02-16"
      decimals="-5"
      unitRef="USD">18600000</GTBP:FairValueOfStockOptionsGrantedForConsultants>
    <us-gaap:ShareBasedCompensation
      contextRef="From2021-01-012021-03-31_custom_EmployeesMember"
      decimals="-5"
      unitRef="USD">14300000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-01-012022-03-31_custom_EmployeesMember"
      decimals="0"
      unitRef="USD">447000</us-gaap:ShareBasedCompensation>
    <GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedTounVestOutstandingNumber
      contextRef="AsOf2022-03-31_custom_OfficersEmployeesAndBoardOfDirectorsMember"
      decimals="INF"
      unitRef="Shares">291700</GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedTounVestOutstandingNumber>
    <GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToUnVestOutstandingAggregateIntrinsicValue
      contextRef="AsOf2022-03-31_custom_OfficersEmployeesAndBoardOfDirectorsMember"
      decimals="-5"
      unitRef="USD">1400000</GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToUnVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum
      contextRef="From2021-02-152021-02-15_srt_MinimumMember"
      decimals="INF"
      unitRef="Pure">0.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum
      contextRef="From2021-02-152021-02-15_srt_MaximumMember"
      decimals="INF"
      unitRef="Pure">0.03</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
    <us-gaap:SharesIssued contextRef="AsOf2021-02-16" decimals="INF" unitRef="Shares">2850090</us-gaap:SharesIssued>
    <GTBP:CommonStockConsultantToFairValue
      contextRef="From2021-02-152021-02-16"
      decimals="-5"
      unitRef="USD">10700000</GTBP:CommonStockConsultantToFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="AsOf2021-02-16" decimals="INF" unitRef="Shares">1934817</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="From2021-02-152021-02-16"
      decimals="INF"
      unitRef="Shares">915273</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="From2021-02-152021-02-16">P2Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensation
      contextRef="From2021-01-012021-03-31"
      decimals="-5"
      unitRef="USD">8500000</us-gaap:ShareBasedCompensation>
    <us-gaap:SharesIssued contextRef="AsOf2021-03-31" decimals="INF" unitRef="Shares">1957374</us-gaap:SharesIssued>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-01-012022-03-31_custom_ConsultingMember"
      decimals="0"
      unitRef="USD">872000</us-gaap:ShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="From2022-01-012022-03-31_custom_ConsultingMember"
      decimals="INF"
      unitRef="Shares">46500</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="From2022-01-012022-03-31_custom_ConsultingMember"
      decimals="INF"
      unitRef="Shares">116247</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedTounVestOutstandingNumber
      contextRef="AsOf2022-03-31_custom_ConsultingMember"
      decimals="INF"
      unitRef="Shares">389570</GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedTounVestOutstandingNumber>
    <GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToUnVestOutstandingAggregateIntrinsicValue
      contextRef="AsOf2022-03-31_custom_ConsultingMember"
      decimals="-5"
      unitRef="USD">1300000</GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToUnVestOutstandingAggregateIntrinsicValue>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2022-03-31_custom_SeriesCPreferredStocksMember"
      decimals="INF"
      unitRef="Shares">96230</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2022-03-31_custom_SeriesCPreferredStocksMember"
      decimals="INF"
      unitRef="Shares">96230</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2021-03-31_custom_SeriesCPreferredStocksMember"
      decimals="INF"
      unitRef="Shares">96230</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2021-03-31_custom_SeriesCPreferredStocksMember"
      decimals="INF"
      unitRef="Shares">96230</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2022-03-31_custom_SeriesCPreferredStocksMember"
      decimals="INF"
      unitRef="USDPShares">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2021-03-31_custom_SeriesCPreferredStocksMember"
      decimals="INF"
      unitRef="USDPShares">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2022-03-31_custom_SeriesCPreferredStocksMember"
      decimals="INF"
      unitRef="Shares">96230</us-gaap:PreferredStockSharesIssued>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2021-02-152021-02-16_custom_SeriesKPreferredStocksMember"
      decimals="INF"
      unitRef="Shares">115000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2021-02-16_custom_SeriesKPreferredStocksMember"
      decimals="INF"
      unitRef="USDPShares">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockConvertibleSharesIssuable
      contextRef="AsOf2021-02-16_custom_SeriesKPreferredStocksMember"
      decimals="INF"
      unitRef="Shares">100</us-gaap:PreferredStockConvertibleSharesIssuable>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2022-03-31_custom_SeriesKPreferredStocksMember"
      decimals="INF"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2022-03-31_custom_SeriesKPreferredStocksMember"
      decimals="INF"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2021-12-31_custom_SeriesKPreferredStocksMember"
      decimals="INF"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2021-12-31_custom_SeriesKPreferredStocksMember"
      decimals="INF"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="From2022-01-01to2022-03-31">&lt;p id="xdx_894_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_z1QoQDPZe3W6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Stock
warrant transactions for the three months ended March 31, 2022:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BF_zL76BPA8JD5d" style="display: none"&gt;Schedule
of  Warrant Activity&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Number of&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Weighted Average&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Warrants
&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Exercise Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%"&gt;Outstanding at December 31, 2021:&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20220101__20220331_zmsj6DS0orD9" style="width: 16%; text-align: right" title="Warrants Outstanding,Beginning Balance"&gt;2,337,274&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20220101__20220331_z4mRwCIdZ5oh" style="width: 16%; text-align: right" title="Weighted Average Exercise Price, Beginning Balance"&gt;5.30&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20220101__20220331_zbM6PbxiHEng" style="text-align: right" title="Number of Warrants, Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0899"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue_pid_c20220101__20220331_zWMlhOOt7pG9" style="text-align: right" title="Weighted Average Exercise Price, Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0901"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Forfeited/canceled&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeited_iN_pid_di_c20220101__20220331_zJcvJ1Sr3zF5" style="text-align: right" title="Number of Warrants, Forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0903"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue_pid_c20220101__20220331_zHF7dlCWyH6b" style="text-align: right" title="Weighted Average Exercise Price, Forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0905"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Exercised&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20220101__20220331_zEoGKelxWMke" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Warrants, Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0907"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20220101__20220331_zJhvs1KP25ji" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0909"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Warrants outstanding at March 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20220101__20220331_zNxAOaFzLKi4" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants Outstanding, Ending Balance"&gt;2,337,274&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20220101__20220331_zOiOMdTfCkzf" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Ending Balance"&gt;5.30&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Warrants exercisable at March 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable_iI_pid_c20220331_zZkuBvyoStr2" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants Exercisable"&gt;2,337,274&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20220331_zXXcxag5t8Eb" style="border-bottom: Black 2.5pt double; text-align: right" title="Exercisable"&gt;5.30&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares">2337274</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2021-12-31"
      decimals="INF"
      unitRef="USDPShares">5.30</GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber contextRef="AsOf2022-03-31" decimals="INF" unitRef="Shares">2337274</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2022-03-31"
      decimals="INF"
      unitRef="USDPShares">5.30</GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice>
    <GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable contextRef="AsOf2022-03-31" decimals="INF" unitRef="Shares">2337274</GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable>
    <GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2022-03-31"
      decimals="INF"
      unitRef="USDPShares">5.30</GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2022-01-01to2022-03-31">&lt;p id="xdx_89C_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zoV3yKJSBuWf" style="margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Stock option transactions for the three
months ended March 31, 2022:&lt;/span&gt;&lt;/p&gt;



&lt;p style="margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B9_zbXKwz9p29kb" style="display: none"&gt;Schedule
of Options Activity&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Number of&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Weighted Average&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Options&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Exercise Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%"&gt;Options outstanding at December 31, 2021:&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20220101__20220331_zgPtBAAs4vk7" style="width: 16%; text-align: right" title="Options outstanding, beginning"&gt;302,500&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20220101__20220331_zE8is2UMksP7" style="width: 16%; text-align: right" title="Exercise Price of Warrants or Rights"&gt;3.05&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20220101__20220331_zWfdsNbefRzg" style="text-align: right" title="Number of Options, Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0925"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20220101__20220331_zCzO2SX6nm6f" style="text-align: right" title="Weighted Average Exercise Price, Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0927"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Forfeited/canceled&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_pid_c20220101__20220331_zSaLArFlb7P8" style="text-align: right" title="Number of Options, Forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0929"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20220101__20220331_zqEnKSqrIMnh" style="text-align: right" title="Weighted Average Exercise Price, Forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0931"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Exercised&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionEquityInstrumentsExercised_pid_c20220101__20220331_zwky8LS3Vypk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Options, Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0933"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20220101__20220331_zqYEMfzBiDXc" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0935"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Options outstanding at March 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20220101__20220331_zhwZPBmMv7s9" style="border-bottom: Black 2.5pt double; text-align: right" title="Options outstanding, Ending"&gt;302,500&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20220101__20220331_zBa7eB8VWFWa" style="border-bottom: Black 2.5pt double; text-align: right" title="Exercise Price of Warrants or Rights"&gt;3.05&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Options exercisable at March 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20220331_zkSnJVkHaEY5" style="border-bottom: Black 2.5pt double; text-align: right" title="Options exercisable"&gt;111,215&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20220331_zHow2t57AW68" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Exercisable"&gt;3.05&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares">302500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2021-12-31"
      decimals="INF"
      unitRef="USDPShares">3.05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2022-03-31" decimals="INF" unitRef="Shares">302500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2022-03-31"
      decimals="INF"
      unitRef="USDPShares">3.05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="AsOf2022-03-31" decimals="INF" unitRef="Shares">111215</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2022-03-31"
      decimals="INF"
      unitRef="USDPShares">3.05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <GTBP:NumberofsharesUnvestedOptions
      contextRef="From2022-01-01to2022-03-31"
      decimals="INF"
      unitRef="Shares">191285</GTBP:NumberofsharesUnvestedOptions>
    <GTBP:NumberofValueUnvestedOptions
      contextRef="From2022-01-01to2022-03-31"
      decimals="INF"
      unitRef="Shares">511115</GTBP:NumberofValueUnvestedOptions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2022-01-01to2022-03-31">&lt;p id="xdx_800_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zkNEWs4XXv5" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Note
8 &#x2013; &lt;span id="xdx_829_z5ILQcczdnc9"&gt;Commitments and Contingencies&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.7pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Litigation&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt; involved in certain legal proceedings
that arise from time to time in the ordinary course of our business. Except for income tax contingencies, we record accruals for contingencies
to the extent that our management concludes that the occurrence is probable and that the related amounts of loss can be reasonably estimated.
Legal expenses associated with the contingency are expensed as incurred. There is no current or pending litigation of any significance
with the exception of the matters that have arisen under, and are being handled in, the normal course of business.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;On
August 28, 2019, a complaint was filed in the Superior Court of California, County of Los Angeles, West Judicial District, Santa Monica
Courthouse, Unlimited Civil Division by Jeffrey Lion, an individual (&#x201c;Lion&#x201d;), and by Daniel Vallera, an individual (&#x201c;Vallera&#x201d;).
Lion and Vallera are referred to jointly as the &#x201c;Plaintiffs.&#x201d; The complaint was filed against GT Biopharma, Inc. and its
subsidiary Oxis Biotech, Inc. (either of them or jointly, the &#x201c;Company&#x201d;). The Plaintiffs alleged breach of a license agreement
between the Plaintiffs and the Company entered into on or about September 3, 2015. A settlement of the case was reached on February 7,
2022 in the amount of $&lt;span id="xdx_90B_eus-gaap--LitigationSettlementExpense_c20220206__20220207_zNoVfISTexhd" title="Litigation settlement expense"&gt;425,000&lt;/span&gt;. This amount was fully accrued at December 31, 2021. The settlement amount was subsequently paid on March
4, 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Significant Agreements&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research
and Development Agreements&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is a party to a scientific research agreement with the Regents of the University of Minnesota, effective June 16, 2021. This
scientific research agreement aims to work with the Company with three major goals in mind: (1) support the Company&#x2019;s TriKE&lt;sup&gt;&#xae;
&lt;/sup&gt;product development and GMP manufacturing efforts; (2) TriKE&lt;sup&gt;&#xae;&lt;/sup&gt; pharmacokinetics optimization in humans; and (3) investigation
of the patient&#x2019;s native NK cell population based on insights obtained from the analysis of the human data generated during our
GTB-3550 clinical trial. The major deliverables proposed here are: (1) creation of IND enabling data for TriKE&lt;sup&gt;&#xae;&lt;/sup&gt; constructs
in support of our product development and GMP manufacturing efforts; (2) TriKE&lt;sup&gt;&#xae;&lt;/sup&gt; platform drug delivery changes to allow
transition to alternative drug delivery means and extended PK in humans; and (3) gain an increased understanding of changes in the patient&#x2019;s
native NK cell population as a result of TriKE&lt;sup&gt;&#xae; &lt;/sup&gt;therapy. Most studies will use TriKE&lt;sup&gt;&#xae;&lt;/sup&gt; DNA/amino acid sequences
created by us under current UMN/GTB licensing terms. The term of this agreement shall expire on June 30, 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
University of Minnesota shall use reasonable efforts to complete the project for a fixed sum of $&lt;span id="xdx_903_ecustom--ProjectFee_pn5n6_c20220101__20220331_zdoinf8BizIf" title="Project fees"&gt;2.1&lt;/span&gt; million. The Company recorded expense
of $&lt;span id="xdx_90B_ecustom--RecordedExpenses_pn5n6_c20220101__20220331_zqI1cqtO9sb9" title="Recorded expenses"&gt;1.1&lt;/span&gt; million through March 31, 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90B_eus-gaap--OtherCommitmentsDescription_c20201001__20201005_z25qPgmWY3Lg" title="Other commitments, description"&gt;On
October 5, 2020, GT Biopharma entered into a Master Services Agreement with a third-party product manufacturer to perform biologic development
and manufacturing services on behalf of the Company. Associated with this, the Company has subsequently signed five Statements of Work
for the research and development of products for use in clinical trials. At March 31 2022, the Company&#x2019;s commitments in relation
to these Statements of Work and any related Change Orders totaled approximately $&lt;span id="xdx_905_ecustom--ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurred_pn5n6_c20220101__20220331__us-gaap--TypeOfArrangementAxis__custom--MasterServicesAgreementMember__dei--LegalEntityAxis__custom--CytovanceBiologicsIncMember_z4IqnhIZpFF4" title="Commitment amount for services, total"&gt;13.0&lt;/span&gt; million, of which $&lt;span id="xdx_908_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross_pn5n6_c20220101__20220331__us-gaap--TypeOfArrangementAxis__custom--MasterServicesAgreementMember__dei--LegalEntityAxis__custom--CytovanceBiologicsIncMember_z2invhO1hb5" title="Commitment cost incurred"&gt;8.4&lt;/span&gt; million was incurred at
that date and an additional $&lt;span id="xdx_90D_ecustom--ResearchAndDevelopmentArrangementContractToPerformExpectedCostsIncurred_pn5n6_c20220101__20220331__us-gaap--TypeOfArrangementAxis__custom--MasterServicesAgreementMember__dei--LegalEntityAxis__custom--CytovanceBiologicsIncMember_z8h1UDfF6TIg" title="Compensation cost expected to be incurred in future"&gt;4.6&lt;/span&gt; million is in process during fiscal year 2022&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Patent
and License Agreements&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;2016
Exclusive Patent License Agreement&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is party to an exclusive worldwide license agreement with the Regents of the University of Minnesota, (&#x201c;UofMN&#x201d;),
to further develop and commercialize cancer therapies using TriKE&lt;sup&gt;&#xae;&lt;/sup&gt; technology developed by researchers at the UofMN to
target NK cells to cancer. Under the terms of the 2016 agreement, the Company receives exclusive rights to conduct research and to develop,
make, use, sell, and import TriKE&lt;sup&gt;&#xae;&lt;/sup&gt; technology worldwide for the treatment of any disease, state, or condition in humans.
The Company is responsible for obtaining all permits, licenses, authorizations, registrations, and regulatory approvals required or granted
by any governmental authority anywhere in the world that is responsible for the regulation of products such as the TriKE&lt;sup&gt;&#xae;&lt;/sup&gt;
technology, including without limitation the FDA and the European Agency for the Evaluation of Medicinal Products in the European Union.
Under the agreement, the UofMN received an upfront payment of $&lt;span id="xdx_903_ecustom--ProceedsFromUpfrontAmount_iI_pn5n6_c20220331__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_z9K1qR4xc8R4"&gt;0.2
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million, and an annual License Maintenance fee
of $&lt;span id="xdx_90C_ecustom--AnnualMaintananceFee_pn5n6_c20220101__20220331__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zGmFyuGQglu6"&gt;0.1
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million beginning in 2021. The agreement also
includes &lt;span id="xdx_903_ecustom--RoyaltyFeePercentage_pid_dp_uPure_c20220101__20220331__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zKl4mAtYvDkf"&gt;4%
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;royalty fees, (not to exceed 6%) under
subsequent license agreements or amendments to this agreement or minimum annual royalty payments ranging from $&lt;span id="xdx_90E_ecustom--AnnualRoyaltyPayments_pn4n6_c20220101__20220331__srt--RangeAxis__srt--MinimumMember__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_ztyoCtKLY0Ll"&gt;0.25
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million to $&lt;span id="xdx_905_ecustom--AnnualRoyaltyPayments_pn5n6_c20220101__20220331__srt--RangeAxis__srt--MaximumMember__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zgaQhcCqFhM8"&gt;5.0
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million. The agreement also includes certain
performance milestone payments totaling $&lt;span id="xdx_907_ecustom--PerformanceMilestonePayments_pn5n6_c20220101__20220331__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zrwhEO0YkQh9"&gt;3.1
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million, and one-time sales milestone payments
of $&lt;span id="xdx_907_ecustom--SalesMilestonePayments_pn5n6_c20220101__20220331__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zPuMtqyAwnWl"&gt;1.0
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million upon reaching $&lt;span id="xdx_901_ecustom--GrossSales_pn6n6_c20220101__20220331__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_z6mqku6t5Pif"&gt;250
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million in gross sales, and $&lt;span id="xdx_905_ecustom--SalesRevenue_pn5n6_c20220101__20220331__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zMy56DuChP9"&gt;5.0
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million upon reaching $&lt;span id="xdx_900_ecustom--CummulativeGrossSales_pn6n6_c20220101__20220331__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zOhmnnYP5Qt1"&gt;500
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million dollars in cumulative gross sales of
Licensed Products.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;2021
Patent License Agreement&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
March 26, 2021, the Company signed an agreement specific to the B7H3 targeted TriKE&lt;sup&gt;&#xae;&lt;/sup&gt;. Under the agreement, the UofMN received
an upfront license fee of $&lt;span id="xdx_90A_ecustom--UpfrontLicenseFee_c20210325__20210326__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_zgyPliO9g329" title="Upfront license fee"&gt;20,000&lt;/span&gt; and will receive an annual License Maintenance fee of $&lt;span id="xdx_902_ecustom--LicenseMaintenanceFeeReceivable_iI_c20220331__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_z4DarsZtep43" title="License maintenance fee, receivable"&gt;5,000&lt;/span&gt; beginning in 2022, &lt;span id="xdx_906_ecustom--NetSalesPercentage_pid_dp_uPure_c20220101__20220331__srt--RangeAxis__srt--MinimumMember__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_zycDcOcLhsG3" title="Net sales percentage"&gt;2.5%&lt;/span&gt; to &lt;span id="xdx_904_ecustom--NetSalesPercentage_pid_dp_uPure_c20220101__20220331__srt--RangeAxis__srt--MaximumMember__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_zncDE4bb855f" title="Net sales percentage"&gt;5%&lt;/span&gt; royalty
fees, or minimum annual royalty payments of $&lt;span id="xdx_900_ecustom--AnnualRoyaltyPayments_pn4n6_c20220101__20220331__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_zhR2MH5smYl" title="Annual royalty payments"&gt;0.25&lt;/span&gt; million beginning in the year after the first commercial sales of Licensed Product,
and $&lt;span id="xdx_906_ecustom--MaintananceFee_pn5n6_c20220101__20220331__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_zNZRerpobAgl" title="Maintanance fee"&gt;2.0&lt;/span&gt; million beginning in the fifth year after the first commercial sale of such Licensed Product. The agreement also includes certain
performance milestone payments totaling $&lt;span id="xdx_909_ecustom--PerformanceMilestonePayments_pn5n6_c20220101__20220331__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_zfkyZl5G4bl8" title="Performance milestone payments"&gt;3.1&lt;/span&gt; million-, and one-time sales milestone payments of $&lt;span id="xdx_904_ecustom--SalesMilestonePayments_pn5n6_c20220101__20220331__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_zXmlmRHF5E69" title="Sales milestone payments"&gt;1.0&lt;/span&gt; million upon reaching $&lt;span id="xdx_901_ecustom--GrossSales_pn6n6_c20220101__20220331__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_zx4cZYsF6EF1" title="Gross sales"&gt;250&lt;/span&gt; million
in gross sales, and $&lt;span id="xdx_90C_ecustom--SalesRevenue_pn5n6_c20220101__20220331__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_zOOXqVYoN219" title="Sales revenue"&gt;5.0&lt;/span&gt; million upon reaching $&lt;span id="xdx_907_ecustom--CummulativeGrossSales_pn6n6_c20220101__20220331__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_zs18T8hPDJtd" title="Cummulative gross sales"&gt;500&lt;/span&gt; million dollars in cumulative gross sales of Licensed Products. There is no double
payment intended; if one of the milestone payments has been paid under the 2016 agreement no further payment is due for the corresponding
milestone above.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Lease
Agreements&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 16.95pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
November 19, 2021 the Company entered into a sublease with Aimmune Therapeutics, Inc. for &lt;span id="xdx_900_eus-gaap--AreaOfLand_iI_uSqft_c20211119__srt--CounterpartyNameAxis__custom--AimmuneTherapeuticsIncMember_zjcfzQNqhB9d" title="Area of land"&gt;4,500
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;square feet of office space located in Brisbane,
California having a &lt;span id="xdx_90E_eus-gaap--LesseeOperatingSubleaseOptionToExtend_c20211118__20211119__srt--CounterpartyNameAxis__custom--AimmuneTherapeuticsIncMember_zIoZsJGUss27" title="Commencement date"&gt;commencement
date of January 1, 2022 and maturing on June 30, 2024&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;.
Additionally, on February 8, 2022, the Company entered into a lease of a photocopier, which matures on February 7, 2025. &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Rent expense related to these leases reflected
on the Company&#x2019;s Condensed Consolidated Statements of Operations totaled $&lt;span id="xdx_90A_eus-gaap--PaymentsForRent_c20220101__20220331_zBCFA3X6efk7" title="Rent expense"&gt;29,000&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_891_ecustom--ScheduleOfOtherInformationRelatedLeasesUnderNOnCancellableTableTextBlock_zLGVnlqeHhB2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Other
information related to leases and future minimum lease payments under non-cancellable operating leases were as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;span id="xdx_8B1_zfme6KpWNgD8" style="display: none"&gt;Schedule of Other Information Related Leases Under Non-Cancellable&lt;/span&gt;&lt;/span&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;March 31, 2022&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(Unaudited)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-style: normal; font-weight: normal; text-align: left"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; width: 82%; text-align: left"&gt;Operating cash flows from operating leases&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--OperatingLeasePayments_c20220101__20220331_zOvD28bx9yKi" style="width: 14%; text-align: right" title="Operating cash flows from operating leases"&gt;20,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-style: normal; font-weight: normal; text-align: left"&gt;Right-of-use assets obtained in exchange for lease liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Operating leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_c20220101__20220331_zrJwZZ6jXZO1" style="text-align: right" title="Right of use assets operating leases"&gt;260,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-style: normal; font-weight: normal; text-align: left"&gt;Weighted-average remaining lease term (in years):&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Operating leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20220331_ziwy9rtDmqjj" title="Weighted average remaining lease term operating leases"&gt;2.5&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-style: normal; font-weight: normal; text-align: left"&gt;Weighted-average discount rate:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Operating leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20220331_zDW9dVBUYrN2" title="Weighted average discount rate operating leases"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AF_zec0kjqf9Sa8" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_897_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zgOezNxtO318" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Future
minimum lease payments under non-cancellable operating leases were as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B0_zJPDTRAHFnQc" style="display: none"&gt;Schedule
of Future Minimum Lease Payments&lt;/span&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20220331_z6qXdtgac6aa" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;March 31, 2022&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(Unaudited)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b/&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_maOLLzd8y_zLQ1XYQeq8Nc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 82%; text-align: left"&gt;Within one year&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;90,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maOLLzd8y_zPfQgTZaLSF7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;After one year and within two years&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;122,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maOLLzd8y_zwEDGHHMoiG5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;After two years and within three years&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;65,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_iI_maOLLzd8y_zW30AWZmxwJ3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Thereafter&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1023"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--OperatingLeaseLiability_iTI_mtOLLzd8y_zHteqIgSavc2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Total future minimum lease payments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;277,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_zPnXSc3irq71" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less &#x2013; discount&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(30,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_zRs1RhF2rN3i" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Lease liability&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;247,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LitigationSettlementExpense
      contextRef="From2022-02-062022-02-07"
      decimals="0"
      unitRef="USD">425000</us-gaap:LitigationSettlementExpense>
    <GTBP:ProjectFee
      contextRef="From2022-01-01to2022-03-31"
      decimals="-5"
      unitRef="USD">2100000</GTBP:ProjectFee>
    <GTBP:RecordedExpenses
      contextRef="From2022-01-01to2022-03-31"
      decimals="-5"
      unitRef="USD">1100000</GTBP:RecordedExpenses>
    <us-gaap:OtherCommitmentsDescription contextRef="From2020-10-012020-10-05">On
October 5, 2020, GT Biopharma entered into a Master Services Agreement with a third-party product manufacturer to perform biologic development
and manufacturing services on behalf of the Company. Associated with this, the Company has subsequently signed five Statements of Work
for the research and development of products for use in clinical trials. At March 31 2022, the Company&#x2019;s commitments in relation
to these Statements of Work and any related Change Orders totaled approximately $13.0 million, of which $8.4 million was incurred at
that date and an additional $4.6 million is in process during fiscal year 2022</us-gaap:OtherCommitmentsDescription>
    <GTBP:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurred
      contextRef="From2022-01-012022-03-31_custom_MasterServicesAgreementMember_custom_CytovanceBiologicsIncMember"
      decimals="-5"
      unitRef="USD">13000000.0</GTBP:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurred>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross
      contextRef="From2022-01-012022-03-31_custom_MasterServicesAgreementMember_custom_CytovanceBiologicsIncMember"
      decimals="-5"
      unitRef="USD">8400000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross>
    <GTBP:ResearchAndDevelopmentArrangementContractToPerformExpectedCostsIncurred
      contextRef="From2022-01-012022-03-31_custom_MasterServicesAgreementMember_custom_CytovanceBiologicsIncMember"
      decimals="-5"
      unitRef="USD">4600000</GTBP:ResearchAndDevelopmentArrangementContractToPerformExpectedCostsIncurred>
    <GTBP:ProceedsFromUpfrontAmount
      contextRef="AsOf2022-03-31_custom_TwoThousandSixteenPatentLicenseAgreementMember"
      decimals="-5"
      unitRef="USD">200000</GTBP:ProceedsFromUpfrontAmount>
    <GTBP:AnnualMaintananceFee
      contextRef="From2022-01-012022-03-31_custom_TwoThousandSixteenPatentLicenseAgreementMember"
      decimals="-5"
      unitRef="USD">100000</GTBP:AnnualMaintananceFee>
    <GTBP:RoyaltyFeePercentage
      contextRef="From2022-01-012022-03-31_custom_TwoThousandSixteenPatentLicenseAgreementMember"
      decimals="INF"
      unitRef="Pure">0.04</GTBP:RoyaltyFeePercentage>
    <GTBP:AnnualRoyaltyPayments
      contextRef="From2022-01-012022-03-31_srt_MinimumMember_custom_TwoThousandSixteenPatentLicenseAgreementMember"
      decimals="-4"
      unitRef="USD">250000</GTBP:AnnualRoyaltyPayments>
    <GTBP:AnnualRoyaltyPayments
      contextRef="From2022-01-012022-03-31_srt_MaximumMember_custom_TwoThousandSixteenPatentLicenseAgreementMember"
      decimals="-5"
      unitRef="USD">5000000.0</GTBP:AnnualRoyaltyPayments>
    <GTBP:PerformanceMilestonePayments
      contextRef="From2022-01-012022-03-31_custom_TwoThousandSixteenPatentLicenseAgreementMember"
      decimals="-5"
      unitRef="USD">3100000</GTBP:PerformanceMilestonePayments>
    <GTBP:SalesMilestonePayments
      contextRef="From2022-01-012022-03-31_custom_TwoThousandSixteenPatentLicenseAgreementMember"
      decimals="-5"
      unitRef="USD">1000000.0</GTBP:SalesMilestonePayments>
    <GTBP:GrossSales
      contextRef="From2022-01-012022-03-31_custom_TwoThousandSixteenPatentLicenseAgreementMember"
      decimals="-6"
      unitRef="USD">250000000</GTBP:GrossSales>
    <GTBP:SalesRevenue
      contextRef="From2022-01-012022-03-31_custom_TwoThousandSixteenPatentLicenseAgreementMember"
      decimals="-5"
      unitRef="USD">5000000.0</GTBP:SalesRevenue>
    <GTBP:CummulativeGrossSales
      contextRef="From2022-01-012022-03-31_custom_TwoThousandSixteenPatentLicenseAgreementMember"
      decimals="-6"
      unitRef="USD">500000000</GTBP:CummulativeGrossSales>
    <GTBP:UpfrontLicenseFee
      contextRef="From2021-03-252021-03-26_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember"
      decimals="0"
      unitRef="USD">20000</GTBP:UpfrontLicenseFee>
    <GTBP:LicenseMaintenanceFeeReceivable
      contextRef="AsOf2022-03-31_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember"
      decimals="0"
      unitRef="USD">5000</GTBP:LicenseMaintenanceFeeReceivable>
    <GTBP:NetSalesPercentage
      contextRef="From2022-01-012022-03-31_srt_MinimumMember_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember"
      decimals="INF"
      unitRef="Pure">0.025</GTBP:NetSalesPercentage>
    <GTBP:NetSalesPercentage
      contextRef="From2022-01-012022-03-31_srt_MaximumMember_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember"
      decimals="INF"
      unitRef="Pure">0.05</GTBP:NetSalesPercentage>
    <GTBP:AnnualRoyaltyPayments
      contextRef="From2022-01-012022-03-31_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember"
      decimals="-4"
      unitRef="USD">250000</GTBP:AnnualRoyaltyPayments>
    <GTBP:MaintananceFee
      contextRef="From2022-01-012022-03-31_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember"
      decimals="-5"
      unitRef="USD">2000000.0</GTBP:MaintananceFee>
    <GTBP:PerformanceMilestonePayments
      contextRef="From2022-01-012022-03-31_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember"
      decimals="-5"
      unitRef="USD">3100000</GTBP:PerformanceMilestonePayments>
    <GTBP:SalesMilestonePayments
      contextRef="From2022-01-012022-03-31_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember"
      decimals="-5"
      unitRef="USD">1000000.0</GTBP:SalesMilestonePayments>
    <GTBP:GrossSales
      contextRef="From2022-01-012022-03-31_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember"
      decimals="-6"
      unitRef="USD">250000000</GTBP:GrossSales>
    <GTBP:SalesRevenue
      contextRef="From2022-01-012022-03-31_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember"
      decimals="-5"
      unitRef="USD">5000000.0</GTBP:SalesRevenue>
    <GTBP:CummulativeGrossSales
      contextRef="From2022-01-012022-03-31_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember"
      decimals="-6"
      unitRef="USD">500000000</GTBP:CummulativeGrossSales>
    <us-gaap:AreaOfLand
      contextRef="AsOf2021-11-19_custom_AimmuneTherapeuticsIncMember"
      decimals="INF"
      unitRef="Sqft">4500</us-gaap:AreaOfLand>
    <us-gaap:LesseeOperatingSubleaseOptionToExtend contextRef="From2021-11-182021-11-19_custom_AimmuneTherapeuticsIncMember">commencement
date of January 1, 2022 and maturing on June 30, 2024</us-gaap:LesseeOperatingSubleaseOptionToExtend>
    <us-gaap:PaymentsForRent
      contextRef="From2022-01-01to2022-03-31"
      decimals="0"
      unitRef="USD">29000</us-gaap:PaymentsForRent>
    <GTBP:ScheduleOfOtherInformationRelatedLeasesUnderNOnCancellableTableTextBlock contextRef="From2022-01-01to2022-03-31">&lt;p id="xdx_891_ecustom--ScheduleOfOtherInformationRelatedLeasesUnderNOnCancellableTableTextBlock_zLGVnlqeHhB2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Other
information related to leases and future minimum lease payments under non-cancellable operating leases were as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;span id="xdx_8B1_zfme6KpWNgD8" style="display: none"&gt;Schedule of Other Information Related Leases Under Non-Cancellable&lt;/span&gt;&lt;/span&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;March 31, 2022&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(Unaudited)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-style: normal; font-weight: normal; text-align: left"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; width: 82%; text-align: left"&gt;Operating cash flows from operating leases&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--OperatingLeasePayments_c20220101__20220331_zOvD28bx9yKi" style="width: 14%; text-align: right" title="Operating cash flows from operating leases"&gt;20,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-style: normal; font-weight: normal; text-align: left"&gt;Right-of-use assets obtained in exchange for lease liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Operating leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_c20220101__20220331_zrJwZZ6jXZO1" style="text-align: right" title="Right of use assets operating leases"&gt;260,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-style: normal; font-weight: normal; text-align: left"&gt;Weighted-average remaining lease term (in years):&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Operating leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20220331_ziwy9rtDmqjj" title="Weighted average remaining lease term operating leases"&gt;2.5&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-style: normal; font-weight: normal; text-align: left"&gt;Weighted-average discount rate:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Operating leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20220331_zDW9dVBUYrN2" title="Weighted average discount rate operating leases"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</GTBP:ScheduleOfOtherInformationRelatedLeasesUnderNOnCancellableTableTextBlock>
    <us-gaap:OperatingLeasePayments
      contextRef="From2022-01-01to2022-03-31"
      decimals="-3"
      unitRef="USD">20000000</us-gaap:OperatingLeasePayments>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="From2022-01-01to2022-03-31"
      decimals="-3"
      unitRef="USD">260000000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="AsOf2022-03-31">P2Y6M</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="AsOf2022-03-31" decimals="INF" unitRef="Pure">0.10</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="From2022-01-01to2022-03-31">&lt;p id="xdx_897_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zgOezNxtO318" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Future
minimum lease payments under non-cancellable operating leases were as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B0_zJPDTRAHFnQc" style="display: none"&gt;Schedule
of Future Minimum Lease Payments&lt;/span&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20220331_z6qXdtgac6aa" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;March 31, 2022&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(Unaudited)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b/&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_maOLLzd8y_zLQ1XYQeq8Nc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 82%; text-align: left"&gt;Within one year&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;90,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maOLLzd8y_zPfQgTZaLSF7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;After one year and within two years&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;122,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maOLLzd8y_zwEDGHHMoiG5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;After two years and within three years&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;65,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_iI_maOLLzd8y_zW30AWZmxwJ3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Thereafter&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1023"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--OperatingLeaseLiability_iTI_mtOLLzd8y_zHteqIgSavc2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Total future minimum lease payments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;277,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_zPnXSc3irq71" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less &#x2013; discount&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(30,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_zRs1RhF2rN3i" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Lease liability&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;247,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">90000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">122000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">65000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:OperatingLeaseLiability contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">277000000</us-gaap:OperatingLeaseLiability>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">30000000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">247000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2022-01-01to2022-03-31">&lt;p id="xdx_809_eus-gaap--SubsequentEventsTextBlock_z3ofp2iCfzj7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Note
9 - &lt;span id="xdx_824_zyRotnA9YbJ8"&gt;Subsequent Events&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: normal 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-style: normal; font-weight: normal"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: normal 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-style: normal; font-weight: normal"&gt;On
April 29, 2022, the Company entered into a settlement agreement with its former Chief Executive Officer (&#x201c;Officer&#x201d;) and received
&lt;span id="xdx_902_eus-gaap--StockRepurchasedDuringPeriodShares_pid_c20220428__20220429__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_ztJetsFNl71d" title="Number of shares received"&gt;1,845,000&lt;/span&gt; shares of its common stock in full and final settlement of all its claims against the Officer. The common stock certificates
were received by the Company on May 2, 2022 and the common shares were subsequently cancelled.&lt;/span&gt;&lt;/p&gt;

</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="From2022-04-282022-04-29_us-gaap_SubsequentEventMember_srt_ChiefExecutiveOfficerMember"
      decimals="INF"
      unitRef="Shares">1845000</us-gaap:StockRepurchasedDuringPeriodShares>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>55
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MQ_\5*]K#)G4D<2"!"I *W;0^5$-%VQZF/9CD(%:3F-D&NOWU.SMIRH\TT/$
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MYNB<X5S(Z9:+%YD"*/*:9X6<6:E2Y;5MRSB%G,HK7D*!;U9<Y%3AK5C;LA1
M$^.49[;G.*&=4U98\ZEY]B#F4UZIC!7P((BL\IR*MUO(^'9FN=;NP2-;ITH_
ML.?3DJ[A"=1S^2#PSFY1$I9#(1DOB(#5S+IQKQ=NI!V,Q7<&6WEP3;24)><O
M^N8NF5F.9@09Q$I#4/S9P *R3",AC[\:4*O]IG8\O-ZA_V+$HY@EE;#@V0^6
MJ'1FC2V2P(I6F7KDVU^A$332>#'/I/E/MHVM8Y&XDHKGC3,RR%E1_]+7)A '
M#HC3[^ U#E[7(3CAX#<.OA%:,S.R/E-%YU/!MT1H:T33%R8VQAO5L$(OXY,2
M^):AGYHO>)'@HD!"\$KRC"54X<V3PA]<+24)7Y&O)0BJHR[)^7-!JX2AS07Y
M1)Z?/I/SLPMR1EA!OJ6\DK1(Y-16R$SCVW'#XK9FX9U@X9-[7JA4DB_()GGO
M;Z.B5I:WDW7K#0+>4W%%?/>2>([G]?!9?-S=':#CMU'V#9Y_ N^NB'D.^ZB2
M/VZ64@G,X3\'T(,6/3#HP0GT1]A 44%OW <]=8^XEB6-869A$Y @-F#-25^\
M_C_..VFC5MIH,'!-YA5K\N6UU'DJKP=0PQ8U_)> 2: B3@EF*];\!IM9J9>E
M+X UTL@@Z9ZXF7O..)K:F\/H'!NY8>"T1N](1BW):)#D$[8V%'Y)UE!@$#)#
MEB;8 YA.'=W]R#DKX@S+$>-S%@21,3ES@TMO$A*H T96@N<$^TC\0C )]3-3
MRF0M:*%+77$L\16+0<A+ GF9\3< 68>&">RV7$B25$)_1*6 ?P* Y'6]@JY7
M<F^"N2LWXZH+YQ+[O"S!-.KL[:(ONM%1X'Q_-.I$]]C(B_S0ZP_ON WO>#"\
MOW$IZ]CLNUL?P_'1QT=!X'48'AMY$\<YP7#2,IP,YSY&6Y#SNG=<[ I@(/U=
M9]_TG4'Q=[CRN#8*V[8&[VW8SI&F3^..[.&O_'Q7< ^FEOLQ = 7E4;!(,1/
M]+X&Z# 4X23L7US7VTOP!B4L4EJL00_.%66";&A6@1ZV"0BVJ<L[8W3),J;>
M>N5YQPOD'JU0CY&>:+W4]]/,]0>I/Q>X8\S8WUCZF2XC[":X!WP!19<9$ DQ
M=@O%^@=2 _VN5H(NZ\'/_X>\VD]2=WB4?N,*.^U'*J]1$_3$MZOFV":,1B?6
M8#\8W=$@T]]QBZ][6"^KVC4\9(5=R^D2ZS'#R1%%)[CMQZL[/%\U-Y,8V%F)
M3*D W"OB9IO%S5C)*M7=YC7,:^#HD))SY7;G;9^9>S7V3Q#?CUQW>.;^,+M^
M3&NZP9F U8D)@).NUH!Y7BFI4($>A1\5U#/AO& <NF[8U71LZ8:>/YGXXXXL
M^V"[GX-8FU.01*Y5H>HM<ONT/6G=F/-%Y_FM/H&98\0>ICZ^X41?,]SN9[!"
M2.<J0EJB/A'5-XJ7YE"QY J/*.8RQ5,D"&V [U><J]V-_D![+IW_ U!+ P04
M    "  52+!4>J^D&J@"   )!@  &    'AL+W=O<FMS:&5E=',O<VAE970U
M+GAM;(U444_;,!#^*Z>(!Y" M$F!#;65:,LT)! 5'=L#VH.;7!(+Q\YLIX5_
MO[.39AUKJ[TD/ON^[[[SG6^X5OK5%(@6WDHAS2@HK*VNP] D!9;,G*L*)9UD
M2I?,DJGST%0:6>I!I0BC7N\R+!F7P7CH]^9Z/%2U%5SB7(.IRY+I]PD*M1X%
M_6"S\<3SPKJ-<#RL6(X+M,_57),5=BPI+U$:KB1HS$;!3?]Z>N'\O<-WCFNS
MM0:7R5*I5V?<I:.@YP2AP,0Z!D:_%4Y1"$=$,GZUG$$7T@&WUQOV+SYWRF7)
M#$Z5^,%36XR"3P&DF+%:V">U_HIM/EY@HH3Q7UBWOKT DMI85;9@4E!RV?S9
M6WL/6P#BV0V(6D#T$3#8 XA;0.P3;93YM&;,LO%0JS5HYTUL;N'OQJ,I&RY=
M%1=6TRDGG!U/E4RI)I@"K8P2/&66C(6E'Q7+&E 9/%:HF;MU \?/DM4I)Y\3
M.)XS32X%6IXP<0)G\+R8P?'1"1P!E_"M4+5A,C7#T))2%R],6E631E6T1U4,
M#XJ(#=R2NO1O?$@9=FE&FS0GT4'"!Z;/(>Z?0M2+HAUZIO\/[Q^0$W>W'GN^
MP1Z^QRSC"6H#=#TPXYIZ6I'U\H#E$O7/ Q$&782!CQ#OB3###+7V92WIQ1M?
M/KC1FLG<%Y;ZS!9P)U.^XFG-Q"G<OB6"2BMS6!14V+,)<VTQ9^]-'SBI<V6L
MIG+KAF*"$C-.9R_W%![NJ&7,(?$7G?B+@]>S(_ZV="?5Y82[&JMAOO3,;H2M
MQH/!U3!<;1?[7Y_^(/I\V7DUHL.M5U6BSOVP,9"H6MJF\[K=;I[=^&?\87]"
M<ZX92W]HFB%)?95S>E4",Z+LG5^1,MT,GL:PJO)O=ZDL30*_+&A6HW8.=)XI
M93>&"]!-__%O4$L#!!0    ( !5(L%3-*.6'"@@  %8P   8    >&PO=V]R
M:W-H965T<R]S:&5E=#8N>&ULM5M;;]LV%/XKA#%@+1#7(JF+520!6LOV.J!#
MT#3;P[ '1F)BH;+H2G22_OL=R8IEB10=-^P>&LL^-Y[SB3P?R9T_BN);N>)<
MHJ=UEI<7HY64F_>321FO^)J5[\2&Y_#+G2C63,)C<3\I-P5G2:VTSB;$<?S)
MFJ7YZ/*\_NZJN#P76YFE.;\J4+E=KUGQXR//Q./%"(^>O_B2WJ]D]<7D\GS#
M[ODUES>;JP*>)GLK2;KF>9F*'!7\[F+T ;]?4J]2J"7^3OEC>? 954.Y%>);
M]? IN1@Y540\X[&L3##X\\!G/,LJ2Q#']\;H:.^S4CS\_&Q]40\>!G/+2CX3
MV3]I(E<7H^D()?R.;3/Y13S^P9L!U0'&(BOK?]%C(^N,4+PMI5@WRA#!.LUW
M?]E3DX@#!>(-*)!&@?05R( ";11H3X$.*;B-@MM7\ <4O$;!ZX<4#"CXC8+?
M4\!T0"%H%(*Z6+OLUJ6)F&27YX5X1$4E#=:J#W5]:VVH2)I74+R6!?R:@IZ\
MG(D\ 6#Q!,&G4F1IPB0\7$OX XB3)1)W\"3B;RN1);PH?T?S[]M4_D!O(GZ7
MQJE\B][<Y&R;I*#W%HW1S76$WOSV%OV&TAQ]78EMR?*D/)](B+;R.8F;R#[N
M(B,#D5T!)GE1U,& >_3O9[Z^Y<5_&DLSLZ696*\!]4?-1"\SLV(%+]&GLMRR
MVXR;#,[-!C\DD#1X'UF&KEB:C"%?,[9))3P;C"[,1K]P"1,09&W.BCS-[TN3
MK:79UE<!L735)H"O/<C('F2DMN,.V/G([].\"@9FC8SE,3]##RS;<L0DBGC\
M#E%\AHA#'!U*=J;]VG0UL3Y<TO/)PV'U50FO*Q$9PZMF^_?EAL7\8@33><F+
M!SZZ1+IZ:CSY/O7\KKN%*C;V0B\(@Z[<4B-'0I>VX^MDF^ZS34_-=KG#[$O2
MO;/M'<1$7,^!_WI)5^4\@J>*7&2,]46I[R3!W2?!-2:AF:1BL89%NV3ULB<%
M3&8P9\$LAF!.0K>"%4DUOR5I 2NC*+2SE-'/R[$S<Y5BN[U46?(T=Y728)>$
MI =22]Z6>F^^'L/>OGS>+RC?,]!UZ?>4,*GOXD.\=@+U]X'ZQD#K90#>L2J.
M>+= E/4Z UTBJM(&\6IA931[ JQ\!5:]0D>6/,U])8-3F!EZJ++D;*EU1O2U
M"O:U"EY?*Q.& A7J,*T/8FBZCVMJ!ON3A-EZFY:KJN.J$<UO)<"ZC,46OMAN
MJIX]$9OZ-8"?/US?U//WV/%UT#)Z.P%:ENQ$ENS,ITKZQV[@]M;ZA2I%2&^!
M7NHL>3C4ES'<ES$TEA$:Z >8FYH:';2OO$AA\?USC*LI[!!XNN*%FIZ@M_2J
M(KCWRAL#/2'CH0KX7K8M>5J^WDZG9MAI^8]CN6IG#0704AI'11:AGJOV3QI)
M/R2#<PD^('3XR(!VH>Y:OA3F/!A-/86L8=5DL$Y6Z^KAH',A07+#?M1\IEI:
M61P7E5J:2PY6I':HQC!.F&8:0Z;.2"-"H*/NO=;S1JR#5S)U^^VYK<B7&G]T
M.G4&>A_<TB5LYDN_HH0&U,Z:<#KC"()0;>8U@H%/W6'4MIP%FTG+\)#Y$R_B
MM*Q7[4=6%"R7^E?O]4RCR88E0Y$M0W.L(5O3/J@M.5N:G77+V[(Q;*9CIY77
MB%65;X3>, !;PH'-C&.P.4QSM-G>9FE<L0]8%/+[,Y1SN9,;F!J-KDZ!HG=T
M:\.6KSE6&1)Q_<#MX\R2O^6 OX$F#+>$#/\D(SM22"/H5#KBAJX!=BTEP:_@
M)%4"61&OZ@D]X0\\$YN:(K#[@M?;LUKT&3V>@CY+AB);AN98P\"HUV< MMPM
MC[GKUKRE>]C,]UY9<R-056:#0V<8IRVWP69R\Q>\*)DH]2NO)1(PLV4HLF5H
M;LO0 JM4:DQ"/^AO"1^7Z^[ MSR'F'G./$_T&_"?6;'?$<;:#7CG&-^<:41(
MGY/J9#0]/-'P(D+)M)>HA49N[!./N+W&:*D1)*Z#AQ+:\BQBYEG]A+9[[,<S
MJO*&T%<IHD:,.!X.U+Y<(VGLR\G!R8V=HQO].-4##@4YFN.=_@:FS@S&M \<
ME9M ]T+[>%AHY,:^1[VIVP>.*DAPB(=2VE(=8NE\1I]3M3W78D<5H\3QE=3J
MQ(9W-$G;\),C#7\UL"QCSUN6Q[:]S.9.6$-L&8IL&9K;,K2P96AIP5 7%BW+
M(F:698*%:>>=J&0!ED4\@-*6*Y#3N<+N5:Q:L5@AK=7NBA:]MDYS;!F*B'HN
M--9-FBJQ4:46MJ):6C#4K73+L\CI/*N9=$O$Z]-&(_Y4)@#SY #\6B) S$1@
M=R/ETVXW)-I6E!1= 3,5R7./?X:Z^].[)YE6NWS7/ 85F6HCCHCFC,,XM;=4
M@)BI@+VC=;.C4UX;6\3!EJ$Y4?MXUU5Z6%NG)T>\=:^1M)2!'J$,U@_AJ=J+
M3X=W46C;BU-S+_[3I_!FNR<@T):AR):A.54YP33H7P*QY6UYQ%NWKBW[H&;V
M\>H3>ZKV\-BGPX@[N&-E;N)-^R%FU5- 9>LDPI:A!57YPMASW1[[6!X5ZV:]
M917TR*VNEVQB$&U-U.M7?2JJ$5&HJ#F^4]Y.U9D?^,&T?Y]&(P=L-71(GZWJ
M!A@$TX'M=-IV[/3(3:P7;7/H<ZXV[3JJJA&CA+JJ9&0.]83V<7)P8;JZ<0]#
M 4Y>HHS?@67G70".BMTE]MV#%)OZ#O6MD%*LZX\KSA)>5 +P^YT0\OFANI:]
M_U\)+O\'4$L#!!0    ( !5(L%1) ;DZ/@<  &$>   8    >&PO=V]R:W-H
M965T<R]S:&5E=#<N>&ULK5E;<^*X$OXK*FH?DJIEL&7,)96DBA!REJH)I$(R
M^ZS8 K1C6QQ)SF5__;9DL,$7!3+S$FQ'W>JON]5?2[I\X^*G7%.JT'L<)?*J
MM59J<]'IR&!-8R*_\0U-X#]++F*BX%6L.G(C* F-4!QUL./T.C%A2>OZTGQ[
M$->7/%412^B#0#*-8R(^;FC$WZY:;FOWX9&MUDI_Z%Q?;LB*+JAZWCP(>.OD
M6D(6TT0RGB!!EU>MD7LQ]OI:P(SXP>B;W'M&&LH+YS_URS2\:CG:(AK10&D5
M!'Y>Z9A&D=8$=OQ_J[25SZD%]Y]WVN\,> #S0B0=\^AO%JKU56O00B%=DC12
MC_SM+[H%Y&M] 8^D^8O>MF.=%@I2J7B\%08+8I9DO^1]ZX@] =!3+X"W K@L
MT&T0\+8"G@&:669@W1)%KB\%?T-"CP9M^L'XQD@#&I;H,"Z4@/\RD%/78YZ$
M$!0:(GB2/&(A4?"R4/ #T5(2\24:$[E&=Q!QB<Z>$Y*&#,:<HS9Z7MRBLS_.
MT1^()>AIS5-)DE!>=A18IO5W@JT5-YD5N,$*#]WS1*TEFH UX:%\!Q#EL/ .
MU@VV*KPGXAORW#\1=C"NL6=\O+AK,<?+O>P9?5Z3ET>+O]#=]_G?"W3W.+]'
M\X?)X^AI.OL?&HV?IC^F3]/)PC)--Y^F:Z;I-DPS@V4?<5D;@$RR9R3UVGZ]
M;OO=KG/9>=UW2\TH/.SU^_FP [O\W"[?"G\4_@.9G*63XK#Z YX$+*(HV1JL
MO^KG0"?:6:K3D27G"(J5((HEJVRU,\6HO+#XJ9?;T[/Z::%X\-.L_A %/(:2
M*(DI*E 6D:3BE06TUHF96G_//8,^+KFP.F8X<!H<V,\-[G_-8/ ;7R[!7"'_
M1#3>1/R#4HE@%:(73D2H5V_(P.&*BUI$_8JUW6Z_A*@ZQNU"5M1#&N20!E9(
M4&Y>J5#L1:<!5V#TAGP0_<:D3 &GC@7DB81ZK#/ %A;K3)H(+^2&!/2J!4RG
M]=#6-:HK"H,*T#YVZF$.<YA#.\PU2594E\<E80*]DBBE)BA4L%>B*0Q%C+RP
MB*F/.FC#BDEM=U"*3\T87;7JS':=@A><(PTO5F%$(0.1T,S8YLLVK%-$I*2J
MON([%;.P5[+<;L-1D3N$MT=[KA7><P)-3\3^A40S!0C6$K0Q/ZDR*2AID I3
M;FJ1N55DW3(RZ_1?0(8+9-C.-29P\C!R69A,7=BEVR>UU"VXS?6LKCR;)H'0
MF7$.69T]Z<D!UX:P$-%W7:X:/.G5I&ZODB754;C?4'[<@BM=.UGNK-:VAG3#
M)6O(XV[5QF'90NM47XAVP:RN?QR*LYWOSS4@$@0\U72[*ZHZ\O!1Z,IJC8A?
M13OPRA6G9A1VAPT1*5C9M=/RV>T^A'+9L99)M\JZ;;>21];IOQ"E@KY=.W_O
MY]HN"BQ1%*91M7"LZDY@-+?*W;TFYG8+ZG;MW*W[3+,G.'O>M6KS/%JCO%6K
M15;EV+:/7;\<JIIA7F_0;;"\8&-W>%(C/IW]F"R.;\1Q09_83I\+$AF>9]#E
M;%O?.G?@*DEZOE=.7/M<IR<N+F@2VVDRC_2#X*\,]F;HY0--#:;/8XVK/%D'
M[C<S)2Z8$G_"E*5DN)O.1K/Q\<E0,"2V,R0X+Z TE&@I>&SZ6Y($)CV@F8^A
M]9"ZOZ]UH57Q"84 UW!HM]=OJ-FX8%%L9]%#:/2=BH!) ^V-"$&:TO[7^7(+
MJTK._J !4\&IV,ZIS>$ZV*C4 K-J/@58E6%=[/@-T J*Q7:*K5W/=RP!@$>L
MYU_GSRVX*EMC?]C%#>@*FL5VFM7HBH;HH)O0H&LQ50FR[?8&Y4U]S3",<6.J
M%4R*/]D%ZU@0A6[HBB6)#@%DV0/L#7E8:VV5%@?#7KD[JQGEXV'#$00NN!-_
MLI7=VCI)PD^LK&Y(^WC0*UM9'87[OM^0XE[!O)YCK>J+YX>'[Y/[R>QI]!W=
M3A?C[_/%\^-D@>9W**_X0/QW\\?[T=-T/K/M@KR"*3T[4TXM[9Q=](2%\QL4
M'<(KN-+#GW6P/*9(D??ZVF 7/P7BKRLZA+AW1FL_I+4ESFP^:YODV6L89[>G
M=@Q>0:N>G58?JV<LV>;]8"L$==H<IJX2<Y"Q286F*J5/!;.!9"6H.<:O#5F5
M.W&O?"!LM_,+X2A8V+.S\.1=MY@IDVL-0%><-"$Q%\I@#>F+0B&39IN;[6[S
M0V:-'W99:9Q&YC(CI$L6,(72C;XW"OG&')V"PM'B69_P.VVG5^N@WT7F7I7,
MNW[3?MDKR-RSD_EXKWG<G9H:C($Y6Y5;E(>GJ_L' ;8MJ'WN4\!7R=X;#)R&
M3:A7D+UG)_NC#I"/.?*PSW,*TG[E]L3U<9G0.GN7=3$5*W.'*9%)Y.R"*_^:
MWY..S.U@Z?N->S'.;CL+-=GEZST1T$Y(* )+4.E\ZX/S17:?F;THOC%7@B]<
M*1Z;QS4E(15Z /Q_R<&AVQ<]07ZK?/T?4$L#!!0    ( !5(L%0FDAUW9P,
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M<)4FR6LX$Q#N="^Y?G71!U<@9&0JXAT$QLHQ0VO)^*+\_ !S254A^%*P2S:
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M;0ZYT!Y(+KQ5\IK=$QO7R+OD:[\8VXE[D&!:7P5QD<0<.7?GM@I""DP/15J
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M[$7A[Y!0COY"[:7@L,EJ,8NV"N4>-U'=X59Q<+1%)ZBF!8D?TH9T38G0K5@
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MDL**5;GY(C<?H>$SL/X2F6OW2S:U;33T25)I(XL&C!D47-0C>VKJT &,@S<
MM %0EW<=R&5YR0R;3Y7<$&6MT9N=.*H.C<EQ80_ESBC\RA%GYM>,*_*5Y140
MN2+77#"1<):33T(;56'UC9[V#0:RYOVD<7I1.Z5O.(W(9RE,ILF52"'=Q?<Q
MP39+^I+E!=WK\#-3)R0*>X0&E.[Q%[6L(^<O^C'K2ZZ37.I*@29_G2^1-0KE
M[STQXC9&[&+$O[:R>YW:*WJJ2Y; S,<[J$$]@C__0QKP(O+[;V,:AF?D'8')
M?08>:,-1UI"2E44\6H2VD%4+X1T(WFAMF$BY6),-*""'7!"3R4KCICXZ)7?X
M8*15[J)>M;Y_G(V'IYMD[?&2PP?!JI0C^,A[$/C2Y/P?=-296I_>0FI#/N"S
MH\F-U!I3=U&\!=,9P91(8B?PO>+(S#$X(*,>'0]Q=*6B9SLS]\V[RZ0RQP94
M@>0?L40U^7#2BR?#UOHPIN3(;0YB[UX:Y'- Z+ W&M,=G[5=_2D.O$M(H%B"
M>N$:_FI^X]YD.'Z#G_OV%C\:]8(XV/*C$\S;;H9ARR^BO2#8]5[;'5@^D]'$
MJ6HE<WSHK4@,6Z(8%#BAVB F [*01<G$LW,Q.M,=Z9&,@[)*>";X7T,X K9"
M9%@ W#A\Q=D6HD/DZ$U5>E9]6RU^;(-M)7GN@G@=JQMXA)R$S4B;,=JGV/>@
MI8!G?,35-_S37568)Y9PV*.326=\=80H"%5*A9>*"+SP-?5$%@4HEWW)2E16
MK<D6O;MLCO)565&@@]YH$'7"-\!M]'?P>BWOGRW&H!>/X\[XD\6H!=RB=Y=[
MBC'&RS[HA&^ VSS.W3NYJX*>TW='SVAA=U)0J%;;>Y"<LR7/N7DFK)"50+UX
M1MIBTP"O5K"CU<LM[*:%W2LF-'/]C/ZO"'>6H=?1Y(X^+V#-A;#W<\ER9 XV
M?C1V\?$BCR,[JP^NIE&5V#QQK2MGC)EMF,(TL%+'Y-A;9$RL :]@E_EA6/O#
MR#2L9][5D\&@%=>9O:@.>U7_F73R:.J >0RIF_W?_W"_T^W@>:]=3Z?Q]+&B
M=>/3[K9MXWG=+6W-ZYX3:[:V#VP.*X0&)Z.!3U3=Q]4+(TO7.RVEP4[,33-L
M?4%9 _R^DJB^9F$#M,WT_%]02P,$%     @ %4BP5#H6Q,WS @  008  !D
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MC\I>H/-,4LCMQCKH_C7F?P!02P,$%     @ %4BP5!R)2HB,!   :@L  !D
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M:Y\ET9#%81R_@Y=TOB8.+SF!=P=+R^Z$20ME:@WLK\726(UU\?<[X*,.?.3
M1_]%(-^%HCZ\-!5/X=K#1C.@-^#-"7,P9K_\-(VCZ(J=--><!OO3O3$U9 R[
ME]URD[.%&51<6Z96S.: ,&7%Y<ZA3JX,6PG)92KDNFD7806885^2B08P[=F7
MSG[56K3*\H(0?F;QV$]8XH]"-AF.DNDP3L8=/?:6'O:_+0#[W;+%6H-[,NQ>
M#E:8,5Y@$40?&)<954-XE)- ^=.\A'0ZO%2U=/XC/W_LZ TJP#F5<TU25K')
M*!F.XP\#]\J<BE6JRA+G"K9H^NR?]@N'QQ*XQK!"W[$'.?BMEL#B9'C$(Q0!
M32X1G2>+;ALKBL+Y?P+P5QP%;M9MH-@U:$0U#J^.*[B/T=798"ML[L1S562@
M31.;*/%C%HV)YR=8ZAHG-HLN'->(8LG35.G,878 %'#&#Y3J"N.#8:H*<".X
M#21\KX7=X6D%&@O%<35MNH;'\I3XTZ-YBH91$@_#\;_)E.@UB)(&ASG5[NL*
MK+3 SSN,X?%F^,?"@Y<TYW(-SDQZ,$.]+5*4/>)TY%_\W\'O:*P19LWMGM"@
M(^2:>31Q07\S=WJ!7*2IQN?!O:MB8S&&[&0,-9 OJ,D;+4JMTVJLCO=6H^%%
MC&,$GQ:9JL@E$E@\?7/M<\["BU?#XFU''<PX7X.,+H,,I0\1'_D3UY9<-@%O
MX]U'27-E:,0Q3AP.UD-,#ETOY^Z.<3EI)K1;7JAK'Q!&LP='')OUJ5Y:58D4
M@QF>Q^&9D[G#E&PX=; 9T/DS9&O,T3E"N7O*)>BCM)C KK8?MOBJR>D!=!J-
MST?AV25E@ORC6FLKO"O2>XF77]W4"AE[982_M3,XV/'Q$L$H8HJPBO=EQ=N<
ML'Y.*"JOIMH+,:D%KBN9^X#7VT:HVA2]_)Q(3(CC:(3S^MA5'?3VGQ+TVFUY
MU)*(T*Q"W=MND5PT^]-!O-E"<>? D!M6P I50W\R]IAN-KOF@ %VV]126=S-
MW&..RS!H$L#O*X75U1[(0+=>SW\ 4$L#!!0    ( !5(L%2&$-E'Z00   $+
M   9    >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;*56VVX;-Q!]WZ\8J&F1
M +$N*\5175N [21H@*8P["9YIG9'6L)<<DMRI:A?WS-<W>S: =H^V.*2<SES
M.^3YVOG[4#%'^E8;&RYZ58S-V6 0BHIK%?JN88N3A?.UBOCTRT%H/*LR*=5F
MD ^'IX-::=N;G:>]&S\[=VTTVO*-I]#6M?*;*S9N?=$;]78;MWI91=D8S,X;
MM>0[CI^;&X^OP=Y*J6NV03M+GA<7O<O1V=5$Y)/ %\WK<+0FB63NW+U\?"PO
M>D,!Q(:+*!84?E9\S<:((<#X<VNSMW<IBL?KG?4/*7;$,E>!KYWYJLM87?2F
M/2IYH5H3;]WZ5][&\T;L%<Z$])_6G6P.CT4;HJNWROBNM>U^U;=M'HX4IL-G
M%/*M0IYP=XX2RG<JJMFY=VOR(@UKLDBA)FV TU:*<A<]3C7TXNP=>[U2DAGZ
M3:NY-CINS@<1EN5\4&RM7'56\F>LC.F3L[$*]-Z67#[4'P#1'E:^@W65?]?@
M)^7[-!Z]IGR8Y]^Q-]Z'.4[VQO\YS =F)WNSDV1V\C^S]UTK,G=GH5$%7_0P
M6(']BGNSWUWD[)1^^F&:CT:_T%.>Z%WKM5UFL6+:L/+$DGV(%ES/V>_R-WQ-
M(G'MZD;9#>D06D@5["-FEM;*>V5C@(R*5*",V,6YHD5K2X7YB\I0A$Q0W2 U
MWJUT&LJM2FM*6@)9YG5@BHZ4)3<W>JF2/#8:M:%"A4K6@F7KE"IG2@!M&XBY
MHFB]9ULPN<4>7E$INV22%:!YS$?<-$R\ J[0IX\RUX7SI1*]M8Y5=GEW39/I
M-NB%TIY6RK3)*'8"'R+6@0JC0M ++0$'Q&SVN=5VFS7DU :<8Q6<T:6*^+A2
M)GF\2\2I; G?QM <.> 3JEF%UHO-F(R@+N(>H/T&3-8X'U$W:E!35R;42>P0
M:X>XDX29+980X5L*(L9 RS[E%UGXH^*L/#3(+@C-@=;LN3-74AO$JZ(K;5VM
M4=7&ZT*V:E>R.>!8. .N3K) #&I&;D#:3?)V1G>X&,K6< 843[2E>+T\R&<8
MY:)"+Q[W929C+;TYREY^MJHM-<)\E=U%5]S3#5 QO:"\/YWB9]P?OLEN=;@_
M67B6[$2$%"(A>H;,)*<?:=3/3^G'[/VW!F2/2%?. %2JXRA_*P+YS\?G1B^8
M7B*M,C;A%7R,\7=Z$"CU2I=2MHUF=/<)G60?I)6^[%KIZZZ)7L#V\/5P.)35
M>)I64@__#.(U^DRN$72$33N!<*8P+B#QDN:;5((/C'JB0K<=':#?['VJ\WZ,
MV\ AB58:EP12!NFCL %1QY 5KJ[A)Z3$8OC@2M<"(]6YC:UTQT$+E[RHT;%:
MYY8?I*Z;)3KJN<"8WFW+(<*2$7.=B&2^203E69X(TE1ID,$E+1 _8TW;$'TK
MK?[(^Z.Z/$AF-^]%[&CIF/(JB%D704/Z8")(/AX'VQ%2V$U<HT+,9+I+QYV)
M#LF.T_Z-K2[;_6/2CI7T1]U=G1UY[Z:EN_D>,K?GPBVM_BNQ\U+8$9E#UZ6F
MRX1W084MZ$'*^)!0_L&#3_'%!OP5U\P=WL<\E0)Y1+8D9#N=Y'UZZC(='#U+
M:O;+]/B2' %C]T+9[^[?=Y?=L^8@WCT.D98EFH(,+Z Z[+]]TR/?/;BZC^B:
M],B9NX@G4UI6>*.R%P&<+QSNT^V'.-B_>F=_ U!+ P04    "  52+!462DL
MH><(  #9&0  &0   'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6S-65MSV[@5
M?N>OP*C;3G:&EGB1+"FQ/>,XR7:GLVO/>MM]Z/0!(B&)&Y)0 -"*^^O['0"D
MJ9MCM_O0ASB\X'PXE^]<0%ULI?JLUT(8]K4J:WTY6!NS>3L:Z6PM*JZ'<B-J
MO%E*57&#6[4:Z8T2/+="53E*HNA\5/&B'EQ=V&=WZNI"-J8L:G&GF&ZJBJO'
M]Z*4V\M!/&@?_%*LUH8>C*XN-GPE[H7Y^^9.X6[4H>1%)6I=R)HIL;P<7,=O
MWX]IO5WPCT)L=>^:D24+*3_3S8_YY2 BA40I,D,('/\]B!M1E@0$-;YXS$&W
M)0GVKUOT3]9VV++@6MS(\K<B-^O+P6S <K'D36E^D=N_"F_/A/ R66K[EVW=
MV@0[9HTVLO+"N*^*VOW/OWH_] 1FT0F!Q LD5F^WD=7R S?\ZD+)+5.T&FAT
M84VUTE"NJ"DH]T;A;0$Y<W5O9/9Y+<M<*/V7/\V2>/J.??S2%.;Q8F2 3ZM&
MF<=Z[["2$U@I^TG69JW9QSH7^:[\"'IURB6M<N^39P%_XFK(TCAD290DS^"E
MG;&IQ4M/X#G#V#^O%]HH\.%?SV"..\RQQ1S_(0Y\%HL2\*W>\$Q<#I!A6J@'
M,;CZ61H13)G%CM^QT_NQ7]<BN)'5AM>/_HUFO#%KJ8I_BYQE?%,87C*NF5PR
M^#9;=\YE6SR=3J(PBNP_%@VC*&;QI/\@9D"O9!U8'79O?M2ZX8M2L-LZ^"06
MJD&&L_C<HF,/H'/DL$:NT.9F+4#B.N=&8EDFZP=80TGJW]6P6;,-?[206(CL
MS50#(XK:". 87-B5?+528L4-KBK9U!;].Y;.AK.@*LH2F*%=Y_W""N@)&,Z,
M)%]@=1R'XS@-TR0)])H#FQYFUC:FK6U&6@B\V@A;1*Q^/@9A@.7;=0%G BF:
MG8=1,@ZV4)+QDLKDTYX6^8/(1+40BEP?D'.&%#> 4P4MZA5+DVF8S&=!JX+5
M*2A:_W*S V']RQYX:7<PL#T>QIWI3@^_?]XHPB=3S%H)1,!EZT:H0N9,4-+N
MT6+(;GB=H61RXZ.SXY@/3XC/@.P$(,@<(&F+L"IA&E7C!CX^0M5D'H7S^=P3
MG%R"9J2=,I"0RV6140R8J#:E?!0"EP2[D%SEI&Y>*(1,*LVNB4_*\L,M1F<Q
MH \<05<:==>L68$+ZG1"!3<?;RW6TR-V\^F6O:'42J)WMWYO>QN_^]Y9V3Z%
M89D 4XAIRZ8L']D#2(M;Y[B5XMA<?&E@(UE>]WA,E(P0Q0E#_@V3";MK%&)?
MF\#SL-,9MFXV2GXMT)P$MDC3/[<)M,_?1<<"KT=152(OG!S86PI/\9:%9BO9
MH^"PY+9F1Q*ZGU,4EE)85*,#X8H18B,L.\B'9:']:W8BQZ1+YY^YSOD7L,[%
M'T3Z+,R0@J>;;!VR<9A.Y^$XFK)X-CQ_&0%WM0T0&;FJ+<V0+.-A^E_1> =E
M/)[:&DD%>,D+Y?*QC<634Y-Y'$ZC*&CJE@TG"TY'[:"C]BEF(^N/%',J!..V
M$%C1+:Z)"#W5L<[MV,^L0'RE:T$E=MD@/UNWZ*$K\TC@H*>RLP$IPJAC0>N=
M9$-QIZIOF;"7;+#/P#.!7P**ZUUB60%;&US"X)T6K+=\UVU=/L4L_7^A[6[7
M*W2WP3%+*<-MFOJ6LV=L$LZH0\]1':(A,B"<I^-P%D_9''TZF::]I/V?$V-&
M]2><3Z9(N+&'"UZ3(3V:!8";)I0A1)M#PK&6<$J@T;B  \GU/)"-?#<^#R>0
M/Q$&"A;M36E%=MNV?AXFX^DI"5\-L5//P\$.B8G^A<ZH#=E62&WZ,+O3V3R<
M3%^4T_V=3B=M^H<G[1T..D(I!,+-:O=X@9'BYNF%FRK9M0GVE"(5CG &Z':R
MF,/':=0S65MH=L,V';35-:1ZX!P'-MA9$NHY0?:&_.C;ZGT+L*=;VV:#=IB"
M8CAC:G@S1\0IUX)^KBE!(Z7PGM*;DI(8OH%>#X5LM,^3ECA=:6(8+RM7S7C^
M>^/H9*LX'>_T4TUW3'66.^)[9WCO_NW N\<G8Y)\;XMZ+G2QJBUL[ 9O1GZZ
M=P.@W]C[YQ"='.D&:5/X.9&RT. $'=(-"<N-Z0W9[0!+,[7LQ;"7Q-TQPE$Y
M\-E&T$R@D+EIN#>_JVZ".9FKY%K!P2@7?+P^]-C06\V^9?6:/[C)1?,*Z2]M
MN'RHD"?VS0L,\R0-;%OJ^>:;^X,QA2E=(<'N@MFTQ=9G/A8B/S/R;,<!"ZX+
M>%TWB]_AP/9TL1"U0,LO>!G(;8V]U\4&#:A"0S'N%"-7@E*/G5+R.=.L7J@D
MF!0-B=CC9?U4:P^$=>^8.0Q^_1;S<"#:\051+R\>BAQ]0K,W35T*#5"<GPH8
MR6D@SD56<D)9/#XEP?=LT1A7]&B @#\VO/5J<-RK9SVO4H;O;NW->X6K,.2X
MIHX*4IL3$D&..B3+QH6F+# \Y/Z,1 &R-8DUF_!59&IK/5!@/$TC+PQU<- ,
M]ST86A>^@IV=([51Q:)I3UROT,.6Y,,/#:3=P0%VIZG4DOW&E7)M$JMO;=72
MN]\;VA7.=<'6W3*#OYIG3H JS<%I]]C@\I;=9VN1-Z6=:STTNZ;J1L?.GQNK
M++VR'_D@?PWO\94(.D4_?A4J*]!P[A2&A^#VJ34=/;&_Q3"7ICCH8[CZCDV&
M:13\0$" /F-GP2>IEJ+ W<@=E_WC=A-WU[E [FZVY_"#C3HYX>#:SPK?D#L:
MSM!6E>,]F6W;C:A"]$_![I!N:S>"C?:#Z5(7F1^L?-T6K4<WY%%X/W 3<8=*
M Q/:-MA-8>:U_ZI$H[>3&>Y2IN61N_.]\#1A@A<3I@5^"6':M?M\\8_E-WF3
M1@E-PO21:QA-7L^:$SOM!7]OEU;H><;$<1PF\<0+'4Z3.UD>XRR<S"9L B&,
M.S1=*Q%03&L9[%/"EYN^SM*KQ(\6F1,4\H>J5O8%##KVA7C4^]Q>";6R/RI0
M$VEJX[Z\=T^[WRVNW>?ZI^7N1P_HO8*AK!1+B.)4-QFX\:6],7)C/]XOI#&R
MLI=KP5&#:0'>+R6F#G]#&W2_YES]!U!+ P04    "  52+!4EL<#?! *  "3
M%P  &0   'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6RU6%EO&\D1?I]?46#L
M0 8HBH<NVY( 2;9WUY$M0[+7#T$>FC,]9._.3-/=/:*47Y^OJN>@K"-(D "R
M.4?=QU?5<[2V[D^_U#K0;5E4_GBP#&'U9F?'ITM=*C^R*UWA36Y=J0)NW6+'
MKYQ6F3"5Q<YT/-[?*96I!B='\NR+.SFR=2A,I;\X\G59*G=WI@N[/AY,!NV#
M*[-8!GZP<W*T4@M]K<.WU1>'NYU.2F9*77EC*W(Z/QZ<3MZ<[3*]$/QN]-IO
M7!-[,K?V3[[Y+3L>C-D@7>@TL 2%GQM]KHN"!<&,'XW,0:>2&3>O6^D?Q'?X
M,E=>G]OBN\G"\GAP.*!,YZHNPI5=_ZH;?_987FH++__3.M+N30>4UC[8LF&&
M!:6IXJ^Z;>*PP7 X?H)AVC!,Q>ZH2*Q\IX(Z.7)V38ZI(8TOQ%7AAG&FXJ1<
M!X>W!GSAY-R6I0F(<O"DJHS.;15,M=!5:K0_V@E0P80[:2/N+(J;/B%N1I\@
M8.GI?97I[#[_#DSK[)NV]IU-GQ7X2;D1S29#FHZGTV?DS3I_9R)O]M_X2^^,
M3POK:Z?I[Z=S'QR*YA_/:-WMM.Z*UMW_592?%<>-^L:O5*J/!^A$K]V-'IQ\
MMD$GA_37OQQ.)Y.W]+RC%R:8A9*^^+K4"8A7JKHCX\E4-[:XT1DN*-4NH*^I
MT M5T,K95.L,0GP2EBJ0<L9KRITM*:!1*=CX"XZPU&0=:-'HE-K:@=#FA N:
MUQ[N>#^B][>I7@4"LH EM2Q!W8)ZP] AK35Z/X4L-'#J:E5X8;A'E;!F:-2W
M ?Z2&,>J2E4!6#@&3)\6=0;7Y:W8EZ:U<Y"@V6]X-U?S0DNP.AJG"Q40#%7:
MFB,)'U ?GE)5T9Q?*V\KL-V1]O"=:4?)A81+WP(X/10J[VUJ1,S:A*7([<V_
M0QAU2PQ%G &Q*QMQ:IP85UF*ML(O1R#E+%#1)Q%V<?Z\650F-[ NU4FG3$N<
M&S)^ #N#=DTHENI&QU165*-KW5!"P%;--:M9XK:0@A@*=\5H6&QDM<_H996<
MU@N@%DT/N64GKR$,E.6J0!T%6L.]W$1A(NNZ7FEGX-,YI 46=JX*@P171@WY
M817N^.F%]72*>!5<$M\1:_I89P91+;AG@S-I&-*UJH)B $( $A&XM+770_J&
M#D(S0.VYN3',<F-DJLSOZ*/.<Z?OT!&V8L]A68;7&2J-MKB9IN.W_$XN)V]?
MQ>B \9VJC"[H=U44VJFG6)O7+3>*0V811#1O)-"81)I3SBWTAT6D4%#*2X0:
M.5\D@";/_:B1Q=7Q:&C5 @\0H5^^TIFQJZ5"NH;T6Y6.1*\)/O'UW)O,<'->
MWJ*^0!=TNFRHMC0J1[NF6DHNN<:HX:9)#6ATKHE!O9W$_BU@SQQ=DBZE1%&R
M*=<Y;'1:&C.9Z[#6.E;#)K-TH:86F4"JG=0-0L25[$C-L630-4I;EW.8.Y.*
MVQO1*7D=0A$;ORGY%)-;8B3&0!!D?-!S  IB<#!,>+RT11F;G3E?T.YT;S@>
MC^FZZZQ IZWQGJZ OLJERX3M?:=OL.2L1.T&S4\ JVBE'*H:?BCR@"_VV #V
M&U%];'JXN$(@&_CAVV\5-AGG3>R-3Z9"]]F )*.6M:PY:(]*TV1?YN:$4V.0
M]6>5*5-Z-HJWJ%YS:WCS ,1 CS\0_85E*$;$L)1D;VAK\@J+W6IE7=CDDVET
M\!9!<.9O[U$YDX/=MTG\H>=^.&A/N$E^B=(B=':/OYI=AV[Q0)I"!RV& -?_
M0$QD:"ATR"URCPTT9G<ZFM $_X!;EVFP7$5[$K+Q\%[[W"\_8(SRN$?MN1L4
MM.^S'>.DH-FX;#LF&A9D-2S -*IS+!38+AR;">3CI9KFQA9V@:1D??U(/?4,
M#,.^5<:XI1&"O"V')M8H_ >3QOCAO30NT0'<_/I'K05E>&* /.>:N0Y@+=M"
M^XXZ2#AJ<0ZV]0*[-NQDPL:_.)<Y*[PY8&5!LQ0$:$:=P+2 H+& V416N>&C
M59)N+"VFBM,7>-G,=_^8B7%8P;5V5)]C7BTT7;I,1AP*1D!Q!3-O94+#ZQ<T
MF8W&=#C:I=W1/GU1H8WY10-0&_T+4-E/L*L4&'.(4B1^2/ASG_==7O$$;KC1
M746&%5\_A,+_O-W;(?/-YI\^=P.*HY7S\$.9-:F2('%PM>.9:?[)@(@=09+K
MU(I70A[BBWM]^M//>#1-2E,4S:#DJ..OXFG7!N,3X[>N6#3E6B?29./1I.5#
MX2Y@/BM">EMHVHP!BL4FIMW5=E\FSMZI IY#'&IYJ[*!8\HK#;*Z__)5W%F2
MOJ@?!M;+M,!5%N^DFAB).ZUX#Q@S)7"A\:A5NU)WD<FAJMAN67?9J>E>YQ4$
MOJ"]T;A]\)A3U#G5;-5)T_\2+#!BJ;' [$ZA5"YK?$&S/H(Q\B#<EE7;H[C]
M(]PQ\I/>)*I7<HK&\(LRIWO].^1BX7BM%7%1Q3V''G#OC?MWF2T*Y:1AT[JL
MN651Z!L"4;5)4R$9?6G08B3I3Y[L)D!R!(QI,\3N UF#6UR"'8M?Z52F6W,<
M.#OX=88CA5MHQH5[E0V YZD>9_MTM/>2\,<YQ<V8X\VQXQAQ%-A;NL"HT<D&
M+,# S_8FKAZ\Y[*-3Z\LBF&WT+*%<)N?FK+D$?U5^D_7P:2^6;\81G>''&'_
MH^;M,.>/,WQZRN$<<LXG/QQ#4H$[1/T,R_M<57J8],LSK_6<*A7;'C4F8R4#
M#XOZB-'"FT]SL*8X;II)@YS*^C ;R]M=&B6G6688B3%XL01N[DZ'PX=X_K/K
MT6]9 %=+&VQJ@3@X9ZR7!@D6O7&N;6QD+!6[W!4GMCD==1#?C0,1S#M=SE]Y
M=);8ZM&Y@L-O%LL/5]X6)A,Y]Z?))1I2QDT_-= FKZ5$+ADG@4OQ*UC\(-79
MTEC!,<QK]J4#D^AXU]("53@_5=N"OF@;WEQLU,L'NBAHS:<^7N?16';MW] U
M;ZQU(2$42U HO257C247D?N;*/D,)>>]DJ0=ODV^M[Y5"@<HL+U"T?@E;#19
MW)&:DVX#5]U)K81TN-8._>A98=3<\#%4^S?)9>='RA)SMCW"Y0,/7S0-F,A'
MP&V;;_/>@(.RYE3,&1ZC9N!\'.=LVK,Z>\G[4?1W^2"GLVV<;YU:</7P1\J.
MEE"B)6U!R1U6&__J$6$ AH=B,N-3.1^ 5C_"-!G32_H@=9#\G^J T3UJX&U
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MXG#CJ'<8*!B\,=P%5 YN J&#5>O?XF)RCO_FR?S9Y#*974XN!?ZX$O13_*P
MT2E4%M:'^^76J;,B:=!/T%'X 5UWJS4"Q0)1E$^+./T IN#4%HQ!@B4.CN6S
MSR.!6-FQ#\,;"&DI-4F))AX>!UX_($ J"M*Y7+3@&O!LQS(?<10G>-O*%4A
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MVV[;, Q]]U<0Q@JT0!L[3MIF11*@Z04;L )%K\^*1<="9<F3Y*3Y^U%RXF9
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M3=\H:'P /:^T=IN))^B^>F9_ U!+ P04    "  52+!4YZ_IA!@#  "6"@
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MHVZ[AZ('1AY'0B112U)V ^R/7TI61;NQ"3G101=;'S-/,_/(>10UV7+Q*",
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M<,,4>SHH:X#[2RG-=F(/J/\E1.]02P,$%     @ %4BP5(55HU58 @  SP4
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M)/)KOOT5ZA\4ZGA1GHCR7[2MG_4'*"J$S--:K#)(XZSZRY[K0K0$..@1D%I
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M*;$=E66MXTQ(7NA)_8B63)6F=\U=X@X28NJ1GCP,"[$=AK=O8/JRUH_:X_8
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MEP2--Z#]0FNWG_@ S;=I\AM02P,$%     @ %4BP5$?O":.] @  *@<  !D
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MOG8P/@#O"ZW=R?$3./P_TK]02P,$%     @ %4BP5 9LA-(P P  [A,   T
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ME?$%%-3CAU5A%<XT775[5V3C4-ULD(G2*=--F"Y9FT8#P3*0H_EL#G>CBA!
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MJ'?Q3KU#O-0^/'KN:[S_.ZF.UVO]X_:WY7T3GQ?%#6<'_P^6OU!+ P04
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M97/T9]WOB?DG4$L! A0#%     @ %4BP5 =!36*!    L0   !
M     ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    "  52+!49INX
MR^X    K @  $0              @ &O    9&]C4')O<',O8V]R92YX;6Q0
M2P$"% ,4    "  52+!4F5R<(Q &  "<)P  $P              @ ', 0
M>&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( !5(L%2P9[*<104  /L5
M   8              " @0T(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q0
M2P$"% ,4    "  52+!4F<>](H@%  "@%0  &               @(&(#0
M>&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @ %4BP5&)LQ'@=
M P  T@H  !@              ("!1A,  'AL+W=O<FMS:&5E=',O<VAE970S
M+GAM;%!+ 0(4 Q0    ( !5(L%2%5,-SF 0  *,.   8              "
M@9D6  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4    "  52+!4
M>J^D&J@"   )!@  &               @(%G&P  >&PO=V]R:W-H965T<R]S
M:&5E=#4N>&UL4$L! A0#%     @ %4BP5,THY8<*"   5C   !@
M     ("!11X  'AL+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    (
M !5(L%1) ;DZ/@<  &$>   8              " @84F  !X;"]W;W)K<VAE
M971S+W-H965T-RYX;6Q02P$"% ,4    "  52+!4)I(==V<#  !^!P  &
M            @('Y+0  >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#
M%     @ %4BP5(%-&M&6%   R#@  !@              ("!EC$  'AL+W=O
M<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0    ( !5(L%1U?<ZT6@0  %@+
M   9              " @6)&  !X;"]W;W)K<VAE971S+W-H965T,3 N>&UL
M4$L! A0#%     @ %4BP5#H6Q,WS @  008  !D              ("!\TH
M 'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4    "  52+!4'(E*
MB(P$  !J"P  &0              @($=3@  >&PO=V]R:W-H965T<R]S:&5E
M=#$R+GAM;%!+ 0(4 Q0    ( !5(L%2&$-E'Z00   $+   9
M  " @>!2  !X;"]W;W)K<VAE971S+W-H965T,3,N>&UL4$L! A0#%     @
M%4BP5%DI+*'G"   V1D  !D              ("! %@  'AL+W=O<FMS:&5E
M=',O<VAE970Q-"YX;6Q02P$"% ,4    "  52+!4EL<#?! *  "3%P  &0
M            @($>80  >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4
M Q0    ( !5(L%2V]T:K1@(  /,$   9              " @65K  !X;"]W
M;W)K<VAE971S+W-H965T,38N>&UL4$L! A0#%     @ %4BP5%RC'4*P%0
MRD   !D              ("!XFT  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX
M;6Q02P$"% ,4    "  52+!4"$F,L.4"   F!@  &0              @(')
M@P  >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    ( !5(L%10
MC)+$@ 0  +4,   9              " @>6&  !X;"]W;W)K<VAE971S+W-H
M965T,3DN>&UL4$L! A0#%     @ %4BP5-%K)GR# @  ;@4  !D
M     ("!G(L  'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( !5(L%1%:^7\:00  (H/   9              "
M@9R;  !X;"]W;W)K<VAE971S+W-H965T,C4N>&UL4$L! A0#%     @ %4BP
M5*36==;# P  5 \  !D              ("!/*   'AL+W=O<FMS:&5E=',O
M<VAE970R-BYX;6Q02P$"% ,4    "  52+!4HQSF,2($  !C&0  &0
M        @($VI   >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0
M   ( !5(L%0:>V6 W@(  #$(   9              " @8^H  !X;"]W;W)K
M<VAE971S+W-H965T,C@N>&UL4$L! A0#%     @ %4BP5(55HU58 @  SP4
M !D              ("!I*L  'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q0
M2P$"% ,4    "  52+!4(:&K53\"  "_!0  &0              @($SK@
M>&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    ( !5(L%3WX__7
M5@4  *L8   9              " @:FP  !X;"]W;W)K<VAE971S+W-H965T
M,S$N>&UL4$L! A0#%     @ %4BP5,)">AZM P  8PT  !D
M ("!-K8  'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q02P$"% ,4    "  5
M2+!4_'<J//H!  !6!   &0              @($:N@  >&PO=V]R:W-H965T
M<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    ( !5(L%3_X5]C#0,  +T+   9
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M970S."YX;6Q02P$"% ,4    "  52+!4+?Y< 44'  #-'@  &0
M    @(&0T0  >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0    (
M !5(L%0&VB2^ 0(  $L$   9              " @0S9  !X;"]W;W)K<VAE
M971S+W-H965T-# N>&UL4$L! A0#%     @ %4BP5 9LA-(P P  [A,   T
M             ( !1-L  'AL+W-T>6QE<RYX;6Q02P$"% ,4    "  52+!4
MEXJ[',     3 @  "P              @ &?W@  7W)E;',O+G)E;'-02P$"
M% ,4    "  52+!4PWH7F[8#   Z&P  #P              @ &(WP  >&PO
M=V]R:V)O;VLN>&UL4$L! A0#%     @ %4BP5#QA]1J- 0  3Q@  !H
M         ( !:^,  'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#
M%     @ %4BP5)C$(26B 0  IA@  !,              ( !,.4  %M#;VYT
D96YT7U1Y<&5S72YX;6Q02P4&     #  ,  '#0   ^<

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>141</ContextCount>
  <ElementCount>261</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>50</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/BalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/BalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/StatementsOfOperations</Role>
      <ShortName>Condensed Consolidated Statements of Operations (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - Condensed Consolidated Statements of Operations (Unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/StatementsOfOperationsParenthetical</Role>
      <ShortName>Condensed Consolidated Statements of Operations (Unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/StatementsOfStockholdersEquityDeficit</Role>
      <ShortName>Condensed Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00000007 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/StatementsOfCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>00000008 - Disclosure - Organization and Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/OrganizationAndOperations</Role>
      <ShortName>Organization and Operations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>00000009 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>00000010 - Disclosure - Fair Value of Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/FairValueOfFinancialInstruments</Role>
      <ShortName>Fair Value of Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>00000011 - Disclosure - Accounts Payable</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/AccountsPayable</Role>
      <ShortName>Accounts Payable</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>00000012 - Disclosure - Convertible Notes Payable</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://gtbiopharma.com/role/ConvertibleNotesPayable</Role>
      <ShortName>Convertible Notes Payable</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>00000013 - Disclosure - Derivative Liability</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/DerivativeLiability</Role>
      <ShortName>Derivative Liability</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>00000014 - Disclosure - Stockholders??? Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders??? Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>00000015 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>00000016 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>00000017 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://gtbiopharma.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>00000018 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://gtbiopharma.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>00000019 - Disclosure - Fair Value of Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/FairValueOfFinancialInstrumentsTables</Role>
      <ShortName>Fair Value of Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://gtbiopharma.com/role/FairValueOfFinancialInstruments</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>00000020 - Disclosure - Accounts Payable (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/AccountsPayableTables</Role>
      <ShortName>Accounts Payable (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://gtbiopharma.com/role/AccountsPayable</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>00000021 - Disclosure - Derivative Liability (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/DerivativeLiabilityTables</Role>
      <ShortName>Derivative Liability (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://gtbiopharma.com/role/DerivativeLiability</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>00000022 - Disclosure - Stockholders??? Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/StockholdersEquityTables</Role>
      <ShortName>Stockholders??? Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://gtbiopharma.com/role/StockholdersEquity</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>00000023 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/CommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://gtbiopharma.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>00000024 - Disclosure - Schedule of Anti-dilutive Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/ScheduleOfAnti-dilutiveSecuritiesDetails</Role>
      <ShortName>Schedule of Anti-dilutive Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>00000025 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative</Role>
      <ShortName>Summary of Significant Accounting Policies (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>00000026 - Disclosure - Schedule of Estimated Fair Value of Financial Instrument (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/ScheduleOfEstimatedFairValueOfFinancialInstrumentDetails</Role>
      <ShortName>Schedule of Estimated Fair Value of Financial Instrument (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>00000027 - Disclosure - Schedule of Fair Value Hierarchy Financial Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/ScheduleOfFairValueHierarchyFinancialAssetsDetails</Role>
      <ShortName>Schedule of Fair Value Hierarchy Financial Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>00000028 - Disclosure - Schedule of Derivative Liability Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/ScheduleOfDerivativeLiabilityTransactionsDetails</Role>
      <ShortName>Schedule of Derivative Liability Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>00000029 - Disclosure - Schedule of Accounts Payable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/ScheduleOfAccountsPayableDetails</Role>
      <ShortName>Schedule of Accounts Payable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>00000030 - Disclosure - Accounts Payable (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/AccountsPayableDetailsNarrative</Role>
      <ShortName>Accounts Payable (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://gtbiopharma.com/role/AccountsPayableTables</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>00000031 - Disclosure - Convertible Notes Payable (Details Narrative)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://gtbiopharma.com/role/ConvertibleNotesPayableDetailsNarrative</Role>
      <ShortName>Convertible Notes Payable (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://gtbiopharma.com/role/ConvertibleNotesPayable</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>00000032 - Disclosure - Schedule of Derivative Liabilities Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/ScheduleOfDerivativeLiabilitiesAssumptionsDetails</Role>
      <ShortName>Schedule of Derivative Liabilities Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>00000033 - Disclosure - Derivative Liability (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/DerivativeLiabilityDetailsNarrative</Role>
      <ShortName>Derivative Liability (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://gtbiopharma.com/role/DerivativeLiabilityTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>00000034 - Disclosure - Schedule of Warrant Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/ScheduleOfWarrantActivityDetails</Role>
      <ShortName>Schedule of Warrant Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>00000035 - Disclosure - Schedule of Options Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/ScheduleOfOptionsActivityDetails</Role>
      <ShortName>Schedule of Options Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>00000036 - Disclosure - Stockholders??? Equity (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative</Role>
      <ShortName>Stockholders??? Equity (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://gtbiopharma.com/role/StockholdersEquityTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>00000037 - Disclosure - Schedule of Other Information Related Leases Under Non-Cancellable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/ScheduleOfOtherInformationRelatedLeasesUnderNon-cancellableDetails</Role>
      <ShortName>Schedule of Other Information Related Leases Under Non-Cancellable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>00000038 - Disclosure - Schedule of Future Minimum Lease Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/ScheduleOfFutureMinimumLeasePaymentsDetails</Role>
      <ShortName>Schedule of Future Minimum Lease Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>00000039 - Disclosure - Commitments and Contingencies (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative</Role>
      <ShortName>Commitments and Contingencies (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://gtbiopharma.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>00000040 - Disclosure - Subsequent Events (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/SubsequentEventsDetailsNarrative</Role>
      <ShortName>Subsequent Events (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://gtbiopharma.com/role/SubsequentEvents</ParentRole>
      <Position>40</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="form10-q.htm">form10-q.htm</File>
    <File>ex10-1.htm</File>
    <File>ex10-2.htm</File>
    <File>ex31-1.htm</File>
    <File>ex31-2.htm</File>
    <File>ex32-1.htm</File>
    <File>ex32-2.htm</File>
    <File>gtbp-20220331.xsd</File>
    <File>gtbp-20220331_cal.xml</File>
    <File>gtbp-20220331_def.xml</File>
    <File>gtbp-20220331_lab.xml</File>
    <File>gtbp-20220331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="428">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="31">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>60
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "form10-q.htm": {
   "axisCustom": 0,
   "axisStandard": 16,
   "contextCount": 141,
   "dts": {
    "calculationLink": {
     "local": [
      "gtbp-20220331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "gtbp-20220331_def.xml"
     ]
    },
    "inline": {
     "local": [
      "form10-q.htm"
     ]
    },
    "labelLink": {
     "local": [
      "gtbp-20220331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "gtbp-20220331_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "gtbp-20220331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 422,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 85,
    "http://gtbiopharma.com/20220331": 39,
    "http://xbrl.sec.gov/dei/2022": 5,
    "total": 129
   },
   "keyCustom": 60,
   "keyStandard": 201,
   "memberCustom": 30,
   "memberStandard": 20,
   "nsprefix": "GTBP",
   "nsuri": "http://gtbiopharma.com/20220331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "role": "http://gtbiopharma.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000010 - Disclosure - Fair Value of Financial Instruments",
     "role": "http://gtbiopharma.com/role/FairValueOfFinancialInstruments",
     "shortName": "Fair Value of Financial Instruments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000011 - Disclosure - Accounts Payable",
     "role": "http://gtbiopharma.com/role/AccountsPayable",
     "shortName": "Accounts Payable",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000012 - Disclosure - Convertible Notes Payable",
     "role": "http://gtbiopharma.com/role/ConvertibleNotesPayable",
     "shortName": "Convertible Notes Payable",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativesAndFairValueTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000013 - Disclosure - Derivative Liability",
     "role": "http://gtbiopharma.com/role/DerivativeLiability",
     "shortName": "Derivative Liability",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativesAndFairValueTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000014 - Disclosure - Stockholders\u2019 Equity",
     "role": "http://gtbiopharma.com/role/StockholdersEquity",
     "shortName": "Stockholders\u2019 Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000015 - Disclosure - Commitments and Contingencies",
     "role": "http://gtbiopharma.com/role/CommitmentsAndContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000016 - Disclosure - Subsequent Events",
     "role": "http://gtbiopharma.com/role/SubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000017 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000018 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "role": "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000019 - Disclosure - Fair Value of Financial Instruments (Tables)",
     "role": "http://gtbiopharma.com/role/FairValueOfFinancialInstrumentsTables",
     "shortName": "Fair Value of Financial Instruments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2022-03-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000002 - Statement - Condensed Consolidated Balance Sheets",
     "role": "http://gtbiopharma.com/role/BalanceSheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2022-03-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000020 - Disclosure - Accounts Payable (Tables)",
     "role": "http://gtbiopharma.com/role/AccountsPayableTables",
     "shortName": "Accounts Payable (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:DerivativesAndFairValueTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000021 - Disclosure - Derivative Liability (Tables)",
     "role": "http://gtbiopharma.com/role/DerivativeLiabilityTables",
     "shortName": "Derivative Liability (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:DerivativesAndFairValueTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000022 - Disclosure - Stockholders\u2019 Equity (Tables)",
     "role": "http://gtbiopharma.com/role/StockholdersEquityTables",
     "shortName": "Stockholders\u2019 Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "GTBP:ScheduleOfOtherInformationRelatedLeasesUnderNOnCancellableTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000023 - Disclosure - Commitments and Contingencies (Tables)",
     "role": "http://gtbiopharma.com/role/CommitmentsAndContingenciesTables",
     "shortName": "Commitments and Contingencies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "GTBP:ScheduleOfOtherInformationRelatedLeasesUnderNOnCancellableTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000024 - Disclosure - Schedule of Anti-dilutive Securities (Details)",
     "role": "http://gtbiopharma.com/role/ScheduleOfAnti-dilutiveSecuritiesDetails",
     "shortName": "Schedule of Anti-dilutive Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000025 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)",
     "role": "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative",
     "shortName": "Summary of Significant Accounting Policies (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "GTBP:LiquidityPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2022-03-31",
      "decimals": "-5",
      "lang": null,
      "name": "GTBP:CashOnHandAndShortTermInvestment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2022-03-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000026 - Disclosure - Schedule of Estimated Fair Value of Financial Instrument (Details)",
     "role": "http://gtbiopharma.com/role/ScheduleOfEstimatedFairValueOfFinancialInstrumentDetails",
     "shortName": "Schedule of Estimated Fair Value of Financial Instrument (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2022-03-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2022-03-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FairValueNetAssetLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000027 - Disclosure - Schedule of Fair Value Hierarchy Financial Assets (Details)",
     "role": "http://gtbiopharma.com/role/ScheduleOfFairValueHierarchyFinancialAssetsDetails",
     "shortName": "Schedule of Fair Value Hierarchy Financial Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2022-03-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FairValueNetAssetLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2021-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DerivativeLiabilitiesCurrent",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000028 - Disclosure - Schedule of Derivative Liability Transactions (Details)",
     "role": "http://gtbiopharma.com/role/ScheduleOfDerivativeLiabilityTransactionsDetails",
     "shortName": "Schedule of Derivative Liability Transactions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:IncreaseDecreaseInDerivativeLiabilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2022-03-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccountsPayableRelatedPartiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000029 - Disclosure - Schedule of Accounts Payable (Details)",
     "role": "http://gtbiopharma.com/role/ScheduleOfAccountsPayableDetails",
     "shortName": "Schedule of Accounts Payable (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2022-03-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccountsPayableRelatedPartiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2022-03-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "USDPShares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)",
     "role": "http://gtbiopharma.com/role/BalanceSheetsParenthetical",
     "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2022-03-31",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2022-03-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccountsPayableCurrent",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000030 - Disclosure - Accounts Payable (Details Narrative)",
     "role": "http://gtbiopharma.com/role/AccountsPayableDetailsNarrative",
     "shortName": "Accounts Payable (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2022-03-31_custom_VendorMember",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:AccountsPayableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-02-152021-02-16",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtConversionConvertedInstrumentSharesIssued1",
      "reportCount": 1,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000031 - Disclosure - Convertible Notes Payable (Details Narrative)",
     "role": "http://gtbiopharma.com/role/ConvertibleNotesPayableDetailsNarrative",
     "shortName": "Convertible Notes Payable (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:ConvertibleNotesPayable",
       "span",
       "span",
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2020-12-31",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:ConvertibleNotesPayable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "us-gaap:DerivativesAndFairValueTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2022-03-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:SharePrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USDPShares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000032 - Disclosure - Schedule of Derivative Liabilities Assumptions (Details)",
     "role": "http://gtbiopharma.com/role/ScheduleOfDerivativeLiabilitiesAssumptionsDetails",
     "shortName": "Schedule of Derivative Liabilities Assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "us-gaap:DerivativesAndFairValueTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2022-03-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:SharePrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USDPShares",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:DerivativesAndFairValueTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DerivativeGainOnDerivative",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000033 - Disclosure - Derivative Liability (Details Narrative)",
     "role": "http://gtbiopharma.com/role/DerivativeLiabilityDetailsNarrative",
     "shortName": "Derivative Liability (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:DerivativesAndFairValueTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DerivativeGainOnDerivative",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2021-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000034 - Disclosure - Schedule of Warrant Activity (Details)",
     "role": "http://gtbiopharma.com/role/ScheduleOfWarrantActivityDetails",
     "shortName": "Schedule of Warrant Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2021-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2021-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000035 - Disclosure - Schedule of Options Activity (Details)",
     "role": "http://gtbiopharma.com/role/ScheduleOfOptionsActivityDetails",
     "shortName": "Schedule of Options Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2021-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2022-03-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000036 - Disclosure - Stockholders\u2019 Equity (Details Narrative)",
     "role": "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative",
     "shortName": "Stockholders\u2019 Equity (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2021-02-16",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:SharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "GTBP:ScheduleOfOtherInformationRelatedLeasesUnderNOnCancellableTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000037 - Disclosure - Schedule of Other Information Related Leases Under Non-Cancellable (Details)",
     "role": "http://gtbiopharma.com/role/ScheduleOfOtherInformationRelatedLeasesUnderNon-cancellableDetails",
     "shortName": "Schedule of Other Information Related Leases Under Non-Cancellable (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "GTBP:ScheduleOfOtherInformationRelatedLeasesUnderNOnCancellableTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2022-03-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000038 - Disclosure - Schedule of Future Minimum Lease Payments (Details)",
     "role": "http://gtbiopharma.com/role/ScheduleOfFutureMinimumLeasePaymentsDetails",
     "shortName": "Schedule of Future Minimum Lease Payments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2022-03-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2022-02-062022-02-07",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LitigationSettlementExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000039 - Disclosure - Commitments and Contingencies (Details Narrative)",
     "role": "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative",
     "shortName": "Commitments and Contingencies (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2022-02-062022-02-07",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LitigationSettlementExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)",
     "role": "http://gtbiopharma.com/role/StatementsOfOperations",
     "shortName": "Condensed Consolidated Statements of Operations (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2022-04-282022-04-29_us-gaap_SubsequentEventMember_srt_ChiefExecutiveOfficerMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockRepurchasedDuringPeriodShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000040 - Disclosure - Subsequent Events (Details Narrative)",
     "role": "http://gtbiopharma.com/role/SubsequentEventsDetailsNarrative",
     "shortName": "Subsequent Events (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2022-04-282022-04-29_us-gaap_SubsequentEventMember_srt_ChiefExecutiveOfficerMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockRepurchasedDuringPeriodShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2022-01-012022-03-31_custom_OfficersAndDirectorsMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000005 - Statement - Condensed Consolidated Statements of Operations (Unaudited) (Parenthetical)",
     "role": "http://gtbiopharma.com/role/StatementsOfOperationsParenthetical",
     "shortName": "Condensed Consolidated Statements of Operations (Unaudited) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2022-01-012022-03-31_custom_OfficersAndDirectorsMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2020-12-31_us-gaap_PreferredStockMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000006 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited)",
     "role": "http://gtbiopharma.com/role/StatementsOfStockholdersEquityDeficit",
     "shortName": "Condensed Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2020-12-31_us-gaap_PreferredStockMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000007 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "role": "http://gtbiopharma.com/role/StatementsOfCashFlows",
     "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": "-3",
      "lang": null,
      "name": "GTBP:StockBasedCompensationForServices",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000008 - Disclosure - Organization and Operations",
     "role": "http://gtbiopharma.com/role/OrganizationAndOperations",
     "shortName": "Organization and Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000009 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 50,
   "tag": {
    "GTBP_AccruedInterestAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued interest amount.",
        "label": "Accrued interest amount"
       }
      }
     },
     "localname": "AccruedInterestAmount",
     "nsuri": "http://gtbiopharma.com/20220331",
     "presentation": [
      "http://gtbiopharma.com/role/ConvertibleNotesPayableDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "GTBP_AdoptionofAsuTwentyTwentyZeroSixMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adoption of ASU 2020-06 [Member]",
        "label": "Adoption of ASU 2020-06 [Member]"
       }
      }
     },
     "localname": "AdoptionofAsuTwentyTwentyZeroSixMember",
     "nsuri": "http://gtbiopharma.com/20220331",
     "presentation": [
      "http://gtbiopharma.com/role/ConvertibleNotesPayableDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "GTBP_AimmuneTherapeuticsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aimmune Therapeutics Inc [Member]",
        "label": "Aimmune Therapeutics Inc [Member]"
       }
      }
     },
     "localname": "AimmuneTherapeuticsIncMember",
     "nsuri": "http://gtbiopharma.com/20220331",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "GTBP_AnnualMaintananceFee": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual maintanance fee.",
        "label": "Annual maintanance fee"
       }
      }
     },
     "localname": "AnnualMaintananceFee",
     "nsuri": "http://gtbiopharma.com/20220331",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "GTBP_AnnualRoyaltyPayments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual royalty payments.",
        "label": "Annual royalty payments"
       }
      }
     },
     "localname": "AnnualRoyaltyPayments",
     "nsuri": "http://gtbiopharma.com/20220331",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "GTBP_AuguestOneTwentyEighteenAndJanuaryTwentySixTwentyTwentyOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "August 1, 2018 and January 26, 2021 [Member]",
        "label": "August 1, 2018 and January 26, 2021 [Member]"
       }
      }
     },
     "localname": "AuguestOneTwentyEighteenAndJanuaryTwentySixTwentyTwentyOneMember",
     "nsuri": "http://gtbiopharma.com/20220331",
     "presentation": [
      "http://gtbiopharma.com/role/ConvertibleNotesPayableDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "GTBP_CashOnHandAndShortTermInvestment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash on hand and short term investment",
        "label": "[custom:CashOnHandAndShortTermInvestment-0]"
       }
      }
     },
     "localname": "CashOnHandAndShortTermInvestment",
     "nsuri": "http://gtbiopharma.com/20220331",
     "presentation": [
      "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "GTBP_CashPaidDuringYearFor": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash paid during the year for [Abstract]",
        "label": "Cash paid during the year for:"
       }
      }
     },
     "localname": "CashPaidDuringYearFor",
     "nsuri": "http://gtbiopharma.com/20220331",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "GTBP_CommonSharesIssuableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Shares Issuable [Member]",
        "label": "Common Shares Issuable [Member]"
       }
      }
     },
     "localname": "CommonSharesIssuableMember",
     "nsuri": "http://gtbiopharma.com/20220331",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "GTBP_CommonStockConsultantToFairValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock Consultant To Fair Value.",
        "label": "Common stock consultant to fair value"
       }
      }
     },
     "localname": "CommonStockConsultantToFairValue",
     "nsuri": "http://gtbiopharma.com/20220331",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "GTBP_CommonStockIssuable": {
     "auth_ref": [],
     "calculation": {
      "http://gtbiopharma.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock Issuable.",
        "label": "Common stock issuable 0 shares and 327,298 shares at March 31, 2022 and December 31, 2021, respectively"
       }
      }
     },
     "localname": "CommonStockIssuable",
     "nsuri": "http://gtbiopharma.com/20220331",
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "GTBP_CommonStockIssuableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock Issuable [Member]",
        "label": "Common Stock Issuable [Member]"
       }
      }
     },
     "localname": "CommonStockIssuableMember",
     "nsuri": "http://gtbiopharma.com/20220331",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "GTBP_CommonStockIssuableShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock Issuable, Shares.",
        "label": "Common stock issuable, shares"
       }
      }
     },
     "localname": "CommonStockIssuableShares",
     "nsuri": "http://gtbiopharma.com/20220331",
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "GTBP_CommonStockSharesGrantedForConsultants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock shares granted for consultants.",
        "label": "Common stock shares granted for consultants"
       }
      }
     },
     "localname": "CommonStockSharesGrantedForConsultants",
     "nsuri": "http://gtbiopharma.com/20220331",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "GTBP_ConsultingAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consulting Agreements [Member]",
        "label": "Consulting Agreements [Member]"
       }
      }
     },
     "localname": "ConsultingAgreementsMember",
     "nsuri": "http://gtbiopharma.com/20220331",
     "presentation": [
      "http://gtbiopharma.com/role/ConvertibleNotesPayableDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "GTBP_ConsultingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consultings [Member]",
        "label": "Consultings [Member]"
       }
      }
     },
     "localname": "ConsultingMember",
     "nsuri": "http://gtbiopharma.com/20220331",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "GTBP_ConvertibleNotesPayableIssuedForConsultingServices": {
     "auth_ref": [],
     "calculation": {
      "http://gtbiopharma.com/role/StatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible notes payable issued for consulting services.",
        "label": "Convertible notes payable issued for consulting services"
       }
      }
     },
     "localname": "ConvertibleNotesPayableIssuedForConsultingServices",
     "nsuri": "http://gtbiopharma.com/20220331",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "GTBP_ConvertibleNotesPayableIssuedInExchangeForConsultingServices": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible notes payable issued in exchange for consulting services.",
        "label": "Notes payable in exchange of consulting services"
       }
      }
     },
     "localname": "ConvertibleNotesPayableIssuedInExchangeForConsultingServices",
     "nsuri": "http://gtbiopharma.com/20220331",
     "presentation": [
      "http://gtbiopharma.com/role/ConvertibleNotesPayableDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "GTBP_CorporateNotesAndCommercialPaperMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporate Notes and Commercial Paper [Member]",
        "label": "Corporate Notes and Commercial Paper [Member]"
       }
      }
     },
     "localname": "CorporateNotesAndCommercialPaperMember",
     "nsuri": "http://gtbiopharma.com/20220331",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfFairValueHierarchyFinancialAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "GTBP_CummulativeGrossSales": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cummulative gross sales.",
        "label": "Cummulative gross sales"
       }
      }
     },
     "localname": "CummulativeGrossSales",
     "nsuri": "http://gtbiopharma.com/20220331",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "GTBP_CytovanceBiologicsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cytovance Biologics, Inc. [Member]",
        "label": "Cytovance Biologics, Inc. [Member]"
       }
      }
     },
     "localname": "CytovanceBiologicsIncMember",
     "nsuri": "http://gtbiopharma.com/20220331",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "GTBP_DerivativeLiabilityFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative liability fair value assumptions expected term 1.",
        "label": "Expected life (in years)"
       }
      }
     },
     "localname": "DerivativeLiabilityFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://gtbiopharma.com/20220331",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfDerivativeLiabilitiesAssumptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "GTBP_DisclosureDerivativeLiabilityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Liability"
       }
      }
     },
     "localname": "DisclosureDerivativeLiabilityAbstract",
     "nsuri": "http://gtbiopharma.com/20220331",
     "xbrltype": "stringItemType"
    },
    "GTBP_DuringTwentyTwentyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "During 2020 [Member]",
        "label": "During 2020 [Member]"
       }
      }
     },
     "localname": "DuringTwentyTwentyMember",
     "nsuri": "http://gtbiopharma.com/20220331",
     "presentation": [
      "http://gtbiopharma.com/role/ConvertibleNotesPayableDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "GTBP_EmployeesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employees [Member]",
        "label": "Employees [Member]"
       }
      }
     },
     "localname": "EmployeesMember",
     "nsuri": "http://gtbiopharma.com/20220331",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "GTBP_EmploymentAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employment Agreements [Member]",
        "label": "Employment Agreements [Member]"
       }
      }
     },
     "localname": "EmploymentAgreementsMember",
     "nsuri": "http://gtbiopharma.com/20220331",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "GTBP_ExtinguishmentOfDebtDiscountUponAdoptionOfAsu202006": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extinguishment of debt discount upon adoption of ASU 2020-06.",
        "label": "Extinguishment of debt discount upon adoption of ASU 2020-06"
       }
      }
     },
     "localname": "ExtinguishmentOfDebtDiscountUponAdoptionOfAsu202006",
     "nsuri": "http://gtbiopharma.com/20220331",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "GTBP_ExtinguishmentOfUnamortizedDebtDiscountAndAdjustmentToAccumulatedDeficitUponAdoption": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extinguishment of unamortized debt discount and adjustment to accumulated deficit upon adoption of ASU 2020-06.",
        "label": "Extinguishment of unamortized debt discount and adjustment to accumulated deficit upon adoption of ASU 2020-06"
       }
      }
     },
     "localname": "ExtinguishmentOfUnamortizedDebtDiscountAndAdjustmentToAccumulatedDeficitUponAdoption",
     "nsuri": "http://gtbiopharma.com/20220331",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "GTBP_ExtinguishmentOfWarrants": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Extinguishment"
       }
      }
     },
     "localname": "ExtinguishmentOfWarrants",
     "nsuri": "http://gtbiopharma.com/20220331",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfDerivativeLiabilityTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "GTBP_FairValueOfStockOptionsGrantedForConsultants": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair Value Of Stock Options Granted For Consultants.",
        "label": "Fair value of stock options granted f0r consultants"
       }
      }
     },
     "localname": "FairValueOfStockOptionsGrantedForConsultants",
     "nsuri": "http://gtbiopharma.com/20220331",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "GTBP_FiscalTwentyNinteenandTwentyTwentyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal 2019 and 2020 [Member]",
        "label": "Fiscal 2019 and 2020 [Member]"
       }
      }
     },
     "localname": "FiscalTwentyNinteenandTwentyTwentyMember",
     "nsuri": "http://gtbiopharma.com/20220331",
     "presentation": [
      "http://gtbiopharma.com/role/ConvertibleNotesPayableDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "GTBP_ForbearanceAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Forbearance Agreements [Member]",
        "label": "Forbearance Agreements [Member]"
       }
      }
     },
     "localname": "ForbearanceAgreementsMember",
     "nsuri": "http://gtbiopharma.com/20220331",
     "presentation": [
      "http://gtbiopharma.com/role/ConvertibleNotesPayableDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "GTBP_GrossSales": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross sales.",
        "label": "Gross sales"
       }
      }
     },
     "localname": "GrossSales",
     "nsuri": "http://gtbiopharma.com/20220331",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "GTBP_IncreaseDecreaseInDeposit": {
     "auth_ref": [],
     "calculation": {
      "http://gtbiopharma.com/role/StatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase decrease in deposit",
        "label": "Increase in deposits"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeposit",
     "nsuri": "http://gtbiopharma.com/20220331",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "GTBP_InterestExpenseDueAmortizationOfDebtDiscount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest expense due amortization of debt discount.",
        "label": "Interest expense due amortization of debt discount"
       }
      }
     },
     "localname": "InterestExpenseDueAmortizationOfDebtDiscount",
     "nsuri": "http://gtbiopharma.com/20220331",
     "presentation": [
      "http://gtbiopharma.com/role/ConvertibleNotesPayableDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "GTBP_JanuaryOneTwentyTwentyOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "January 1, 2021 [Member]",
        "label": "January 1, 2021 [Member]"
       }
      }
     },
     "localname": "JanuaryOneTwentyTwentyOneMember",
     "nsuri": "http://gtbiopharma.com/20220331",
     "presentation": [
      "http://gtbiopharma.com/role/ConvertibleNotesPayableDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "GTBP_LicenseMaintenanceFeeReceivable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License maintenance fee, receivable.",
        "label": "License maintenance fee, receivable"
       }
      }
     },
     "localname": "LicenseMaintenanceFeeReceivable",
     "nsuri": "http://gtbiopharma.com/20220331",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "GTBP_LiquidityPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liquidity Policy [Text Block]",
        "label": "Liquidity"
       }
      }
     },
     "localname": "LiquidityPolicyTextBlock",
     "nsuri": "http://gtbiopharma.com/20220331",
     "presentation": [
      "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "GTBP_MaintananceFee": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maintanance fee.",
        "label": "Maintanance fee"
       }
      }
     },
     "localname": "MaintananceFee",
     "nsuri": "http://gtbiopharma.com/20220331",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "GTBP_MasterServicesAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Master Services Agreement [Member]",
        "label": "Master Services Agreement [Member]"
       }
      }
     },
     "localname": "MasterServicesAgreementMember",
     "nsuri": "http://gtbiopharma.com/20220331",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "GTBP_NetSalesPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net sales percentage.",
        "label": "Net sales percentage"
       }
      }
     },
     "localname": "NetSalesPercentage",
     "nsuri": "http://gtbiopharma.com/20220331",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "pureItemType"
    },
    "GTBP_NotesPayableIssuedForForbearanceAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Notes Payable Issued For Forbearance Agreement [Member]",
        "label": "Notes Payable Issued For Forbearance Agreement [Member]"
       }
      }
     },
     "localname": "NotesPayableIssuedForForbearanceAgreementMember",
     "nsuri": "http://gtbiopharma.com/20220331",
     "presentation": [
      "http://gtbiopharma.com/role/ConvertibleNotesPayableDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "GTBP_NotesPayableIssuedForSettlementAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Notes Payable Issued For Settlement Agreements [Member]",
        "label": "Notes Payable Issued For Settlement Agreements [Member]"
       }
      }
     },
     "localname": "NotesPayableIssuedForSettlementAgreementsMember",
     "nsuri": "http://gtbiopharma.com/20220331",
     "presentation": [
      "http://gtbiopharma.com/role/ConvertibleNotesPayableDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "GTBP_NumberofValueUnvestedOptions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of value unvested options.",
        "label": "Number of shares unvested, value"
       }
      }
     },
     "localname": "NumberofValueUnvestedOptions",
     "nsuri": "http://gtbiopharma.com/20220331",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "GTBP_NumberofsharesUnvestedOptions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares unvested options.",
        "label": "Number of shares unvested"
       }
      }
     },
     "localname": "NumberofsharesUnvestedOptions",
     "nsuri": "http://gtbiopharma.com/20220331",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "GTBP_OfficeSpaceAndEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Office Space And Equipment [Member]",
        "label": "Office Space And Equipment [Member]"
       }
      }
     },
     "localname": "OfficeSpaceAndEquipmentMember",
     "nsuri": "http://gtbiopharma.com/20220331",
     "presentation": [
      "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "GTBP_OfficersAndDirectorsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Officers and Directors [Member]",
        "label": "Officers and Directors [Member]"
       }
      }
     },
     "localname": "OfficersAndDirectorsMember",
     "nsuri": "http://gtbiopharma.com/20220331",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfOperationsParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "GTBP_OfficersEmployeesAndBoardOfDirectorsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Officers Employees And Board Of Directors [Member]",
        "label": "Officers Employees And Board Of Directors [Member]"
       }
      }
     },
     "localname": "OfficersEmployeesAndBoardOfDirectorsMember",
     "nsuri": "http://gtbiopharma.com/20220331",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "GTBP_OptionsToPurchaseCommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Options to Purchase Common Stock [Member]",
        "label": "Options to Purchase Common Stock [Member]"
       }
      }
     },
     "localname": "OptionsToPurchaseCommonStockMember",
     "nsuri": "http://gtbiopharma.com/20220331",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfAnti-dilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "GTBP_PerformanceMilestonePayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Performance milestone payments.",
        "label": "Performance milestone payments"
       }
      }
     },
     "localname": "PerformanceMilestonePayments",
     "nsuri": "http://gtbiopharma.com/20220331",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "GTBP_ProceedsFromUpfrontAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Received upfront payment.",
        "label": "Received upfront payment"
       }
      }
     },
     "localname": "ProceedsFromUpfrontAmount",
     "nsuri": "http://gtbiopharma.com/20220331",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "GTBP_ProjectFee": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Project fee.",
        "label": "Project fees"
       }
      }
     },
     "localname": "ProjectFee",
     "nsuri": "http://gtbiopharma.com/20220331",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "GTBP_RecordedExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Recorded expenses.",
        "label": "Recorded expenses"
       }
      }
     },
     "localname": "RecordedExpenses",
     "nsuri": "http://gtbiopharma.com/20220331",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "GTBP_ResearchAndDevelopmentArrangementContractToPerformExpectedCostsIncurred": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Compensation cost expected to be incurred in future.",
        "label": "Compensation cost expected to be incurred in future"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformExpectedCostsIncurred",
     "nsuri": "http://gtbiopharma.com/20220331",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "GTBP_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurred": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and development arrangement contract to perform for others costs incurred.",
        "label": "Commitment amount for services, total"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurred",
     "nsuri": "http://gtbiopharma.com/20220331",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "GTBP_RightofuseAssetsAndLeaseLiabilitiesRecognizedPursuantToLeaseAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rightof use assets and lease liabilities recognized pursuant to lease agreement.",
        "label": "Right-of-use assets and lease liabilities recognized pursuant to lease agreement"
       }
      }
     },
     "localname": "RightofuseAssetsAndLeaseLiabilitiesRecognizedPursuantToLeaseAgreement",
     "nsuri": "http://gtbiopharma.com/20220331",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "GTBP_RoyaltyFeePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty fee percentage.",
        "label": "[custom:RoyaltyFeePercentage]"
       }
      }
     },
     "localname": "RoyaltyFeePercentage",
     "nsuri": "http://gtbiopharma.com/20220331",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "pureItemType"
    },
    "GTBP_SalesMilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales milestone payments.",
        "label": "Sales milestone payments"
       }
      }
     },
     "localname": "SalesMilestonePayments",
     "nsuri": "http://gtbiopharma.com/20220331",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "GTBP_SalesRevenue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales revenue.",
        "label": "Sales revenue"
       }
      }
     },
     "localname": "SalesRevenue",
     "nsuri": "http://gtbiopharma.com/20220331",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "GTBP_ScheduleOfOtherInformationRelatedLeasesUnderNOnCancellableTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Other Information Related Leases Under Non Cancellable [Table Text Block]",
        "label": "Schedule of Other Information Related Leases Under Non-Cancellable"
       }
      }
     },
     "localname": "ScheduleOfOtherInformationRelatedLeasesUnderNOnCancellableTableTextBlock",
     "nsuri": "http://gtbiopharma.com/20220331",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "GTBP_SeriesCPreferredStocksMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series C Preferred Stocks [Member]",
        "label": "Series C Preferred Stocks [Member]"
       }
      }
     },
     "localname": "SeriesCPreferredStocksMember",
     "nsuri": "http://gtbiopharma.com/20220331",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "GTBP_SeriesKPreferredStocksMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series K Preferred Stocks [Member]",
        "label": "Series K Preferred Stocks [Member]"
       }
      }
     },
     "localname": "SeriesKPreferredStocksMember",
     "nsuri": "http://gtbiopharma.com/20220331",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Based Compensation Arrangements By Share Based Payment Award Non Options Equity Instruments Exercisable.",
        "label": "Warrants Exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable",
     "nsuri": "http://gtbiopharma.com/20220331",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeited": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Based Compensation Arrangements By Share Based Payment Award Non Options Equity Instruments Forfeited",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Non Options Equity Instruments Forfeited",
        "negatedLabel": "Number of Warrants, Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeited",
     "nsuri": "http://gtbiopharma.com/20220331",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Based Compensation Arrangement By ShareBased Payment Award Non Options Exercisable Weighted Average Exercise Price.",
        "label": "Exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://gtbiopharma.com/20220331",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangements by share based payment award non options outstanding weighted average exercise price.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Non Options Outstanding Weighted Average Exercise Price",
        "periodEndLabel": "Weighted Average Exercise Price, Ending Balance",
        "periodStartLabel": "Weighted Average Exercise Price, Beginning Balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://gtbiopharma.com/20220331",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionEquityInstrumentsExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Based Compensation Arrangement By Share Based Payment Award Option Equity Instruments Exercised.",
        "label": "Number of Options, Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionEquityInstrumentsExercised",
     "nsuri": "http://gtbiopharma.com/20220331",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfOptionsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToUnVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To unvest Outstanding Aggregate Intrinsic Value.",
        "label": "[custom:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToUnVestOutstandingAggregateIntrinsicValue-0]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToUnVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://gtbiopharma.com/20220331",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedTounVestOutstandingNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected to unvest Outstanding Number.",
        "label": "[custom:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedTounVestOutstandingNumber-0]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedTounVestOutstandingNumber",
     "nsuri": "http://gtbiopharma.com/20220331",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "GTBP_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Based Compensation Arrangements By Share Based Paymen tAward Non Options Exercises In Period Weighted Average Exercise Price.",
        "label": "Weighted Average Exercise Price, Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://gtbiopharma.com/20220331",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "GTBP_ShortTermInvestmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short-Term Investments [Member]",
        "label": "Short-Term Investments [Member]"
       }
      }
     },
     "localname": "ShortTermInvestmentMember",
     "nsuri": "http://gtbiopharma.com/20220331",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfEstimatedFairValueOfFinancialInstrumentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "GTBP_StockBasedCompensationForServices": {
     "auth_ref": [],
     "calculation": {
      "http://gtbiopharma.com/role/StatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock based compensation for services",
        "label": "Stock based compensation for services"
       }
      }
     },
     "localname": "StockBasedCompensationForServices",
     "nsuri": "http://gtbiopharma.com/20220331",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "GTBP_StockBasedCompensationToOfficersAndBoardOfDirectors": {
     "auth_ref": [],
     "calculation": {
      "http://gtbiopharma.com/role/StatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock based compensation to officers and board of directors.",
        "label": "Stock based compensation to officers, employees and board of directors"
       }
      }
     },
     "localname": "StockBasedCompensationToOfficersAndBoardOfDirectors",
     "nsuri": "http://gtbiopharma.com/20220331",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "GTBP_StockIssuedDuringPeriodShareIssuanceOfCommonStockForResearchAndDevelopmentAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of common stock for research and development agreement, shares.",
        "label": "Issuance of common stock for research and development agreement, Shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodShareIssuanceOfCommonStockForResearchAndDevelopmentAgreement",
     "nsuri": "http://gtbiopharma.com/20220331",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "GTBP_StockIssuedDuringPeriodSharesCancellation": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cancellation of common stock, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesCancellation",
     "nsuri": "http://gtbiopharma.com/20220331",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "GTBP_StockIssuedDuringPeriodSharesCommonSharesIssuedUponExerciseOfWarrants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common shares issued upon exercise of warrants, shares.",
        "label": "Common shares issued upon exercise of warrants, Shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesCommonSharesIssuedUponExerciseOfWarrants",
     "nsuri": "http://gtbiopharma.com/20220331",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "GTBP_StockIssuedDuringPeriodSharesCommonSharesIssuedUponMandatoryConversionOfNotesPayableAndAccruedInterest": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common shares issued upon mandatory conversion of notes payable and accrued interest, shares.",
        "label": "Common shares issued upon mandatory conversion of notes payable and accrued interest, Shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesCommonSharesIssuedUponMandatoryConversionOfNotesPayableAndAccruedInterest",
     "nsuri": "http://gtbiopharma.com/20220331",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "GTBP_StockIssuedDuringPeriodSharesEquityCompensationToOfficersAndBoardOfDirectors": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period shares equity compensation to officers and board of directors",
        "label": "Equity compensation to officers and board of directors, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEquityCompensationToOfficersAndBoardOfDirectors",
     "nsuri": "http://gtbiopharma.com/20220331",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "GTBP_StockIssuedDuringPeriodSharesIssuanceOfCommonStockInPublicOfferingNetOfCost": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of common stock in public offering, net of cost, shares.",
        "label": "Issuance of common stock in public offering, net of cost, Shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesIssuanceOfCommonStockInPublicOfferingNetOfCost",
     "nsuri": "http://gtbiopharma.com/20220331",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "GTBP_StockIssuedDuringPeriodValueCancellation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cancellation of common stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueCancellation",
     "nsuri": "http://gtbiopharma.com/20220331",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "GTBP_StockIssuedDuringPeriodValueCommonSharesIssuedUponExerciseOfWarrants": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common shares issued upon exercise of warrants.",
        "label": "Common shares issued upon exercise of warrants"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueCommonSharesIssuedUponExerciseOfWarrants",
     "nsuri": "http://gtbiopharma.com/20220331",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "GTBP_StockIssuedDuringPeriodValueCommonSharesIssuedUponMandatoryConversionOfNotesPayableAndAccruedInterest": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common shares issued upon mandatory conversion of notes payable and accrued interest.",
        "label": "Common shares issued upon mandatory conversion of notes payable and accrued interest"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueCommonSharesIssuedUponMandatoryConversionOfNotesPayableAndAccruedInterest",
     "nsuri": "http://gtbiopharma.com/20220331",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "GTBP_StockIssuedDuringPeriodValueEquityCompensationToOfficersAndBoardOfDirectors": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity compensation to officers and board of directors.",
        "label": "Equity compensation to officers and board of directors"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEquityCompensationToOfficersAndBoardOfDirectors",
     "nsuri": "http://gtbiopharma.com/20220331",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "GTBP_StockIssuedDuringPeriodValueIssuanceOfCommonStockForResearchAndDevelopmentAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of common stock for research and development agreement.",
        "label": "Issuance of common stock for research and development agreement"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueIssuanceOfCommonStockForResearchAndDevelopmentAgreement",
     "nsuri": "http://gtbiopharma.com/20220331",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "GTBP_StockIssuedDuringPeriodValueIssuanceOfCommonStockInPublicOfferingNetOfCost": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of common stock in public offering, net of cost.",
        "label": "Issuance of common stock in public offering, net of cost"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueIssuanceOfCommonStockInPublicOfferingNetOfCost",
     "nsuri": "http://gtbiopharma.com/20220331",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "GTBP_TwoThousandAndTwentyOnePatentLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2021 Patent License Agreement [Member]",
        "label": "2021 Patent License Agreement [Member]"
       }
      }
     },
     "localname": "TwoThousandAndTwentyOnePatentLicenseAgreementMember",
     "nsuri": "http://gtbiopharma.com/20220331",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "GTBP_TwoThousandSixteenPatentLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2016  Patent License Agreement [Member]",
        "label": "2016 Patent License Agreement [Member]"
       }
      }
     },
     "localname": "TwoThousandSixteenPatentLicenseAgreementMember",
     "nsuri": "http://gtbiopharma.com/20220331",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "GTBP_UnvestedRestrictedCommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unvested Restricted Common Stock [Member]"
       }
      }
     },
     "localname": "UnvestedRestrictedCommonStockMember",
     "nsuri": "http://gtbiopharma.com/20220331",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfAnti-dilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "GTBP_UpfrontLicenseFee": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront license fee.",
        "label": "Upfront license fee"
       }
      }
     },
     "localname": "UpfrontLicenseFee",
     "nsuri": "http://gtbiopharma.com/20220331",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "GTBP_VendorMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vendor [Member]",
        "label": "Vendor [Member]"
       }
      }
     },
     "localname": "VendorMember",
     "nsuri": "http://gtbiopharma.com/20220331",
     "presentation": [
      "http://gtbiopharma.com/role/AccountsPayableDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "GTBP_WarrantsToPurchaseCommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants to Purchase Common Stock [Member]",
        "label": "Warrants to Purchase Common Stock [Member]"
       }
      }
     },
     "localname": "WarrantsToPurchaseCommonStockMember",
     "nsuri": "http://gtbiopharma.com/20220331",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfAnti-dilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "GTBP_WorkingCapital": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Working capital",
        "label": "[custom:WorkingCapital-0]"
       }
      }
     },
     "localname": "WorkingCapital",
     "nsuri": "http://gtbiopharma.com/20220331",
     "presentation": [
      "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r436"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r436"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r433",
      "r435",
      "r436"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r437"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r442"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r439"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r436"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "xbrltype": "trueItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r429"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r430"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r431"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r432"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r441"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "srt_ChiefExecutiveOfficerMember": {
     "auth_ref": [
      "r138"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chief Executive Officer [Member]"
       }
      }
     },
     "localname": "ChiefExecutiveOfficerMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative",
      "http://gtbiopharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ChiefFinancialOfficerMember": {
     "auth_ref": [
      "r138"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chief Financial Officer [Member]"
       }
      }
     },
     "localname": "ChiefFinancialOfficerMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r33",
      "r35",
      "r73",
      "r74",
      "r179",
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_DirectorMember": {
     "auth_ref": [
      "r138"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Director [Member]"
       }
      }
     },
     "localname": "DirectorMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r156",
      "r158",
      "r159",
      "r160",
      "r178",
      "r212",
      "r247",
      "r248",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r395",
      "r396",
      "r419",
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r156",
      "r158",
      "r159",
      "r160",
      "r178",
      "r212",
      "r247",
      "r248",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r395",
      "r396",
      "r419",
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r150",
      "r156",
      "r158",
      "r159",
      "r160",
      "r178",
      "r212",
      "r233",
      "r247",
      "r248",
      "r279",
      "r280",
      "r281",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r395",
      "r396",
      "r419",
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r150",
      "r156",
      "r158",
      "r159",
      "r160",
      "r178",
      "r212",
      "r233",
      "r247",
      "r248",
      "r279",
      "r280",
      "r281",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r395",
      "r396",
      "r419",
      "r420"
     ],
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r34",
      "r35",
      "r73",
      "r74",
      "r179",
      "r213"
     ],
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r138",
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfOperationsParenthetical",
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative",
      "http://gtbiopharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfOperationsParenthetical",
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative",
      "http://gtbiopharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r24"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
        "label": "Accounts Payable"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/AccountsPayable"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r23",
      "r359"
     ],
     "calculation": {
      "http://gtbiopharma.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://gtbiopharma.com/role/ScheduleOfAccountsPayableDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts payable",
        "totalLabel": "Total accounts payable",
        "verboseLabel": "Accounts payable current"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/AccountsPayableDetailsNarrative",
      "http://gtbiopharma.com/role/BalanceSheets",
      "http://gtbiopharma.com/role/ScheduleOfAccountsPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableOtherCurrent": {
     "auth_ref": [
      "r23"
     ],
     "calculation": {
      "http://gtbiopharma.com/role/ScheduleOfAccountsPayableDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccountsPayableCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer.",
        "label": "Other accounts payable"
       }
      }
     },
     "localname": "AccountsPayableOtherCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfAccountsPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableRelatedPartiesCurrent": {
     "auth_ref": [
      "r23",
      "r72",
      "r354",
      "r356"
     ],
     "calculation": {
      "http://gtbiopharma.com/role/ScheduleOfAccountsPayableDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccountsPayableCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount for accounts payable to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts payable to a third-party manufacturer"
       }
      }
     },
     "localname": "AccountsPayableRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfAccountsPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r27"
     ],
     "calculation": {
      "http://gtbiopharma.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
     "auth_ref": [
      "r38",
      "r39",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).",
        "label": "Accumulated Other Comprehensive Income (Loss) [Table]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r15",
      "r359"
     ],
     "calculation": {
      "http://gtbiopharma.com/role/BalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional paid in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r78",
      "r79",
      "r80",
      "r285",
      "r286",
      "r287",
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net loss to net cash (used in) operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r283"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfOperationsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r99"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Total anti-dilutive securities"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfAnti-dilutiveSecuritiesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r99"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfAnti-dilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfAnti-dilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r99"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfAnti-dilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AreaOfLand": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area of land held.",
        "label": "Area of land"
       }
      }
     },
     "localname": "AreaOfLand",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "areaItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://gtbiopharma.com/role/ConvertibleNotesPayableDetailsNarrative",
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r8",
      "r71",
      "r118",
      "r127",
      "r133",
      "r143",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r295",
      "r299",
      "r327",
      "r357",
      "r359",
      "r375",
      "r387"
     ],
     "calculation": {
      "http://gtbiopharma.com/role/BalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "TOTAL ASSETS"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r4",
      "r22",
      "r71",
      "r143",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r295",
      "r299",
      "r327",
      "r357",
      "r359"
     ],
     "calculation": {
      "http://gtbiopharma.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current assets"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r140",
      "r145"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfEstimatedFairValueOfFinancialInstrumentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardDateAxis": {
     "auth_ref": [
      "r251",
      "r252",
      "r253",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r273",
      "r274",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by date or year award under share-based payment arrangement is granted.",
        "label": "Award Date [Axis]"
       }
      }
     },
     "localname": "AwardDateAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ConvertibleNotesPayableDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardDateDomain": {
     "auth_ref": [
      "r251",
      "r252",
      "r253",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r273",
      "r274",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date or year award under share-based payment arrangement is granted."
       }
      }
     },
     "localname": "AwardDateDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ConvertibleNotesPayableDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r77"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.",
        "label": "Basis of Presentation and Principles of Consolidation"
       }
      }
     },
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Member]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfEstimatedFairValueOfFinancialInstrumentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r60"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash Equivalents and Short-Term Investments"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "auth_ref": [
      "r22"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.",
        "label": "Total cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r53",
      "r59",
      "r65"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash at End of Period",
        "periodStartLabel": "Cash at Beginning of Period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r53",
      "r328"
     ],
     "calculation": {
      "http://gtbiopharma.com/role/StatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net Increase (Decrease) in Cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r6"
     ],
     "calculation": {
      "http://gtbiopharma.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFDICInsuredAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.",
        "label": "FDIC amount"
       }
      }
     },
     "localname": "CashFDICInsuredAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r12",
      "r13",
      "r14",
      "r68",
      "r71",
      "r92",
      "r93",
      "r94",
      "r96",
      "r98",
      "r104",
      "r105",
      "r106",
      "r143",
      "r164",
      "r168",
      "r169",
      "r170",
      "r173",
      "r174",
      "r209",
      "r210",
      "r215",
      "r219",
      "r225",
      "r327",
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheets",
      "http://gtbiopharma.com/role/BalanceSheetsParenthetical",
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r151",
      "r152",
      "r153",
      "r161",
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r78",
      "r79",
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common stock, par value"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheetsParenthetical",
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheetsParenthetical",
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common stock, shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r14",
      "r225"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common stock, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r14",
      "r359"
     ],
     "calculation": {
      "http://gtbiopharma.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common stock, par value $0.001, 750,000,000 shares authorized, 32,345,717 shares and 32,061,989 shares issued and outstanding as of March 31, 2022 and December 31, 2021, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationRelatedCostsPolicyTextBlock": {
     "auth_ref": [
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.",
        "label": "Stock-Based Compensation"
       }
      }
     },
     "localname": "CompensationRelatedCostsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r109",
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConversionOfStockSharesConverted1": {
     "auth_ref": [
      "r62",
      "r63",
      "r64"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Conversion of common stock"
       }
      }
     },
     "localname": "ConversionOfStockSharesConverted1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ConvertibleNotesPayableDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ConvertibleNotesPayable": {
     "auth_ref": [
      "r11",
      "r377",
      "r388",
      "r402"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.",
        "label": "Convertible Notes Payable [Default Label]",
        "verboseLabel": "Convertible notes payable"
       }
      }
     },
     "localname": "ConvertibleNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ConvertibleNotesPayableDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleNotesPayableCurrent": {
     "auth_ref": [
      "r27"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.",
        "label": "Convertible notes payable"
       }
      }
     },
     "localname": "ConvertibleNotesPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ConvertibleNotesPayableDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtConversionConvertedInstrumentAmount1": {
     "auth_ref": [
      "r62",
      "r64"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Debt converted amount",
        "verboseLabel": "Debt Conversion, Converted Instrument, Amount"
       }
      }
     },
     "localname": "DebtConversionConvertedInstrumentAmount1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ConvertibleNotesPayableDetailsNarrative",
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtConversionConvertedInstrumentRate": {
     "auth_ref": [
      "r62",
      "r64"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Dividend or interest rate associated with the financial instrument issued in exchange for the original debt being converted in a noncash or part noncash transaction. Noncash are transactions that affect recognized assets or liabilities but that do not result in cash receipts or cash payments. Part noncash refers to that portion of the transaction not resulting in cash receipts or cash payments.",
        "label": "Debt conversion rate"
       }
      }
     },
     "localname": "DebtConversionConvertedInstrumentRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ConvertibleNotesPayableDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": {
     "auth_ref": [
      "r62",
      "r64"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period.",
        "label": "Converted conversion of common stock",
        "verboseLabel": "Debt Conversion, Converted Instrument, Shares Issued"
       }
      }
     },
     "localname": "DebtConversionConvertedInstrumentSharesIssued1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ConvertibleNotesPayableDetailsNarrative",
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r67",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r192",
      "r199",
      "r200",
      "r201",
      "r207"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Convertible Notes Payable"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ConvertibleNotesPayable"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r9",
      "r10",
      "r11",
      "r70",
      "r76",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r182",
      "r188",
      "r189",
      "r190",
      "r191",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r203",
      "r204",
      "r205",
      "r206",
      "r338",
      "r376",
      "r377",
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ConvertibleNotesPayableDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature": {
     "auth_ref": [
      "r227"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of a favorable spread to a debt holder between the amount of debt being converted and the value of the securities received upon conversion. This is an embedded conversion feature of convertible debt issued that is in-the-money at the commitment date.",
        "label": "Beneficial conversion feature"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleBeneficialConversionFeature",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ConvertibleNotesPayableDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentConvertibleConversionPrice1": {
     "auth_ref": [
      "r177",
      "r202"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The price per share of the conversion feature embedded in the debt instrument.",
        "label": "Conversion price per share"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionPrice1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ConvertibleNotesPayableDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r175",
      "r203",
      "r204",
      "r337",
      "r338",
      "r339"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt instrument, face amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ConvertibleNotesPayableDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r29",
      "r70",
      "r76",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r182",
      "r188",
      "r189",
      "r190",
      "r191",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r203",
      "r204",
      "r205",
      "r206",
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ConvertibleNotesPayableDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscount": {
     "auth_ref": [
      "r188",
      "r336",
      "r339"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt discount.",
        "label": "Unamortized debt discount"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ConvertibleNotesPayableDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleRealizedGain": {
     "auth_ref": [
      "r141"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Unrealized gains"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleRealizedGain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfEstimatedFairValueOfFinancialInstrumentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss": {
     "auth_ref": [
      "r141"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Fair value"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleRealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfEstimatedFairValueOfFinancialInstrumentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss": {
     "auth_ref": [
      "r141"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Unrealized losses"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleRealizedLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfEstimatedFairValueOfFinancialInstrumentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "auth_ref": [
      "r142"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Schedule of Estimated Fair Value of Financial Instrument"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/FairValueOfFinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]"
       }
      }
     },
     "localname": "DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfOperationsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Defined Benefit Plan Disclosure [Line Items]"
       }
      }
     },
     "localname": "DefinedBenefitPlanDisclosureLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/AccountsPayableDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DepositsAssetsNoncurrent": {
     "auth_ref": [
      "r7"
     ],
     "calculation": {
      "http://gtbiopharma.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer.",
        "label": "Deposits"
       }
      }
     },
     "localname": "DepositsAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeGainLossOnDerivativeNet": {
     "auth_ref": [
      "r308"
     ],
     "calculation": {
      "http://gtbiopharma.com/role/StatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://gtbiopharma.com/role/StatementsOfOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.",
        "label": "Derivative, Gain (Loss) on Derivative, Net",
        "negatedLabel": "Change in fair value of derivative liability"
       }
      }
     },
     "localname": "DerivativeGainLossOnDerivativeNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows",
      "http://gtbiopharma.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeGainOnDerivative": {
     "auth_ref": [
      "r308"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in the fair value of derivatives recognized in the income statement.",
        "label": "Derivative, Gain on Derivative"
       }
      }
     },
     "localname": "DerivativeGainOnDerivative",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/DerivativeLiabilityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilitiesCurrent": {
     "auth_ref": [
      "r32"
     ],
     "calculation": {
      "http://gtbiopharma.com/role/BalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative liability",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "DerivativeLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheets",
      "http://gtbiopharma.com/role/ScheduleOfDerivativeLiabilityTransactionsDetails",
      "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilityMeasurementInput": {
     "auth_ref": [
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of input used to measure derivative liability.",
        "label": "Expected dividend yield"
       }
      }
     },
     "localname": "DerivativeLiabilityMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfDerivativeLiabilitiesAssumptionsDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_DerivativesAndFairValueTextBlock": {
     "auth_ref": [
      "r314",
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for derivatives and fair value of assets and liabilities.",
        "label": "Derivatives and Fair Value [Text Block]",
        "verboseLabel": "Derivative Liability"
       }
      }
     },
     "localname": "DerivativesAndFairValueTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/DerivativeLiability"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DerivativesPolicyTextBlock": {
     "auth_ref": [
      "r75",
      "r304",
      "r305",
      "r306",
      "r307",
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.",
        "label": "Derivative Financial Instruments"
       }
      }
     },
     "localname": "DerivativesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r43",
      "r83",
      "r84",
      "r85",
      "r86",
      "r87",
      "r91",
      "r92",
      "r96",
      "r97",
      "r98",
      "r101",
      "r102",
      "r312",
      "r313",
      "r382",
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Net loss per share - basic and diluted"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r99",
      "r100"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Net Earnings (Loss) Per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r38",
      "r39",
      "r40",
      "r78",
      "r79",
      "r80",
      "r82",
      "r88",
      "r90",
      "r103",
      "r144",
      "r225",
      "r228",
      "r285",
      "r286",
      "r287",
      "r291",
      "r292",
      "r311",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r351",
      "r397",
      "r398",
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquityDeficit",
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "auth_ref": [
      "r57",
      "r208"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.",
        "label": "Fair value of warrants"
       }
      }
     },
     "localname": "FairValueAdjustmentOfWarrants",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfDerivativeLiabilitiesAssumptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": {
     "auth_ref": [
      "r315",
      "r316",
      "r317",
      "r321",
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.",
        "label": "Schedule of Fair Value Hierarchy Financial Assets"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/FairValueOfFinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfDerivativeLiabilitiesAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": {
     "auth_ref": [
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfDerivativeLiabilitiesAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "auth_ref": [
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Schedule of Derivative Liabilities Assumptions"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/DerivativeLiabilityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r190",
      "r203",
      "r204",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r246",
      "r316",
      "r363",
      "r364",
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfFairValueHierarchyFinancialAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/FairValueOfFinancialInstruments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r190",
      "r234",
      "r235",
      "r240",
      "r246",
      "r316",
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfFairValueHierarchyFinancialAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r190",
      "r203",
      "r204",
      "r234",
      "r235",
      "r240",
      "r246",
      "r316",
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfFairValueHierarchyFinancialAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r190",
      "r203",
      "r204",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r246",
      "r316",
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfFairValueHierarchyFinancialAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]"
       }
      }
     },
     "localname": "FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfEstimatedFairValueOfFinancialInstrumentDetails",
      "http://gtbiopharma.com/role/ScheduleOfFairValueHierarchyFinancialAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareTable": {
     "auth_ref": [
      "r323"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investments in certain entities that calculate net asset value per share or equivalent measured at fair value on a recurring or nonrecurring basis.",
        "label": "Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Table]"
       }
      }
     },
     "localname": "FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfEstimatedFairValueOfFinancialInstrumentDetails",
      "http://gtbiopharma.com/role/ScheduleOfFairValueHierarchyFinancialAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r190",
      "r203",
      "r204",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r246",
      "r363",
      "r364",
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfFairValueHierarchyFinancialAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueNetAssetLiability": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of asset after deduction of liability.",
        "label": "Total financial assets"
       }
      }
     },
     "localname": "FairValueNetAssetLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfFairValueHierarchyFinancialAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r324",
      "r326"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "verboseLabel": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "auth_ref": [
      "r61"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.",
        "label": "Income taxes"
       }
      }
     },
     "localname": "IncomeTaxesPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDerivativeLiabilities": {
     "auth_ref": [
      "r56"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the period in the carrying value of derivative instruments reported as liabilities that are due to be disposed of within one year (or the normal operating cycle, if longer).",
        "label": "Change in fair value"
       }
      }
     },
     "localname": "IncreaseDecreaseInDerivativeLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfDerivativeLiabilityTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInterestPayableNet": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://gtbiopharma.com/role/StatementsOfCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in interest payable, which represents the amount owed to note holders, bond holders, and other parties for interest earned on loans or credit extended to the reporting entity.",
        "label": "Increase in accrued interest"
       }
      }
     },
     "localname": "IncreaseDecreaseInInterestPayableNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "auth_ref": [
      "r56",
      "r345"
     ],
     "calculation": {
      "http://gtbiopharma.com/role/StatementsOfCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation for operating lease.",
        "label": "(Decrease) in operating lease liability"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://gtbiopharma.com/role/StatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid.",
        "label": "Increase (decrease) in accounts payable and accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpense": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://gtbiopharma.com/role/StatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.",
        "label": "Increase (Decrease) in Prepaid Expense",
        "negatedLabel": "(Increase) decrease in prepaid expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseDebtExcludingAmortization": {
     "auth_ref": [
      "r48",
      "r197",
      "r205",
      "r206"
     ],
     "calculation": {
      "http://gtbiopharma.com/role/StatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs.",
        "label": "Interest expense"
       }
      }
     },
     "localname": "InterestExpenseDebtExcludingAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaid": {
     "auth_ref": [
      "r61"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, including, but not limited to, capitalized interest and payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount; classified as operating and investing activities.",
        "label": "Interest"
       }
      }
     },
     "localname": "InterestPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfEstimatedFairValueOfFinancialInstrumentDetails",
      "http://gtbiopharma.com/role/ScheduleOfFairValueHierarchyFinancialAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value."
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfEstimatedFairValueOfFinancialInstrumentDetails",
      "http://gtbiopharma.com/role/ScheduleOfFairValueHierarchyFinancialAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InvestmentsAndCash": {
     "auth_ref": [
      "r392"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of investments and unrestricted cash as of the balance sheet date.",
        "label": "Investments and Cash"
       }
      }
     },
     "localname": "InvestmentsAndCash",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims": {
     "auth_ref": [
      "r57"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.",
        "label": "Fair value upon issuance of warrants"
       }
      }
     },
     "localname": "IssuanceOfStockAndWarrantsForServicesOrClaims",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfDerivativeLiabilityTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Schedule of Future Minimum Lease Payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r349"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Lease liability"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r349"
     ],
     "calculation": {
      "http://gtbiopharma.com/role/ScheduleOfFutureMinimumLeasePaymentsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r349"
     ],
     "calculation": {
      "http://gtbiopharma.com/role/ScheduleOfFutureMinimumLeasePaymentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "After one year and within two years"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r349"
     ],
     "calculation": {
      "http://gtbiopharma.com/role/ScheduleOfFutureMinimumLeasePaymentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "After two years and within three years"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r349"
     ],
     "calculation": {
      "http://gtbiopharma.com/role/ScheduleOfFutureMinimumLeasePaymentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.",
        "label": "Within one year"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r349"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less \u2013 discount"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingSubleaseOptionToExtend": {
     "auth_ref": [
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of terms and conditions of option to extend operating sublease.",
        "label": "Commencement date"
       }
      }
     },
     "localname": "LesseeOperatingSubleaseOptionToExtend",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r26",
      "r71",
      "r128",
      "r143",
      "r164",
      "r165",
      "r166",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r296",
      "r299",
      "r300",
      "r327",
      "r357",
      "r358"
     ],
     "calculation": {
      "http://gtbiopharma.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r19",
      "r71",
      "r143",
      "r327",
      "r359",
      "r378",
      "r391"
     ],
     "calculation": {
      "http://gtbiopharma.com/role/BalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "TOTAL LIABILITIES AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r5",
      "r28",
      "r71",
      "r143",
      "r164",
      "r165",
      "r166",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r296",
      "r299",
      "r300",
      "r327",
      "r357",
      "r358",
      "r359"
     ],
     "calculation": {
      "http://gtbiopharma.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LitigationSettlementExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.",
        "label": "Litigation settlement expense"
       }
      }
     },
     "localname": "LitigationSettlementExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r162",
      "r163"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MarketableSecuritiesUnrealizedGainLoss": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://gtbiopharma.com/role/StatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://gtbiopharma.com/role/StatementsOfOperations": {
       "order": 4.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment in marketable security.",
        "label": "Marketable Securities, Unrealized Gain (Loss)",
        "negatedLabel": "Unrealized loss on marketable securities"
       }
      }
     },
     "localname": "MarketableSecuritiesUnrealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows",
      "http://gtbiopharma.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MeasurementInputExpectedDividendRateMember": {
     "auth_ref": [
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year.",
        "label": "Measurement Input, Expected Dividend Rate [Member]"
       }
      }
     },
     "localname": "MeasurementInputExpectedDividendRateMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfDerivativeLiabilitiesAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputExpectedTermMember": {
     "auth_ref": [
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date.",
        "label": "Measurement Input, Expected Term [Member]"
       }
      }
     },
     "localname": "MeasurementInputExpectedTermMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfDerivativeLiabilitiesAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "auth_ref": [
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns.",
        "label": "Measurement Input, Price Volatility [Member]"
       }
      }
     },
     "localname": "MeasurementInputPriceVolatilityMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfDerivativeLiabilitiesAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "auth_ref": [
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss.",
        "label": "Measurement Input, Risk Free Interest Rate [Member]"
       }
      }
     },
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfDerivativeLiabilitiesAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfDerivativeLiabilitiesAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability."
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfDerivativeLiabilitiesAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r234"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfFairValueHierarchyFinancialAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r53"
     ],
     "calculation": {
      "http://gtbiopharma.com/role/StatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net Cash Provided by Financing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM FINANCING ACTIVITIES"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r53"
     ],
     "calculation": {
      "http://gtbiopharma.com/role/StatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net Cash Provided by Investing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM INVESTING ACTIVITIES"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r53",
      "r55",
      "r58"
     ],
     "calculation": {
      "http://gtbiopharma.com/role/StatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "negatedLabel": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net Cash (Used in) Operating Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows",
      "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM OPERATING ACTIVITIES"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r1",
      "r36",
      "r37",
      "r40",
      "r42",
      "r58",
      "r71",
      "r81",
      "r83",
      "r84",
      "r85",
      "r86",
      "r89",
      "r90",
      "r95",
      "r118",
      "r126",
      "r129",
      "r132",
      "r134",
      "r143",
      "r164",
      "r165",
      "r166",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r313",
      "r327",
      "r381",
      "r393"
     ],
     "calculation": {
      "http://gtbiopharma.com/role/StatementsOfOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "negatedLabel": "Net Income (Loss) Attributable to Parent",
        "totalLabel": "Net Loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfOperations",
      "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING ACTIVITIES"
       }
      }
     },
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://gtbiopharma.com/role/StatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "negatedTotalLabel": "Total Other (Income) Expense"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other (Income) Expense"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NotesIssued1": {
     "auth_ref": [
      "r62",
      "r63",
      "r64"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value of notes issued in noncash investing and financing activities.",
        "label": "Convertible notes payable issued for accrued expenses"
       }
      }
     },
     "localname": "NotesIssued1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesPayable": {
     "auth_ref": [
      "r11",
      "r377",
      "r389"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.",
        "label": "Notes payable"
       }
      }
     },
     "localname": "NotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ConvertibleNotesPayableDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r118",
      "r126",
      "r129",
      "r132",
      "r134"
     ],
     "calculation": {
      "http://gtbiopharma.com/role/StatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "negatedTotalLabel": "Loss from Operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r341"
     ],
     "calculation": {
      "http://gtbiopharma.com/role/ScheduleOfFutureMinimumLeasePaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating lease,liability",
        "totalLabel": "Total future minimum lease payments"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfFutureMinimumLeasePaymentsDetails",
      "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r341"
     ],
     "calculation": {
      "http://gtbiopharma.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Current operating lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r341"
     ],
     "calculation": {
      "http://gtbiopharma.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Non-current operating lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r342",
      "r345"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating cash flows from operating leases"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfOtherInformationRelatedLeasesUnderNon-cancellableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r340"
     ],
     "calculation": {
      "http://gtbiopharma.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating lease right-of-use asset",
        "verboseLabel": "Operating lease, right-of-use asset"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheets",
      "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://gtbiopharma.com/role/StatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for right-of-use asset from operating lease.",
        "label": "Change in operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r348",
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Weighted average discount rate operating leases"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfOtherInformationRelatedLeasesUnderNon-cancellableDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r347",
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Weighted average remaining lease term operating leases"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfOtherInformationRelatedLeasesUnderNon-cancellableDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r2",
      "r77",
      "r115",
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.",
        "label": "Organization and Operations"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/OrganizationAndOperations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherCommitmentsDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the nature and terms of commitment.",
        "label": "Other commitments, description"
       }
      }
     },
     "localname": "OtherCommitmentsDescription",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://gtbiopharma.com/role/StatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "negatedLabel": "Interest income"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsForRent": {
     "auth_ref": [
      "r54"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash payments to lessor's for use of assets under operating leases.",
        "label": "Rent expense"
       }
      }
     },
     "localname": "PaymentsForRent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PreferredStockConvertibleSharesIssuable": {
     "auth_ref": [
      "r211"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of common shares issuable upon conversion of preferred stock.",
        "label": "Convertible shares issuable"
       }
      }
     },
     "localname": "PreferredStockConvertibleSharesIssuable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.",
        "label": "Preferred Stock [Member]"
       }
      }
     },
     "localname": "PreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r13",
      "r209"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred stock, par value"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheetsParenthetical",
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred stock, shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheetsParenthetical",
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r13",
      "r209"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "verboseLabel": "Preferred stock, shares issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheetsParenthetical",
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "verboseLabel": "Preferred stock, shares outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheetsParenthetical",
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r13",
      "r359"
     ],
     "calculation": {
      "http://gtbiopharma.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Convertible Preferred stock"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "auth_ref": [
      "r3",
      "r20",
      "r146",
      "r147"
     ],
     "calculation": {
      "http://gtbiopharma.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://gtbiopharma.com/role/StatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from issuance of common stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfMediumTermNotes": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://gtbiopharma.com/role/StatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a debt funding received on a regular basis with maturities ranging from 5-10 years.",
        "label": "Proceeds from issuance of notes payable"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfMediumTermNotes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSalesOfAssetsInvestingActivities": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://gtbiopharma.com/role/StatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate cash proceeds received from a combination of transactions that are classified as investing activities in which assets, which may include one or more investments, are sold to third-party buyers. This element can be used by entities to aggregate proceeds from all asset sales that are classified as investing activities.",
        "label": "Sale of investments"
       }
      }
     },
     "localname": "ProceedsFromSalesOfAssetsInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://gtbiopharma.com/role/StatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.",
        "label": "Proceeds from exercise of warrants"
       }
      }
     },
     "localname": "ProceedsFromWarrantExercises",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r1",
      "r36",
      "r37",
      "r40",
      "r52",
      "r71",
      "r81",
      "r89",
      "r90",
      "r118",
      "r126",
      "r129",
      "r132",
      "r134",
      "r143",
      "r164",
      "r165",
      "r166",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r294",
      "r297",
      "r298",
      "r301",
      "r302",
      "r313",
      "r327",
      "r383"
     ],
     "calculation": {
      "http://gtbiopharma.com/role/StatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows",
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r149"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r148"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "auth_ref": [
      "r241",
      "r352",
      "r353",
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party transaction.",
        "label": "Related Party Transaction [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/AccountsPayableDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "auth_ref": [
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction between related party."
       }
      }
     },
     "localname": "RelatedPartyTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/AccountsPayableDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross": {
     "auth_ref": [
      "r289",
      "r290"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of costs incurred under a research and development arrangement accounted for as a contract to perform research and development for others.",
        "label": "Commitment cost incurred"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r288",
      "r373",
      "r421"
     ],
     "calculation": {
      "http://gtbiopharma.com/role/StatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Costs"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r16",
      "r228",
      "r359",
      "r390",
      "r400",
      "r401"
     ],
     "calculation": {
      "http://gtbiopharma.com/role/BalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r78",
      "r79",
      "r80",
      "r82",
      "r88",
      "r90",
      "r144",
      "r285",
      "r286",
      "r287",
      "r291",
      "r292",
      "r311",
      "r397",
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r41",
      "r71",
      "r116",
      "r117",
      "r125",
      "r130",
      "r131",
      "r135",
      "r136",
      "r137",
      "r143",
      "r164",
      "r165",
      "r166",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r327",
      "r383"
     ],
     "calculation": {
      "http://gtbiopharma.com/role/StatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r346",
      "r350"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right of use assets operating leases"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfOtherInformationRelatedLeasesUnderNon-cancellableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.",
        "label": "Schedule of Accounts Payable"
       }
      }
     },
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/AccountsPayableTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r99"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfAnti-dilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r99"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Anti-dilutive Securities"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable": {
     "auth_ref": [
      "r231",
      "r232"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule, table or text reflecting arrangements that are not equity-based payments, or pension and other postretirement benefits, with individual employees. The arrangements (for example, profit sharing, deferred bonuses or certain split-dollar life insurance arrangements) are generally based on employment contracts between the entity and one or more selected officers or key employees, and which contain a promise by the employer to pay certain amounts at designated future dates, sometimes including a period after retirement, upon compliance with stipulated requirements. This type of arrangement is distinguished from broader based employee benefit plans as it is usually tailored to the employee. Disclosure also typically includes the amount of related compensation expense recognized during the reporting period and the carrying amount as of the balance sheet date of the related liability.",
        "label": "Schedule of Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits, by Title of Individual and by Type of Deferred Compensation [Table]"
       }
      }
     },
     "localname": "ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfOperationsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": {
     "auth_ref": [
      "r242",
      "r243",
      "r244",
      "r245",
      "r246"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Defined Benefit Plans Disclosures [Table]"
       }
      }
     },
     "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/AccountsPayableDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of derivative liabilities at fair value.",
        "label": "Schedule of Derivative Liability Transactions"
       }
      }
     },
     "localname": "ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/FairValueOfFinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r149"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r255",
      "r272",
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Schedule of Options Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShortTermDebtTable": {
     "auth_ref": [
      "r25"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to borrowings under which repayment was required in less than twelve months (or normal operating cycle, if longer) after its issuance. It may include: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date and measures of the maximum and average amount outstanding during the period; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation.",
        "label": "Schedule of Short-Term Debt [Table]"
       }
      }
     },
     "localname": "ScheduleOfShortTermDebtTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ConvertibleNotesPayableDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "auth_ref": [
      "r229",
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Schedule of Warrant Activity"
       }
      }
     },
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r119",
      "r120",
      "r121",
      "r122",
      "r123",
      "r124",
      "r136"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segments"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://gtbiopharma.com/role/StatementsOfOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, general and administrative (including $447 and $14,296 expense from stock compensation granted to officers, employees and directors during the three months ended March 31, 2022 and 2021, respectively)"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SeriesCPreferredStockMember": {
     "auth_ref": [
      "r12",
      "r13",
      "r225"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series C preferred stock.",
        "label": "Series C Preferred Stock [Member]"
       }
      }
     },
     "localname": "SeriesCPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheets",
      "http://gtbiopharma.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r56"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Vested period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription": {
     "auth_ref": [
      "r249",
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of terms of share-based payment arrangement. Includes, but is not limited to, type of award or grantee and reason for issuance.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Description"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue": {
     "auth_ref": [
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average intrinsic value of award forfeited under share-based payment arrangement. Excludes share and unit options.",
        "label": "Weighted Average Exercise Price, Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue": {
     "auth_ref": [
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average intrinsic value of award granted under share-based payment arrangement. Excludes share and unit options.",
        "label": "Weighted Average Exercise Price, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": {
     "auth_ref": [
      "r265"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of non-option equity instruments exercised by participants.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised",
        "negatedLabel": "Number of Warrants, Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": {
     "auth_ref": [
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net number of non-option equity instruments granted to participants.",
        "label": "Number of Warrants, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": {
     "auth_ref": [
      "r256",
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number",
        "periodEndLabel": "Warrants Outstanding, Ending Balance",
        "periodStartLabel": "Warrants Outstanding,Beginning Balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r258"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Options exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfOptionsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r258"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Options Exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfOptionsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "auth_ref": [
      "r260"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net number of share options (or share units) granted during the period.",
        "label": "Number of Options, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfOptionsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r284"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Options outstanding intrinsic value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r256",
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Options outstanding, Ending",
        "periodStartLabel": "Options outstanding, beginning"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfOptionsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r256",
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Exercise Price of Warrants or Rights",
        "periodStartLabel": "Exercise Price of Warrants or Rights"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfOptionsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r276"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Vested shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": {
     "auth_ref": [
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r261"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "verboseLabel": "Weighted Average Exercise Price, Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfOptionsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "verboseLabel": "Weighted Average Exercise Price, Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfOptionsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r260"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "verboseLabel": "Weighted Average Exercise Price, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfOptionsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Stock Price"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfDerivativeLiabilitiesAssumptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of non-vested options forfeited.",
        "label": "Number of Options, Forfeited"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfOptionsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options vested.",
        "label": "Remaining vested shares"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharesIssued": {
     "auth_ref": [
      "r225"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.",
        "label": "Shares issued"
       }
      }
     },
     "localname": "SharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending balance, shares",
        "periodStartLabel": "Beginning balance, shares"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermDebtLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Short-Term Debt [Line Items]"
       }
      }
     },
     "localname": "ShortTermDebtLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/ConvertibleNotesPayableDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShortTermInvestments": {
     "auth_ref": [
      "r21",
      "r379",
      "r380",
      "r386"
     ],
     "calculation": {
      "http://gtbiopharma.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.",
        "label": "Short-term investments",
        "verboseLabel": "Short term investment"
       }
      }
     },
     "localname": "ShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheets",
      "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r66",
      "r77"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r12",
      "r13",
      "r14",
      "r68",
      "r71",
      "r92",
      "r93",
      "r94",
      "r96",
      "r98",
      "r104",
      "r105",
      "r106",
      "r143",
      "r164",
      "r168",
      "r169",
      "r170",
      "r173",
      "r174",
      "r209",
      "r210",
      "r215",
      "r219",
      "r225",
      "r327",
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheets",
      "http://gtbiopharma.com/role/BalanceSheetsParenthetical",
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r31",
      "r38",
      "r39",
      "r40",
      "r78",
      "r79",
      "r80",
      "r82",
      "r88",
      "r90",
      "r103",
      "r144",
      "r225",
      "r228",
      "r285",
      "r286",
      "r287",
      "r291",
      "r292",
      "r311",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r351",
      "r397",
      "r398",
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquityDeficit",
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheets",
      "http://gtbiopharma.com/role/BalanceSheetsParenthetical",
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r78",
      "r79",
      "r80",
      "r103",
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheets",
      "http://gtbiopharma.com/role/BalanceSheetsParenthetical",
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssued1": {
     "auth_ref": [
      "r62",
      "r63",
      "r64"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value of stock issued in noncash financing activities.",
        "label": "Common stock issued upon conversion of notes payable and accrued interest"
       }
      }
     },
     "localname": "StockIssued1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r30",
      "r193",
      "r225",
      "r226",
      "r228"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.",
        "label": "Issuance of common stock for services, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r13",
      "r14",
      "r225",
      "r228"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Conversion of Preferred Series J-1 to common stock, Shares",
        "verboseLabel": "Preferred stock shares designated"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquityDeficit",
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesOther": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued attributable to transactions classified as other.",
        "label": "Issuance of common shares as equity, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r13",
      "r14",
      "r225",
      "r228"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.",
        "label": "Issuance of common stock for services"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueIssuedForServices",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r13",
      "r14",
      "r225",
      "r228"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Conversion of Preferred Series J-1 to common stock",
        "verboseLabel": "Stock Issued During Period, Value, New Issues"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquityDeficit",
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueOther": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of shares of stock issued attributable to transactions classified as other.",
        "label": "Issuance of common shares for common shares issuable"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchasedAndRetiredDuringPeriodShares": {
     "auth_ref": [
      "r13",
      "r14",
      "r225",
      "r228"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased and retired during the period.",
        "label": "Common shares cancelled and returned"
       }
      }
     },
     "localname": "StockRepurchasedAndRetiredDuringPeriodShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockRepurchasedDuringPeriodShares": {
     "auth_ref": [
      "r13",
      "r14",
      "r225",
      "r228"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.",
        "label": "Number of shares received"
       }
      }
     },
     "localname": "StockRepurchasedDuringPeriodShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r14",
      "r17",
      "r18",
      "r71",
      "r139",
      "r143",
      "r327",
      "r359"
     ],
     "calculation": {
      "http://gtbiopharma.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance, value",
        "periodStartLabel": "Beginning balance, value",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheets",
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquityDeficit",
      "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r69",
      "r210",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r228",
      "r230",
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders\u2019 Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r335",
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r335",
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r335",
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r335",
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r360",
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r293"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://gtbiopharma.com/role/ConvertibleNotesPayableDetailsNarrative",
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UnusualRisksAndUncertaintiesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the nature of the unusual risk or uncertainty, if estimable, such as the threat of expropriation of its assets by a foreign government, rapid technological obsolescence in the industry, risk of natural disaster from earthquake or weather events, and availability of or continuation of a labor force at a reasonable cost.",
        "label": "COVID-19"
       }
      }
     },
     "localname": "UnusualRisksAndUncertaintiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r107",
      "r108",
      "r110",
      "r111",
      "r112",
      "r113",
      "r114"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Accounting Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r91",
      "r98"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted average common shares outstanding - basic and diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfOperations"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 5
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org/topic&trid=2134479"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27357-111563"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031898-161870"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "https://asc.fasb.org/topic&trid=2208564"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "710",
   "URI": "https://asc.fasb.org/extlink&oid=6409733&loc=d3e19524-108361"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "10",
   "Topic": "710",
   "URI": "https://asc.fasb.org/extlink&oid=6409875&loc=d3e20015-108363"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2439-114920"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f(1))",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org/topic&trid=2197479"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41675-113959"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "815",
   "URI": "https://asc.fasb.org/topic&trid=2229140"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL7498348-110258"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "820",
   "URI": "https://asc.fasb.org/topic&trid=2155941"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "https://asc.fasb.org/topic&trid=2122774"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(4))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(5))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(g))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16)(a))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.1,2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(13))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r422": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12"
  },
  "r423": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r424": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r425": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r426": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r427": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g"
  },
  "r428": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d"
  },
  "r429": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r430": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r431": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d"
  },
  "r432": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r433": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r434": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r435": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r436": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r437": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r438": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r439": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(7)(c))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r440": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r441": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  },
  "r442": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "8",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(n))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>61
<FILENAME>0001493152-22-013539-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001493152-22-013539-xbrl.zip
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MX?\/@NF>K1>MWSR]H'\ 4$L#!!0    ( !5(L%2BS/O51BP  ,I7 0 *
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MSGY/R[F25T#3J,,640H,L2!E-LM _6--EH274YP3/"YX'J@:>+7.00C G1B
M)4(:3Y9'<A[8"@7^2,.L8E;N<.AI7F8%L[HV?2N<:#$1@=S=C4Z9U_,KX$1(
MT<,Q:5I3BR;"0NQ+W$+A]LK5>W(_3/>;$WGKA875_(^=';"V9)J\!"(:RWT8
MX*\2K0SXX7YT/B-TZR6^Z +I-<_VH]]$6N+7T<Z.=66].C[]S<V2U[HSS O0
M85Y&+V;%/NCK&J2>_^PP%?'GZ.GN<]@.DZ<J@85>,KIR\O[]QX/CX].SM__U
MP]X/]/?%QX,C][=]AQTO!N(6,P-S<?_:A^N0%!-<]-Z_VE#$RT]N#%#Y2<%R
M!U'DL_K)I')$OSAVOUCT,]1>!\\&F^FV<3^ZO)[!^P\T: #Q?G0FII*W^BS'
M#7P:_NB)^Q5^\^K)Y3'^SR?\']P=^"_L<\N6#T%=^;PSE"!P8.P9':,]!E@5
MG0%,[F/]A(@:0\]>;?1P4CA9/NLU4'\GA)8(H:$50E:Y;9= I&8BHR.?Z2"R
M*JX!HG(LV5APP\@,M7!O]#<-RP%R73035*QF:(DHAL&*')D_:]Y>TV:M%966
M^B -'5KZGT2S5&2PW*E,\)+!X*;4)*^VKB8*>#/LILP2THD6V:^:XN]@4OT>
M[R<(3%2'D:G3P$[J3/-$C11($#:O8(M)R2+,"Q?C#7_B_8MBJ-I?MV0RHDBZ
M;/VT#<=4@HTDY6>#@AE$_US$K-3/:#^R<CJ(MEYL1T9]8=W *&!M:&>%3^!4
MMI[#</@&>@R^! ,#-J;^Z&,6-@]T+5LQ7\R/ 1YTF&?E33<TGR' 6V9H] %-
M@E*8,33@1QGB*'BARAD^@88>X:,Q>6=_VOO7MKMM@3K2[RWQ2C54P(7I1A]3
M5)E& 5KAO*:7L,M@:=)C3D/=QT<#8\:#96SI]GO+7N!'1V4+&,88]B;CJYDL
M(H)-# "^RQ9PU\ ,PS\($921@US[O1KF&AQ#HDRL)0/\%BIG, !GP;L?AV.C
MP>;/L[N*&[>6K82OXEN+[;\%B5+P-3PH6#H0G>%A5Y2+HD(94P:F>LZF#AA$
MRWR\NDPKB7DF3"+^BBZ*''C[!Z$_RP(,M??OC]BA4@[_)- X9\-GCN91Y4AN
MH]Q1D\07?0>#< E,TUM/M^U"0J&))F.I32D81Q*1H6F**QQ15-$>)'8'-F[#
M^S_FRJ""/W">")U3W%3 UEBRPDZ;D=1T?QE$Y^T+ 4^ZB"_87'70!CZ/<\;=
M!2'^U-K)]M?P/)P)_,!..@]9SB!B3<$^ZTWP!%>46-?]J$2$%+2;@DU5P@KK
M$.L^B]]G;9L'7)H,'-*%2AU/D-$^N]4DO1I%-//BQ>#%BY_=3W ^Y-JS^ED#
M\[4C!&RO]>=.NQLI3;8W&=[P'X7>"HL\+(X^<)"R1:=I'C3^BR7C&XEQ#'=X
M04#QB[H;C 6#E^ALL7X6> UZ2?L](ASW\@2&"EPS Z^BU>QX$1V!+C8F[?0(
M1M9Y.J@1(),%7&&92NT =7Q'I42BUS% I/L]\A5.IWPM"7S/1PT(@9;=$.W,
M2E/I)'R &]=IH@$CU_%P.DV,0;IQF]OF .*L!$7"CF79P_/;7ZKZ,MGKVWS'
M5ZQP* O0DAODZM='7-(3V=)E]WO)W=;][/GMU_TX)."CDN:2I?G)%Y21+O*B
M)O&T5-,A"+>0'I#RF.H()@7)-)? $](\@06-!QRL6 #CF[H0C:D$MB;M6S!*
M 9W>B77#9HQJ]7M>]#<<OQZ]QP=:_$QMH2+H>$Y91HV ^QRZ8(RC5!@;%0!7
M*$4;'B8.[$VSR8GF9K^'AN<$_L7XJC-,4=)5&^*]5<0+[5 DJCMZW]"U;(V8
MWB^)8MNM1Z9FCAAQH3P+T ;%0H#P,J-K\B^%!,L48V8@X11Y'#%"H<WG^)@)
M9#6L_:Q#L->*8#_K$.R'P-_6.>V?V#_.FAL*R<M&C(77&XG-K7M]_+^[P$HZ
M/_=7^+E_R],R*U"T!,?&\JCI1ETT[^;^QV%<#<FHP%KPRI2WDAEQL%J.QCC/
MAEF'B"5&3;W-X7\^L5D!^@WJ.&>(GBP\'SS8&CL8:F%97D?Z8%#GV[ 1EJ%Q
M$\R5XU@1O(6!6(Y:/VCT(WRI\W+,"TVL88]"-MP9RC7A78T17,#T! P9MC8*
MP0\#%-F%5G&!@:<A?@/SY,GX:"/\<@?##Q+[R!A!,%YED.W D5>%#2ZR0 KY
MQ*\H=!)C$2UJLF058!L&D6!-ZU@4JP.IW&\Y$%K@ LNT<!N42 'T 8M+E+&!
M42N/D&*D!6(%$=CX@BT^9^ %ZH_=&()V!PA@$^DA"?$.5*]0!!%F.Q*NH$([
M(L30_ EOQ=O1U@SG/B48)=2TIE(69'!@@ ,"XQBV)1/ZJ&! /7Q\G(O4;!/<
MF'#."*%U:5HG3"07[W5K)SLTVA=/+#RLQ\&N'A7KM=[=4$XB61Z)TDC+>F\(
M30SXRF*FDA_K)DZ(\8M+66&T5D[8X(*#D T25+R2#T;WP0;[O9OY8'0#&PRW
M*^!Z-X:9VN,B0+(>2VHAT69L;AVW'O';1R*NXFT'N%%QGE51_2B'!VU1L-5D
M=J,W0J6EEL1DE[V[N=)P7\(\NY6KM>M#^!4(LB2P-E(PUWG.D;U7 L%!(@Y\
M"4+)2+N$TMH)A.NX$J8:_)%PO?M/-[XW#_II-F_3/%VBR#*-\';LL:EQ+M%
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M.0S7ZC!\WCD,'P(C7^>TG]OVS]Q'(CJ6(S F;2-4Y-9OK(X^*_4L-W))'[-
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MND<J>WO9[QVJ? ;*Y%0,L!#10P:8?MG;V^OW/@BM,A$=IO-D%YXM52$1$'_
MZSK4R@Q%AE5GC@ZB__RTM_?\ :_F*[P\3_<Z-\]:W3Q/]SH_SX9Q_>_8C!5,
MJ).L4#K(T7?8:<U.0H.[4 75_Z P0OY1&'=;I7%.\VR\HKJ(EF.ADS 7U#"
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M-(BS$-D+F;/$7AY2KU#QG$V0^(BXB=#C>,',#D=.BOI!^^@!0D'6/2J1Q5@
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M+2,1WW>U&CL7$(<-=HV2O(D&/F60!ECQY*3)KB8V*]U@%UP;5JL5MZ8W^+V
M57IKU5,B SNT%*YEH?I0R*Z*EL<*](%2?:PEE@_NFL=Q-2J*(;(U%I-MQ?2:
MEZ450UG<\>)NM^HX*L4 E<:U3@/KQFX')D2=WKOG7L1'[^O[&U!+ P04
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MJP+JE3J>LPF(CXB;"#V.%\SL<>2D:![='PH02HI>H1)9C *@8P6Z=/<T#E3
MS9A%L9J9@JNU&$EC-<?=.)WTX &ULL*VID#D(!=<7++NVX)5LNXN/I5MP@KW
MA'7S*3E/'-F!O.0P%D1*3(!FA[$T8_*(Q%0)7"\Y7SH.I0EB93)X2O+#6L6>
M]29:!2+$:</>@>1" =;TY-O]&HQY.A*L#9=YE\4H<?J!5T_/WXGW5-7C.#T/
M_2EW#O5 QZFG7+H)(RNZPL2>% G0B^\6^<CYC7!$;5VGY[Q+4(HR%?7-;U'-
M9=[^:J:_3!"6"<(2I <IW^\'95X*@]"%5W7S[.?IL$)Y@(!G\+@OK4*9@*$
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M0T.RFLU;/&2N"QS VW"^*Y<<],H9RKYATD_]"GJ]88(&..E$C5VPW&B=DC/
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M<<D3XB412>@BT^*MA657WS">3WQ$M%:MR3YHL=&C1<IWEYP*!&>O5A4+U9@
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M1840!.V@UP2P;(8^[BX4#R/-]_FZIIRKZ(*03__\$3Z?(RK)NL(#%7]%OID
M3B J_?DCPA[]B__O\XQ2M;F(C.<(*<4YQ= SC>HCDZ)2+?!$=>4I)V6,+S(4
M;O\;?:*FG#*&TCE%GUW\[_^8(OWI\\<9>=SG_V2SU!4$HG!.=7419#O<&%#9
M[,5G]$+K/4]0T";X1?0_9ZX?AK*"X,MJ\NR<NA0Y_I[*(UA4683")PI#EU7A
M J [9]HGRKQX*&LH4+&N9SX4K#N6H&%<S?]U@/?1!5\$E+!IL.=CU!DG.9^0
M'7%3*,[/@Y[A)!!ZY1)__$!?Z(:R*&P'XB<*F\XL)\(Q^A-E6!KVV9& 7<9@
MW[6:_4;][9M>O]IO] + 3Q3DGX<7O4;MKMOL-QN]MV^JK3K5^%7[6FU]:5"U
M]NUML]=KMEN?/PXO3HDI+$;M)Z=.H#369"GS]DW]0^T#Q=*%?"5*[D0I^H@3
MEO2?%K&)'%VUN[<(3O(\[!J>A>=!A2X.@ !@-EN7>7UJ!I8#'@="*+1E!@/R
M*9=C!HO)9?]^]/?ZVR4/$5C(\$NR1%PPY"DS\NF"T6JM29.7I88S2N)P/(W[
M$9WO.[M@Z.QWXDR6SUP2^'3HO,% :GA$-'J;*,XX04!"_^\9?4;^1M?QUM^&
M^R$?MQ9YEP/$;U2L9SP"!26<G&CAC%RA$1-\UH05]TE_8 M0BE1I5@2NNB)P
MWW44E@-%G'?!3$8YG*?L/0K]2O42MB=5=F?9&\G*E-/^/8//VOE0ED7 29JB
M R^A7($)\[12RA<_!8FH)EADC=;JV/!0"@&(0C&AJB/X$2O1?3P^GY)B<I2L
M4$SAG?">DD>4-@'(VZ&D3($:1"]L//,37.JDJKR&?V<JN;S+CF&@/VI&($>D
M-9I0[CCF]YA 7LG*VS>(_-2#S38C7:10-@D$:E4CKE8THD,N;AB9I[<^5.K7
MQ<?[7F5V58A$'P2\/P?=-Q&X^1R@5$CR4@L78&<7MYS"3Z@<DZ'P8WUTXT/"
MF>4O4:G%-N6SOAHB*)RD0FQS-IGLKUKA6[U:?6!_YJ,TV2-.5#UM]BI4IM'.
M'\UH+P%*K78<5MN,XZ"$:Z[H[XB5P&''M24G34,^0D)+40/[/YBC \=_(K=Z
M<0>M<7,I3L#Q62Q0Q:7JMV^N(++92--Q!7O5CK&F'6N0DC*^TKC0VWXQ?PIU
MI7(GE*:[N]BEE5I])UX\8+)YFF9SOO;I1/UFDA.T\M*_F4\BKQ( +RL<5O!S
M2D?V1!&A!-8=(>T2H"X80Q6;!@VO]7D+D5;NCDJ-[W_H671"Y'XO7E]\^^:R
MV>Y\K79OJQFJV:I]"')Y)Z7>[QK/'*^]?8/I@%V@8N-/<2JES@"/%]P$"B)6
M:2J%_"4.NM]_'BK41^P6K7\WAGC.D&XUY-LGKK,KRKPLBMQ,18A9GZR 3MG^
M!;[AH2M W!K@?.6? _!SLU8U):2*,U,;R=P LJJNS&NRX*-DT\?+^\N?U[PZ
M*D<1:695P./%0@W,%/D12YT[&PH!Y]E%'8C<$X<7;H*-NR:L\VZ="S:7V'^6
M-2:O6T^$[8R+[7WNN6FNG?.$I)M<L_;]!UN<+\"W*1^95?4!X.RBDL\R19;.
MXPD%H7AIAN,)46U/ONY@\;T$TO "QLH:;?]IK9U%'7&\(UIFD *E3#**S!7J
M+TJ45 $:N11R#FM6GA#N)/&%3@NS1%L9<Q)<D"_?KV ;UI1$93^BDJT NAXB
MQFA^Z'[H?3!H80X35Z(3IN,CZ+9M!B:&A?,4HJ4-LXL*D8>)*_D[^Z&R%IR?
M3DI[ &16'6C>Y4"K@J  537_N4'Y"^/M/*O=_F6/U:K7-1"9\_1X^=E%F:;I
MMV]N.05*''4I/@H^_C.SEJB7 S!CO3&K*WS[X9IKEQJ5&#%CSRYZ.M0 #N_]
M(@(KY5C!J^*%5PU];"M]^4GRQFI\_^UK_HE]:#PQ46.U?/79Q27RHT-.\@M8
MUYETY84,<=%MI8,"9^2^?.+U[U^:CY7K<:ND"U%CM/+^LXM:U0>A-7P8+WPZ
M,DH$Q#]PYI]]?*7+S_7%;)HK11>,>KT=1Z(T'N"T4>3>F;?B6&B&-(^',TZD
M@-6<B;[&W9DJQ4D"M8 S!*$ 0J7*"2\2^)D0+.)5!7#^_/OVY]>O7J?RMW.?
MBX!_SO>=7>09/WYE_0"^D5'PWYG(TL;BY&7CKC$NW\G?Y;\1 +WZ3B1J3"6;
M1SE/D+0M:U'_^[\RRY0^J8C5(ICA9U$2>5B&0E(HZKB:0J&$F-M9Y+8L)!XM
MVFI]K":U;KM<6'K[QBBC 04(WNM2[+NAM2*%%Y_.DXI34+O-2ZSLK72I#E>[
M5 TR;852KGR((A#916#FLB.JP?$3BHP$#:R';8T/KI+%)F1>$,; $^8P/%$X
MK! &0KWY%-G9E!V>=5+Z$.S BSJVA@!K^1]9Y*<)1.JR--LG6'>,K47%RH5-
M!S=GV"$Q-=[1$QS_^G)?4FJC2A2=K*OO/",+TE:1A8PRSE#_I3_0-$/-.(5Z
MY$0=X$8"BFPZ"=F>LA,;#JQS296.2U,Z3$MGV#AOT6A<#8?T8P5RC2@6;%TO
M-':"INR.G=VU%6-@]5#Y+]/+=/U/5U-8[6KWFMCJ"B(VW>N+AUXPH92!4P7N
M(81H1%V7/?C&H+TZO#Y$W.B(-[/R9$UI.*?X"4 1 GKW/?*T@"PNX=3'T6WP
MCGE/33B5&D$1)4V<*)I]?2KZ]T&'.)-""=00F!>@9_HW^5'.5,RKR8\2T,\H
M9<;7SA3  Y) ,RQ%VG15ZAUZ(!(Y2M514*!.9-SS8'6G:1-.6P7^B7.#B6$D
M-^-,D&#Q/D.J0N]8 \LADEQTP? OP@'?0%Z$[L)@F _";9<J@8) R:D:5:$I
M@9NK'P+*A35=4=#-1J<FMI :I^FJS[X3OE4:BN*O2"SRIM>?7?S&6T ]E?#M
M&W,+ -62*;NQ])0RXCW70/_JJ@9'<W_M9#[0A6C7/+943RRT2%ZG4-.0B ,1
MR:TB2SBF%><40/'MG&IBU\/QI!):YS2.(NV"*]J[?(:S+H+W=;Y]DZ<+6$&[
M8*R+9"6-ZF7[<:NJ 9"M@$!]_V%];:&^TD5C(XKQ-.7=6[\6M<GUT\VC?C\>
M1:9@WN_?I&!4O/H5MRLYCLX=VR-"E>(H$0$'*([GD<HI'-8;+*0*]B:>WU*(
M^5G/']0ITE7T%L6RRV_?\/(4X3;'[A,]#GD<3(@Q-5;D)VU"F;]^0/@  IL
M1E BG=ID!007I5GZDQ^$Y&?FDW69[P78^),KU@"T(+">A!VH>:T/K-:54"(F
M!9F)89:U@@)G(/#AM-S+RRZX;@UP@8ZTX'6#)=B :DU*U\QE) 6[B!&H+J$V
M8/,%/4EEK$.4K)8[ Y0:(L]85N8^;:Y"?CP:7DHLW'W-;RU))2\GO.#-EWLU
MN[J@0^FJVX [&!K@W!-7Y>@9!MV 9<VJ!^P@(3=?ZBJ4@.J3N]Q6\E>_AC]_
M/$WBW+;L <XV6Y9?JL8U3 ]L .-VPVNL=:NC=>L7<E/-N,>GGTIZGO^I].9:
MEXMUG^,&P+;=ZGATSJP7%U]%86MS;!]I'#]Z^\8_7L8M&4:<3[G#?#CR2JI)
M*HVB#4DFF;"N&K$V0L;8S^ZQ/1*%Z_A=XIRHWQ-$[\9*)R$$9!P^/T*5A"\2
M)_&0$W%0@W=/8%#Q($J!4P25PMLOH.#7GY![Q[WWC)NI79(8=8(B5=LXO$-8
MDU3"V%:T.5!__X%"::T5RJP9EH;;9^#W;+0GWX;MXN67J^NI,%D/&M@M']94
ME>M\M2#V?^S>G!;>.#GA.?CK6O*Z]=MD#==BDI-(LY("755]^P;IPBTWIYBB
M,0 B0S0#JJJ.=&S"K<^Y<+>_&HND9'G4F"C8UC6B^\@(#&!S,(."*=,%ICA8
MP*]7E>I7]:_0MB7KBE28D"U8*^]N>/292Q"K]LD8A2Q3= N?I$\%61, #U%@
M=4:9']1_SYJMJS,*3\4CC[#&(>;H3(&F,R7&WB=DP4?:VUR..#(V&&,+L57B
M"<[HH0AI2E[B>V)EA(@G_:TU? 3.^K-G QY^TE]TJ>8IL=S-=$S/3^@!>) M
MCV\TB$MBUG5.^XYI=",0;I*+^]'K1::58M0ZU3>.;W%'?R(8D3M6A[D8CW9>
MJ<#Q1'-MV"*ALA4F6S,W5PGDJ!@/%<#=9X< V38$ZPP1V+E+RW/HINNI3IE/
MIKB?ZC0" CW9O@_E&;+D4RZ#@E?^ RDCXWG.4( </AG]Q)KQ^T3?D%.J85<K
M:6J29UFDY>Q-SS.QM2TML;$V'O2'4KSK:/N5LCV!/VX?JH>G6F69<>D._:ED
M-3!N]<8>(-;B(=(+1**Q(NN2@'5#5I 3' _?L70^P^;*&;90>.\4:70)AN;?
M,W9K?8R4+M5NWP"J258 &>83==5L55NU9O6&0BE#NWM;[9-!O9'(MI_4''2V
MZ:'X_W,"-9"0JG)3 U,#$.9#X@JK5U9%S6H^QG,=#0^<2EV45B=1Q?-$@/69
MHR8*+HC\GZHK YIF<!\\[E/!E5[TB7@[LFI]R8E(2 '5FP"@J7B($ZDD.8>)
M4N_N)$X7D-8+[TDT7 >\<2R)>07S^2,7U1:5;80Z]SJ-WHG('.LK<TM+B(6M
M/0/&6)5E]ZJ&'@2LCCUC76-%)+$88LESRN:1I#"?&L'3$,A<2($DM>J)+*)4
M035W4E.-!QUJ<^I='8SPR4GO$R!WA9.R?@FN,.PW2"B^<G%R-2GOT"0#P WJ
M5./4"74ERD\G:M]+J7T_#?M>6)/*EJRA)VJR6SSMO,PIJ,>7L_))V?,84G@V
M>2G\JH@5\4$+$F><46Q/6:E#E=?)S&MBMZH2)\Y52(S?4M:P:!I].?B:+E!U
M<37^/9+@,:F%6PIA+OE"6#K#9]#@Y@H.[^DQ.]&14*%O1?-+(I.BC$\05*GJ
M4-8U[&'O@49UH7I_-$FKO'8;ET^^>)6)&]44630FDW44F0>"3D[D?/%2DU#[
ME- (+-(%PE=5SEZS3O;*6>ZH*V>KQJ#B6DQ;KJ:U^U\;7?=*FMLVO&9M3?2J
MU J'&?KLX@:,48!*[#S9+GTL0\_2KST\*"9?7E *U'B>P"'47H.8)-3"I/'
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M?9AXT(EE/*[FJOY3J#4>V$+,QB-DC16?U)+U*:^>"-.C4M>0%,-GTZ84B\W
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MX?*9IN/"QKU!%I)79RADU%K7QA\?J#9^_!!7@LG2K63]E"&$GLH(6FB62IQ
MFH"]?8,ALV_!("/;B>=KB7-*@.BCAK04WR C^LKX@>A!%KLX$5V%B#$&V$*:
MS%!Q]1=%%2:[.?MJ2D,I-9D":!""< L]\A$J.A(0*.%]V[A&0T!!3]!%,KK7
MM+SV>_#O-I4$P&F3#SXL5/&KJ*$;<^,Y%)9S29\. ?$0FC[%Y6L4SR!F(V 0
MX!,PY30L/PCR*5%-'!IA;BE&2<2XR>"S(..2% +Z04=$LWBYE&NC'<%4ER#+
MMF\H'8.C];9Y'UUA\T4,4?1.L:]K535DQ"KDY&[G[^_.ET?F+/'<,&)6UAVS
M7JQ&KJ7!HE+[ J[U_+5P/SZ[Z.G3*39<2-P=5*&69*$LNMA\=O]S,M*ZJ4X:
M@Y!><BI4VR-G*K5CVI9WIFW[/':P@$^_!.G7M-B0DR_/B%\KPENL#19_JH7V
M ^R/T>O.+@@QD%T>44YZ$-O;45"(#6>BX4A=":[-^VAK^D<RMXD&F82;@<LK
M.!L2=<$(B.P#=(TE&SL]P$S%J<'31$8!1A8%0NAIJCY4H0 Y%'XA*-K/**)%
M^0(.\I8YR]LW7X",O3N.G?H*)ZFBE>-XITY5%(&0QA0K\M7P3<82H>'8AYR(
MHQ45176/*,X"0** "*<(-3,IY)WREN8L$0N4:]%OBV4\$N_:"X H/EQ9$21,
MA]-M'OGVS5($9OC0>\40  RB(I HG^36W-*?SI:6R<@A<+R,?@<S1T7A3B(0
MD8H 484J\4P<]0Z[=Y;^]*5:[9"/S*?WAI1SLQFR]V3I3='QT[&D*F"L&^)N
M*U0/\+IBI!CX"FM*$E:T*51)!F6]I->HV>] 3^(4P0B]#3(MZ8$0Q^U\TACE
M4C6@:!S.OI9;NLE[\.(L:3(UZH:JF;4BW$WMMW'W9-TFXF):.%319A_R#"B.
MGT*-)"*.)GI5YR?>1/I (A^"ISC/F&O&.\@%I4YD';E4E&8H@!-P(H-O^JM+
M1@L$@=LH3P4*K4D\E227R(R1\ 21>$FQU=RU*DDZ>DB7L 7G6U<X8V7H[/7;
M-[@CQZ R[HTPMC<#"9._#GA 4A]SW8)!UXA6<8A(3J.&'T96-RBV;"YNO,,_
MF0)#[G*]W9(?HFTN;''V3\PHHA7 N9=JE+Y6@;#% V./$,9%. 'QXQ$3#(\/
M)EYCN:@?1$Y3$3B-PE=%:IS3$,"[&HLY]/_9>]?FM)6F;?2[J_P?]*:>NRJI
MPEX@SBMKIPH?8\>G^)CDBTN@ 12#A'6P#;]^3_?,Z(0D!)8P)-[U[OM929 T
MT]/3QZN[C9&F\Z@0?4SIX7$47)7ORO.% !KB2DA4H/C ZU3(8, 7(S,&Y7U%
M,P<0?T)C,?+J>&\?&9;F2B\6>$#6,=S0OB3NDA 0(VP3! 4\W0&&+;9!O%+!
M#EP'=U@MP JIK/8MT;O-G,%!2V'PA\?U3!#8V(\ (S]DFUZMI-7PFRT6PW<;
M?#]=S.:&((Z&0EBERL.FMPK>ZA,.6\3;_C(NBP=BR#F:@,CT$^W1H0:D/49G
M:1SG@56\VI&X)^XGH[)YKO]\O*KL5_+(;VG!2QE?ZOCAB[O&@*NSM#/+X0O7
M83&QF&6&-&(RQ[*<(:M;05W@=S6>M<$ 64O3'?@EO8H]@W^T0TQ]6[H" \+W
M"N3#(<2&F9H&I2_BX.B?^NK]+/JW5I=#(>D_^2O_N#[G%Y^:C"8;&M%V+ W"
MQ]N@R?$GCXYB4J'#53=3R0)O$,RK0#6AJ8*^I1*%ZEEJ?Z'D^+^@=]T,=)8\
M(S8K[C^AO[[7SNY'>E6OW:O:?0>^4"P52_?W^%_E<NE^\G37/2*_K^ZNCLLI
M^C1[;\ZZ/J_J(CYK\=.*MZ/&V^(]D880AJ=+9A8UICN@HAG.Q2=HHX@G+SB#
M>Q9E=W]=_7#N&F=G1\J"';"7,"0Z'=FGV]."?$?"<[I3ZQNIF\3.?46%K!7V
MYX/;U*=&YA:]"4/_N$_AH4<>5278<^A<_TI?!$$T>!5,$#AR7\3/!$X"CRFQ
MRFG6R[)HDA>@=+@ =7NZQV.8P@7IV3 ?4)8I(\VF0F8&A>[8SW?9K^^U(\ZO
M'F$FO<K.T>/CP<G^H)U(G^"K<J9&J1Y!C? UQUN.U4M]8T U@\7-0 DR-O8X
MDC;[X>HL_N@^/A))H+V7P]:X<_3C\4!.5?D2>&/^=(IJ]1J@$_7J3UV3'?-A
M'6W$51U7G8GRT+L"4,4-UR3MO1)DF7[#6URF,/M@UI+)H<T-_"_B-5$L)(DG
MQ*BK]-< ^(" !-H$F#ZF]@ WWJBVAA$YH3@H5M38V ? QOPK:U#&'>'-#15?
M&>'9S.-.=5-8&=(S,46=S_9Z6Y=?-2H$3):Z#FL;X1)R9(IG!H!;:QI.KR^-
MG#9U!7B>G)X_/0!+X9D'_W"[0F#2$35*N\0$JU3 )Z)_U_'56&&EMJ9;U(\9
MNDP&(@R0"#UTB 8#I<U] BO78UF/<#;+[9$7C"%]2:J&:+Q70V1:#=%8GVH(
ME/2"1U:*IQ.3UODC+6YTAPJBP:5F/8#BO0'W%X)5=D*VVJ_Y4SU_/RD=Z<;A
MSZ/*U=?N:R(GN62?4X1;PFGJXOU$/6Z>?+>_6M95Y<.7W?/;H[TM:"(0A$ZL
M9TW9ZH>;>8*B*!>9,J>.QT"5OA)E8/>E %2;'N@  T/T7 U=0="9)(X+PCX#
MHXTEA/2PAUH'DA@:C]CV-(/^5M4L;,AD.#;**NI?]37Z<6HW8.(;0TB(,+-&
MD @JH$6AJ- = =!T2I?CV\ MHU*N WMCOA?]14&B#*<;0\QN@Y7@&6N4H@\0
M46(K'(RWI2.;O7M@&; LT\%\(MJ$/)X4#&$,P;X1@25B\;V)C4#P::!.K332
MLO3>^Y[JSF[)=WUMP*&8@O_P@#5*_ X_VH2C*/B;&%-+E1")&IAVWTH1,FR3
M@4:>>"A37(?-#=\R5 GP#IBPQN5 7M!G'M//BI2!=!TRIP$2:;0M8CZAZ3O&
M-V@F<SPH7VJ8I,-P*;@Z&$\2L#26JL9L*F8ZZ'/2$QAMH0=5APA0O7N;O4O<
M C:FO&[3 R@ DE5CJQH9EH5FMG!_Q++IJZ!X0./\3PDK(KLF90BZ/!O0*]Q1
MXU?&GS+"_)>X6 +(0O!"60)/'3Y)<3.!")'9IX(G#5#4J)BM0B"PZT*^W\>,
MH2=^1L;40I?:Y\:SN&<0:Q]23E8],=MG:D=Q[+[!81>4G8::3N_/A  L&O$0
MDDEM)&0\X V;*$-IB(EPNB)-3+0"D -^RO?/J#GHAX>&34 -G!J6+3W1)0 *
M&5,@"%]"YN H;\A-4G5'+[+EM 7F RZ0_F1H5 -M;J KJXQ%\?LZ\= 2C&*+
MG'?W*7\-(086LGZK?NLW\,/[B?)]]/6W=O=;ONG]"6;NP?VD]K-HW;SL7+55
M[<,7#WFZN>'N>GULWG4522RYJ8AT8@S $C@?HJ(05_1 4[PTP?)!,JC%0<63
M\D!%DSA#UK++S7;RL*_/(&3X+U#G0Q>[Z>]PZLMP8EV$BP+C\2W@&0PMN\]L
M;@0>XGJ7E\?%@L3@Y7'K,:E!0VUQ7H'#6Q'Y;207Q,:1$P %LQU0KD+],I-8
MU>C&W8BK8?D(M1W T'OT$_A6[(0$97<@YT=48-.=TQWXMEH(T!D3D)K.X$YX
MKZ:M'OPW!MP(O =^X#(%SV?X(H?^!DU@BX'<YTB70 67*H*4MO+"SV=[<X-1
M1DI/F+6Z5F^E6/A<IO"4RT1D2BTT:6WF\_>3IVZ]=7OWO7Y\.UCM.NQ7Z*;&
M_>3LUVGSXOQH>'C:9J-=J%;RJ(*\CDG:+<C22KX,4[XJZQTC.,.TANR4!OE/
MJ:_U^H,Q]V8"^3/48$- P[FUD@$7%WP@K+8,*@ZE0]\D4'V6%$[9T4\P";LH
MP#P:OT!M;DBTNY"%Z4PABQGAQBT;\4+NC^F&R)A'>Z0NY7A0$:C5F#&OC$:F
M\8)2EI(J$=,3,1,N&JA@16:QOY+ZY*G>>.X_/'R@KK,-IW[M[<RWH06&T\4L
M).<L;WV['(^8$/\G,RX7V?2UNIKK+DTP',I$!\_@DA= O;JX+J]NG7J\U/+C
MV5C1-(+WE(.B'RH'Z WW(2&\\@V50(H?XC4L!#1B->$*5&1V!M1L0IM0V%2L
M 80/#<"D%(2C,#'L4.FA6&1;NB,2?WKLEB+X'K-BX 5@1+IM[P [C&8],]X*
M$JNYQS:]4 S.3$9>7Z7;A%5(X(P"7G4%F&JW?UYH 7Y\M8MB\! ,W+]@/P>O
M87-CJ-"WFAI]%1J*L 1_$/HHA)+H**:I@25O^^U>MR3!T9F]"NAF8X QDIZB
M\3(M0#KB. 7N#?"HH5^ZL\A9A'CW>16!J%NBB(]#>RPFKU-+YO;![4O%&MCU
M/=65S/BP%%K*3/31\D5PJ;D=U8<SB#]:*_'S5M[# ;T>"&#P=6PZ\AP^Y@8D
M5!:G>OY^<GCZ.#@?]V\O=\@?ZSWLWT_(]\ZWVW[GR=SO?O@"I-G<N!4NMTL>
MR4>?]0ETK6]R]\!+>/@:%%S95-@KIFI).P;]/V[UXD'K:D>4GV5NS,6L8-=0
M/54O%M*Z\LHH&S#6O>@%WB $))("/"Y&(G);GK<10'^U#;LO-/M4J,T;(R1J
M"/U_Q=-.P1H\B 8Q9X1EQ48HD5E1*60.>#S'MSBJ#Z]V^:XV-V PB#""@AM0
M(K< )@2JY"$;/6+SK[.B*O=7'5%+25[<+E'01(;;-OX";?HK^YD0ZL@]LY8Z
M: AI&8>@WBUL1#]2AWL ;:#<)*?OS/L:-9FHC31F8%>+9\JL?]=JI]&'XT'Z
M_!"^,,1O[FT%8'BQ2, /X=F'Z3\0@0R,F @P]X*+VU5-SY'J4?WL%UAD/>-5
MG@#KLX65,EIKSMQ\*W("%ENCVW[-T5E%*OW3HV.POEV8$<!J>TPN", 1IJBA
M$2LVA_. &G[-XY8%H'9CV7(4\]S79..DH)XM,!\A8J[G6_'VBG+SBBYKV6+X
MG5F6O2R?K)/7@V5B95U0P&'^4Z.?4,QH85:8EHA"%+(T.*NFYV(2X5<&-.J@
M/QPYOA^Q53#@&YH/](>\$2'U24VCS5O*ML?^'ZG0.!;7Z+0M6\%\\8#5"76=
MP8 %> 3P+&KY[Q+VCUC6NX1=Q5/)2<*6UX-E8B5L2/)1Z]*3: 4JR48\'M^&
M5(%M,UFH&R++J; Z]3&'\_"7^&' '-H;C# @TAW6,8\<=&<T9>^&AJ<6;!>K
MRQA:L-+N-.L'J)@F9M9YU"=8X.IKXCL%;(JNR*[[@MA[[D.^.=&[+$S$<B=E
MU9\Z:5U>GIV?-AXZ+U[J9"_BP[,R)TG?S2*#,CW 3"X6BL6HD=,L=4)O32A%
M!;=IBG:M16A7*LE ._OGZ>W=195,NM7ETJZT59)?1;MR8Q;MIMN00=LQE'#8
M!QJEM21+0Z( CC%[H/1[8C^=] C7QWN5,&B$>T'GZ"!Y@?4"Y&"@ NL4I+D
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M?=41EPJU8JG0K#?R.>+I1K\14"Q?JKI5OI]<]"[VGT8WY1_'M96OG_.!?H)
MH%?C]F;AE9?170?K11AJZU*S'G9-HE+VH?^5V%$G]JG[R>6@<7%0[)'1067E
MCW;1TLC]^\EPM/]\.[[<Z[4Z4-;L(\B:5TBN84$,FSR.#>E&!G2$8;@R/=QQ
M4;,=."!68\)+IRRI3P:\9E +]XSD#^"_XII@LFH;*CO$B%L85<@[6NRQCV]N
M'.F68V)9UBZ?<>N?5'>P=^2-JM/<GPZT(0/^2\X(PI=3$/Q*:,PTO >_1%1N
M. :@ZI/SZV%I<G!YW>AJ+JH<GN$U:K.46^0G,FBS/0VVKB9VV5ZO2O<UO#R!
M:K(^5I;XYP!T_**-E5'Q?LQN$X= OQ[1PQDAA&Z![!/15</<EBY8N8F+?Z^P
M_CZ."4TOH2\$XZ&L!]+^"?U?KD@/,*^7HCDI Y G ] ;?E!@FN?O)]7]QL]K
M>7CZNU/Z$WK %.\GW5;Q\J5[:I<G@#IC5'AO]K)LR>+K%0MZSNNQ"]H@NG'!
MU:XD-XH%B2M.?G22R\%<BP8Z$= 'O$X$I^X<^<T-KS6T$OHX=,3J:B8TK<.9
M>UT$F=-%\2)67UV=Q;F'<9Q88;!F%;LK>U_#CL+N&R 8PG81KF'5; &*M]!R
MH6)Q:)C^<GE6;0I0<+1+H/V F.J^+1TA5M5DK6)\S_ N 8H^O0O>.4&4KTHX
M6%838MY[>;!&V-N9W3>LX/JFRW+'TI#R%9A,2J]GDI[";#/Z2]\>L3+?SPVX
M'64T&K"QN 76]$V\&T^GRZ?GXE" D:GA4 ##^XJD:MTN8:V6IXXOKNJ9*B ^
M/4"<,[8@XL7 V%[;G6.FJP7L'FZPET7P"#;M<7?]!]@QZ1L9EXKOG8PS[61<
M*KZW,OXKK7._"@/CW*=&W0FP?N,=Q.JT, IH*+<W@R=UA5(R21?ZO[!>)G1Y
M.LY8W-P0\\HMJ=/72-?W 7#L+.SRKCP0Z.7VI)%GB]>FLTHC*C>-#FH,^K>&
M8W9"'6D2U@.ZR0HI)QPH$*7/6/\U@WX'&M>(CA/8E85+8:[:AG1IVF@0);3?
MO8Z0UT%7Z#60NC"I)G1XIPHKC0/B1]3.^ZK[R=[QWE6O,=!&QJM"B9%=L!O?
M?YSOZ8/:\;?.\DMB+TD';[2O-U>0(._!PZ4M^8A*E%-EC!/(F"UWT+K:P7)*
M*F1;5S<22\-4L!N:6\?L%C#SKFB27"M^*DA[I&UOG1JJ.]R$R<#]%SAD1[/Z
MS#;\>.6T;7RL4B]N5>')65VWQ7?JI<8GU@K*-WH)__R5J#W(WNP:$*_I,*]J
M'\>#NS+V_)G^%>O-[*VA4:IN58J?_I6.8-.F^V.//5G#JEW>3">X/_H/^R]B
M3@S$0TU"W"I8]JVM76\TRIVIV38UYW>A+1C',[..XCY:L^[DX MUH,NG^!AK
M6,5:5%%=2'=N6K 5YN%HP=7[FIMUT=,(+9KX%]WU+YHUK][RS7-YYHL&)T"4
MT6YN?!3]RT0Q[2>FE%E_+M$#V_<:I4NU=V E_H50"HA-B,9B3/EY)<=*[,,X
MX8:5[#+'IP-EBO8S(5.3>WA=(WL3](WQWN+6!;MUS^'GZ/;$3[3AD*C@>0T@
M* Y696!U5%$']N8[7>H!8C=5[HUCBSDV*P9[='-'=TC].@@T=EF%N$UZALD;
MU%#^IM>BXUTP5KMI4HI1;Q0/4?$QKTTM7QMM!. $=,GY^^@UX,>$]=/8=$ZE
M=Y@21:.7"3?"_\:_-W8!@RSEZ*)1'_30#KX4?@ZSH8(OED)L^2E$)8N?/':#
MA9%0E/D@0H%M>C!PJEG0''Q,%!,FX-'WHG?,V,R=KUBJ%KAT<_N9\][DVI#7
MIKN! N;4^]^+7(E?'8M12^":LP'95*2QB V_KYAX"=UC:\2V (\809H%6,1B
M'=VQ:I[1ANW#NP% !S:GB(IA^CI%Y2W>-2S.'<(=5:<HY1\BY3W!) 8CPN:&
MJ-#?=[]SK.B.0MG#[>#T3-C30:7@]FSW;90%)2B3;4M'-KV/JMOC%^XO;P!,
M;P_U6&W11#%D"U-YZR:BO%E:0!.5'LW 0-FP9L;J2EL!YRP!8:)A%NB+&;#+
MA%G0'KN6@I^]P$/:I\8WJ&&F3"WI6K$>8!!<AS?;:Z%Q3I=]Y ;RJ$ #U<JD
M\07TRN^XMJ$2:#[IP4RX6<&N#G;:H$M#,P%^)T*F^UZJ4? AW X3>T=0B3'0
MR!/;SM!U-.&6AIB5BHLD;G5;:6(N![M6!YJ"1O'R%/,F($:J!_>32DFO*^,G
MM=.LKTI>XJU\L@.JDC&ZMN?)@A@'+#"X.?&Y^\F/ZL&%U26E4:>Z*A3^K_T%
MTH2;&V7DZ%+ILQ1RY>2=^TGS2"_91Y.=TJ#QX0MLDL4>T19-',O9_A.<JSSF
MP+9M7]W!DZ(-(*Y(9=B5,B#7\-]Q74AV I-AT[_F?D*^&_WOVFWUV]UJ(\(P
MJ>6-.O&/( 8W(G+"I[\M$'8=^<@L+<>B?VE]RK112/ZXJ9R[AQ3O)T=G6G'T
MH_5P?OF0IGO(OGL:LR__']51) ;KBH1F#:[@H8$:6Y:3W$&A5)FC*T+$1Z.2
M'\&^J,&B_E08_:GOQ(/T%R3CS+X2";]/.H44#2OB#S"*EC?4X:1_-2'J?-]^
M7V1XD2 WYEQ>!HR6]7V5L[^N,*\GFXNY%ML]A,[F?]%^H1<G^9LVC+;!DC7-
MZUJHE&N132< GLLF?<)_^-K:Y=%WX__<E[IPY$:@[BUDVX<L?S'5 H0)="2U
M *D\TLMZ.;*U]A$6"X*QYG72#B"?6[H*_V??V[0H>#[[.GJY.C;+3[\[+N89
MOOHAO$UYH7XO<VXSL7\U?^E]TH920JJWH-<&93NZU'(875TOR(W:JO9SB>*K
M9FH/\I+;%2"T ^P4;'67"6.UBH/BG7Y0_U'][3*69]E(/= ;:9F,D6O>_TW;
M^T:NPQ<:<DF>U?QF!0Z[/O=A@\;*^[ G=V>3TU*I\K17CSKL 2K-%3GMYAJ=
MMKS0U5[&B1]5'UZNJHW1L-3V:F7<R$XVVF.^':=LUK">6N15IM.KFT1=>8/,
M-)=ETAG!N3>-B!:-^=M7HJT,TN::DL;[D=M,IF0=-W\?MT:U&-MJL4X7R[.X
M>"^*V"UF<$]*S4*E.?NBK&4_$X\U]Y=KHJ7@S=IQY_B@V/]M/:8PSQ;CTY0*
MN5R=I9#7_/!;RS794AQ^I[*S.]YQOM[*G13FVD*G_S$+U3Z'6L]%5$%5)_V[
ML,RJR-G)JW1!_"5R:_I\9&8F9PJ./6]?G%Y]JU=^/G>2S,T<%&HN1NB2%&LU
MI[Z0>0?R8AK?8*NDMVJ2$^6>53*V."<CL_I#/OMVHQ;+<UB,KVW*DZ')F 'C
MRK5"O3&_A%W1WDI1;%/+VAJ<='_6OAUTKFH_BKT%K;G9/)32G*N4YS7GUNCD
M]K(VY28MI_?0/*KN[C<C3RZ-*3;SZ)9BBRW07BTO8RN6H68:6\ODI?G=@A2&
MUL1LGYW^/#E_',B_YS:47JE'LK.47LU+TQJE,KM%?V:MW/QX-!_(TRL(?D=.
M+04YY99S</!4Z1TP]4=BD=9BD>^ J7? U#M@ZB_8\#M@*@]@R^O"*Z62G%7B
M^V9@/1N_3JY_D.JJ J9*6R5YB:GN1J%9F]TH>850%:_.QOG&(F;'6(=?R]:W
M@5P_OU/>"# U'Y"F6OJC@30A1SN7(U=_G\N7YN2AW6R^%6SJ%><_,]"W0N=?
M7CS8DM?I(V^M,G;*WU)_G17*.W9J=M:W^AI3*ZV%-3O/&[P3:X&5$G=C"2E=
MN5PH+A#'_./A,J^RSE* #^YNO]=.3E_V+W^_-5:J.A.\O.:'OR"\/8]C#\JB
MM8)'36ON9<*CY QG4ZX</*JX3$-R7B9=&T34DAAT6GV62N^(J#R3VG(V=N2\
M=N J(* X)V? J&6Y4"SF-'IL-=CDU26+83DZV7E4ZXV17MFW4T3/\D5 U6;6
M$_Y5)Q>K^UYE8+TQZ&E*@;VQ ;4>D*?%KOV,2.SD4#\</'8O]V\?']80\I0-
M)X44",RNS)")9@&>$F=7RO>3R9$Y^FKO[I8O&RO=J4SL<]$9'J7W&1[9SO H
MO<_PR(FK\VRRV:+JV[9:NGJBT7,=H&P\9=VYU7/]DO"6Q?0'9P;5^OR/:%DG
MMDK<C^K,F=G'[B='Y8N>V9Z<GI5>-<AM.0T5N_16&\_0'Y%)!Y/PEK)69+]9
M7U/ROD9,Z"DWQK[/T(#7Z\&H(#6ECV'(!^) ?/F+3^\-&1,:,E;O)WOMYV>M
MUBL?[WJM86,:,N)X%E\?QJ_N^7CM&!F7KU,KQL!F/TLK %P4YU-I-GV ^1=R
MUKZ^^O[XM=7.'@OFG>H* ^ \NK2B*C9=2;LS=O_39=$3\D0&H:RW^ZLC?>38
M%OZD)'(I^[]5XZER8]2/?N> -81/21G!O'.FM9P;K66WQK_6_?FC=J->6KV\
M:"VO!:T/<J-U6=#ZY)#4+W9:C_O#05ZT+F<)*ETA3/E?VC1W#:#,:Z&^_CXE
M\O>)\C40J$P6N#JG6(YR5L^(C9:\\%7''DR]GPY2>$JMZ3&5;@_$/G"HYR7T
MSV#_X+C^5'T<'7@1SR76"N"RP(.CZY*ZL+!\D9U90"3C3R55&]+HD\@@>ELK
MR,W9P=LW!]>NP!$D>1KOQS3/,64)#*^O?C_5?!#UJ0G4R(Q T;JGEJGN$2BD
M7<,<P6A6 @.&(.(*([2("?&I"V5$3*&*CF5RV!V9C[996D 5O1IP[2X3!G;Q
MJ5\==Z7T*;K4U4"5Y0?16E"N<A!6NH->\1Y5:WVX*05)8V8)UM]'NF7;&R+:
M]GYW5H0!TMZ=N?M4S0T$]11R<4Z%/&GW)C?[5;+WM*/EX\Z)S<$.,-D]O;%I
M#>M'G4XE#=\>:)0CT&<QP9$%:+E:J%?+?QX6=.7.*HU3N32O\?TXEZ&SWTX+
M_^'GF58%S_2#LT,HKC88ZQVZ,1=$00!_Y4&]U?_YTSA5_]+<ET>7<E1-6;;0
MC4;1&CUWOK[41XV_,>OFT;J:&ZU=Z,9!K?F[]W#SO?+[';J1$ZU=Z,:C\=A]
MV;<JCI8# NP=NO'G=.U<@\3V6FBMOT]W_'T2? WD:#A(UU@N8D-N&OW=_F'_
MQNJ\(S9R"06$VU;E!@6H%BJ-V4& -<EZYWH$;XK8^*..*7M80E-^QVTD$RB[
MCH?1&JC^IK@-^['V,+0/C[I:^1VWL1;YZ5#SG*7EGO/LI+/6AYM6D-3><1MO
M;76\%6[C_>Z\\N[,G31Z!6YC7I=PLEO<EU]&X^HCJ;_C-M8O>9Q="Q:Y4:@T
MJ^^)X95P+9?F.[X?YS)T]MMIX3_\/-.IX'HQGQ&?<W>6*MY/GKJ/.X=[G9UJ
ML;( /B(7A,=_;7=7[:D>':^$H>37O$<T(SGO[M%W/BFV]D1\'75:MGL?$UOT
M[/H,ID5?>3\9[K\\=6[,_DFM_9I3C>DCT[(DHRL%*\0+V#3'UR2'_@+^1G57
M+@V$^)*4(37:;*)N;MB&]'_!YB_-8K!#<,3&=QW3)+K-K4;5/_^Y<M7^UGIH
M6_IN1["D]^+J(B\NL1>/'65\?2S_NCQN?_A2DHN%8K$8;".S+5WC?FU%&R"!
M(K=NFXIN,6%I8?L@()+=-PF1AO2 ^I9$=)6H(>IB+ <64Y 4DU"[4V+=BZQ_
M&4>O##K+N[NACC[-^TG_Z.QFHI.*,?%,^Z2./MX12:[FDZY]]'/IG[F8R)(>
M4<M;+;C:"J3QIUH+A:;R'E:K"OE9;(PFI>Q3H\&[ML(Y88]*M?M@(T]&);)3
MZC9ZWZ^&SSDDD -46C:F9$YG/^U1))N2,PB39+BFI&FF@B;0H\4G<^9:V5R;
M>B??[$W-;FZ1;(I<,5-D4MQW]HN'#QUU5\XPN<350BW<=)3M8X=0C:A#B\2V
M,E#TSA0F*M?D9!AVD;*A<#PQ,XI8A0H8J/1!6W#-LN++H6[QE=0M-\K94G=V
MF/K(LAS@]?/NE4V=J9:NWBDFM3IM"[I2$_-)ZQ#KW-P=*-K0XI?SZ.GP4J[>
M_I ?'O*)6D]ORFO0+3DC>E :7S9X'L]\P8)*B>PS_>JT88Q2<:H<(W@J$?RU
ME?2;J,N0U]I+N:]]=FN)([UC$L4B>X3]WR,]\H)Q)G.4'Q?M8?>YV&_D""_X
M\&6WK^@](FFZSYU?\#2BY5H$:6<,&TA)J,C^\)&1G/3Q3RURPD IG="?ILBG
M-::DO]-^1G242Z^C8ZPX%]B=_1>;VB^.9O4!VW/>%;*<WZG&R8G]?*H?U\M*
MONG&D*L77-8;)9]3R\K:#%FY4+YZ2IJN1\8^-='JJTNTZ%NSE]HGV>>WYZ[Q
M?5BS)G+[^R(]\^(T4DS29U]7$SR1=<L496MFSZ_70NI,!+3?TWEY>IJO.Z1R
M3<[OD!;)'1X]7VC%T>#@SGG55)JEY0[#V\D^"=CJ=""S95TH8Z B]1WIW]#?
M^6=K[&E69V# >(V8'&"QY)\!N-@;[R?#'^.*=?.S^O.YOD*' ^# S8V*A-GO
MTF<IE":2*_>3;ZK656Z)4ZWW/GP1VY?X_M<CY1//@GGFG=.P2F+NN169>Y[_
MM?<3[??!\=-H\N-&D5>%^<0V-C=&;"- ?4NS;***7+4W$2;'V2S9CV'QDJRM
M^TG_^.OAK\[UU8].8U:2%;8==[_R:M>QUFG0.6QND:&8PU6)>L&L!-JL-.&N
M+X5Z?OQ">K^>[+N#>08LI%R3EQS\KVU*_]"%(6PAMXV_!3$;OLXIQX_5F_'-
MP\W%KWGRT2G7%)ZEQL:L%:=FVQ5#M?X^TI?8'9->_?_-L18VY2VO U^D_<"Z
M7-A,OC+_B(Y5OG;KL/*8.$HSWGR_) .%'M"%8D[#S?3R_5!I7>Q.ZK9R/^DI
MYU<O3W?#X:27:W%[K1*9,G/M F$LV8:D4)-(,]6M$5T]%+[K3I=ZH-3KF*HJ
MS#5Q&5YPN@'E*<XAYT:4]4)%GMV'<M72Q,NE=G;E([5"N3R[>N25:>,$1_V<
M.A1FT@6?/.S?6.V#;]U*+<?8:6PX&-<G*:%K_@=4P<W#F/Y#ROGVUYKS!^Y6
M,P&RLH>5G? H%1J-^4O/,BJ3#&W;E2'7KA"Q72%2+'9.]O8[9NMXD8X#"Z0O
M8V/)K#1R7GFRU@F Z(/*68XT"J72>S?KG(XI.PE"+Y2\*IF:O?N)76U?OEP\
MW/;/.JL2CPT%!A>/K$:4*.6T9!P;SN>"2R894&-6HNP6](N K>"\?0X21)2-
M$3$5Y$[J28U,0W4Z!*IZ_H$2(&+9DN&8T*UE! +:DAR+P+AP_-N185.&Q18N
M^)PM=>B#FDIM:FM[<R.J&LL_P5QZ5BSZ*I6T(=0]56V51O6 YJGJ-5^AE=>=
MS6?<CWW%.<$..K=$5PVW3\[AR=/7-KD>[=W4/TBV9L/!3#F<'7Y/,Q?"HF&%
M?TUI;WS5O?&U*?=N.ZJZ&;E;HNPV@*73<PIK2& 'RCZ6](3+V5[55$/T=<T_
MH[I'V79VQK05@*Y$/G$_L>ZN;JO=[[W+X<.J"$$W(UJ-S8C6[B='_4ZOT3C]
M>GQ4@2Y/.EIXP#O8:F6-4J.9R?P<LVE^Q"&]^0:3VO_2VTXMDX$&"30D^^8&
MI[L$@'$J6:&8<U>Q^C&YKE799?9G$%,EG&'J%I.VIBWRM%RQX8VI?[9$0Q:J
M94'N/F%&NA!0@1H[HH[O[K >:9X4INX+O&%*/_KQVKZ[ASPPCYYL/2NFND=5
M95 SMIR>0]7_N4ZNG^D[QOM@TA*BMW3UF!H0BCEF?W^EO;#_8/]+?^\.3G_8
M?V@H!S_D)\75IKMQ&YVE3I-WF$:MOG9#&:ABN;H=Y2(%=7&;V,]T61*LU[(W
M-]!R*C6PTIHO5))KK-AQ6SK7I0/2-O%O2_QO"V"@@3XW52R\>-;L/BOG)N;0
M$LP*Y)>4GDD(('TM5JP!AMZ V-PF@)^11T>SQU#WW"5@,"+_6N+TGHE)P*"D
M-I]ATCLD.)GRM&)3 Y3]T8+W80- ^M(I1JZ'=.21;E&%"XOR'?JN^Z(+JL%)
M"7E:$Y7P<JFV#(X^VSN];-D/#P_M;HBCW1W.!N>EW& <4D_>HGM=+DL?G1T$
M.?GBJJ^8Q/KPI;Q=B7(F&4-3QT*RX(>4':DQ&3[VW="Q>P38%3SD$8I]D"FT
M4N#@J[S.>$DL<%7^=J)<WMU9O_IAH>;*<8M?'^AQ:8"F87;A3+Y(3X&X*@C*
M'-4581/!(O5"!:)XD3D/QB?((U:,#MW<\%,Q4R\D=_-@>1;-JMER\UNLG$KC
MU$^&+=PK8M/+"#=%:KE*[6\Q>9<7:CK2-S>Z&A@X8)4T1?^78J19JU&S(MZT
M12@CX3UW(BV#ZFP3-V#;EIH,!'55O1D/GZ^;UT^E5)9GZ+,[<WZ6?A@_V[]6
MVYK<'HW,1FX&;Y194&K.%QY.L% S6].\!=9)5O-VE.Z(5B9A8YK:'52W&(,G
M(G6P+AH9%G"G#@H>:J/8BH:=!.A/.^Q/$H0D\8?,^*6<*K2P)5B[/0XRO"Z-
M3(V*H3%13"O:+(^SRG4,M*2UQ*7\#/%:UH9X\"5!4\S/0$R,8Q6[$.*>#.>6
MUTS;[@"E$C-=SJC%20T<2@Z_02-LN-]*:;<^N6L=V^6EFNOS;ID_EG9C^5CS
M$$P-*-',5,D,_Z"9IW^PHIQY<*=76N.CZ]_EQELZ#*O(J*X_42D7JO+TH-W\
M^#31/Y%R<T]6TM!\]T1F>R+TKK2I%8!*_N]S19;G7I]35^38T8DDEPL1/@@B
MI3%9397+E0T%4S:U"M&NBSXBZ2/4XQ (U9/!F+T-[KE<_!S] /YCZ?.GS0W7
MF.L; \H8UIR!S@.E0UKH!X4<BV)-+OL4#(R .>^VH%-$CTQK+M\JIV3TY/+G
MT?AV_^+[R/*\$UB%S[HM2%VE(SRR^4PC;P<QWD"QMD6W(C1%_$(S<!A*Y6UY
M9IA=Z=$/]\ 4IH:[WM%&@!)S75'&2.&$YD<?1^R1KN(,;/8O@A$*TG-?Z_29
M-:Y1_E39K[:E"\>$-D@V2ZN3& XLA'D(_ACX$HO8J_":+GN%U*7:7"(O,-+"
M0D>F3S2309#0W=G<,.G;50"%H-2*>.E'2H&!@VT,*(D'"B)#+(?N)/0[V^@1
M!.@BP\,UXSODM&/^E<+J,/&_'7VD:'@+*4TLF]X5;0BKH92G7HKJ(-A$.,6?
MZ,_I)67NCD+E*_T2I<)'[1/KV0O'9?>I0^._Z-Q3 MI(70=P_[[$VWQ!AFD7
MOY;#3;1^-7X\7QT;YZ;LWL2S>6(#*9SOK*];+>&ZQ8=V^66CWJVN8E:*KE4G
M;$O 1@38J,"&0='%6=) LVQ$)>G26>MJK_4]02:#IC@0!RUNH$05\$>-\HM(
ME8F^H'AY-S?XL]?$'-)'<2%@L(O'WRVX;/7S7$&0U-G(Z!A((<5EE^=Q*ID^
M*_GT<88.9=2=% +B6[]^_/5JO&_=AE2UM]R"Y"Y8.O(I\%9JW9UFZQFXC?'[
MS$#3E[<;<;)G<X,+GT(FL;&#K&-CKU$@O_:^[==O*J;^4EUJ .OU>F1=@D]S
MR8EY@T^O.?K=_J^'$_MN]V>E])81HJPY07!!J5 JRX5B]2^([_QYZ6?61H:\
M@"M!OOSW_[:VJ'U&!NJ_TH72(Y_IZQX=,/-@ONMG-LO^7TF6MK9$U8:J/:4O
MVPK5^=<PVC-7XXYT[3BB@DKQI?ZV,8ILSC==VED,M[9VFX?[""=(]ED"H?&O
MU#*5MM;Y+)W1F\[(>F8  4NR_ZE_Q&/P3UYQABC,^.\?2N@HFIM$>=AJ$WI_
MZ<M'>&;^Y@J,Q*&^"SBJSF.V4?#M_D7!:MF"?%SRAQO9ZQC*U'RP84.WJ',/
M'ME[)#,_20V@"E_Z>#$L!;U1K#\R'%S'.SB+=P9/X1V5O?:T,:E^9BP<Z?O\
M8]0.\'A$]" /@(U#\U)(N>THI'3RR^I$QSX"6T$0W=1.X@R?P^N=BSB,0JJ%
M9]VF.2E&N5V;%35YCT6L;RS"O6QNE)E=.YP?-1-XD5E48H:GX=V :4?CYNAQ
M8O1KI<%$#<8@?,[S&\8:XI>^G,N925"AN.2@0M)Y7S=;1Y??JA<_JY4H;/L(
MONU!NI<:=GCU6><#8 _7]BTS1I!TDKVGL=6P'V]JH_6!J&=\Q.)X*_7H8$(J
MZ#DGSN;&N^^/3IY49/^+OLBRJ##3SQ%5IGZWA?>!W=PXXEG')9R=YP#G]86C
M ,8TZ"280"$8SRE2KR+?&FUP''B&/J>5H!1'(218\)=?;W3[P*C_JO;]1?*!
MK\XP#=!0C_SP$BWP:@HE;[(> MAD;C (^EQSUMZ]IMQNZE2Q=4+&97>)HOV2
MO@6UECJZ=RX<DT2JK\FOVLZO;K$R*M<[44;C7%5R,]>33L/,HS\XJVS)/EZ!
MS;[.3JA,E1/ IO@4+Z:IW!W&FP834GO8V=G1U?/S9I2!-J<RG[F0[*D;$>RO
MR?5")8&R\Y6&O7K@<$C'91>YRT\/K[;%T,2 ?1X436LCM%1C9",$!9J*7]T@
M4' K\#@5P%2J;O$$P;_25G%;QK92Q5HXU)D?<=;3(ESN%@*U9V&XIV<!H:K]
M!VMX5/KKV&AGJKKS':*3KM;1E($G,0^( BBS $Y3&$FL%"P=+D3PIM%M68X?
M)O^+F,:5]I*VOF /.SE%U1.HCEQJ'^N'PXE7L.[MR*^5NVQ/"_OU"72*U"1%
M=V0;+Q1SBY73$87_.F[K&=B'E>WZ+/N0W2DP#EGS)'0^@"G;231F"$;R@B,>
MJ%S2/6PC95-W7*9XE](VGDA\Z'];NH:G ]P.UF&;8-^1H4$?FC 3UK4>R<N(
MZ!;]W!-'@T)C")20\ =ZC^BOJ'F*>-#X#Z^U+/D#Q"'BWSG*48 < [C8OF&Q
M_MAPI3SE5Z2N"MQCE$W,0?'9D8#&93UXS_$>6M+'*Z=M&R.M(U7JQ2VY^ E_
MXTV9LA#>*7TE:@]Z!M)W89\YC('OZU3J>!&5\V?Z5RQL[KVU4:IN58J?_A4S
M/X#K>/+1Y;PC7P4F?"SP$27\G<T-[T/;4@N P92C :7,65SA0D;R&P5 ET !
M@3L*$:Y/'X#BY$DS'&O@TS:SU4RJ(&\Z-1/VQ9>K9CBON6TDIGIC5,X/][IZ
M]>GJL;\T/2*[>B3<[F<N/3)C;\M4)VWJ_7?Z*%40RP\=&K% &0 M\!CT6V20
M>JFCC#1L;VM+(4FP3:^,^T20K^E202: 1&(!(V?HL#"'BJ3'&@6NT:C!Q=40
MM:@IS_=TS1^MF&+VEA=8$H&=?:9L]ARH#P%EA$;Z>5>TPYNN>GD+YHZWH09$
M:=^>GQT^.5YBY"BL2;&.P;<](%! -"2&PN8A5:I65ZMB0Q5G%^(PII\R351'
M] T4%3-A\MI39@_:56#[".F\N0&SHCV/83LP FU:+UB$WPM?,8ZC>S;4;&$?
MQHUZ;'OCO6=UN'ZF2-\9CW?'VN&P?D9<YK^)H\A\0C^"(-GS]C+D^LSR%\9R
MP)A^DV)[37 =RVBEZIJ2+5T]4#03L:%Q/56CQP%'/WH_<>[TLZ/.T:%="O56
MA:DY;T=KUEVU%MM==?=^<MLX/;MK:@]??Y=@GI;8J"3&&XY7'(B7.&]RI;.G
M3"-N;H#\AV2;1'2P]0,SS6*;'HDF,L]\H#M32W!/Z-]B?*KKZ*H"(I"J)=OK
M3 U=M)\TB]7&X2,.Y= >/?+-#5/CKAQ5?6VZ;\7MV*U01T^Q^D)+\J_R&E*6
M93(ZK&=UAP'J^/HXQ(X5Y=FF0=<R'A&)/('N8^9C,(VUN=&ZVI4J#;[M+KUL
MTA/<-D][NGO6+.BW8UE:5X,M@Z8="+85V"AJX*N@Z]&;0U W&J$[;(ZV=-4G
MA'7A>8:R[390@6Q)0Z) ^V1,=&'"3,<QF739)KAE(U IU%@>T:,U5"_]YNV6
M+9G]DO4RAW^W;/IQ[!Y&7^;V1+?6#(.7O6QV16K+LH@-0M8W7?64G\6Y?DF
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MEZPN;L_ *(A*;_8GH[NY@;B":*8M9Z'LX\-=,R/:_-#N6@_'W:^W!Q.Y%,!
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M+H82R!?Z%KI]J#E/>=HXNC.(:0T3L8!4G(-%HQS[:3\W<2'O9D"V@4%*\X@
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M ',0(,G9?65CT'*Y7I CNPI%,E0J3LF0!_\O@OV:&513N\3W$UNH%ZY=A-!
MF9'(@Y7AY?/ND?JK:GA0EK"NDH(RJ"!ES(^OJ[>>FQZ9LZ0?4%'=CL1]+LB1
MKQ+4=WW-)GY[@$\X%:M)9.TY9&HS7YG*5QW/PNW3VD7[1?NZ#P%!SL*N2>CZ
MT06)O^A#U!8%?_K-% BM;6DO6WU-50G]#=VMK+VTS4&QT6Q^^+(58WC,HEQ6
M9*]F0?9I 0Z)I.N^HONGXEJB[4NH*T/LD=R=#OKGYW9]=-A,+U6R.Y]FL;3H
M^>1E&GTY,,PNH1=2_:<#$G.0_3W,HFE,_#5TUW^OG;&TC19]]L>=I^/2E5F>
M'%03KZ/[PDP.O/SV%_)@*1>2D\V!=$+*V_CUH*X.=N_&7WUM(F?>QFR/I_HF
M]S&L 6?XAH($:GB)\_B""[G),SBKE:^&=?<]ZVKO&X??R.#E[O2!)%YM]X4+
M1@WFY:YZ/'?%.,AI'8&W/OEYVB]9LRUD<3"N0D_T&V(%RG'_R2I]NY"KO[7T
M F793)%@HBW$%'D'3<*+DAFKN0$!(QA("8;F9^U07I!O\3E)-9SV@,S%N+/'
M66<=:-F/Y]>SE]:Y<C Y^:95D@,MTCZC;]BMG9,VJQU]D3/HZ9P^^A+)B8L+
MX+P8.2I:4WZ;:$T"(Y]KYZ?J=7?W8=*=0_#FS].K$,%Y#5O/'<%9B*N78LN&
MU09AA%-X@<CJJXT<?=A]CQ;3S4XGOQZ<G:>Q<66;\K26\#VZRC<H:<OORN U
MRB"+T?13AC@<2[(RF.+2'S\Z+TJO:C?V/6=^39@S[:[77;SSD=R(X0C/[/%A
MD%K[]Y/>K]W6Z#?IC\V'E<8/K2'6,;)\HH!54='H4]]H3U,,#F4]E5E?#=%R
M0Q-A-UZ]S"O/B#"[1L##.*R$C2AQ7PL-EGLF4=CL3875'+&YF^RAOZAZ)F_X
MI(M777'T9-NE[?0B<T5/1DISI!TGG<"H78,PBX-1[D;#*!=\^?W$N"V/OQU?
M[3AW75<>YD)XQB6\.CH>#KFY,0<>,LA9>5[$$!2Q>3]I__CV/&F.Y.9#.Q44
MD9]#+!+Q'8+X#D',#8*XPG [5V]D@;-;BQVO/<"02S)CI8"&4U/\7C%*8CY4
M8>_"WFFUK,K3@S?0-H)&!:DM4%QOC":,VV5NT,%R48Z<1+7"P,%*/NRT,&QP
MOZ%9\LWI@W51#T<AN"#Q9X2A0P(KG5DY5GLSH&!YNQ@U5/1/!@K6,V3B("XM
M 8G65:VS-NE>3J+ @?QEF6+/Y(6Q+ME1>B[M$XL;B"3U8HB!W<FY?/6CI@]K
M<R2NLCR4!(C('PL(G)I<^HK9]&<&GR\6A*&%Q]7'<\"5<M(R#P;M^D4CZ2)F
M"CN35P"F.Q<Z>M95#(#_7G,?'_?U;U>/YM&I/@?L/].S*;\-1/=/@016,IO+
MEP 'C&6?YX=QX^2J?#L>/21=YB5#OLH)(. UQP'.!?:?)44R0@$^_MP_[4YV
MM+T?G95% 983C+%U0@'&!#E6',V1D]>: O'7?_YUL3,\?:I;S>0@R#YO)+2*
M0+^Y B-9 #G2!D;6&,;Q)H&4!$;=4>IDIW%[=W"G+!9(67&.?3.<1ZKXRLK#
M^(3,6B\47R:EB=.8H;@QY9.'*_WX]N&KLO^S.B7M2<[8J*SNS-0^<Y/RI5*I
M()=RNARK(>6+^3#@G%"]K\:S;%?KK;M:8XHM\X;LY<"6?[(H3PO9:]Q/3D]Z
MXR?UH-_^77\-9"]W>!8#$)&7SL!1R9?__M_6EG2@D8'ZKW1!3^\S?=FC0_0.
MO*3R6<(24DHU:6M+W$M5>TKOH[%]N;^H(;AI+O1(.DQ(%(8J7@_;QBB*!2(R
M+/CJR,Y%/L()DGV6KL<C^OV6J;2USF?IC%XY1M8S PA8JOB?^D<\!O_D\9W@
MN?_^H82.HKE)E(>M-J&7A[Y\A&?&J4RW)4@\#3?R,\0H^';_HF"U;$$^+EDI
M;%QFH,,(H&E.2YX>XIW8F=M7[<!TOM%EO5-O@L'VF/9!YJA8J_XRK,B^%[P)
MJ\/?E CM3OQXY,2A2.3A:VR2)K5)&E%2GK64%=O@B#V+M<E7I!ZVTU-A9$!7
MT<0\(;K]J9%">].T1IF7BM1G/[[6^\6G_LZWP6Q2%Y+'  4H'K6$I1"\2HW
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MB@OLL*G1'1C!#/MKLQ@Z3D_GOQ$CT96AX>AL4CH5EI;4H01'XU>Q#)T^-I;
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MZ)=N]KH'M>NCGI\W7=P;XT["-P8JO4T\\KJ S8S%920AUXY;*]NUF=RJH0F
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M>1V&D9P5OA7>2*J('IG&DTU"3W*1WH,>B73=W=/]D &-; RI'N"+A(<@QH\
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M;+E3,C$!##U'H"B+%),EI37\*D70$-X#7JNZ!"XR^@.BH:FRAF@)7IJ7:Q(
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M$#S<GTNI:#*\W*-1P.]2]8&-@V,)&T<TG4ZU@N+_]L:G)ZSQ8DU6V4H:TBO
M,("\5ILVV/^FAH$C=4A64H<-YHP'+1S,. T"#V"A@"<'J9>OJQ?^.W;W-Q+S
MDM?$O-=-S$M>$_,^8F(>#?OB)*Q#V/==L8_W&[5 D.,D;4NUP<BARE(75[.3
M9@-,#H?6C_O>8(D  ?;WN.#W>E0JD IVYY&@+A^(%^7(D!E$-NJ[6Y5W'N\,
M<E)$0ETEF&"6A&"4KQ$,S@I1=>QKDYG_1!Y9?UXEGB'+/B;\+R!KAYXXM<4.
M!TZG"N'1L[XW!!/P?^)A7)OZR+2?NUDR;)+Y27THIJ6B?5,A-N4JGE+H:7@
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M#><).4Y(8K#S/(1?A0C1X@0AGXV[E 4XY<2KG(*2>D1!QZ0%[,0OW<:A;9_
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MBM;$(MT(M*,0THLBCS-G^2V]Z$0=XD"-P?DTM!SR97H3^N)I2M0]0_JM^IE
M:9Q#Q%ZUH8L!]0. !=K0Q0%UH7MU9=577>C-<"L4!66(93^X,A2]N).Y4(3Y
M&64H$8^EXS$VA52A>#H1FCJB^0_2B-A_72,Z[>]1=K4=PQ+%*'E5C"X&U \
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MY#,1S3*U[?^\A 6=EY'#2P#M^I1W]I0#*PDY@J@IZ//EC#H0?4C%0R$T#"I
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M7[=48PJ4%(*^4: D G5P!HYC>V],YRUH /C#PP@PX,TQ0K,8>(3X4"(-&U+
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MY9R/ R*O,_=<+^5O<WMH L-___/=X<';[T/7?UME?4:G4^++?0I<1ICRPI/
MWM*9T0'HI?\ZOZ#$J*17F4*VK0KH!T../P? T<5\Z:7DGNI%_2;O+$;]+85@
M>\5;Q1=?QW^OYL<?O%W?C[=>19^V-N*MIHJ!\$IJ*2_LH5==+BZNHSI%86L5
MMR+,2FJL&JA>5;EHN4)<MO4ZRL1B29T4-VEU<)B+C;/!VM8+O"!.2 J]O%DO
M^%R47!1,;+WP\]%#:MLH:]6+/A<TET<86Z\ 3221U,1J,+U*<J&U-NS8>JV(
M"UY.X,+FVP:Q-!WB!F+AZ&,[8$ <\W/L(^)&TZ0JM%Y'^< \Q"LVZQ1F:XE:
MG,Y)Y-NKJTJ^;2BE&\28W /J^,6YOGH]YD+\.AYR2,N*B6VO7N-9=<%],A7G
MH'JGN&1.UNRMUVT^IY"8HS&E"H[V;MXN-10KYB>"&6+V9!%+K,TY]LM6V\K]
M]#K-)R,2.DUH,J:24*BBLU/F4BE%_CI#'D>V/"HO467%7GI%YE,3"446NO])
M&CLE)OR8=*1;YNT40^F5E#_"3WHYN>!XVW52+..,&[,*2*N1HPHIBIU7LN*,
MN5@O58'U^LEE,DK/H'>*JK8C@:<-&W<PG=7;DHJ[Z967SX7H]R01!"2([!;
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MZ"-\HNQ'O!/0F1G#FP0F:;SDMON\F_];D'^.,/EQ*'[<PQ@!;B\2'S['^,M
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MW8;A?9(2ST]A5#;;C=^9 4(Y#N"("]G>6.\H9#S)"#L=J8K 5G-30,#VY>'
M$]J^N=Y+9BSG^>!%>18J/?$(>0KC:;Y/)YAKA'1F 1(8'NLJ 8Y=QF:7&2;I
M'2+SB_@!)>G&P4?.M,)I[0@XH.C@C&\*$CKQ+;PP.'M<L/5[J2",";>Y(Z#
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M8O&S^2+"3PB)RT)MM1H?]OTH_.YF!M4 LPEMWZXJ>UFRDF(8!\?8(\%HLG0
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MK%O^G]]0DJZ&:L$JHLVO_+#>!-H"]*K6#\-OI9U_985_4+!^FPVHAK5U)5I
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M/V2Y\<GB,PT]F54R(5N$4 .LV"!*@*""$I:0M:<61)6D91+<I)B2$).&8)<
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M47YEN**&3)5M<G.<06V"FFE"8^DHU'VJ-H(HHHL3LG3>UN6AK"[0.4W'^HI
MW,11'B(HYW!PV3O6.>17KX"N1\A@/KAOTI.Q2B,9O YUV@*PKDK)H G9HG".
MZ,_.>5!=/JT"*S]Z6>@K#%/(VN2%%FZ;'U)!,%Z^#IV,*FRJ(F,/C]% Q^B1
M*I2[NE&1 P@=^P73MT!PL'HA0^03OBYHKH7U1@A:TA%L9!DVB3?)O#8A1Q4
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MXL:NT9;NIWGW<O>.)UBEV%MOKKQ8]?I!6\#F2;X(K'T,W_SJO.V5D(1=/")
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ME2KJW/EW>:>\B@P<TW(&.K":SARP,!66FC ;3S)R*)I,*0FKH89@2N>K8ZJ
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MB@,G8^A-FOP-^[GL4?OF)UB-+^#JMU8I0!^T=U*GM]A/T@ 'Y_P=8_$N85\
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MU1#1SP[W9*KM\\&# X@SM@*=^I# [<S+1\1DP_?I'A@Y<$5OQ::F0AI6.YA
M'=RV+$JU*A&>FRBPTA+6)4U;2"8,LX$T2-7MPS/5CFJ>O1Z55NR!WZ3X)4R*
M+'KC*91_"?/GI,AO4KI%M=KMTN2E>7NV,TKL6:+%QZCG,+WU N@^Q<$B\"RV
MB*^':@Y*=G7!*.0INS_SHLDOM&SDE84OU1'J@P4<G!7$4WCB.1$'3HHF]Y)%
M/V?O>>+E*ZWQ[)?[%JS.M[RA@F?.NF#9[P+V31JJ3%."FAQR0NV[;/JUUG5G
M^9KKGCMCE0UUW!D^=1#]=CX[1W1;[D1:Z+6+A=$'W/%--JNL:#]"\U_$L;X+
M7U4!]49JL'@S"K,09%\JT^9=W3VPUW>.WWWO]ET31D6#IY%4@K#:9P"E\ 8)
M[XC&SR MU0KETU[U(V*&3ZNJY&&UB1E8U0.K)R,>.UOT:@=9XI?9_FB4R#9)
M\_ ?Y1QQAA_SLS#SI;EXQBC#:K@)R*67/7"948G&A[.(F%8I="P,2#DH* M:
M=O-D>%)7+[%-="UOB)B;T]OZ&%:$1<61J.7;&8:^E9N$1C39?;(I,OJ,%L[I
M 7LG1"VD.0S\Y"D._X&#FR+-"B_.[Q,F4\=%"(T]2ZFPF#"G24*.)5XV(H73
MY\=(Z2Q)9S>\+V2I(JHOH%WY"7K4RP6]ZBM.B,0C+>YVGH_I@>#?BW"GN<2D
ME8;5\"90Y6$GB"GQ(\A*#=Z;[;+8J'W?4(;8CM/ [_>"LNO+:"^8.#P$J&C[
M97S^ZC_3(_7.^YE5)EG9J?/DPF#Q8 9+)*?959$H9@39E00I=TW"F#BBO%R6
M3MEO[LAE9=%N=E!\/V56<V]9D=53*@6K4740A>T0+HO":HW@;0<7 $LU  ]+
M9'$U0\&V:E%833&(L]\>C0*42-N6H\]/5'XBXWK>?FK8DZ76,U.#U5JC,"NN
M3_'U3'D*],3UV\.<YRH;7_U$\'K#+"S#*\Q:<XPRK#:=@%P(?Z?O(;,R:)0T
M/T2H(NO*<IC7<^JXA5OT;:#<)W4-Z/JH5 %62QJBU5YK;!1I_&/3L-:CA48%
MD4"(\3$/WP'&FI&7Z#M!-Z2[M^GCT"O"6.\*U;_#JGTY.+G30^^CN#U@\%.Z
M=W2&^?]>QF=XEV2A[#1!(0FK\H=@BN<$7 X%I0)=J@5<9:'Q<17\K<AR:L5]
MPGN>/ R_//V0GP:/+,+:6#K1N-;9_"A]6.2;!EX\K:]*H5N[/#RC\TYYYT'S
M\GS+]C!=9,=/GK?[C>^%G])72KH;!U*!W][_%CU&UAJL@[ML*#TNH2V8U!$J
MY9Q6LKIVP57K0'TZJL;628V&L*(4H.K5@!.3^M:BKOG;@C)0XS"KVJ2.W5?M
M*@Z8Q_Z<1 &],LU>,QVH;ZD.S$;00]6T##M*Y>*.&JE._D*\S62+KY),V@\D
M8H":0H=../ZL,]1P8?0U%?_&5?737"?729QT+9"XH&8:D!K%#*C0/BS[2UNO
M;JA2U55;G>$T?&$O,_SDA3%ES3IN_G:-I5/VH!*@%C/'*L2,UE)'B.J6G0J1
M14#[)U*$H[;[Y*6_XYP>>]YAOTC9X/L0DU5U1 -6*G-E#6BF":@51P(6<]!7
MZJC1/T)-">T&=M2:HP;,0Q@KQP^3$ =(TKWU7D1'X+</<*I?BDOV#$;'9T"K
M/$_#QX+WECQ!-Y[#E0P_(FTECY"U@" $J!74V*29.,B@U))U5.GBGNY-BG=>
M&&@&I"$=0..2,53EWO77E>HW=/>ZU$:ENKMQZM3+GF_2Y"4,</#Q[2&CX3GU
MRF#E$W=%N25@K@VH;TT +1O^:!FH*@0]OJ&O:3FD9;]!S;JJ*0M6^UZRE!13
MVU>B#:BC3@ ]LGWKHL"V[T5(7TZ:VKX2;?CMJP,]LGWKHMRW+T5)_X]NC+UX
M$0VYNR7<2T/V>#WY814'W3^T)/FE97'B\J."^@E5".VME^/SS0;[TE6[702
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MCHM/^4NDY.DT#I0F75,12@?*?M- =!12ID' X$K+_[FB$3E14=%9''Q'A$>
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M<'EX!,E+4%ZTLR1>T@1C?*4R.*+FTR 0CU>]\,:CP65TZFUHUAE<<[L7EU7
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M+J$[F$ (YC-+EEY4NK,QJ<HG=7$D">CSW>3UA%N",$[SA+!_5.M/O"B85%K
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M&[,3S^,Z?GQ:CCH4LL#B7C\Z[R5P7?-H8RE#J'Y)1X)BA</3R+#:RA30!^J
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M,"TR+FAT;5!+ 0(4 Q0    ( !5(L%1LA:<O#P@  +9/   *
M  "  3\N  !E>#,Q+3$N:'1M4$L! A0#%     @ %4BP5% /;13X!P  :DT
M  H              ( !=C8  &5X,S$M,BYH=&U02P$"% ,4    "  52+!4
MQM(I/D$$  !S%P  "@              @ &6/@  97@S,BTQ+FAT;5!+ 0(4
M Q0    ( !5(L%3O^XV1+@0  ,$4   *              "  ?]"  !E>#,R
M+3(N:'1M4$L! A0#%     @ %4BP5(%0J5:9# $ ?JL*  P
M ( !54<  &9O<FTQ,"UQ+FAT;5!+ 0(4 Q0    ( !5(L%24 $FBRA   #NX
M   1              "  1A4 0!G=&)P+3(P,C(P,S,Q+GAS9%!+ 0(4 Q0
M   ( !5(L%3-R\6^&@T  ).A   5              "  1%E 0!G=&)P+3(P
M,C(P,S,Q7V-A;"YX;6Q02P$"% ,4    "  52+!43VU-K^XD  !,30( %0
M            @ %><@$ 9W1B<"TR,#(R,#,S,5]D968N>&UL4$L! A0#%
M  @ %4BP5+;,ES]J7@  XUP% !4              ( !?Y<! &=T8G M,C R
M,C S,S%?;&%B+GAM;%!+ 0(4 Q0    ( !5(L%3)_%#MD#<  !:B P 5
M          "  1SV 0!G=&)P+3(P,C(P,S,Q7W!R92YX;6Q02P4&      P
,# #5 @  WRT"

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
